<html lang="en"><head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
    <link rel="shortcut icon" href="./favicon.png">
    <link rel="preload" href="./static/media/SourceSansPro-Regular.DZLUzqI4.woff2" as="font" type="font/woff2" crossorigin="">
    <link rel="preload" href="./static/media/SourceSansPro-SemiBold.sKQIyTMz.woff2" as="font" type="font/woff2" crossorigin="">
    <link rel="preload" href="./static/media/SourceSansPro-Bold.-6c9oR8J.woff2" as="font" type="font/woff2" crossorigin="">

    <title>app</title>

    <!-- initialize window.prerenderReady to false and then set to true in React app when app is ready for indexing -->
    <script>
      window.prerenderReady = false
    </script>
    <script type="module" crossorigin="" src="./static/js/index.BlylrL8P.js"></script>
    <link rel="stylesheet" crossorigin="" href="./static/css/index.DpJG_94W.css">
  <style media=""></style><style data-emotion="st-emotion-cache-global" data-s=""></style><style data-emotion="st-emotion-cache" data-s=""></style><link rel="modulepreload" as="script" crossorigin="" href="https://pieree369-olmocr.hf.space/static/js/index.BqlD3NTA.js"><link rel="modulepreload" as="script" crossorigin="" href="https://pieree369-olmocr.hf.space/static/js/index.DW_MHI2K.js"><link rel="modulepreload" as="script" crossorigin="" href="https://pieree369-olmocr.hf.space/static/js/FormClearHelper.UtDFKbpT.js"><link rel="modulepreload" as="script" crossorigin="" href="https://pieree369-olmocr.hf.space/static/js/FileHelper.DV2KuUj6.js"><link rel="modulepreload" as="script" crossorigin="" href="https://pieree369-olmocr.hf.space/static/js/ProgressBar.BtMHwdZZ.js"><link rel="modulepreload" as="script" crossorigin="" href="https://pieree369-olmocr.hf.space/static/js/Hooks.YZgOFmbn.js"><link rel="modulepreload" as="script" crossorigin="" href="https://pieree369-olmocr.hf.space/static/js/UploadFileInfo.C-jY39rj.js"></head>
  <body>
    <noscript>You need to enable JavaScript to run this app.</noscript>
    <div id="root"><div class=""><div class="withScreencast" data-testid="stScreencast"><div class="stApp stAppEmbeddingId-t7984a0afjhj st-emotion-cache-1r4qj8v ee4bbma0" data-testid="stApp" data-test-script-state="notRunning" data-test-connection-state="CONNECTED"><header tabindex="-1" class="stAppHeader st-emotion-cache-12fmjuu e4hpqof0" data-testid="stHeader"><div class="stDecoration st-emotion-cache-1dp5vir e4hpqof1" data-testid="stDecoration" id="stDecoration"></div><div class="stAppToolbar st-emotion-cache-15ecox0 e4hpqof2" data-testid="stToolbar"><div class="stToolbarActions st-emotion-cache-1p1m4ay e1i26tt72" data-testid="stToolbarActions"></div><span id="MainMenu" class="stMainMenu st-emotion-cache-czk5ss ev04twb8" data-testid="stMainMenu" aria-haspopup="true" aria-expanded="false"><button kind="headerNoPadding" data-testid="stBaseButton-headerNoPadding" aria-label="" class="st-emotion-cache-l1ktzw em9zgd018"><svg viewBox="0 0 24 24" aria-hidden="true" focusable="false" fill="currentColor" xmlns="http://www.w3.org/2000/svg" class="e144pc0f1 st-emotion-cache-1pbsqtx ex0cdmw0"><path fill="none" d="M0 0h24v24H0V0z"></path><path d="M12 8c1.1 0 2-.9 2-2s-.9-2-2-2-2 .9-2 2 .9 2 2 2zm0 2c-1.1 0-2 .9-2 2s.9 2 2 2 2-.9 2-2-.9-2-2-2zm0 6c-1.1 0-2 .9-2 2s.9 2 2 2 2-.9 2-2-.9-2-2-2z"></path></svg></button></span></div></header><div class="stAppViewContainer appview-container st-emotion-cache-1yiq2ps eht7o1d0" data-testid="stAppViewContainer" data-layout="narrow"><section tabindex="0" class="stMain st-emotion-cache-bm2z3a eht7o1d1" data-testid="stMain"><div class="stMainBlockContainer block-container st-emotion-cache-mtjnbi eht7o1d4" data-testid="stMainBlockContainer"><div data-testid="stVerticalBlockBorderWrapper" data-test-scroll-behavior="normal" class="st-emotion-cache-0 eu6p4el5"><div class="st-emotion-cache-b95f0i eu6p4el4"><div class="stVerticalBlock st-emotion-cache-1n76uvr eu6p4el3" data-testid="stVerticalBlock" width="704"><div class="stElementContainer element-container st-emotion-cache-kj6hex eu6p4el1" data-testid="stElementContainer" data-stale="false" width="auto"><div class="stHeading" data-testid="stHeading"><div data-testid="stMarkdownContainer" class="st-emotion-cache-1104ytp e1icttdg0"><div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 id="olmocr">OLMOCR<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#olmocr" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div></div></div></div><div class="stElementContainer element-container st-emotion-cache-kj6hex eu6p4el1" data-testid="stElementContainer" data-stale="false" width="auto"><div class="st-emotion-cache-8atqhb e1mlolmg0"><div class="stFileUploader st-emotion-cache-0 e17y52ym15" data-testid="stFileUploader" width="704"><label data-testid="stWidgetLabel" aria-hidden="true" class="st-emotion-cache-1s2v671 e1dx5vew0"><div data-testid="stMarkdownContainer" class="st-emotion-cache-wq5ihp e1icttdg0"><p>Upload a PDF or Image</p></div></label><section role="presentation" tabindex="0" data-testid="stFileUploaderDropzone" aria-label="Upload a PDF or Image" class="st-emotion-cache-1gulkj5 e17y52ym0"><input data-testid="stFileUploaderDropzoneInput" accept="application/streamlit,.pdf,.png,.jpg,.jpeg" type="file" style="border: 0px; clip: rect(0px, 0px, 0px, 0px); clip-path: inset(50%); height: 1px; margin: 0px -1px -1px 0px; overflow: hidden; padding: 0px; position: absolute; width: 1px; white-space: nowrap;" tabindex="-1"><div data-testid="stFileUploaderDropzoneInstructions" class="st-emotion-cache-u8hs99 e17y52ym1"><span class="st-emotion-cache-nwtri e17y52ym2"><svg viewBox="0 0 24 24" aria-hidden="true" focusable="false" fill="currentColor" xmlns="http://www.w3.org/2000/svg" class="e144pc0f1 st-emotion-cache-6rlrad ex0cdmw0"><path fill="none" d="M0 0h24v24H0V0z"></path><path d="M19.35 10.04A7.49 7.49 0 0012 4C9.11 4 6.6 5.64 5.35 8.04A5.994 5.994 0 000 14c0 3.31 2.69 6 6 6h13c2.76 0 5-2.24 5-5 0-2.64-2.05-4.78-4.65-4.96zM19 18H6c-2.21 0-4-1.79-4-4 0-2.05 1.53-3.76 3.56-3.97l1.07-.11.5-.95A5.469 5.469 0 0112 6c2.62 0 4.88 1.86 5.39 4.43l.3 1.5 1.53.11A2.98 2.98 0 0122 15c0 1.65-1.35 3-3 3zM8 13h2.55v3h2.9v-3H16l-4-4z"></path></svg></span><div class="st-emotion-cache-j7qwjs e17y52ym4"><span class="st-emotion-cache-9ycgxx e17y52ym3">Drag and drop file here</span><small class="st-emotion-cache-1rpn56r ejh2rmr0">Limit 200MB per file • PDF, PNG, JPG, JPEG</small></div></div><button kind="secondary" data-testid="stBaseButton-secondary" aria-label="" class="st-emotion-cache-ocsh0s em9zgd02">Browse files</button></section><div class="st-emotion-cache-fis6aj e17y52ym5"><ul class="st-emotion-cache-14m29r0 e17y52ym6"><li class="st-emotion-cache-1l95nvm e17y52ym7"><div class="stFileUploaderFile st-emotion-cache-12xsiil e17y52ym10" data-testid="stFileUploaderFile"><div class="st-emotion-cache-10ix4kq e17y52ym12"><svg viewBox="0 0 24 24" aria-hidden="true" focusable="false" fill="currentColor" xmlns="http://www.w3.org/2000/svg" class="e144pc0f1 st-emotion-cache-4mjat2 ex0cdmw0"><path fill="none" d="M0 0h24v24H0V0z"></path><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zM6 20V4h7v5h5v11H6z"></path></svg></div><div class="stFileUploaderFileData st-emotion-cache-1l4firl e17y52ym8"><div class="stFileUploaderFileName st-emotion-cache-1uixxvy e17y52ym9" data-testid="stFileUploaderFileName" title="1501_PDFsam_Pharmacology_and_Pharmacotherapeutics,_24e_etc_Z_Library.pdf">1501_PDFsam_Pharmacology_and_Pharmacotherapeutics,_24e_etc_Z_Library.pdf</div><small class="st-emotion-cache-1rpn56r ejh2rmr0">3.0MB</small></div><div data-testid="stFileUploaderDeleteBtn"><button kind="minimal" data-testid="stBaseButton-minimal" aria-label="" class="st-emotion-cache-8ccstr em9zgd06"><svg viewBox="0 0 24 24" aria-hidden="true" focusable="false" fill="currentColor" xmlns="http://www.w3.org/2000/svg" class="e144pc0f1 st-emotion-cache-1pbsqtx ex0cdmw0"><path fill="none" d="M0 0h24v24H0V0z"></path><path d="M19 6.41L17.59 5 12 10.59 6.41 5 5 6.41 10.59 12 5 17.59 6.41 19 12 13.41 17.59 19 19 17.59 13.41 12 19 6.41z"></path></svg></button></div></div></li></ul></div></div></div></div><div class="stElementContainer element-container st-emotion-cache-kj6hex eu6p4el1" data-testid="stElementContainer" data-stale="false" width="auto"><div class="stButton st-emotion-cache-8atqhb e1mlolmg0" data-testid="stButton"><button kind="secondary" data-testid="stBaseButton-secondary" aria-label="" class="st-emotion-cache-ocsh0s em9zgd02"><div data-testid="stMarkdownContainer" class="st-emotion-cache-1hyd1ho e1icttdg0"><p>Submit</p></div></button></div></div><div class="stElementContainer element-container st-emotion-cache-kj6hex eu6p4el1" data-testid="stElementContainer" data-stale="false" width="auto"><div class="stMarkdown" data-testid="stMarkdown"><div data-testid="stMarkdownContainer" class="st-emotion-cache-1104ytp e1icttdg0"><p><strong>Processing file:</strong> 1501_PDFsam_Pharmacology_and_Pharmacotherapeutics,_24e_etc_Z_Library.pdf</p></div></div></div><div class="stElementContainer element-container st-emotion-cache-kj6hex eu6p4el1" data-testid="stElementContainer" data-stale="false" width="auto"><div class="stMarkdown" data-testid="stMarkdown"><div data-testid="stMarkdownContainer" class="st-emotion-cache-1104ytp e1icttdg0"><p>resorption is in equilibrium with osteoblast-mediated re-formation of new bone material. Calcitriol, in physiological amounts acts as a hormone for the mineralisation of new bone. It stimulates bone mineralisation by:
(a) Providing mineral for incorporation into bone matrix through increased intestinal absorption of calcium and phosphorus; and
(b) Regulating the function of osteoblasts, which possess calcitriol receptors. In vitro, it modulates the proliferation of cultured osteoblasts. However in large doses, it is a potent bone resorptive agent.
The osteoclast originates from hematopoietic cell of early macrophage lineage. The increase in osteoclasts stimulated by calcitriol may indicate a maturational effect of the hormone on myeloid hematopoietic precursor cells, which differentiate into functional osteoclasts. Thus, the vitamin D metabolite alters the number but not the function of osteoclasts.</p>
<ul>
<li>Kidney: Calcitriol
(a) Stimulates the tubular reabsorption of calcium and phosphorus; and
(b) Inhibits the tubular renal formation of calcitriol by negative feedback.</li>
<li>Intestine: Calcitriol stimulates the intestinal absorption of calcium and phosphate. This is its main action. In the absence of vitamin D, absorption of dietary calcium is about 10<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>15</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">15 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">15%</span></span></span></span></span>, and that of phosphorus is about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>60</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">60 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">60%</span></span></span></span></span>, which increases markedly in response to calcitriol. Its deficiency also prevents the adaptive increase in the absorptive capacity of the small intestine for calcium when the dietary calcium supply is low or its requirements are increased.</li>
</ul>
<p>Calcium homeostatic mechanism: A tendency to hypocalcemia, as in chronic calcium deficiency (nutritional):
(i) Stimulates PTH secretion (secondary hyperparathyroidism).
(ii) PTH corrects this tendency first by stimulating renal reabsorption of calcium.
(iii) Continued excess of PTH in continued calcium deficiency stimulates the renal production of calcitriol;
(iv) Calcitriol enhances intestinal absorption of calcium;
(v) Increased metabolism of 25 OHD to calcitriol by PTH further aggravates vitamin D deficiency.
High PTH levels also cause phosphaturia and hypophosphatemia. If increase in intestinal absorption of calcium is not possible, the elevated plasma PTH mobilises the bone calcium, leading to osteoporosis. Persistently very high plasma calcitriol levels as in hypervitaminosis D, cause excessive intestinal calcium absorption and hypercalciuria with or without hypercalcemia.
(2) Muscle: The uptake of radiocalcium by the sarcoplasmic reticulum is subnormal in vitamin D deficiency; it can be corrected by its administration. Clinically, muscle weakness is a prominent feature of deficiency; and may be the only manifestation in old persons.
(3) Cellular growth and differentiation: Like the Vitamin A metabolite retinoic acid, calcitriol inhibit the proliferation and promote the differentiation of several tissues. Under certain conditions, keratinocyte-derived calcitriol may induce epidermal differentiation locally and inhibit the proliferation of epithelial cells. The active analogues of vitamin D are used topically in the treatment of psoriasis (Chapter 71).</p>
<p>Calcitriol also promotes in vitro differentiation of myeloid precursor cells towards cells with the properties of mature macrophages. VDR is also expressed in other tissues, not</p>
<p>primarily related to calcium metabolism such as pancreas, skeletal and cardiac muscle and thyroid gland. It promotes cell differentiation and apoptosis, and prevents angiogenesis. (4) Immunoregulatory properties: Receptors for calcitriol are expressed in activated, proliferating human B lymphocytes and T lymphocytes, but they cannot be detected in quiescent lymphocytes. It is a potent immunoregulator. People with vitamin D deficiency are more prone to infections such as tuberculosis. Receptors for calcitriol are also present in a variety of nonleukemic cancer cells.
(5) Miscellaneous: Calcitriol inhibits renin production but increases that of insulin.</p>
<p>Absorption, fate and excretion: The main source of vitamin D is that formed in the skin by the action of direct sunshine. Intermittent exposure to sunshine, is enough to maintain adequate plasma levels of 25 OHD . Skin pigmentation blocks the penetration of UV rays into the skin and reduces its synthesis.</p>
<p>Given orally, vitamin D is absorbed adequately from the distal small bowel in the presence of bile salts. Its bioavailability increases by <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span> (serum levels of 25 OHD ) if taken with major meals. The absorption is defective in patients with obstructive jaundice and in those with steatorrhoea. Mineral oil interferes with the absorption of dietary vitamin.</p>
<p>Vitamin D is converted in the liver to 25 OHD which circulates ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>88</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">88 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">88%</span></span></span></span></span> ) in the plasma bound to a specific vitamin D binding carrier protein. It is the main circulating and storage form of vitamin D. Its estimation is used to assess the vitamin D status of an individual.</p>
<p>The hepatic conversion of cholecalciferol to 25 OHD is very efficient in the case of vitamin D derived from the skin as the latter is presented to the liver at very slow rates. Vitamin D absorbed from the gut is presented to the liver in relatively larger quantities at a time; as a protective mechanism, the liver degrades it and excretes the metabolites in the bile. Hence, adequate exposure to natural or artificial sunlight is far more efficient in maintaining plasma 25 OHD levels than oral administration of vitamin D.</p>
<p>In the proximal renal tubules 25 OHD is converted to the active metabolite <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo separator="true">,</mo><mn>25</mn><mo stretchy="false">(</mo><mrow><mi mathvariant="normal">O</mi><mi mathvariant="normal">H</mi></mrow><msub><mo stretchy="false">)</mo><mn>2</mn></msub><mi mathvariant="normal">D</mi></mrow><annotation encoding="application/x-tex">1,25(\mathrm{OH})_{2} \mathrm{D}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">25</span><span class="mopen">(</span><span class="mord"><span class="mord mathrm">OH</span></span><span class="mclose"><span class="mclose">)</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord mathrm">D</span></span></span></span></span>. Only small quantities of 25 OHD are so converted; much more is converted to another metabolite <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>24</mn><mo separator="true">,</mo><mn>25</mn><mo stretchy="false">(</mo><mrow><mi mathvariant="normal">O</mi><mi mathvariant="normal">H</mi></mrow><msub><mo stretchy="false">)</mo><mn>2</mn></msub><mi mathvariant="normal">D</mi></mrow><annotation encoding="application/x-tex">24,25(\mathrm{OH})_{2} \mathrm{D}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">24</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">25</span><span class="mopen">(</span><span class="mord"><span class="mord mathrm">OH</span></span><span class="mclose"><span class="mclose">)</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord mathrm">D</span></span></span></span></span>. Whereas the production of 25 OHD in the liver depends upon the supply of vitamin D to the liver, the production of calcitriol is strictly regulated by the demands of the organism. The renal production of calcitriol requires the presence of PTH.</p>
<p>The metabolic degradation of 25 OHD in the liver is increased with resultant depletion of vitamin D in:
(a) Hyperparathyroidism, primary or secondary and,
(b) Patients on anticonvulsants, phenobarbitone and phenytoin. The anticonvulsants may lead to rickets and osteomalacia by acclerating metabolism of vitamin D and by increasing the resistance of target organs (intestine and bone) to vitamin D. Phenytoin also inhibits calcium absorption from GI tract.</p>
<p>The hepatic production of 25 OHD is inhibited by glucocorticoids and INH, by 25 OHD itself and by calcitriol.</p>
<p>The renal production of calcitriol is stimulated by a diet poor in calcium or phosphorus, and is inhibited by a phosphorus rich diet. Low calcium diet acts through stimulation of PTH release; low phosphorus diet acts directly.</p>
<p>Excess of vitamin D is stored in the body fat. The mammalian liver contains limited amount of vitamin D. Very little vitamin D is found in the urine.</p>
<p>Apart from the kidney, calcitriol is also synthesised extrarenally during pregnancy, and</p>
<p>in patients with granulomatous and lymphoproliferative disorders. Extrarenal 1hydroxylases have been identified in a variety of tissues including activated macrophages.</p>
<p>Assay: An international unit of vitamin D is the specific biological activity of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.025</mn><mi>μ</mi><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">0.025 \mu \mathrm{~g}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">0.025</span><span class="mord mathnormal">μ</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span></span></span></span></span>. of pure calciferol ( 1 mg calciferol <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>=</mo><mn>40</mn><mo separator="true">,</mo><mn>000</mn><mrow><mi mathvariant="normal">I</mi><mi mathvariant="normal">U</mi></mrow></mrow><annotation encoding="application/x-tex">=40,000 \mathrm{IU}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.3669em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord">40</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">000</span><span class="mord"><span class="mord mathrm">IU</span></span></span></span></span></span> ). Specific and sensitive immunoassays can measure the plasma levels of 25 OHD and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo separator="true">,</mo><mn>25</mn><mo stretchy="false">(</mo><mrow><mi mathvariant="normal">O</mi><mi mathvariant="normal">H</mi></mrow><msub><mo stretchy="false">)</mo><mn>2</mn></msub><mi mathvariant="normal">D</mi></mrow><annotation encoding="application/x-tex">1,25(\mathrm{OH})_{2} \mathrm{D}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">25</span><span class="mopen">(</span><span class="mord"><span class="mord mathrm">OH</span></span><span class="mclose"><span class="mclose">)</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord mathrm">D</span></span></span></span></span>; the normal levels are <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mo>−</mo><mn>80</mn><mrow><mi mathvariant="normal">n</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">30-80 \mathrm{ng} / \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">30</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">80</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">ng</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>15</mn><mo>−</mo><mn>60</mn><mrow><mi mathvariant="normal">p</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">15-60 \mathrm{pg} / \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">15</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">60</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">pg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span>, respectively.</p>
<p>Adverse reactions: Hypervitaminosis D is likely to occur in an individual with normal vitamin D sensitivity receiving 50,000 units or more per day for weeks to months. It gives rise to generalised decalcification of bones, hypercalcemia, hyperphosphatemia, hypercalciuria and metastatic calcification. It does not occur following excessive exposure to sunlight.</p>
<p>As vitamin D is stored in body fat for several months, unwittingly administered supraphysiological does of vitamin D for prolonged period to make baby's bone strong can end up in toxicity.</p>
<p>Acute calcitriol toxicity kills rats even before they develop hypercalcemia. The mechanism of this lethal action is probably an inordinate rise in intracellular concentration of calcitriol, causing generalised cellular poisoning.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="preparations-and-dosage">Preparations and dosage:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#preparations-and-dosage" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>(i) Calciferol contains 40,000 units of antirachitic activity per mg.
(ii) Vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">D</mi><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{D}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">D</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> oily injection (Arachitol) 300,000 and 600,000 units of vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">D</mi><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{D}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">D</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>. The same preparation may be given orally and will be cheaper.
(iii) Shark liver oil contains 6,000 units of vitamin A activity and 1,000 units of antirachitic activity per ml. Dose: 0.5 to 1.5 ml daily orally.
(iv) For other preparations containing both vitamins A and D, see Chapter 78.
(v) Vitamin D sachet 60,000 units
(vi) Vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">D</mi><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{D}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">D</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> capsules 1000 units, once daily.</p>
<p>Therapeutic uses: Current evidence suggests that daily requirement of vitamin D is 400 IU/day for subject less than 1 year of age and 600 IU/day for subjects in the age range of 170 years. All breast fed infants are considered to have higher risk of insufficient vitamin D because often the vitamin D status of mother is unknown, more so in developing countries. Unfortified cow's milk is a poor source of vitamin D (about 1 mcg of activity per liter); so is human milk. Hence supplementation with 400 IU is recommended and is not a bad idea to give vitamin D to all children. However excess vitamin D may cause more harm than good. This must be remembered while prescribing vitamin D suppplements to infants and children whose 'vitaminised' food may already be supplying their daily requirement. One teaspoonful ( 5 ml ) of cod liver oil gives about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>650</mn><mi mathvariant="normal">U</mi><mo stretchy="false">(</mo><mn>85</mn><mi mathvariant="normal">U</mi><mi mathvariant="normal">/</mi><mi mathvariant="normal">g</mi><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">650 \mathrm{U}(85 \mathrm{U} / \mathrm{g})</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">650</span><span class="mord mathrm">U</span><span class="mopen">(</span><span class="mord">85</span><span class="mord mathrm">U</span><span class="mord">/</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span><span class="mclose">)</span></span></span></span></span> while 5 ml halibut liver oil contains <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3</mn><mo separator="true">,</mo><mn>000</mn><mi mathvariant="normal">U</mi></mrow><annotation encoding="application/x-tex">3,000 \mathrm{U}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord">3</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">000</span><span class="mord mathrm">U</span></span></span></span></span> of vitamin D .</p>
<p>It is necessary to supplement elementary calcium ( 1 g per day) while repleting vitamin deficiency.</p>
<p>Vitamin D supplementation of the pregnant mother is superior to supplementation of the lactating mother because some vitamin D is transferred across the placenta and is stored in the fetus, to be utilised in the first few months of extrauterine life.</p>
<p>Daily vitamin D requiremnt is about 800 units for subjects aged more than 70 years. Vitamin D supplementation is essential in the elderly in whom both skin synthesis and GI absorption are impaired.</p>
<p>The commonest cause of vitamin D deficiency is a deficient intake or absorption of calcium (because of high phytate and oxalate content of a cereal-vegetables based diet); this explains why vitamin D deficiency is common in the tropical countries with abundant sunlight. Further, unlike in the rich western countries, the foods are not fortified with vitamin D. It must be noted that the sun rays which induce vitamin D activity in the skin are in the ultraviolet range and can get absorbed by atmosphere, by glass and by buildings. Vitamin D deficiency can also occur in intestinal malabsorption as in obstructive jaundice; in hepatic cirrhosis, chronic kidney disease, primary hyperparathyroidism and during treatment with anticonvulsants and glucocorticoids. Generally, a serum level of 25 OHD below 20ng/ml is considered diagnostic of vitamin D deficiency.</p>
<p>Vitamin D deficiency leads to rickets in children and osteomalacia in adults, with low plasma inorganic phosphorus, normal or low plasma calcium, hypocalciuria, hyperphosphaturia and aminoaciduria. Unlike osteoporosis, osteomalacia is accompanied by localised or generalised bone pains, and tenderness on pressing the sternum or the anterior tibia.</p>
<p>The commercially available vitamin D , cholecalciferol <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">(</mo><msub><mi mathvariant="normal">D</mi><mn>3</mn></msub><mo fence="true">)</mo></mrow><annotation encoding="application/x-tex">\left(\mathrm{D}_{3}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord"><span class="mord mathrm">D</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">)</span></span></span></span></span></span> is preferred for routine use. Its uses are:</p>
<ul>
<li>For prevention and treatment of vitamin D deficiency: Unless the pregnant women receive vitamin D supplements, there is hardly any store of vitamin D in the newborn, and its administration is recommended from the first month especially in breast fed infants. If the diet is deficient in older children, the daily requirement can be easily supplied by a teaspoon of cod liver oil. Excessive administration must be avoided.
Rickets in children and osteomalacia in adults are best treated with oral or IM dose of 300,000-600,000 units ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>7.5</mn><mo>−</mo><mn>15</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">7.5-15 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">7.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">15</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> ) of calciferol once and repeated 4-6 weeks later, if the blood chemistry so indicates. Simultaneously, calcium must also be prescribed in order to facilitate the calcification of the osteoid.</li>
</ul>
<p>Administration of a single IM dose of 600,000 units is desirable in patients with chronic obstructive jaundice and also once in 6 months in patients on long-term therapy with anticonvulsants and glucocorticoids and in elderly people.</p>
<p>For the prevention and treatment of nutritional vitamin D deficiency, the preparation of choice is cholecalciferol. Alphacalcidiol and calcitriol which are more expensive are not appropriate for that purpose (see later). Calcitriol often causes hypercalciuria and less frequently hypercalcaemia.</p>
<ul>
<li>Vitamin D 'resistant' rickets and osteomalacia: This term is applied to rickets and osteomalacia not due to vitamin D deficiency but due to chronic renal insufficiency, hereditary hypo-phosphatemic rickets and hypophosphatasia. Vitamin D in large doses (upto <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mo separator="true">,</mo><mn>000</mn><mi mathvariant="normal">U</mi><mo separator="true">,</mo><mn>1.25</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">50,000 \mathrm{U}, 1.25 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord">50</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">000</span><span class="mord mathrm">U</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">1.25</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span>, daily) is required to bring about healing of bone lesions in such patients. Alfacalcidiol and calcitriol are preferred in these conditions. Vitamin D requirements for patients with steatorrhoea and liver damage with bone disease are 4,000 to 12,000 units per day.</li>
<li>In hypoparathyroidism: Oral vitamin D together with oral calcium is used to treat hypoparathyroidism. Daily doses of 50,000 to 250,000 units ( 1.25 to 6.25 mg ) of cholecalciferol are needed. However, alphacalcidol or calcitriol is preferred because of their rapid action.
Currently a person is considered as vitamin D deficient if serum conentration is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&lt;</mo><mn>20</mn></mrow><annotation encoding="application/x-tex">&lt;20</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&lt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">20</span></span></span></span></span> <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">n</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">\mathrm{ng} / \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">ng</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span>. Optimal level is believed to be <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>25</mn><mrow><mi mathvariant="normal">n</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">&gt;25 \mathrm{ng} / \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">25</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">ng</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span>. However, supplementation of vitamin D</li>
</ul>
<p>only on the basis of serum level of 25 OHD is not justified. No one knows whether vitamin D supplementation for such level does any good, though too low vitamin D levels is a problem. Rickets or other bone diseases (with lower bone density) are not expected till the 25 OHD levels reach <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&lt;</mo><mn>15</mn><mrow><mi mathvariant="normal">n</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">&lt;15 \mathrm{ng} / \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&lt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">15</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">ng</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span>. ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&lt;</mo><mn>37</mn><mrow><mi mathvariant="normal">n</mi><mi mathvariant="normal">m</mi><mi mathvariant="normal">o</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi><mi mathvariant="normal">L</mi></mrow><annotation encoding="application/x-tex">&lt;37 \mathrm{nmol} / \mathrm{L}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&lt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">37</span><span class="mord"><span class="mord mathrm">nmol</span></span><span class="mord">/</span><span class="mord mathrm">L</span></span></span></span></span> ).</p>
<p>Significance of serum vitamin D levels: There are several factors that determine serum total 25-OHD levels. Apart from deficient Vitamin D and calcium intake, genetic polymorphism can cause low levels of vitamin D. Thus, total 25-OHD levels are consistently lower in black Americans than in white Americans, which would qualify them as vitamin D deficient. However, they possess higher BMD, higher calcium levels and only slightly higher PTH levels than their white counterparts. This is because of lower levels of vitamin D binding protein in the black due to genetic polymorphism. The levels of bioavailable 25-OHD in black are equivalent to those in white Americans. Giving them vitamin D, simply on the basis of low levels of total 25-OHD would invite vitamin D toxicity. Thus, low levels of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mo>−</mo><mrow><mi mathvariant="normal">O</mi><mi mathvariant="normal">H</mi><mi mathvariant="normal">D</mi></mrow></mrow><annotation encoding="application/x-tex">25-\mathrm{OHD}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">25</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord"><span class="mord mathrm">OHD</span></span></span></span></span></span> do not always indicate vitamin D deficiency unless accompanied by hypocalcemia, hyperparathyroidism and low BMD. Too high levels of vitamin D have been associated with increase risk of "stroke and coronary occlusion".</p>
<p>Measurement of serum and 24 hour urinary calcium may be useful for judging the adequacy of the therapy. Urinary calcium should be in the range of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>100</mn><mo>−</mo><mn>250</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mn>24</mn></mrow><annotation encoding="application/x-tex">100-250 \mathrm{mg} / 24</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">100</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">250</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/24</span></span></span></span></span> hours. Levels more than 250 mg should be avoided.</p>
<p>There is a considerable confusion regarding the supplementation with vitamin D. The latter has been projected as a panacea that can prevent and treat a big list of chronic disorders such as cardiovascular diseases, DM and cancer. This assumption also leads to increasing requests for vitamin D measurement in the blood - an expensive test for routine use. However, the effectiveness of vitamin D supplementation has been definitely proved only in rickets and osteomalacia. There is at present no evidence that vitamin D supplements in normal subjects reduce the risk of cardiovascular diseases, DM and cancer.</p>
<p>Synthetic vitamin D analogues: <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mo stretchy="false">(</mo><mrow><mi mathvariant="normal">O</mi><mi mathvariant="normal">H</mi></mrow><mo stretchy="false">)</mo><msub><mi mathvariant="normal">D</mi><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">25(\mathrm{OH}) \mathrm{D}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">25</span><span class="mopen">(</span><span class="mord"><span class="mord mathrm">OH</span></span><span class="mclose">)</span><span class="mord"><span class="mord mathrm">D</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> (Calcifediol, Calcidiol), 1-alpha (OH) <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">D</mi><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{D}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">D</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> (Alfacalcidiol) and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo separator="true">,</mo><mn>25</mn><mo stretchy="false">(</mo><mrow><mi mathvariant="normal">O</mi><mi mathvariant="normal">H</mi></mrow><msub><mo stretchy="false">)</mo><mn>2</mn></msub><msub><mi mathvariant="normal">D</mi><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">1,25(\mathrm{OH})_{2} \mathrm{D}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">25</span><span class="mopen">(</span><span class="mord"><span class="mord mathrm">OH</span></span><span class="mclose"><span class="mclose">)</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord"><span class="mord mathrm">D</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> (Calcitriol) are the synthetic vitamin D analogues used in therapeutics (Table 70.9). Unlike calciferol, calcifediol is absorbed from the gut even in patients with fat malabsorption. It is the drug of choice in liver disease with vitamin D deficiency. It is converted in the kidney to calcitriol. Calcitriol supplies the active vitamin D metabolite directly. All of them have antirachitic activity. However, in contrast to calciferol, which is recommended in treating nutritional rickets and osteomalacia, calcitriol and alfacalcidiol are to be used primarily in the treatment of:</p>
<p>Table 70.9
Commonly used compounds with vitamin D activity</p>
<table><thead><tr><th style="text-align: center;">Property</th><th style="text-align: center;">Ergocalciferol and cholecalciferol</th><th style="text-align: center;">Calcifediol</th><th style="text-align: center;">Calcitriol</th><th style="text-align: center;">Alfacalcidiol</th></tr></thead><tbody><tr><td style="text-align: center;">Physiological dose (mcg/day)</td><td style="text-align: center;">10</td><td style="text-align: center;">5</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mo>−</mo><mn>1.0</mn></mrow><annotation encoding="application/x-tex">0.5-1.0</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">1.0</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mo>−</mo><mn>1.0</mn></mrow><annotation encoding="application/x-tex">0.5-1.0</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">1.0</span></span></span></span></span></td></tr><tr><td style="text-align: center;">Pharmacological dose (mcg/day)</td><td style="text-align: center;">1200</td><td style="text-align: center;">50</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mo>−</mo><msup><mn>3.0</mn><mi>b</mi></msup></mrow><annotation encoding="application/x-tex">0.5-3.0^{b}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8491em;"></span><span class="mord">3.</span><span class="mord"><span class="mord">0</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathnormal mtight">b</span></span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mo>−</mo><mn>3.0</mn></mrow><annotation encoding="application/x-tex">0.5-3.0</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">3.0</span></span></span></span></span></td></tr><tr><td style="text-align: center;">Onset of maximum effect (days)</td><td style="text-align: center;">30</td><td style="text-align: center;">15</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mo>−</mo><mn>3</mn></mrow><annotation encoding="application/x-tex">2-3</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">3</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mo>−</mo><mn>3</mn></mrow><annotation encoding="application/x-tex">2-3</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">3</span></span></span></span></span></td></tr><tr><td style="text-align: center;">Duration of toxicity (if it occurs) after cessation of therapy (weeks)</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>6</mn><mo>−</mo><mn>18</mn></mrow><annotation encoding="application/x-tex">6-18</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">6</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">18</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4</mn><mo>−</mo><mn>12</mn></mrow><annotation encoding="application/x-tex">4-12</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">4</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">12</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mo>−</mo><mn>1.0</mn></mrow><annotation encoding="application/x-tex">0.5-1.0</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">1.0</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mo>−</mo><mn>1.0</mn></mrow><annotation encoding="application/x-tex">0.5-1.0</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">1.0</span></span></span></span></span></td></tr><tr><td style="text-align: center;">Available as</td><td style="text-align: center;">Variable</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mo separator="true">,</mo><mn>50</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">20,50 \mathrm{mcg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">20</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">50</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span></span></span></span></span> capsules</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.25</mn><mo separator="true">,</mo><mn>0.5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">0.25,0.5 \mathrm{mcg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">0.25</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">0.5</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span></span></span></span></span> tablets</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mo>−</mo><mn>1.0</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">0.5-1.0 \mathrm{mcg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">1.0</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span></span></span></span></span> tablets</td></tr></tbody></table>
<p>'Will cure nutritional rickets and osteomalacia.
"Used in other conditions listed above.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mtext>a&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">{ }^{\text {a }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6644em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6644em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">a&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> Dose may be as high as 10 mcg in vitamin D 'dependent' rickets.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="hypoparathyroidism">- Hypoparathyroidism.<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#hypoparathyroidism" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Renal osteodystrophy due to chronic renal failure.</li>
<li>Renal tubular defect with vitamin D 'resistant' rickets and osteomalacia; and</li>
<li>Vitamin D 'dependent' rickets.</li>
</ul>
<p>Calcipotriol, an analogue of calcitriol suppresses cell proliferation and promotes cell differentiation to the same degree as calcitriol but is 200 times weaker than the latter compound in its action on calcium metabolism. It is used topically to treat of psoriasis (Chapter 71).</p>
<p>Paricalcitol is a synthetic calcitriol derivative which reduces PTH release without producing hypercalcemia except in overdoses. It is useful in treating secondary hyperparathyroidism in patients with chronic renal failure.</p>
<p>22-Oxacalcitriol is another calcitriol derivative which is a potent suppressor of PTH gene, with limited activity on the intestine and the bone. It has similar uses as paricalcitol.</p>
<p>Dihydrotachysterol (DHT): Action of this reduction product of calciferol is faster and shorter lived than that of vitamin D and its antirachitic property is negligible.</p>
<p>Table 70.10 summarises the actions of the 'calcitropic' hormones, calcitriol, PTH and calcitonin.</p>
<p>Table 70.10
Actions of calcitropic hormones</p>
<table><thead><tr><th style="text-align: center;">Calcitriol</th><th style="text-align: center;"></th><th style="text-align: center;">PTH</th><th style="text-align: center;">Calcitonin</th></tr></thead><tbody><tr><td style="text-align: center;">Intestinal absorption</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mi mathvariant="normal">&amp;</mi><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">O</mi></mrow><mn>4</mn></msub><mo>↑</mo></mrow><annotation encoding="application/x-tex">\mathrm{Ca} \&amp; \mathrm{PO}_{4} \uparrow</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord mathrm">Ca</span></span><span class="mord">&amp;</span><span class="mord"><span class="mord"><span class="mord mathrm">PO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">↑</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mi mathvariant="normal">&amp;</mi><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">O</mi></mrow><mn>4</mn></msub><mo>↑</mo></mrow><annotation encoding="application/x-tex">\mathrm{Ca} \&amp; \mathrm{PO}_{4} \uparrow</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord mathrm">Ca</span></span><span class="mord">&amp;</span><span class="mord"><span class="mord"><span class="mord mathrm">PO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">↑</span></span></span></span></span> (via calcitriol)</td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Kidney</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mi mathvariant="normal">&amp;</mi><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">O</mi></mrow><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{Ca} \&amp; \mathrm{PO}_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8444em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">Ca</span></span><span class="mord">&amp;</span><span class="mord"><span class="mord"><span class="mord mathrm">PO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> reabsorption <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>↑</mo></mrow><annotation encoding="application/x-tex">\uparrow</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mrel">↑</span></span></span></span></span></td><td style="text-align: center;">Ca reabsorption <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>↑</mo><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">O</mi></mrow><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">\uparrow \mathrm{PO}_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mrel">↑</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> reabsorption <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>↓</mo></mrow><annotation encoding="application/x-tex">\downarrow</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mrel">↓</span></span></span></span></span>, Calcitriol synthesis <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>↑</mo></mrow><annotation encoding="application/x-tex">\uparrow</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mrel">↑</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mi mathvariant="normal">&amp;</mi><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">O</mi></mrow><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{Ca} \&amp; \mathrm{PO}_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8444em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">Ca</span></span><span class="mord">&amp;</span><span class="mord"><span class="mord"><span class="mord mathrm">PO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> reabsorption <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>↓</mo></mrow><annotation encoding="application/x-tex">\downarrow</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mrel">↓</span></span></span></span></span>,</td></tr><tr><td style="text-align: center;">Bone</td><td style="text-align: center;">Calcification of osteoid'; resorption of bone <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>↑</mo></mrow><annotation encoding="application/x-tex">\uparrow</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mrel">↑</span></span></span></span></span> in toxic doses</td><td style="text-align: center;">Bone formation <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span></span></span></span></span> bone resorption on acute administration; Bone resorption <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span></span></span></span></span> bone formation"</td><td style="text-align: center;">Osteoclastic bone resorption <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>↓</mo></mrow><annotation encoding="application/x-tex">\downarrow</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mrel">↓</span></span></span></span></span>,</td></tr><tr><td style="text-align: center;">Plasma levels</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mi mathvariant="normal">&amp;</mi><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">O</mi></mrow><mn>4</mn></msub><mo>↑</mo></mrow><annotation encoding="application/x-tex">\mathrm{Ca} \&amp; \mathrm{PO}_{4} \uparrow</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord mathrm">Ca</span></span><span class="mord">&amp;</span><span class="mord"><span class="mord"><span class="mord mathrm">PO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">↑</span></span></span></span></span> from</td><td style="text-align: center;">Hypercalcemia and low to normal</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mo>↓</mo></mrow><annotation encoding="application/x-tex">\mathrm{Ca} \downarrow</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord mathrm">Ca</span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">↓</span></span></span></span></span> &lt;br&gt; hypophosphatemia</td></tr><tr><td style="text-align: center;">Urinary excretion</td><td style="text-align: center;">Ca normalises'; hypercalciuria in toxic doses</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mo>↑</mo></mrow><annotation encoding="application/x-tex">\mathrm{Ca} \uparrow</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord mathrm">Ca</span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">↑</span></span></span></span></span> due to hypercalcemia; <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">O</mi></mrow><mn>4</mn></msub><mo>↑</mo></mrow><annotation encoding="application/x-tex">\mathrm{PO}_{4} \uparrow</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">↑</span></span></span></span></span> by direct tubular action</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mi mathvariant="normal">&amp;</mi><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">O</mi></mrow><mn>4</mn></msub><mo>↑</mo></mrow><annotation encoding="application/x-tex">\mathrm{Ca} \&amp; \mathrm{PO}_{4} \uparrow</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord mathrm">Ca</span></span><span class="mord">&amp;</span><span class="mord"><span class="mord"><span class="mord mathrm">PO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">↑</span></span></span></span></span></td></tr></tbody></table>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mo>=</mo></mrow><annotation encoding="application/x-tex">\mathrm{Ca}=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord"><span class="mord mathrm">Ca</span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span></span></span></span></span> Calcium and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">O</mi></mrow><mn>4</mn></msub><mo>=</mo></mrow><annotation encoding="application/x-tex">\mathrm{PO}_{4}=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span></span></span></span></span> phosphates,
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>∗</mo><mo>=</mo></mrow><annotation encoding="application/x-tex">*=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4653em;"></span><span class="mord">∗</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span></span></span></span></span> In physiological doses.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mo lspace="0em" rspace="0em">∗</mo></msup><mo>=</mo></mrow><annotation encoding="application/x-tex">{ }^{*}=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6887em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6887em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∗</span></span></span></span></span></span></span></span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span></span></span></span></span> In chronic high concentration.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mrow><mo>∗</mo><mo>∗</mo></mrow></msup><mo>=</mo></mrow><annotation encoding="application/x-tex">{ }^{* *}=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6887em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6887em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∗∗</span></span></span></span></span></span></span></span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span></span></span></span></span> Only in the presence of hypercalcemia.
BISPHOSPHONATES: These synthetic non-hydrolysable pyrophosphate analogues were developed initially as water softeners. They are characterised by phosphorus-carbonphosphorus ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">P</mi><mo>−</mo><mi mathvariant="normal">C</mi><mo>−</mo><mi mathvariant="normal">P</mi></mrow><annotation encoding="application/x-tex">\mathrm{P}-\mathrm{C}-\mathrm{P}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7667em; vertical-align: -0.0833em;"></span><span class="mord mathrm">P</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.7667em; vertical-align: -0.0833em;"></span><span class="mord mathrm">C</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathrm">P</span></span></span></span></span> ) bonds. Their potency depends on the length and the structure of the side chain.</p>
<p>Mechanism of action: Bisphosphonates have a strong affinity for the bone apatite; they:</p>
<ul>
<li>Are effective calcium chelators and get deposited in the bone mineral selectively under the osteoclasts. So the their effects are localised.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="inhibit-the-dissolution-of-bone-crystal">- Inhibit the dissolution of bone crystal<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#inhibit-the-dissolution-of-bone-crystal" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>After ingestion by the osteoclasts, are metabolised to toxic compounds that impair their functions and hasten their death by apoptosis;</li>
<li>May stimulate osteoblasts to release osteoclast inhibitory factor;</li>
<li>Also block hydroxyapatite crystal growth. High doses inhibit bone mineralisation. This is a disadvantage. This property is less with newer compounds.
They are useful for preventing bone resorption and helping to reduce the vertebral and hip fractures in osteoporosis; and in treating life-threatening hypercalcemia. The various drugs used differ in their ability to inhibit bone resorption relative to their ability to inhibit bone mineralisation.</li>
</ul>
<p>It is necessary to correct the disturbances of calcium and mineral metabolism before starting the therapy.</p>
<p>Absorption, fate and excretion: Given orally, their bioavailability is low, 1-3% of the ingested dose. Food, iron, calcium, aluminium, magnesium, milk, tea, coffee and fruit juices interfere with their absorption. They are rapidly cleared from the plasma, with <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span> deposited in the bone, and the remaining excreted unchanged in the urine. They cross the placenta and get deposited in the fetal bone.</p>
<p>Adverse reactions: Bisphosphonates in the doses used are generally well tolerated. The ADR include:
(i) General: Headache. IV injection releases cytokines resulting in fever, joint pains, myalgia and ocular inflammation.
(ii) Gastrointestinal: Nausea, abdominal pain and diarrhoea. Occasionally, they</p>
<p>(particularly alendronate) may cause heartburn, esophagitis and esophageal ulcers. These are relatively common.
(iii) Renal: Renal failure and electrolyte abnormalities have been reported following IV use. Zolendronate is nephrotoxic and can cause acute tubular necrosis.
(iv) Miscellaneous: Excessive doses cause demineralisation of bones. Zolendronate causes hypocalcemia. Fractures of the jaw at the sites of pre-existing infection, can occur during the IV use, of bisphosphonates. These are secondary to osteonecrosis as a result of suppression of bone remodelling.</p>
<p>Preparations and dosage: Table 70.11.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="table-70-11">Table 70.11<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-70-11" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="bisphosphonate-preparations">Bisphosphonate preparations<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#bisphosphonate-preparations" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<table><thead><tr><th style="text-align: left;">Drug</th><th style="text-align: left;">Dose</th></tr></thead><tbody><tr><td style="text-align: left;">Alendronate</td><td style="text-align: left;">70 mg once a week</td></tr><tr><td style="text-align: left;">Risendronate</td><td style="text-align: left;">35 mg once a week <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>75</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">75 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">75</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day for two consecutive days once a month</td></tr><tr><td style="text-align: left;">Ibandronate</td><td style="text-align: left;">150 mg once a month 3 mg IV bolus every 3 months</td></tr><tr><td style="text-align: left;">Zolendronate</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mo separator="true">,</mo><mn>5</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">4 \mathrm{mg}, 5 \mathrm{~min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8623em; vertical-align: -0.1944em;"></span><span class="mord">4</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">5</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">min</span></span></span></span></span></span>. slow IV infusion once a year</td></tr><tr><td style="text-align: left;">Pamidronate</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>60</mn><mo>−</mo><mn>90</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">60-90 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">60</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">90</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> IV infusion over 2-24 hours.</td></tr></tbody></table>
<p>Doses are oral unless specified;
Clodronate, Etidronate and Tiludronate are other bisphosphonates.
`preventive dose <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>35</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">35 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">35</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> week
The patient should be instructed to take the drug on empty stomach in the morning with 250 ml (a glass) of water, in the erect posture; not to lie down for at least <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow><annotation encoding="application/x-tex">1 / 2</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1/2</span></span></span></span></span> to 1 hour after that; and not to eat or drink anything except water for a similar period. In practice, GI adverse reactions can occur even after following these instructions. He should also be instructed to report any dyspeptic symptoms immediately. A patient with upper GI symptoms should not be prescribed an oral bisphosphanate.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="therapeutic-uses">Therapeutic uses:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Osteoporosis: See later. They may be used concurrently with prolonged glucocorticoid therapy to prevent osteoporosis.</li>
<li>Paget's disease: Paget's disease of bone (osteitis deformans) is a focal skeletal disorder characterised by: excessive bone resorption followed by excessive bone deposition, that results in structurally disorganised (mosaic) and functionally weak bone, local hypervascularity and marrow fibrosis. Most patients are asymptomatic, at least initially. Clinically, it causes bone pains, bone deformities, fractures, compressive neurological syndromes and high output heart failure. X-rays show concurrent osteolysis and osteosclerosis side by side. Serum calcium and phosphorus are usually normal; but the serum alkaline phosphatase is commonly elevated. Hypercalciuria and less commonly hypercalcemia may occur. The basic pathogenic feature is increased number, size and resorptive activity of the osteoclasts which erode the bone. Compensatory excessive bone deposition occurs at the sites of resorption.
The current treatment includes the use of:
(a) Bisphosphonates, especially parenteral zolendronate and pamidronate, which circumvent the problem of low oral bioavailability, impair the activity of osteoclasts and prevent osteoclastic resorption; and
(b) Osteoprotegerin: The osteoblasts have on their surface a protein called Receptor</li>
</ul>
<p>Activator of Nf-Kappa B Ligand (RANKL), also called osteoclast differentiation factor (ODF). RANKL initiates osteoclastogenesis by binding to RANK, its receptor, on the surface of bone mesenchymal osteoclast precursors. Osteoprotegerin (OPG) is a decoy receptor for RANKL, competes with RANKL for RANK, binds to the latter and disables it, thus inhibiting osteoclastogenesis. It has not so for demonstrated antigenicity in humans.</p>
<p>The above drugs administered parenterally have prolonged action (months to years after a course of therapy). They induce remission, relieve bone pains and prevent fractures. They do not cure the disease, and recurrence can occur. Further, their prolonged biological effects raise the spectre of possible oversuppression of bone resorption (frozen bone), leading to inhibition of skeletal metabolic activity and osteonecrosis.</p>
<ul>
<li>Several non-controlled studies have reported the beneficial effects of bisphosphonates in patients with avascular necrosis of femur. They have been found to decrease pain, lower articular collapse and improve mobility.</li>
<li>In malignancy: Clodronate orally and pamidronate, ibandronate and zoledronic acid are administered by slow IV infusion to treat hypercalcaemia and shrink metastasis in breast cancer and multiple myeloma.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="osteoporosis-management">Osteoporosis - Management<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#osteoporosis-management" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Osteoporosis is a multifactorial disease in which there is a diminution in the quantity of trabecular and cortical bone mass, leading to increased frequency of fractures. The common fractures are those of the vertebral bodies, ribs, wrist and the neck of femur (hip fracture). The commonest types of osteoporosis are postmenopausal (Type I) and senile (Type II) (Table 70.12).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="table-70-12">Table 70.12<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-70-12" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="primary-osteoporosis">Primary osteoporosis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#primary-osteoporosis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<table><thead><tr><th style="text-align: left;"></th><th style="text-align: center;">Type I</th><th style="text-align: center;">Type II</th></tr></thead><tbody><tr><td style="text-align: left;">Age</td><td style="text-align: center;">Postmenopausal</td><td style="text-align: center;">Senile</td></tr><tr><td style="text-align: left;">F:M</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>6</mn><mo>:</mo><mn>1</mn></mrow><annotation encoding="application/x-tex">6: 1</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">6</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">:</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">1</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mo>:</mo><mn>1</mn></mrow><annotation encoding="application/x-tex">2: 1</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">2</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">:</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">1</span></span></span></span></span></td></tr><tr><td style="text-align: left;">Calcium deficiency</td><td style="text-align: center;">No</td><td style="text-align: center;">Yes</td></tr><tr><td style="text-align: left;">Bone turnover</td><td style="text-align: center;">High</td><td style="text-align: center;">Low</td></tr><tr><td style="text-align: left;">Deficient estrogen</td><td style="text-align: center;">Yes</td><td style="text-align: center;">No</td></tr><tr><td style="text-align: left;">Functional state</td><td style="text-align: center;">Osteoclastic excess</td><td style="text-align: center;">Osteoblastic deficiency</td></tr><tr><td style="text-align: left;">Type of fracture</td><td style="text-align: center;">Vertebral crush</td><td style="text-align: center;">Vertebral wedge; long bones</td></tr></tbody></table>
<p>The bone mass normally increases upto the age of 30 years, after which there is a gradual but progressive diminution in it, faster in women than in men, accelerated after menopause.</p>
<p>The bone mass is best estimated by bone densitometry which measures Bone Mineral Density (BMD) and compares it to the mean in a group of healthy young women with peak bone mass. It is expressed as <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="bold">T</mi></mrow><annotation encoding="application/x-tex">\mathbf{T}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6861em;"></span><span class="mord mathbf">T</span></span></span></span></span> score which stands for its difference in standard deviation from the said mean. The normal value for T score is +1 to -1 . Osteopenia is said to be present when the T score is between -1.0 and -2.5 . A T score of -1 to -2.0 requires only 'general health measures' such as dietary advice, physical exercise, calcium and vitamin D; these measures should in fact be prescribed for all peri- and post-menopausal women, unless contraindicated. A T score from -2.0 to -2.5 mandates antiresorptive drug treatment in the presence of one or more risk factors for osteoporosis.</p>
<p>Osteoporosis is diagnosed when the individual has a non-traumatic, non-pathological fracture of the spine or when the T score is lower than -2.5 in the hip or the spine.</p>
<p>Management: Table 70.13 outlines the principles.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="table-70-13">Table 70.13<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-70-13" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Principles of management of postmenopausal osteoporosis</p>
<ul>
<li>Risk factor control.</li>
<li>BMD determination</li>
<li>Lifestyle changes, diet, exercise</li>
<li>Analgesics as needed.</li>
<li>Short period of bed rest following a fracture of the spine.</li>
<li>Calcium and vitamin D.</li>
<li>Antiresorptive drugs: Estrogen; SERM; Biphosphonate; Calcitonin.</li>
<li>Anabolic drugs: Parathyroid hormone (PTH).</li>
</ul>
<p>The dietary modifications advised are reduction in the consumption of:
(a) Common salt as calcium is co-excreted with sodium in increased quantities in the urine;
(b) Animal foods (except milk) as they are acid-ash producing and increase calciuria, and,
(c) Alcohol and to stop smoking.</p>
<p>A daily calcium intake of 1200-1500 mg with a vitamin D intake of 800 IU/day and regular physical exercise are recommended in adolescents and in all postmenopausal women. The exercises recommended are walking and resistance exercise (weight lifting), under supervision.</p>
<p>In subjects with adequate calcium intake and normal skeletal homeostasis, supplementation with vitamin D probably plays small role in strengthening bone mass. However, in subjects with severe Vitamin D deficiency ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mrow><mi mathvariant="normal">O</mi><mi mathvariant="normal">H</mi><mi mathvariant="normal">D</mi></mrow><mo>&lt;</mo><mn>37</mn><mrow><mi mathvariant="normal">n</mi><mi mathvariant="normal">m</mi><mi mathvariant="normal">o</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi><mi mathvariant="normal">L</mi></mrow><annotation encoding="application/x-tex">25 \mathrm{OHD}&lt;37 \mathrm{nmol} / \mathrm{L}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7224em; vertical-align: -0.0391em;"></span><span class="mord">25</span><span class="mord"><span class="mord mathrm">OHD</span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">&lt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">37</span><span class="mord"><span class="mord mathrm">nmol</span></span><span class="mord">/</span><span class="mord mathrm">L</span></span></span></span></span> ) and/ or low calcium intake, skeletal microstructure is disrupted. High concentration of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo separator="true">,</mo><mn>25</mn><mo stretchy="false">(</mo><mrow><mi mathvariant="normal">O</mi><mi mathvariant="normal">H</mi></mrow><mo stretchy="false">)</mo><mn>2</mn><mi mathvariant="normal">D</mi></mrow><annotation encoding="application/x-tex">1,25(\mathrm{OH}) 2 \mathrm{D}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">25</span><span class="mopen">(</span><span class="mord"><span class="mord mathrm">OH</span></span><span class="mclose">)</span><span class="mord">2</span><span class="mord mathrm">D</span></span></span></span></span> in these subjects results in bone fragility and increased bone resorption. Physiologically maintenance of normocalcemia takes precedence over skeletal integrity; thus bone is lost and its mineralization is suppressed in order to restore circulating calcium concentration. Supplementation of Vitamin D along with calcium would be beneficial in such patients with osteoporosis.</p>
<p>Bisphosphonates are the first drug of choice for treating post-menopausal osteoporosis. Alendronate, risendronate and others have been used in combination with calcium and vitamin D. They reduce the incidence of vertebral and hip fractures, but prolonged treatment over years is needed. Alendronate 70 mg once a week is usually preferred (see earlier).</p>
<p>RALOXIFENE: This analogue of tamoxifen is a 'selective estrogen receptor modulator' (SERM) and has beneficial effects on the bone and CVS. It may be preferred in middle and late postmenopause. It causes dose-dependent increase in the osteoblastic activity. Unlike estrogen it reduces the risk of breast cancer but not of post-menopausal vasomotor symptoms.</p>
<p>Given orally, it undergoes extensive hepatic first-pass metabolism and has low bioavailability. It has an active metabolite. It is used in the dose of 60 mg OD in the prophylaxis of menopausal osteoporosis. Adverse effects include hot flushes, leg cramps and thromboembolic disease.</p>
<p>HRT (Chapter 67) may be preferred in selective early menopausal women with menopausal symptoms.</p>
<p>Calcitonin (SC/IM/intranasal), in general, is less effective and more expensive for prevention of bone loss in women 5 years beyond menopause. However, it is more effective in relieving severe bone pain.</p>
<p>The above drugs do not truly increase the bone mass though they may increase BMD and reduce fracture rate.</p>
<p>Parathyroid hormone (PTH, Teriparatide): Intermittent (i.e. 20 mcg once daily) SC, h-PTH-1-34 increases BMD, bone mass and bone strength by stimulating periosteal and endosteal bone formation. It is the first drug available with anabolic action on the bone. Further, it reduces the fracture rate.</p>
<p>Strontium ranolate is claimed to stimulate bone formation and reduction bone resorption; the mechanism of action is not clear.</p>
<p>Denosumab is a monoclonal antibody against RANKL and blocks osteoclast formation and activation. Given SC in a dose of 60 mg every 6 months, it increases BMD and decreases markers for bone turnover.</p>
<p>Drug-induced osteoporosis: Many drugs can cause/worsen osteoporosis. These include heparin, warfarin, cyclosporine, glucocorticoids, medroxyprogesterone acetate,</p>
<p>antiepileptic drugs such as phenobarbitone, phenytoin and carbmazepine, anticancer drugs and thyroid hormones. Caution should be exercised and perhaps BMD monitored during their long term use. For example, minimum effective doses of glucocorticoids and thyroxine should be used; "injectable MPA as a birth control measure should be used longer than 2 years only if other methods are not applicable" (FDA recommendation). Calcium and vitamin D supplements should be routinely prescribed during prolonged use of such drugs. In contrast, thiazide diuretics and perhaps statins can minimise bone loss. Hence, a thiazide may be the preferred drug if an osteoporotic patient also has hypertension or nephrolithiasis.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="fluoride">Fluoride<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#fluoride" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The fluoride ion is widely distributed in nature. It is of medical interest mainly because of its toxicity and to some extent due to its possible clinical applications. It can enter the human body through edible plants, drinking water, fluorine containing pesticides, contaminated food additives and by inhalation of fluoride dust and gases. Tea leaves contain fluoride; and a case of a female who used to drink 100 or more cups of Chinese tea daily and developed severe fluorosis has been reported.</p>
<p>Pharmacological actions: With the exception of its actions on the teeth in very low concentrations, the actions of fluoride are toxic (see below).</p>
<p>Children who drink water containing fluorine (1 part per million) have been shown to develop permanent teeth which are resistant to the development of caries. Topical application of fluoride solution to the teeth after eruption is claimed to reduce the decay.</p>
<p>Fluoride inhibits several enzymes and diminishes tissue respiration and anaerobic glycolysis in excised organs. It is a useful in vitro anticoagulant.</p>
<p>Absorption, fate and excretion: Fluoride is absorbed from the GI tract, the lungs and the skin. In the body, fluoride can be detected in all tissues but is preferentially deposited in bones and teeth. It is excreted mainly by the kidneys and in small amounts by the sweat glands, the lactating breast and the GI tract.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="adverse-reactions">Adverse reactions:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#adverse-reactions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Acute poisoning: Acute poisoning results from ingestion of insecticides containing fluoride salts. The symptoms are due to:
(a) Irritation of the GI tract: nausea, vomiting, abdominal pain and diarrhoea;
(b) Hypocalcemia caused by binding of plasma calcium (increased irritability of the central nervous system); and
(c) Medullary depression leading to fall in BP and respiratory paralysis.</li>
</ul>
<p>Treatment is symptomatic and consists of stomach wash with lime water, IV fluids, IV calcium and treatment of respiratory and cardiac failure.</p>
<ul>
<li>Chronic poisoning (Fluorosis): Chronic fluoride poisoning is usually reported following drinking contaminated water. It causes two main changes:
(1) Osteosclerosis and
(2) Mottled enamel of the teeth.</li>
</ul>
<p>Osteosclerosis consists of an increase in density and calcification of bones and varies greatly in severity. It results in various body deformities. Mottling affects only the developing teeth, teeth which have already erupted being spared.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="therapeutic-uses">Therapeutic uses:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Dental caries can be defined as "the localised destruction of susceptible dental hard tissue by acidic byproducts from bacterial fermentation of dietary carbohydrates". It is the most common but preventable disease in children. Treated in early stages, the pathological changes can be reversed.
Endogenous microorganisms, mostly mutant streptococci and lactobacillus species present in the biofilms (colonising the tooth surface) produce weak acid, following fermentation of residual food carbohydrates. The decreased pH leads to demineralisation of tooth tissues. This is naturally prevented by saliva which acts as a buffer and raises the biofilm pH . It can also be reversed by uptake of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mo separator="true">,</mo><mi mathvariant="normal">P</mi></mrow><annotation encoding="application/x-tex">\mathrm{Ca}, \mathrm{P}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord mathrm">Ca</span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord mathrm">P</span></span></span></span></span> and fluoride. Once the tooth is</li>
</ul>
<p>destroyed, its treatment becomes difficult, and may need maintenance therapy throughout life.</p>
<p>The fluoride ion is one of the micronutrients that has been demonstrated beyond doubt to have a clear effect on dental caries in humans and laboratory animals. A Cochrane review indicated that the use of fluoride tooth paste or gel is highly effective, safe and acceptable. Frequent sipping of sugar containing drinks and eating sugar containing foods such as chocolate, sweets and pastries should be avoided. Replacing such snacks with fruits, vegetables, cheese or nuts is advisable.</p>
<p>Further, rinsing the mouth after eating, and regular brushing of the teeth with fluoridecontaining tooth paste at least twice a day after meals is advisable. Decrease or lack of saliva helps the pathological process. Chewing of clove/cardamom may be beneficial. It also prevents bad breath.</p>
<p>Fluoridation of water supplies is perhaps the most effective strategy for reducing the dental caries in a community. Systemic fluoride is most effective in the reduction of lesions on the incisors and the smooth buccal and lingual surfaces and least effective for the cavities and fissures of the molars. Hence, sealing the cavities and fissures with inert polymer to prevent the start of new lesions is valuable as a complement to water fluoridation. However, while recommending such procedure, the geographical information regarding the fluoride content of drinking water should be taken into consideration, particularly in the population with anatomic fluorosis.</p>
<p>The best way to prevent caries is maintaining optimal oral hygiene so as to reduce the causative microbial agents. The teeth should be brushed with a tooth paste and flossed twice a day. Pregnant women should be urged to have all open lesions restored and to follow good dietary practices to reduce the transmission of cariogenic microbes to the fetus.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="magnesium-metabolism">Magnesium Metabolism<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#magnesium-metabolism" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Magnesium is an important constituent of the human body. The average amount of body magnesium in an adult weighing 70 kg is about 2,000 mEq . Of this, approximately <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mo>−</mo><mn>70</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50-70 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">50</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">70%</span></span></span></span></span> is in bones, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">1 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">1%</span></span></span></span></span> is in the ECF and the remaining is intracellular, where it is concentrated mainly in the mitochondria. Bone acts as a magnesium reservoir during depletion. The plasma magnesium levels vary from 1.5 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2.0</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">E</mi><mi mathvariant="normal">q</mi></mrow><mi mathvariant="normal">/</mi><mn>1</mn></mrow><annotation encoding="application/x-tex">2.0 \mathrm{mEq} / 1</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">2.0</span><span class="mord"><span class="mord mathrm">mEq</span></span><span class="mord">/1</span></span></span></span></span>; nearly <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>33</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">33 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">33%</span></span></span></span></span> of this is bound to plasma proteins. Cardiac and skeletal muscles, liver, brain and kidneys contain appreciable amounts of magnesium.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="physiological-functions-and-pharmacological-actions">Physiological functions and pharmacological actions:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#physiological-functions-and-pharmacological-actions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>CNS: It is a CNS depressant and low magnesium level may evoke increased irritability, confusion and convulsions. Magnesium also possesses local anaesthetic activity and depresses myoneural transmission by reducing the quantal release of acetylcholine and by antagonising its depolarising effect at the motor end plates, and by reducing the excitability of muscle cell membrane. Administration of large doses of magnesium resulting in plasma levels over <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">E</mi><mi mathvariant="normal">q</mi></mrow><mi mathvariant="normal">/</mi><mn>1</mn></mrow><annotation encoding="application/x-tex">10 \mathrm{mEq} / 1</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">10</span><span class="mord"><span class="mord mathrm">mEq</span></span><span class="mord">/1</span></span></span></span></span> can produce fatal respiratory paralysis. The CNS and the myoneural junction depression produced by magnesium can be antagonised by calcium.</li>
<li>CVS: The cardiac muscle appears to be less susceptible to the depressant effect of magnesium than the skeletal muscle. However, heart block, prolonged PR interval and widening of QRS complex may result if the plasma level exceed <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">E</mi><mi mathvariant="normal">q</mi></mrow><mi mathvariant="normal">/</mi><mn>1</mn></mrow><annotation encoding="application/x-tex">10 \mathrm{mEq} / 1</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">10</span><span class="mord"><span class="mord mathrm">mEq</span></span><span class="mord">/1</span></span></span></span></span>. Magnesium causes peripheral vasodilatation and may cause hypotension.</li>
<li>Miscellaneous: Magnesium is a co-factor of many vital enzymes like membrane ATPase. An activating role for magnesium has also been postulated in the uptake and storage of catecholamines within the osmophilic granules of the sympathetic nerve endings and in the activation of ribosomes by the messenger RNA.
Absorption, fate and excretion: Magnesium and calcium probably have common transport mechanisms across the gut and the renal tubules. The daily intake of magnesium in Americans is 20-40 mEq and of this, nearly <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>3</mn><mrow><mi mathvariant="normal">r</mi><mi mathvariant="normal">d</mi></mrow></mrow><annotation encoding="application/x-tex">1 / 3 \mathrm{rd}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1/3</span><span class="mord"><span class="mord mathrm">rd</span></span></span></span></span></span> is absorbed from the GI tract. Low levels of magnesium intake enhance calcium absorption. Magnesium is excreted by the kidney by glomerular filtration. Increased urinary excretion occurs in hyperparathyroidism and in diuresis induced by glucose and by thiazide/loop diuretics. Only 3 to 5% of filtered magnesium appears in urine; the rest is reabsorbed. PTH appears to be essential for both its GI as well as renal tubular reabsorption. Renal impairment may cause magnesium retention and toxicity even with oral magnesium salts.</li>
</ul>
<p>Magnesium deficiency: Table 70.14 gives the common causes of hypomagnesemia.</p>
<p>Table 70.14
Common causes of hypomagnesemia</p>
<div data-testid="stMarkdownPre" class="st-emotion-cache-acwcvw e1icttdg5"><div class="stCode st-emotion-cache-6ml83 e1xss9yb4" data-testid="stCode"><pre class="st-emotion-cache-1nqbjoj e1xss9yb2"><div style="background-color: transparent;"><code style="white-space: pre;"><span>- Severe and continued diarrhoea or fistulour discharge
</span>    - Chronic alcoholism
    - Diabetic ketoacidosis
    - Hyperthyroidism
    - Thiazide/loop diuretic therapy
    - Intestinal malabsorption
    - Hyperparathyroidism
    - Renal tubular acidosis
    - Aldosteronism; and
    - During recovery from acute tubular necrosis</code></div></pre><div class="st-emotion-cache-chk1w8 e1xss9yb3"><button data-testid="stCodeCopyButton" title="Copy to clipboard" data-clipboard-text="- Severe and continued diarrhoea or fistulour discharge
    - Chronic alcoholism
    - Diabetic ketoacidosis
    - Hyperthyroidism
    - Thiazide/loop diuretic therapy
    - Intestinal malabsorption
    - Hyperparathyroidism
    - Renal tubular acidosis
    - Aldosteronism; and
    - During recovery from acute tubular necrosis" style="top: 0px; right: 0px;" class="st-emotion-cache-1lyayqq e1xss9yb5"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><rect x="9" y="9" width="13" height="13" rx="2" ry="2"></rect><path d="M5 15H4a2 2 0 0 1-2-2V4a2 2 0 0 1 2-2h9a2 2 0 0 1 2 2v1"></path></svg></button></div></div></div>
<p>Magnesium deficiency is characterised by weakness and mental disturbances like restlessness, and aggressiveness. Involuntary movements, and rarely tetany may develop. Cardiac arrhythmias of ventricular origin have been reported. The serum magnesium level may be as low as <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.8</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">E</mi><mi mathvariant="normal">q</mi></mrow><mi mathvariant="normal">/</mi><mn>1</mn></mrow><annotation encoding="application/x-tex">0.8 \mathrm{mEq} / 1</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">0.8</span><span class="mord"><span class="mord mathrm">mEq</span></span><span class="mord">/1</span></span></span></span></span>. A low serum level, however, is not necessarily diagnostic of magnesium deficiency.</p>
<p>Magnesium deficiency is usually associated with low level of intracellular potassium, particularly in the skeletal muscle. The plasma potassium levels are usually normal.</p>
<p>Acute hypomagnesemia stimulates PTH secretion; however chronic hypomagnesemia impairs PTH synthesis and release, and causes hypocalcemia. Such patients show symptoms similar to hypoparathyroidism; however, they do not respond till magnesium is given.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-uses-of-magnesium-salts">Therapeutic uses of magnesium salts:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses-of-magnesium-salts" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Hypocalcaemia resistant to treatment: It may respond only after administering magnesium.</li>
<li>In magnesium deficiency: Magnesium deficiency can be treated by daily administration of approximately 300 mEq of magnesium given as magnesium hydroxide mixture. If oral medication is not possible, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4</mn><mo>−</mo><mn>8</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">4-8 \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">4</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord">8</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span>. of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span> magnesium sulfate can be given IV slowly.</li>
<li>As antacids and osmotic purgatives: See Chapters 43; and 42.</li>
<li>As anticonvulsant: Magnesium sulfate is used to control seizures in toxemia of pregnancy where it is considered superior to diazepam and phenytoin. It is administered during labour and for 24 hours afterwards. A <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">20 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">20%</span></span></span></span></span> solution is usually administered IM or IV for this purpose. In toxemia of pregnancy, parenteral magnesium sulfate also achieves a moderate reduction in blood pressure. Care must be taken to keep a calcium preparation handy to counter excessive central depression with magnesium.</li>
<li>In cardiac arrhythmias: Hypomagnesemia is known to occur in the immediate post-MI period and may be associated with cardiac arrhythmias. This responds to IV magnesium sulphate, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow><mo separator="true">,</mo><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">4 \mathrm{ml}, 50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9444em; vertical-align: -0.1944em;"></span><span class="mord">4</span><span class="mord"><span class="mord mathrm">ml</span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">50%</span></span></span></span></span> given over 15 minutes. It may be repeated if needed.</li>
<li>To lower raised intracranial tension: Hypertonic solution of magnesium sulfate is sometimes used rectally to reduce increased intracranial tension.
Local uses: Magnesium sulfate in the concentration of 25 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span> in glycerine is used topically for alleviation of inflammation. It acts by exerting an osmotic effect.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="section-xiv-drugs-used-in-common-skin-and-eye-disorders">SECTION XIV Drugs Used in Common Skin and Eye Disorders<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#section-xiv-drugs-used-in-common-skin-and-eye-disorders" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="outline">OUTLINE<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#outline" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Chapter 71: Pharmacotherapy of Common Skin Disorders and Skin Protectives
Chapter 72: Ocular Pharmacology</p>
<p>71</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="pharmacotherapy-of-common-skin-disorders-and-skin-protectives">Pharmacotherapy of Common Skin Disorders and Skin Protectives<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacotherapy-of-common-skin-disorders-and-skin-protectives" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Skin diseases are common in clinical practice, more so in the warm and humid tropical countries. It forms a barrier between the organism and its external environment. The skin, the target tissue of drug treatment, is also a route of drug administration. It can act as a drug reservoir and is also a site for drug metabolism. It is important in regulation of body temperature and water loss. Application of drugs to the skin can affect the function(s) of internal organs.</p>
<p>Anatomy and Physiology of the Skin: Anatomically, the skin consists of three distinct layers (Fig. 71.1):
<img src="data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0aHBwgJC4nICIsIxwcKDcpLDAxNDQ0Hyc5PTgyPC4zNDL/2wBDAQkJCQwLDBgNDRgyIRwhMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjL/wAARCAHxAjcDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD3+iiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAqpqNsLuxmhIB3KSPqOlW6awoA4vWIzf6Ba3KKpmt38t8jj5eoP1Iq5N4ogj8LTapJYNIsOY3gO1dxHUAtgVYFuv2jVNOb7sqiWMY/E/rWBY2lzrGnxaabe0mtFuCbyKdiHAz/CMHnGaANPwfdmcXCGymso5sTxwSsCVVuMDHGOM11q1xf2Y2HjRNTOqI9hcReQIsjEZX3/ABrVvfGfh3TgxudYt49pwfmzz+FAHQUlcFffFvw1au8dvNNeuBkCCMnd9M4rPf4qXt2Y/wCyfCupXCuPlaRAoz+fSgD0wnFGa8vXxB8TdRZDB4dtLAZ2t57k/jwDT38PfEjUsi+8RWlqqn5BbRc4PqStAHpLzLGpZnVQOpYgVQufEOk2iO1xqVpHsGWBmXI/DNcL/wAKllui39peK9Wukflo/NZBn1GGrRs/hD4UtmWSW2mu5guGe4mZ934E0AWrz4peErMlTqglk25VIo2bd9MCseX4w2Eir9g0XVL3ccfJCQM/jiuvsfB/h7TkVbbR7JdpyCYVJ/PFa0VrBBH5ccSIuc4VQBQB5uPG3jfUAW03wftVG+Y3EgHH/fVK1l8TtXLg3lhpSN8w2gsV9uQa9M2D86AgzQB5efhp4iv5GbVPGd4yyD94sCqvPt8td34d0X+wNFg077VNdCLP72ZsscnPNa20UuKAOb8b6dc6r4M1Wws4vMuZoCqJkDJyPX6U/wAF6dc6V4P0qxu4zHcQQKkiZBwQOeRXQEGgLgYoA8sTwZrU/ijxlMAbWHUoQltNuGCcdMVz+neE/E9t4Ufw1H4atIpCrrJqUhQlxnIxzkE9Ole5bfwpcf5zQB4vH4M8Rv4d8KQS6dtn066PnKHXhBwG611fhDw9qOleN/FWoXduUtb6UNA+4HeMn/Gu920Y6c/jQBVvoJLmxuIYZjFJJGypIvVSQQD/AFrxm48NeMZdJuNDv/D9nqJZmEWqOVDKpPBPIP6V7hto2j/69AHkq+BNXstU8EBEE8OmKwupdwwhO3157Vta74c1G7+Jmiavb22+yt0YSuGGFP0r0Db+frSbc9aAPFNI8NeKPC15qcdv4as9TlupzJHezMp2A+xOePpRpHgrxHb+CfFulXWnAXd/MJYTGw2uSyk456da9sxSbf8A9VAHlnifwfrN14G8OrYW/marpYiY27MMEqvIya73w7PqV3o0Eur2YtL0j95CpBHT2rWK5GO1KFxxQAo6UUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABSNS0UAYeq/wCi39leAkAsYZP905P8wK54209n46ltrSQw+fG8xUH5ZTkYDD2ya67VbUXenTRY525B9xzXLapcbf7H13kMpCS8c84zQBwifCG6t/OOr3slzYKgm2rLjbJuO4AY6YArvdL+GfhC2RZU0S3kZ0GTMobPH0qXV5U8U+Xp+nstxbRz7b1o5QpiIwQPfOa29BnM2mRqTl4yUP4E4/QUAPstC0zTdv2HT7e32jC+WgGB+FaKrgYwBS80tADdtG0egp1FADdvNOoooATFGKWigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoozRmgAooooAKKKM0AFFFFABRRRQAUUUUAIRkGuRvLMSabqumMP9W5nQ+gPIxXX9qw9RUW+tWk5ACTAwuT79KAMjS9WsdC8KzajcxhUjfa0kUJLSMccnA5Namjzqb+6RcBblVuY1PXaQBWZoCxwapf6VKFKBtyggHd1z9Kkt7G90nxE9zc3STQXsnlrlMGFNvCj0GRQB1nWnU3nNOoAKKM0ZoAKKM0ZoAKKTNJkZ60AOopm4etOzQK4tFNzRmgY6im0UCHUU3NKDQMWjNJQOtAC0UUUAFFFFABRRmigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAEDAjjmjIry5/HHjW5mYWnhTy0bOxppOnpnpXKax45+JKKBNbWdgFblm+XIP1NA+Vnve4etLkV8zX3inxvDiebxXaoHPCRXKtj8Acirul+K/Ev2qCCPxpDcX1yQI4JE3qPqQaA5WfRmRS5ryx/E3xC0yNhcaLZ33O0Nbvg/UjJpI/G/jV45JJfD9tbrH97z5wn86B8kux6nkUbhXi1x8VfEgke1NjpttOVOHlul2j9ea561+L/iTR9SSXVJrS/s2bDxQ4yvuDk0C5WfRWRSbhmuc0nxnpureFRr8Ql+zDhlClmUgDIwO/NNg8V6frWm6i2lzO0lvGwbKkFDgfyoEdEZ4lODIoPpmnhh1zj615Vb6zoMVsrSxySyv9+R8li3c/nUy+KtPtx/od5eQjqFwSp+oxTsaui7HqG4UZrgdL8VanqzSwWtxbF0wd7wkcfn1rAv8A4n2FtqEtpeaxPG8JKP5Fsy8/WkT7N9T1wsB1pA6nvXhzfEzQriQMYdYvkXIEoGQT+C112iS6fr2jjUIIbq3Qk4EhIcY78gUFKlc9EDCl3CvL5vFdvbxNJBq17sPC+aeOO/QYFVT8SrmONVS4jdyPl+Qnd+OaCXTkmetbhRuFeQzfETVSoSW4ghBGdyockenXg1v2uqrfRQhtfmVpQD5YkG7J7dKBqm2d9uBpdwxnoPevONavtT0y5RLO9nXcmWe4ceWPx9ag0v4jC2sZEuc31zk7WRsA+2aBSpyienbhWZrcDXGmTeUu6WP94gH94dK4C3+LlzcyyRxeGLgmPqTcAA/Q4qxYfFOTUA5/sC6iKsVwW3Bj6A4oJ5Zdi3qU4luYNQhleCO6gZXkDEMnGGb2xW5PYi18MxQi7kuWi2uk0z5Z/mzknvxmuF1XVvIuI44LK8FpcxsqxTtsKbhhtoIyRium1fwu+rXOlar9umW1sbY/6Iuf3rbT1oBprc7C3nWW3ilz99A3PXpU2c14be+O/FkcjafpOl3DlG2q3ksAhPQHI5xVu30X4kX+Li88SLp+5QTHGM8/nxQNQk9j2beOaN4rxyT4faiF8658ZXm4nLsW2rnvUzeFNKhiLy+Lr35B8zfa0A/lQUqUmeul1AyTxSedF/z0T/voV4tLo/haaMpJ40uHQ9Va+T/Cqf8Awifgf/oapMf9fy0D9jLqe4XN5b20Ek00qrHGpZiT2H/6q4rVPiH9mYCy06afdwgJ2lvfHcVyFl4f8B2jIX1tbghw37y8Ug+3v/8AXq/F4eiS3mu4tXiNkCWZ4vmIU9AMGgpUrbl+Lxl4omVmNlbWiknZ9obbxR/wkevEMP7WsN3RtgyB+NZaR+HIEjnEE9x1AaeTaBnnPSqU/iTSo08u00xCWYD72QAehOKZShFG7/bOpoo36wM9CxnwM/Sr9lqXiG306aWDULfU5AchO6D69TXINq/nkgaYhjXqVP3j6Vb0vxJLYy+Ra6VBA0sgDRlsFu3U0D5YvoaR+JF4GZfLmO1ipxbcAj8ali+IV5KhfPlgf89IMf1qz4k0u6e0F9Z5jkiXm3VchmPXNco1lqxdnS1iUt9/MZYn9aBOmjoE+J00ZfKwXKD+6dpX8K1rD4lWU8Ye5s541IJBQbskda83uNNvInV0gEbxgsySAIGX2JqG0F3J5b28rrE7GSIOu4f3Tt/HvSI9mrnuOk+ILfWJWWGCZQEDhnTAIPQitkVyXgKC6XQ2uL0t58khXLnnavA/SusBFBkx1FJupNw9aBDqTNJmgnAoAMj1FLurxka14g8b+M9U07T/ABANGt7Bwixg5MnvjNavh+98W+G/FT6TrtzNqmmvEZFvzCwCHGeT09aAPUcilzXlvgv4lQarret29/ex7I5v9EAHWMEjJP4iujtfiX4WvdUGnwakjTFN+7+HH1oA6+kzXCSfF3whHfi0a/beW27xGdmc4+90rL8dfEcaHrGh2tldQCC5kD3D43YjIOCDn6UAeoUVi2XijSL/AFBNPtrpXuXhE6p3KEAg/rTh4k0w6pdab9pX7VbR+ZKn91eef0NAGxmiuEm+LXhGC5jgbUtzSNtBVMgHOOT2qe6+KXhSz1GKxfUlaSXG1o13IM+rdBQB2lGaiilSaNZI2DKwBBHcGuf8Q+OtC8MuqaldhZGxiNBub8qAOlzRWDpvi7RNX0mTU7S/ia1i++5bG361k6f8T/C+pamNPhv8XDNsXzF2hj7HvQB2maK5bXvH/h7w1cvbanfLFOiBzHjJwelVk+JvhaS3My6guAgk2kYYjnoPwoA7LIorn/D3jHRfFFvJLpd4svl/fQ/Ky+5HWsi++KnhOw1U6dLqGZlbazIhZFPu3QUAdvRmsa68S6VZW9pNPdoqXTBISDncT2qXUte07SZLOK9uFie7fy4Qf4m4/wARQBqZork9Z+IvhvQJ57e+vws8DBXiVdzZPt+NVbj4q+E4NOjvTqAeN+0a7mH1A6UAdtmis3R9Zsde06O/0+dZreT7rCigD5jn8ZTOzyXWuarNKFwvlbI0J9CCOlVLy9tL7yJX0yQpMceZNcFtx+gbisI3LLcCb7OpuVJMmRkOf93t+Feu+EdVtLHwxJq3iGzt2hVwkbJagbencj3oNotyMHR/htBqem3FxPqFrbQsMtncGh9stwayv7H8D6dFJK+qahc3FvJhkhXCyEHqG28D8asfEDxPYazeW50e8dbM4Etuo8tcjuduM1y11FNexxvbW8kkWQN0cYUfTjk/jQDdtj07T/HI13STodnI2kMAI4byZ9xK9D681yXjnwzrHhuaJn1G61CzuBnzg7Yz6YFaHhv4Y6zqzxzXKtp1mAdpfl2yOw7fnWb4j13xDZ6Qvh68RktYnZY5m/1kgz1z9KY5N2vIq2t/BFp6wmRWlVRIGCFpD+L5FLql3BqtqkccWpzXUkfyDykCN+S1LpHivTNKto3GhW1zOjAZnkZieOuDkAe1bc3xSe8tYobO0stMuACCfIBUjsBx1pCWx1fwYuJYPB2sgQvP5EjOkCgE7sDgA/Suh8EjW5vCutS61DsneV2jXChgm0YB2/TvXK/AKV3vtbVnLKUjYDPU5bNbXh+8F78RNbs9Bu5DYJGzXsVydwMhXClCc45xxx3oMepl+II1tDdiODcs0UUkcoUjyiEAIz0681zctlqSQiT7QzJ5Pn71wRs9cgV1Ta1Jqdk9o6rBFBM8RgbBMpU4yfQcVFb2TPdolvGPMlDKIyfkZf7xHZRngdfm6Uzq3KXgua8h8RRMVZ0kASUynAT0xjg9evNV9UtIbzVblbqZoWkkyY5IgXCjgcgY7V1OkQ2ata3Fut3fPD0KIsa8nkkAjPTvXOXuuXtxrV5PJbhznauyEHC+jZAyetA7OxWSz05XKx2QnAwBvDgD6bcCtDTdY1HSmxYWMjWvmfvY1ViAO+M1St9eM06QsNiMcbtqhU9ziuhQqZoodN1drqTfyFXbGB3yTigEuxt69pkDwRXyW0OIFZ5IWBCuCOeB3rDubZtVt4GNvbwhfmUQkD6ZrqZn1Z4XT7NajcpXJcn17YriLzQtV0uye8vV85UYlltDlsH0BxQU2PPh4nvkem9aoagbbQJ7drqeWJ2bKMmGCkeuOlaek6UmqwtLHLeRIsXmBmA+b269eaybfU5LVJo2tZLlg+1oJ4Vbav49TQJnSR2t7q+kC4muEmt48u4lHDY9cdKxxrQmgZY1SJd20COMBVx9eakPiS+ksXtRAkMMilTF5aqQD64FZMmpCwCj7ILgtjC8DA/woBs2UnMmSiZQcZDqufzqC5u5gksMOoNZSrGZFgjClrhugGcYFa00umxaMNQ/sSV0SMPI/mfIp745559q566vrXVMQW1obeQt+7aH5pM+2aBNmzpWuyx6bAl9CjN5rLKHUuyAgdPwrvdK1q3g8Mxzg+bKofy4QQJHOSQADz0rj9Oh1JdBm03+ywsvkNi4mABZsdeDweKt+HtQj0C2jt9QsjPqBlxbKuHfleu49O/ekZ1E7D/EWnalqeowyWGoyaR9rgE8ihVJzgZB4PPNebajb2tvJLZzeP72WQDDJFEWz7cLXod94luLmeVb5bW01S3dhHCjlm8rn5m4wM8d6860nxRew6vci18O2F2XPmK7Kgwe5z700KDViCzstNklRYYPEmpoUy6kmNf1ArctrbSII0U+AtTmZedzzsT/AOhYqy3jLxarfKmi2a9fIZxlR/3zWa3jbxFOWZ/FejWzHrCIyduPfZQXc2ReacMf8W6uQPr/APXqS3m0+4vIoT8Pp4ldgC7nhR69axtMfxPr2pKtp40sppywZ4oty5X2+WvX5ZvIt2mmkARFy5PoKC4xucrfWHhXT7lbZ9FhkmxuKKDx+OaZZ38kXmW+l+HAts/3xISFP5muc1DXNXknKSWqmeTnJAXbHnjNMOq6k6t5t15UePuRysePxxQF7Gzq9nqGppCW0mO3WM5O1wAfzNS6Tp5glhA0CCVWkUPMZATj8GxXNm7mmlV45buNY3yFeUneenPPSrVgl7e30cNrLIZC27YrleO+BQB1Wr6laWVwlva20L4XdJIEZwvt8vesibWpjKoihWMJyzrFhh/30K2dT8Mn+z5WsJpYJHO+Rldhlf4h1+tcibeQmSeKE7ANqSTSE5OR07npQNsutrOo3U8qPqE5QDDGOLAP6VH9puIgJvPfOf8AVSHGaZ9n1CaQNl5flzmNwi59waI7GR5XLbJtoHMs2Py5oFcu6bqtxbagxulV7Z0x9nfBGSDyCee/rWjpl1p4h1BLHT/IuFTCknKlmIwBn3OawLyKO0tzPcpbhBn5muSen41c8BXUWr655djb/wCjBg8sqSMV4xgYJ+lDJcrIuwWHxStYFht5dPMaDCkg8j161L5XxY/566f+R/xr1MKMUuPYUjlueV+T8WP+eun/AJH/ABo8r4s/89dP/I/416pgegowPQUAcB4cj+IKazGdckszY4+cRDBNd4TwSe3NPx+FGDQB43HofhX4j6pqFxbtc6RqtvM0cnlyBWYjGDj0qvoR1rwh8RbHw1LrY1TTb1WDJKQzRjB64x6frXYeIfhXpGt6i+o29zdaZeyHLzWrkbvwzVjwv8NdJ8NXhv8AzZ76/brcXDliPpkmgDhvCtlbwr8QiIYvMjuH8s7BlVy+QPQdP0pnhXTtC034NPrF3YhpDE4kkj4kYEdM5ruovhppMGt3upxT3SNebvOiWQhGLHJOM1oWfgrTLTwg3hohpbFlKnceeaAPHJYtal+GNwLfw3plloxh3x3LtvlYbuOc9eKn1G3hksfh60qIxdtrO4HK7W4Pr/8AWrubb4O6bFBJaT6tqU9gQRHaNOwjQfQH8a0r74ZaRf8Ah/T9IllnCWDFoZkchxnPGQfegDn7NYbb9oK5AMcSf2aERRgDOF4FZ8DRyfFnxWyMpH9n7cgg4Pz11Gr/AAr07VhYy/2lfQX1onlrdpIfMZfc55PFT6D8MtI8P3V1dW89zJPdQmKV5JCS2e/X3NAHnvh3RtP/AOFL6zdmzia4laRmkKgnIPH0q1P4b0uH4Cm4Wzi89YlmWXHzhiw5z+Jr0iz8D6bZeFbjw/E0htZixZieeaml8H2Evg4+GS0gsjGIyQfmwCD/AEoAd4KeWTwTo7ysXla0jJLdSdorz/wZaQal8WfFcmqwxyzwsBAkvzbBk5wDXqek6ZFpGlWunwEmG3jWNC3JwOK5TxF8NLDXNX/tWC9utOvjgPNbOVLDuDz3oA848Yp4d05pNO0CdglzqCDUQmQkXI74x6V1vxL0bRrD4cq1tBFHJCYjayRqAWbIx83fIzW/Y/DPw/ZaFdaV5MkyXTb5ZZXLOW7HJPByB09Ky7X4Q6fHeRSXusalfW0Lh4raeZiikdO/NAHJaZpEPiH4r2H9s2qSkaPHI8bcjcFWrmm6Dp7/ABzv4jaRGG2tFMcZX5Rnf2r0iLwlYxeLT4jXd9r8jyAoOFC8f4UW3hKxtfFdz4iRpPtc8YjcE8YGf8aAPKtXt20Lx74nXSc2/n6b5hSIAc81X8K2Gs3Pw7WO20jQ5rGZGMlzcFhJknkk7uCK9cfwjp7+JptdYM1xLAYGU/dKnP8AjXMXvwf0+5ndYNW1C2sZHLSWaSt5bZ5xjNAHB3lu9j4K8Kx3V9DdGLUuJoz8u3PAya674lSRTa/4KSOSN3S/BKqQSBlP8K6bUvhtoGo+FoNAMDQ2sBBjaI4YN/ez1JrI0/4P6TZ3tpfT399dXdrIHjkllY4wQQME47UAZOgaRZ3/AMa/FMl3bRzmKJDHvXO3KoOlZ/w60LTZk8ayTWkLMlzLFGWAO1eTgD8BXp+neFLHTfE2o67Cz/ab8ASgngYxjH5CotE8HWGhR6qlrJKRqUrSzbmPDNnOPzoA5j4Irt+HsYyBi4k6Ciuu8L+GLPwrpH9m2LyGHzGky5ycmigD5tOn6FYzxzJPq2nz8gJJbbiePdqs3fiKa/hbTU8QynT3GGElqFA/8e69K9Wvb/Vf7YFkr6fcXDWZeK32bS8uDznPAzWZol74f8Ps2lIqz6vdM00sCEOFkxyu4DjgDj3pnTybanjj21jZvMtvfWV8CNq7hls+wrV8MT+JrKRp/DulyCRF2yn7w574x7GuutNPvNa8U39xa2GmaVeqAJIbld7qhH3l5HrT/CGqXPhq61fTzEuq3UcyqZYAd7A55JB6D096COWzMHVvGHjPS/LFzeX1uzNiTzosAH25rmr+YavI0l9rN3ctnLb4ywHHbLcV6XqOk3+j6/DrPiovq1kZEKFDhbUk4+ZeTjp6Vrapp2maRYjV9Nu3hS7mEpTaGEpwAFGOg4FBThc8ij8P6U8If+30RsZKmIZB/OpLPSbq20y+v4RbNp9vKEe6kj3MRzjav4V7l4fso7LR5by+haN5CZZTPghR2x6CuS1bUPD+o+ILR9ZmLaXMWECbMRnoAx9utAez0uZfwVuYo/Hl7ELgFZoPk/h34z2/Guu8MXNna+PL3TfC+mFoDI327UJXzuOM7VyK53whpOmt8brg6WI/7PtYi6+U+VUn/wDVXaeGr7wvq/jq9Gl3NxDd2pIa3DgRSnoW2456+vakYS7Hn3iDVdPsPEj2jOZL0XLtJGEwMZJG41tWvifUoXlvLfT7UtKoLZk4IGeOnHWpZrDRf+Eg8QWuvwIZopfPgZBh2QjJAPOevSuD12HwxqJVfD2nXixRqZJLmRCeeOOmKZtFux3um+JrnT2nvrnT0+0ScSbJ/lAHYDHHU0t18QFubdol0qDDgq3nTEDGPXBqsfBvhIWsTRRy3NzIMtKZM4P5Yz7VcPgW307Tbi7ubq7mgCb0tQwXaegO7HFBprY5G/vEZrOK30aG1zIAT5mcqR/u+9egW/2D+xI4o9Nie3VdrzyMFAOM9cdaXw94d0K80yC9ktDcykdbhhIyn04ArI8QeH44vEVpDpEkNlDOrC8ycpk42kjPB60BZrUfdyXrWwnsbtvNZ8JB9oIXaP8Aa7n2rPz4qJVm+0QxD77Bi2c9iOwqe7iv9Hu4bGTUNOmMwG2Yx48serfNzVmTT/EyWc5g0+wvT1huN42suP7uSc596ALWga1f2KzWt0lvIu8vGiTcoDknt+lVdQs7nW9VnukmktRgACOES89zkkVnxWviu20STU7+4jsHJwLeOMuz/jmr2i6Z4z1KzeebUUs8t+7RkJLD1PNAaDn0GO3tzLPd3O1Bl5XtwOPU81j6lo9v5Rv7eQXEMK4llb92Ysjj1yDkVHqGq6rbatLpVxf296mRHvPCq3RgRkkgDB6960xpNnNoebnxC4t5zjbEm2MsDzkZ5H49hQLfYp6b4hsJtOt9O1S/tk0xFO63V8yPn09a0XuPDxvbSPRJxZ3skoAaWEbpPYMDlfyrK0vwJp+qTGODWbG4jALYgj/eAZ6feOPyqh4w0DRvDTC1064vTqpjMqM8y7UUdccdelAao6vVBq9t4itbPUbiX7BcAAuspLbjkEdOccc1N4IvwNWu7cxoLhWeO3WY5JYAkHJ6ZrO0fTNXtPBCatb+IJJFMRuAki7ucHjr/s1eOjJfeJLPWrjyzBBFFcGAL952IXdx0/KkTJ3ibGseEYo/CupXssUUWq3WGnkVt4PbGT2Gf0rgG+FWm6LpX2zWtckS2UZfykyD7g5r0PVU8WWNpc393NHfWa3BK2UERLyQnIAzk8jg9Koaf4cj1O3eWV5UnBKhJBkRjtxQRRSbOL0/T/hfuZCLq5lYbQZVyW9xzWwB8P8ASbVLePQpbk5PBtwzH681TutA8ezeIIbD+1FiiKlhdQQ4VRzgH34q4/w58US3PnzeJUeTHLNCcn8Qe2aZrqKniLw5pUi3OleEroXIONy2oQqPqCas3fjXUdZ0q4gtfCuousg2En5f1rj/ABPY+INH1vTtPm8UvcXk7hRtTBjHYn1ruD4A1q4iij1PxXeyEN8wjGwMOhoC8jmodZ1fULmS2bw7m8RMlJ7ohlHr93pWb/wnNzbajLY3/hy1urgYVVjbdk+521S13w5pkvi230PRby63Bwt3cTyZVc9gf89a7AfBjTVtsRX9wtwW3ed1PT/61BNpPZEJ1/xE1t5lp4RsrSMcs1w/UH/gNYv/AAm3iiW/lgsbLSLaeAHeRg5+hxVS5+H1xouqE+IJ7ibRyTtmhblvqO1dD/wrrwj9vtIIWv5PtS5WVJeFB6ZwO+aAtIpWWt+OtdY3La1p9naj5TIHwD+FclqOrajZawGm1tZdr4kNoxG33GMV6pd/DzwhoulNNPZXEqQjLLv5Y9uMck0uj/8ACNSJJb6d4YmWOVSHLREZ46EkUD5GzgreU3wkuNNs9a1O1Ykea12ykH6DNWv7B1Qwmf8A4RGz8vG4tcT5b/gRK9a0L7wz4bhtLdzpOp2E1wXWOONjsyDjn5adB8MJJpLaeGRpoDuSeKWT5c8YIpCtJHI6zYLaRGa4h0WAkZFsH3t6DqK9b+CtqJdCl1L+zobLfmNfKUASDIy3T2rF8L+HdPsLyWO40a0LQI7+eG3HcAcd/avTfB+lS6ZpBEk5k89zKqkcIDzgfnQRUT6nRDpS0g4FLQZBRRRQAUUUUAFJilooATBpaKKACiiigAooooASilooASloooASloooAMUlLRQAmaWiigApvenUUAJS0UUAJiilooA8X0RNR8DQ2dlqqR3zXF0Iba7DfOAxAwSTnFbP2a10vxJqeqvdWgto4d7WyRgyI/8AePGemOlebv4u1q61+z0zUAL+BbnEFz5e0scjDLwOldT4hsbDQ5tPu/PubrXc/KiLua5XPIZSduO2famdSdyG18I3/i3Vn1/V9QaG1kH7pLX5WdBzhu9U9G8FaZr2taxJZz3ljbQukcUkTFTkZBHPXGBW9F8QUt7h9P1HQbqzumj/AHUAC5kB9Oa5zXYdc8E51fRLiWOw1Egy29x8xhduffHegGlbQ09KOt2s2r6dqF9Hqeh2ts5+0SlSQwBwOO4wOtY3h+71uSKLW9QtrP7JCT5c12xUFQf4F3AZ/CpTd6j4k0/UNH8P2UcNsTjUL53IDN3OBXnWt67qepW9vp13Or29iDHGqcKcHr79+uaCG7Haan48Gv8AiLzoxfw6ZAh8+CIBt4B78dDXe6fq2heJdLsoLfRTPZzAxspX/UdOK8Y8K6qdDumnuYWbT76NrdyvGfp+I9q9b8M6/beF/DcVvdaXdQRW3WQqPnUjhs59qCoSvuYvgzTLfw/8cbmwtZCLVLaRgWPQAH+VdX4Zh0uTxhbmGQ6pdQvIwu4cIsCkH5W6Z64/GuV8A3dlqPxF8ReJnI+wwwlt8hxhWDevrXReGNRu7nxXb6ncWNroWlys0dtFEi77tjnlioP15Pakc8rXM/xd4eudY8Z317b6gluljPCWEh+UqUGf511uo6noen6c4kW2kV1OIYgCZG9MCszWb2ystU8WS6g8ZiJgARzjc2xcAfzqr4N0mxkae5nIllEiyx+ZjIB6kd8UHTT2KUtpdXytqUVtFo2mwjzFZuGkccgEehxVC68SanrZhg1mxeDw7OvlzTojKSw6N6gfd5rp5oT4p8UPBJgaXpbAMg6TTdwfYYH51qWRvNZsL+21XTRZoWMEaHkOhH3h/ntTK5WclpNpd+B9YkttOkl1LT72PzbeEclW9d3TFT31q8N815rth5CXDgSS2zM5B7cZOO/OMVgW/h3xPqF7drp2sbBYN5EEztghR0TAHoKuwz+LNQvINA1MhVziSRcAY7Ekd+tAk7HQ3fg61MJvPtMrCOJpFDYyRjgE+n+NO0aXW4/Dstvp5W5mhk2RPMpUBTz7dMkVmazpmp2enn+2NYI0iE7pfLzvYcYAOPY1qjxpo5On6bpMrXlxcxYi8tSfLABwzfjQPQraPcDVvFlw94bkXtvEEMRIaFSOMge/XmtVP+Ene9i3fZobUZDAHqPbnrWVoDx6NrWotqwW1uZwHaeZgok24zj2p918QdBkM9tFeNFMykRSPGdjfQ4oHddTBsfCPiDTft13axWL37KFjd23bm3HcTk8Egj8qt6N4uun0+6tNa0OOK+tW2ooT93JnjPpXUeH9J/srTpLi6uCbi4JmmZnO1enT2rC1KE2CXF9rupC5a7by7e2t1DFh2A7jkUCtbUwtf8AC95pGkp4n0yZrW9jYSy28JGw7jk4/E+tWNGvfDfiLVbtNdtzBqLHLRXkgHJ67TxxVIaLr1wLXw7e6itnaXu665JZwueI+e/Pr2roZPhx4cnsyL65ee5Zgpu2lw24duvtQTrfQwJ/Ednoeq3Ph2zgaeIxPAFWUeW2RgHJPqfWuu0KCS00O+S5cO9tYGNpJCNquTvCj6AivKLExafruq6ZbWsl39olWG2uWAJRweM56ckc161ZaZeald3FrdXdqmmyhI7m3ZsO7hByOPb8qRnJvlZu2WvXcngO01Gxt4bmdY0V1aQBRjAY5yB+tEc27W7sDHzwxStsOVBO7PIrO8N+H7aTTNU8LX4LW9rcAqqMUOxiWXpjPam63PLpfjOxW30uZLLygk90GHl4/hGM5z1/Sgik7SRfj1mB9bm0yNX86NN54O0n/IqhdxP4fstT1CGa4u5ZyPLhcjEZ4HHtUr2cS+KEuxehJTER9mwMuOec4rO8ca9Z6Npkcd7Z3c0U+cPbrnYe2eRTOx2tcy9b8K6h4j8K2ubiI6xHIJ0mKjdj+6T7Z/SsbUtS+Ik+mzWJtYLQ2oG+6VgDIB16n2rV0/4laZb+H4biSwvY4FbyWyoODzyec9qkh8THxY2oRHSppPD8cZbzt2HlIBwFGaDN26M6DQtL0yfSLW4Wzt/Mk/eO+Sf3mBk5zz0rK0bXX0zWbu3vbxZrSWQrBIXyUbqQR1A681lf8JjYaklppVlNLokbExlbmPBZf9k81fj1jwjomqLojxGW8yAWaPcSWBPX3BoKuaut3ra7C+maPcWM8mR57bgTGvqO1Z/iDTP7CsYL2yuZ/MjmQsg2/Pg9elcv4gh07Qp5de8JyeVe2s3k3NuQdr5zk4I9RXaabY3t74ftbjxDfr9oUmXdGAAFODtwcZPFArpsbrt+mrWNt9ljkuoVYiRIe0gUFc/jirOgeJIr9JraezawmtVAYTYXfwBlR1Ncz4T8c6fBfSaPdWr2CNI3k3LqVWb3Oe9X5NI1zVGvdWvpIUkiybWKEbwyKc8n1NAKT6FnXPE2lX1lLAbWeVEYMxCbenbnp1rXfXbPTLWwQQMRKuI0jG8L04JHFM0+S017w9mazitfNTZJGdu6M+/rXEWniODwgzeZcx6nbNcGNCsQxE3HUkcD6GhDbtqbInvpNlrZQRi/kCoY3PH3iT+lerWayLZwLKFEioAwXoDjtXm+iWmtXniCK8hs7K2kGHmkDFt6H8OuK9PAOBnrQc1SV2LS0UUjMKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigD54u18ReO7+C80KyhtNO06TNo0vylj2BGPQCuW8R+O9eutTZJVitLu3HkvLAMMfx/Otq28e2vh/RL/T7LTZ7PU5SV+d87cj7x461wMGn3eqtczggeWDJNNI21QeuMnvQbN6aHTeHrrxF4t1uCVLvzbrSommSSQ8kehPfOa7BNU174k2dzaSCHTdNtkxdyMu7dKOw9B96vN9CvtQ8KatbXagwidCORnejd/wCRr0WKG78PaS1tbXmn3um6ojyTTTHG1zyO/uRigIHNR+H9a0jSb3U9LvRBpKxlXuVc4uPwxj0rldJ06PVNTt7SSVokmfY0iruK5PpXZa140Q+DbjRlgigLqsaWscZUxHnec5ORjGKn+DeiNfazLqErsLe0wpAHDt7/AJ0wsr6DPEOmQad408PeG8pLbWwAfgDeW5JI/Guz8RXD+LtSbw3bn7Ho9vJ5d1PIMZYcBEHfv3rmdINrq/xgv7++miNvZZYPIwUDb8uPwrovFuoQ6zGt9pOli8it0d47/wA4LEj8ZJXHJHOOaC0g+GOi6dJH4pF7EHtTJ5DxkfLsXJ6fQ1e+Gtx4cj129s7HVJboySlrW3nTJhAHPf8A2T+dSfBxGbwNqGphg15cTyFmk+6SAP0rn7G8GleNLX+1JrJLmW4xLbWDgGNiSAcZOe2cAd6Rzvcn8V2mg3/xPu/7cunhSIw+VGv3JDsXlvp0/Kq/jC80q519bXSL6a11RofLE8EhEaqOicHHSofE9oL3Vde8R3Nvuk068j24+VZEACkHP+c1oajrGgXmnfZNG0thqWoIJExCfl38ls+2f1oNobHReGG+w+BY7jSoXu55VMu2R/mkkIxktz6CovFvi6fw/wCHrS4dI7fUrplXynORHzzz9BXN+HtcX4fXd34f1pblbZX321yqFhg/w/hj9ajltD8Sb7UtRe2lGm21q0ViXBG9+Tux+JFM05ny6C6C/iyRbrV9DeyuLa9kcyJKcBGUn5gcdOK2PC2ky63p6anqckltqDXRab7M2xZdp7gYyOa5PSJfEl34Lt9A0DTniUM8dzeO+Bwx3Y4/SpG8c2+g6NbeGdGzBdoRHNeTgqqP0ZsdevfNBKajqzqr1ptZ8bLomu6cGslUz2UkZ4fA5DDHPT9aw5zL8OfFEwtdLtZNPvAZImA2uh/u5x6r+ta+peJtSsLLTNO0AR63qcyfNdcOoz1Jx0qtoR17xTq+oW2u3rWp08iPy7H5VZioPfP96gqT6dWYmt+JH13y5db0GCGJAPLWblpFzyVbGc/lXd6vbQy+GrWPSdDh1KAophjfgIvrnHp+NMn8AaTc2wt57m9kjz+8VpQQ+fX5a5G11TW/BvihdKluEbR4pFgjgfhijfdI9eB2oH8L1GX+q6pZQSeEL+0upXu4w6OzliDnlAT2wP1re+H9klzLNcyXBuDYr9liSRBmDnJ9sjkVc8Xyme9S0W/tbZEhaa4Mkf7xY8HLK2R6H8qxvCVxcaF4bFkIrqV72ZjFOyny0UnAO7GCf8aCep1Wuw6ZrCXFgx33lpH56bG2mPtkMPrXmGq6VqdppUL3NyIUVTNBJnIJP8Tc/rXpl1YwaPLZXCxxKjqYZ5CM5LDqTn1H61jJ4c2Sk6x5J08MAwklBV19AKCpavQ5u0Sw0/w0umaZctf6w91HP5kcYYO4YHBOc4GK69NGtR4pmlu4J5dRuLQTQKH2pE23aQG5546iuen0a7tI3utOih2wzg/aLHmVI+MjaKhtdTth4igS4/tDVLCGdVSZgQY3JBw3HXJNIyltY7DSdWt9M15Li6uBDE1kUunaYyCOZSqhSxGSevbtV/ULkad4U1JtW1y3uQ+Zbd3AT5TnaKm8Q6Pp9pqml3iRRLby3Wy5VmGxgQTuIPfOPzpdT0HwvaeIFN/ZyXVxqjIioyF0Tb0xjAUc0GCdtSjFYtfazp+swbGt2gw8gY574x61p6tIg0q8V2iLLCzBGwfmAz0qPT3Sxgvbe4ballKylj0EYUGvLZYo/HU+s6nplmyyRSqsMqT4aTkBjjGcYps7OZKJw8et6zC0OrzO01qZGUIxJiY8gjb09a9J8F+OtI0jwkhkt71UWYmRljLRxZ6DORx17dq8+1Kxurbwvd2twQpsr/G0jBJbcSevtXUnXUt/g9aWFve2gupwYpIDguVKgZ68df50jGLs9DuPGkfhvWdP02DU5SDdzILV4AC5yeOfTPetHSbnRbnWrjTrS1El1ZxgSXDRjsAB83cjIrmdI8O6bpVhDreuaz/aM9pDiHDBkhJzgKvXPPHNM8PS+Ldevp3/ALUazsWJ8pZoiJZUPHc9vp2pmvN1NjxvpOnJLp+sXNrNK0E33Lfocgncw4yBg81Yhs7HxhdxavFq88mmwviO3Q7BvXqd2eR7V5/q+jazqevzeGdK1ae/tU/eyvOcrAx9+meaow69qWhSnwjcawkVskhSa5jGcIcfKOfagTmr7HpXjy10C78OyLrcyxxIP3bIR5gYcgCsbwf4ou9F8Hq2qWF08asyWpWPLFMEru546e9cj4o8P+HINNstV0PVvtUaXEZnSWZWI+ZQSR+dejz+PdI0y/stNuI5vKljTbcgZjPygfzNAbvQx/COnxa6Yr5NQa3cXElzdWEZLByzEgt0wME1c8cRWenaTZaNY2NvEdSulTaUAQ84OePf0NSa3px0/wAU6ZqOiyW1tLeMUmhOFFwMZHOavW3htdZePU/Etqo1SMlU8p/lUdiPegpXex0vg5BHbXCNGkciyBTGh4AAHT2rqM5ANeW39jrPhq0gk8PE3CwFmuPtDbnZPQGuz8L+J7bxHZb4yEuo/wDXQZyy/X0pHNOLT1OhopOcUo6UEBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAfGuk6Dq/ibVTBDDK8sjnzJXUjb6lvSvcLPwLa6XolppMdhBewvKHvnlJBOOcjBB64rUh2x6LdweG5befULfCPIUxubvuwMGsrxH4rtvDn9nHWL2aG+SIyyQwJlZCcjBJ6cimdUYKO5z/AIsj8N+MtNuVsp/supaQCgRkILKDjGO/avLZ9C12IrEbC92YDoFjYj1yK39Q8Ttf6xb+J7W0tbCZJwhRGy0gyeSOnTFe22+p3Goz6dJpsVtLYzRh7g7/AJ4hgYAFBNlNngWleDvEfijUGVoHVjzJNP8ALgH6/jX0F4d0K18M6GLKyjUssZLt/ff1/p9KZeSaXogu9cLySGXbHKYmMgOM4AUHjrVq5bUZXsptOeJYmbdP5uclCOAOKEaxpqK0Pm0ap/Zniu+nu7MXCtPJ5ttuKgnce4xUOoeKL+6W8toJGt7C5l837MpIUDnCj25r3bXfht4Z1i8m1KdWic/NJ5TnBIHfB4rzzxh4D8O6Z4S/tzR9QkZCQFWTOJc/XmgwlCSO28DXEOi/A28vLoeZG6yvt6dVHFc34Q065n1zRkW8gS22tN58K73JGW2EnOMCuo0mxntvgnp8DQ2c0Vyo8xbl2RQrYHVe/Bqn4LaBfEmqQwWiQW1labYxAcxDIwSSTljkkVJjY5ma71o+KL3w6IRLBNdNdvFuAeZCchcntyPyr0XRdJuJ9cbXL60FisUPkW1r8pCJ3Jx3+UVxXi+2l0+XRvFUAbdFcBJWA6r05/KvQ9RtrTU4LLWlnuGW3QzxpC5AkHUgjIz2qkdNNWWpFeabFrmr2d/b38ElpbbkeFQrq546nBrmdM8dS23i8+Gb5LMxrI2LmNgq4xkDGfwq7YyavJpMmo+F4kgtrhgwsbiPaUbPzE8fT8q4u28PReKdQ8U3624j+zoFh8skYlABbBH1oKbW6L2qatqHgDx+0Nopm0nUD5ogLABieTtOeuT9Kks7/wAMReK9a1bWkSAyqGSGbDAqc8gL3rU8P3GjeLPA1kPEhQSW8n2cs7FWDrkDBGDkgVfj+EnhkXXnTrc3HYLLIxGM/XNAlFvW5wekhpPHd7P4WuntdJk4ku2G1Igew3DH0r1rw/pljo+nlYLxJ5J2Msly7qTKcdeMDtjiuF8aaroEXhG/0OwspYWjZUUIhQF89d38Vc3q32my0nR9n2zzNHMa3b5ZY2V23ev+0KYRfKz2qS2vRq0U0d0BYrGVa329W9c1leI9P0bVru3s7mZIdUYFrV0P7xT6/me9arXD3+ko9nMscs8AeFic4JGRx3rJ0/wyrXdjq+tbZ9ct02GeIlVfp2/Cg01a0KbeDNPhH23Wrua+njy7u5Ch8Dpxjj2q5Yarp3inw3P/AGThUiJXy8coy84wfoK5P4jW91eeL9AtoLyX99IN0CHAwDy3FHhhz4Y+Jmp6JJ/qL4CWEnoTtGcfiDSJ5rSSOmeyTVGt9bWO4upRD9ne0DgJkYBJB7gjtWhpegW1nhbmVbiZHJQvIcRrn0J5xVfUodT0cXF/o1t9pMnMloe57svpXNNrOpsuo6jcaS0dxJaBQY3bg4Oc5wABxTG7Lc39I1fTdT8VanBZEfuIlil2/dfOckVyFu9vovi1razsDcWl9I0ULByzJLgnfgHoMelXfhzapY+CbzW5Gxc3rOWduMccc/nRdy6vcfEHS9M0L7KltBGszytEpxu5bDY5JyaTM6j0JdAtNa0pdY0nWbe6uL64m+1R3TfNDkN2x04Oa9Gtrp7nxArnUbNraSBXhtDjzQe7fSnSaRfxWuqNBqMjy3XMKyjCweuMVU8NaXaPFb6hLar/AGpbp9meU/eG0dM0jlYy8iiGu31vOEME8AdlYjB5OT+lYt3oFjpsT6xpNggu7WJmiSNiEfr2Bwf/AK1Mlk1W9u2m161S2WaR7URI53eURhScdMkmorjwmkMUsUmvXUFkSgijZ9oTBBwGJ56EfjTOum7xPF9Y1OTW49XupI3imkaOWSEqQFIGDx9TXY/DDwboet6FJf38Zu7gPs8pmIVMdMY71d17R4pPiM+nRlWh1DTNmT0+XbgjHc1yHhLxddeDbTWNLaLfdElYYwOTLyKRCsnqdjovgexl8fXb2rN/ZViwYwliwMnUflxVzXvEllF42vUVXS/sLFlh5JWUnqMewJ/Ks3SfD2s6H4cbXLnVrxZS32prSBFZm74bOOuKufD+HTr+bUvEepKGv2fcxm5WOPA5B6dP50y9Xpscunjq1sPActvYWv2bWLmQrO4yC2cktz3z/OuI0rRtS8Q6gLWxgeaVvmYse/qSa2vF+op4l8VS/wBn26+Vu8qBYkwJMH72PfFet/Dbw1BoGmTwTyxPqshDXSKeYwegP60GcVzs8R1fw5q/h+QjUbSWKMHG/PyH244rvtY8Y6Rqnw1itYoFjvSUgWHvGwYc/Q4r2K80y11K0a2vYUmt3+8rjI/+sa8q134MYmM+h3oQE5EUxztPoDQW6bi9CV/AHiG50yx1P+3ZZNSgjWWGNgNi8DCjj04zWxH8TrTSdMKeIYmh1ePIkt4xuLEDrketYdj4L8e3Fqttda4LaAAIFDksFHTBxXUeG/hzpWkTPdX0n9p37jDyXOWH4A/4UFRUr6HPQX+ufEXzn3yaRocBPmNgh5QOSMntj6V6J8O9D03SNE83T1RhPI2ZAclgpxyap+JfMtPDs0en2SzSzkRCFMJkMdp6Y7V1WgabDpOiWdnbw+SqRjcmc4Y8tz9aRlVutzVHSlpBwOaWgxCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA8n8P6vDG2r6ToenpMbCJWSVuPtLnd1456CuB+JfiGXXLm20mC1Xz4F8y6EfzbW5yufQAA1qWfheRdSl0TSvGUtuuzJsyMui9wTnqMelbeq+CLPQPCF6+jxr/apiwbmQ/O+Tzg8c44pnU7uOh45qKQXsUVzCYo5tqrKqDCKAOoP944r174Q/YZ/DcsqQr9sRvKmcjkrztB/CuV8KeG73XvEMWn6k8osbKIPcQTd2ZeBg9/mFXbO7/wCFWeM7u3vCzaXfAvG0S/d9Mj2HFBEFZ3PTfDx0S3tpo9Ilj8pZj5u0/wAfcH9KzPG/jH/hErNJjZNOsqkLID8qN71lap4i8BS2UV1LLDKyy+bHDD98uMYyOvauG8ZahqeuCx1vUbf7LpUUy/ZrAttknUYy3069u1BpOoktDp/Akvie6ml1q5tzJaXsm1oTwMd3H5frWd8ZZ7BhY6fDKUnt25gVcKVPOR6niuw0rxTp1sltcX+oR2ltdxr9ms5V2tFtAzk+hrjNY1Oy8afFHTLaF1m021yzMuPnxjP16UETdoHVa7fWN1o/h/w+LwpZTFUeOS1DeZjHyjJ4bk0uy20LTNRNr4durEEpAs0gwJBuGCBnpk/pVHxZ4jRtS0a2sLRb6NbgS2xk+RomUr1JyNowKZqfivVD4Ri1DWWiuFbUh5aWg3BY1AznB7ENSMFo0aurxWfiLwzeaRBqRt2tlDXTGLOeM+vrjmsPwV47sdI0WLS9YjuY5YPlSQJuV0/h57cV02kaxY+JtTkvtKu7gJbQ/Pauu1JMgEZPenNDdXujx6hrOdJ+yyF5I4cEFAeAeKo67PdGFqXja/8AEkc2m+EtOnkmf5TdSjaqA/TNdT4W8OxeHdDisV+aRvnuHP8AE5PP6VNq2t2Wh6G+reU8tsADiDuD3ry7RPFmov4ru2s53trfVV3WX2tcqpH5eh/SgHZPUmCReGvHepaS+nxXi3hW5tIZxhPMJHOcccE17BbyyNaRvIojcoC67s7favO/FdjpXiPW9P0a+iuv7bRQXurVDsjOO554/GqMnhDU315NAm8WSnT/ACSUiaUCUYwAAD1FJAnYpardat4z8Tx+GJLiB4YLnzme3GfLUY4zjk8V6brOjx6j4WutLb598BVSRySBwf0ryfQtNg8M+O9Qura6eHStNdIZnm+YsXOMZr2yGVZIo3QhkcBhjuKAhaSZ5d8N4bXUoonv5pV1TSJWg2iYgEDIAK9+ldhPrVzbeLZoJ7lRp6WxkaMx8qfXdXmXirTLNPEWoappUtxaX1q4YwCMt5z5+8uO3X1rTbStZ1bQINW8W+JnsrBx+8t1TYfXBJJ/KmSptLQW21HVvE3xBXXdCtUuLC0PkKZThdp6sOvvWj8V9Gumh0/X7MPHc2kirK8XVU5z/M12Xhqy0qz0G2TRQPsLLlG/ve5rXmijuY2ilVZI2G1lI4PsRSL5fd9TC0zxXoUmj207axA6iFQ7O/OQBnNcl4m8TDxsn/CM+Fme4aYkXN0FxGiex71pQeE/D2oeIbq2m8Lm3S2wY5+RHPnnpj3rrtP0mx0u38ixtI7aPP3Y1wPxxTCzaszKfT4bDR7Dw7aCHbIvl5lOAiDG44+maxJ7fTbLXBLBdObfS4jLKy/L5jcjp6Zx06VneMdQuX1uwEcMdx9slSG2t2GSVDcucc/xVv8AiPTl02W0SGXUW1J4Q/lxQtIrKBygx93p71Jz1ZXZs+GtTu57qDVNYklhk1UhbazT5o0THByfUcmrS29z5uu6RaTtbzzKZ4Jiv3WfOcevSsm08Z640Fslx4QvoIXAjWcHeyN03FQoI/OtS2judH1XR11S+juLqVHiecJt3n5cDr7mgyMLX9Mm0+9s3iaS41WbyzcSSMVikCNnj0PWtW+0+w8R6UsN5B50JOWQjo49/atHxj9qbT4YrVIcvIFZpFyB6c9q83+IGtanoep2ekWM62i36Is8rRcI33TsbOKaNaU+V6mFeao0XxL0iCe+WSGym8mIRIAEQ9Fz3PH6VL8TfB0mmX0niuwmI/e5eMLjY3YitfxR4ctfDXhfTntSZjDexzSyzEFpCQc849667xvZDUvBGqwqpyYWkUD1AoNeW8WeZ2HxM1+HSGGoaP8AbYXQqtwDtDA8c4H1rldPtfFOqwTabpUV4LK5kJMIJ2L82eTXdeEfG0dh4J0y1eKOWY3YtNjHgLkZJHtuP5V3HiC9vDo4GgoJZZG2GeJgBCB1J4/TNAlFyWrOU0PwpY/DrRZvEOr7bi/ROAOQhPZc9frVL4e+KDrXj7UruSMW41GMMsQOQxXPf8aXx/qn9uaXovh6yv4r65mkVbh4ecsoIbOM471Z8UeGrnwxbaPrGhWxeTS12zxIOXXjcT+VAa302O3m8TW8WqR6ZDFJcSlGaV4xlYsDOCc8VVtvFMkvhq41X7D5jRSFBDA+8sA2K5WzutKv7uPWvCywPfy7vtltLcrGD8uDlT1qLR9UsdNt59YvGSxYytbRx2z74EbnJcDpyKCnPzOnuPEl9pkd3qmpwJbaV5CPbo3D+aV5U++c/lVfwHb6ncxXWvatJKJr/mKBjxEnOOPoa5fRxqnxB122bUXWXR9OYhnj4S5kB7D06/nXrSKsZXGAuO3b8KC46u7Odv1h17xZYaNFqU0E1q/2qeOPPzAcgE59q9GGMVw/gm2vLjUdT1fUI7Y+ZL5VtJEAWMYA6n65ruqRyVJc0riUtFFBAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHj3xS8OT6PqNt410aEme2b/S0XoyZBGf1rfiuNN8UeF1lKpPbzx7/ACg3RwMgcc9QK7u5t4rqB4Zo1kjcbWVuhB615JeeC/EXgrU59Q8Jhbywmbe+nseUP+znig1p1OXRnKaV49v4LuRZLa6a6gLW6W0EJ2ykHCljjsAOpp/g/RG8SeOlh1K0W9jti813IxLCN2IITOcccj8K6KLVfFWtLLbaX4PXTriQ4ku51UBM8E8Ek/XFd34F8HjwhojWskq3F3M5luJv77H/APWaBTlfZml/wi2hm4E/9lW3mg5DbM4+lYvj/wABW/jLSI4UcW11b/NbuB0/2foa7MDjvS9f/r0GZ8hal4I8U2mr/wBnT6fczShvLjkVSUYdjnsPxruvg34dlt/HOpG9jDS2EZhbAyA5PT/x2vbvEWoppPh2+v5PuwQs3HrjArg/g7ZyW/hS+126DLLqUzTv6kDJH6GgbdzI+Kup3GlamYoo7aO3a1YI4iO/eeD8w4Hat208Oi30PTbF2MnnWUn7s42hmRjnj61wsFnZa74lEl1eal/ZlxqCrFJcjdHKysMp3KjleuK9qWNP+EhiRMbIbYYXHA5IoEeL/D/V9Qs9KvdLiFqkmn3Di5acEFYhkZ4IzgkV2mmTS391YNd+IYLkSiRvs8agLOhK465P/wCusDxXpi+CviFFrggDaPqX7u7AXcqnHO76kVvS+K/B+nxw3Au7QlV/deXESyj0GB3po6qck1qV/iZe/YfBs9vGq+bdFYYk9ST2H41k/EDwm2l/D3Qb62TD6V5bSFeuC2T+pNLo1le/EfxrBrE9rPb6Hprh4FlGPNYEEcH6V6vr9pDeaBeWs0atE8TAgjjGOKTZjUmnLQ4u21iW8OlCwsGkgvbYGW+XGYiFxz6mobiLSPDNqmsazcpPqtvEQt07bZJB6BeM/lXISaV4u8JwrYaNqqy2RAkCMgJTcM4GR0FO0nwNe+M7s3niXVTNLs3QwxjABGMg/wD1qdzT2ysavhvwlJrXwz1me+WT7VqbPcIrDlSBlePrS+DvFcU3hG2sb5ZjcrKbF/LU5XryfQc16rozrPpVuyIEATaUxjGK8YutGg8OfEq/0i9ka20vWMTxSK23Djk8+5X9aDKnJqR3Fx4ZCQxS6aY4r6EBEuZwWOzuD71hfFSSKLwRJbzKryzSIiAY4OCOBXXNqmm20AVtQt1SMbTmUcADrXDCVPiN42s7W1jM2h6WTLNOfuyuCMDP4UHTOSUTqPCK2sXhewtrO5W4iijCl19e9WF0hodYa9trhkM53Txtlg/GOPToK4ufS9Z+GniS5ksNOm1LQbs7/Ki5MNSXHxMvL63kttL8Nal9rZdqtKgVUz/ESTRcI1Y8uo7xf4hvr/XbbwtoU4SdiHu7hMHyl9PY9K19a1SaL+zrJbuOGG6Ox5ZB+8ZeBuH1HT8ao/D3wdcaVZ3Ota4y+ZcEyuCPmY+/tk9B14qw08d29/c3+ly3Nx5reXHuXZbKpO09fft6UXMJVH0NO/0yPW9d0w2saxxWvywSyKVdSOWKg47Y7VzviHSvFej+JtGkj1661KOW42iFoh8qck5ZVAGOetbWjxx+K7CNF1nyTZIEVIWPmI2SSWJ/AUaZoi6n4juhe62JJLePyY0t7o5OR94gHryaRkd/eXdtY2Mt1czpBCiktISPlFea3saDTD4j0rV21SC2ujcP53Ow9SBtxwPeofDMUun3WueE/ETi/srbNxFcTybgqnlQx69wK6C1t9XfQbiH7JplpDcW5WC1g4LsfXjFAGvbtc+JLaFrqyjTTZ7cONx/eJLk+/GOKqP4fs/Evh6bSNUBneFjGJG++uDlefpioNL8T6nb+GDe3ujTTPE6wpHblS8g4GeSABWpZ3csFzqEvkP5ksIuRBxuyABt+vFAHlniu71yPRrzQpdDD21rHhLpXGdqEAMec9K7XSdXtLvwjpl1ezLHHdwouZT1LDkGi20jUda8L3d3fyOl3cByscgCmNCSfLOPTAH4Vwuk6RJ4m+D50tMi9sZCqBm5DIOPpzTOiE76nIQXt/4F165s7/TIZraSfIknQsqqTyVI9q2X+J8Wn2l5p+kWscMeQ1rIisS5P3gcnPc11PhvVdO8UaS2geJ4YY9Stf3ckM2AT05Bpdc8P+FfB+k3F3DZQm8cbLdHJkZnPTAOfU0DtpozmPhpD/afivUdd1BEhntYy6W+3HJGcgH+eO9dXZa/d+I3/tHRr6Nl4jl0q5YfKB95+3rXnsd/4i8Ka/FdapGkVzqNptDSjAVDjrtGMjHTFQR602jeJrKe4vIZ7KIY86zi2eenGV6D9aBKdlY9U1Lwf4W16bz4ZYYLp/l8yznGSccjAJ/lXEaL4V0688b3Wh2EFxqEFsm+U3D4CuMfSq+seMo9C1Jo9P0aC3mjybSaOUsAHGCSM4J59K9H+EOhTxWN34jv1YXupkH5lwQvA6dulBM5K2hN4e1/Snv5vD8FubK9sxhrcrgHHGV9vxp3izWlt9Lks9OeG41SceVBbeaAxzWxrXgO01HxLb+IbadrXUYRtLKPlkHHX8qfo3w+0XSb9tSMJuNRd95nlYk59h2pXGq1o2Lng3SW0bwvZWktutvcBcyojZG8nJ5roh0pgGKcOlBgLRRRQAUUUUAFFFFABRRRQAUUUUAFGaKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACmkU6koAaFxTsUYoxQAUUUhNAHmHxk1JxpFjoURbzdRuFRgP7nJP8hXd6Vp8OiaFb2KELFbwhC30GK8wuUbxl8cYo0+ay0WPe3PG7ABH1ya7/xpbS33hy50+3nt4prlRGvn8g5/Ec9KAOb8AzaB9t1TRre3vluFm85475chs5wRkkdu1ddpAM9/f3PJUyCNDjjaAOn45rzqw+ID+FbEabqej3c9/aL5T3EduVVsdPX3p+l/Fe3sbBIW8PaoW5JIiPJJJ9PpQB6rc2cF7CYbmFJom6pINwP4GspPBvhyNlZdD08MpyCLdc5/KuN/4XJbf9C7qv8A36P+FJ/wuO2/6F7Vf+/J/wAKAPTIoI4Y1jiRVVegC4Aqpq4/4ldxyB+7Irz7/hcdv/0L2q/9+j/hVPVfizBd2DRjQtUT5lJJiYdGB9PSiwG5c2/2iYdOUjTB7ERj/CodLlFk0M4+RY23gY42D738xXLP8TYXvGYaLqOTKGA8s/3MVXT4jWvlKG0XUDtVFIEZwVIO7t34oA9d0dvIuryzwQA/nIM5Gw4A/kap+MvDOleI9KYalb73hBMbqcMp9jXntr8U4ILi2uH0TUiyIYZSIj8/p2961Lr4w272koHh/VRlCP8AVNxx9KAOct/h34enu4RJHO4cncDMfm4zXovgWwttOtZ7e0jSKLCHCjvg5P415lafECC3V0Oj6iWVSVby2ypJBz09DWvo/wAUILC9vH/sXUikpB2CNvl5PHT3oA9Z1DUbXTbdp7p1RR26knsAKyfsN7rriS+3W1iMFII2IaT/AH/T6V5lD4+tpfF02sz6Nq9xAYlWGNoyVjbJyQMe4/Kt+b4yW8cLt/YGqBscFomxnoO1AG54suzdEaRZ3MMLwFHlVmKZXsoPbI71z3jCe1i0uS28gaTG8ZkllQYfJ78dB15riH8ZyrNqVzLp14LS5IeQPEcSHtub+6O1bemfEnTW0911PQbu5N7GqOqxHYygcAZzxgmgDoNY8M+HbGyi1Oyu3gvZoPLaWGXb5ikckgdTyead4b8C+Edy6no93cDUkQ/vRctkMRjnnnrXG2njjwhZSiafSdQuAWJjEinao9BxTL3x5ow1hZLHRrm1W6jCKNmD1zlBjk4FAHRaJpSNql8n2qW7+2y/Z795l3AMvQDJ6ZWuxt9NsXkttR1S5YTaZK8cGyQpHgdMqOO1ec6f45jsZR5mlaqtukpkRPIYFmwQNxxzwTVfTfGVtHqN/c6nZarO5fdFshI8lcnkjnmgD13wlLZm2v47KYyRxXbrktkdAeKimS70fxIb6SYSWt5KIzu6xjb0H4gV5v4d+LFpazzLHpF7MzruIhjb5iM/MRjv3rV1b4qwX1g0Y0HVlYOrbvJbAAYH09qAPQ/EEWpPZR/2Zdw2snmDzGlUYZMHI9jzXnngjS0HiDxVpkTyQ3FteF0cjIZSW4I7jimal8TNM1uyS3vfDmqyR5V/ljYZI5znFc1Y+PrfS/iVe6x/ZN/5d9CqiIoQ4YZ7Y5HNA02tjsdc+Fo168W4dYrC58ze13byHe3TnGB/OtPw/wDC+10zVo9T1LVLrV7qL/VG6JKp74yRVH/hcdsP+Ze1X/v03+FJ/wALjtv+hd1X/v0f8KAcmzqfF/gjSvGNiltqCsrR/wCqlj4KV5ynwa1SxSe1tNRtJ7ORSq/abdWZM9weSK3f+Fx23/Qvar/36P8AhR/wuO3/AOhe1XH/AFyb/CgS0M3wr8D7PTr5L3Wbv7a0TbkiAwvXPP416/GixoqIoVFAAUDAArzP/hclv/0L2q/9+m/wpP8Ahcdv/wBC9qv/AH5P+FAHqGKK8v8A+Fx2/wD0L2q/9+j/AIUf8Ljt/wDoXtV/79H/AAoA9QyKWvLv+FyW/wD0L2q/9+j/AIUf8Ljt/wDoXtV/79H/AAoA9Rory7/hcdv/ANC9qv8A36P+FH/C47f/AKF7Vf8Av0f8KAPUaK8u/wCFx2//AEL2q/8Afo/4Uf8AC47f/oXtV/79H/CgD1Gmk15h/wALjtv+he1X/vyf8K7rw/rS6/o8V+lvLbiT/lnKMMPrQBga/wDE3RPD2sPpd3Fevcou4iGIMMfn7VTsPi3oOo6hb2cNtqQknfYpeDCg+5zxXJ6zqt5onxku7iz0mXU3NqB5MfUdeehrqdA8ZaxqerWtpc+DryxhkY7riQHCYB/2aAPQ8nFIGB5ryV77xP478Uatp+l6m2k2WmSGLzVUlncEjnkccVWv/E/jXwnoM1nqcSz3ktwtvZ3bHiTJxkj9e9AHsZbH19KUtzj/AD/nivKY9I+IOhXen6kmsHVo5nX7TZspAjU9SDk+v6ViwHxr4n8b6zYadr0lpZ2cqNhgWxwDgc9OaAPV9H8S2et3eoW1vHOj2MvlSGVNoJ56c8jitjdxXhE3iLXrfw743f8AtKY3FldpHFInBX7+cfXFS63L460zwhZeKhrjkoitLaYPK9yTnmgD3LcO5x9aA4zjIz9a8d8TeOr+/vdL0mx1m30dLi0E91eSjaVJz93n1A/OpfCfi2507xlbeH5/EUOu294D5VxG2SrehwaAPXt3Gc0m8d+PrWL4r1C50vwpqV/ZgmeGBmj4zzXivhvxD4h1H7PeWHjOG41N2XzdNvMIF9VBzQB9CbucUu714+teU6X4j1TRPFniGx1m8aSNbM3UBZtyphfug+mQawPBvxD1OPQPE9xqt1LLNEPPtvMfkKxAAA/4EKAPdN4/Gjf9a8Kl8X67YaFoWjXOsCC91OH7RLqFy/ESnBA/8eq9oPi+80HxdY6VceKbfxBYX42CVG+aN84A4J45oA9n3VT1PVbXR9Mn1C8k2W8K7nbrxnH9a8h1rVNcu77Uhf8Ai6DQPs7N5FqGBkkXHpkd/asm5vNe8V/CK71CfWGAspmWYbT/AKSgYgbufcH8KAPddL1OHV9LttRtg/kXEQlTcMHBq2WwCT0AzXD/AAu02+sPBli15qDXazxJJErLjylI4UfSsnxFqeveJPHcnhbR9VOkw20AllnRCzOSTx1GB8tAHZr4rsD4rbw8BN9sEXm8phSPrmtvcMH29q8N8PWmr2PxXvItWuxdXUVi22cDBkGCc9a6n4b61qWpeD9Yub29mnniuJ1jkdslQGbGPpQB6UTgZorw3TviNqulfDO1vZZjd6jPePGrzNn5RRQB7pRRRQAUUUUAIelUNXvV0/SLy7chRDCz5J9Aa0O1cd8Sp4oPA+orI4UzKIk/2mPAA+uaAOS+CdnLcWereIblT5uoXLFWI/hyf8Kn+KWi6hdXEc1uZbi2kXLxRzKkkUi4CtGDyepz16V2fgnSE0HwbptiBt2wq7ezMMkfmay7qLSdX+Ituhguze2EfnrOkh8k9PlIBxnn07UAO02xvE8MaZY6lL9qvrhgZXZAGK8ZGMdq65bK2RVUQR4UYHyisu1BufEM8wyYrZBGh7Bud36Yrb7UARfZbf8A54Rf98Cj7Lb/APPCL/vgVNRQBD9lt/8AnhF/3wKy9ftoP7Lb9zGP3iD7g/vCtqsjxE2NLK9zKmP++hQBgJaxEWzCNC5upBwo7BgB09qZBYwSx2tsuxTJavE3yj74xjt161YtPm+w8feu5Mf+PU+JRHbwTngx37A+uCf5UAVY4Y5rWdfLQbo1u4xtGS65yv5AVs6mkM3h/wAyNIx5mwFgo7kA1nyN9h1BgBjyZ94B6COTgj9KliDPo15Yg5a1kDfVch+PzoAyrjT7ePUrkKqYWFA7bR84G0VleJbltNttQS0t43nmMiqGAAGOM57VsSyx3krzQyL++dUznttyR+G2udmsF8XeK4I1vJLaOBZJXZFDD5yp5zkdqANvw7rNvZeDLCVbWK7kDiJzFtYIcjOT6DNZniK9l/tuG3lmZYS3mzwBRsWLGMDjk55yPWsbxH4efwTNprWN9fXzzybLi1EeI3jJHOFGAcZqCHUY/F9zeWNm80MkAEMMbR7ZZYh8xILDGQSw6jgCgDo9Z0211vw/Lapd6jHZZX94YNqnnIBG3dj36U/Ux8un6dNYxWlrFGNhhkRs9BuyCcD6mrWi6xqFxoU2lR2b3axAQwysUJ2jjDgnk8dqms7afTtNmmvrNIGHyPcXbb12jgYAJwOvagCo9raX+uS20yW1nYw2iFQrKzPy3TH4V0ehaQHVpbyASpG/+hvMqlwpAz0x79qtaV4etLWFnkCXMsr+b5jxgYyBwPQcfrVbWL6+t9esLO1mCR3EbLtIH3sNg5/AUAWtatrYfYsRxqPtAzwP7rGuK8Qwst5qU9pDCILjMZIdcZGecdTmtOe/v7iOfRtUijuZ4QpSeIsuWP8AEenrVK4E3hTXbm4u1W8tDCJDH5YJBH9zPbPFAEOmrpttrVhNprCVP9XchkC4J4znHTmutvtJu5NQll+02q6Y1uVMDxjIfsQa4a6lvNXvrjWNOtZLW2t4QWjAGHGSTnnriu8udOg8U+FIraWaWOOaNGLROQRgjjP4UAT6H9lfRYXdYT5S7GcgY+XgnP4V5/4qFlH8T/Cmp2rwTwzO0B8sqV6rzkfWultPD9wdDvvD9nePa+VINkoO47W5wc9ciud+JejQaF4M024s12/2bdI4AGAc9SfyoA9RFtbk/wCpjPvtFL9lt/8AnhF/3wKZYSieyglBBDxqeDx0qzQBD9lt/wDnhF/3wKPstv8A88Iv++BU1FAEP2W3/wCeEX/fAo+y2/8Azwi/74FTUUAQ/Zbf/nhF/wB8Cj7Lb/8APCL/AL4FTUUAQ/Zbf/nhF/3wKPstv/zwi/74FTUUAQ/Zbf8A54Rf98Cj7Lb/APPCL/vgVNRQBD9lt/8AnhF/3wKPstv/AM8Iv++BU1FAEBtLf/nhH/3yKkCKihVUBR2HAp9FAHj+vReI9G+J9zrml6K99E9uI8jAHf8AxrQtvGnjSSWKKTwg0cbOFd94+UHqev1r04genSjb3oA8sitdb8C+K9WubTTZdRsNTbzx5TDKvycH/vqsjUvDnjjxZ4fu9RviYrpLoT2dgxHyqOcZ/Kvaiv4UmOaAPK59X8c67/Zmm6fpc2lmJkN3dM64ZVIyB+X61o+B9F1HT/GniS5u4HWGdl8uVv4+Bz+lehhemefrS44weaAPEbzwtrMmjeOIRYPvvb5ZIB/fUF+R+ldf4p0a/u/hS+nQQM139nVfLHXPNd/R9KAPGNQ8I31hfaFrv9j/AG+OO0EF3anrnkg/r+laXhuw1PUPHMN9F4cj0fTLaL5hIAXZj3B7V6rjpnnHTNAA70AY3ie31O58OXkekSKl80Z8suMgn0x714pqeharrmjW9mng5rPXBIqyaijhQMHkgA19C0mPegDxz4j+DdWlt9GuNOie4uRCtpcsvXbzkn8zWf4w8AalLrWhxadbObSe2jhvCo4G3bnP5V7nx6UUAeT+O/B1/Hr2i6zptguoWtknkzWrY+ZRjoOPSodO0jU9a8UQ3Nr4fj0aytkYsZQGLtj5cenNevH8qTH+fWgDwXS9D1fSLrVo9V8JSarqM8rCC7MmVCkcDr0q94c8La/D8MfFGkXFg0dzNLm3hJGDk5OMV7Zj8e9LjHTrQBxvw3l1X/hFraz1TT2s5LRViQN1YAYzWLrulav4b+IB8U6ZYNqNtdwCGeBDh0IzyD6c16aBjpSEUAePaBaeItZ+JF5rF/pEljby2jRRBznHB6n15rN0T/hMvC2l6rodv4eedri5kZLgMAoViT/Wvc8flRt5zQB4LB8O9b1D4X2dqLXytVtrt3EbkDcjdTRXvWBRQA6iiigAooooAQmvLfGsn/CS/ELQ/DkR3w2x+13IU9CMlQfxAP416Nqd/Fpmm3N9OW8qCMyPtGTgDNecfCezk1K51fxZdfNJfzEQlh0jGMfyoA6jx/rdx4d8HXV7ZJ+9UBFbGQgyBn8qwPhvNp0PhzUNYtNWnvFuH3ypKf8AUsM5UDPqcfhVb4jpf67q9n4dtp2jD4kNvIu1LoA8jd7emD0rb0zw1ZaGYdJsYDCLpvtFzFu3KuD90cDj5v0oA6fR4ZIrFXlGJ5mMsnP8RrRpFAGMdBwBTqACiiigBKx/EP8Ax5xepmTH/fQzWzWNq4D3unIfumZsgd8LmgCrPZpY32mRISVNyzc++TTrOzS8GpWkuVzcM34EnB/StaezjuJ4ZnzvhbcuD35/xqjaER+Ir+PH30jYc/WgB97pCXHmOhxIYTGM9+OM/ma57WtbtfCbxTXzoZZ4PLWFeTM+SOn5V2ZPPTnpXlnirSp9Y8RadriaUdRFveCGNQ2BHGAMseOeS35UAQ3OiuYPt1xcywXd0fNjsYpTGkHGfmwec55yK5rV7+5hGm3FvI9s+tWhtEihkZY43XADH25rsvENhqcGoXNtbaeZQX85LoRFsk9V/DPT2ri/Fc8+haxoz+YlgrR+VHJOmRCON7FcjrhaAO/0vwz4p1LR30/xHqvkrGE+zz2EjLIcf3m4PpxUUnhB/Dd8usm6a6tdOtpCkDD5pJCG+8e+c1v6Vq0mleEY9Q1S7bUtoB860i3GRT0OM1gap8QJ9R09IdFs7lLt7uOJlZTvijJUl2XqOM0AZ1vb6jLZ6Xf6bpM0f9oyh2SE7TaAgktngtnPQ1ua3q3iDwxpskJ0qTXU2HZIgxx6OP8A9dd0o2xjJ4A5xxzRkMpORg9cH86AOX0bxNfXEFjLqenfZYr1R5e05KNnG1gcd/TNb8+nWl1fW95LHuntydjZ6ZrhPt2na5rl9fajq/lQ2btFa20T7SpAyW9zyKW7l8WNpsNzHKwjV22HcVcxkH52H5UAWdSzHq+pyKu9mRWIU8gAjkUuq6vpmq65ps8cwe2hZS0v8IJIxn8qr6fcXT6wkl0h+0sqLM+3CyZTiqmraVp3/CINNeRpEXuwLl8AFAMghT2xnigCGTVtW0vVNU0HSfD4vrGSRiWFwWYblAztIwBxmuu8FXStov2YHH2dtpUnBHc/rXLaNpeoXyTX2hajBbW8o8qWeQeaSo/Ec471d0h5LOS5v4o3uJLaAhYYDjz/AJsEk9zQB1Lym08QSHGUmg3t6llwBiuX8T6la+MfhzrEUMFzDP5EhW3nULJkDg4yeM/yrbN7cXY0nUWs5bWeX5GikHKZGcGuM0TWbu+1/UtOvNEgudVa4aCaQSBGjgJwpxg8Dn0oA7L4d339o+BtLnJBfytrYPQj/wDVXU15z8IJvL8O3umyFRJZXjxsAc4HBH869G60ALRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAJS0UUAJijFLRQAUUUUAFFFFACYoxS0UAFFFFABRRRQAmKMUtFABRRRQAmKWiigAooooAKKKKACkNLTTQBjeI41utPFg4DLduInQjqh4b9DTLiWx8IaBH5No4s4NqLHBGWxlsdB9c1JK32jxJDH/DbRlz9W4/oaittdW91t9N/s6fYoz9oZVMZ9h3JzQA7R4bxbSS71K4iuixMsDiMqUjOSBz0OMVLpC/ann1Fwd0zbYyeyDOMfhRrMrfZorKI7ZLltgx2H+RWnbwrBCkUYwiAKo9AKAJM0tFFABRRRQAVja3+7azuOoimHA/2uP61s1keIF/4l3mf3JUP/jwoA1Ky5IZF8QwXCqTGYmVj75AFacR3xqT1IzTiD+FAGT4gvXsNJlkiIWaTEUX++eBVTR7+xs5LfRIWlkuBD5rOqEqeTn5hxnOa434reLW02e00m2CedMSryMceVuGAw9+tbPw71/RbrSINLtJCt1bDYyTEeY3JJb6ZNAHReJNVl0rR5biCGWaY4RFjjMhDHvgelebajpNt4r8SabpGoyQXmqQQEXsnlOjKjbeVycZGK7zxetzDp8WqR3txDBYv50sUIG6VeRjke4ry2x+JtnN8R4dVEQg0ue22FGhXzFbjklRnnNAGzYfDfxfAt7Y/wDCTvHYFSIOAT3x2rvfDXheHQ7NGuCtzqTIFuLvGDIAeMjp6Va0fxLpWuWEd7Y3UbwucAk4wfTnvVzUb0WWmXN18pEURcBjgHA9aAPHPGfjw3XjOTQWguLnSUxFKkGQzyHH8XbvXrei6bDo+kQ2cCSIiJwsj7iOnBPevIPAPjHww/iHUL6704WEty+ZJ5TvRpCeg5OO/avbEnimQ+W6uMdVOaAPMFtItZtVK20EUyBmCPKqvK+Tg4z2wDTp5rS8RIraO/e+hG2W4ZW2JkYIzjDD0oktn+xzWVwdiwylYZgihXX13D5sitLwLem6tb6yjj8+Llork8oW+7jPXqKAL9ldfavCsNwGBltJtqkD7wUlRn8Kz9S0+e98RnTGeAaXb3IvrguSvBOdvJ5HWjS55I7XUNPkiWOSTLKAMD5Gwce9JrepaBFfw3WvM8dpcW6tFIN+DjPXZ/WgCDTNN0+XxHf2UdzLBZSMdgjOEnOORnpx7Vo6U66R4ulsGkkaFLb9y2MkoMHB455zWFYeIbDUdEvUjsbm1t/OJs3uFK/LwCVJPXAPWrrQJ4fuNKu7K+F1BIfnMz7mAIPQ0AbP9uw+INI+32KSL9ju8MJUZc7SVyM1a1yBdKin1vSrW1/tCQqJJJn271GeMk9a1rhIJ9Kl8mNTHJGXUKMZ71gWvh2y1+yN3qJnlF5AqS27SkKuPQZ4PPWgDmvh9qsUvjXVgyfZZtQVbn7K6/OjchufTCivVBx1r5+utXltPi2fEFsCNLguFsGmByrbsL/7NXvySB0DjlSMg+ooAlopu8eh/KjePQ/lQA6im7x6H8qN49D+VADqKbvHofypN4oAfRTN49R+dL5i+o/MUAOopvmL6j8xR5i+o/MUAOopnmD1H5ik8xfUfnQA+jOBSZBGQePWuE+KfiPUPDvh2NtPPlzXMyw+cekYPegDvNwozXjVz4f8TWnh9NV0rxfNf6ggDtbgqyuOuBXf6Z4oEXhK21XX8WMpT98j8EEcdPegDp80m4Zx3rj9C+I/h/X777Db3DRXTD5ElRl3j2yMGuQs/iBDoXjXxRDrN5cSQrOq2sCoWx97OMCgD2CisPS/FmjavpL6laXiNbxqWkJOCmBzkVzp+LnhYXy25un8tm2ify22fnQB32aM5rE1jxXo2h6fHe316iRSruixkmT6Yqj4c8e6D4maWOxuitxECzwyqVYL689qAOpzRmuHvfin4YsdUNm92zbW2tMiMUU5xyRXRXviHSrHSxqNxexLasoZX3cNQBrZorj9C+JHh/X9QFjBctFct9xJUZd/0JGD+dbdl4h0zUNTvNNtboSXlmcTxBTlPrQBq0VhReL9EmGoFL+PGnnF0SCPL6dePcVi6f8AFTwzqF6LdLp4wzbY5JY2VXPbBxQB29FMDcDmuS1L4keHtM1f+zZLlpJ1OHKISqH3PSgDr80Zrzvxt4ut774e6rf6BqQL28iRtJH1UllyP1rWHjHTdC8MaXPq93+/ntY3C7SWc7RngUAdcDS5rlfDfxA0PxPcyW1lM63EalzFIjK20d+RVC/+K3hazj3petcBWKt5UbHbj14oA7mmk1inxZow8PDXGvohYFc+YT39Mdc15p4z+Jdrq2n2EWgXs0E4vow4KFS6YOevagD2eimJkqOc8UUAPooooAKYTzT6ilfYjsTjA60Ac95NxdLrc9syrO+6CIs2F4GRk9utZ3gKz1Cyhmgn1KG4hiJRoo33+VJnJ+YgHoRxWpYacNT8NeRLLLF9qBd3hfa/PXBq/pVjp1nC/wDZ6RgOcyOnO9gAMk9zgCgCDP2rxHg8rbQ+vRjj+lbQrG03L6pqchA3b1Xj021sj1oAWiiigAooooAKzdbjEmkz5424f8iDWlVLVFL6ZcqOvlmgCWzkMtnDIerRqx/EVMxwCaqaW4fTLZh08pR+lWn+630oA+dPHNhP4m8R6jFpukXVzqWQ32hj8kcSkkFRn1z1xXn2h6rqGiam99BcSW90nyBtu47geAa+jtFsLO/8SR3NlqCx3tpCFvLcDJdCWC8545zXMeJfhqmra3fSxaElqZCJFu1uv3XUbiV28cAnrQBg2vxi8QXOitptxpkd7qc7GNWCfKQc8Yx1rm9S+G/i+wsYtTFj+8lJkkWDiSE8ZHoB9K9w8AeANK8K2PnwtFd3cmT9qCc7fQHJ4qz8Q7+607wvMLa1lmWciF2gkKOgPccGgD5zlttatNDtbzzZLK1im2FEJUh+MnAHOM5Nb+lw+OPFlymgf2lcyWUy7vPYfIU653fXiux8IeJfDF08sGrpfzxwE7Z9TTekBxgruIwOmK9b0mPS10uE6SsH2HGYzDjaQTng/XmgD5Q1rw7f+FvEU2j3c/lRSYBuGX5Sp53D3/xq94Y1nxDBqyaZp+s3KWtxOYluAvmBj6gntXtXjrRofEPibS7PVIok0iImR5mk2l2xgL06c/yrsNL8M6JpCKNO062twpypRAOfWgDwrWNN8TadqDWVzrzG0EirPMUAVBIQM/jWaYfGXhDULfQrLUWH2qQPb+Sm5XVj94+nXNep+MrdbnU7ux+zmW0ugnnjZlWKnJG7scYqLVBd6X4wtNU03Trmeyj04CQufkGDgAHHJ6UAco3hbxq2mm9m14AQXD+btH3eSCRxzk1OfB/ia+t7CO48RwyRTxkIJYlKgDA79a7kaPq+q+H45Fv/ALDBOzTzQtAS5B+YDrxXPafcyX/2bTZ545LZZP3bvDsZFPYc+1AGNceEda1WVNPbxakqhTEEWEeWvBGAPXFLrPgjxFoOnrI3iOIkYVI1iAPpxXZR2Xhi48QJ4agN5HfWqrOXi+UdSdxPcnGKx45P7U8UaxpMeoTSy6bGJd8gJz04HPo1AGZY2PiGdFt4fHsIdAiNGUwVJH3eeppzaV4n0oNHc+MRArXRgjHlbtzfh06V3fhnSdK1TSI7i40+CSZJdxZk+YsuQCffmr1vLBBrN9Z3qoMN9pjZumDnP5f1oA8n1nwPJYeF7+zi8Ui4u7Yfa5bIRKvzL827Oc/wiuq8M+Gtb1rw7YajH4yu0WWIHYIFIXsRnd2xXMeMdIHi/wCJA0jR0t9PlMJllvI8b7gHIIJ7jArsfhDcSQ6Fe6JPIGl0u5aH6jrn9RQBZ/4QTxB/0O15/wCA6/40f8IJ4g/6Ha8/8Bx/jXfUtAHAf8IH4g/6Ha8/8Bx/jR/wgfiD/odrz/wHH+Nd9ijFAHA/8IH4g/6Ha8/8Bx/jUc/w+164haKTxvfbT/dhAP57q9CxS0AeXD4UaoBgeONX/M//ABVH/CqdV/6HjV/zP/xVeoYoxQB5h/wqnVf+h41f8z/8VR/wqnVf+h41f8z/APFV6ftFG0UAeYf8Kp1X/oeNX/M//FUg+FGqDP8AxXOr8+5/+Kr1DaKMUAY3hrRZdA0dLCfUZ9QdWLGef7xz2rn/AIhaxplnDp+maxYNcWWoTeUz9ozwAc/jXc4rK1zw/p3iKway1K2WaEnIyBlT6g9jQB5TrfgSz8P6TNrHh7xNcWPkqZEjMuVbvjrXOeI9c1nX9F8IzXYQm4dkLyOUjdwzAbh0PQetelN8GvDMjbZWvpYAdwie4yuffjmui1TwTomr6JFpNxahbaEAReWdrJj0oA8r1zStaOv6G2snRLPbdL5L2jc49OFFbHgy3tJvil4y+0xQPIJQU8xRnqQcZrqdL+GOh6bqcV+73d3LD/qhczb1T0wMdqZqPwt0S/1a71UTXsN9ctukkil259sY6UAeZy3Gl6dq3jqN4Hl0lPLKwQMVBcleNw7Z7VT1uLxC/wAOC76bpGnaQArLGCDMynpg46/jXstp8PfD1noFzoyWha1ujmYuQXc+pbFY4+Dfhp4vKuHvZ4VGIo5JsrH7gYoA4aJbeTxp4Dg1LabY6ahRZOELbU7V0fjmHwtYaldSwgw+IGsZPJ+ynbxtP3gv1rrr34eaFqGlWNhcpM62Ixby+ZiROPXHsKboXw80TQ7yW9VJbq7lQo01y+9tp4I5oA8n8LWmuz+A5JbSDQZNPdJBM8z/AL0+uflPP41T063kU+EdL1C7guNIkuZGWVG+QHLHac4z/wDWr1OX4SeHnmYxPewQO5d7eKfbGT9MVtah4H0LUdDg0iSzCW9vzCY/lZG/vA+v+NAHC/FS10+0fQm063iTUlvE8gRKACO+cfQVJ4DlEXxU8ZGdlQu0ZO44yRnP5V0+m/DXQ7DUIr6U3N7PC26I3cnmBPoMdaTXPhjoOuaq+pSie3upRiVrd9m8e4oA8z0uHTtRsfHqajfC2tGulJmXoGAXA/E4qndrrmg6TpMmtafpmqaNE6NDPBhXAP3c4AJOD6167pnw38PaTp19YW9vIba9H75JH3AnHX9KoRfCTw8txG0r3k0ELBoreSbKIR7YoA622nW401JY1Kh4dyq3JUYrzT4V2mlXmha0NRWB7x7yX7QJgNwGByfTqa9XWMRQ7YkAAXCgfyrwjU7bTo9c1aXW/D+qw3rthFsAVjuRk4JwO9AFOCC2tvhJ4visj/oyamoiz6ZTitDWNUH9v+G7HStMhvtZXTocvdSny4wY1P3TkfjXQfDrwTJdeBNS03XLOW1t7+681IQcOqDGM8deK6PWvhlomrtbzg3Fvd28SxRzwybW2qAACcc8CgDzXT4tTtfjPYjUXsUungbzI7HG1RkcHAHNavww0bT5/BOv3ktrE88k86EuA3QDpn612ml/C7w/pGsxatbG7N7Hn96824tnrnitrRfCmnaDpNxptkHFvO7O4ZucsMHFAHgjr/xb3w+hUi2/tkibnC7d56+1dr8XdP02LTdAuLaGBZRdxqrJjJXB/wABXcRfD/QYvDsmhG3eSydy5DsCwJOcg44rHj+EWhl4zc3V/OIXDQq8+RGB0AFAHoCcIv0opwHFFAC0UUUAFUdWmNvplzLjJVDgVerN14Z0W7/65/4UALp0P2bS4YweUj6/5+tcx8NEji8P3ESTvMy3UgcsjKQc5xz1rrI5Y4bGOSV1jRVBLMcAd+tcz4Ednh1Yfbo7yL7aRGY02hRtXjO0Z7880AbGkEnUNS/66qf/AB2tkGsa0Ji8RXsZ/wCWqK4/AAH9TWyKAFooooAKKKKACq91GZbaVO7Iy/mDVimOM/SgDM0CUvpMQxjy2aP8Acf0qh441n+wfCOoXwnMDhCI5NhbaxHHSrejD7PcX1n1CS7xnuG5P865/wCJ9xdx+EZo4bGK6tpfkuQ4OUU5+Ye9AHj/AMMNau7Hxk082oLm4U+cZFyrhcng9jycc9TXda74gfV7rUtUBnTTbXTmaBWBRZiXKENnr3rivDHhzTdUhngjvbXT/sN2DFNLJ+8lJI3Bh34AxWR4qiuLCdNFhu3uLyWQq2yQsiqTxHg8Zzz+NAHb6f8AE650+7httMtbc2AtYtlqz/MCUBY7iexq/wCJPGOk+JvBsEdxGLvVriRvstrasdykYGT+deaeHvC9qfEEWja1FN51ydkE9tMv7pv4gST168V7P4M8I+HvCWrXMa2cvnwYUajdsMOWzwvvxQB4is9hHpLaVfT3NtfpdGW7R0yGHy8dPY16dL8Q9OW2Tw7p5Nlpv2UBdQAIETY3Ec9SfSvT7/wvomqAm80y2lJ+8SuCc+4rLfwB4WtLB1XSEeONjcBCzEswH156dOlAHmWo2Gr+OLnSb7StStZotNhVYFlDRSXG0AM20kZBI64713mjfEy3v9Xg0e60u+gvi3lyHyWKK3Q/NjGM15ve69DHqOoXOi6bqkGoXP7kTvHlLSNSAQoGfT0r2zw1HZvodhLBMLr90uLl49rycfeIwKAPPb+3nk8UardLl7eGZlmiD/M4cBdo9P8A69Ro/ibUbOSKYSDSoYtwjQjeSG+XnuAAMgV0PjW1tbW5F0fMMM5RbtbcgOm1iUkP0Y5P0qDStLV7q6jbWZ00d1UlZGC+Yx7Dvj6UAdhAn2zwxGtxIG822G91+Ucr19q850Dwkml6ZZzw3sjJMWjLS8l3OMMD6V1XiHxBp1jp39kWLrJcOEiSNASqjGclunStLUorRdCg8lo3traRG/dnIwueBj8KAOEt/DesJcar41F5tvZ7eVYoVYKuNpCkk+hyaoXnhCfQG0nxLa213eX9wdl9FHIDu3gjJx9R+Vbuq3Wr6tp8/hGxsZNzfu5LoPhEQ985+var9tf6wwOi2ciRSWQWFXxu8wbQN3OfU/lQA/w04k03VrS/m+yKhCGXeFMYxgcnvVq58O2tpp2n2slxLd2+02rySyZZ1fA5Ix2FZMdne2d/f6a8SX1xNbk/OdqzHIIDYx05q/d3mpzWM9jc6SLZbW0ScTq3yCUA/KOc8UAea+KPDlrofjrT7fwdPLbalGhMxkbEaJz1Y8E9eM5rS+F2s30fj/U49UUh9QHyyCMokjrwSuf92vQvFehxa54VmaOyWe7KCRRG3ls7LzgsCDjj1p9v4bTVLLQ7y+tvsN9p+HWOI8KdpBB56c0AdYOaWqg1C03lPtUW5TgguKsggjI5HqKAHUUgOaWgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigBKjeGN2y0aMemSO1S0YoAaoAPTFOoooAKKKKACiiigAooooAKKKKACszXjjRrv8A65/4Vp1U1CEXFlPEwyGXBx6UAY3iOK1l8G3aXlrJdQeQd8MRwzjaeB+tZHgzWbWTUp9HtljjiigSWKJVGUUnGGI6niul01Re6FAs/Ikhw+D2715bpdivhX4iXKaBb213p8aZvXafMkGeSWOPTnFAHp18Ps+t2M/aXMJz78/0rZFY2qeXdaQLqBlk2BZonB4Pv9MGtO0mW4to5lOVdQR+IoAnooooAKKKKACkNLSUAY1wRZ+IoJTwlynlk/7Xb9BVjWbQ3uj3VuFBZ4yAD0putWpnsw6f6yFhIn4Z/oat2d0l5aR3EfIdc0AeVHRNIi8Y6fAdBtItNuIy0lzKwBM4/h6dRgH8azNVTSNY8aWGh6JaxWsEM/nXVy6KGmccgBupHC+3Wu38WeEdPvZ1u7m1ae33mSQR8PE399T2/wDrVUtvh/4e1K3sLjTtRupHtZ/OWZpt7Z/utwOPY0Acro9rb6n8RLKzWCzVrKeW5me1GY3YMVCnIGG+bn3rf+Lmkz6la2Gy+e3hhYvIOcNjHP1ro7/T08KWVxfaDp8CmWczXgx98EEkgeuSK4608YjXg+l+JJFtBqDebp+1ANkYz/rPQ8j8qAHWfikWPis3Ml5fNarGFFoYxjd+ea2m+I1tqKWsmkkGNpQk6yjDoc4I/LmuK8c6hqlvPHLHLZPGxEQu4P3chHbkZP4Vt2gspo7Syl0OTEVqZ1uAfLLgZbIwOeaAOX1O010+JNR1TwXeXM+nRTFrjfIxQOT8wC9CMn0rX8Danrv/AAmYuNZGo7ZlMEcMUQW3UE8MRkYx9K1dB166sdM8+CFYrVpziJkAMzHJZc9mGD+Vbt58SdMgsHmtoLq4nwSsIjwSfQ+goAyZtL/4R7xNeajctLrOqagxSO1U/LHF9Og7/lVjWPD9/Np7TzrDaWqAFoQTITk9Ofu49q6bwxamS2bV52SS7vPnZlH3R0CZ9v8AGtfUIFuLC4hKhldCpHrxQB59pVrGHSK7sm23Uf2dJLeNRGFH8WRz0HJpuj3FtBZ6tolhdPdw28JYtsxhv/r1k2d9caPcy3t9KY7G3P2a1jEvAcjuPwNaXhKSLS9bHmBGm1HCzpC24Ak8ZHYfe/KgDVubzUoJli0lVmGox7w2MeXjhj+lZGga/d6H4iTQLzRZI7+7LmO4dsrKdpPXr29K6KFJdL1WCylOY45WMTH+4wACn8c/nWZJrug6r8TbWyuI7hNQ07d9mmDfu3ypz+hNAD7m71Kw1uzvdYt4IZJnXC27l1GBjGSBya3dcmi1S5Ph+O5mt7qRPNZkTKlR1UmsvxJrOga5bPYWmrWr31u+8IkgLgjI4H41s+GNS+3acVmm8y5gPlyMwwR2oAu6Nctc6ZGXGJIxscDoCP8A6xFX5o/MhkTn5lI64rl74atbvf2miNCt6zpPG0y5AUnDcfQV08Hmi3i8/b5u0b9vTOOcfjQBzGk6Jp8tjcW00KmWKaRTIR+8GScHd1rQ8OXAWCawedppLNygdjklegJPfiqGr2722rq9tJcbrsgNFEdoOBjlucVJY20+h3EAKQx29y+11ReQxPBLd6AOnFLTQeadQAUUUUAFFFFABRRRQAUUUUAFFFFABRSZoyKAFoopM0ALRSZpaACiikzQAtFJkUtABRRRQAUUZpM0ALRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABTHGVYeop9NPXNAGRoH7uzktj1t5TH+lct4lN9oGsyT6J4ct7pb6P8A0ubzArOem3r6DFdPCps/Ekq4/d3abl9NwyT+mKp+N9ObUfDszwxmS4tsTxASbPmU565HHFAFrRdWstYsZLa2ASSBFinhA/1RK/d/CptBkxZNbHrbyGP8BkD+Vch4A0pVvLjW49TVl1GIedYqysEkGAWBGc4wa6yBhbeIJ4uALiMSL7kDn+dAGzSZoz+VZGp6s8Mn2OxjE163RP4UHqxoA1HnjiUs7BQO5PH51XGqWBxi9tzn0kFcjqE1jpmq6fF4ivZrq4vpNkSrxGh54woHp3rRW90G5uNRs5LXb9gUNKzRsBjnkH2xQB0wcMMg5HrTx0rz+21VbOKbXdF2T6G8SuWeTGMZ3Y3Hr04rtNN1K31TT4b20kWSGVdyspz/AJ5oAtOAeCOCMVkWLDTtQk09/wDVyEyQeg9V/DNbPXmqOo2RuoQ0TbJ4zvjb3FAFvIdex9s9awdX0zTYYjciGJZi2F3PsBPp1xmkt5Z4mkuYR8+c3NseSp9VqS4/fhrqNVurST/WRPyU+lAHNSxaRqchhe1EMkRIkt7sMnzZ6qxIH49KsR2FtbfuxEsIbk/aU8yMemHGP51fu9OX7OtzADcwdmH+si+h7ioRE8KLJHJI0DdZV+ZD6BlOSPwoAhvbSG8hjlntIEvYj5kMqndDIw5wT0H8604v7N8T2HlzwiO5h+Vk+60Z6cf7J59qpSLhTL5YjjY4aaL54n+q9R+VZ91b3cM4vtPnMFwv3WHzRSjup7/nQBz2ueDNZ0e/+1w51CxXMnlc5BA6kDnoSM1Ts57HxDpipYsIEOGeJxmWHHUbRy3Xt6Vv+KPHV8nhO+WOI6dq8KBkDx+YsgP9w4I/OsD4eabd+NNNurzUIjZ30TgxXUShTL1JBXp6c4oA6zTr6fwyAYIWu9LwNyQnc8Xqdo5H0rsNP13TdWtw9ndxvkcqThh25B5Brnm0fVtP0+XzUXU5wCY2jIjfOOAegI+tcraajdyC4uJNJNl9kI+0tKvBBbp8meec8UAW9ch0rTtRlXV7Q3Kgu0LBScM3IOB6eprzDwjr2p6H44TyrqW5ja68uYFgQ8YOMnjgDNerXUXh3xBp9/cWEj3LxIrbW3hVxj1/xrn102Gb7Zd3On21sksbrby7iGOP4FAOcDjmgDvPEqIl/YamuWVioIzxgHOa4a2vdG8A+NrjT77UPtFhq0TTOzkEwO3UZ7ZH867nXYo28G2yRxPF8yCKIn5sk9Px/rXn/iTRLLxX4r0a3jso7S93q95PNJjKqMbQuec4HagBnhK00Ow8baz5QS1s7i2/0MyNhZs4JZT35xXTxR3k3w11KO2lkju4d0itEfnOO+ea6bXvCGk63HYQSBIDZuHh8sAFRyMAenP8qzIbcWfiW40O9czWl9DtQ42EAZ+UFcetADfD9xc2mm6Pd3tzNczSwStK0v38KpIB4rai8X2LaLBqkkN1HDNL5Sp5LFgd23lcZ/GsPxIW0CDTbLSdHmljtsuk6PkQr3BJOTnnPWsLVtQ1S/k0mzsNUiW5vZubVVAVIxkseRnse9AHfeIbiG1tre6klRDFOpXc2C2QRgf57VLrcBvNHk8rh0xIm3+8OlcSbX+0Z9S0bUH2tYh3hMrcHJyhX6Diuu8I3T3fhqzM5ZpVjCSFuuR6/nQBrWM63FnDKpJDKDk1arD0ORYpbzTyT/o8mFH+ycf1rbzxQAtFJketGRQAtFJmjI6d6AFopM0ZoAWimliKY8yRrud0VfUmgCSg9KqSanZxLvkvLdF9WkAFTxzRzwrJE6ujjKspyCPUGgDlNN8dW+oeOb7wwto6S2i5M7OCrcZ6VZ8X+L4fCcFhLLbPOLu5FuArgbSe/v0ryQXmt2Hxq16XQNPjvrvHMUrbQBt69RR461XxdqC6Iuv6NBp9uL5SksUm4s3p94+9AHv+/gGoLm4+zWktzsMnloW2jqcdq8z8fz37+KLSG48RLo+kJEXdoiDK544wQawvCfiW6i8Sapo1vrdzqtk9m8sM86AMpAb1A9qAPVvDHiE+ItIF99hntCXKeXL1471tg8Dr+NeA3GvawPhRaXUGoyRXcmoeUJVA4BcD0r1DwT4e1PR7R7jU9bn1GS5RXAcABMjPGADQB1obP09ao6vqiaRpF5qDxmRbaIysinBIHavMPibr2pWPi3TLGbUbvTtDkUmW4t4t3zccdD6mq2nS3svhrxNGniFdZ0g2LtE8mPMjba3UYGKAPT/DWvJ4j0G01aOFokuQSI2OSOSP6Vr56cHmvnvS/D3iS3+Gg1+HxJcW8cMReC2RRgAE9eK1vEXj3U49B8NWTXxsjqMQkur1VyVQAg4GDzQB7cGz/wDXo3jHWvCbDxZDonizTBpXie61uyuX8m4gniwVzjDD5RSah4ti1zxbqY1TxRdaNY2r+Vbw28ZZm/2jwaAPa9U1S20fTLi+uyVhgUu+BniuZ1b4i2Om+H9L1dLWWaHUJlijAO0jPevMV1y98TeDvEmjzatPcppyiSC68sK00fHB4FUtb0ma2+FXh51v55XubyNow+MQnaQMcdKAPoxJMqDjGf8AP9akzXiN/B4n8Baxod3Pr81+t5MIp4JQNozjpgCva42LRqfUCgB9FFFABRRRQAUUUUAFFFFABRRRQAUhpaSgDN1iBmtftEY/fW58xMD07fjUV/qEI8OXN7J5Zj8hm2uflJweD1+lX7uVYbSaSQ4RELE+wHNec+MtdtdM8HQafcaYdTEmTPbK+0ogO7d0PagDN0LQLTUTaSaPbyWovYmaa5s7l9lud2cBCQOfXArv1thYaxpVsjvJst3jLuSWYDaMknvXB/DPRr+LXrrWrC3istCu418uHaNzEAdscd67rUr6Ky1eS9mYiOzh27cfeL4IA9ehoAs6rqUyzJptgVN/KDgt0jXuT+uPpWHbahLb6rFpNisd1aujfb9R8wZjkweCPrtx9agv9Uv/AAzpZ1yTS5r/AFC+kVXhj6xJ2HTtk/nVfUrPTU1mz0qxgit7jVmF1ewtHuZlUZ5/u8gUASWsK6JHNbywT6pHaSGQ3tyA7xF+Rt3HoM+1T6Ilylvq0A1a11C9nBkghuECmNTnAY4561LdWEl1ban9mkjitxJGp3n5SqDBz9MVy7aJZDxLda3Feec1/D9naSyfa0YPVgB1NAHWXkVk3hKXSb6ytXuntmkNhZ8LIQD93AH05p/hCP8As4yWKWxtoHiE0VuxyYhwNufrk1iQaXLJpa33hXUI7q+02OS0D3SZMjbe7e2fSug0P+0pNQtZNXWEaitni5ER4Db2x/MUAdTQRQKWgDMvbKQT/bLXidBgjP319KoxsWke5ssxTjma1f8Ai+ldBiqN7p0VywlUmOdfuyIcH8fUUAZsbIJXu9Ow5k/11sTg5HXA7GnII53a60+Xybj/AJaQPwCfcdvqKr3EPlymXUYCrjhb2Ac/j6VG9rNPtuo2S9Qfdnh+WVR+pNAEoWIXJCubC9xzGw/dyf0pjRRCU/aE+xTnjeg3RSf8BB5/EVE13JL/AKLIyXH/AEwuPklX3B5JNIbxoP3BfcjcC2vflP8AwEnOaAIr2w2KY7m1jeNu5G6Nvoeqn6cVBa2aWcqzWbyRlByqHGPqoOGHvk1fS4FoRHE5gVhg204wr+yNUUyRGRBb5tbgciCT5c/7poAs3HimKwsvMu4iCxCpKnKFjx9R19KztF086zEHvZ2Wz8xjFCr4MvXJJHXnIx04qDUrQavp97pzEW97MhzvXCyMOmRnjmqXhazudKSyXWoZZZLEHyzCmRAckYOe2DmgDopdHsbTV/sdrFHBDd253pHhRkEYOBWBf6XH4es5tV1542s40ZfKjBd8k8FWIypOOeR2rotQurfULi0udOurc3UDkhZDjevpn61FqVtfz2Bj1C6gkMvC2ywhh+JzzQBVtNR0/VPDkmmT30bX9pCJZFD/ADRkZKkk/Qetc7qqpJ4JF7YWYm1izlCpK0YLRlmHJz2w1atvp8J0v7ZbaNYTXSrm7mC4EgHUD1OK5LxXqt8kLW4BtNPu545bm8zgLGMKFX8gPwNAHQXvhTxQsFhr0Ovvc6naRblglQJGwIywOM96Q3fiTUbS21/VNKWyks3b90j7tw4+b6cVX8UeLn1jSD4e8Ho+oymJEluos+XEoAONw7kVuWPiSyTwZaWlxbzCR4BAIkGcvjBAOe2RQB1kjQ6ppBVHUieE7fyNcNI2n6ZqNvcRiBL+4iMEckq5EcoJAb/Z+UfrTdIfTdMkXXNR1KVPsCeSY1kzHhs4yO5yTVPU9F0vXPFENmbgtp9+A48ltrDIzjPbPWgC1f6ZJbaS9/f67YNPvDyuz5GO43D5iPbGKk8P+KdI0vW7mzk1i3ltpYlkjnLY9c8dqytR+GnhfTxqHlaJqd88MYO3dkOCM/LxyRXFeG/C+jSTPf8A9mz/AGSKcxxLcW+VLd0c+3H50AeqyfELwpFrcNzHrNuRIhjlwG4xyD09TSH4weFBIY1uJnOSBtiJ3fSrN34N8OppKXtho9hFKhWUPHCOgOTg/QV0NnpGmbIbmOwt0YqGBCcjNAHFt8Y9JNwYo9I1eQ5wCIMbvpk1FcfFHUBcstt4R1N4j90soBP/AI9XpflrkHYv5Uu3jB59eKAPMpvG3jp3zaeB5TCQMGSQBvx5on1n4ozsr2+hWNujD/VtISR+len0YHWgDzSW1+K12kUiXulWpx8yAZ/P5aWfwx8Q9Qji+0+KYIZFHzCCEAfy5r0r2pcD0oA8y/4Vx4hvYFW/8Z3wkBzi3XaPzBFPX4S+db+Vf+JdYujnOftDqP8A0KvSsUtAHnUHwe8OrA0V3JqN3k5zJdyYH4Zrt9M0230nTILC1UrbwIERSckAe9XqKAPLdB8O6rbfGPWdXns5EsJk/dzcYY4xV/4n6FqOs2uiJp9q9w0GoJJIFx8q4Iz9Oa9BxzRigDx3xN4Z1az+JJ8QDRP7espIQiQsAfKbA7Hiq+m6B4lm8fSaveaGtpBPYPFHHDjZGSDgduea9q/l7Ud/agDw6Xwhr7fDOy08abMbuPUVleLjIXeDnr6Cva7ONorC3jcYZYlUj0IFTfzpR0oA828bWXia28QwalpthHrGnMu2WwkQEA+vP41ymjeC9cmvvEerNov9lx3Fm8UNijffYg9QOO9e59zSY5oA86s9B1OP4Lro72rjUPszIYT1ySf8a5vWPAmuT+HvDWo29kk19pcYSWymwRIO46EV7V3o9KAPHNN0XxL4h8R2M8/hux8P2Ns2+XbCheT6EDio7nwzrnhbxTqVxa+GrXXtOvZDIgkRS8Z9yR0r2fv7elFAHkeh+C9fm8N+IJL22trO51CMrDaRRqvlrwcZA9qyLjQ/FWqeCdH0u50KSGbT76IYBB3oActXudH0oA89+JGialq02gtYWjz+Rdq8uz+EetegxgrGoPXApad2oAKKKKACiiigAooooAKKKKAGs2KY0yIjOzAKo3Ek8Y9axdavLqS9ttNsJkimuNxabqUC9cD15rz+7lm8NXAi8QzDVQXJnu45GBgjJwNygj+VAHpT+ItIiQPLqVvGh4DNIAP51chvba4i8yG4ikTONyuCK8t8ef8ACO64uhWMmtW9pp5dZSI0JaRQDgZA47dcVuXV74U03SbbUYWa4hdlto/Kkb5mA4yB245NAHS6hOL67TTIn+9h5j/sen481x3jXwV4e8R6vaXd1qn2Z4U8uSOKTBdRngj6Gq2gW+m6jdyS3l6lrLvZFt0nyY2YYAyCc/nU9rpvhvwteavpialNc6jeRSTLA4Dsh2HJU44PHegC0nizStG0ZLPw/DLcxWxEBdVLCJjwMgdauwaZJa61aSXNpLqMlyGlecuBHA4xgBce5+mK4nw94gt/C/hXURZ6Jey3Sj7VPNer8srF8AHGBnB4xXXD+1fHOhIZWvdA8uXLqCpMqex5oAfpFtqfiLV01PU1lsBaOyi1WQMJB0BYYpLu3Tw/rOra3NcefdXpCW67ceRGAM4/HJ9ycVnWU+l+Coza6XPPqmqznyi8smSxH5Dv2qvqH9ppqNjAbiH+37kiRbWRSVCZOSe2QAR+HrQBXk15PtVhZtaS6kWl/wCPC2bPl5OWllHOBnkDjGa1/HkHiSHVdM1LR7VpNP0/MtzFE4zJ0wu3qe9ZY1rR7vXdSsPDsX2XxVJGsck7Idp2su4YPBHHXFdbY+G3s9dOtXGqXBuprfynt3dfL392Ax7frQByvhrxTAPFGn2EUMenw3ULS3VugyPPOcqT2IwMiu08PK91c32pyIV8+XbFkYIRcDH5g1zWlR2yadLYWzmbUpLtopbmSAqxHG5hkccH9K9BggEFskScBVx+PrQBMvSlpBS0AFJilooAYyKy4IBHoazbjRbaSXzYd1vN/fiwK1TSYoA56407UApRvJvYuwkyr/8AfWf6VnyxXFqpX7PNAvaNh50f6D+tdhto20AcA93ZWykXCT22P4o1O1vfb1H50kG66j26fqVrdIeWt2YKQfcE5rvTbxN96ND9RVZtHsGB/wBFiUt94oNpP4igDgr64v7dBBd6ddFF+6Y1L7T7EDj8avyaBrGpWkMseoNYkDYcDJljxzu98HHPoK2tR0+LTIlurTeuyRfMXcWBXPPXIrTu5If7KlaSYwRGLmRf4BjqKAMDwxpthHp1xpX2G5CWkrLvuskyZJ5B4yOPfrW3DotlaPJJBAFdxgtknjHbPSuS0abRoNe063h8T3NzMYD5ULkbJc4y2ccn2z613vTA6AUAZHh793phs3xm3dkYY69/61zz2Fu+uXWj6lAJ7G5iKru6AE56fWt6ZnsPEcb7R5N4mwn+6y8/rkCsrxlBNFJYX1u5EkcmCPVepoAzPh5f+HbMan4f0yM201lcOpjlkBkk5PIHBI9ODUXg221C/wDGGu6reWnkWizmO1R4iCBk5YdsnisTQdRlsviJd/25ZrCupkJZzxx8YYZzuxwfxraurTxL4K8OXtxb39vPY2r+anmBmkWIZyCT1wKAN27ih03xZBM0KfZr6PynXbldwJx7dSO1ZviDw9ZaNdDxBp9oFmE4e4ZCTwRtzjt1qnHHrup6RY6rqNxbyxebujjjBAw2Ap+uf5Va0iLxVd2ebi7t761uHff5i4aIAEADp3APNAFrw7FNN4u1PUp761miuo18mON/nVQMfMM+47CrFr4Skt7LW7R7lHhvp3uIUVceSW/z19q5K31TSNH1LUNUjsWl1KwhERjEmTvGAVGDjnk/hW1Jq/iCwsk8TT75bK4jVm0xyim34JOCe/1NAGz4UuBdaJLp0jDfDuhI9iP/AK5rU0CZpdMVHb54mZCPoTj9BXF+FdZmn8WSb7CWxgvkLJDLgnIB5yOK7Cw/0XWr23IAEuJk/ID+eaANkdKWgdKKACiiigAooooAKKKKACiiigBKMUtFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAebX+pNo+nXeuWOlXGoX81xJHFg7sDjBAJ4H+FU9buZrnSra31RrWzvrq3V7lzEu6Y7jiPp2AFWrxtV8Oa8jTX7w6PaK0iIB8s+R0Y54xj361Q1K1sYza6hqOm3V5rWoscQQS+Ytup43qOwxQBk6VYWvhaC/R4LXVJJgJobO8jXK8jp17E0+512LULjSp9I0SGyuow4e1mISFE3Lu+Vcrnv0zU2o2+m3t3NJGI54LWHEt2hw8UigfKVx8x45GRXW+H7fTb3whbapfWkNw7QiRykAXcMdl/D1oA52x8O6bNo9rBdX0MFxb332lZ7SEfvMFSA2R6irt3onhjUbvUZYZru4v9SZN7QE+YgUDIUk8A7SOMdam015PEF5G+k6OkWhz2zGO5lQLIsuDj5cYx071Us2m0250/QdcjEOpzBzBf23CjltqsR39qANrUdefStKgtH0wLbBVRReMCSBwCevoOSe9Zuo2PinXtIungvYYJGhzDaxNzzjGfanawG1myh0++miF980DwScecASwIPr8oNS6BPo+mahJqV5bS22oTwhJmBzENvAUZ/i68UAQjQtDi0XSbTWruLTtVjZZnMUm2QvkfxcHHHejVdSv28YJPosNjdf2fGsVytyAsgBOdyuRnGG9e1YOueG9H13xveajqN5apHND5cdvdKBIr87WAz0ya1ZvCf2mzE/iLXhDKF8oC2crFJHjChlBwTQBan8UaVa+PZ4f7GQzw2Ykku4kBIYgED9awbxNa1mzfxFeag1nerKJdItkJ2hcHhkA5J46irGi+D9cgu3fT9dulgeRWa7ki2DYowEAzgr0x06CvRrDRrWwdrst512/W4lOT9Aew9qAMLQLy9JGo6tY3DXbgKAqAKq+vXr+FdPa6vZXL+Wk6+YOqtwa5u/vfE+l6fd/vLK7vZZcWMH+rynfscmqmv8Ahua8dr60vha69c24SJHf5FYcnA/PtQB3wpa4zw9ca5pNlDa64jSvGmJZl5UHsQ3fPcV18Uiyxq6MCrdCKAJKKKKACiiigAooooAKKKKAK93AtzaywN0dSv5is/SjHf6MIbmNJAu6ORGUMOCQAQfatYnrWPZr9j1y6t+qXCiZfY8LigCtJpYtNSia10nS0sreNikoTa8bew24x170eEdUvdW0mWe+MRkWd4wY1IXaOlcj4u1G3svGUVpHrOqQ39xGRDbhj9nJI7/Nx1rc8FWWoeH4ItCvEuLoiPznvmOUZz1GaAN3xDbmbTDKpYPbsJxjr8pBx+lU9dUXuhwXQDHbtbaOvzYU/wAzXQSIskbowyrKQfpXO6cZJ9EvLOTcZbdnUZHTuMfmKAOd8TpBf/D2b7RJLbfZpiEkjXLDaxC/QVlaprmtajZQabrOmXFpo0jKk9+uGLr3LAHhTk5/lV8aXqWsw/YrW6zaqmbiJsDL9SPpXTac9vqGi3Gnanp3lWkGYClwNwlQd8HsRQBYupNNi8OvFDNEIoYCyAMBjAODj6iufh17+wtNl321zLHdYNqYxksSBkc47kn8K5vwXZaT4r8V+I7mOJW0z5ILeEdBtJOVHQV2U0f2jw+baQ7mtLhU8wnJA3DBDfQ0AcifCM+heF5L2d0fULm6aZj0wHYsFPvyOfbioPiD4ltLn4a3Gm6nexDWfKEnkQhuODjnAFdxBPqHiKy1ix1TTDaRxyFbaXdnzUySGHHXArE0pIdYmfR5tHilia3y9+65wccKfegB0khsvD3hfVi2DCUSR854YgV1epuIr/TbxM7Wk8tm7bSuf51wk9zfv4eXSJXGbe4CMyR8ptIIHpjHeu2uHW88MJMo3FFU8eqkZ/SgDoQeKWoLWYXFrFOvSRA4/EVMKAFooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooArXlnDe20lvPGskcilWBHY1xkXgm40jxM+uWFy10zoIjDcEcKPQ9q7s03HPoaAPJ9UtNJ0nxdFrl+BbSwNk2cdwrB3IwDt7k5ziktrjTV1uXW31LWbgpITHZNCY0HPC4K9qtfEjTdIs3uNdvZJ5pI0VjbxYwACAGPFYOieNI5xDpugwmfUppBPN55GPKA+6pOOeR70AdjJ40uE1Syja0GnadLL5W+dcbzx93OAOtU9M0zTr/XJnTUk1LSLJjLJHctvkhlGWypHbkVFN4hXxX4Lvr250OMX2myl47S5yvzr0wQecn0rL1PW5rvRNk8cWm3BCGWwtV+aUEjJJ54x70Adbbzu8YuhbLNf3U7NaK4wIwMqGOfbn8aSze41DWpdLvVvvOhHmmcQlbdj2CkjHf1NcbbreQafbaLp928OsX372GSTny4d2Sgz+HSuj8Y+IL3QNa8NWr6usHmttnzHuE2MA5IHHP0oAiY6zt1SS7tfMvIGItog6750x16URarHpQtr8wx3cW7ZcwqDJJaHGeSOPwxW/daJpmm+I38VXE87XPlCFYwxKnrwB6kmsSWXStOvLyL+xPskV+rTXLvNgyELx1OBnAGKAN3xHqekXGl2+n3b3UUWq4SNreM7h37DjpVTxdoMn/CER6bp6XU7Wpj8pVlw7bcjLNiqfg/xKNR0nULm6tbjy7FwsH2qIeYBjgDjpzxV3ULq8t9CfV9VimuVwGSwtgSR9e+enegBLm00a+utP1LU4pJb6yUN+5+ZUb3I+lbculaXrdzY6sw814ATBIGwOcj+pqr/Z15czWF1Y3RsbNUJltDGCZMjjcSM8fWs/SNVltNMvbC1iiu76zLNGkcg2zAnPHPGCcfhQAfEa6/s/QIr5IbyeWCZWiitf4z0w3ByvX9Ki8FeLrTU5v7OLNDeGPzTayqVeM8bhg84BOM+1V/HHiDUrH4dtdtbxWuozKEWNsMUYjPHXnrXOfDy1S50a61SWzvP7ctyry3Vyu0zA5+UYwMcelAHsgINLVe1nW4t45VPDrnNWBQAUUUUAFFFFABRRRQAlZGuI8Sw30Q+eBsnHUqeP6mteo54hNA8Z6MpBoA5nxT4StvFi2bS3TpbxsJWVMDzB2564/GuS0/XrDTrzTLHUNQuZmtrtolezU/Z48kbVc4OSOe/au802Rl065spifMtg0f/AcHafyFeKaTeQ+FtLutZu2uJwdSkFrapGCtywbqcjPHH50AfQatuAOfyrFtl8nxTdxhm2zwiXB6cELxVDwXrmt67ZtdapYQW1u6Brd4ifn+oJ4/Kr+trJbS22pwEYgYCUH+JD2/M5oAzNLA0/xVe2bfcnO7GMDLc/1rk/DfhOD/AIWnrNzLqEji2ffHa8qAHJxnPUcV0ni2WXT5f7UtMu4j3xY6M+MD9Ca818MHVbPVry68Tw31pLr7fZ7e/UrmI9On/AuPxoA9B1bwmNK8W6NrPh+wZSZGivFhcKpQ9CRg+prQttPl0rUp7CS7kuIr5HkG8Z+fJ4/ACpn19NF1vS9CnlWRJosm4lkG8nnGR7kVc1SdE1vS/mU/vCDyPl+U4P0/xoAxvDEV7L4lvbqe/V7cwrEtqTzGyAKWx780Xd0+iazdTW8W/wAs7/KHBkD54H02/rW1YQRR+ItSuHCK6qgXA527ea5nxLEuvvO9ksr26wsZJNpUZQDAB75yelAEGganp2v6pr0MFx50giy1t5ZBjbByN3euk8JzpeaFLbY+VC0eOn1rzbxjoYjj0KPwfmHULeNppVhceZsHchvvchh3rf8AhncX9pKYNZ3rdXUbPlxt34Y9uMHAoA7nw/KG05rcNk20jRAegU4H6Ctgc8isS2T7F4juIeNl2olX2K4B/U1tDpQA6ijNGaACiijNABSZpSa4b4i+JNQ8OW2kvYFAbm9WKXcP4SDQB3GaM81VmmZLaSVeqoSOPYmuT+Hvie61zwrJqWrTQo6XLoXJ2qFGMcn8aAO3HSmk8mse28V6Hd35sYNUtpLgfwLIDmqctxqg8ZLGLq0XTBFuaIsBJn160AdKDmlrIHibRTdw2o1O1aeUfIiyqSf1rRmuoLeJpZpkjjXks5wBQBLmjNZQ8SaK18tkup2puGG4IJQSRRB4k0a41FrCLUbd7lesYcZoA1aM+9Z2o69pWkoWv76CDAyQ7gH8qrTeI9N/sSbVLe8t5bdELBvMGCewzmgDazxRnvXM+GPFtprXhu21K5uLWCRyRInnLhCGIAPpxj86r6z4iW/06VfDurWH2uKRQ5klAG3PPU0AdbS5rPsL+F1itpLu3e8CAyIkgJ6dcelTw6hZ3E7wQ3MMkyfejRwSPqKALVFIDkcUtABRRRQAUUUUAFFFFABRRRQAUUUUABqvczrbW0szdI1Zj+Aqc1ha+73Kw6bAxEkzgyFRnagIJz9RkUAeO+KNUiuvEMCQa0FvLhHa4icboSmCVUj1x29RV/w1p/hHSo/DOqubtbx0cwlskM2V4bBx1rnZ7RrDWfEFxd6DFDpszGJJpAN8WDgOgPXOB3716HY+I/D/AIb8DaPFqFjdPGIhDj7MAQwABJGeM9aAN6XTkl0o6nrt0uzaXMcaAKpYY6j7x44z0ri7aPTrlLdrOwuGKPJ5dy0pJcEHO7JyRz+ldDd3tu/gXUfJuFW2LsLZpE37RjgBc9f8azNIhFrbSMbB7cFY447uTOJULDIC/wAPfj0oA27PWfDk19p7XyC3v7YC3gaUdTjov1wTVS48ITXvi+41LxFLBPpVqxmtGdyGQk5x6YrEvtAtE0nULiw16W9IvgyBIxIbeQZAH3uMcitbVtQ+2WEXg7U547u/miP2mZWKAYxzxnmgCzZz6hd+Jrq91HUrSXw5aATWpjAGM568c4wKz9f1fSprq1XxHZTvb6nOi2iqAAgDAgsfqPyqSw8K2tt4RntLm4kh0S1iYq38cjY/1h+mBge1QR2+na7Y+F7Wzsr7VtMt5WYXwchomBP3uOaAOomRZG1lbceYI0iHBz0A7/hTLG/1o63Je3UtvH4Z+yK6lgAwYgZJOP61DHdzaVpGrW6R24uUmJiaViqzbyTgnHUKT+NZ+gaiuq6NeeG9QsULvEWt4XfKzRntuPpwKALx03xDPYahdaTr0MwvZFe2MiDZHHn5sEA9qf4Y0Gw0TXZ7fT4ijCENckyFlMhPIGe3fpRo2rr4a0LSNN1i0jsbi6kMFtDbfOiDgDJ49apWtt4h0K/upp7mG9u7wSC3TG0HAJGSM89BQBwvxmj1mK5LyPNcaQzq/nDaFgYAjAwfrya3vgxdz3FteRILx9POAj3LBsN0IHJrnfGaXGheATa6xLdDVNVuWlEQlLJHyeP932rN+GaaqYNXOjzj7S9k7QIZSCr8c7cc/WgD3vQj5UU9mf8Al3lKDP8AdwP/AK9bA6V5h8JtV1fUTf8A9tTJNdo2xnXsR2/U16gOlABRRRQAUUUUAFFFFABSGlpDQBi3Y+xa1Hc9IbgeVIfRuxP8qwPiBoNjP4be7Ci3msmM8LRBQd2OQFOAScd/Sut1K1F5YSQkc43L9RzWLqdpYeI/CTw6xGWg2/vwDhlYenuMmgDntBmh0nxOLu/1tFivraKO2s3c7g2TyVHyjPHSvQLiJbm2eJwpDqQdwrxTw/eR6prkF9rXh61XTYXMem3sqASMVHyKODuOenI616p4Z1TVdWtbiXVNJbTmWUpEjOWLL68jigDPitjrXhya0mLefZyMikcH5chf0rFnvm1fw7Z2ZhIu4WEmHjDFAmMEkjGa65MWviGWMBQt3Hv9ORgViSwv/b39mXUk0NpI7ugicjzN2ODQBF4Z8KWl1ejxJqNzHqd+6bUkKjbEATgKvQEZ9KbFpNprHjnV5DfJNsgWMxpK2+F+DnHTp71h6d4ju/Det3fhLSNGmurqOffH5jkKIzj5s4+v1qS6uvEvgxp746Laag96+Xlt08tlY8LuABzjA5oA2Uu57ZG83c0qA2pbBJY5AQn3Kgmo9eUQW9tZwvItvp0Qkm8t9m4Y6Z454NO0qbxBYW7y6xbxG4vIjJtXjY3ZOnXBPNZk7N4g8PTzS27ixEEkkkjMf30hHBPoBz+dAFLUtMj0XT9L12LVxayfaUWaRlyTGWGUzg8YJ/OtzxhfaPLcafMmoRfbnXMMUbtmZCO2306/hXOa3aahqWiz+HzMsVq80XnS4BCDK5+gx3qr4j8IQeEta0bWNIsdQuFtodsrQr5oOQRzzxnNAHdaf5+s6RBdW8xGo2LkIZP4l7BuvUDP4Vrw+IkhZYNUiNncEcbh8rfQiuL8N64JbX7ZaN9hvS5WSwvBt8xQcLz1HGB0712Ka7Y3CC01WA20jjHlzD5ZD7HvQBuRzxyoHR1ZT3BzUlc1dabZ2MTXWm6gLAjkYb919CvSucb4u6HYxtBev5t0g+7afOrfjxigD0fNNkkVF3MwUepOK8rbxx408SRh/DHh3yrZsbbq7bGfXAx0qT/hAvFOvYm8R+J5o1LAtbWYIT8DkUAdreeMNAsLyK0uNUt1uJWCIgO4kk4xxXFfGuJ5tH0WONzHI1+qq/8AdODg10GjfDHwvossc8WnrPcJg+bcfO2fXnvVvxf4QTxXBp8TXRt1tLlZ/lTduwOntQByE3gTxilvI7eMXKbOQUAzx06VyemvpsfwMni1S7uYYZNQZSbYAvIRj5R9f6175JAJIXj4G5ducZrzub4TwN4Fbw+NQcypctcxXGzlWOOMZ6cCgDy7XBD/AGTpV3YeF7jSIo7qNReuQrSfMowec/8A667i8cv8UiXOWOinOR32irc/wx8Q67p0dvrvih2WB1aFEi44xjPIz0/SujPgJW8Rpq7X7F1sfshTy+vygbs59s4oA4n4PeBdIvtJj8Q3sZnvFuW8rcxxHjI6Z5rs/itx8OtVIzkRnr9DWt4L8Lr4R0BdLS5NwFkZ/MZdpOTnFTeK/Dw8TeHrvSjP5C3C7fMA3Y4NAHiviHwjp2l/DLQtRs1dNQmmiDXIdg3zNjHXpzWn418Kad4Z0vwvqWmoY7w3cSyTZOZCy5JJr0DWfASav4T07QzfGMWbxv5ojzv2kHpnjpU/ivwWnifTdNtHuzD9imSUMEzv2jGCM8UAeb+JJtFl+Id6yabe+IrxlCNCoHlwdsDJHNVvAumxXkvjTTb2xa3gjAkWxZtwhYbulddqHw51q28U3WreHNbNkl6d1whjzz3I5rQ8N/DqbQ9R1K7m1qe7a/j2yh02ktzznPv0oA821bSbGL4NacbQJHNeXYWZ1PJJk2jP0GK2vFfgnR/Cfw6E9hEy3NwYWmlZiSxyvvxW2nwjnXS/7LPiCVrRbhZ4kMP3SH3Efe9q63xT4SXxJ4di0lrloAhQmRUyTt7dfagDzPx7jw22jeJ9Juli1V7dYmhxkyJgZOPb1rrvhNolpZ+HzrIuhd6hqDb7ic9j/d/CpoPhrA/imLXNSvDeeTB5MNsU2qoGMc59qu+FfBMnhXU7prPUnfTJmytm0fEZ9jmgDshS0i9KWgAooooAKKKKACiiigAooooAKKKKAEJ7VzcUT3l3q9wbgxR7DAjqMFRjOc+uSa6Nj+XevN/EHiS88OeEIb6waPzjdhCJVJViXAw2MY4OfpQBleE7G0i1xnhtbrW45A8U1/LMNqFTnGzHYrjrWlLdT+INQE0Fnf2N+JHgFu/EZjBwX6d+MfU1NoPiCeTRb+9v5bJ43YIltpy/KrEDq3Iz+NZ8N1f6H9pgsbi2NzOUVXupQwU44UYP3j7elAEviXU/C1mbDS0ufMuo2LQRh90bOcAlyOpHFZ8ninVVvo9V0qzOoadZyfZ72NkKsCACWXrhQGHatHU9HbRkt9WvzYl5W8t0cHq2BkY5J/wrEjvbW4tE0efUr7SUF0z+aYdq3g2A4Hy8Dt07UAS32mQ6gk2oeH9Jt2syftYuXnCq0275gfXGWrRhvFv9RvZ7eCKTVpLZZ/soIBkZewPXHNT+HLTXNStTYXD28dhE52mBdnyAnHtkjHaoBdaTB8RbzQ7jTDaTiy2LqEbFjs468kDt2zxQBp+G9Tihh1nVdbF9ZxNgSRXq7YYxz8qZAyPxqkLPVbD+0bp9cU6TeGP7BFAPujcM4GfTPNWPCNottpF/p98Ybvw2PmtbueUO82eobnjHy9u9P1Mard2Av9Is4I7e2BW0guDtDLzubBORkEj8KAKniF4TYWVjp81q6cyswlDPvwcj9TzXO6Nd6eb20urNpEu7dTIIXcYTp8jZHOe30p9voV14ospxZtb2E1vljbuflf8A56cg5UbvepNMupo44r3VdPS2XRwFuEt03eZj3Gc9O/rQB6XpF/d65pclxPpz6bcB2WNZ/mYYAw3QcZ9PSuR8PXN9d62n2vxJbaukFy8eyKIoYm2/7xzV/SbTVrbz/E19qtxdoInlt9PiUIm3HAIIyW49az/DrzT62t4NCj02zvbgyxEZEsjBcEMCfr2xQBynxhn1BPEgfVbFJ9EiUC2HmbC0hXk574JPFJ8GEhkfUtUvpVAsYRCq7fuoRzyev3a9D8ZeBbTxHdW2pmeSOa0BJCHIkUA8Y59R2ry/wV4t07QNR1rTL7TZcahc4EIUqUTnlge3IoA634OSWsj6q9ju+zNMxj3dce9etjpXm3wu02CwgmNsqrFMolULnABJ9a9JHQUAFFFFABRRRQAUUUUAFBoooAaRxWLakW2u3Vq3EdwPNQepz838xW52rG1IGHVNPuh03+UfoxGf5CgDM07wrFpmsXuo3N808MrB4oZsbYMc5X05/lWjpHiC31e8vbaCGdfsrhPMkQhX4ByD071fvbWO9sJbeRA6SKQVJIB/Ec1xula14lsdTttMvdCtFiaRo/Mt5h9xQdpKls9McmgDote3wLa30aFmglG4/wCyeD+tU/FVqd9jqMLbZIJQo+bAOex/KtrUrf7Xp08BJ+Zeo65HNY0Pmaz4M2ZP2rySOeokA/xoA5nRNZsr/wAd3GoJPb26iARThm++eccn3NTfEzxGmnw6dYPavNaXkqtcSiMsqID+hyBTLbQ9PutL1O6W1RL5H+0A5IBCgfLj0+U/nRo2oaZqPw6vbsRpdOA5mgmb7rA4x6gZHWgDpNTlhFlpE8Dj7KZEwT/cKHB/lWJY6fqkepS6ZHPEkUijziF3BQpPGOg3ZrJ8N+C9M1jRbLVre6u4AoLGBJt8YZf4e/eszxl4hv7Dwlc21msgv76dYhLHwzBuh+vWgDs7rw8dF0cvC812zRGGY5zlTnBA/wBnJP4VyE/iPULSyg0lPEenaSFY/NdRlnCY+U5LDngVyXh678S6vDLoD+KBZyWucW5/1sx252gtnrwPxrY0zwLoqNJqGrag81zGB+6KM0iyf7QA+71596AM7TPF9xoN/eixvz4he4O6WRLRuD/dyCRjn9K2dLk8ea0txpdumnadBIxkZpRllDZ5UZBxWg6rKYJomtLWCOVYWtVTAPynLZ6kHHY8d66Gx8JWWp6VBevdtaxyJukS2chMd+Tkg4680AcJH8Po5NYksdd1i81GBo9yrZjBV/8AdGTjgV1vhq30Xw0JIRp0LIvDTbMSoPV1POP9rgVZ0vUJdDvJmltjesD5atGuXUDofTHvUdxp83ifXbSd7s2zBTPGsJ4Cg7cMcctn1zQB0h09liXUPD11Ggc7mhHMUo6ngdD71p6RrEWqQupQxXMR2zQMfmQ/4da5ZfO0vV3isrhBdKu+W2U5Sde5C/eDfjjnpWtc2v8AasEOt6M/lXwAIJ48wf3XH6e1AHS9qXHFZ+kaiuqadHcqNjHhk7qR1FaNACYo2/SlooATbRjmlooAQDFGKWigBMUYpaKAEx0oxS0UAJijFLRQAm2jbS0UAAooooAKKKKACiiigAooooAKKKKACiiigBrVxur2jaO12/2WK6067JfbKgYQzYwpIx93getdpTGjVgQwBBGCD3oA8n1XV47Tw5JofhxtOHiCUqzx28YCtnksMgA9awfD+i65N4yaDULnS5LwIsslu4OEVeNy4XAbmvStR+Hfh3UL6G8ltGjkhk8xTE5UZx3x+NcnrFzY6fqirDC9o1zL9mgdFyZiODubqoz6ZoAp65Nay+NDKJBdWcNyk1ytzK7LGQeBGBkdvanR2d1rsd7d388qaJbyGffdRjziB2UDJC1fm8HWT6e1/c38VreWFx9qmMHzjauG2Hke/wCdWPDFxptzBqutxaze3NvqitDBa3CY2EDGFBJHNAGdca7ZaVp41zQ9UvPLvohDawNEWjhKkbmx1ydp/Oo31+DxH4g06fy7i2iijK3TvbqBe9PlB+8OntWl4ft9Y0TTG0SGZnlWRn2LGCURiSNx42nkdM1dtYL9dTu4pvPbUIYg/mCPzdwPRUcng0AcjHf/AGOaXTLTT1txCMRQXLsVQc/dHOW478dKt2f2jU/t6SX6QWjcbpJmGCAMMoGeQecdKsxTJ4rvr20s7O9tNWhiAa5vxuEb5PGCeen61ei8NarN4cSCx0vTLS/guFR5uMSx5BZhgcEgmgChDbajBbrZRyrbpcR/vtQmUh5VXgYx0457Z71Lf6zplpoTaPpMcskGR5903Afrkk8Ve1vGj36Ra3JPLovlr5arKzyTTkj5Qvp9449BTp44p/HNppiaBM2lyWhd1xiEnjG5OmR/jQBT8Nx6nrOpzxIZYNPhj2CV5W3bx/Dtz2+Xn3rqNPWGfVLbyJpLsWcDfvWB5fcw6nqeormbjQf7d1LVNWbUdW0P7OTG5VyEZFGSQM9McVueHdZtNE0yG01O6SCCWXy7AzN88o9/ckk/jQBb8P6lrdzc3N3raxWFqZGigt5WAc4bg+nIHrXDX+j21x8XNZ0q4URxanp5f7QR8yEYyV9OtepatotjrMEUd9EJEikEqZONrDPOfxrzTxsEb4qeGp4ZG2zM1tOw+6FJHGfXigDvvCtjHa6bvjTarHCA9Qo6ZroaiijWKJY0ACqMACpaACiiigAooooAKKKKACiiigA7VkeIPl0wzZ5hcSAfStesfxAN+niDtPIsZ+hzn+VAGnEd0CNjqoOK4i6t47Dxu13pUMt9qE7hbsPK4WCLaOVGdpOcV28fyxKPRcfpXPNq2rrFqTrpUO6CVVtx52DKp27mPHHUn8BQB0YHGMVh6fIbTXrzT3+5JieIbcA5J3AfTipb/XFtNAm1KGI3RiTLRw8ndnkD6VSW8F/eaHq3kyQLPGy7XGGXdt4I/CgDIure80q8vbaxhSbzYiCJG24RsgY/HNc7ovhGW2N5aaABbvdRsl5NcMX8lyd2AhyvPrius8c2yzLZOQwVpCsgQ4OzufwyTXMeHfE66Pr2qaFZ2s9zfS3CmIl94K+WMMxPQdu9AFnSPFFr4Mt28N62rGSHJWeOJQrKe+1eRjjt3qG/mvLvS7O/8MQwXty0ZSMyxghimDlQRwee9dhoOgSRTXGp6vFbvql0oWUoM7FH8IY8kVzniyebRNLvn0a3aW5gmzBHCMffzkAD0wKAMiK6OqeGtQ1vU/C4tdds1IWRFGXfswx3H9KZ8J7/AEmz0271DV9Xil1W5YyS+cxLIO45HsOKzfC0nxM0B4YZNM+12N3Lvfzm5UE85JHHHauj8U/C/wAJ3SvqcySWdw/zyC3flmJ5AGR60AU4Lux8V3up3Gh6e8tjauPMPQTHJ+4c56546HvW5o+iR65ZQRvqsqwqrrPZx/IJN2O/DDpV7QNC1DTNLjtLBodNgjUCGMIHaQ45Lk9OnT1NZO+SXX55EWH+0Pmj8u0fADD7zMeOT2oAXwprU2lXmpWviP7LYwwt/oiOQWMYxyW5Y/jUV7e20eu3GoaSJQuzbG9uRtZiMlsHA/KmW2iaBqHiLUtW1uNbu7ihJWK4jwNgUnBBJz3qTwRDpniAzzxQyW1lYzOILR0CBCVIJHcqdxPpzQBRjXTYopZlS9l1dwrearcI3JxweQa6nQtTgt3Nw7FI52CzqQQIpemcdg39Ky9K1WXQrjUrf7Gk6q+9JYz8oQZABOOD7UTX8mo6qIL+2ksjqMJjjI5UsOmfcZHNAHQl/wCwddMjsF0+/blu0cn9AeB9a6UHIGOlY1jGms+Ho4bwK+9Nj+xBwCPyzT9Ankn0sLLjdGzRjBzwGwP0FAGuOlLRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAMbJVh7GuG1G81S08K30+jw2z3lvdSb/tONqJk5PrXdHrXNa7pxR5bjyDc2dyvlXduCeV/vDmgDz3wjrx1Pw/ql/Bo1u11cbpL0ZwkoAySF6+ver1kNN/sWzuYLS4DPeBZGg/dLB0z1B4q1eeCbSXbf8AhSeGMCERi134BwTx16nODmuL1geIrO/W6Gn36x206j7Eke4SMMEtlRjGPU9qAPWtFt4bu11SO1nk8qZii3APzdMHBrltGufGsWo32gw2zpa2sDJb390hbzHBAUluOMDNcFJr/iixVNf0+3k059VuDbrbqjMvBPO3nB46+9aun6p4j8QXcfhLW72aK6eSR1u3Uq6lDhdp6YIY8e1AHXyyWLaHFN4l10/b9OP+ljTpQBzwA4GfSsbS/EFjpvhZ57C5vNO021uXRhOhmkuFdeCAMbRub3rn4vDnijS9aurqKJXnZ8XVzdugimPYhOM/lmvS7GBZnD2WlRXF+8QS4u5kKxnBzwhxnnuBQBx0/gnVvsGmag+uXL3styXgjJ4KNuZR7HHf2xXodvpfiFIY1Oqx5ZAJC0RZkOOQpzxSDwi813Hf3Op3BvUGI2TG2L/dGPw57GtE2WrRf6q/jcHvKuSPpgUAcvHI15r17p95pWp3UVmpkSe4Y+VKw7KNvPPPXvU9hd2mt6da3viLRkivYZG+z27oTIoBwDiug/se4nObnUZ3UnJRMAH9KuWmmWtnzFEA3Qt1P5mgCsIrvUxuuA1va9olOGb6n+lcJ8WbSDTNB0nUIk2iyvoyEXuDnPNeoY4ri/irYtd/DvVdpCtFH5oY8/dBoA621ffbQtjG5B/KrPaue8G341Lwjpd0GLb7dTk/WuhHSgAooooAKKKKACiiigAoooNAAaxdRJm1awth0DNMfwxj+dbJOaxrMfadeu7nGUiAiU+/Of6UAWNY0+41Cy8i2vZbOTerebD1wDkj8elcbf8AgWW3Waz08XFxBqkgOo3EtyA6gY+7x6gfrXU+I9Z/sTR2ukieV2dYo1Qc7mOAfpk1W8La42p2r2t3cQyanbHFykQI255A574IoAu+HvD9n4b0ePTbEOYEJYGRsk59aj1ZmOo6bAq5bzfMz6BSM1tA8Vj3f7zxHYoONqO316UARa6iPc2SOgkXEh2k4BwvSsLwZp+mXEp1G2eZbq2Z4ZUXhOWJGe7Y6daveLY/Pu9Pid2VfM+6DjdngisOCS+stc1ax0iGNpLlcQODxBhBywzzyDQBY0e91i58caxol9q1tLa+WXSKD5ZYgSMDqe3fFLBpg0W/lht5Glgglikc3MyguTnJyRWXokl54X8WoNeuEnnvLfdNc+SR8/GFDYxx6Dnith5ZrnWG1AWclza+YY44lUhnYEYJyeBz3oAsz6jd34urwSzW1jDbciE8tJ82QG78Y7VhaXeRW95p0l5CZmnbJ8+Bldc9CMnk9K2dA1aAavq1ncotttcMYpGzgkDv06ela+qanYR2iyJ5U85fyYRGNzBj6dccc/hQBh6p9rm8Uw6pa28lzaW2Vb58Depwe3saIfDY1PXl1y2WNLS9iV5cnLo4BIKkdOvPXOK2NM1TTLfUf+EbM4OoLEJZI2UjeCASeevWoYrk+Grv7NPGBpUjEwSqM+Se6n0H+FAHO67pV7YzRLItnO90roxKbTIwHHOeD/Wp7W3ttWsprmxsiutpCttLbPKEDJkZ5x6c5ro/EFrJd21rqVmRJJZt5ypgMrqRz9TjOK4rW7u23S32mm4s3wHklCENGSQD1HIx+tAGvqPhafTLOG70xgix7ZLm2lbKMVHY9iP8KuT6tDr3guLVvswTLK4w+/ysc7s+361Hd61q8WkJ/Z2mHU7L7DvFw8o3O+F4YA5J65p3h7VNO1LwVEksEOnNNEVltSdvlvjkYPIoA2fDjFYbqJTmOOban02qf6ml0hkh1PULMNwrh1X2I/xNU/DDlDJGXMjSR+du9s7R/KrN7GbbxPZzxYBuFMEnvwWB/QUAby0tIKWgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKaRzzinUhFAGLe+HbO68x499vM5Db4nKgMO+BwfxrC1fSPEi2l1bWd/JOblRtuAqhomHt0xgV2+KTbntQB51f6J4gu7fR0RHWSxcNKXjTbKcEE4HTr1xW9B4bN7c3t3q8cIlnKeX5OQ0W3PRuDzxXUYoAoAyIPDthDMZmRppM5BncvjjsDkCtZUCqFUAAdB6U6igAooooAMUUUUAJWbr1n/aGhX1rhT5sLL83TpWmajkGUIxu46etAHBfB+7Nx4FiiaQubaV4GHYYxXoNeYfCtmtNU8S6Q7KrW96ziEHoDxn9K9OByM0ALRRRQAUUUUAFFFFABSGlpDQBXupvJtpZP7qk1S0KJo9Kjkf8A1k2ZnHueadruf7FuQAeQAMfWp3M66Zm2CGbYNm7hc44/CgDzr4p2Sw3Wnaokuo+akqAJBLti+Vs/PkitfU4tUtLZtTgntLGzlgQyPDDum8w4wSQpz271jJA2uvJB4gLzXV5DJGbZX8y1jdQcdfutyOg9Kv8AhPXdQ0SyttJ8VIIbmSYw2ewZ3x84z+WKAO401pBptr58okk8pd7kY3HHXHaqXMvids8eVANv/As/4VjanH4yMlyum39gkhkUwRSKD8mecmtXSzNJq901yF88QxB9pyM89DQBn6/HcS60j28XmyQRpIEJx0Y5/SoPCjhbq6uJpIgAGXeSAW+bJ684HIqbxG0y6xFEsvlfbEWASDqAWO7Hvg1xT2ujy/E62P8AaN/aeThXtrhtkcxCkAoc89uMCgDp9Z8V6Rqkr6Zb25vpQxEeB8occcE9+azrW2uZFtLeKW4kcuscDea2Bj78nB5HIIz2rW1HR7YXOo+TEIY4IAqiIc/OQzH1zkdatwyQr4qtoY2jgtra32RIv8Zft+GKADV4ZdIvG1ZbRLyJoljnTYC4bPDjjnr69BXOPpGsR6Nqev2dnC2oTKTBBux5aYwWXHG7HSr2q6/I88q3M7QMWkiFqV6Db1J/GpdV8S6xpElpY2mlK1vcwrHa3W7IEm3PzLjAHHWgDM8Ma/oOj+Eba+1W436iA277XGDcbs8qOpxngVleGR4r8aeNF1fUlmttDt93lwSrtEgPYgdTx39amlhtl+J2jxajbQX+uSQBr2ZUBWIgLgqCPrXa6RdldW1y6uWuooonCKsrEx7Vz8yZPfPoOlAElhE+hauunqWawnUtFuP+rYZJGfTFY0F2moa7q9jLbmSO7bYrvyQQvTHplataj4hs9TstOvdPZnWWR4kyMEFhtz9K5nTdSu7v4tLaR2cn2Czi8p5VT5S+3cWY/XIoAs2/iuPwf4K1BpwDLayGKGP+85z/ACxV3wto0/iHwdDf6lNH9vvAZjLGgxhhxx61m32k6BrOpXVtrTNHazTtj59oaQEhcY68E1P4eGs6Jq13aW+qW9z4fsGaKRJF2yQY7Lj71AHSeFJGvJJLjYiC3T7L8p4JBzn9a0NYZU1HS5M/P552j1+VqoeBLcwaCzsjL50zON3UjtV6eH7V4pgDn93bQGVR/tZx/JqANwUtIvSjNACE4pagurj7PazTBQxjRmwTjOBmvKrH4peKtVSSbTfBrXVukrR+YkzY4JHp7UAeuZpa4nwp8QINev5dLv7KXTdWjGTay/xeu31612ZlRSAzAE+pxQA+im7xjOePWk81MZ3DH1oAfRTPMBbAYZ9M0LKjdGB+hoAfSZpplQHDMAcZAJrG8Wa63hzwze6vHCs7W6bghbAbnHWgDbpazNA1M6xoNjqJjEZuYVl2A525GcVoF1XgsBj1NAD6KYrhuQcj25o81M43DrjqKAH0ZphkUYycfWkDqxIVlLDtmgB2c8jml3DFcI3jnUI7TxDcT6OYl0wkQlnIE/AIPTjrUVt8RpZ9T8MWhsEA1mMuzeYf3WB245oA9BophlQHDEA+hNLvBH4fnQA6ikBzS0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAU1vumnUjdDQB5foIbS/jXrVrtVEv7dJgD1Y5bJH5V6ehyua8z8UZ0n4teH9TCAC5ha2Z2PHfge/wA1emL0oAdRRRQAUUUUAFFFFABSGloNAFe7j821lQ90Iz+FYai9ufBxi02RYL42+yKSTkK+ByeldEeRXOx3kmlw6qsVs1xLbs00cKdWB6AZ+lAHFxeF4JPDM9vrE7ahqNndG4lj0o7ZGYheGHPPH611+jwTafoz3Fzeys82Gto74gmE7QAueO/061x6eN9S0a2s77UtGtbCbUL8wThidxB2hT1689fat2PVZPFFrdaNqlqmn6qCXtVZgwYdnGO1AE0WlXrqmo3xs18UhGjhOfk27hg7SeuAK2NJ81dXu1uGUzmOMsVGATzkisHXbGPTNEtb2/uZpNaRFtl1C3Qs6E4JO0djt9K128zStZsnuJGmW5jEDzNx844H55NADPFVpJcyaebfb9oWQshbpxzjPauT1CCPxf4pisr6e3gENsWggWUOfODY3ADniu/1nTF1KzIyVmj+eJ16qw5rgLvQIdT0NrqNmi1rS9zRXAYK2N2SCTxg5oA1BZ6xolzBPqt6b2Mwut5OkJwxLAKMZ4IHfNaMFkuo6D9jhkBvbTHkynknH3Tn0JqhqfjN9O+H0Opz20c1/Mgjjthhw79O3br0rnruDWtPtVvtKlhiu762KGCJsiOXH3Rk8YJ4zQB3mm6vp2tWcUUkkK3cqFWiyN4OMHisi+0lPEejf2dKETUbGTKhj0Gcbs/7p/OuJ0K28Y6R4an1i+dLwxODDHEqvIdxwxGzpx65q5Br9gt/b3dtqV4ksqEu08Z3o4zkMAAccdKALmkWWgyXN5o4fxBDPcTm3+0SE8lSRlX28DitnV/A91Y+E9Ts9Bvr2S8ukAU3E+cYz0IHv+laWm+KbSSZbfUI4o5iQRKg3I2e5PO38cGuqXGBgjHbHegDwBJfiKbqyt5obGJ7GMlVuOBxnLHkZNX/APhLfHsqSxNc6DCX+TLMF3EnHB3flXXeMLBL/VPJWZ4J5GiRJE7Dfhhz6itnWNKtNI8Pj7PpUF28JRgkrBckEZbJP48UAeY6dp/xDu78zW8GkTiyPkqXO5Q/c9cbuKu6lqvxOYvYzQaWTlS3lg8k/wAPXnNbFhqGo6ZqOoLYWtrFp92fOM3zEiRjzjJO/k/w9K63QNCaJkursNuT7iyY3Fv7x9+lAHFafD8W7G0S3ht9J2KMgueefXmq9pP8VbrVJ7qFNJMkQ8hxu49fWvWb68jsLKW4kPyxqSPc+n1PSqXh21aHSkkkH7ydjMfoxyPyBoA4Tzvi/wD88NH/AD/+yoE3xfPAt9H/AD/+yr1IdOuaWgDIZrw6A51ARrdG2bzQn3d2DnFcZ8GQv/CJ3R45vZen++1eg3kDTWk8aEB3jZR9SD/jXl2geG/HnhvTLnT7BNMKSzPIssh+ZcsT6+9ADfG/l2fxb8L3Vo+bllcSqv8AcG08/pXJ2XiS08Q3upah4hvdcjZ5SltHp6N5cage2a7/AMMeAtW/4SVvEfim/S5v/L8qKKMYVF4z/IVlJ4S8XeEbu/h8OW1lqFhduWjFwQPJz9SKAOe/4SLXT8KNaSeS+V7S5jFrdzKVdkLr6/Wp9d0TUtA+HS6uuvXs97eLEcmTATdtNdAfh74huvAOo6ffaik+qX0qSFWA2RAMDgY+lb3irwlf6x4CstFtmjF1AsIbcePlAz/KgDzbxLpet+G9O8PXllr17JqN+ypKXk+T5vQVs6npepeCvF3haS31m8njv5hBcRzvuBJKg8fjXV+KfBuoaza+Hordo86fIjS5I5AHarPjLwre6/rHhy7tWjCafc+bKT3Hy9PyNAHBa5qemR+K9SHiXxPeOxbZbWmmvnyuOjDn8qo6Pqt1qPwi8YQ3F3NcR28wjgaX7wQsOtbFh4N8Y+Fda1E6Zp+nanBeS7xc3DDdGD9SCcVa0z4deILTwl4m0i5ktXl1RxKjLkAOWye/TrQB33gY/wDFC6J/15x/yFedzWEviL4yappt1qV7DZwW6uI4JNvJLe3tXp3hnTptI8Madp9wV822t0jcjoSAOleTTya7D8atZm8PwW89ytsu6Kc4DDLe4oAvaTe6p4c8Va94aj1R5rcWrT20122fs529c8Z6GuLn1TSotFvGXxLrGoa+mZPMtgfJ69O/A+teiQeAtc1Ua5quszW8WqajbmGGKPO2AenU5zz+dYlr4S8df8I03htNM0myt1jKfbFILsP++u/0oAytU1bXdfsvAkK6lPDdXwaOWSNsbvu8n9ea6PxBaTfD7xD4fvbLU76W1urgQXMVzLvyCQOPzNc74g0DV9DfwLpUTQrqUDsEP8BbK9a68eGfFvirxJpt54mitbO00yXzUjtznzmB78n0FAHNQX91d6d8QEmuZJYY+Igx4UEKf602xb/ioPhxyARbPx+BxXTW/wAPdUjh8WqzxE6s2YB+Cjn8qIfh7qqap4SuGeHZpMDxz57kgjj86AOW1TUtOfxPqg8QeJ76eZ5SkFppmT5XXAOM89u1dT8GtbvtU03Ure6nmlS2uCsRnXDhcDANZumeEvGXhvV9Qj0/S9Mure7uGlF3OQSgJJHBOe9dL8OPCWreF31P+1HhkNzL5ivF7496AO/WnU1eBinUAFFFFADNw9aWvP8AQvF/jHUNagtdQ8HvZ2rkh5zJnb+ld01zDG215UVsZwWHNAFiioxKhQuGBUdxyKalxFISEkVsdcGgCQmjPFQG6h/hlQknaBuHJx0rF8Na3f6ta3kmp6etgYrgxRjfuDrgYOe2aAOj7UVXF3AW2CaPf/d3DNPeaOIAu6qOnJAoAlzRUaSxyAFHVgehB604uqgE8CgB1FQJd28rbY5o2brgMCacs0bgsjqwHUqc4oAloqITRshcSKVGeQfSkNxEE3mRAn94sMUATUhGQajSeOUExurgdSpBxTXu7eM7XlRTjOCw6UAcd8QPDt9rc+h3Vgokk0+8WZoycZXcuf5V2sWfKXIwcDiuf8YeKYPCnh6TVJE84ghY0B6knA/CtjTr1b+wt7ldv72NXwpzgkZxmgC1SZpks8UK5lkVB6sQKp6hqUdpp9zcRlJWijLhA3X645oAv54zThXNeDfEzeJvDUGr3EKWxkJBTdxgfWt+K5glO2OVHPoDmgCaioTdQDOZUGODzT0lSRd0bBx6qcigB27nFFc94p8Sx+H/AA/fajCIriW2Qt5XmYyau+HtTOtaHaag0Sxm4jDlFOQM0AavasW+H2PWba7xiOX91Iff+H+tbVU9Qs1v7KW3bjcpwR1B9R70AcX8RvDHh/VbBdU1u7lt0s0JjZHIyewAzyTxWPaXOnWWn6Dr66p9itLaB4zHdrvnl5bGTyRn69xXQ+IbWfWfCUlsum219f27qGgnOFyD97OD2rA1x/C3h3Uxcapps1zqU9krPAT5kMYAC7cE4HT0oA6rTfEF3N4Xn1fWdNEaRsXjijPmFkydp68kg1DPruneIk/shme1vZrdZ4xL8pQsPlH1+lT2/ivTLRNCsltniXVEUW4ijHlplQdp54/+tWxe6NYahe213cWyPNbOHjkxyCP8igBui3kl3psbzRlZ0yki+jD/AOtXJeILeCx1W6e6DmBwJo4lLBJiAAVbt2zW/eY0PVxqBciyuMLcEn7jdm/kK2ZYre+tSkqJLDIOQeQRQB5bbolrrVnqCm2uYHtndbYO22MkjIUev/16tzWGhPpss+lQyHU3czR2t1cSJhj1zzwDgVpar4XudHlhvdGVZYYX3+Q6ZK9c4/Pp2qvJdDW5VunsY/OSJo7kIcgqRwe3zCgDNm1658BeXA4bVL++AaOxg5I65PPGPxqfSdU0fxHcSRanYPoer7zMqyJlmULgsMcYx2qjHZ3dv9m1LT9SsPtVuBGI5kEjhN3IDEZBwTwKvQ6c2ryXM11qUZn/AII5erDHPX7vU8CgCqFfVNMlt7S1Sa3tXdFuYjjaobr2yceua73wrN/xLfs7SO/lcoX67D0P5Vxem3jQabL4fCQQwJJmSWHlEj5J565zjtXXaXEJL99XWXytPMKpGhOAVA+8fTrQA7xF4bOsKstvP5FyuDuxwcdAfSs/+wdXuGja6eGZlxkyO+3p1Cjg/iK1W8TWzXRhtre4ugv+seFAQv5kUXXiExQM8Om3ssg6L5YHHc9aAF07w/HbETXUn2qfGASMKvsFHGPwrVlmjt4ZJHdUSMZZj0A9ayl8TWskcflwzySuoPlxpkg46Gqr2d94gI+2o1rp4bP2cj5pef4vQe1ADWJ8UXkZaORNMt5AwY8ee3Uceg4rpwoAGABgce1MSJY0CJ8qhdox2qWgAxSYpaKAExRtH+TS0UAJtA6CkK5p1FADQuPf60uPxpaKAEx+NGKWigBMf5zRtpaKAEwKyIPDWmW2v3GtxQbb+4QJJJuJyBntn3rYpKAEC47fWlx+dLRQBkaj4c03VdTsdQu4PMubFi0D7j8hP41q7aXFLQAmKNo9BS0UAJijHrS0UAIBiloooAKKKKAOF8NS/EE6yg8RRacun7GJNv8Ae3Y44zXE+HvDkfxH1TWtW169ujFBcNBbRxybfLwB6579q6bS7D4lpqls2oXti9mHHnKq8le+Mmqa+BvFHhnXNSufC11bNZ3xZmhucny2IxkYIoA5nXIdf0TSdM8MNrRlt9QvjHHNG2WSL5vl6+1dUnw0XQNZ0698PanLDIpIuUmkDCVe+KqyfCa6l8Ox41KRdbS4+1LMWyA/OQM9vmNWofCPjDW9Z02fxHewR2ungFUtiQZGwOTzg0Ac14M8JReJvEOt3l3fXKx2d6WhiRyAG9f5VRspZW+EficLLI0n9qKiNuO7O5AOe1eneCfCt94em1mS7Mf+mXBlj2Y6Guesvh3rFv4J1fSGkg+03WoLcxkdCgZTg/lQBzfiTwbD4X8LaX4jsr67GrK0Lys8m4EkcjH41W8Y+Jl1fxxb2OrC/uNNgtlc2trkFpMDJ+leoeMvC17r3g2DSrVo/Pj8rO7GPlxmsfWPAmtJqllrWh3EEeoQwCGWOVQUccZ4/CgDn/hzqU0fjo6fpUWow6HLAWa2vEY+W4zyCa9C+IMWpzeDNQi0gkXZQYAbaSuRnH4A1ieFPB/iCDxXN4i1+/hMrRmJLW2TbGo5H9a6TxhoEviPw/NYW9y1vMcNG6kjkUAeGaNceHLe906MXOo6HrCuPMkuQSkjfxA5x15rop9ZXwdqPjGz80FLiH7VbjdkEnPA9uauX3w98X+IbfTdN1mWwFpaSBjcQpiVwvTJya0fHnwwuPEmsaRc2DokVunlXDOfmZBjA/SgDgNH8R3eheANc0WeZxdzbfIVuC/mZBx69KuaxdrZaho/hnU1v7jSrWzWR7a1Y7pHYluQO3IrtNe+F0uq/ELTdbhMS2EKx+dH3LIc5/WtHxZ4H1C51+28Q+HbiOC/iAR0lGUkUdiKAOF8H6wdN8aR2+iWep22l3cLrKl4p2xOBncDgcDHT3rNiTw3qLai9/eanrmttMxR7RP3ffAGM8V6DpXgXXr/AF261bxJfRo7QtFBBagBEz35zWZpHgXxp4f0ybRNMuNOFm7krdvGTKoOc4OaAOQ1AtrXwTjvdQkle506/MEOTg7Dt4bj3r2/wbo1poPhiztrRpWjaMSkyMW5Iya4Cy+GWtJ8NLzw3PNCLl7v7Ski9G6dfyr0DwlZ6zY+H4LbW5InuoxsBi6bR0FAHARWUfj74iaxaazPObHT8JDBG+1SeOaztL0ceHvFvinTI7iWW3jsQYQ7hyqkHAzj0o1UvZ/EjUX8O6rb6ZqDIv2qC9wiOMD5lJxTfBdre6t4w8UCScXcssAiNyo/dlsHgH059aAM5J4ovhDosV1qx0+zkumE6oPnmTIJA5FV7G70zTvG+gjw1HqlvBNJtllucqJRg9Aa6aX4V6ufDOixQzwDUNNmaQI/zRvnGOAfb1o1TwH4213WtM1LULjT4vsdwriK3TGFHXnJ680AU9M8M2viv4jeJra+nuBbxkHbG+Mn6496raZrV/4V8MeN7O0upXTTJhFamQ8x538/oK9D8NeFL3SfGeuatO0ZgvceWB17dazLL4dTyy+LodSaP7NrMhaEr95fvcn/AL6oA5LWPAWlQ/DGTXBPdnUWh86WVpfvkjkH2r1TwJ/yJWkn/p3Xp+NcBeeDfiBd+F28NvfWAswNgn/jdewPNeleGNNm0nw7ZWNxjzYYgjbTxn2oA2aafpTqKAMm/t5Ybhb60XdIMCVP7y9/0rMvfDWj6vNcaoltFPdyQGIeZyp7gEfXFdORmsyfTXjma4sHEMp+8uPlk+ooA4bztYsrnSF1zwuby6tCTbz2Q/dw44XgDjj3q/Nq/iDWdQEliy6VbaddMl4LhS3moCOc8AcA106awsDCG+ge3kPGcblPvkcD8a59vBWiXOtT6nb6hNG9wxeeKKYFJST3z/Q0ALZ+OdL1nUrnS2t5GsUjbdelcwMAMk7ulWbSa50aLzbJv7Q0Y8oIzueIZ5xj7wFcRqPwx1GPwfHplvqiTNb3bTpGDjfEdvyE59j+ddF4Tlii1Se8vLK50xobZbZIJ5lZCARyoHrigDtbHULXU4PPtZVkQHaSp5U9wR2PsajutG069Ie4tIpGXozLyKwbmwTU7p5NE8+zmI2vdICq8Hpg8H8q0RYa1bSo8GoJOuMOsyZz9MYoAbJ4N0d5hKLcowIICNgAjvimzeEbC6dVuJriZFJZUeTOD09KsOviBlwj2aEnrtbj9abJpurXLYm1Py0x/wAsFwT+eaAEt/DOi6cAfs8fH8ch6CqWqXi69G2lafCZ0Zts0+P3aAcEZHBPWtGHw3YqzPMJLiU9ZJHOf0xWlbWsNpCIYUCRjoooAS2tUtbdIYlVEUAYUYFSlafS0ARiNRj5Rx04pwGO1OooASloooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAIW/14p0n3xRRQAp/1Zpq/cSiigBR91v940qfd/E0UUAC9F/3ab2H+7RRQA5P6UH7goooAD1Wg/fT6UUUAIfvilb71FFABTf7v+9RRQAo+6aF70UUAfNXxw/5HOX/AHE/lXo3wT/5AU/1X+VFFAHqDfcamRfcoooAePun60nf8aKKAJKT+KiigBaKKKAEpp+7+NFFAFLVf+PGX6VxtvRRQA4/fqzH0joooA6y2/49Iv8AdH8qsUUUAKOhpR0oooAQdaWiigApaKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAP//Z" alt="img-0.jpeg"></p>
<ul>
<li>The epidermis.</li>
<li>The dermis; and</li>
<li>The subcutaneous tissue.</li>
</ul>
<p>The epidermis, consists of a multilayered, keratinising, stratified, squamous epithelium. The outermost part of the epidermis is the lipid rich stratum corneum which prevents water loss from the body. It also protects against noxious agents in the environment.</p>
<p>The dermis is a thick, highly vascular layer made up of ground substance, fibroblasts and collagen fibres, together with the appendages of the skin, sweat glands and pilosebaceous follicles, embedded in it. This layer is richly supplied with nerves. It is metabolically active. The subcutaneous tissue is a fibro-fatty layer with varying quantities of adipose tissue in different regions of the body. This layer provides physical and thermal protection to the deeper structures of the body.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="principles-of-drug-application">Principles of Drug Application<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#principles-of-drug-application" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>To be effective, a drug must enter the skin in adequate concentration. Topical drug treatment aims at providing high concentration of the drug at the site of application with minimal systemic absorption, to avoid systemic adverse effects.</p>
<p>Drugs are applied to the skin in various formulations in pharmacologically inactive vehicles. However, the therapeutic effects depend not only on the properties of the drug but also on those of the vehicle. Occasionally, the vehicle itself may cause local irritation.</p>
<p>The absorption of drugs into the skin is slow and incomplete. It depends on:</p>
<ul>
<li>The lipid solubility of the preparation</li>
<li>The state of hydration of the stratum corneum - Increased hydration increases the drug penetration</li>
<li>Drug concentration in the vehicle</li>
<li>Thickness of the skin (the thicker the skin the lower the drug penetration). This is important as the thickness of the skin varies in different regions of the body (e.g. face and intertriginous areas versus the palms), and with age. The skin in the neonates is highly permeable to drugs; on the other hand the ageing skin is relatively less permeable to drugs.</li>
<li>Quantity of the preparation applied, which varies with the extent of the skin lesion. Large amounts of 'very potent' glucocorticoids (Chapter 66) can cause serious systemic toxicity. The following quantities of preparations are generally sufficient for one application for the indicated areas in adults: head, face, hand or anogenital area 2 g ; an arm, anterior or posterior trunk 3 g ; a leg 4 g ; the entire body <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mo>−</mo><mn>30</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">25-30 \mathrm{~g}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">25</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">30</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span></span></span></span></span>;</li>
<li>The presence of inflamed skin which allows higher penetration of a drug; and</li>
<li>The use of an occlusive dressing which increases the drug penetration into the skin.</li>
</ul>
<p>An absorbed drug may be stored in the skin for prolonged periods e.g. a topical glucocorticoid applied to the skin under occlusion for 24 hours can establish a reservoir lasting for upto 2 weeks.</p>
<p>To help in the understanding of skin lesions, it is necessary to be acquainted with various descriptive terms used to characterise these lesions. This is important for defining the skin lesions in a given case and also in formulating a differential diagnosis. Macule is a flat, coloured lesion, less than 2 cm in diameter, which is not raised above the surface of the surrounding skin. A macule larger than 2 cms is called a patch. Papule is a small solid lesion with diameter less than 1 cm , raised above the surface of the surrounding skin, and hence palpable. A raised lesion larger than 1 cm which is firm and easily palpable is called a nodule. It differs from a papule in size, palpability and depth. A small fluid-filled lesion less than 1 cm in diameter, often translucent, is called a vesicle. When the vesicle is filled with leucocytes, it is designated as a pustule. A raised fluid filled lesion more than 1 cm in diameter is called a bulla. A soft, raised, encapsulated lesion which contains semisolid or liquid material is a cyst. A raised erythematous papule which is usually due to short lived dermal oedema is identified as a wheal.</p>
<p>In the examination of the skin, one must consider:</p>
<ul>
<li>
<p>The type(s) of primary lesion(s)</p>
</li>
<li>
<p>The shape of the individual lesions(s)</p>
</li>
<li>
<p>Their arrangement</p>
</li>
<li>
<p>The distribution of the eruption; and</p>
</li>
<li>
<p>Presence of itching</p>
</li>
</ul>
<p>The description of various skin lesions is beyond the scope of this book. However, the pharmacotherapy of some selected, common, dermatological conditions seen in general practice is described below.</p>
<p>As in other areas of medicine, rational therapy in skin disorders depends upon proper diagnosis. Not all skin diseases need urgent treatment. Some, like very localised psoriasis of the elbow, are best left alone. In cases where the diagnosis is not immediately obvious, the prescription of a bland local application such as oily cream (while awaiting specialist opinion) is better than the indiscriminate use of a blunderbuss commercial preparation containing an antibiotic, a glucocorticoid, an antihistaminic and perhaps a local anaesthetic, in the hope that 'something will work'. The use of such an irrational preparation can change the morphology of the lesions and make the subsequent diagnosis difficult.</p>
<p>The next step is to choose between local and systemic therapy. Whenever such choice exists, local treatment is always preferable to systemic. However, the local use of some drugs such as antihistaminics and (most) antibiotics is best avoided because of the possibility of inducing allergic dermatitis. While selecting drugs one should consider the physical properties of the formulations and morphology of the skin lesions rather than the etiologic diagnosis. Further, local skin therapy is modified by the changing patterns of the presenting dermatoses.</p>
<p>Intradermal and transdermal drug administration: This is discussed in Chapter 1.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="vehicles-and-formulations">Vehicles and Formulations<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#vehicles-and-formulations" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Vehicles: Skin therapy is usually symptomatic and topical. Topical preparations consist of two parts: (1) the base or vehicle and (2) the active ingredient(s). The important vehicles are liquids, powders, oils and ointment/cream bases. Such vehicles have several important functions:</p>
<ul>
<li>They form a reservoir for the active ingredient.</li>
<li>They allow local release of suitable amounts of the active drug.</li>
<li>They provide a reasonably safe infrastructure for practical application; and</li>
<li>Many vehicles are also useful for their physical actions such as soothing, lubricating, cooling, drying, moisturising, softening, hydrating or protecting effects.
The factors which influence the choice of a vehicle are listed in Table 71.1.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="table-71-1">Table 71.1<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-71-1" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Factors determining the choice of a vehicle</p>
<ul>
<li>Inhydrating or drying property.</li>
<li>Its ability to assist in the absorption of the active ingredient.</li>
<li>Its physical and chemical interactions with the stratum corneum; and</li>
<li>The stability of the final formulation.</li>
</ul>
<p>Depending upon the vehicle, the skin preparations can be grouped as powders, wet dressings, lotions, paints, and lubricants such as creams, ointments and pastes.</p>
<ul>
<li>Powders act by their physical property of absorbing moisture. They contain ingredients such as talc, starch, chalk, cellulose, menthol and zinc or magnesium stearate. They can also produce a cooling effect. They protect the skin by reducing friction especially in the intertriginous areas such as axillae and groins and in the skin folds under the female breasts. In the presence of exudate, they can cause crusting.</li>
<li>Wet dressings are soft dressing material soaked in aqueous solutions containing ingredients such as isotonic saline, aluminium acetate and potassium permanganate ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.01</mn><mo>−</mo><mn>0.05</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.01-0.05 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.01</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.05%</span></span></span></span></span> ). They are used in acute exudative inflammation with marked oozing. They cause local cooling. Lotions are liquid preparations with a viscosity a little higher than that of water and alcohol; e.g. the calamine lotion. Lotions are used to treat subacute inflammation, after the marked exudation has stopped. Evaporation of water from the lotion has a cooling effect whereas the residual dry powder acts as a protective. However, lotions sometimes cause excessive drying. But, those containing glycerol or propylene glycol, when applied to dry and scaly skin, help to retain water in the epidermis. Addition of alcohol ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>15</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">15 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">15%</span></span></span></span></span> ) and menthol ( 0.25 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2.0</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">2.0 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">2.0%</span></span></span></span></span> ) enhances the cooling effect. Phenol ( 0.5 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1.0</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">1.0 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">1.0%</span></span></span></span></span> ) camphor ( 1 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">3 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">3%</span></span></span></span></span> ), salicylic acid ( 1 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">2 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">2%</span></span></span></span></span> ) and coal tar ( 1 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">3 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">3%</span></span></span></span></span> ) impart an antipruritic and keratolytic action to the lotion.</li>
<li>Lubricating preparations (Emollients) include plain oil, liniment, gel, water-in-oil emulsion (most but not all ointments), oil-in-water emulsion (most cosmetic, washable, vanishing creams) and paste. Water in oil creams behave like oils and are suitable vehicle for lipid soluble agents. Vegetable oils, liquid, soft and hard paraffin, lard, lanolin and beeswax are important ingredients of lubricating preparations. Emollients soothe, smoothen and hydrate the skin and are indicated for dry or scaling disorders. Ointments</li>
</ul>
<p>and pastes are more hydrating, whereas creams and gels though pleasant, cause more drying.</p>
<ul>
<li>Pastes are stiffer and more adhesive than other lubricating preparations, and are made of a finely divided insoluble powder such as zinc oxide, incorporated into an ointment base. They protect the skin from external irritants and from sunlight. They also protect it from friction caused by clothing and bandages.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="choice-of-preparation">Choice of Preparation<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#choice-of-preparation" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>From the therapeutic viewpoint, the skin lesions are divided into (a) oozing and (b) dry types.</p>
<ul>
<li>An oozing dermatosis is associated with dilatation of subepidermal capillaries (erythema), edema and disruption of the epidermis by formation of vesicles. When oozing is copious, folded muslin soaked in a lotion such as an aqueous solution of potassium permanganate ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo>:</mo><mn>5</mn><mo separator="true">,</mo><mn>000</mn></mrow><annotation encoding="application/x-tex">1: 5,000</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">1</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">:</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">5</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">000</span></span></span></span></span> or <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo>:</mo><mn>10</mn><mo separator="true">,</mo><mn>000</mn></mrow><annotation encoding="application/x-tex">1: 10,000</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">1</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">:</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">10</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">000</span></span></span></span></span> ) is applied half-hourly. Evaporation of water produces surface cooling, capillary constriction and reduces oozing. At that stage, a shake lotion (aqueous suspension) such as calamine lotion is substituted and applied every hour. This formulation, in addition to producing surface cooling, forms an adsorbing layer on the lesion. When oozing is very little, calamine lotion is likely to cake, leading to cracking of the skin due to excessive drying. Such lesions are best treated with a liniment or a cream, e.g. zinc cream which produces an emollient effect. Thus, zinc cream is preferred for keeping the skin soft. When oozing ceases but the lesion still appears moist, a paste is applied. It acts as an adsorbing, protective and splinting agent. Some dermatoses may be associated with infection as indicated by a seropurulent discharge. In such instances, an appropriate antimicrobial agent such as povidone, bacitracin or neomycin is incorporated into the formulation. Judicious incorporation of a glucocorticoid hastens the subsidence of inflammatory phenomenon. The dangers of local glucocorticoid therapy are discussed in Chapter 66.</li>
<li>Dry skin lesions are best treated with an ointment or a paste. An ointment (generally) promotes dermal hydration and percutaneous absorption of the incorporated drug, thus allowing an active pharmacologic effect on the skin.
In cases of urticaria and acne vulgaris, a lotion is generally preferred to other forms of applications although the skin lesions are dry.</li>
</ul>
<p>When penetration of an active drug through the epidermis into the dermis is desired, the base must be chosen with care. In general, penetration of medicaments is better from an aqueous base than from an oily base. Further, raising the local temperature of the skin and its hydration as by a polyethylene occlusive dressing enhances penetration of the active drug such as a glucocorticoid.</p>
<p>Pruritus: In the management of pruritus, identification and rectification of the underlying cause are important. When pruritus is a skin manifestation of systemic diseases such as drug allergy, obstructive jaundice, Hodgkin's disease, chronic iron deficiency and psychological illness, it responds poorly to antihistaminic drugs. The exact mechanism of itch/pruritus is not clear but it probably involves both, central and peripheral components. Generally, it is associated with local liberation of histamine and other autocoids. Histamine causes itch by stimulating ' C ' nerve fibers different from those that signal pain. The impulse is carried to thalamus, via spino-thalamic track; it leads to liberation of endogenous opioids. Experimentally, naloxone, an opioid antagonist relieves itch to some extent. Presence of pain has inhibitory effect on itch; thus when local inflammation subsides and pain is reduced, one feels like scratching the area. Conversely, excessive scratching may relieve itch but causes pain.</p>
<p>Topical antihistaminics and local anaesthetics are generally partially effective. Antihistaminics or anxiolytics such as doxepin or hydroxyzine given systemically, however,</p>
<p>are useful in itching due to inflammatory or allergic skin diseases; In such cases, these can be combined with topical steroid application. Minor local conditions may respond to calamine lotion and/ or <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">2 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">2%</span></span></span></span></span> menthol in aqueous cream. Emollients or urea cream may be useful when pruritus is associated with dry skin (Chapter 23). In cases of pruritus ani, presence of piles, local candidiasis or oxyuriasis should be looked for and treated.</p>
<p>Pruritus due to neuropathy (diabetes, vitamin deficiency) may respond to carbamazepine, gabapentin and local anaesthetics.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="keratolytic-agents">Keratolytic Agents<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#keratolytic-agents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Keratolytics are the drugs which, when applied locally, cause a mild peeling of the superficial layers of the skin.</p>
<p>SALICYLIC ACID: It is an irritant and causes peeling and comedolysis;. 0.5 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">2 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">2%</span></span></span></span></span> is used to treat acne vulgaris. A <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>6</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">6 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">6%</span></span></span></span></span> ointment is useful in the treatment of dandruff, seborrheic dermatitis and psoriasis. A thicker preparation in the form of a collodion is used locally to treat warts and thick calluses. It also has antifungal action</p>
<p>PROPYLENE GLYCOL: A <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">2 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">2%</span></span></span></span></span> aqueous solution of propylene glycol is used as a vehicle. Higher concentrations (upto 70%) affect the keratin and soften the skin, leading to desquamation. It is used in combination with salicylic acid to treat ichthyosis.</p>
<p>UREA: Urea, in the form of cream or ointment, softens the skin and is used in the treatment of psoriasis and atopic dermatitis. It has hydrating, keratolytic and antipruritic actions on the skin. It increases the absorption of hydrocortisone when used in combination.</p>
<p>BENZOYL PEROXIDE: This drug is available as 5-10% cream or lotion and is used for mild to moderate acne. It is effective mainly because of its keratolytic effect although it also has some bacteriostatic activity against acne bacilli.</p>
<p>TRETINOIN: It acts on the nuclear retinoid receptors and normalises follicular keratinisation. It is used topically to treat acne vulgaris and other disorders of keratin. Whatever little is absorbed from the available preparations has not been reported to cause any systemic toxicity, particularly teratogenicity (see later).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drug-therapy-of-bacterial-and-viral-skin-infections">Drug Therapy of Bacterial and Viral Skin Infections<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-therapy-of-bacterial-and-viral-skin-infections" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Impetigo: This is a common skin condition, characterised by superficial infection by Staphylococcus aureus or streptococci. Generally, it is a mixed infection. The primary lesion is a superficial pustule that ruptures and forms a typical yellow brown crust. The lesion may occur on normal skin or may be superimposed upon another skin disease such as pediculosis. The condition usually responds well to topical antimicrobial therapy but systemic antibiotics are necessary in certain circumstances. Improvement of personal hygiene is more important.</p>
<p>After gentle cleaning and debridement of the adherent crusts, application of an ointment containing povidone iodine <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span>, chlorhexidine <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">1 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">1%</span></span></span></span></span>, neomycin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">1 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">1%</span></span></span></span></span>, framycetin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1.5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">1.5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">1.5%</span></span></span></span></span>, bacitracin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">1 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">1%</span></span></span></span></span> or mupirocin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">2 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">2%</span></span></span></span></span> is recommended. Topical use of antibiotics such as tetracycline and gentamicin and should be avoided for fear of sensitisation and development of drug resistance.</p>
<p>Since glomerulonephritis can develop in children following streptococcal infections of the skin, systemic antibacterial therapy must be considered for impetigo in children between one and eleven years of age. Systemic therapy is also recommended in patients with renal and heart disease, with coexisting eczema and in those on immunosuppressive drugs. In such circumstances, a penicillinase-resistant penicillin like cloxacillin, erythromycin or cotrimoxazole should be given in full doses for 10 to 12 days.</p>
<p>Furuncle or boil: This is an acute infection of the hair follicle commonly caused by staphylococci. In healthy individuals, it responds to fomentation and the use of local antiseptics like povidone iodine and chlorhexidine (Chapter 62). In severe cases and in those with persistent lesions, a cream containing neomycin, framycetin or mupirocin may be applied. Patients who develop boils frequently may require long term treatment with an appropriate antibiotic. In such cases, an underlying systemic disease like diabetes mellitus or uremia should be excluded.</p>
<p>Herpes simplex and Herpes zoster: Herpes simplex can be treated by topical application of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span> acylovir or of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">1 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">1%</span></span></span></span></span> penciclovir. Both these drugs are applied 4 to 5 times a day. Topical acyclovir is, however, less effective than systemic acyclovir (Chapter 59), and it offers no significant clinical advantage in recurrent genital herpes.</p>
<p>Infections due to herpes zoster also respond to oral acyclovir, but to a lesser extent than herpes simplex. In severe cases of herpes zoster, acyclovir is administered orally 800 mg 5 times a day for 7 days. It can be also given IV in dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">10 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">10</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> every 8 hours for 5 days in immunocompromised patients. Alternatively, vidarabine can be infused IV in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>15</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">15 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">15</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> once daily, over 12 hours, at a concentration of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">0.5 \mathrm{mg} / \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">0.5</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span>. Use of glucocorticoids in herpes zoster is contraindicated.</p>
<p>Post-herpetic neuralgia may respond to local application of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">2 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">2%</span></span></span></span></span> capsaicin, and to analgesics. Drugs like amitryptyline, carbamazepine and gabapentin also may be beneficial. (Chapter 11).</p>
<p>Warts: Warts are human papilloma-virus-induced benign proliferation of the skin and mucosa. Most of the patients do not need any treatment as warts are known to undergo spontaneous regression within 1 to 2 years. Several methods are used to treat warts. These range from cryotherapy and electro-desiccation to carbon dioxide laser ablation. Warts can also be treated by local application of keratolytic agents like salicylic acid in flexible</p>
<p>collodion. Other topical drugs include podophyllin 15 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">25 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">25%</span></span></span></span></span> solution, trichloracetic acid and phenol. Formaldehyde ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span> solution) and podophyllin are particularly useful in the management of plantar warts. Silver nitrate in the form of pencil may be used to cauterise the warts. Care must be taken to protect the surrounding skin. (Also see Chapter 53).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drug-therapy-of-fungal-skin-infections">Drug Therapy of Fungal Skin Infections<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-therapy-of-fungal-skin-infections" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>For therapeutic purposes, fungus infections (mycoses) have been classified as superficial (affecting the skin, and its appendages hair and nails), subcutaneous and deep. The common fungi which cause superficial skin infection are:</p>
<ul>
<li>Dermatophytes (trichophyton, micros-poron and epidermophyton) which cause ringworm (dermatophytosis).</li>
<li>Candida species which cause mucocutaneous candidiasis; and</li>
<li>Pityrosporon orbiculare, also known as Malassezia furfur, which causes tinea versicolor (Chapter 50).
Majority of superficial fungal infections can be treated by local antifungal agents, and azoles are preferred because of their wide spectrum and safety. Only chronic, resistant infections may need systemic antifungal therapy. Because tinea infections of the foot are often complicated by bacterial infections and other factors, an ideal antifungal medication for the foot should have antifungal and antibacterial properties.</li>
</ul>
<p>AZOLES: Various azoles used to treat skin fungal infections are listed in Table 71.2. They are described in detail in Chapter 50.</p>
<p>Table 71.2
Azoles for dermal skin infections
Clotrimazole, Miconazole, Econazole, Butaconazole, Oxiconazole, Sulconazole, Ticonazole, Sertraconazole, Luliconazole</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="for-systemic-use">- For systemic use:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#for-systemic-use" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Ketoconazole, Itraconazole, Fluconazole, Voriconazole. (These can also be used locally.)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo><mo>−</mo><mo>−</mo><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">---&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">−</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">−</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">&gt;</span></span></span></span></span></p>
<p><sup><a href="#user-content-fn-0" id="user-content-fnref-0" data-footnote-ref="true" aria-describedby="footnote-label">1</a></sup>Imidazoles like clotrimazole and miconazole are preferred for treating mild to moderate, localised Candida or Tinea pedis/cruris infection. They are used locally as creams, powders, lotions, and as vaginal tablets or suppositories. Generally, they are safe and do not stain the skin or clothing.</p>
<p>In patients with chronic, extensive infection, infection of the scalp and nails resistant to local therapy and in immunocompromised patients, systemic therapy with itraconazole or fluconazole is indicated. Ketoconazole is not preferred because of its toxicity profile. In all fungal infections, therapy has to be carried out for a few weeks to 3-4 months, depending on the severity, (For griesofulvin, see Chapter 50).</p>
<p>BENZOIC ACID AND SALICYLIC ACID: Salicylic acid is a weak antifungal agent but</p>
<p>has keratolytic properties. Benzoic acid compound ointment (Whitfield's ointment) containing <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>6</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">6 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">6%</span></span></span></span></span> of benzoic acid and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">3 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">3%</span></span></span></span></span> of salicylic acid. It is effective in treating dermatophytosis. It is relatively cheap and is in use for ages. Sometimes it may cause local irritation.</p>
<p>TERBINAFINE is an allylamine. Applied as <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">1 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">1%</span></span></span></span></span> cream or solution daily for 1-2 weeks, it is effective in Tinea corporis and onychomycosis. It can also be used orally. Naftifine 1% has similar activity (Chapter 50).</p>
<p>Butenafine, a benzylamine ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">1 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">1%</span></span></span></span></span> ) is also available for tinea pedis infection.
TOLNAFTATE: This drug, used as <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">1 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">1%</span></span></span></span></span> solution/cream, is effective in the treatment of superficial fungal infections of the skin caused by trichophyton and epidermophyton. The drug is not effective against fungal infection of nails and hair, and relapses are frequent when it is employed in the treatment of Trichophyton rubrum of the trunk. It is nonirritating, nonstaining and odourless.</p>
<p>UNDECYLENIC ACID: This drug is applied to the skin in the concentrations of 2 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>15</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">15 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">15%</span></span></span></span></span>, sometimes in combination with zinc undecylenate in the treatment of dermatophytoses, particularly tinea pedis.</p>
<p>CICLOPIROX OLAMINE: This drug is as effective as the imidazoles in the treatment of cutaneous candidiasis and dermatophytoses, as well as in tinea versicolor. It causes minor local but no systemic adverse effects. Its use should be avoided in pregnant and lactating women. It is available as <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">1 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">1%</span></span></span></span></span> cream.</p>
<p>SELENIUM SULFIDE: This drug has been used in the treatment of tinea versicolor. It is also temporarily effective in the treatment of dandruff. It has mild toxicity but possesses unpleasant odour. It is irritant to the eyes. The drug is commonly used as a <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2.5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">2.5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">2.5%</span></span></span></span></span> suspension; the preparation is applied once daily for 5 days to the wet skin, lathered in place for 15-20 minutes and then washed thoroughly. After that, one application once a month is continued to prevent re-infection.</p>
<p>ICHTHAMMOL (Ammonium ichthosulfonate): Ichthammol consists of the ammonium salts of the sulfonic acids in an oily substance prepared from the distillate of bituminous schist or shell or from other sources, together with ammonium sulfate and water. It is an almost black, viscid liquid with a strong odour and soluble in water. It is slightly irritant to the skin. Ichthammol is used as <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">10 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">10%</span></span></span></span></span> cream and ointment in the treatment of resistant dermatomycoses and other chronic skin diseases.</p>
<p>TAVABOROLE: This antifungal drug, used as <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span> solution topically, is effective against onychomycosis due to T. rubrum or T. mentagrophytes. It blocks fungal protein synthesis and has broad spectrum of activity against yeast, moulds and dermatophytes. Systemic absorption is minimal. It is applied once daily for 48 weeks.</p>
<p>Ciclopirox 8% used similarly is probably equally effective and much cheaper. Other drugs used for toe nail onychomycosis are terbinafine and itraconazole, which are given orally for 3 months; but with them cure rate are less and relapses are common.</p>
<p>Other topical fungicidal agents include tincture iodine, iodophors, haloprogin, phenol, oxidising agents e.g. potassium permanganate and dyes like gentian violet. Fungicidal actions of iodochlorhydroxyquinoline 3% and nystatin are discussed earlier.</p>
<p>Choice of antifungal therapy: It depends on the site involved and the type of infection. Small localised lesions are best treated with keratolytic agents like salicylic acid (Whitfield's ointment) or topical application of an azole. Systemic antifungal therapy with</p>
<p>an azole or griseofulvin is required for extensive lesions, very chronic lesions, tinea capitis, and fungal infections of the nails (Chapter 50).</p>
<p>Tinea versicolor is caused by the fungus Malassezia furfur, also known as Pityrosporon orbiculare. It causes patches of lesions on the chest, shoulder and back. These patches often appear as hypopigmented areas particularly on a dark skin. Many topical fungicides are effective, but preparations containing salicylic acid <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">1 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">1%</span></span></span></span></span>, sodium thiosulphate <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">10 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">10%</span></span></span></span></span>, or selenium sulphide <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2.5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">2.5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">2.5%</span></span></span></span></span> are preferred. Sometimes, these preparations have to be used daily for 3-4 weeks to clear the infections. Repeated infection from the infected clothing must be prevented by proper treatment of clothing.</p>
<p>It must be emphasised that fungal skin infections and scabies (discussed later) are common among the population from warm and humid climates, particularly in those with unhygienic habits. Simple personal hygiene and environmental control measures usually suffice to limit the infection and hence, preventive measures such as cleanliness and mass education are far more important than any drug.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="dandruff-and-seborrhoeic-dermatitis">Dandruff and Seborrhoeic Dermatitis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#dandruff-and-seborrhoeic-dermatitis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>These conditions are the manifestations of an abnormal immune response to Pityrospora ovale, a constituent of the normal skin flora. The lipase in these organisms splits triglycerides into fatty acids, and the latter are thought to be responsible for the dermal irritation. There is often an atopic background. There are several predisposing factors: genetic; winter season; excessive sweating and sebum production; a change in the composition of the sebum; alkalinity of the skin; an emotional component; and a neurological component as in Parkinsonism and other neurological disorders.</p>
<p>Dandruff is scaling and moderate itching of the scalp without inflammation of the skin; the scales are white, dry and loose.</p>
<p>Seborrhoeic dermatitis is an acute, subacute or chronic scaly dermatitis affecting areas of sebaceous activity such as the scalp, hairline, forehead, face (especially the nasolabial folds), retroauricular areas, the external ear canals, the presternal and the interscapular areas. The scales are either dry, gray and flaky, or yellowish and greasy. In severe cases, there may be seborrhoeic eczema with or without oozing of the skin. The disease commonly affects the neonates in whom it lasts for about one year and postpuberal persons in whom it is chronic and recurrent in spite of treatment.</p>
<p>The drugs effective in dandruff and seborrhea are listed in Table 71.3. They are usually applied to the scalp as shampoos. It appears that the common denominator in the actions of these drugs is an anti-pityrosporal action, although other actions such as cytostatic, antiinflammatory and antiseptic may also be contributory.</p>
<p>Table 71.3
Drugs effective in dandruff and seborrhoeic dermatitis
Imidazoles (ketoconazole 2% shampoo, cream or scalp gel)
Salicylic acid ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">2 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">2%</span></span></span></span></span> aqueous cream)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="anti-inflammatory">- Anti-inflammatory:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#anti-inflammatory" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Mild corticosteroid topically</p>
<ul>
<li>Cytostatic:</li>
</ul>
<p>Selenium sulfide ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2.5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">2.5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">2.5%</span></span></span></span></span> shampoo) <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">{ }^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>
Zinc pyrithione ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">1 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">1%</span></span></span></span></span> shampoo weekly) <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">{ }^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>
Sulfur ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">2 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">2%</span></span></span></span></span> aquous cream) Tar (tar B.P.C. 3%)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo><mo>−</mo><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">--&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">−</span><span class="mord">−</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">&gt;</span></span></span></span></span></p>
<p><sup><a href="#user-content-fn-0" id="user-content-fnref-0-2" data-footnote-ref="true" aria-describedby="footnote-label">1</a></sup></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="also-have-antipityrosporal-action">'Also have antipityrosporal action<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#also-have-antipityrosporal-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Topical azole (ketoconazole/miconazole) or ciclopirox are the most effective treatment in these conditions. Their high affinity for the keratin of the skin and the hair leaves a prolonged residual anti-pityrosporal activity at the site of application. Therefore, the remission after their use is usually long lasting. Oral ketoconazole is rarely justified because the lesions are generally localised to small areas of the skin and the drug is toxic. Topical corticosteroid treatment (hydrocortisone 1%) is almost as effective as topical azoles but recurrence is invariable after stopping the treatment. The other drugs listed in the table are moderately effective but recurrence is invariable after stopping the treatment. In view of the chronic and recurrent nature of the illness in adults, the treatment has to continue indefinitely.</p>
<p>In addition to drug therapy, the predisposing causes such as mental stress, excessive sweating and skin alkalinity need treatment; the last factor can be taken care of by application of lemon juice to the affected areas of the skin. Comb of other user should be avoided.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drug-therapy-of-scabies-and-pediculosis">Drug Therapy of Scabies and Pediculosis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-therapy-of-scabies-and-pediculosis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Scabies: Scabies is caused by the itch mite Sarcoptes scabiei var. hominis. The female mite burrows into the superficial layers of the skin to form tortuous channels in which the eggs are deposited. Transmission of the mites occurs by close body contact. Away from the human body, the itch mite survives in a moist environment for 1-2 days only. Unhygienic conditions and crowded housing favour the spread of the infection, which is characterised by intense itching, usually worse at night. It is important to note that scabies can give rise to urticarial rash and eczematous lesions, which can be mistaken and wrongly treated with local and even oral steroid therapy. The principles of treatment are:</p>
<ul>
<li>All members of the household must receive the treatment simultaneously.</li>
<li>The medicament is applied to the whole body surface below the lower jaw. Contact with the eyes and the urethral meatus should be avoided carefully for fear of irritation.</li>
<li>The drug is applied 3-4 times at 12-24 hour intervals, with bathing and scrubbing of the body before and after the complete course.</li>
<li>Complications are treated either simultaneously or after the basic treatment is over.</li>
<li>Intimate clothing and bedding used during the previous 48 hours should be disinfected by boiling or by steam, and</li>
<li>Education regarding personal hygiene.</li>
</ul>
<p>Drugs used in the treatment of scabies are:
SULFUR: The scabicidal effects of sulfur, the oldest remedy, is probably due to its conversion into hydrogen sulfide and parathionic acid. In addition to its use in scabies, sulfur is also employed in the treatment of other chronic skin conditions like psoriasis and seborrhoea.</p>
<p>Sulfur ointment contains 5% ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2.5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">2.5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">2.5%</span></span></span></span></span> in children) of sublimated sulfur in a simple ointment base. Because it is irritant, it should not be applied to the face. It stains the clothes and has an unpleasant odour. Hence, though cheap, it is now obsolete.</p>
<p>BENZYL BENZOATE: Benzyl benzoate is a highly efficient acaricide and is the drug of choice. It is usually applied in the form of benzyl benzoate <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">25 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">25%</span></span></span></span></span> emulsion. Even after cure of infection, the itching may persist for a few weeks but usually responds to calamine liniment. Children are treated with <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>12.5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">12.5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">12.5%</span></span></span></span></span> application. Secondary bacterial infection can be successfully treated only after the primary infestation is eradicated. The drug is slightly irritant and has an unpleasant smell.</p>
<p>Although effective in pediculosis, benzyl benzoate is not recommended in its treatment because of its feeble ovicidal activity and short duration of action.</p>
<p>PERMETHRIN, 5% application, left for 12 hours, is highly effective (see later).
GAMMA BENZENE HEXACHLORIDE (GBH): This gamma isomer of hexachlorocyclohexane (Fig 71.2) is an insecticide, larvicide and acaricide. Applied externally, it is not so toxic; but when ingested, it can cause convulsions. The drug is excreted slowly from the body. The other serious but rare toxic manifestation is aplastic anaemia (Chapter 62).</p>
<p><img src="data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0aHBwgJC4nICIsIxwcKDcpLDAxNDQ0Hyc5PTgyPC4zNDL/2wBDAQkJCQwLDBgNDRgyIRwhMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjL/wAARCACeAMEDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD30rmgLhcU6igBAKWiigBp5o28U6igBoHHTpSbeafRQBR1LS7LVbN7W9t45onBBV1BrybXfhdq/h25OqeBb2aBl+ZrVm4b2+ntXsxo4oA8z0L4ianb+DtQ1fxRpT2j2J255XzTg8AdR0/Wsu3u/ilrNh/btrNZ28JUvDZFMll7Z5610Hxd0yW++H96LaPJhcTsqjlguSa0tB8ZaJc+EINRS9gjiigBdXcKVIHTHrn+dAHH6h8TNaj8N6TdrZi0v5b9bW6jnjOMc5K9PT3rv/FmsT6L4Sv9TtShmgh8yPcMgnjFeSePPEEfjXwnpF3DZS2lvJqoiWQ4BcYYbhxV/wAYfCuy0jwhqWoprWpytbwF/LllBRunB4oA7qy1rXNU+HVvqtjHFJq01qJFTbhS2OlcTp3w38R+LrhL/wAa6nKIw2VtIz0rvvh0c/D/AET/AK9l/lXU4FAGVonh3S/DtmLXTLRLePqdo5J961Nv1pRS0ANCgdqCuTmnUUANAwKWlooAaRkYxkUgXBzT6KAEopaKACiiigAooooAKKKKACiiigApDS0UARyxJNG0ciK6MMMrDIIrip/hR4QnmklfTmXzG3MiTOqE/wC7nFdwaQigDmLvw14a1GO00OSFP9AYXEdvGxUp23ce5rb1LTbbVtMn0+8jL286bJFBIyPrXHWCj/hcuonAz/Zg/wDQ1rvFHX60AVdL0220jToLCzjKW8CBI1JJwB7mrgoAxS0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABSGg9q5fxf4ztfCsMSGGS6vrg4gtouWagDJ0/8A5LLqH/YMH/oa13y9/rXjVp4vm0jxzHq3iLQrrT/7QgFskpYNGpLAjOCcdK7nRfF51XxZqeifZ9ossMJAfvg0AdbRTRmnCgAooooAKKKKACiiigAooooAKKKKACiikJxQAtFM3jcBkAnpz1pwOc0ALRRRQAUUUUAFFFFACHOOK8t1zyU+OmitcsBH9jYKX4Xd82MZ75xXqZrlfGPgiw8XwQedK9teQNuguYxlkPX2z9M0AP8AFl3oVnYRS68kb24mXy1cA/P24/GuQ8GMr/FXxHJHjy2iRlA6Adqt2nwruJ72GbxF4nu9ait3DwwSRbFUjoD87ZrptK8IW2leJdQ1qO4dpL1QrRkcKB6c0AdIKUUg70tABRRRQAUUUUAFFFNbPagB1FIpyOuaWgAooooAK474k61f6VoFna6VN5Goatfw6dDOBnyTITl/qAD+JFdjXKfEDw5d+I9AhGmuianp93Ff2RkOFMsZyAT7gsPqRQBi3fwy8B2Fmo1FRFdydNRub5luHkH8Yct178cVZs9e1Hw/4X0mxVm8U6rNI1vDNaOAjhcndJIchcLjPUk9jWXqfivT9ZtYrfxD8Odcur+LO20k0wToHPXZIflK9Pm4rnLbRfEfh/RNKt7601TTtEvNRu7rUIdEJeeBXA8lCYxkLnOdv6cCgDvLXx1fR6lqWl63oLadqFpp76lEkd2s8c8K5Bw4UYOccEe9ZJ+Kt7FoVj4iufCt1DoFzsV7sXSNJGW4yIgMsobgHIJ67elc9aaMyeNNRvNJ8Pa1b6bceH7m2invVmd5psg87yWUEABQ2CSCQK2NW0nUZPgTo2mx6fctepHYB7YQsZF2uhbK4yMYOeKAOi0/xrqL+J7LRtZ8Oy6V/aUcr2ErXSymQxjcyuqj5GAOepqtP4+1W41jWdL0PwtLqM+lShJna9SFCCoK4JByx5GMduTzVjxLZ3c/xH8EXUNtPJbWz3xnmWMlIt0GF3tjC5PAzR4Ps7q18U+MZp7WaGO41FHhkkjKiRREoypI5HUZFAGQPitcy+HI/E1r4XupfD6hftF3Jcqjp8219keCXCngnK5INdPr3ia8027srDStHm1W+u0aRQJBDDGi4yzyEHGc8AA1wdno+pp+zY+lPpt4uoG2lAtDbuJsmdmA2Yz0IPStLxd/aY17R4b/APt2Pwz9g/e/2OsnmG6yMLL5Y3hNvT3oA6bwz4rudY1XUdH1PSX0vVbARvJB56zI6PnayuAM9OmBisD4kX82m+LPBNzb2c15Mt3cLHbREBpGaLaoyTgDJGSeg57c0/h/pj2PxC1y5g0LUtO0y7s4TayXgkZpdrEMWZiSGJJO1jnGOBmtTx8dQtfE/hDVLPSbzUorK5uHuEtYi5VDEQT6ZxnAOMkYHJoAu2HjmWLVLnTPEmlnRbqK0e+VvtAnilgT77K4A5XupGcc9Kz/APhY+ox6TH4guPClzD4bfa4vDdq04iOAJTABnbyD94nHOKytZ069+JGuyzWlhfWOn2ek3VpFcX8DQNNcToFwEYbtqgct68fXnbbSNNPhuDSJfBXiOfxAI0tpLSS5u0tHYcM5kEmwRnk8H2oA9CvPHV63ia90DRPDz6ndW8MM4k+2LFEyOCSSxB2kcYHOcnpjNSaZ401LW9Bmu9O8OvJqtpfNZXmnSXiR+S6jLESYIYcr6ZyfTmt4X0mfTviJ4gb7FLBZ/YLGKCRlbY2xGBVXP3scZPPvXOtqHiHwvpvi99M0PUZ76/8AEEotZFs3kWNGRP35UKSyjBwRkE/qAdNovjjVtT8YP4cufDn2aS3i826uIr1Z1twQdobauNzY+7nODmo/+E/1S9F5d6D4Xl1PSLSR4jd/bEiadk+/5MZBLgYODkZxxUHgbUNP0uKDR7XQ/Ei3Fy7S3WoX2lyRiaUjc0kjnpnHA+gritJ8Pad4Y0640fW/DXiW81O3lkFvLYS3RgvVLEoVMbhEPIzkDHU5OaAO+vviRDu8Pro2mXGqNr0EstoI5BGQUC8NngDk7jnjaevSpbDx+yzazbeI9LbRbvSrYXkqCcXCSQHPzKwAycjGMdce9Yml+HrrS/EfgBItGeyt7O0vjPFEzzR2zyKrbTI2TkknGTzzjpUfjDwtqPiLxb4ktbe2mWO68OxwQXBQiJplmLhN547DPoDQBrD4hana2dtq+reFprDQLhkAvWu0eSJXICPJEBlVJIzgkjNdfqx/4k19kcfZ5Pf+E142dI0jUtJttMi8E+I5dYlKRXNve3N5HbRHjc7SFypUckY68V7NqEbHRrqGJWLfZ3RVGSSdpAHqf60AeU+E/HWq6D8MtK1B/C9zPolpCEnvvtSLIQGKsyxEZKg9yQT6d67XU/GdyNcGjeHtHbV75YFubgtOIIoI2+7lyDlj1CgdK51NLv8A/hnn+zBYXX2/+yjGLXyW83dz8uzrn2xWPfeG4NL8Xzarruja1d6dqNjahJtOefdazRRhGWRIiG5xncQRnp3oA7P/AISTxx/0T4f+DuH/AOJorkvs3gv/AKFbx1/361D/AOLooA9jooooAKMCiigBMAdhS4HpRRQAgAHQClwKKKADA9KTA9KWigAwPSgAAYAoooAMD0oxRRQAYHpSYHpS0UAFFFFACYHpS4oooAKMD0oooAMAdBRgelFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFc/oeuatq19ci78PzadYBFe0uJrhGacE/xIvMZxg4JJ57dK2ri4htYHnuJY4YUGXkkcKqj1JPagCais681F4dJN9Y27aiCgeNLeRPnU85DMwBGO+azfA/iseNPDMOtrZm0SZ3VYjJvICsVznA64oA6OiiigAooooAKK53xp4nk8I6BNq40ua+hhG6Ty5VQJyAM5OeSewNamj3/9qaPZX5jMRubeOYxls7NyhsZ46Zx0HSgC9RRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRXOeNfFEnhDQZdWGlzX0MIzJ5cqIE5AGdxzyT2BqaXxLBaeDR4kvIJVgFmt3JFEN7KCoYqOmcZxzjpzigDdoryn/hoHwj/z5a1/4DJ/8XRQB3nhy61i5tD/AGtpVtYbEQRCG88/eMck/Iu3HHr3rmPjRNPF8MdVSK2EqSIokkMgXyx5ic478kDH612Oi6jZappcE9hdQXMOxVLwyBwDgZU4JwR6VzHxeimm+FuuJbxmR/KRtqjJ2iRST+ABP4UAXvB8+ry6DaQalplvZQRWkSwtFeec0g24OR5a7eMHqeteffCu78Vv8LNPh8NWemqYpJt0+qO4WQmRjhFTnGDgkkfQ9u98O+MNAv8AwjFfQajAbW1t41mkbKJG237hZuN3HTOeR6iuc+BN9azfDW0s4rmJrmCSUyxK4LrmRiCR1APuKANzwf46/t3wxqOpatbDTrnSpZYL+PdvWNo1yxB7jGePbv1ptrr3ibX/AAx/wkOjw2FvbyI01rZXcLvLNGOhLq4CFsZA2tgEda4vwpDFrml/E7QLa6hF9earfeREzgM27IU467cjBNN8AX/gmLwzFpniGSLSdZ09TDd297dPASQfvAFgDkdh6nj1APTvBvieDxh4Ws9bt4jEs4IaItuMbKSrLnAzyOuBxin+JfElt4btLZ5YpJ7m8uEtbS2jxumlboMngDuT2A7nAMvhu20m10SFNEto7fT2y0SRwmMck5IBGeTzk9fpiuJ+LkN7ZS+GfE9tay3Vvol/511DEMt5bbcsPptx/wACz2JABU+KMnjFPAGrvcw6NNYSw4mjgMiywDI+YMxxIAf9lScjitrUPEGp+GPhXp+radY210LbTYXlWaYxlRsUDaAp3dc4JXp1rD8f+OtF8RfDLWo9AuDqLvbqZBFGwECFlyXJAwewHUntjJDvEeu6XJ8A32ajaMZNKit0VZ1JMmxMp1zuGRkdfagDV0XxT401qbSLuPQLJNIvbMSNM8zKxlMW4HAyUjLcDKscYPfFX/A3izUvE769HfWdtbzaZqElkEhkZlJTrlj1yc4O0cdqu+A9QstQ8DaILO6gmMVhbpIsThvLYRr8rAHg8dDXB+C/E+j+FvFXjbTddvksLibWZruFZwR5sbn5Svr2496AOs8NeLdW1bxpr2g6lY2lq2lJCf8ARpmlDmQbh8xVeNuP4RzUlv4m1PxFrOs6d4fNnbR6TIIJrq9iaUSTYJKqiupAGMFi3XtXK+Ctatp/jL40a4YWkl2lp5ENwwSSQLHgEKTnJGDjqM4ODxVK61rSfCfxU12GDXW0FLqOOe7W9tTLFczMM7oQMFcBjkknLHGCBQB1Hg7xt4i8Qavf6XeaFYxyaXcm2vrmK9YLu5wyRlDwdvdq9AFcR4D1LwgVu7Tw9rUOo39xK13dyM/76aRj8zkYHHQYUYFbPhjxXaeKhqEthbXCWtnctbCeUKFmdfvFME5Ucc8Z/CgDU1S6msdMubq3tZLuaKNnS3jOGlYDIUE8DNcJ4k8W+LfBiW+raxY6RPorTrFcLZvL51uG6NubhwD/ALIzkcDrWr8UdZ1XQPh9qWoaNuW8jCgSqu4xKWAZ8ewzz269q8y+INz4Vvfhm0uiy3GrXCSQGbUZmeZ4csM7nc/Kxz90c89AKAPRfiP4v1jwbpMGo2NnZz27zRwuZXdnDMT0RQMjA/vZyenFVvEmv/EHSbSfWbTRNIl0y3UyvZPM5u/LXkkkfIDjJwN3/Aqz/jLf20/w7s7+CaOa2/tK3cPC4cMAT0Iznv0rbvfHWi65oFzB4cu4tW1G6t3W3s7c5cswwDID/q1BIyWwAPyoAzfEXxHvoPhrb+MtBtLSW1lRS4u5G3Rsz7MbVHzYbg8jpVrWNa+IMdgdV0jRtIeySMSGzuJZDdyKBkkbflU45C5Y49+K5rxv4dPhX9nSTRGkEklukBkZehdp1d8e25jj2ArsLX4i+H9Q0lH0e+TUb9ov3OnwDMzuBwCnVRnGWOAOpNAGF4m8UW3jH4C6rrdrG0QntSHiY5MbhwGXP1HHtg8ZrduNX1DQPhdY6rp9nbXRs9LjnlSeZo8IsQJxhTuPscfWuN1rRovA/wCz9d6LqFzBHqFxEXaMyDMkrSKSqj+LAIHHpnvW3quv6U3wJnddSsyJNENsmJ1JMpgA2dfvc9OvtQB5n/w0Z4m/6Bekfk//AMXRXjm0+p/WigD75ChegA+lLTHbA3c4xnFKpzn2OKAEWGJECLGiqP4QoA9adsXOdoye+KRiQBg96EOc/WgBdq5ztH5VHJa28syTSQRPKn3HZAWX6HtUtFABRimsSMAdTxTS3BwTxQAJBFEpWOJEBOSFUDJp+1c52jP0pMnpn2zQhJz6UAKFUZwAM8nio2toHlSV4I2kT7rlASv0PapaKAGMFBzgZ65x7V5n4Uv7XSdW12DxhiLWJb+R0ub5MpNbHiMROeNoGRsBGMnivT6MD0oA8vm8PyeJfHia9ocX9lw2mny266j9nK+fLICAUQ7d6oCSHOASQOccd9oGi2fh7RLXSbCPZbWybF9WPUsT3JJJPuTWlgelGMUABGetRLFFCipHGiIMkKowB78VI2egpB94j05oA8u+NuoW0XhixsxKjXX9oQTfZ1OXEYLZfA52+9ej2Etlcwfa7F4JYpst5sGCHPTqOD6VaOAwHSkUckYFAHm/xyu4F+Gt/YCVDd3LReXCCC7BZFZiF6kADn0zXd6Pc2GoWMd9ZPBMsqjdLEVOSB0JHcVoYooATaM5wMijav8AdH5UtFABgelFFFAH/9k=" alt="img-1.jpeg"></p>
<p>FIG. 71.2 Gamma benzene hexachloride
A vanishing cream containing <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">1 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">1%</span></span></span></span></span> of the drug, applied to properly dried skin all over the body below the neck in the form of a thin film without preliminary bathing, results in total eradication of scabies. The film is left over for a period of 12 hours following which the patient is given a bath. An average adult requires 25 g of the cream per treatment. Unlike benzyl benzoate and sulfur, the agent is odourless and non-irritant and can, therefore, be applied safely to the face but care should be taken to prevent contact with eyes and mucus membranes. The agent is neurotoxic, if absorbed. The treatment may be repeated after a week. Not more than two applications should be used during pregnancy.</p>
<p>Because of enhanced skin absorption and the risk of CNS toxicity, gammexane should be avoided in infants and children.</p>
<p>It is also useful in pediculosis.
As an insecticide 0.1 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.5%</span></span></span></span></span> solution in kerosene is lethal to flies and mosquitoes. It may be combined with other insecticides, such as a pyrethroid (permethrin) to obtain a rapid, lethal effect.</p>
<p>IVERMECTIN: Given orally in a single dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>200</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">200 \mathrm{mcg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">200</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span>, ivermectin, an antifilarial drug, (Chapter 60), is reported to be highly effective in clearing up scabies. Repetition of the dose after two weeks gives almost <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>95</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">95 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">95%</span></span></span></span></span> cure.</p>
<p>MONOSULPHIRAM: It is an effective acaricide and is used as <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">25 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">25%</span></span></span></span></span> solution diluted with 2 to 3 parts of water. It is also incorporated in soap, recommended for the prophylaxis of scabies. The drug may cause mild irritation. Adults using this drug should avoid alcohol because monosulphiram is related chemically to disulfiram (Chapter 6).</p>
<p>CROTAMITON: This is available as <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">10 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">10%</span></span></span></span></span> lotion and as cream. It is applied thrice at 24 hour intervals, followed by a bath.</p>
<p>Pediculosis: Pediculosis, a common condition in tropical countries, is caused by the louse Pediculus humanus and usually affects the scalp (capitis), the body (corporis) and pubic area (pubis). It is responsible for intense itching and may cause impetigo and eczematous lesions. Further, during famine and natural calamities, the body louse can act as a vector for typhus, relapsing and trench fevers. Finding of nits or the lice on hair clinches the diagnosis. The drugs used are given in Table 71.4.</p>
<p>Table 71.4
Drugs used in pediculosis</p>
<p><sup><a href="#user-content-fn-0" id="user-content-fnref-0-3" data-footnote-ref="true" aria-describedby="footnote-label">1</a></sup>PERMETHRIN: This is a synthetic pyrethroid, available as <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">1 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">1%</span></span></span></span></span> cream or lotion. Applied</p>
<p>to clean damp hair, left on for 10 minutes and then rinsed off the hair, it is an effective pediculocide with a residual effect for two weeks. The small quantity absorbed is rapidly metabolised to inactive compounds, and excreted in the urine. It may cause local reactions. It does not have the biological disadvantages of gammexane, and is usually preferred (Chapter 62).</p>
<p>MALATHION: This organophosphorus compound applied as <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.5%</span></span></span></span></span> lotion is rapidly pediculocidal and ovicidal in the treatment of head lice, even in patients resistant to permethrin. The drug is well tolerated and no systemic adverse effects have been reported. It is usually applied and left in place for 8-12 hours, and the application is repeated 7-9 days later. It is inflammable because of the alcohol base. Care should be taken to keep the lotion away from heat and open flame, and to avoid its contact with the eyes.</p>
<p>DICOPHANE (DDT): Used as a 10% dusting powder, it is an effective pediculocide. Its prolonged residual effect makes it lethal to the larvae which hatch out later. (See Chapter 62).</p>
<p>For pediculosis capitis, permethrin cream/lotion is preferred for initial treatment. For failures, malathion, the fastest-acting and the most ovicidal pediculocide, is recommended. However, it has an objectionable odour. Because it is inflammable, a hair dryer and a curling iron should not be used during the treatment.</p>
<p>In resistant cases, ivermectin is safe and highly effective when used as two doses of 200<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>400</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">400 \mathrm{mcg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">400</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> each, a week apart; the second dose is required as the drug is not ovicidal.</p>
<p>The other drugs used are Gamma BHC, DDT and kerosene. Gamma BHC (lotion, cream <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">1 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">1%</span></span></span></span></span> or shampoo <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">2 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">2%</span></span></span></span></span> ) and DDT ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">2 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">2%</span></span></span></span></span> dusting powder) are generally used as two applications, 7-10 days apart. The application of kerosene, though not very pleasant, is the cheapest and effective treatment for head lice. It destroys lice and suffocates nits by covering them with an impervious film. Usually, one tablespoonful of kerosene is rubbed into the whole scalp and the head wrapped in a piece of cloth. Two hours later, it is washed thoroughly with soap and water. Kerosene does not cause irritation and usually, a single application is all that is necessary. Of course, the individual must keep away from fire.</p>
<p>In patients with pediculosis corporis or pubis, DDT used as <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">10 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">10%</span></span></span></span></span> dusting powder is highly effective. A single application can give an adequate residual effect against the larvae which hatch out later. Gamma BHC is also equally effective. However, its persistence in the environment and its degradation to toxic products makes it undesirable in this condition. Further, lice can develop resistance to all above drugs. Hence, malathion or newer pyrethroids are preferred. The clothing should be disinfected with heat and all the contacts are treated simultaneously.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drug-therapy-of-acne-vulgaris">Drug Therapy of Acne Vulgaris<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-therapy-of-acne-vulgaris" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Acne vulgaris (pimples) is a common, chronic skin disorder, particularly in teenagers, and it generally regresses with time. However, it can persist for a long time and in some individuals, can cause disfigurement and permanent scarring.</p>
<p>It usually affects the face but can also spread to the trunk. Acne is known to develop frequently in patients with androgen excess. Most patients with acne probably have sebaceous glands that are hyperresponsive to androgens, rather than have over production of androgens.</p>
<p>Pathophysiology: The important features are:</p>
<ul>
<li>Increased sebum production by the sebaceous glands.</li>
<li>Hyperkeratinisation and excessive desquamation of epithelial cells from the walls of the hair follicle, leading to blockade of the follicular openings.</li>
<li>Formation of comedone, a fleshy, hyperkeratotic plug blocking the opening of the pilosebaceous follicle ('Black' and 'White' heads).</li>
<li>Proliferation of locally present Propionibacterium acnes and a few Staphylococci. These bacteria split the sebaceous fat to form irritant fatty acids leading to.</li>
<li>Local inflammation</li>
</ul>
<p>The therapy of acne is, therefore, directed to:</p>
<ul>
<li>Counteract the excessive production of sebum.</li>
<li>Prevent the abnormal desquamation of epithelial cells in sebaceous follicles; and</li>
<li>Treat and control the growth of P. acnes.</li>
</ul>
<p>Drugs used in the treatment of acne are given in Table 71.5. Dietary modifications have not been shown to modify the course of acne vulgaris and undue diet restrictions are unnecessary. However, the application of cosmetic oils and greases to the affected area should be avoided. Prolonged and vigorous washing will not resolve the lesions. On the contrary, scrubbing may damage the delicate openings of the hair follicles, and block the flow of sebum, thus worsening the acne.</p>
<p>Table 71.5
Drugs used in the treatment of acne
Local: Erythromycin, Clindamycin, Azelaic acid, Benzoyl peroxide
Systemic: Tetracyclines, Erythromycin, Minocycline, Cotrimoxazole
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo><mo>−</mo><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">--&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">−</span><span class="mord">−</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">&gt;</span></span></span></span></span></p>
<p><sup><a href="#user-content-fn-0" id="user-content-fnref-0-4" data-footnote-ref="true" aria-describedby="footnote-label">1</a></sup></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="comedolytics-and-exfoliants">Comedolytics and exfoliants:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#comedolytics-and-exfoliants" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>TRETINOIN (Trans-retinoic acid, Retin-A) used topically is an effective local comedolytic. It enhances the penetration of other anti-acne agents into the epidermis. Frequent application of this agent, however, produces redness and peeling of the skin. Improved appearance may take as long as two months to develop. It is applied as 0.01 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.025</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.025 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.025%</span></span></span></span></span> gel, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.025</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.025 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.025%</span></span></span></span></span> lotion or as <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.025</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.025 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.025%</span></span></span></span></span> cream. Gels are preferred in hot and humid climate and cream in cold and dry climate. People using retinoic acid should avoid exposure to sun because of increased susceptibility to sunburns. Its long term use should be avoided for fear of possible photocarcinogenesis. It should be avoided in pregnancy.</p>
<p>Tretinoin is also useful in treating acanthosis nigricans and skin striae such as those of Cushing's syndrome.</p>
<p>ADAPALENE: This <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>3</mn><mtext>rd&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">3^{\text {rd }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8491em;"></span><span class="mord"><span class="mord">3</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">rd&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> generation retinoid selectively binds to retinoid receptors. Used as <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.1</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.1 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.1%</span></span></span></span></span> cream, it acts like tretinoin but is claimed to be less irritant. It is stable in sunlight.</p>
<p>Salicylic acid has a keratolytic property and is used as 0.5 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">2 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">2%</span></span></span></span></span> hydroalcoholic formulation.</p>
<p>All these drugs can be combined with local or systemic antimicrobial agents.
Sebostatics: Sebaceous glands are androgen dependent and therefore, estrogens and antiandrogenic drugs are useful in therapy of acne. Estrogens are usually prescribed as COC pill containing ethinyl estradiol 50 mcg and a non androgenic progestin such as desogestrel or cyproterone acetate 2 mg . The COC pill must be given for 3-4 months before substantial improvement is observed. More prolonged therapy is needed to avoid relapse.</p>
<p>Cyproterone acetate, a potent antiandrogen, can be used in place of OC pill but is more expensive (Chapter 69). Spironolactone in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mo>−</mo><mn>200</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">50-200 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">50</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">200</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day reduces sebum production, but again several months of therapy is required to get maximal benefit. Combination OC pills containing cyproterone acetate 2 mg (Diane, Ginette) are also effective. For obvious reasons only women should receive the antiandrogen therapy.</p>
<p>ISOTRETINOIN (13-cis-retinoic acid): This vitamin A metabolite, given orally, as well as applied topically, can cause prolonged remission, permanent in <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">40 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">40%</span></span></span></span></span>, In fact, oral isotretinoin would be a drug of choice for most patients with acne but for its serious toxic effects and cost. It: (a) causes marked atrophy of sebaceous glands, and inhibits sebaceous secretion (Sebostatic action), (b) normalises keratinisation of the hair follicle, thus reducing the formation of comedones; and (c) suppresses inflammation by inhibiting growth of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>P</mi></mrow><annotation encoding="application/x-tex">P</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.13889em;">P</span></span></span></span></span>. acne.</p>
<p>A dramatic reduction in the oiliness of the skin is apparent within a month of starting treatment. It is usually prescribed at a dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mo>−</mo><mn>1</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">0.5-1 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> body weight daily for 3-4 months. Its bioavailability is increased if it is taken during or after meals. The improvement persists even after its stoppage.</p>
<p>Adverse reactions: Common effects include dryness of the skin and itching. Less commonly, it can cause hyperlipidaemia, hypercalcaemia, photosensitivity, hair loss, arthralgia, intracranial hypertension, premature fusion of epiphyses, depression and psychosis.</p>
<p>The drug is highly teratogenic and if it is used in women of child-bearing age, pregnancy should be ruled out and two methods of contraception should be continued for one month after stopping the treatment. There is no risk to male patients treated with this drug. Anyone taking this drug should not donate blood for one month after stopping it. Due to its</p>
<p>toxicity and high cost, the drug should be reserved for severe pustular acne not responding to other medications. This drug is not useful in the treatment of psoriasis.</p>
<p>Antimicrobial drugs for P. acnes: Antibiotics used against P. acnes are listed in Table 71.5. Applied locally once or twice daily, they exert a beneficial effect both by killing <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>P</mi></mrow><annotation encoding="application/x-tex">P</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.13889em;">P</span></span></span></span></span>. acnes and indirectly, by inhibiting the production of proinflammatory mediators by the organisms. Combination of erythromycin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">3 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">3%</span></span></span></span></span> with benzoyl peroxide <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span> appears to be highly effective. Clindamycin is also effective.</p>
<p>Benzoyl peroxide ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2.5</mn><mo>−</mo><mn>10</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">2.5-10 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">10%</span></span></span></span></span> ) as gel or lotion is lipophilic and suppresses effectively the growth of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>P</mi></mrow><annotation encoding="application/x-tex">P</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.13889em;">P</span></span></span></span></span>. acnes. It is also keratolytic. Drug resistance does not develop. It has no antiinflammatory property. It can cause local irritation and allergy.</p>
<p>Antibiotics used for the systemic therapy of acne include doxycycline (100-200 mg daily), minocycline, erythromycin (500-1000 mg daily) and co-trimoxazole. Generally, doxycycline is preferred. These drugs need to be given for 4-6 weeks and then tapered off gradually by 10 to 12 weeks. This is followed by topical treatment with tretinoin and benzyl peroxide for 6 months.</p>
<p>The suggested therapeutic approach for treating acne is outlined in the Table 71.6.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="table-71-6">Table 71.6<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-71-6" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="drug-therapy-of-acne-vulgaris">Drug therapy of acne vulgaris<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-therapy-of-acne-vulgaris" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Mild cases without inflammation Topical: tretinoin cream/gel; adapalene <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.1</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.1 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.1%</span></span></span></span></span> gel; salicylic acid, benzoyl peroxide</li>
<li>Mild cases with inflammation Topical antibiotics, benzoyl peroxide or combination of erythromy cin and benzoyl peroxide for 4 to 6 weeks.</li>
<li>Severe cases with inflammation Topical tretinoin plus systemic antibiotic therapy. If response is unsatisfactory, particularly in multinodular cystic lesions, add oral isotretinoin. In women of reproductive age, use OC pill or cy proterone acetate.</li>
</ul>
<p>To prevent recurrence, topical treatment must be continued for 6 months.
Rarely, severe acne may be associated with fulminating systemic symptomatology such as fever, arthralgia, glomerulonephritis and bone pain. In such case, addition of oral short term glucocorticoids to antibiotics may be useful.</p>
<p>Agents that predispose to the formation of comedones include topical agents such as lanolin, butyl stearate, lauryl alcohol and paraffin in commercial cosmetic and hair preparation. Industrial compounds that contain impure paraffin oil, halogenated hydrocarbons, coal tar and its derivatives can also precipitate or worsen the condition. Local or systemic glucocorticoids used for long periods can also cause acne.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drug-therapy-of-allergic-skin-disorders">Drug Therapy of Allergic Skin Disorders<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-therapy-of-allergic-skin-disorders" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Urticaria: See Chapter 23.
Atopic Dermatitis: Atopy is defined as a genetically determined tendency to hyper-react to common environmental allergens with the production of IgE and immediate hypersensitivity/ allergic (Type I) reaction. Majority of the patients have a family history of asthma or hay fever. Atopic dermatitis, a chronic condition, is a cutaneous expression of the atopic state. The clinical presentation differs according to the age of the patient. The infantile form is the most common and is characterised by weeping and encrusted inflammatory lesions distributed on the face, neck and extensor surfaces. Itching is prominent. Secondary infection may be present. Atopic dermatitis in infants often resolves spontaneously. The treatment includes:</p>
<ul>
<li>Avoidance of cutaneous irritants like soaps, detergents and hot water.</li>
<li>Adequate cutaneous hydration; and</li>
<li>Judicious use of mild topical glucocorticoids to control itching and inflammation (Chapter 66).
Infection should be treated with systemic antibiotics. Oral sedative <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>-antihistaminics may be useful to control the itching. The role of dietary allergens in atopic dermatitis is controversial. However, if such an allergen can be identified, particularly in children, it should be avoided. For local application low potency steroids are to be preferred and used for consecutive two weeks. Severe exacerbations need to be treated with high potency topical steroids and/or systemic glucocorticoid therapy. Although such treatment will generally clear the skin, the lesions may return after stoppage of therapy.</li>
</ul>
<p>An antidepressant, doxepin, (Chapter 14), 5% cream exhibits significant antipruritic activity in atopic dermatitis. It has some antihistaminic property. It can get absorbed from the skin and may cause drowsiness and anticholinergic effects.</p>
<p>Immunomodulating agents such as calcineurin inhibitor, tacrolimus have been reported to be useful when given orally. They are, however, toxic. Tacrolimus ointment is also claimed to be effective (Chapter 74).</p>
<p>Allergic contact dermatitis: This condition is caused by contact of the skin with some offending agents. The commonest type is plant dermatitis caused by members of the Rhus family. It is characterised by erythema, vesiculation, and severe itching at the areas of contact. The other common sensitisers include preservatives in topical preparations, fragrances, formaldehyde, potassium dichromate, detergent, rubber curing agents, synthetic paints, plastic/synthetic bed and pillows and drugs. Chronic and excessive exposure to water and detergents can initiate or aggravate hand dermatitis. The condition is common in housewives and food handlers. However, many times, the offending agent is difficult to identify. The ideal treatment is to avoid the offending agent. Symptomatic relief can be achieved by local calamine lotion or with topical glucocorticoids for about two weeks.</p>
<p>Eczema: Eczema is a common form of inflammation of the skin (dermatitis), with variable clinical and histological features. It may be the common final expression of allergic conditions, such as atopic dermatitis, contact dermatitis, or may accompany seborrheic dermatitis (see earlier). Initial lesions occur as erythematous macules, papules, or vesicles which later coalesce to form patches and plaques. Eczema is associated with</p>
<p>itching and may be of two types:</p>
<ul>
<li>Weeping (oozing); or</li>
<li>Dry</li>
</ul>
<p>As in other allergic disorders, attempts should be made to identify the offending agents and eliminate them. These are commonly found in food additives, perfumes, cosmetics, insecticides, mosquito repellents, environmental chemicals, synthetic fibres often in clothing, plants, flowers, pollen etc.</p>
<p>Most of the cases of localised eczemas respond well to calamine lotion/liniment or to a mild topical glucocorticoid preparation such as 1-2% hydrocortisone (Chapter 66). Once the eczema is controlled, attempts should be made to reduce the concentration of and finally stop the glucocorticoid therapy.</p>
<p>Due to adverse effects of long term administration of glucocorticoids on the skin, some physicians prefer tar preparations. Other topical preparations which are useful in eczema are potassium permanganate solution used for bringing about drying of weeping lesions; and zinc containing creams, pastes, calamine liniment to counteract excessive dry lesions. A simple emulsifying ointment like rose ointment or a cream containing urea, which acts by increasing the hydration, can also be used for dry lesions.</p>
<p>Systemic glucocorticoid therapy has no place in routine treatment of chronic eczema, but it can be beneficial in the acute form of the disease. Antihistaminics should not be used topically because of their propensity to cause contact dermatitis. In general, antibacterial agents are used only in severe infections.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drug-therapy-of-psoriasis">Drug Therapy of Psoriasis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-therapy-of-psoriasis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Psoriasis is a common, chronic, inflammatory dermatosis. It is characterised by erythematous, well demarcated plaques, and rounded scales which look like silvery mica. Pruritus may be present. Lesions are usually symmetrical and occur on the extensor surfaces such as the elbows and knees, and on the scalp. About <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span> of the patients have involvement of the finger nails and some have psoriatic arthritis. Genetic predisposition to psoriasis is known. Further, drug-induced flares of psoriasis can occur (Table 71.7). Infections, particularly due to streptococci can trigger an attack.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="table-71-7">Table 71.7<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-71-7" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="possible-risk-factors-in-psoriasis">Possible risk factors in psoriasis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#possible-risk-factors-in-psoriasis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Injury to the skin.</li>
<li>Infection, particularly streptococcal.</li>
<li>Some systemic drugs (beta blockers, ACE inhibitors, lithium, indomethacin, chloroquine).</li>
<li>Psychological stress.</li>
</ul>
<p>Pathogenesis: The commonest variety of psoriasis is characterised by plaques, which consist of greatly thickened horny layer of the skin (hyperkeratosis). They are characterised by hyperproliferation of the epidermal keratinocytes and inflammation of both the epidermis and the dermis, along with angiogenesis. These changes are due to cytokines released by T-lymphocyte, which initate autoimmune dermal response to unidentified antigenic stimuli (keratinocyte proteins). The affected dermis shows predominance of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">D</mi></mrow><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{CD}_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">CD</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> lymphocytes. The activated T cells from the dermis cause the keratocytes to proliferate; the inflammatory changes include infiltration of the epidermis by leucocytes. It is now known that TNF-a is the primary activator of the T-lymphocytes and it also contributes to the maintenance of a complex inflammatory reaction. The permissive role of bacterial superantigens in its pathogenesis is now well established.</p>
<p>The current therapy only suppresses the disease and recurrence is common. However, the disease may undergo spontaneous remission.</p>
<p>Treatment of psoriasis: It depends on the type, the location and the extent of the lesions. The patients are advised to avoid known exacerbating factors (Table 71.7).</p>
<p>Mild cases of psoriasis may not warrant any drug therapy, since the drugs used can produce toxicity. Indications for drug treatment are:</p>
<ul>
<li>Marked local symptoms such as pain and itching.</li>
<li>Prominent hand, leg or facial lesions</li>
<li>Diminished mobility.</li>
</ul>
<p>Drugs used in the treatment of psoriasis are listed in Table 71.8. These drugs either cause keratolysis and/or inhibit cell division. They do not cure the disease.</p>
<p>Table 71.8
Drugs used in psoriasis</p>
<ul>
<li>Emollients</li>
<li>Keratolytic agents: Salicylic acid 2-10%.</li>
<li>Cytostatic agents: Coal tar, Dithranol</li>
<li>Glucocorticoids.</li>
<li>Calcipotriol, Tacalcitol</li>
<li>Retinoids</li>
</ul>
<p>Systemic therapy</p>
<ul>
<li>Etretinate, Acitretin</li>
<li>Immunosuppressants: Methotrexate, Cyclosporine, Mycophenolate mofetil.</li>
<li>Biological agents
(a) T cell activation inhibitors: Alefacept
(b) TNF- <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span> inhibitors: Etanercept, Infliximab.
(c) IL-12 and IL-23 blocker: Ustekinumab</li>
<li>Systemic Glucocorticoids.</li>
</ul>
<p>Phototherapy</p>
<ul>
<li>Ultraviolet B irradiation with or without Coal tar application.</li>
<li>Ultraviolet therapy with Psoralens.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo><mo>−</mo></mrow><annotation encoding="application/x-tex">--</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">−</span><span class="mord">−</span></span></span></span></span>
<img src="data:image/jpeg;base64,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" alt="img-2.jpeg"></li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="i-topical-therapy">I Topical therapy:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i-topical-therapy" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Emollients: These act by hydrating and softening the scales. They are used in mild cases. The commonly used emollients are yellow, soft paraffin and aqueous cream. Although greasy emollients are sometimes preferred, they are less well accepted by the patients.</p>
<p>Salicylic acid: This is the most widely used keratolytic agent, used either alone or with coal tar. It is an irritant, and care should be taken to avoid contact with the eyes (see earlier).</p>
<p>Cytostatic agents (dithranol and coal tar) are used, along with UVB phototherapy, in the treatment of psoriasis and other hyperplastic skin disorders. In these conditions they restore a normal rate of epidermal proliferation. In severe cases, systemic therapy with either etretinate or methotrexate (see later) both of which, act as cytostatic agents in the skin, may be needed.</p>
<p>Crude coal tar ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">3 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">3%</span></span></span></span></span> ointment) : This has been used to treat chronic, lichenified lesions. Coal tar, even in low concentration, has an unpleasant odour, and can cause irritation and acneform eruption. Hence it is less acceptable.</p>
<p>DITHRANOL (Anthralin): This synthetic substitute for chrysarobin reduces the epidermal cell DNA synthesis and mitotic activity (antimitotic) of the hyperplastic epidermis. It is an irritant and should not be applied to the face, scalp and to tender skin.</p>
<p>The drug is used as an ointment, paste or paint. Since some patients are allergic to this drug, a preliminary test on a patch of skin should be carried out. It is used in the increasing concentrations of 0.05 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.5%</span></span></span></span></span>, for <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow><annotation encoding="application/x-tex">1 / 2</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1/2</span></span></span></span></span> hour daily along with ultraviolet B light therapy, for 2 to 3 weeks. It stains the skin and fabric brown and is not suitable for treatment of lesions on the face.</p>
<p>A commercial preparation, Derobin, contains dithranol <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1.15</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">1.15 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">1.15%</span></span></span></span></span> with salicylic acid and coal tar.</p>
<p>GLUCOCORTICOIDS: Topical glucocorticoid preparations of the mild and moderately potent varieties (Chapter 66) are preferred because of their efficacy, high degree of acceptability to the patients and low cost. Once a day application to the lesions is probably as effective as the twice a day regimen and is less liable to cause ADR. They act mainly as anti-inflammatory agents. Relapse rate is higher than with other forms of therapy. The use of potent and very potent, topical, glucocorticoid preparations should be reserved for the specialist.</p>
<p>CALCIPOTRIOL: This vitamin D derivative is applied locally to mild to moderate psoriatic lesions. It has minimal effect on calcium metabolism. The drug is as effective as topical, medium potency glucocorticoids but is much less toxic. It is applied daily as an ointment containing <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mi mathvariant="normal">g</mi></mrow><annotation encoding="application/x-tex">50 \mathrm{mcg} / \mathrm{g}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">50</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span><span class="mord">/</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span></span></span></span> for about 8 weeks. The ointment is colourless, does not stain clothes and does not have unpleasant smell. It can sometimes cause irritation and hypercalcemia. Tacalcitol is another vitamin D analogue which is effective. Combination of a topical vitamin D analogue and phototherapy is a well accepted regimen for psoriasis.</p>
<p>II Systemic therapy: Although most patients with psoriasis respond to local therapy, about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">20 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">20%</span></span></span></span></span> may require systemic therapy. The latter is expensive, more toxic and needs supervision. The drugs used are:</p>
<p>ETRETINATE: This second generation retinoid is also known as methoxsalen. It inhibits keratinisation and proliferation, and normalises differentiation of epithelial tissues. Used alone, it has limited efficacy in psoriasis. It is usually combined with psoralen and UV-A phototherapy in chronic plaque psoriasis. The drug accumulates in the adipose tissue and</p>
<p>the liver. It is administered orally in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mo>−</mo><mn>1.0</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">0.5-1.0 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1.0</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> per day.
The adverse reactions include dryness, scaly erythema and tenderness. It is teratogenic and should not be used in woman of the reproductive age until pregnancy is excluded. Further, the patient must avoid pregnancy during treatment and for at least 3 years after the treatment is over because of its long half life (about 120 days). Similarly, anyone taking this drug should not donate blood for 3 years after stopping it. The drug has no sebostatic action and is of no use in acne.</p>
<p>Acitretin, a metabolite of etretinate, is now preferred to etretinate in therapy. Its limitations are similar to those of etretinate. Topical tazarotene, a retinoid applied once daily, is also effective.</p>
<p>METHOTREXATE: This folic acid antagonist acts by blocking DNA synthesis and inhibiting cell proliferation. Methotrexate may also act as an immunosuppressant. It is given orally in 3 doses, usually <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2.5</mn><mo>−</mo><mn>5.0</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">2.5-5.0 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">5.0</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span>. at 12 hourly, intervals, every week. It is preferred in severe case with arthritis, where coal tar-U V therapy has failed. It should be used only in patients with normal hematological, renal and hepatic status. The drug is usually well tolerated in the doses recommended. The main long term toxicity is hepatic cirrhosis (Chapter 61).</p>
<p>CYCLOSPORINE: This drug is used as an immunosuppressant and acts by inhibiting the production of IL2, a cytokine necessary for proliferation of activated T cells, and other T cell cytokines (Chapter 25). The important adverse effects are hypertension and renal toxicity which may be irreversible. It is reserved for patients with severe refractory psoriasis.</p>
<p>MYCOPHENOLATE MOFETIL: This immunosuppressant has been reported to be useful in the treatment of psoriasis. Adverse effects reported are mild and dosedependent. The drug has also been used to treat pyoderma gangrenosum, pemphigus vulgaris and systemic vasculitis.</p>
<p>Biological agents: Recently, biological agents have been introduced in the treatment of psoriasis (Table 71.8). Given parenterally, they are effective in about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mo>−</mo><mn>70</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">30-70 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">30</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">70%</span></span></span></span></span> of patients with moderate to severe psoriasis. They are:
(1) Alefacept binds to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">D</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{CD}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">CD</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> on activated T cells and impairs the co-stimulatory signals of leucocyte-function-associated antigen-3 (LFA-3). This decreases the number of T cells.
(2) Infliximab inihibits TNF- <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span> functionally.
(3) Etanercept is a recombinant human TNF receptor antagonist (Chapter 75).
(4) Adalimumab, humanised <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">IgG</mi><mo>⁡</mo></mrow><mn>1</mn></msub><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">A</mi><mi mathvariant="normal">b</mi></mrow></mrow><annotation encoding="application/x-tex">\operatorname{IgG}_{1} \mathrm{mAb}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9386em; vertical-align: -0.2441em;"></span><span class="mop"><span class="mop"><span class="mord mathrm">IgG</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.207em;"><span style="top: -2.4559em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.2441em;"><span></span></span></span></span></span></span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord"><span class="mord mathrm">mAb</span></span></span></span></span></span>, blocks TNF- <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span>. Chances of development of neutralising antibody are less compared to infliximab.
(5) Ustekinumab: This human monoclonal antibody reduces skin inflammation by blocking the activity of IL-12 and IL-23. It is indicatd in patients with moderate to severe plaque psoriasis who cannot take standard therapy.</p>
<p>In addition, TNF <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span> inhibitors, golimumab and certolizumab, are approved for psoriatic arthritis. They are all very expensive.</p>
<p>Selective phosphodiesterase -4(PDE-4) inhibitor, apremilast, is also available for psoriatic arthritis.</p>
<p>Systemic glucocorticoids: Systemic glucocorticoid therapy, though very effective, needs high doses to suppress the disease, and therefore causes ADR. Further, the relapse rate is high. Hence, it should be reserved for acutely ill patients with erythrodermic psoriasis.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drug-therapy-of-alopecia">Drug Therapy of Alopecia<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-therapy-of-alopecia" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Alopecia is loss of hair in any region of the body. The hair are of two types: vellus hair which are fine, light coloured and straight; and terminal hair which are thicker, dark and may be curly. In the neonate, terminal hair are present on the scalp and in the regions of eyelashes and eyebrows; these are the androgen independent or nonsexual hair. At about the age of 8-10 years, the weak adrenal androgens cause a slight rise in the plasma testosterone level, and terminal hair appear on the forearms and legs in both boys and girls (ambisexual hair). At puberty, with the further rise in the plasma testosterone level into the adult female range, terminal hair appear in the pubic and axillary regions; these hair are also ambisexual. Boys with further advanced puberty and adult males develop terminal hair in other regions such as face and trunk (sexual hair).</p>
<p>The circulating testosterone is converted in the skin into dihydrotesterone (DHT) which acts on the hair follicles and is responsible for the growth of the ambisexual and sexual hair; it is also responsible for the (normal) temporal recession in normal adult males, and for the (abnormal) temporal recession in adult females and the (abnormal) growth of sexual hair in women and in children of both sexes. Further, it is responsible for the excessive loss of scalp hair in women with elevated plasma androgen levels.</p>
<p>Hair growth is cyclic, with phases of growth (anagen), involution (catagen) and resting (telogen). In the scalp, about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>80</mn><mo>−</mo><mn>88</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">80-88 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">80</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">88%</span></span></span></span></span> of the hair are in anagen (for about 3 years), <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo>−</mo><mn>2</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">1-2 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">1</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">2%</span></span></span></span></span> are in catagen (for about 3 weeks) and the rest <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mo>−</mo><mn>20</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">10-20 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">10</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">20%</span></span></span></span></span> are in telogen (for about 3 months), after which hair are shed. The growth of scalp hair is asynchronous, with hair in a given area in different phases; there is a balance among anagen, catagen and telogen hair in all regions of the scalp. A disruption of this balance causes many more hair to enter the telogen phase, and about 3 months later they are shed in bulk causing alopecia; this is called telogen effluvium. After that, the hair grow again. Severe stress can cause telogen effluvium; but as sudden severe hair loss occurs three months after the stressful event, the latter is likely to be forgotten. Similarly, an abundance of estrogen during pregnancy and COC pills use (Chapter 68) prolongs the anagen of the scalp hair which is responsible for their lush appearance in these women. However, about 3 months after delivery or cessation of COC pills, these hair enter the telogen and are shed, causing alopecia. Some time later, the hair growth may return to normal.</p>
<p>Alopecia of the scalp can be:
I Scarring which is associated with inflammation, fibrosis and destruction of the hair follicles due to primary skin disorders such as lichen planus or systemic diseases such as lupus erythematosus. Such alopecia is permanent.</p>
<p>II Non scarring in which the hair follicles are preserved, and the alopecia is temporary and reversible following correction of cause. Dandruff is perhaps the commonest cause. The other causes of non-scarring alopecia are: crash dieting, physical trauma, iron deficiency, hypothyroidism, chronic malnutrition, chronic illness, androgen excess and androgenetic alopecia. It can also be caused by drugs.</p>
<p>The forms of alopecia of the scalp are:</p>
<ul>
<li>
<p>Androgenic alopecia.</p>
</li>
<li>
<p>Androgenetic alopecia (male pattern)</p>
</li>
<li>
<p>Alopecia areata, and</p>
</li>
<li>
<p>Drug induced (See Table 71.10).</p>
</li>
</ul>
<p>Table 71.10
Some dermatological reactions to drugs used systemically and topically</p>
<table><thead><tr><th style="text-align: left;">Skin reaction</th><th style="text-align: left;">Examples of implicated drugs</th></tr></thead><tbody><tr><td style="text-align: left;">Urticaria</td><td style="text-align: left;">Penicillins, NSAID, sulfonamides, captopril, enalapril</td></tr><tr><td style="text-align: left;">Acne or aggravation of &lt;br&gt; existing acne</td><td style="text-align: left;">Corticosteroids, androgenic and anabolic steroids, phenytoin, OC containing androgenic progestogens, iodides, cytotoxic therapy, &lt;br&gt; lithium, danazol, barbiturates, isoniazid</td></tr><tr><td style="text-align: left;">Exfoliative dermatitis</td><td style="text-align: left;">NSAID, sulfonamides, gold salts</td></tr><tr><td style="text-align: left;">Contact dermatitis</td><td style="text-align: left;">Topical antimicrobials like penicillin, chloramphenicol, neomycin; sulfonamides; topical antihistaminics; cream and lotion &lt;br&gt; preservatives; lanolin cosmetics</td></tr><tr><td style="text-align: left;">Purpura</td><td style="text-align: left;">Corticosteroids, anticoagulants, aspirin, barbiturates, thiazides, sulfonamides, sulfonylureas, cytotoxic drugs</td></tr><tr><td style="text-align: left;">Stevens Johnson syndrome</td><td style="text-align: left;">Sulfonamides, barbiturates, NSAID, phenytoin, allopurinol</td></tr><tr><td style="text-align: left;">SLE like reaction</td><td style="text-align: left;">Hydrallazine, procainamide, phenytoin, isoniazid, alpha methyldopa</td></tr><tr><td style="text-align: left;">Fixed drug eruption</td><td style="text-align: left;">Phenolphthalein, barbiturates, aspirin, sulphonamides, quinine, tetracyclines</td></tr><tr><td style="text-align: left;">Photosensitivity</td><td style="text-align: left;">Demeclocycline, phenothiazines, griseofulvin, nalidixic acid, sulphonamides, sulphonylureas, thiazides, piroxicam</td></tr><tr><td style="text-align: left;">Alopecia</td><td style="text-align: left;">Cytotoxic drugs, heparin, androgens, OC pill, carbimazole, vitamin A (large doses), beta blockers, levodopa, thallium</td></tr><tr><td style="text-align: left;">Hirsutism</td><td style="text-align: left;">See Chapter 69</td></tr></tbody></table>
<p>Androgenic alopecia occurs in women and is due to elevated plasma levels of androgens. They may have other manifestations of hyperandrogenism such as menstrual abnormalities, hirsutism, acne and infertility. The treatment is that of hyperandrogenism (Chapter 69).</p>
<p>Androgenetic alopecia is a hereditary disorder due to excessive conversion of testosterone to DHT in the scalp skin in genetically susceptible men and women. The DHT causes shrinking of the local terminal hair follicles to miniaturised hair follicles. The onset in both sexes is early in life, often in teens. The miniaturised hair of various lengths and diameters are the hallmark of this condition.</p>
<p>In men, the alopecia ranges from bitemporal recession to thinning of the hair in the frontal and vertex regions to complete baldness except in the occipital and temporal regions. In women, the thinning is less severe but is maximum in the frontal and parietal regions. Many of them have normal menses, pregnancies and plasma levels of androgens. Endocrine testing is not required if the above described characteristic pattern of hair loss is present, and there is no evidence of hyperandrogenism.</p>
<p>Treatment: This comprises of topical minoxidil (see below) in both sexes and oral finasteride in men (Chapter 69). The response to finasteride is better in the frontal region of the scalp, which has higher levels of 5 -alpha reductase, than in the occipital region (which has higher levels of aromatase).</p>
<p>It must be remembered that androgens cause:
(a) The vellus-hair follicles to be replaced by terminal hair follicles in the region of ambosexual and sexual hair; and
(b) Miniaturisation of the terminal hair follicles of the scalp.</p>
<p>As these changes are irreversible, complete reversal of hirsutism (Chapter 69) and of androgenic/androgenetic alopecia is not to be expected.</p>
<p>Alopecia areata (which is non-scarring) causes patches of complete baldness, varying in size, in any region of the body including the scalp. The bald areas may coalesce to produce large areas of baldness. The condition is due to an autoimmune disorder of the hair follicles. The hair tend to regrow on the bald patches but recurrence is common. The treatment comprises of topical minoxidil and a topically injected glucocorticoid.</p>
<p>Minoxidil, an antihypertensive agent (see Chapter 30), when applied locally as a 2-5%</p>
<p>solution twice a day over a prolonged period, may produce some hair growth in a few patients. The results are best in mild cases and good to excellent results are seldom seen in more than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">30 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">30%</span></span></span></span></span> of patients even after prolonged use. Minoxidil increases the dermal blood flow causes an elongation and normalisation of the hair follicles. New hair follicles are not formed. Cosmetically acceptable hair growth is uncommon, and the beneficial effect ceases when the treatment is discontinued. One ml of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">2 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">2%</span></span></span></span></span> solution is applied to dry scalp twice daily. The dose of 2 ml per day should not be exceeded. The therapy is prolonged, expensive and results are unpredictable.</p>
<p>There is no reliable and safe treatment for irreversible alopecia. Had there been one, many dermatologists themselves would not have been bald! It would be better and perhaps cheaper to use a wig!</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drugs-affecting-skin-pigmentation">Drugs Affecting Skin Pigmentation<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drugs-affecting-skin-pigmentation" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Drugs can be used:</p>
<ul>
<li>To decrease localised hyperpigmentation such as freckles and post-inflammatory pigmentation.</li>
<li>To increase pigmentation in acquired, localised, skin disorders with hypopigmentation such as vitiligo; and</li>
<li>To treat acanthosis nigricans (see later).</li>
</ul>
<p>Hydroquinone and monobenzone are used as skin bleaching agents whereas the psoralen compounds (trioxsalen and methoxsalen) are used concurrently with exposure to UV light for stimulating melanin synthesis and repigmentation. These drugs are not recommended below the age of 12 years.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="i-demelanising-agents">I Demelanising agents<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i-demelanising-agents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>HYDROQUINONE: This drug inhibits tyrosinase and hence melanin synthesis in the melanocytes of the skin. It is also toxic to the melanocytes. It is commonly used in the form of a <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mo>−</mo><mn>4</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">2-4 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">4%</span></span></span></span></span> cream or lotion in the treatment of freckles, post-inflammatory pigmentation, and melasma of pregnancy and that due to oral contraceptives. Its effect is reversed by sunlight and hence it is used in combination with an opaque sunscreen.</p>
<p>MONOBENZONE: This is a mono-benzyl ether of hydroquinone and has similar properties. However, it causes total, irreversible depigmentation. The incidence of skin allergy to this drug is high.</p>
<p>Vitiligo is probably an autoimmune disorder. It may be localised or generalised. The treatment is unsatisfactory. The affected skin can be painted by artificial tanning preparations or with 1-2% dihydroxyacetone in 50:50 water and acetone. The concentration should be adjusted to suit the patient.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="ii-melanising-agents">II Melanising agents<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ii-melanising-agents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>TRIOXSALEN (Trisoralen): Given orally, it may be effective in the treatment of vitiligo. By increasing the skin pigmentation, it increases the tolerance of the skin to UV light. For large lesions of vitiligo, it is given in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.6</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">0.6 \mathrm{mg} / \mathrm{kg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">0.6</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mord">/</span></span></span></span></span> day <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mo>−</mo><mn>3</mn></mrow><annotation encoding="application/x-tex">2-3</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">3</span></span></span></span></span> times a week 2 hours before exposure to 5-10 minutes of direct, mid-day sunlight. Exposure is increased by 2 minutes per day until erythema sets in. If the desired effect is not obtained after 90 min of exposure, the dose is increased gradually upto a maximum of 80 mg daily. Re-pigmentation is usually evident after 3-4 months of treatment. Blue-grey, plastic sunglasses, opaque to UV rays, and a light-screening lipstick should be used during UV exposure in order to protect the eyes and the lips. The drug sometimes causes cutaneous reaction. It is contraindicated in patients with diseases associated with photosensitivity such as porphyria and systemic lupus erythematosus, and should not be given concurrently with other photosensitising drugs.</p>
<p>METHOXSALEN (Oxsoralen): This psoralene compound is used topically and orally to treat small vitiliginous lesions. Topical application of a 0.1 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">1 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">1%</span></span></span></span></span> lotion is followed by exposure to sunlight or a UV lamp. This causes erythematous reaction and activation of melanocytes. Topical use can cause acute, vesicular, cutaneous photosensitivity reaction. The drug can also be given orally in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">20 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">20</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day (single dose), 2-4 hours before exposure to UV light. Commonly it causes gastric discomfort. It can accelerate skin aging. There is an increased risk of severe sunburn, skin wrinkling, cataract and skin cancer</p>
<p>following long term therapy.
Acanthosis nigricans: This is hyperpigmented, velvety thickening of the skin occurring most commonly on the neck, in the axillae and in the groins. It is believed to be a manifestation of hyperinsulinemia due to insulin resistance. The drugs used locally are: tretinoin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.025</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.025 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.025%</span></span></span></span></span> cream; adapalene <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.1</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.1 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.1%</span></span></span></span></span> gel; and calcipotriene <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.005</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.005 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.005%</span></span></span></span></span> cream, ointment or gel.</p>
<p>Commercial skin lightening creams may alter the chemical structure of the skin by inhibiting synthesis of melanin. The common basic ingredients in these creams are hydroquinone, mercury and highly potent fluorinated steroids along with chemicals of unknown safety. Constant use of these agents can give rise to skin rashes, dirty grayish brown waxy pigmentation, colloid millium, superficial fungal infection, viral warts, severe acne vulgaris, folliculitis and striae formation. The skin becomes thinner and wound healing is delayed. Percutaneous absorption may cause renal damage. In fact, what one needs is a cosmetic that would improve the appearance of the skin or enhance its attractiveness without altering the basic structure.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="sunscreens-and-barrier-preparations">Sunscreens and Barrier Preparations<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#sunscreens-and-barrier-preparations" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Solar UV radiation that can damage the skin is of three types according to wavelengths: UVA1, UVA2 and UVB. Of these, UVA forms <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>15</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">15 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">15%</span></span></span></span></span> of the total radiation and is mainly responsible for photo-ageing and photo-toxicity. UVB is mostly absorbed in the epidermis and causes sunburn and tanning. UVA2 is also erythemogenic. Chronic exposure to both, UVA and UVB can damage the DNA, suppress immune mechanisms and can cause skin ageing and cancer in animals.</p>
<p>Skin can be protected from solar UV radiation by:
(1) Inorganic preparations such as zinc oxide, calamine and titanium dioxide which are opaque to all wavelengths of light and reflect them (Reflectant sunscreens); thus they are physical barriers; and
(2) Organic chemicals that absorb UVA and UVB at the skin surface (Absorbent sunscreens). Examples are aminobenzoates, benzophosphophenones-3 (oxybenzone), methoxycinnamate (octinoxate), a salicylate (octisalate), octocrylone and a dibenzylmethane (avobenzene) (Table 71.9).</p>
<p>Table 71.9
Types of sunscreens</p>
<ul>
<li>UVB, UVA2/1</li>
</ul>
<p>Zinc oxide, Calamine, Titanium dioxide</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="ii-organic-absorbent-sunscreens">II. Organic (absorbent) sunscreens:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ii-organic-absorbent-sunscreens" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>UVB</li>
</ul>
<p>PABA and PABA derivatives: Octyl dimethyl PABA (Padimat O)</p>
<p>Cinnamates: Octyl methoxycinnamate, Cinoxate
Salicylates: Octyl salycilates (Octisalate), Homosalate, Trolamine salycilates Octocrylene, Phenylbenzimidazole sulphonic acid (Ensulizole)</p>
<ul>
<li>UVB, UVA1</li>
</ul>
<p>Benzophenones: Oxybenzone, Dioxy-benzone, Sulisobenzone
Terephthalydine dicamphor sulphonic acid (Ecamsule)</p>
<ul>
<li>UVA1</li>
</ul>
<p>Butyl methoxydibenzoyl methane (Avobenzone)</p>
<ul>
<li>UVA2</li>
</ul>
<p>Methyl anthranilate (Merdimate)</p>
<p>I. Inorganic (reflectant) sunscreens:</p>
<ul>
<li>UVB, UVA2/1</li>
</ul>
<p>Zinc oxide, Calamine, Titanium dioxide
II. Organic (absorbent) sunscreens:</p>
<ul>
<li>UVB</li>
</ul>
<p>PABA and PABA derivatives: Octyl dimethyl PABA (Padimat O)
Cinnamates: Octyl methoxy cinnamate, Cinoxate
Salicylates: Octyl saly cilates (Octisalate), Homosalate, Trolamine saly cilates Octocrylene, Phenylbenzimidazole sulphonic acid (Ensulizole)</p>
<ul>
<li>UVB, UVA1</li>
</ul>
<p>Benzophenones: Oxybenzone, Dioxy-benzone, Sulisobenzone
Terephthalydine dicamphor sulphonic acid (Ecamsule)</p>
<ul>
<li>UVA1</li>
</ul>
<p>Butyl methoxydibenzoyl methane (Avobenzone)</p>
<ul>
<li>UVA2</li>
</ul>
<p>Methyl anthranilate (Merdimate)
Since none of these agents give complete protection from solar UV radiation, they are usually combined to increase photostability and to broaden their spectrum. A newer agent, ecamsule, has broad protective spectrum.</p>
<p>Barrier preparations: They are used as water repellents to protect the skin against nappy rash. They contain a water repellent such as dimethicone along with zinc oxide. They are used as creams or ointments.</p>
<p>Dihydroxyacetone (DHA), a pigment agent, is commonly used for sunless tanning. It binds to stratum corneum and changes the skin colour from white to orange-brown which lasts for 5-7 days.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="cosmetics-tooth-powders-and-dermal-fillers">Cosmetics, Tooth Powders and Dermal Fillers<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#cosmetics-tooth-powders-and-dermal-fillers" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Various preparations of cosmetic dusting powders contain mainly talc (native magnesium silicate with small amounts of aluminium silicate) which acts as an adsorbent and provides 'slip'. Another substance which also acts as an adsorbent and a mild antiseptic, added to such powders, is zinc stearate, a light, impalpable, amorphous powder. Zinc oxide is commonly used to cover the 'shine', while chalk acts as a colour carrier. However, starch is a better absorbent of moisture than the substances mentioned above. Addition of phenol, menthol and camphor exert a local antipruritic and cooling action. To these basic ingredients, various antiseptics like boric acid and salicylic acid may be added. A powder containing salicylic acid 5 g , boric acid 5 g , camphor 5 g , starch 30 g and talc to 100 g can be easily and economically prepared at home. The powder has absorbent, mild antiseptic, antipruritic and cooling properties; it may be applied to the axillae and the groins once or twice daily, with benefit. Application of such powders may cause blocking of the sweat gland pores and hence, after-cleansing is essential. Use of talc on surgical gloves is known to cause granulomatous reaction in wounds.</p>
<p>Baby powder generally contains zinc stearate and talc in the proportion of 1 to 2 . There is no evidence that they are superior to good quality regular talc powder. In general, it is better to avoid such medicated powders in babies as they tend to form cake in skin fold causing dermatitis and may also get into the lungs. Similarly there appears to be no need for special 'baby soap' or 'baby oil'. Any non-perfumed quality soft soap and good quality usual oil (e.g. coconut oil) is adequate.</p>
<p>There is no evidence to suggest that medicated cosmetic powders are any better than non-medicated ones for routine use in individuals with healthy skin. Medicated powders are costly, liable to produce skin sensitisation and rashes.</p>
<p>Tooth powders contain simple chalk as the basic ingredient, with added white soap, surfactants, saccharin, colour and flavour. Tooth paste or gels contain abrasives (calcium salts, silica), fluoride, and detergents. Various antiseptics and deodorants like clove oil, peppermint oil and lemon oil are added to these basic ingredients. Evidence suggests that non-medicated tooth pastes are as effective as medicated ones and possess the additional advantage of being cheaper and more acceptable. No toothpaste or powder can, however, act as a substitute for simple and repeated cleansing of mouth immediately after eating.</p>
<p>Shampoos are liquid soaps or detergents used to wash the hair and clean the scalp of scales or dandruff. They are expensive cleansers. Toilet soap can be used for the same purposes at a much lower cost. Shampoos are also used as vehicles for applying medicaments to the scalp. Medicated shampoos usually contain various antimicrobial agents such as selenium sulphide, ketoconazole, povidone and cetrimide.</p>
<p>Most of the commercial cold creams are modifications of a popular emollient preparation, rose water ointment, which contains spermaceti (a waxy substance obtained from the head of the sperm whale), bleached bees wax, almond or prussic oil, rose water and rose oil. Such creams are useful for their soothing and moisturising effect.</p>
<p>Dermal fillers given by injection are used for soft tissue augmentation of facial wrinkles and folds to give an young look. They are used in conjunction with botulinum toxin A. Majority of them consist of hyaluronic acid derived from bacteria or human/bovine collagen. Some contain a biodegradable synthetic polymer. They are used to remove facial</p>
<p>wrinkles and lipoatrophy. Their effect lasts for 6-24 months. Usually, they are well tolerated; but occasionally may cause local bleeding, infection or skin discoloration; and rarely necrosis and nodule/granuloma formation. Prior skin testing for allergy is essential.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="anhidrotics-and-deodorants">Anhidrotics and Deodorants<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#anhidrotics-and-deodorants" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Sweating is common in the tropics and no drug should be used to block this normal physiological response. It could, however, become excessive (hyperhidrosis). The eccrine sweat glands, although anatomically innervated by sympathetic nerves, are physiologically cholinergic. Anhidrotics (antiperspirants) are the drugs used for controlling hyperhidrosis. They are:</p>
<ul>
<li>Systemic anhidrotics: e.g. anticholinergic agents such as belladonna alkaloids and synthetic substitutes like methantheline. These are discussed elsewhere. None of the available systemic anhidrotics, however, has a sufficiently predictable action without adverse effects.</li>
<li>Local anhidrotics: e.g. aluminium salts like aluminium chlorhydrate, formalin, glutaraldehyde and esters of hyoscine.
Aluminium chlorhydrate acts by local astringent action and blocks the sweat ducts at the skin surface. Formalin acts by forming keratin plugs in the orifices of sweat ducts; its frequent use may cause allergic reactions. Glutaraldehyde is a tanning agent with antibacterial and deodorant activity. Anticholinergic drugs like propantheline bromide and esters of hyoscine are also effective when applied locally in the form of lotions.</li>
</ul>
<p>Mild hyperhridrosis of the feet is easily managed by foot-baths with potassium permanganate, 1:10,000, and simple talcum powder. Individuals should be instructed to avoid nylon socks and rubber footwear and to use open sandals. Where an emotional factor is suspected, counselling and small doses of an anxiolytic agent may help.</p>
<p>Undesirable body odour results from the action of bacteria on the organic substances in the apocrine sweat. Excess eccrine sweat promotes this process by increasing wetness, which encourages bacterial growth. Anhidrotics, by virtue of their drying action, also act as deodorants. The other drugs used are:</p>
<ul>
<li>Cleansers such as Sodium carbonate <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">20 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">20%</span></span></span></span></span> in talc.</li>
<li>Aluminium salts, e.g., Aluminium chloride hexahydrate.</li>
<li>Antibacterials which retard bacterial decomposition of the apocrine sweat e.g.</li>
</ul>
<p>Hexachlorophane, Tetrachlorosalicylanilide, Trichlo-carbon, Thiram and Bithionol; and</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="masking-perfumes">- Masking perfumes<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#masking-perfumes" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Some of these agents can cause irritation, allergy, contact dermatitis and photosensitivity reactions.</p>
<p>It may be noted that there is a great demand for deodorants in today's society and it is estimated that an affluent country like the USA spends more than half a billion dollars a year on being 'nice to be near'. They are popular more because of fragrance (exotic) than anything else! Most of us do not really smell as much as we are made to believe by the advertisers, and simple measures like personal cleanliness, shaving of axillae, daily bath with ordinary soft soap, and applying, if required, a simple adsorbent like talcum powder will provide similar good results as any expensive spray without risk of 'deodorant allergy'.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drug-induced-skin-disorders">Drug-Induced Skin Disorders<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-induced-skin-disorders" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Adverse skin reactions to drugs are frequent in clinical practice (Table 71.10). The most common are exanthematous reactions (rashes) and urticaria. Other relatively rare reactions are erythema multiforme, Stevens Johnson syndrome, exfoliative dermatitis and toxic epidermal necrolysis. Some reactions have an immunological basis.</p>
<p>Urticaria can be produced by allergic mechanism by several drugs such as ampicillin and antisera; and by drugs which liberate autocoids such as histamine. Urticaria can be dangerous if accompanied by angioedema of the larynx (Chapter 23).</p>
<p>Photosensitivity disorders of the skin can occur following topical as well as systemic administration of drugs. They are either phototoxic or photoallergic in nature.</p>
<p>Phototoxicity is a nonimmunologic reaction, usually occurring as erythema that desquamates or 'peels' within several days; edema and vesicles may appear.</p>
<p>Photoallergy is an immunologic cell mediated process and usually manifests as intensely pruritic, eczematous dermatitis, which later leads to local, thickened, 'leathery' changes in sun-exposed areas.</p>
<p>The treatment of drug-induced skin reactions includes:</p>
<ul>
<li>Stoppage of the offending agent</li>
<li>Systemic antihistaminic therapy; and</li>
<li>Use of glucocorticoids and SC adrenaline in severe cases.</li>
</ul>
<p>Exfoliative dermatitis, Stevens-Johnson syndrome, and allergic vasculitis are serious drug reactions and will need systemic glucocorticoid therapy.</p>
<p>With the first occurrence of an allergic drug reaction, the patient should be informed that he/she is allergic to the particular drug, and its future administration should be avoided.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="7-2">7.2<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#7-2" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="ocular-pharmacology">Ocular Pharmacology<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ocular-pharmacology" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Eye complaints are common in general practice and some of them, if neglected, can lead to blindness. The eye is readily accessible to observation, and the diagnosis of several eye diseases can be made easily. The drug treatment of eye problems is largely concerned with alleviation of inflammation, control of infection and reduction in intraocular pressure.</p>
<p>Anatomy and Physiology of the Eye: Fig. 72.1 depicts the various parts of the eyeball. The human eyeball is composed of three concencornea tric layers from outwards in: (a) the and cornea and sclera; (b) the iris, ciliary body and choroid; and the lens; and (c) the retina.
<img src="data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0aHBwgJC4nICIsIxwcKDcpLDAxNDQ0Hyc5PTgyPC4zNDL/2wBDAQkJCQwLDBgNDRgyIRwhMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjL/wAARCAGoAjwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD3+iiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAGkZzWTaeHNMsNcu9Yt4Ct7dKFlfcTkD2rYoxQA3HFcvrnw98N+Ib8Xmoafvn7ujlM/XHWuqooA4a/wDBWk+H/DWtnRLJo57q3KsoYncccAA1g+Bfhpos/hjTrrVtMkW+XmSN5GCkg8Er0Neg69rll4d0qbUr9mWCLBbaMnkgevvTPDfiKx8UaPFqemszW8hIG4YIIODmgBt94Y0nUZtPlntR/wAS9/MtlQlQh+gp2leG9M0W/vb2yhZJ71/MnJYncfoelbAxgUtACDoKWiigAqORA6srcqRgj2qSigDyN/Bnivwdql3c+EbiOe0vJDI9rNjCkjqOOKdZeDvFHijxPaav4ukhit7HmG1hPDN616zgZooA8wPh7xR4S8S6lfeHIoL2z1FzK8EzEbH57496qWfgLW7nTvEuqaoYm1jVbdoUiU5WMYPAP4161ikJ2igDjrDQb6D4XLoboovfsbwlc8ZOf8aztO8Lalb/AAgk8PvGgvzAyBc8ZLZqjD4n1WT41yaGbknThGW8rHfbXqA9KAPF0+GGst4J0ZY/Jj1nS5GkRJBlWB6g8ewrSj8O+K/EepaeNYtbTTbS0KyM1qBmVgc8/kOK9XwPSigDyW68J69oHi7UtW0nS7PU1vlH/HzgeUQoA2/981f8HeG/Eel+N73V9VS3dL2AB2j+XyyCMKAPpXpeKMUAKOlFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRTc0uaAFoppbB9aAc0AOooooAKKKKACiiigAoopDQAhPNKTXHa34uutM8daPoUdtE8F8CXkbO5cEdMcd66eS+tIR+9u4F5x80gHNAFnNOrndH1PWLrV9Siv7O2hsYWH2aaOUMZBgdRk46mtWLVbCWcwR31s8wODGsqkj8KALtFFFABRRRQAUUUUAYHjPTF1fwjqdkVyHhJA9xyP5V5r8AdW/4lOoaLKx822l3BT6Hr+pr2SUK6lXUMp4IPpXgXhYnwn8c73TshIbtmAA6YY7+/8ASgD6BFLTEBxT6ACiiigAooooAKKKKACmsMg06mN0NAHjdjG037RN1JGNyRQ/OQeny/8A169kUV4x4KJ/4Xl4mJJPyD+Qr2kUALRRRQAUUUUAFFFFABRRRQAUhpaQ9KAM2/17StMmEN9qVtbSMMhZZQpxnGeTUUHifQrmVY4NYspZGOAqTqST+deRfEi0sb74x6Lb6lsNm9viUO+1cZbqcil8d+HvBGkaCLjRJYYtVEgNsLa4Lsxz0+8f8igD3LdkcUZ715nP451fTYdE0ew0abUNVns0eRn+VVO1epyPWnaL8RtUm8QyeHtd0UWmq+UzwrG4KPjtnNAHoJv7QCbN1EPJGZPnHyD3p1reQXtuk9rMk0L9HQ5B555rwjwjqOqzr40jms38mRJzNKZQfJPlnC9eego8GeOvEejeBofsPh8XGm2G43Fw7YLAt/DzzyfegD34HijNefxfExJtb0C1WxYWmsRhknZsbDgHB59zUkfxIt5PiO3hT7MQB8vn543jt/KgDvCaMmvOZfikiN4gdNOlmt9LdYkkQZMrnHGPxrKuPid4p0mK11PWPDKQaRcOqq6SZcBuhIyf5UAet5ozXFw+PEfxnbaHJaMlvdWyz29yTw5IBx+tTxeMxd+PJPDVpamTyIhJPNnhTzx+lAHVSzJDG8sjhI1GWZjwBVDTdf0vVnkTT9Qt7lovviKQNiuW+Kl5qFt4MulsrRpY5FKzSq4Xyh69c1xvhbxHF4O8IWc66AI9R1Blit1jcH7Vx9488dPagD23NGTXmMfxG17SdRt7fxXoAsYLptkU8LhgD2zyfeovEPxS1Sy8TXmg6PoTXl1Cu5WycY5560AeqClrP0a6ur3Sba5vbf7NcyJukiB+6fStCgAooooAKKKKACiiigApDQayvEOqx6JoN7qEpAWGJj8x70AePfEPxJrl74pvX0G7kS10KMS3CoxG9ucggdfu969TtfFNrL4JXxDvBh+zGUk+oHT9K8p8FaZ4svdCv7+00ywnh1os073E21mU54xt96XwoL5vCHibwVdIEvbRXkjUnI2kdB69DQBa8P6V4m+JAm1681670yykdltorc7flz1OPpXQeFrbxV4a8ZnRLie51TSHj3/a5eTGcjGSee/Sr3wn1uzvfBVtZoyLcWRMUsfQggntV1/iBZnx3F4XtovtMpXLzRNkRnjIP50AdmDwKWk6iloAKKKKACiiigApD0paQ8igDyzxaf8Ai8nhUf7L/wA1rldC8JDxr4z8Qx6jf3S2drdApGkp+9+fFeheIPC2o6j8RdC1qDy/sdmG83c+G5K9B+FJ4J8K6loev+ILy8EXlX0/mQ7WySOOv4UAcJp66l5/juw0ue4aaFEitwZSSAAmQMnr1/OuS0g6LAdPW5Gq6Nrcc48+9dmZGHfPJ6mvUrf4earNqXip5bn7LHqbK1tNDJ86lQmM/wDfNZFx4L+Ius6fDomq3lg1ijANc9ZSoPr9BQB7LbypNAkkcgkRxlXHcVLVLS7FdM0y3skbcsKBA3TOBirvagAooooAKKKKAGkV4H8YoH0X4haLr0WQXxuOM8jC/wAs177Xl/xx0b+0fBgu1UmSykEvHpyP60Aek2k6XVpFPG2UkTcCPQ1YrivhZqv9q+AdNdn3SQoIGOcklQOtdrQAUUUUAFFFFABRRRQAUxhxycU+mt0NAHjfw+jS9+L/AIrvopA0aALj1PFeyivFvg9/yPXi3/rr/UV7VQAUUUUAFFFFABRRRQAUUUUAFIelLSHpQB4d8R9MtdY+MWh2F4GaCWDDgMVPVu4rv9K+GHhTR7hbi207dIpyplkMmD+NdBcaFpdzqcWpT2MMl5GMJMyjeo9jWlQB4x441e8ufiJFoEuo/wBi6eIQ32qNBvccZAbqMVz3h/8As+P4waXHY6nc6nGsZBu53YiR/bPb6V7nrHhzR9d8s6pp1vd+V9zzUDbfpmoIvCWgQz200Wk2qSWv+pdYwCn09KAPJfC1/aQjx5YSzBLqUzPHEQQSBF1/Q1ueH48fACXaAMwSE4HU7zXoL+GdFl1CXUH022N3KpSSYxjcykYIJ+nFWINF06HSTpcVnEliQQYAo24POMdKAPGtR08x/B/w/r0K7rrS9kqY5wu3n+Qrm547m28NW3xDRGN9JqDSMX4BQ7SOn419EjRdN/sj+yvsUP2Hbs+z7Rtx6Y6VCfDejto66Q2nW/8AZ64Ityg2Z+nSgDx5LvUPCnwiGqxQRtearcebPKybigLYzgjtjNc34xtrNPDEVwfFd1q19KUla1yfLjGAeg4FfR76bZtpv9nvbRtabdnksBt2+mKy4PBPhq3t5YIdEskjm++oiHzfXigDzjxdZPZ+CPC3iiz4utPhhDMB/wAsyvzE/TaK2/hLZyXsGpeKLuLFxqc2QxHO0Z7enNP8aaP4i1BIfDGh2EMOiyoFlmJwEUfwgYruNG0uPR9It7GHOyBAo9T2oAw/iX/yT/VsH/lie9ea6rA9tpXgTV5lYWVpgzS4J2jDDt9a9vvbK21C1ltbuFJoJBho3GQwqL+yrD+zRp32WL7GF2CEqNuPTFAHlfxH8Q6V4osNM0vRLyO9u3vEkCRAnCjdkn07Vc8NRgfG3xDlRkW6jP8A31Xeab4U0HSJ/tGn6TbW8x43xxgH8xVmHR9Pt9Um1GGziS8mAWSdVG5h6E0AaIA5ooFLQAUUUUAFFFFABRRRQAhrD8U+GrbxXpDaZeSzRwswYmJsFsdjx0rcIpNtAFPS9Mt9I0y2sLVSIIECJk84AxWGvgjTk8Zv4mjlnS7eMxvGGGxxz1GPeupxSbaAOE1b4V6HqV493BLd2Ejks/2Vwu4+p4NX/Cvw+0XwnLJcWayS3Mn3p5m3N9OK63FI67kIyRkY4oAYssbyNGsillHzKDyKkBrwrxPaeIPh14zbxRb3E95pVxJuuIi2doJztI7DHQ1694e8QWHiPSotQsJ1kikHY8qfQigDYopBS0AFFFFABRRRQAmKMUtFABgYxiqt7JLDZzyQANKqllU9Mj6VapjrkEYyDwaAOC+Gvjm88X2d/FqcEcN/Zy7JI0BHBz/hXfg14YvmeC/jsysTHp+rHI44yT/TNe4pyM+tAD6KKTNAC0UmaKACsnxJpqar4ev7J+VlhYf1rU3D1qtcXtpAjC4uYIxjnfIF/nQB5B8CdUdIdS0SZvngkEiqT0zndx+Ar2ndgV83aZrtj4R+NN/P9oj/ALMmdw0iHKgM3qPpXoF38c/DUWPskN1esTjESfrQB6juo3V41L8cJpJCbLwvfyQfwsV5P60xviv4xlYPa+Dm8lhlC+7P480DUWz2jNGa8btvib47uphHF4Pj3f7TED/0Krh8dfEMZP8AwiFtgf8ATX/7KgfJI9Y3UufevFn+KPjqORkbwcmVODjcf600fF/xNanfqXhCQRtwvkgk5/OgOVnte6o5pBHC7kZCrnAryK3+OcUQI1Hw7qELn7oEZ5rUi+M/hS9gaKWaa1dozlZEPyH06UCszJ+Cqx3Wr+KNSXKvJdMm09gMV7HXhvwP1jTrc63HPeQxNLds8fmPjcvHPNe2RXMMw3RSpIvqjZoET0UgbPSjNAC0UmaM0ALRRSGgAzgE9q53UfHXhvS7prW71a3SZfvLvGR/hW3dMi2kzSMVQRsWI6gY614Dp88N6Nbi0Pw1JrQld99/elVUYJzjJB4/GgD3eDV7G600ahBdRSWm0t5yuCuB6msVPiB4YcyKNYtsxkAguO/p614laXFxH8Ivs+9o45NZ8qRVY4CZbIB9OK7j4reG9Hg8EWlxa2kFvLbSxeWyjkgnoSOtAHpf9uad/acOnfaU+1zx+bHF3ZfX+dNl1/TItZTSHu41vnGVhz8xrzgSAfGrw+eF/wCJUOv+63FY/iScw/HqCSMZeO2LDjniM9KAPVNU8ZeH9GuBb3+pQQzMOhYZ/H0rSg1SxubEX0N3C9qRuEocbT+NeCeDbnUL6LVL4+E21pp5mVppZUzGMn5drEYxWfLc6vpfg+6064jNrpl5qCqgEqsYgTyp2k4oA90tfHPhu8vRZxavbNNnbguBk+lac+tafbapbabNcot5cjMURPLD2/KvPPHnhjRbT4aNNZ2kcMltGkkU8Y2vu45z1NYsd1Nc+Pfh7PMd8r2B3seD9080Aeuyazp8Wrx6U9yovXTesWfmI45/lWdfeOfDenX32K51a2SfOCvmDg+/PFcPrDB/jtZRrIAf7PcMw/hzsriZ9NuvD9pqUd3oEOvadLI5fUoX3OMehB4xQB9FwXEVxEk0MiPE4yrocgj61574s8U3eifErQ7aS+NvpUlu8lyp4UkFup/Ktb4b3enXfguzbTDOLYZVVnOWX1Ga5Lx9p1vq/wAW/DVjdqWtpYW8xAfvYJ4P5UAeh6R4p0TXjINN1GC4KDcyo4Jxjrirena1Yaqsxs7hJfIcpIV/hI615SdNstC+NlrbabAtrFLYuXRDgH7v+JrR+EkgFv4kYkDF67HJAxQB3I8WaKdLl1Jb+P7JDJ5TybuFb0NVrXx34bu71bODV7V5m6Ksg9z3+leKxMG+CXiEcEf2vwB6bkrZ8YeEtM0T4c6PeWNv5V5mJmnXO5twGc/99UAesWfjHQNQ1JtPtdTt5blSRsVx1H41Lq/ifR9BKjUr+C3duis43Y+leU+KdD07RtR8HXOnWwt5ZpUEjoSC/wAvf1rU8KWVrrfxQ8Wy6nEl09pKIrcS/MEXLDG2gD0ez17TL7TX1C0voZraNSzujg7QOTn04p8Gu6dcaR/asdyjWWC3mg8YBwf1ryERx6V4+8V6bp8Risn0qaV4VPyh9jc4/AVpeH5EHwAfDqQIJB16fOaAPQpfFuiw2lrdSX8Sw3P+qctjdVVfHfhx92NWt8qxUjeOCK8X1a2N94G8D227b5kyrn8OfpXscXgHwyi8aRAc8k4LZP1oA6uiiigAooooAKKKKACiiigAooooAq3llbX9rJa3UKSQyAqyOOCK8R1DTtV+D/iA6lpSyXWgXDjzoOW8sE9fb29a94qrfWNvqFpLa3UKyxSKVZWHBBoAp6Dr1j4h0yG/0+ZZYpAMgNyp9CK1c14PqOmax8IvEJ1PSg8/h24cefDziPJ9q9i0HX7HxHpUWoadMJYZB68qe4PoRQBr0UmaWgAooooAKKKKACk70tJQB5L8ctKk/sSz1+2GJ9PlzlRzg+//AAGvQ/DGqJrPhux1CNgwmiByKXxJpUet6Be6bIisJ4iozzg9jXnHwg8QRWWh32jahOsL6bM2d5xtTj9KAPXfxprsqKWY4HqeK8w1/wCM+k2Uj2uiwyanddB5Z+Qn2IzXKzD4leNpCLmZtI0+TGEAKEr/AFoGk30PV9Z8b+H9BVjf6pArDnYrbj+lcBqHxxM8xh8P6HcXpxgSOMD2xTdK+EmgWjibUPMv7jqTNwufpXbWOnWWmwiKwtoYEHaMYoNo0X1PPWu/ih4oUeZJFpdu3IGACAfcCiH4Ry3373WfEd5OxOWVZGI/M16acdTzSq6BSNoOaaNlRieAfETwZp/hOfTJ7GMtbPnzd7liWGP517JpOi6MLS2u7XTLQeZGpDGJScflWB8WrEXngeWbaN9u4kGT1HNO+H/ijT38E2T3uoRQvADG3muEI/OmSrRkdottHCAiQRKg6BEAFPwQMDpWDe+OfDFphpdbtzu6bGB/rWZdfE/wnbqpGpmXPGIxnH60GvPBHYjPcmjrXC/8La8Jf8/dx/37oHxa8JZ/4+7j/v3SDnid183qaCpYAEBvrXJRfEvwlJGr/wBrhc/wsQCKuWnjvwxdhjFrluNvXfIB/WmHPE25bGCYgy2sDkdC8YOKxdY8IaRfabcY0i1afYxTagXLfUCtW21rS7tFa21G3lDHA2yA5NXhMfbA7/5NAPlkeN+F/hPa6ppU0mt29zZXyzsq7W6IR6Z6Von4beINGbf4f8TTgDkRzSNj8hmvUWkDcAfWk4YHIFIn2Mbanma+MviR4ZKjUtNj1K2XjdGACcd+BmtrRvjho1zItvq9tcabcE4benyj8c12IAX7vH0rK1Xwxoutowv9PhmOMbio3fnQZvDrodPpuu6XrESyWN/BOrdAjc1pA14Zf/Cj7BcfbfC2pTWF0vKxknk+xpbXxz488HusfiTTmvrJOtwnX8W70jCVNxPdKK47wz8SPD3iYLFbXoiuu9vMdr/gK64Nnv8AWggbPClxBJC4OyRShx6EV5hb/Ci/0+a4tNO8S3FvpNwzO8IT5xk8gGvUh1pcDHSgDz7TPhVp9j4Y1DQZ72e5tLqTzIyww0Tc4IPc81wnxC8Iazo/hWKS+8QTahbQ3SRwwFMcEjBJ65Fe+4HpVe6sra9i8q5gjljBztcZGaAOE8R+AP8AhJG0vWLHUJLHVLa3RY5I+jL3z+dVtJ+FP2LxVb+Ib7Wri9vFB8xZFwHyMYHPA5r0pVCqFAAAGAKKAPMrj4YahZancz+H/EEthb3r5mh25A/3fetO3+GOlx+EbnQpppJWuXMr3LcPv9R6YrtZpo4EaWVlREBYsTjgV55Z/FCPW/G0Gh6LZtdWgYi4uByAPUD096AIP+FY6vqO2x1nxLPc6REylIUXaZAOzEc1p+LvhzHr02nXmnahNpt7p8fl27x9AvpXeAAjnnilwOuKAPNtB+Frab4mTxBfazcXl60TJKHHBzjofTiqD/CbU7EXFno/iSe3026cmW3Zc7QeuK9YwPQUuAe1AGD4W8M2vhXQodLtHaRY8lpH6sT3NVdU8Ixal4z0vxGbp0k09GRYguQ2c9/xrqKKAOUufBcNx45g8TNdOHigMPk7eCDjv+Fctd/CW6j1i8n0nX7mxs79ybiJOo+n5/pXqlGB6UAebW/wntrbwPeeGV1KYxXFwLjz2QbgRt4x+Fb3iPwbF4g8M2uivdPEluY8SAZLbAP8K6vAHQUYoA5HXfBEOtvoztePF/ZkiupVQd+BjmsvWvhzO+vXOu6Bq82nahcD96oG5HPckevNehYowPSgDhvDnw6tdGOo3V5fTX99qERinnl/ukfwj8a5r/hTV0IbjS4vEl3ForncLdc5BJzj6e1evYowPSgDgJPhpbvpuh2X9oSgaVIHVwgy+OxrvVGBTsD0ooATPNGaRuK43xn44/4RyW30+xtjeatdHEFuO/uelAHZ5ozXkF/418feGIl1HWtFgl03I8zym+aIep5r0vTNbs9V0W31WKZVtp03K7naB+dAGpmlqrBf2dy5SC6glbGdqSAnFEl/aRE+ZdQptOG3SAYPvQBapM1FDPFcR+ZDKkiHoyMCPzqF9TsUk8tr22D5xtMozmgC3mjNcb4t8YXHh7WtEsYLeKVNRm8tnYnK8E8flXYKSWPHFAD6Q1Wk1Gzhk8uW7gR/7rSAGsLxr4rj8K+HZ9SXy5ZAAIoi/wB8n+lAG5f2UOo2UtpcRq8UilWVu+a8S1LT9X+D+vHUtLElz4dnb99D18vJ/kPX867/AMA6z4k1qGS61pbRYHUGLyHyQTyM/hXX3tjbahaSW1zEskMikMrDrmgCnoGv2PiPSIdR0+XfBIufdD6Edq1Qc14TqFhqvwh8RnUtMWW68OTv+8gz/qxn9MV7DoOvWHiHTIr/AE+dZIZAO/Kn0IoA1qKSloAKKSkJ96AFzUNzcw2kDz3EqxRINzO5wB+Ncd4w+JWjeFY2iMn2q/6LbRcnPvivN0tPGHxMnS61WV9O0jPECHBYe3r+NBSi5aI6jxL8Y7SGR9P8MW76nqBO1XRSyZ/Dr+FeQy6LqEnjG2j8R+ZZrqjhpPKbGcn9K928PeENF8PW+zT7VfNGN0rjLH3rl/i7pbSeHbfVYAftGnzB8jrjg/0NOxt7LlV2dPofhHRdAQHT7ONJMcyMMsa3goCYbH4VzWl+JtOfwxZaneXkUMbxDcWbnI46Vy+rfFdJLlrPw3p82ozEYWQKQgNGxspRij0yUgRlmAwP4s8D8e1c5q/jjw9on/H7qMW/ukZ8w/pXIW/hP4g+MmSXWb/+zLI8+Wvytg+mK6/R/g14Y0/D3ccmozZz5k7Hr+FDZk8Q1sclP8XhdymHQtDu75ugYISCfoBTY5Pir4gG63s4tPgcgZI2sv4E17NZaNp2nxrHZ2UEIUcbUAxVwJjpSMnVmzxCf4R+KtYhZta8Shw6lmhVeM+n865L4Z+CdM8Ta3qOmavJOslqQVjjfaH6g5H4V9OMMIR7V4Na48KfHiROUgvWOMD+9wKCLu9zvbP4P+D7RnY6cZt3aU5ArRtvhn4StZlki0W3DL7H/GutXlRSigRz/wDwhXh3j/iT2n/fH/16P+EK8Of9Ae0/74/+vXQUUBY5O6+G3hS8lEk2i25YDHAP+NZt78HvB95txp3kBevlNjP5131HagDym7+BWguXa0vb23OMookGFPr0rIl+EPijTRv0fxVJx82yQZ3NXttNx1oHdnhjw/FjQFLyxwahChGTkEn2xmki+LVzpzCLxB4fvLV+hdUIX68g17oF96q3WmWN4hS5tIZgwwQ6A0FKpJHnuj/ELw3rYH2e/WJz1SY7P511EMi3Ee+Mq6N0ZGBB/KsfWfhF4W1Zd0VobKbtJATXFXPw08ZeGnabw3rb3MKnIgkPJH/AuKdzWNd9T1LC9TwaZIiSIyOqsrjBVh1FeVxfEvW9DuDaeK9DmiCY3TxLx9c9PyrudD8WaLr0YbT9QikY9ULYYfnRc3U4y3MHXvhho2plp7LdYXmSyyQnALe4rFg13xz8O2EepRnV9KUgeYoJZQP5V6mcNnA/WkaFJkZJFV0IwQ3Sm0TKlGWxV8KfETQvFkY+yTiK4/igmbaw+metdcG4rx7xN8M7G9Y32jSnTb5fmBjJCMff0rO0L4ma/wCELmLSfGdnJJCCFS8UZwOgzjg/zqTmnTcT3MUE1Q0rV7HWLJLuwuo54XHDIf6dqvEjHNBmGao6pq1no9jJeX08cMKAkl2xnHYe9Z/ijxXpnhXTZLu/nVW2kpED8zntgV5Hp+neIfjBqwvNXaSw0OA5jiAI38+h60AGoa14g+L2r/2ZoqyWOiRHMkzAgSDPUn+gr1jwp4R03wppsdrYxr5m355iBuc+ua0tI0aw0TT4rCwgSGCMAbV6nHrWhjigB1FFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQA1uleRyCFv2gh9sLYWzzb5PG/5eBXrjda4Lx54EudfvbTWNHvPsWr2nEchHDA0AdhqTWJ0+4/tJYjaBf3wlAKY968u8f6hoM2haWIdTCaAz4NvZqQ0oB/gHHemXXh/wCJniO1TStVu7O2shgTSwn55BU/ij4bahCNEufDflTSaWgRYLn7rc53fr+lAHF2MunaN440Kbwza6lZ288nlyG7ckSAhu245robLwvZ+K/id4js9TluDaxlXEMcpRS3qcdTVyfwb4317XdJ1bWLmxQWUoYW0Qwo4POc9ea63QPCl7pnjvWdalkjNvegeWo6jHrQBwvhhLnRovHGi2uqPbWli22CW4cnyl+bJz+VcXqKeFm8Ozz2Z1i+1mPltQDMIy3Xd97pXqs3w5vruTxiktxEkessDAR1XG48/wDfVYtr4U8fz+HpfDVy2mWunrEYxMqZeQc470AUdYuLi7j+Hk88hkkaUZY9/lavZtUuzZaRd3SDJjiZwDXnh+H2sy2fhRJpoPN0iUtNt6Ffmxj869LuLaO6tpbeVdySqVYH0IoA8f8ABHgXTvGXhn+3damu59QvmLeZ5zDy/Tbz71yGsQ/2h4K1OLUJJZrzQ7hYYZmkJDKxA59etd5Z+GvHfhVpNK8OzWUuku7NC0/3oQe3XtVhvhneL8O73R47iJ9VvZ1nmmYYXduBwPbAoA6fwF4a0/w/4fgexWUG7jSaUyOW+baM49K6yqWk2r2Wk2drIRviiVGx0yABV6gCrfWNvqNpLaXUSSwyDDo4yCK8QvtO1b4PeIG1TTg9z4cuHHnQkkiPJ/zj1Ne8Yqrf2FtqVpJa3cSywyAqysMgg0AVNC12x8QaVDf2EwkhkA6HlT6H0rV7V4NqNjq/wg8Q/wBo6aHuPDly4E0JBxHk98V6hN4+0GHwsPEJvF+yMPlGRuLdduPWgDorq6htIXmnlWOJBuZ2IAArxrxP8TdS8R3smgeC4Wk3/JJdgZHPXHp9ayby98SfFjUzHGZLHw6rZyQRnHr6mvR/D3hrS/DlmsNhCIicb3x8zn1NBrCk5as5rwp8NLPSCL7Vz/aGpSYZml+ZQfx613mAoAXgAYwKcDszzx16cVwPiz4kWejSNY6cBeakx2rFH0U/4+1B1e7BHY3+p2elWr3F9cJDEoySxHNea+IPHkviuK40Lw1pT3wnUo8zLwBjGR2707Sfh34k8cXSal4vuXt7XIZbYZG4egHavXtE8N6V4etBBplnHAvcqBlvrQc86zktDwD4ceBbXxVe3una1eXCNprYNqp+XGRnvxya+gNG8N6RoMCRadYww7RwwUFj9T1ryrV1fwJ8ZLa+Rttjq4Cyfrx+YFe1xtvXdx7EUGDbYoGO3NOpB1paACiiigBD0rwz46WDWGp6R4gjbaVkVTt6/Kcg/rXunavPfjHpX9p+ALsqMvbkSjnsDk/yoA7DQ7wX+hWN2pyJYVbPvjBrSrzr4Naz/afgC1jJBe0JiOPrn+or0QUALRRSUAFFITjqfevNvGPxb07QJ30/TI/7S1LJURxnKq3Tk/0oA9IZsLnjj3qnc6vYWSg3F3DGD/ecV41FZfFLxqVnuLv+xrKQcIpKHH071pWnwKtJmEmt6zdXp6tjK5NAHoF1448M2LqtzrNqhboC/wDgKW18a+HL0N9n1i2k29cMR/SuWtfgj4Ohi2SWk0xznc8mf1xSXXwP8HXCbY7aeA9zHJ1/SgDvbbVrC7UNb3cMgzjIcVaVgyggjH5ivJLj4GWEMgbSNXvLPaMqu4thvXis+Xwv8UPDYZtL1wajCpJ8qVjk8elAHsN/ptlqVu0F7awzxHqkqBv515t4g+Cmm3U0l9oV3Npl595QjHbn8OlZln8X9a0G7+x+MtCmtzwPOjQgH3wR/WvQtB8d+HvEYAsNRiMp6xsQrflzQB5QNc8aeAJVt9eszf2IOPtC88fXr+ddxoHjjRPEaKLG6Cz/AMUMmA4rv57eG6iaGeNZI3GGVhkNXmXij4OaZeOb7w4503UUO5fLOEJ+nanc1jWaOxVi3PU1Q1fSLLWbN7W/t0mjYYG4DK/SvM7bxp4l8D3sem+MLOSWBjhLtecj6ng16hpWr2OtWgutPuEuIT12dvr3oOpTU0eXXHhrxD8Ob3+1fDNy8+mq2ZbViTgfTv8AWukf436S3hvz44WGrkbRaEHh+n5Zqp43+IK6ddPoujKbjVZRsG0ZWMng5965RfhTrjaW+rPdBda3iZYQDjI56+tDOecFf3To/D3gTV/Hepr4h8ZtKkYIMFr0yOvTsK9nt4Ira3SGGNUiQAKqDAAry7wN8TjJcDQvE6/YtTjIQFlwG7DPpXqysGHvSMHoOFLSdKinnjt4XmmkVI0BLMxwAB1NAEtLXmt18ZNDindba3u7uFG2tPDHlR6812eg+IdP8Rael5p84kRuvPI+ooA16Kbml3UAFKKaWx1+tc/ofiyz1zVdS0+3SQS2D7JC44J46fnQB0VFNzS7qAFopu6jNADqSqOqatZ6NYSXt9MIoI/vMaydR8Y6fp95o1u4lb+1X2wsozjp19OooA6Wimg0ufegBaKTdS0AV7q6hs7eS4uJVjhjG53Y4CiuNX4t+DXuBB/auGLEZMbBc5x1PFTfE/R9Q1rwbc22m/NOCH8sHHmAEcV5rp/ivwdLon9ja74ek0y48ny5Jntx97pnIBPvQB7tbXEF3Ak9vKkkTjKujbgfxqX5Twf8968vtNa0/wCHvw1ik0u/fWEeXZaZ6sxHA9gOKSbxX420c6Zd6np1rPZ3kio0VuG8xNxxnn0yKAO703xFpuq6le2FpKXubNgJl2kY6d/xq5qOoW2ladPf3bhLeFN0jbc4H4V4hoWoeJY/iH4ih8O2cMjTSh5XnOAg2g44/Cta58Z3uv8AgXxjpusQxx6jp8bIwj6OM9R+X60Aes6dqFrqunQ39m/mW86B0OMbgathRjFeQW/jSfw74F8KaZpkUUmpX9uqp5rYSMccn8xVxvHmv6B4j06x1sabd2l+4iWaykLFGJxyPxoA9SwKWvJP+E48Y6n4t1TRtHsbR0s3OZZSQFG0EZ+pqDSfHXjjXY76Gz0+yS500stz5hPJyeB+VAHsWB6UEA9RXksnxQ1M/ClvEqWsS3sdyLd0J+U+pFUtR+JHjHQLDTNU1TTrM22okrHEhO9Tjgn25FAHs/elzXkp8deLdH8RaNa61ZWbWmqEBGhJyuRkZr1gHNADs0hNBPFcp458cWPgzSmnmYSXTjEMAPLH1+nSgB3jzxDo2g+HLh9WCSiVCiQHkuT0wK+ak0+/tUi1e90q4XQnuC3kc7QpJPTtgd69A8MeG9T8b6r/AMJL4okkaAPvt7VzwfTjsK9Uu9Ot7uxezmhja3ZNnlEcY9qDeFFtXKPhq70q+0G2n0fy1ssDYic7eOhq/e39rptk93dzJFCgyWc8V5Ffx3vwo8QJc2chn0W7Y5gJyVPHAH9alsdN1r4vasZ55DZ6BE4AjLffx246/jTNHV5Y2F1HxTr3xB1J9E8KQPHZ5xJc9Mr3IPT+tei+CvhnpfhWJZ5lF3qB5a4lHf2BrpdB8P6b4csEstMt1iiXqR95vqa1wMUjllLm3GhcdqdilooEeX/GzR5LvwpHqduubjTpllUjqBnFdb4I1pNe8I6dfI4YmJVf/eAwf1rR1rT49V0i8spVDLNEy4Prjj9a8t+CmoSWD6x4YuSRJZXDGMHrt3EH9aAPYlp1NXvTqACikozQAVR1ayGo6Xd2bDImiaP8x/8AXq9TSP5UAeE/BO/k03xHregTfKQ7SKGPcEDH5Cvd15r581Ef8In8eobgfJb3kgbp1BXb/OvoQUALSE0tMY849TQB5h8WfGF9pf2Lw/ozYv8AUSELjkopOPwrV8DfDuw8N2kdzcxLc6nL8808nJBPOBXG+HIP+Eq+N+q6hL+9t9OG2PuF4A/ma9sXoMUAKFwBxj2owB0p1Z2r6vZ6Jp01/fTLHDECSSevsKAL+aMivFZvjjqF7cyDQvDU11boT+8kB5+mDW54Y+Mematd/YdXt30m76ATAhWPpzQNpo9Oxmk2j0pkM0c8YkikV0PRlIINS8Y60CKt3p9pexNHc20cysMYZRXn2u/BvQ9Ske4095dMuW6GE4XPuK9LooA8KXT/AIm/D8+ZBONY06MZKdTj2UfNXQaD8a9IupBZ67bT6XdrgESxnBP07V6mygjBAxXO6/4H0HxHbvFf2EJZv+WirtYH6jrQBauf7D8RaW/nta3VnImWbIIx9e1fNuqqbDxde2PgS5vZogD5gj+YD1AwOgrtPEXwd1fSbWd/Deq3EtuRk2jSlTj26VW+HnjHS/BpOla5oklhdFjvvGQknJ7nnA+lAEPwpm8PxXEi35C+IN5Je5yOCe2ehr2QFCOuTXJeKPh9ofje0GsaFcxQ3yfMktucK5HQH0rmdB8dan4f1NfDni+FopQdiXZHGOnPY/WmjppVVszpvGPgay8TQ+fH+41JBmKdOPmHTNYHgn4i6joOsf8ACNeLcqVISC5bt2Gfb0r0eGVJUV43V0blWQ5BrD8U+D9P8S2bJPGEuVBMVwvVD2+tFiqlLm1R6CkiyoGRgynoQcivOPjTez23gfyYGdPtM6Rsy8fKSMiud8G+Nb7whqi+FfFBYRA4trxvulR7967/AMeeHG8WeEbiwtnUzHEkJLcFh0xj6UjkaadmX/Duh6fpWgWdnb2sYiEKk5AO7I5zXP3tjp3w80zXtfsC7sQHMBbKKxIAwBjHXpXP6Z8Rdf0fRxp9/wCFb6a9tl2B4gCrYOM9aq6T4V8SeJdC8R6hq0ktvNqiD7PaO3CBSGHHb7uPxoAmQePx4YHieXXkUmIXH2IJ8oj69fpVDxD4/wBe1LR/C114fuvJuNRd4pUXkFxt/LGatnxfqz+Cf+EbPha/OoCAWeQF8vgY3Zz04qvB4Sv9EPgO1+ySNJDctNdMvIQttzz+FAFyXVfGXgvxLoyazqianZ6lIsRAXHlsTz/Oix8SaosvjhlnCSWfMBAAK8L+dbPxPsLu81bws1tbSTJFqCtIUGdi5Xk/lXOeH9PuNUvvH9lbjdNM2FU9zhaAOhbxHqq/BNtcN2x1AWgk87HOcDmud8T+K/FMfh7wY+lXri+1NMSkr/rGIXnH1NZL6/r4+HUng4+Fb03Aj8gyjGzA75z14rfm0q/ZPhr/AKFMTbFfP+X/AFfK9f1oAWXVfGXgvxHosWtaoupWmpSLCwC7fLYnH6Vbk1rxN4z8Walpeg6mum22n8PLtyXbA4/WtD4n2F3ear4WktrV5hFqCtIVH3RleTWJZnUfh5431qdtHur2w1A+bHLBhju4OOvtQBz3i2XxhP4N1Ox8QSkLY3C/vwuBcL2J/St83esaPceBbSbUDci7uPncoMhPl4HoRzUWsJ4t8V+C9emuLKVIHkD2VnIqiQLznv8ASokvNR8Q6n4NkbRLy1FhdbJfMXoMrz19v0oA6Hwl4r1K08VeINC1+dpPsSmeByOsYGTz7YNZOkeJPFuqaB4g1yykMyNMYrGKRgBGoIG/PfoaX4s+H9Rj1e11vRYp3nuYjZT+QoOFbIyfbDVN4t8K6pp3wt0/StEilcxFXuo4mw7A8kZB9TQBgan4n8S+F7Ww1CXxfa6lKxXz7IFTjcPY9q9z067F/p8F0q7RKgYA9sivnvWraO78LJZaD4LvLeYBPtNzKAxX1xyT3r3nw9lfD9gGVkbyVyp6jigDC+Ij+I4NFjufDsgWaGUPMu3O9PSuI1T4keGtT0V49R0WabVPK2NG9sDiTGOD9a9nIB7VXFjbbyxgiyTn7ooA+f7fwhrtl8LILkWzyyQXwuxaZJKpwciuvvviVLqK6RY+G7eWTUZJE89ZYvljUEbgSehwDXrOwEYI49KiSzgjcukSK3qFFAHmPw6jkj8feLHlRkYyIcHoflXOD9a5nVoJDq3xD2I2WtAFwuecj/PFe7rBGjMyooZuWIGM0020JLkxpl/vcdaAPnfxJoMknhnwXrFzaXE2nW9qiXQtyQ6DA5Hei10nw5e+LtGi8LWN9dmKZJZ5LiVwIgCD3zzxX0V5EZj8souzGNuOMVzHjTUr3wz4ZudS0ayhknjHIK9Bnr/OgDlfh9FInxC8Ws0bBfMUqSMA8L0OKb8P42TVPHIZWAN45XIxn7/Irpvh74rh8X+HV1Dy0juyStwqcYPTP5CusSKNCxWMKWOTgdaAPnUW0o+ANzEY5N39qdNp/l1rpPjBA8nhbwmqoTi5TIAz2X0r2T7JB5Zj8pNh5K44/KnSQRSgB41YDoGGcUAeT/ECN21rwOQrHbKu4gZI+Q9a9aA7014Y32lkBKfdyOn0qpqmqW2j6ZPfXbhIIVLOc/kKAM3xZ4rsPCWkyXt4wLc+VCDy7eleNeHdGv8A4g+KX8S+IYmFiv8AqY24DY6DHpVcPffFrxk91cNJHodsx8tSMbUz0Hua9ltLSO1tkhiQJHGoVVA6Cmkb0qd9WOhRYlVFRVRRtCjoAO1Y/inxTZeGdNa6uHzIeIYgeXP/AOupvEPiCx8N6ZJfXzhVAyi5wXPoBXnnhXwpf/EfXj4j15Hj0sN+4hb+MDoPpQa1KiirIXw34V1X4m6oNd8SF4tLUYht0JG73Ht0qo8Gt/BnxI08RkufD9y2OTlQM859Gr6AtraK1t0hhRUjQYVVHAFVdZ0iz1zS59PvoVkglHIPY9jSORu7uxmh65Za/psV/YTCWKQdjyp9DWoOleB2ek+JPhZ4zgtdNikvtHv5goRRkYz39CPX0HvXvStlQSMHHT0oEOopM0maAA968M8URv4M+NOn6tGNllqGFk2ng9NwP1PNe5da8o+OC2L+HIpZLmKO+tpRJChb5m4PQdutAro9YGAOKjeeOLG+RVz0ywFeP6Z8dtDtdJs4b2O6e5SECYqhILAev1rmHl1P4t+LriWK8urPSIE+TAOF69vWgpRb2PZ9Z8e+HNBZkv8AVIUlH/LNTuauft/jR4Qnukha4uIt5wGkjwv5gmsHSPhJoGnyGa9El/Oe833fyNbOo+B9C1HT3tv7Ot4/kOx0TkHtQbKg7XZ6FaXlvf2sVzazLLBKAyOpyCDVjFeQfBS9urddX8PXDtIunzYVs8Dkjj8q9fHQUGDPJvit4K1bxBrmjaho9sJZbd1WQngKobdk16jZpNHawLcEGYRqJNvTdjnH41YxRQAtRuOc985/KpKYwzQB4v8ACb/RviD4rtpiEnaTIU+mRXtK9K8O8ZLcfD/4oW/iiOMnT7/CXBUcKenP869l03UbXVbCG9spRLbyqGVgenGeaALmfevB/Gc9145+KUfhnzWXS7MgzKp4JBy2fwr3cjcCM9RivCNEkTQvjXrlrfbYze5eJ3OM9cYz1zQVBXlqem2OnWelWaW9lAkMSAABVAz9fWsLxJ4J0bxJbSLc20aXOPkuEUKwP4da6cZxggjHenbQO9VY7+WLVjyHTLj4g/D95NMsrFtV08EmB26AfXHH0q/L8T/HdlH9ovfC/l26kF23dF79q9QwB0YZqGeMTI0UzB43UqyEcEGkzF4dboTR/HOhaxokWprfwwxsPnV2wUbuK0tL8Q6TrJI03UILor1EbcivLrv4NeHbi7kmEtykTtuMSPgA+3FY3iDwLe+E549a8FvNG8AHnQK2WYD2FIxlSaPfc5GRSZrxq1+PNlHpaR3un3J1VV2vEFwGbH045qovxg8UWbJqGpeHHXSpThCoIK/jjmgzsz3HA4rF1/wvpHiS1aHU7OOXjCvtG5foeoqp4W8baR4utBNp048wffhY4dPqK6TPHp9eaBHh1/4N8UfDe7fVfCtzJd6apLS2rknav4/zratNS8N/F7Q5LO7iW31ZF5VuGQ9ip6kZr1chWUgjgjBzXhvxZ0qw8IX9p4l0W5Wz1Qyc26cCXkZOKAKVhqetfDDUxo2vI9xpkrfuZ0ydv0/wr1ay1C31GzjuLWZZIHAKsvOc1xHgq+l+LGgarB4ijiZUfZCUXBjO0c/nXPRDWPhLrKWd+5u9CuX+SQZ+U57envTRvTqtaM7vxr4Rt/FmkmE4juY+YZscg+h+tYPw58Z3Wi3p8J+J5GiuImxbyydCPTJru9P1C31GzS4t5FkhcAq6nII7VynxA8Fr4m037Rany9RtgWhZe+BwDQ0aVYcy5kepqQcHA6cEU/ArzD4W+PJNahbQ9YIi1W0+QB+DIB/UD+VenZpHIGMnrRtpetFAFLVLae6024gtp2glkQqso6ocdRXMeCPBD+FJ7+4n1F724u2Uu7JjoMZP5V2mKKAEA96z9c1SHRNGu9RmKhII2f5jjJA4FaB4ryP446vM2l2XhyyfNzqEoDJj+HoP50Adl4D8VSeMNA/tKa0NsfMKAZ4Yeorquv4Vi+FNFj0Hw3Y6dGB+6jG4gdSeTW0BxQAbRS4AoxS4oAbtH5UbeMdqdRQA0gUuBilooAKKKKACiiigAooooAKr3dvHd2stvKoaOVGRgfcVYprDNAHz/wCE7qX4c/FK70O6JXT75/kLdORlT+mK9/Xn3FeUfGvwxJf6NDrtkpF1p7AsV6lM/wCJH4V1Xw38TJ4o8IWt0XBuIgIpgTzuAxn8aAOwoopCcUANYhQSTgDnmvCPiP4hvPGniaLwjoj77VH/ANJkTkEjqM+1d38UPGi+F9Aa3t/n1G8/dQoOSCe+PpmsP4b+EU0HSPtt18+o3o8yR25IB5xj19aDSnDmZ0fh/QrXw/pFvY2i7Y4wMkjlzjrVvUb+30qwlu7qVY4YkLEs2M+wqy7hFJYgAZJYnAwOteP67cXfxR8Wx+HNLcrpds5M865wccn/AOtTudU5KCF0bTL/AOLPik6ndBoNDs5AEjwcN3x+Ne+W1rFaW6QwRrHFGoVFUYAAqlomjWuhaRBp9nGqxQpjIAG49zWpSOFu+oDpSGlprHAJJ4FADWhRyCVBwcjI707p9PpUXnxiNn8xNo5Y7hgV414z8bar4k8Sr4W8KXOxFIE92mCAe+T2A6ZoBK7sj2nPHp/OuP8AiJ4wbwh4ca6gjEt1M3lQrn+I4Gf1rzabRPHng24i1Oz1WXVo1/1sRbdx6YP86qa9qviX4kXGm2TeH2s4racStITwOnv7UFckr2aLdtpHxO1KFNTfXhBJIN6wcY55FX9F+G09/eSan4yuHvrxzxGG+VfrivQ0xbW0Su6DYiqWJAHAxmsLV/Hfh7RQVu9RjaUf8so/mJ/KmdSpwjuaFv4d0S2i2Q6ZaKg5Py5/mavwWltbR7YIo4o/RBtrzOX4m6vrUpt/DXhyedugklXA/nTo/BnxG8T/ALzUtWTS4HPzRL8rAe2BQJ1ox2PSTPCD/rouP9sVka94m0vQbKW5u7uIlVIVFbLEkccCuZ/4UXIRlvFWoknk/P3qzpvwi0DSLtbrWdVe/dDuAuJcAY/Hmlcl4i6sJ8GdPu5ZNY165haGO/l3Rqwxkc9PavXc1yM/jvwholssB1W1iSJPkijB4HtgVz938cfC0DhYBdXS45eJOAfSg52enZ96M+9eOSfG+adSun+Gb2SY9BImBj86hb4m+N9S50/woIwv3w56/TmgFFs9pz70hIrxU+IfirqZ32+nQ2SpwVIU5/OnwS/Fi7YxS3FrbIR/rGVcfoCc0D5Jdj1LX9A0/wASaVLp+oRCSJxwe6n1FeOzaT42+FtzI2i7tR0Uvu8vG4j1+Xr+NWf+Ee+J3X/hJIOufu//AGNTTzfFiBhAk9pcIFHzhU5/MUByS7Gro3xv0G5KQatDPptx0ZZVOM1D4w0nwr49aO+07XrO21SBQY5jMoBHUA81yupQeM5Iv+Jv4WsNSZ2yHCojD8sZrlLrSmg2reeDbm2mDFpJLWRj8v8A317UBySOwiv/AIh+Hx5aT2Ws28XBMc6O2OwwpzVpfiL4qtFL6h4TnkDHC/Z42OD79a4WI+FkGFn8Q6QchSezD16npW9aaXp85VNH+I8saN1S6Zwd35UXK55o3D8UtYAyfB+pD6wP/hSJ8XJ4WzqHhq/gh/vCNgc/iKlh0j4hW8YksPFenX6Rj5IvlJcDjuBTpdU+JlhDsvvDlnfqfnLbEwB6UXD2si5p/wAXPDVy6JctPaStwwljPH6V1tjrmkamgaz1G2lBHTzAD+RNeYX/AI10+748Q/D9kB5DQw4OO5OKzhYfDrVnVtP1a+0KduBG+7r655ouWq76ntX9k6ez+abKAued+wc++amktbeSMwypG6EYKMBjFeU2nhbxlpw83w94rt9UiyMRGXcxH0IFWP8AhYHirw+fJ1/wzJIV+9LEvX34NM0VWD3Lms/DJkv/AO0fDV+2m3R6qPufhWDrC+P/AARFbaxc63JfQJKBJGEGMc9faur0v4r+G79/LuJZLGXpidf8M11Ed5pus2hWOa3u7eVdrKCCCPoaAcKcvhKFj8YfCNzYwS3GoeTK6gvGUY7Tjp0qPX9Q+H3jLT0GoX9o+V/dyeZho/wzx+NRt8P/AAy7Fm0eHcevLVQuPhX4VuZvMOnbD02q5AH60WM/YSLnwx8OWXhm5v8A7Frlne2F2Q0MayAup9/yrs/Enh2w8S6RLp9/GrowO0nqrdiK8n1P4QRRK1zoGp3FlcryiGQ7T7ZzWj8P/HupWWs/8Il4q3JfLxDO+PnHb9KVjOUHE5zTLnUfhb4kbRtY8yTSblv3NwBkDnqP6ivXbeZLiJZYnV43GUZTkGpPGHhSy8XaHJp92uGHzRSDhlYDjFeVeDPEd14Z1t/B/iKQxtE2LaV+mOn5HjFM1pVOjLfxF8M3VrND4q0BWjv7U7pgn8SjqfyrvvAHjO28Y6AtyHAu4sJcR9CDjk49CasSEMG3hShBDAnjaeor5/0zxPN4T8e6hfaYGOnfaDHMqjK7c8+wNDFWik7o+pgaWuf0zV47q2hvIZfNgmXerZzxW6jqygqcj1pGcoOI+iig8UEDJXEcbO33VGSa8S8Og+OvjBeaq+57HTDiIEZXIPFd38TvEQ0DwVeTRsPtEw8qEZwdxzWf8HvDh0PwZFNKhW5vf3zluuD0oA9EX7op1FFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRiiigCte2kV9ZzWsyho5UKMCOxFeBeH7q8+GXxOl0a4YppV7IdoboRkbWz7A4r6FNeX/GbwqdY8ODVbVCbywO4YHJTuPzxQB6cGyoKnI9agvryKws5ru4YLDChd2PoOa4n4b+Lv7f8AB1tJNIHvIMRTjPJxxn+dcl8bPGQS0tvD1nP5ck4DXLL2UnofyNA+VmR4fgm+Inj268Q6grHTrNiLdG6HHAAH4Zr1/O0j1FYXhG00+x8Maemm4aFo1YsBjex6mpvEWt2/h7Rri/uHUbFJQE/ePag7IJRjc5H4leJrhI18OaUWfUL4hCI+qqeO3fmu5+H/AIOtvCGgpEEzeTKHuJD1J9M1w3wp8M3Ws6pN411pS0sz7rZWHT35/DFel+KvE9j4S0KXU70nYnCqOrN2FM5Kk+Zm2WVeSQKqyatYQsUkvIVYdRvFeFNdeOvibObiG5bS9FZ8KASMgdenWtKD4NacyBrzVLqabvIGxn2xRYqNOTR7Ql9bSRealxG0f97dXnPxJ+Itlpui3Gm6RdrcarcfulSI8pnuSO/PFcy/wdKkrb6/dRQZ+WPk4HpW1ofgDw94YlW+n/eyx8ie4YfKfUelIpUZHN6b4E8Wz6TAJvE11DHcqWuIWkYkDtjmu08IeCNN8JW8n2eRp7mX/WTuMZ+lZWt/Fbw9pjmG0339wDtCwjjd9elYcCfEfxxLL9lT+ydPbgM4KEg/z/CgtOEPU9A1jxJo+hDdfajFEwGdgbLGuEvfinqWqTNa+F9FuLuXoJmGR+XTvXQ+HvgrpVk6XWuXEmqXXcPwn5HrXolpp2naNaGO1toba3QZO0AAe9FyZ1m9jxyz8C+O/FmJPEOqtp8DdYY2IbH04Fdjonwe8KaSFmmga9mByZZzkH8DxUXif4v6BobNbWbnUb3oscJ+UH6/0ri5Ln4jeOnysh0nTZOCPuEj6HrQZe9I9R1PxP4X8IW2ya6trYAfLDEAGP0HSuF1D42vcP5HhvRLi9kPAaUbf5ZFGkfCbRrN1n1B5dQn6/vDhT+BruLDT7LTIvKsrSK3TGMIKDWNC+55u2p/FbxH/DFpcDdyMMB9QKWL4V3uonzdf8SXNw5ydisT/M16nhMdf0ppCZ+XrTsaqjFHDWfwn8KWo+a0ec5+879K6C18K6FZ5+z6VaKT38tSePwrZ6UmOaDRQiiJLeJCGjjRSBwQoBqTBH8R/OnUUyhpQHqSfrS7BnOTmlooGJsHqaNuO5NLRQAAkdCRSlmwQTkHsaSigCnd6Xp98MXVjbTDGBujBIH5VzWo/DLwtqO7Nh5JIxmE7cfgK7DFLighwizyq5+D4tCZNE126tZRkqpYqB+O6oIp/in4UyyS/wBpQZ6MTIcfUivXSFI60AIBSsRKjF7Hm+n/ABmiaYWnivQ3tnxtZ1QOPfIOMCujh0/4deOYSlvHYySlQcRAJIo/CtfUdK0/VITHe2UU69MOBXDar8JdLuHM2k3M2n3AyV2MCoP0FFjKVB9Czc/Bp9IvEvvCutXFnIpz5TOSGx75rkr/AOLXjPS9XfTNRsrWaWJ/LeAoBuPTrjvWnDe/EbwNjex1ewQ5bILHH9Kns/F3gfxb4msdT1iD+ztUtmxIso+Rzxt3N7HpSMHBrc7lfAmh+J9DtZda0a2hvJYw8gtwFK59wK5PUfgtNpxa58La1cWs6jKxMxwfxzXr1tcRTwpJBIkkbD5WQ5B+hqbGRQK54GvjHxt4LuI7bxNpgubRePtCc/rjP516H4f8V6Z4hthNY3KsxHzQtw612lzaW95A0FxEkkTDDI4yCK8o8T/BmN53v/C121hd53eXn5SfYjpTuawrNHe7wc5rzX4peG2ubG312whZr2ylDsUHJUetZ9r4813wZcJpvjOwkZRwl0o6j1z3r0jStZ03XbAXNhOlxEy4ZcjI9iKNzpvGoin4F+JWkeJ7eC0eYw6kEG+KQbdzY7Z60nxK8AWvirSZby3jCarboWhkHVyOin1rjPiV4YWyt4PEmjW6W95ZS73MQxuXknpXqXhHxHb+JvDVrqMTAl1AkA/gbuDSOSUOQ8D8Lnx14rt7nRbLUxGtr+7mWSQq6DOODj+tet6X8LdJsPBdzosg8+a7G+ac95OxHpXMeFGtk+OmrJpZVrZ0PnY6A7T0/GvZyBQTzPqeC+ANWvvDXiC48Ga0SCjH7K7dGHsfQ8cV7Tp9xz5bH6Zrzz4w+Epbywi8R6YCt/YctsHLJ/iMCr/gbxMviPw9Belx9ojGydRwQ3rQb03zx5WejUdv51DbTieFXBGe9Vda1KLSdHu76ZtqQxM2ffHFBz2tozx34gTN4w+KGleF7dle0tm3z49eCc/rXttvAlvCkMahURQqqOwryH4O6ZLqupap4uvQWe7mZYSw5Azk/wBK9kANAC0UUUAFFFFABRRRQAUUUUAFFITTdxzQA+im5ozQA6ikFLQAUUUUAIaguIEuIJIZQGRwQwPpjFTmq91KIYST16CgaV3Y+eba7X4ZfEi9tZt39lz/ADDA4xnjH0H861fAfhaH4g6hrPiHXIjLbzloIATjbx94fn+lQfGqayl/s+1VAdSySXAyVU44PrXcfBrWNNvPBUFnabUuLUlJ0z8xPXP5UFybXunJP4R8ceA5Jzocy32m8tskYDYPoT/Ksvwfo2q/FLWpLvXrstp9jJholGFZs5wK971UZ0a+Qc/6O+OP9k15n8Cp7ceG7+1AC3Md05kXdyeT2oJ55WsepW1rBZ2sdrbxrHFGoVFA4AFeS/HW/hm0uw0SJhJeXFwp2DqBkYroPiL8QJfCv2bT9Khju9UuiVSMn7nTBNcp4W8H6ld6x/wlHi2bzbsjMUTHiMZzk/TrQh04uTO+0S0Fnotna7VXZCqkAYGcCpL2+trKFpru4jijAyWkYDj6VxHiX4mWthcNY6LE2oX5+U+Xkoh7ZxWVpfwz8T+Mpk1DxbqElvbudwtUODjrjb0H1ps6JVVHRFjVvi0huv7P8OafLqVwTt3hCy5+g/nTYfh54u8aSJdeJdTNnasc/Zoz8wHoMf1r1Lw94Q0TwzbLDptlEhUf6xvmc/j1rdAA7UjnlUlI5Lw78OfDvhuMG0skkm7zzfMx/pXVhAqgBQoHQAYxTq4D4gfESHwzALDT8XOsT/LFCozs929qCNza8W+N9I8IWBnvZgZT9yBDlmPbivJri+8YfE+4Crv0zRGYgYJUkfjyaueGvAF7ql8Nf8YyyT3jHcLeQ8Af7Q6D6CvTYYYoYljjjVEXgKqgAU0dEKV9zmPDfw60Pw7H5kUAubk/ennBJzXVFdoxgAeg7UvfPf1oPPWg6YpLYTp60UtFMYUUUUAFFFFABRRRQAUUUUDCiiigAooooAKKKKBBSUtFACUHnrS0UAIULDGBg1zeveA9C8QRFbu0WKXqs0XysDXS0hpCcU9zyw+H/GHgItc+HtQa/sU+Y2spycd/f8q6bwr8ZtM1eZLHWIX0y+JC/vFIUn8eldYAMjIzXB/E7RND/sKS/uNNdp1OEa0QB8+px2oZz1KKWqPXYpY5ow8ciuh6MpyD+NP7V8q+GPiP4i8J5ggaSexDZEN0hzj/AHjyK7y0/aAUlvtmisEA48lsnP4mkc9j17VNF0/WbZrfULWOeNgQQ65ryLxD8M9V8LXT614NunCr8z2m7nA6gZ6j9a3dJ+OPhy+kWK8jnsnJxmVeP0zXS6z420228I32tabcRXqwx5URnOSTjkenNAJtHF+EvHFp4xSbR9VthBqO3y5LduBIMc4z71FcfCHV7Gd18O+IZLSynOZIWPT6cVzHhrR/E/jbxPpfiQxWcNuku6S4tgFyO4IHfOOa+iUBA5HNMqU3JanmcXhpfhb4QvdR0m2k1LV2wZJCCzNyOw7VF4Y+M+l6lKljrMTabe8DEikKx/HpXqZAYYIBrkvE3w68P+J4SLmzSGcZ2zQgKQffHWkQdKr22oWhCPHNDKMHaQQQRXhLo/w0+JhsuRo+pkFWPRCT/SrDeFfHXw7uWudCvH1PTFyWhY7iB9D0/Cs7xV410nxx4ZktNYgOma1bfNEzA4Y+gPWgcXZ3PbNOuRG4wfkfpXn/AMbNbkSwsPD1mSbjUZQp29dufSrHw78Srr/hqITMFurP93Nk84A6/r+lc/4fibx58Xp9WlXdZaUNqHPBIwMfrmg2qpP3j1rwro0eg+GrHT0H+qjG7/ewM/rW3UajAFPoOe4tFFFAwooooAKKKKACiiigDzb4oeM9a8L3WlQaOsLSXkvlkSjPJzjtWXe678U9GtX1C907TprSEb5Vhb5iO/8ADVH46NImqeG2hCmcXGYw3GW5wK0Lxvidrdu+m3FhY2cFwm15VfJVe/egDcu/iZax+CrPXra2aSa8ISG1ZuSxHT8yO1YEuvfFaK0k1E6Vp/2ZAZPJ3kvtx0+71xWP4m0JfC2q+BdNuJUfTYZ8O7DHzZXJ+nFe3AwrAWyoiC5PoVxQBgeCvF0Hi/QhfRRtDMh8uaFuqOO3Sui84A4yv/fVYOlX+k6npV+nh6WEMpkjbysDbKBj+deUN8H/ABhM5mk8SgSOSzDBOCfxoA9281f7yf8AfVI06KpJdAByTmvDP+FN+K/+hnH/AHyf8aF+DPil2Cy+JgYycOAp6fnQB7SdXsf+fuD/AL7rL1PWLJnx9shCqMnLV5k/wK8uJmOuycD+4f8AGuT8V/DuPwvoUmpSatJIwYBI9pXeeff2oNaat7xraBd6f4l+Keo61rE8C6ZZfu4xMeCMnHB+ldB4M03w94T8V6nqcfia0+yXJ2x2yPxjrk/nWN4O+DEesaPaanqd7KiXEYc28YwQMevPrXTt8CfDxP8Ax933PrIP8KDOTuzs28aeGnjZDrFmQQQR5nUGvHvEun6Ro+uyan4Y8YQaebolpYg5Az3Ix9a63/hRPh49bu+/7+D/AAq1afA/wrEGE4u5yehaQcfpQI8+8PHwzY66Nd13xTHqOoryOflB9c55pPGHxFm8RamNJ0q7S009ztlunbbvHfGO2K9LPwW8Ht0t7j0z5g/wryP4g/DW48HRNqMdzHNpzyhEjYYdRngE55z9KDRVGlZHXeFfEPw18FqBDcvdXwA33YiDc99pJr0nwz4+0PxbcTW+kyyvJCu5g6AD+deYavF8PPCGhaU93oa3t1eRK2zf8wyMkk4rFh+J2h6BbzP4T8NCxvpl2vLIwKj8ABQZn0e8scalndVXuSQK53VPHvhnRgwu9WgDjqisCa+XNX8Ya/rkrPqGpTSbuQqthfwrMhHnvlllZiQNipuJGeT/AJ9KAse7eI/jjaNCbbw9bSTzy/uxLKNoBPpjOaTwR4Hmt7l/EOvn7RrFw3mAPyIwecnPevJ7DT5ZLmJ7LSLyWZGDqZOFOD344r6N0mea70e0nuECTSRKXQdFOBkU0dFGCvqX+uCaKT6UtM635BRRRQIKKKKBhRRRQAUlKelIe1Ag49aU9KwZfEtvF4uh8PmBjPLEZRJu4AGf8K3u1Ak7hmko57D8aMd8Uh3Cijae4P8An2oAyeASPzoAWijBHY496PrTBO4UUUUDCiiigAooooAKKKM0AJ3FeafGDWdQ0uLT1sL2aB5Ccon3X69ea9LHUfWvM/iz9sRraVtVFlYlCAPK3ln9Ov1pMzqfCePT6zqt8Gae4MjOMEsvOPrmqc8zzRJGfKGzuqAFvqe9aUuqXCbUTUpZo2B3/Jtx+dZRcE53decmkcWowR4U8nAr0jwh4BvPEvhi4u9A1WaC4GYbi2lBWN+45zz+VeeRNGJY2Y/KGG4jrjPNe5WXxr8O6ZZJY2GlTkpCqoVON7AY5GKBM6v4VeDNQ8G6FcQ6hKrTXMgk2L0TAP8AjXoI615B4K+Kup+IvGq6TdWEcEEkZdQeHXBGMnvxXriNkf8A1qBElFHaigBCK5LxR8O/D/ipXa8tFS6OcXEYCuD7nvXWk0UAfLviDR9a+FOv4sL1pLe5X5WZflkHow6dK6z4f/EvQLG8kh1DT00i6uSDI6ACNye/bH4Zr1Hxr4TtPF3h+axnX94oLwOByr14p4bs9NvLu48H+LrVRqFuxW3uPusfQA/SguLvofQ9rdwXlus9tMs0TAEMpznNWM14EfCXjbwVI934YvmurJTuNs2ckemO9bvhz42QmcWHiiyksLsHBfaQM+6npQTJcrsz2HNGap2Wo2mpWi3NlcxzwsAVeNgwrzrwH4l1fVfiR4j029u2ltLZMwxn+E7gKBWPUM80ua4H4p63qWh6BaXGmXLQSPexxsw7qQciszxn4p1yfxTZ+EtBvI7K7li82S5lHr0A5oA9RzRmvHJ7n4jeDNSsZ9QvP7bsriURSxxRHcmcc9TWhpXijWdP+K0+iavPJJYX0Qks94xs4BI/nQB6nmlrhPif4nufDnhsLYS7NQupFig2jkE9TXUaELyHQ7OPUZjLdiJfNc9WbHJoA5H4h+CL7xZqejXNpPFGtlOJJA4OWAz0rvgven0UAcv408IW3jDR/sczGOVW3xSqOUauLfwb8RzYtpg8SwfYyPL3FPnCfXHXFet4FJtFAGB4Q8LWnhLREsbY7mb5ppSMF29a6ClwKKAExSEUtMkcIjMx4AoAoX853CJT9a8Z+JbSax4t0TwvEeJnDyAH8f616hfXqQ+bdTOEjTLsxPQCvNfA0R8X/FO88SeU7WNqpWCRxjBBAGPqBQdM/dhyntVrax2trHbwrtjjUKB6AVZpo6CloOawtFN3dhjPpRnHWgBawvFfhiy8WaHLpd6zojncroQCrDpjNal7eQ2FlNd3MqxQxKXZ26ACvFfHPxqcGO38KTqSrHzZnQEEdsA0AeX+M/Dl54b8Qz6bcNPIkX+qlk5DLjPXp17Vh16bqdt8Q/H2gW0s9hDc22N6SxIgZu2M153qGk6vpcrJf2E9s46h14/OgaK3f6c1oW91GQHnvpoJUG1BGgOV/KsxVc5O7n6UoDg8kYoGdKo02eDfb3WsXNwD86xDjH4DivoXw9t/4R3T9iui/Z0wr/e6Dr718yWFzfWSma0lnizlFKcgn6V7h8Ktcm1Tw9Lb3kkz3cEh3tID90njGaDelLU78UUpGNv60lM6gooopgFFFFABRRRQIQ0HpQaKAZ55d/8AJbLH/rzb+TV6BeXX2OxnuioYRIX2+uK808VDWtM+I1trWn6PLfxpa+X8vHJz7+9aVl4k17xBO2lX/hqWwtrlGRp2f7uR9TQYp2ujj4dZTxMj6nqXi250yRpCYLSGM4jHUZO3Bq1c+L9XuPhr9ojupUvYL0QC52gGRcrgkHjvTLGHxF4RsbjRR4Vh1QKx+z3RjQ8HoTnrVzVdC1+5+HcEV1brJeyXqSmCCNUEa5U84+lIhXZDrOneJPC2mWfiRtfnuJndBcREgrtOOAAPepfGmuXD67aWl9qV3pWlSWsb+bbpnLsFPJwfU10nj7Tr3UPAcNra27zThoT5a9eCuf5Vja6niDTp7Vn0Yaxpj2saG2dFzC4UZ5OOeDQNpo2PhzJfNHexzazHqdkjAW0uQXC4PXGMdutdwc55615p8O9B1CDXb7WbnTxpdtKpSK1HpnqcV6X9aDWne2oUUUUzQKKKKACiiigQUlLSgAnmgCOQusbsihnCkqp6EgV4L4w8W65qsrQahFZ26QO21QQzAgkDjJ7e1e6X97Bp9jNdTOqJEhYFjgE4yB+J4r5+0jw7qHxL8YX0tpH9mt3ctLI3zBRnj8SKTOeu7bHGFvOkdydzE9cda3tH8Ea74jcJp+nTEZGZZAVUD1ycV754c+DvhzQyss8TX1ypzvmztH4dK9CggigjEcMSRoOiouAPwpHLc8b8LfAm2s5orrXLv7Sy4YW8XCZ9z3/CvT4vDGixeWY9LtVMYwpEecVtUYoA8f1z4N3moeKbvWtP1v7EZm3AKpBX24Fcvpmu678OPiANL1nU5LmxdgrPKflIY43Dvx1r6HIrhviB8OrPxvBC7zm1uYeBKqgkr3B9aAOfj+Nlne+MLfSbGxeazklERnzgknuB+VesZ+Xrj618zaPodv4a+MFnpiqwjt5Cu+Rvv/Lwfbk1614++Idr4V09oLV1uNRl+WKJeQue5oA7c3lv5/kmeLzT0j3jd+VT5ya+W5NG8aLpo8dvPP5gk34Zm3BeTu2/3favcvhz42j8Y6EssxRL+H5Z4x/MUAdnivLfix4Il1SCLX9KUJqVj87beDKo69O/Ir1MA4560x0DqykZBBBFAXtqjzjwH4vXxJo6zsVS9g+SaPofc4963td8FaD4usv9OsUEpHEqfKyn+R/GvLPFWn3Xw18exa5Yox0m8YiaNRgKTyR/MivXtH1OK5hhu7eQSWsy7lYUHQ7VI+ZU8GeCrXwbYTWttczzCWQvulPQccAdK4rwBbvY/GDxTBMVR3iBUEjnJU8V6+CCMjvXBeKvhvFrWsDWtO1GfTdRI2vNEThh7ig51fqZPxqv4V0rS7AuTcTXsbqi8nAyP61L4n03wz4z8SLopvJrLX7SMMk0eUYjsASMGpdI+Faw6xDqWtavPqskP+qE3RfwrU8X/D228SX0Op293JYanENq3EROSPTA60AefazF4t+F0NteSa9/aentcKhhmXtuGe3Wt/4oWbSaVofjC1QiayZJHwP+WbdR+tT2fwlll1OC51zxDdapBAcrBLyufcV3+q6PBqug3GlSjbBLF5eP7oxx/SgDy57yL4i/E/ShDhtN02Bbh88hnYA4/DJ/KvYwOBxXGfD/AMBQ+CLS4iW6N1LMwPmFcYA7ZrtKAFooooAKKKKACiikNACZrP1Gfjyl7nn2qzcziCItnk9BXn/jrxWvhvQJbk/NdTZSFB1JPGaDajH7T6HG+P8AWrrxHrNr4O0QlmlcLcMn54J7V694V8OWfhbQoNOs0UbVBkfGDI+OTXEfCbwdJptnN4g1Rd+o3wLgsOVQnP64/WvUgKDOcuZ3CjPpSHg9a8z8T/GLTtE1OTTdPspdRu4mxIIzgD15xzigkxvDniTWrr4z6hpc2oTPYxkhYmJwPlz0rV8VfGfTfD2ryafb2cl40BxM4bAU5xgV558Pdeh1D4wSanMVtxdZwrt0bbjH1q5a2NvZfGm+0zUoUuINQdkZW5IDksCB2PvQBo/ED4pWHiHwXBYaRva8v+JYupjGOV/WtPw78FtLu/DNi2sLNHfsu+QxttP0P4V0+i/CPwnouoRX0No8k0ZyvmuCoPqOOtd6FwAMDpQBn6LotpoGkwabYpsghUhQepJ71PeafaX8Jiu7aKeM/wAMigirQ60tAHn2ufCDwxq4eSG2NlM38VvwAfoK8p8b/CK78MafJqVpd/a7SMgPuXayg9+Pxr6WNUtV0+HVdMuLG4XdFPGY2H1GM0AfHFol6YPtUAnEETgGRFJCk/1rv/h14oWy8QOl/rCGzkjIIl4bdkYz+GaueBTJ4K+It34d1FVFpcsUw68HjKkfhgV6pq/wt8KauXeXTUhlccyQ/KQfWguMrO5eguYbuFZYJVkjbo6kEH8alxXkLy6p8JNc+x3nm3Xh64b93JydnPr2Neo6XqlprGnx3llMJIZB8rDr+Ip3OuFRSLlFJS0zQKKKKACiiigAPSkxS0UDHKxUYzRuzwelNooFYduI4B4pBgEnJpKKA0HZGSec0me4OD60lFAC5z97nIwc0h60UUDCiiigQUUUZ9qACjNGaYSApYsAo6kkYH50AyXaQM1k674h0/w5YNeahMsceDtBPLkdhXM+KPibpmiObOyP23UDkIkRyoPvjqfauf0LwDr/AI/1JNY8WPJBY53Lb/dYg9AAfuj60mYzqqOiM3d4l+LeqNb2Ye00WNhv3H5cZ6n1Ne5+GPDGn+FdIjsLCJQAMySEcyN6mr+maZaaRYQ2VlCkUES4RVFXaRyNt7iAYpQOaBS0CCiiigBDSHgZNOqKeRYoZJHOEVSzE9hQB8+fFezj1b4mWVlpJKXsyKjyIeQ2ev4Cu18M/Buw0+/TUtZu5NUu85PmD5c+/rXJfDhZPFnxY1TXJ1DRW5J555+6P6V7+OnvQBWns4Z7RrWSNTCw2lMZGMYr521qC9+EnxBS+tUk/syds7VJAdM8qfoMV9JVy/jrwjB4v8PzWTqouFG63kP8LjkUAbWk6nb6xpdvf2r74ZkDKRV3GRXg/wAH/Fc2i65ceDtVOza7CAtxtYdRz68fnXvI5oAxvE+gWviTQbnTbpQVlU7TjOGxwa8h+HupXfhjXbrwdrbgGJv9GJPXnHft0/Wvdj0ryj4xeFmm0+PxPpyldQsCGYr1dRyPy5oLhLlZ6Np115g2Oea0OPTmvPPBPiaLxBoNveowE6DE0fcEV6BBIJo1cGgqrH7SJe1GKBS0GQ3aB2FBHFOpD0oArPdQwkqzYI6jFKl7E4yDWbqI/wBIP0qqHKjAJH0pnQqScbnSUtUZ79IZ2jIJI/wqeCdZ03LmkYOLSuT0UlFAhaQ9DRmql7c+RCcfePAFA0ruyM7ULlPMYswEackk8D1P5V4xplrN8T/iUbhww0bTm+633WIOQPxPWt/4reIZtL0VNMsWLX1/mPC8nb6fjmu3+HvhaPwv4UtrYoPtMo8y4fHJY0G1WVkoo6qKJIo1jRAqqoUD0A7U/NA461Q1jVbfRtLuL+5cJHEpOScZOOKDA4v4seM18N+H3tbSQf2ldqUj2nJjHdse2RWV8JfAS6Zpza7q8Sy3t2CyrIM+Wp65z3Nch4Lsbv4n+P5vEOqR/wCgWzqwRvunBO1f55/CvoSKNY41VRhRwAO1AHy1deFpvEfxU1bSbCZLSVZS8bdApAHTFeneAvhTeaPra65r1+Lu8Rf3SDkD3ya5vwmf+MgNS/3j/wCg176KAHUUUUAFFFFABSEUtIaAPFfjn4ddUs/E9iCs1q4WXZ1xnIP54r0DwB4ni8UeE7W8VgZ40Ecw77gME/jWvrukwa3o13p9yoMc6Ffoex/OvDfhVfz+EPHt94Y1Bmjjmcom7gbgcA/QigD3HXNDsfEGmS2F/CskMgI91PYivD7vRfEvwo1JrizD6hoMjfOAC2wfTrn36V9BjmmTQRXETxSorowwysMgigcW47HA+HfGWi+JLcSWNwgk6NDIcMp9K3i+TnFcZ4o+Dlpd3Laj4cun02+67EOFY/h0rl4fF/i/wVcLY+JdMe6tl6XCDJx65xz+NO50wrX0Z62KWuZ0Px1oWvKPs17HHIeDHMdrV0y4dQwIIP8AdIP8qDdNMKKX5SOpoPHQ5pjuJRSUZoC4tFGaSgBaKKTNAxaKTNLQAUUZHenYQ/xUCG0UMMfd/GsnVfEmlaLC0l/exRYH3dwLfgBQJtI1SaRp0iQtKyogGSzEDFeXX/xbe9l+zeGdKmvLgnaHdcLTYPA3j3xjMJdev2060P8AyyQ4Iz2IHBpGUqyR0HiH4maDpIaG3lN9edFhh55+ork/sPj/AOIcisiPpmmMcHPy/L9Ov9K9K8MfCrw14cKTJai6vF6zT/Nz/uniu5VQqhQAABjApHPKq2cF4S+FuheGQk0kX2y+HWebnB9h0rvUAAAAAGO1LijFBmLRRRQAUUUUAFFFFACGuL+KOtnRPAl/MjFZJk8lPXLccV2h6H1rwv46alNe32leHIA2+R97BT1Jxt/WgDd+BWiPp/hWXUZgfNvpS4yP4Rx/SvWO1ZPh7Txpfh+wsVwBDCq4HHPWtagApCAewpaKAPD/AIy+FZLG7g8V6WpjlR187y+u4Hhv1FehfD7xTF4r8LwXgbEyDZKmeQRxn+tdBqdhBqen3FjcKGiuEMZBGcZHX8K+f/Cd/dfDH4kTaNfsRY3b7OT8uD91vT0BoA+jOTUU8MdxE8UqB43XaysMgjvUkZDoGDZB5B9adtoA+fYI5Phn8SpLGUn+y9Sb92T0Uk4H617bp9yFIQkbW5WuY+KPhFPEvhqWWJcX1oDLCw6nAyR/nvWH8N/Fb+ItECXICX1jiKRSeTjgH+VBvTfMuQ9XHWnVXtpVmiDA9uanoMLW0YtIelLTTQJmPqRzcAe1U6s3zb7piO3FFvB5se7A64ps71pBBf8A/H7L9B/Krul/6hvrVPUB/pjn1/wq1pbfI6+9BnPWkaI6UlLSdOSaRyCMcAkngCuf1K8RRLcSsFhhBOSeMCtC/usKY0PPc15d8Vddew8PLpto5+137iNVXrs5z+uKDphHljzsyPBls3j/AOJVzrtwN2nWLDyQehOfl/LFe8KMKOAMVyXw78LL4U8JW1kyf6S6+ZOfVsc114HFBhJ8zuxCfU14Z8ZPElzq+sWvg7TQWMjqZinOScYH6n8q9b8Ua3B4f8P3mpTsAIUO0E9WPA/UivIvhFos/iLxHeeMNRBYiRvK3D+MnOfw5FAj1bwf4Zg8K+HbfTosM6LmWQD77Y5NdB3pBjHHSl70AeAeE/8Ak4HU/wDeP/oNe/LXgPhP/k4HU/8AeP8A6DXvy0AOooooAKKKKACkNLRQA3HFeH/GjQ207UrHxVZqUlVwkjAcccgn8BivcqxvE+iQeIfDt7pk6grNGVBx0OOKAKvgvxHH4o8M2upRsDI6ASr/AHXA5H510XWvAvg7q03hvxNqHhHUPkkdzsz03g/1Jr3wHJoACCaintobmB4J41kjcYZGHBqekoA86174OeGtVDSWkB0+6Y5DwcAH6CuPfwT8RvC750PVPt1sORHI2P8Ax2vdaMUDUmtjwZPiVruiSLF4n8OzQqOGmVdv44I/rXQ6d8UvCl+n/H/9nf8AuzDH9a9QuLO3uo2jnhjkU9Qwrl9S+GnhXVQfO0iBGY5LxjDZoNFWkhLXV9OvgWs763mA/uODVzp+H0NcRd/AjSS+/T9TvrU4yAXyM+vAqi3wj8V2KZ07xa5Zj8+9TTuarEdz0bgDmk3L6ivOf+EF+JenoXtPEEdy7dUkwuPfJNIPDXxa/wCghbH/ALaL/jRcft0ej7x6igEH0/OvOP8AhGfi1/0ELb/v4v8AjSnwH8Sr9RJc+IoreQceWnP49aLh7dHoxIUHPGOcGqN1remWWPtOoW0WefmfFcQvwa8QXYEuoeLpTK339qnBHpWja/AjQlk3Xt9fXAxwDJ0P5UXJeI7D9Q+J/hSxBzqKzMBkCIBh9DWFL8V5NQPleHNCuryU/dYjj+td/pvwu8JaZgx6TFK4AG+Tk8d66m20+0tEC29tFGvbaoFIh15M8Uj0v4p+KWKzuuj2jdRkoxH9a6HSPgppUbrca5cz6lcdTuOFz/WvVAAOKXFBk5NmXpPh/StDiMemWMNupAB8tQM/XFaW2nUUEiYp1FFAwooooAKKKKACiiigAoopKAGuwUEnsM18+aWW8ZfHqS62mS2tJNw9AqnK/wBa9j8a60vh/wAKX+pFgrRxEL7mvP8A4F6ORp99rc8eZbmTYrH0Gf8AGgD2ACn0lLQAUUUUAJjrXlXxo8I/2roq6zZxZvLIbmKjlkz/AIkH8K9WqOaJJ4nidQyOCrA9waAPPvhL4w/4STw2ttcyg31niJh3K4+U/lXogORXzhcNJ8LPiy8gDf2ddNyB0MbEH9MgV9EwXCXECTROHR1ypB4NAEjgEMGGQevuK+f9Wt5Phz8VFmQFdK1Q4bjgbuo/76BNfQJrhfin4WHiXwpK0S/6ZaZmhbvx1H5ZoKjLldzodMuQHGGBicZB7HNbII9a8t+Guu/2x4ShWVmNzZ4hlBPIwMA/pXcw38seA/zig2nTc/eRtVFPKsMTMxxxVM6omOEbNUbm5e5PzcL6UyYUZN6kbsWJY8kmtqzhEdsoPU81m2ds00oYj5AfzraAwMUMuvNbIy9UjIkWQDOeDUFnN5NwM8KeK17iITRlTWHPE8T7XU47cZoHSalHlZu+YmMhxj61Tu75VUrHyxrKyQOp+maciPIcIpJ+lAKhGLu2Gck7jnOSfwryfTLQ+OfjNJNIrNp+lj5QeVJUhSPx616H411WPwr4Qvb+R1+0PGY4UPdjxx+dUfg/4fbSvCKXk4/0m/fz3YjnB6c/jQyKtS6sj0UDAH0oPFKBxVXULuOw0+4upmAjhjZ2yeOBmkYHinxs1ibV9Z03wpYS7i7AzKvXJzx+WDXrPhTQYvDvhu00yNRmOP5z6sev65rxn4Xae/jD4ian4lvkLRW0jNGWORuyAB+XNfQIGOlADqTvS0h60AeAeE/+TgNS/wB4/wDoNe/LXgPhP/k4DUv94/8AoNe/LQA6iiigAooooAKKKKACmnrTqTFAHgPxm0i60HxXZeKtOXaWYbio6OuME/XJr2TwrrcPiHw7Z6lCQfNQbx6N6VD4x8Ox+KPDd3pjgBnUmNj2bHBry34NeI5NM1S78H35Mbo5eINxz0I/ICgD3OikzS0AFFFFABijFFFACYowKWigBu0Uu0UtFACYFJtFOooATFGKWigBMClxRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUhNLTGOMH35oA8c+PettFpFjokJy93J5jAddo4I/WvQfAuk/2P4N0yzZAsqwgydsseprx/XZR4z+OdrY/M9rZyBGA5AAwGP519AxAKoUdAMUASUUUUAFFFFABSN0paQigDzT4xeFF13wu1/bxk3liDIuByV7j+X5VB8FfFP9r+G/7LuZC13Y4UZPJToD+lemzQrNC8bqGVwQwPfjFfO/l/8ACsPi2pcsunXD9uhjY/0oA+ju1RyxpIhRxlWBUj1zRBKs8KSo25XAYH2p/bNAHg9tEvgT4vyadK5XTdVDMuOisSCPyzivX5NNkX7mGFcJ8adAkvNDh12zG2601w5YDkr1PP4Cuy8Fa8niPwpYakp5kjAf2bHNBpGpKOxKLK43Y8s/WrEOmHOZmx7etaeKXFA3WkxkcSRqFQYAqWkxS0GW+4001kVh8wyKkxRQBWFnAGz5a/lUixqgwqgfSpar3UyW1vJPIQI4lLsfYDNA7s8Z+K1y3iTxtonhS3DOqSiWcDnHBP8AKvZbK2jsrOG2iULHEgRQB0AGBXjnwwifxN4/17xRcKXjR2hhY9ug/kMV7UowKBDq81+NGttpng17SI/vr1xGMHnGRn9DXpBNfPvxFun8U/FrTdDiDNFbSIHUHPIbJP5UAej/AAp8ODw/4Ptwy4muh50mRg88D9MV3tRQQpBBHEgwsahB9AMVLQAUh60tIetAHgHhP/k4DUv94/8AoNe/LXgPhP8A5OA1L/eP/oNe/LQA6iiigAooooAKKKKACiiigBCB6V88/FfSbjwj46tPFVluWKZw7Mv94HkfiMV9DHpXL+PPDUXijwrdWLLmUKZIj6MBkD9KANXQdVj1nQ7PUIvuzxBj7Hof1rU7V4n8D/EUkf2zwvfSYmt3byd3oOo/PJr2sdKAFooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooppOOvSgB1FcF4i+J1hpGqf2Tp9pPqupA4aG2BIX6kA807w58SLXWNTOmX2n3Ol3x+7HcAjd9OKAO7orl18ZwfatagaxukGlRmR5XQhZABn5Tis1fiVZyadpV9Bpt9NDqTFUKISEwSMsQMDpQB3VFR7sY60uT/AProAfWX4g1BNK0G+vZDgQxM2T69B/OtDfx1qvf2NtqNnJa3sKzW8gw8bdDQB4t8DrBtV1bWPFFwCZXcohI67iWP8hXugGKy9E0TTdCs2ttLtEtoCxYogPWs/T/F9pf+LL7w/HFJ9os0DPIfunJI9PagDpaKjD55pQ3OOaAH0UzJxWB4l8WWnhkWRuY3k+2TCFNnYnHt70AdFRUUcokUMPQHrTtxzwfrxQA415P8cvDS6j4ZXVYYsz2ZwxA6oeT+WK9XHTmqWp6fDqmn3FlcLmGdGRx7HigDkfhR4iHiDwXbB3H2m2HlSjP5H9RXd5yK8B+Ds76H4+1fw85wr5IRvVcn+WK9/FAFHVbCPUtLurGUExzxlGH1ryX4P3suieINZ8H3jMHt5C8Kt3GeSK9nI61434x0+58PfFvRvEFpBI0V2yxzCNc555z+dAHso5FLUcJzGG5wRkA9akoAKKKKACiiigArifiprJ0XwDqEqOFlmXyUHc7uD/Ou1zXjXxauDrXijQPDMbFlkmWWZF54z3/AUAdV8JtEGjeBLMFcTXA86T1JOcZru6r2VutpbR26D5IkVF+gGKsGgCC5uI7WCSeVtqIpZj6AV4L8KI38QfE/V9fuMMY8srH1Py/yr1D4nam2leAtUmQhXeIxA5wcsOK5f4FaV9l8Iz37AiS7lJHJ5XH+OaAPWFp1IKWgApD1paTvQB4B4T/5OA1L/eP/AKDXvy14F4TB/wCGgNSPH3j/AOg176tADqKKKACiiigAooooAKKKKACmlcg06igD508f6ZP8P/iHba/YZ8i5kEh7AHow/LNe+6VqEep6XbXsTArPGJBg56jpXN/ErwzH4n8IXVuVBniUyRMexHJ/QVxfwO8UNcadP4evJP8ASLYkxZPUE8j8KAPZhRSCloAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAqreMy2dwynkRsQfwq1UciCRGRhkMCpHqCKAPK/g3ZQXFtq+rS4kvZb6QNIQMgZau21vw3pGp6hp99fhEuLRy0T7wnPHB9f/r1562neKfh34h1C40XTf7S0W6kMpiQ/MhOc/wA6SKy8W/ELxJYXOq2UulaHauJVi3ENIc9/yoASC/up9e+IVtJcvJBDanykOMAeWOlcj/aN9YeF/A0dndPEs0jK+3BDDe3Fd1Y+GNYg1zxxKbKQQXtsUtCTxIdgAH51zt34I8SPovg6FdMmMtjKxnXjKDcTz7c0Aafi2XVL3xfeRan4o/sTT4R+4WEhmk+uASKy/D3ivUn0XxfpY1iW+isbQy2t6V2tjDfj2qW60e/0Lx9ql3qHhWTXDdTbrWdgGVRk4GDS6Z4Y8TzXHi24vNDNsdRsWS2jjACgkNhf1FAFbRPDfjHXvBx1/wD4SK4h2ws8UC9XxnHattfH9zP8HVnaQ/2uz/YwAfmEgbH54Fd94H0+fS/AumWWoR+TNHCUlRj0JJ4z+NePaZ4Te4+Mc2kRzeZpltP9sdFbKgkE/T+IUAe1+ErK5sPDFhBezSS3Xkq0rP13EDP615U3h+88Q/GHX7a21GewjRUMssIyx5bA5Fe4dq8dvP8AhJvC3xI1jXLbQrm9066CjEZxkgtzj8aAFsfFGreD7rxDot/ePqP2C2863lcAMMg4B9cYqPT/AA34l1Xwz/wlE/im7hvnQ3CQqo8tR1CkYqXT/B+t+KJ/EGtanB/Z8mo2xht4DyenG70qKw1vxdpWgDwtN4Wmnu1iMKTxN8jL2bP0oAgPj/VvFWk+H9IsLn7HfajIYridQMqF4JGfWqHjXw1qvh3VtBSfWZ9Q06W9jb9+AXR9w9ByDWgvw71vQfD+hanYRJLq2lu0skCDHmBuSPqMYpmvy+LvHN7o0qeHZ7WytLoPIHPzNyOR6dDQBseF9ZvNF+Ius6Nq15JJbyQi4tfMOAFAyev0NXfhxe6hr+ua7rk93I9m0pgt4SRtABA3D8j+dYXxisfs66Tq1mwGo/8AHoUBGXDDGMD3avR/BuipoXheyskTawQO4xzvPJz+dAG+BRtyCPWgDFOoA5a18CaNaeMJfE0UTi/kJLNuOORtPFdQOBQfpS0AJimPDG7KzorMvQkZI+lSUUAGKKKKACiiigApDS0lACe1eKeFv+Kj+O2q6kF329ihRWHQEjGP1r2ojOefxrk/B3gi28JzX80Vy9xNeS+Y7ORwPT1oA64UvakHSg9KAPIPj/fNB4Xs7NXINxPuK+u3/wDXXdeBLD+zPBOlWpUqUgGQx5ycmuK+LHg3XPFeraSbOMS2MLFZRvUFM4yevtXqVlB5FnDEedkYX8higCeq91ewWcfmXM6RR5xucgCodZ1BdJ0e6vm6QRM+PU44ryXwh4Wl+I0UvibxNdzyxTSMsFqpKqqg8GgD2KO4jnRXikV0boyng5pfOQqWDrjud39e1eb6J4K1vwp44EukTmTw9Ov7+OaXcUx2A61xWo3ekHwD4obR5tQDrdoJWnfodw+7wCKAPYbXwnodj4gfWYbWOO/l5aTue1dEOAK8ze40lfEvgpLuS7+3vZgwbGxGQEOd3B/U9qm1n4r29pqVxYaRpF7qz2xxM9up2p6847UAejUtcRZfEjTbvwZceIvLlRLUlZ4SPmRh2PHtWCnxt0xpWY6VqK2XAW5MbbeT9KAPVaK57W/F+naFoEOr3Ds0M+3ylXqxboP1rYtLk3dnDcCNkEiBwp6gEZoAs0Ug6UtABRRRQAUUUUARugcMCMg8H3r5y8V2Mnw6+K1tqlplLO6k8wEDAwx+cfnX0jXCfFTwxD4h8I3LiPN1ar5kTDrx1H6/pQB2lrcRXdtFcQOHikXcjA9QanryT4J+KzqeiNo91ITdWXCAnkp2/LAr1oUALRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFADSAeMCgdadRigBKWiigBpHIop1FAGdq+mpq2mXFi7tGJVwHTqp9a5/wX4CsvCAuJVnkury4AWS4l+8QOgH5CuxwPSigBtBGRz0p2KKAG4FGO9OooAbRgfnTsUUAcHN8M9Pu/Fx167vLmcrIJY7dm+RGA4x+PNd0oxTsCigAooooAKKKKACiiigAooooAKKKKACiiigAxSYpaKACiiigBMUYpaKAMjxNp76n4b1GzjJDywMBj1rz74TeKLGz8MHQtVuUtr+ylaMxy/ISM4GK9XNcpr3w68M+Irr7TqFgDN3eJthP1I60AY1z8RftPxEs/DejQw3sTf8fcyk/uxwOD045ryGBv+KD8Y+v25P8A0MV9BaB4N0Hwyjf2VYxxMeDIeXI9M9aoL8NvDSaffWItZPs99IJZwZDlmByMelAHDanIE8deAHYZxpzEg98I9UNE1DW9ffVbvTtW0zw/YRXLxyJsXfLyeTke3rXrEnhHSJdS02/eFjcabH5Vu284VcY6d+DWVd/C3wne3z3ctgyvI290SQqhb1KjjPNAHkGlcfC7xqBci4YTHM4/j4bmvU7Pw/Drvwng07y0R57I7SqjO4A4/pWjB8N/DVtp2o2EFm0drqAAniSQgcZ+76de1XtVuP8AhEvCwbTLCW7FsAkUEZyxHagDxbRZrzxdqfh7wveKQmlSs85GcfKxxn9K+iEXaAAMADGK86+G3hy8tbjUtf1KzW0u9RcstvjmNeOv5V6PQAtFAooAKKKKACiiigAqOZFkidGGQylSPY1JSHmgD5v1GBvhn8X47xQy6dcybvl6FGIJH4cfnX0VbzJcQJNEwZHXKsDwa88+Mvhr+2fB73kMPmXVifMXb12fxD9BUPwW8Vf234Y/s+4cm7sTtPqU7H/PpQB6hRSDpS0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFNJwKdTHyRQB5F47+JOr+GPHVpp0LQGwYK0gZPmwT65r0u/1iC08Pz6tvHkpB5qkn24ryDx1o6a58SLuzbO86YWQjsy81U/4SW41n4b6L4biz9uupxaTBuqqhx/7LQB1Xwt8fap4qbVH1h4I4rUK6kIVwDuyST9K9L+22xtPtYuE8jbu8zd8uPrXh+mWK6e3xMtoRiOKAogHGAN9b9szj9nxGJIYWbZJPuaAPTZNTs4bZbmS5iSBukhcbT9KdaajZ36sbS5jmC9TGwNeEeINM1K68K+D7sRS3ml28Obi0jkw7nJOQOp4x+VWPCWp6Jb+IL+60eS/0qb7Ox/sq4U7TjGSCw65oA9ruNZ061nENxewRSn+B3ANcp4p8Vahpfi3w/p1o0P2a/kIl3Lkke1cX4E8CWXjDwfPrWq3Etxqd+zFJ/Mz5JxxgDjqabfaZcaV4h8F2NzqUd/NDO4MyHIA7CgD2S71OxscfarqKHPTzHAqaC4iuYxJDIrxt0ZWBFfOcWtLqXi3Wp9b0LUNcEczQwrAW2xAewH1rs/hDdagNW1W0+x3lrpanfDDcg5Q+n+fSgD18dKWkXpS0AFFFJmgBaKaW5pQaAFpKWigCKWJJo2jkUMjDBB6EV89wtJ8Mfi0YmyunXrBQT02scA/gSTX0QRXlXxv8Nyat4ZTUrePNxYsSxHUoev5c0AeoxSLJEkincrAEEHsalFedfCLxUfEXhJLeZs3dkRDJk8sOoP5EV6IOlAC0UlLQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABTSM06igDi5fCF1J8R4/EZnh+zC2MRiOd5/TFY+kfDB9N+Ik3iBriJrMs0kVuuco5Oc9MetelnpR2oA4K28BT/2l4qluLyP7Pri7VEed0YO7rx71yp+G/jeXQJPDZ1yzj0yMERkKcsD0B+WvZ8D0owM9KAPMNR+HmurY+H5dJ1aK3v8ASYyhyzGOQHPbHvijRPAWt3niZPEHiS5tBIIGiENqmM5wOeBzxXp+OMUUAeTx+BvF+gW82j+HdTtY9KuGba8gJeFSf92rFn8L7qxudAlXUBK1hI0txJKxLSsfTivUMCigDzC88EeIfD/iC+1fwld26R3pzNbzg8H1HHtWv4G8H6rodze6lrepm8v7xsuiMfLjHsK7jAooAB0paKKACoLmeO1gknmcJEgLMx7DrU9UNXtDfaVdWqsFaWNlyegyMUAedz/GvSmnlWx0jUr6GM486CMFT+Ndj4U8Xad4tsWnsS6PGdskLjDofevKtGv/ABd8M7T+yZ/Di6jpqt8lzBySvvxzWpY6zoX/AAjniTW/DwurPVvIMlxFKTlDg9F/CgD2LPGe1GRXC2mtXzfClNTe4b7YbRnMp67hnmuGv/HWuQ+D/DbNfPbrfk/ar/Zu8sAn6UAe59R1/KoLu3hvLWW3nUNHKpRgQOh4ry7wpqusjxb5Vr4hg13RXj+aQna6N9Of51R8Ip4q8Z/2nLJ4lks7e3uGij8tNzE/n0oAp+BvDfiLwj8Ub22gspn0aVm3zZXbtPI79e1e4g8V4inxN1TT/A2qC5kSXU7S8NlHMwxuHBLY9gf0qreeL5tF0eDVrTx6mpXq7GksWjGDnG4dT057UAe85oDA9CDXiWr+KfEXiDxppNhoGoNbwahZxykAZCAj5m/WtXS9T8S+GviGnh/UtT/tO1urd5Y3ZcMCoP5UAesZHrRnjNfP8Hi3V9Wk1N7zxaulanFKy29g8W1XAPHf+ldLq3i7xLHo3h3R/Mgg1fVHKPcIdyhR3HTnigD1vcCeooJA6mvI9eufEvgG+028l159Tsp5limjmjAIye3JqlcXvizxH8TNV0fS9aeytbdA54zsznH8qAPaQwPQ5oyCcA15V4S8Qavo3jXVPD3iLUTdKkHnwSMMZAGT/I1ofDnXdV8T6nrWrXFwf7OWcw20A6YBxuH5UAejUUlLQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABWX4gsJ9U0G+sreZoZpoyqSKeVPrWpSEZoA8b0XxH418K2h0a+8OXWseSdsdzEDgr2zwc0nh3wjrusw+KtW1K0FhJrNs0UNt0ZTg4z+dexOVRCzsoUDktwBRHIkqq6OrKehU5BoA8Ej1HxrZ+CJfCo8L3EsyK0S3QQldmfpzVx9O8Vaf4H8PRw6QbuziBW+094yXYbuP09q9teWKJlWR0Vm4UMwGfpUg6UAeG+H/AA5dXXxGttS0vw1Noel26lpjKpXzMkZAyBx1qH4f+JNS0SDWoYNDur+F7tyksClsPgcHjGOle7FcjqBxiuc8H+E18KWd3AlwZvtFw0+SOmccfpQB5hN8M9Xv/AOoO8IGpXd4b2O2z06DafwFU20mbUdMs9Lsvh/9h1AlUlvZYiUXHBboOtfQGKOtAHkmm+GL/TfilpLfY3+x2+m+U0ypiMMNowPy6VoeIdH1K4+LWmX1rbTfZ1sXjNwqEqjYOMnt1Fel8CjrQB4He2eozQalaeIPBMup6mGP2a9hiOJAemSBz+dWYPAniLTfDGgal9n8++0y4e4NnnnY5Y7R15AOMV7nRQB4/rp1z4iXWm2EehXemQQzLNcTXakbcdhkAHvWn4V0e/tPi14ju57WVbWWJFjmZMK/3uh/GvTCVBXJAOeMnrSlQfwoA8Z+NdhLY3Ol65ppEd85azbaMl1cEdv96vRPA+gQ+HvCVhZxx7XMQkkzwS7DJz+JNYF98NTqni9dYv8AWbme1jmE0dkSNqEDjt0zXoKjAA9KAHUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAc945do/BOsMrMrC2cgqcEcVm/DCRn+HWkO7szGLlmOSeTWl45/wCRI1njP+iv/I1xvw/8ceGdM8C6XZ32s2tvPEm143fkHOaANbx5c6NBrPh+PUheebJcYt/IbC7ufvcj+VQ+IPiWdO1eTTNH0m51WeEAzmEZWP2JJHNc/wCP9X07W9a8I3Wm3MdzAb3bvjORnBqTwJqVnoXjbxXZapMtpcT3PnRLKdu5MnkfmKAOm8O/EjTtch1B3tp7Q6ege5Eo+6ecgc9eK5qf4zzLC99beHL2TS1bH2raACO5xurPtdfsob74hapYwRXUEaLhCNyysA+cjuDWBcPfX/w/ubu48T2tpZvAWj062QKM8/LjP07UAeoat8UNK0nRdK1Nre4lh1LiIRgEg88Hn1FY0HxfaK5ki1PQru1Zk32yEfNPn7uBn0NcLbqlx4U+HyynzU+2MMNz/E1d38RI0b4jeDFK5AlbHH1oA0/CvxKXXdek0e+0y40+82+YiTADK+vU+1VdT+KzLfy22iaJd6mluxWWWIfKCOuOeao6ojN8dUEX3zpbhfY8VyngNZ002+tX8WNoktvO5kgaHOcY5zuHagD0o/E7Sl8HSeIfKnKROI5oMDfGxIGCM+9c/wD8LoEdxbz3GgX0OlTMFS6cYBz+JrjJbfTP+Fb6/Jp1/PfrNqUfnTzRBAzZTOME5Feg+P4IR8HUQRKFW2gKjHT7tAGF408ZXEHxM0EW8V7NZRr5gjhIxcZK9BnnAz1x1rd1b4rNb6tPp2laHd6hLbKGuNmMR+3WuZv7m3s/F3w/uLiVYoUtPmdug+53pdTtdNvvGGrXXhzxFJo2pIw+1QyjbHL7jB5HXtQB6Z4N8X2vjDSmu4YZYHjfy5YpBgq1dKK8u+EXiG81WHUrW6hic2kpU3cKbVlPH5nk16iKAFooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAgurWG9tpLa4jEkMqlXRujD0Nc3/wrfwgeugWZ/wCA/wD16KKALkXg3w9BFbxw6TbIltL5sKheEf1HvXmniO21u08V3T614RPiOxk/49ZLa3dmj9AxGeBx6UUUAbHw08G3lkNYvNW0+O0g1JgFsdvCL83B/A1vwfC7wjb3r3K6TGzNn5G5UfhRRQBsJ4U0NILOFdMgCWbl7dccRse4/M1au9F06/vba8u7SOW4tjmGRhyn0oooAG0bTn1caq1pEb8JsE5HzBfSsTWPh14Z1y7+1Xumo0xOWZeN319aKKANEeFdEGkjS/7NgNkCCISvBIxyfyH5VdvNJsdQ0/7BdWyS2mAvlOOMDpx+FFFAGXrHgvQdctILW+sI2SBQsOOqAdhVPV/hx4Y1qZJ7zTlMqpt3qcEgdj60UUAbmj6Hp2g2Is9OtkghU5wo6nGM1o4oooAWiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA//2Q==" alt="img-3.jpeg"></p>
<p>FIG. 72.1 Anatomy of the eye and pathway for secretion and drainage of aqueous humour in the anterior chamber. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>A</mi><mi>C</mi><mo>=</mo></mrow><annotation encoding="application/x-tex">A C=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal">A</span><span class="mord mathnormal" style="margin-right: 0.07153em;">C</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span></span></span></span></span> Anterior chamber; <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>P</mi><mi>C</mi><mo>=</mo></mrow><annotation encoding="application/x-tex">P C=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.07153em;">PC</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span></span></span></span></span> Posterior chamber; <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>U</mi><mi>S</mi><mi>V</mi><mo>=</mo></mrow><annotation encoding="application/x-tex">U S V=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.10903em;">U</span><span class="mord mathnormal" style="margin-right: 0.05764em;">S</span><span class="mord mathnormal" style="margin-right: 0.22222em;">V</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span></span></span></span></span> Uveoscleral vasculature</p>
<p>The cornea is an almost avascular, transparent structure which acts as an important barrier to foreign matter, including drugs. Drug absorption across the cornea involves penetration through its multiple layers. The sclera is the outermost, dense, imperfectly elastic, opaque, supporting coat of the eyeball; its forward continuation is the cornea.</p>
<p>The conjunctiva is a modified mucous membrane that lines the outer surface of the anteriormost part of the sclera and the inner surface of the eyelids. The conjunctival epithelium is continuous with the corneal epithelium.</p>
<p>The iris, ciliary body and choroid form the uveal tract. The iris is a free, circular diaphragm hanging in front of the lens. The pupillary size is controlled by two types of muscle fibres:
(1) radial, innervated by the sympathetic nerve fibres, causing dilatation of the pupil (mydriasis); and
(2) circular, innervated by the parasympathetic nerve fibres, causing constriction of the pupil (miosis). The ciliary body is made up of unstriated muscle fibres (ciliary muscle) and epithelial cells; the latter secrete aqueous humour into the posterior chamber; that fluid passes through the pupil into the anterior chamber, and from there drains into the canal of</p>
<p>Schlemm. When the ciliary muscle contracts, the zonules which suspend the lens relax, and the lens becomes more convex and is drawn slightly forward. This process is known as accommodation and allows focussing on near objects.</p>
<p>Pharmacokinetics of topically administered ocular drugs: Most drugs in ophthalmic practice are administered topically in the form of eye drops or ointments. The time-course of drug delivery from eye drops into the eyeball follows first order kinetics (Chapter 1). For majority of drugs, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">1 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">1%</span></span></span></span></span> or less of an applied dose is absorbed across the cornea to reach the anterior chamber. Table 72.1 summarises the factors affecting the penetration of ocular drugs. The classical pharmacokinetic theory based on systemic drug administration (Chapter 1) does not apply fully to all ocular drugs.</p>
<p>Table 72.1
Factors influencing penetration of ocular drugs</p>
<ul>
<li>Drug-related: Chemical nature, lipid solubility, dissociation constant and route of administration.</li>
<li>Vehicle-related: Chemical nature, physical state (liquid or solid) and viscocity; and</li>
<li>Formulation-related: Drug concentration, osmolality, tonicity and pH .</li>
<li>Drug-related factors: These are similar to those that govern the classical pharmacokinetics. Topically administered drugs can be absorbed through the cornea, conjunctiva and sclera. Drugs injected subconjunctivally and under the Tenon's capsule as well those injected into the retrobulbar space diffuse through the sclera and the cornea into the anterior and posterior chambers and into the vitreous humour. Systemically administered drugs have to cross the blood-eye barrier, which resembles the blood-brain barrier (Chapter 1), to enter the eye. Hence, drugs with large molecular size such as penicillin, administered systemically, penetrate the normal, uninflamed eye poorly but do so better if the drug is highly lipid-soluble e.g. chloramphenicol or if the eye is severely inflamed. Lipid soluble drugs pass readily through the corneal epithelium and endothelium, whereas the water soluble agents penetrate through the stroma. Therefore, drugs with polar as well non-polar properties penetrate the cornea more freely than the purely polar or purely non-polar compounds.</li>
<li>Vehicle and ocular drug delivery: Most of the ophthalmic drugs are administered in aqueous solution. Since the aqueous solutions are liable to be carried away by the tears, their repeated administration is necessary to maintain their local concentration. Ointment bases act as reservoir for drugs, release them slowly and ensure higher penetration as well as prolonged action. Petrolatum and lanolin are viscous vehicles commonly used as bases in ophthalmic ointments. Other bases used to enhance drug penetration into the eye are a gel-forming base for timolol, and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.5%</span></span></span></span></span> hydroxycellulose for dorzolamide. Polymers are also used to increase the penetration of drugs; these are cellulose-ether, polyvinyl alcohol, carbopol, polyacrylamide, and poloxamer-407. Solid inserts such as pilocarpine ocusert provide a constant rate of release of drugs (zero order kinetics). Liposomes can also serve as drug reservoir and maintain better drug concentration of ocular drugs. Applicaps are yet another form of ophthalmic formulation. Sterility of all commercially available ophthalmic products is essential to prevent ocular infection.</li>
<li>Formulation-related factors: Drug concentration as well as tonicity and pH of the</li>
</ul>
<p>formulation can be adjusted to obtain the desired speed and duration of action of a drug.
After penetration into the eye, the drug may be washed out rapidly from the inflamed eye because of hyperemia. On the other hand, it may accumulate in an ocular tissue e.g. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span> adrenergic receptor agonists bind to and accumulate in the melanin pigment in the iris. This has therapeutic and toxicological implications. Sometimes, the drug may be biotransformed locally into an active compound. Thus dipivefrine is a prodrug for adrenaline, and latanoprost is a prodrug for <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">F</mi></mrow><mrow><mn>2</mn><mi>α</mi></mrow></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGF}_{2 \alpha}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGF</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span><span class="mord mathnormal mtight" style="margin-right: 0.0037em;">α</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> The local toxicity may be due to either the active drug or some other ingredient such as the preservative in the formulation.</p>
<p>Since all ophthalmic medications are liable to be absorbed into the systemic circulation, they can cause systemic toxicity. This is particularly true of drugs reaching the nasal cavity through the nasolacrimal duct; it is more likely to happen with eye drops than with ointments. The final disposal of the ocular drugs may often take place after absorption into systemic circulation.</p>
<p>Systemic administration of drugs: Certain ocular disorders require systemic drug therapy e.g. carbonic anhydrase inhibitors in glaucoma; glucocorticoids in uveitis; and analgesics for ocular pain; antibiotics for deep ocular infections; and antihistaminics for ocular allergy.</p>
<p>General principles of local eye therapy: The selection of the drug(s) depends upon accurate diagnosis, although symptomatic treatment may at times be necessary.</p>
<p>I Nonpharmacological modalities: These include: eye rest; bed rest; proper lighting; protection from strong light, infection and trauma; hot or cold compresses; eye exercises; and nutritional management.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="ii-pharmacological-treatment">II Pharmacological treatment:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ii-pharmacological-treatment" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>
<p>Apart from the diagnosis, choice of the drug depends upon an assessment of the potential/actual threat to vision. Further, the presence of a local condition or a systemic disease that might worsen with the use of a particular drug should be looked for. For example, beta-adrenergic receptor blocker eye drops can aggravate bronchial asthma. Persons with a family history of open angle glaucoma are more likely to develop glaucoma during glucocorticoid therapy. For other problems with topical glucocorticoids, see later.</p>
</li>
<li>
<p>The health-care-giver and the patient should observe hygienic and aseptic practices strictly while applying the medication to the eye.</p>
</li>
<li>
<p>The ophthalmic formulation should be used as purchased and no attempt should be made to dilute it or otherwise modify it.</p>
</li>
<li>
<p>The remnant after the patient gets well should not be stored for future use.</p>
</li>
<li>
<p>Eye drops are convenient for ambulatory patients who are well enough to continue working. Their main disadvantage is their short duration of action and hence the necessity of frequent instillation. Only one drop should be instilled into an eye at one time because that is the capacity of the conjunctival sac. The patient should then lie down with the eye(s) closed. If a drop of another medication needs to be instilled at the same time, then 5 minutes should be allowed to elapse before adding the second drop. Ointments act as reservoir of the drug and have a prolonged action. However, apart from being messy, they may cause blurring of vision.</p>
</li>
<li>
<p>Associated conditions such as diabetes mellitus and hypertension should be treated.</p>
</li>
<li>
<p>Systemic drug therapy may have to be employed in serious ocular conditions and in those which have failed to respond to topical drug therapy.</p>
</li>
<li>
<p>Corneal ulcers and keratitis require specialist treatment.</p>
</li>
</ul>
<p>Classification of drugs used in the eye:
I Antimicrobials: Antibacterials; Antivirals; Antifungals; Antiprotozoals.
II Anti-inflammatory agents such as NSAIDs.
III Glucocorticoids.
IV Antihistaminics and mast cell stabilisers.
V Mydriatics and Miotics.
VI Drugs for glaucoma.
VII Immunomodulatory drugs such as Immunosuppressives, VEGF antibodies and Antimitotic agents.
VIII Local anaesthetics.
IX Diagnostic agents such as Fluorescin and Rose bengal.; and
X Miscellaneous drugs such as tear substitutes and Zinc preparations.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="antimicrobial-agents">Antimicrobial Agents<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#antimicrobial-agents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Eye infections can be caused by bacteria, viruses, fungi and protozoa. Many antimicrobial agents are used topically. Drugs with limited solubility are administered as suspensions, whereas ointments are preferred when prolonged contact with medication is desired. The choice of the appropriate antibiotic depends on clinical diagnosis, the suspected infective agent and its predicted antibiotic sensitivity.</p>
<p>The common eye infections are blepharitis, hordeolum, acute conjunctivitis, infective corneal ulcers, ophthalmia neonatorum, and iridocyclitis. Table 72.2 lists the anti-infective preparations used in eye infections. All fluoroquinolones are active against most Gram negative organisms associated with conjunctivitis. They are, however, not effective against MRSA. Trimethoprim has a broad spectrum of activity including against ocular MRSA. Bacitracin and erythromycin are not effective against Gram-negative organisms.</p>
<p>Table 72.2
Anti-infective drugs used in the eye
Chloramphenicol <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mi mathvariant="normal">%</mi><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">S</mi></mrow><mo separator="true">,</mo><mn>1</mn><mi mathvariant="normal">%</mi><mi mathvariant="normal">O</mi></mrow><annotation encoding="application/x-tex">0.5 \% \mathrm{~S}, 1 \% \mathrm{O}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9444em; vertical-align: -0.1944em;"></span><span class="mord">0.5%</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">S</span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">1%</span><span class="mord mathrm">O</span></span></span></span></span>
Ciprofloxacin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.3</mn><mi mathvariant="normal">%</mi><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">S</mi></mrow></mrow><annotation encoding="application/x-tex">0.3 \% \mathrm{~S}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.3%</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">S</span></span></span></span></span></span>
Norfloxacin/Ofloxacin
Besifloxacin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.6</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.6 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.6%</span></span></span></span></span> S
Gatifloxacin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.3</mn><mi mathvariant="normal">%</mi><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">S</mi></mrow><mo separator="true">,</mo><mi mathvariant="normal">O</mi></mrow><annotation encoding="application/x-tex">0.3 \% \mathrm{~S}, \mathrm{O}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9444em; vertical-align: -0.1944em;"></span><span class="mord">0.3%</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">S</span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord mathrm">O</span></span></span></span></span>
Erythromycin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mi mathvariant="normal">%</mi><mi mathvariant="normal">O</mi></mrow><annotation encoding="application/x-tex">0.5 \% \mathrm{O}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.5%</span><span class="mord mathrm">O</span></span></span></span></span>
Gentamicin/Tobramycin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.3</mn><mi mathvariant="normal">%</mi><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">S</mi></mrow><mo separator="true">,</mo><mi mathvariant="normal">O</mi></mrow><annotation encoding="application/x-tex">0.3 \% \mathrm{~S}, \mathrm{O}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9444em; vertical-align: -0.1944em;"></span><span class="mord">0.3%</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">S</span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord mathrm">O</span></span></span></span></span>
Sulfacetamide <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mi mathvariant="normal">%</mi><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">S</mi></mrow></mrow><annotation encoding="application/x-tex">10 \% \mathrm{~S}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">10%</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">S</span></span></span></span></span></span>
Tetracycline <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">1 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">1%</span></span></span></span></span> S
Combinations:
Bacitracin + Polymyxin B
Trimethoprim + Polymyxin B
Antiviral:
Acyclovir 3% O; 400-800 mg tab oral
Ganciclovir
Foscarnet IV, intravitreal
Idoxuridine <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.1</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.1 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.1%</span></span></span></span></span> S
Vidarabine 3% O
Trifluridine <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">1 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">1%</span></span></span></span></span> S
Antifungal:</p>
<p>Amphoterecin B 0.1-0.5% S; 0.8-1.0 mg subconjunctival; 5 mcg intravitreal
Natamycin 5% S
Fluconazole oral
Ketoconazole oral
Miconazole 5-10 mg subconjuntival
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo><mo>−</mo></mrow><annotation encoding="application/x-tex">--</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">−</span><span class="mord">−</span></span></span></span></span></p>
<div data-testid="stMarkdownPre" class="st-emotion-cache-acwcvw e1icttdg5"><div class="stCode st-emotion-cache-6ml83 e1xss9yb4" data-testid="stCode"><pre class="st-emotion-cache-1nqbjoj e1xss9yb2"><div style="background-color: transparent;"><code style="white-space: pre;"><span>Antibacterial:
</span>    Chloramphenicol 0.5% S, 1% O
    Ciprofloxacin 0.3% S
    Norfloxacin/Ofloxacin
    Besifloxacin 0.6% S
    Gatifloxacin 0.3% S,O
    Erythromycin 0.5% O
    Gentamicin/Tobramycin 0.3% S,O
    Sulfacetamide 10% S
    Tetracycline 1% S
    Combinations:
    Bacitracin + Polymyxin B
    Trimethoprim + Polymyxin B
Antiviral:
    Acyclovir 3% O; 400-800 mg tab oral
    Ganciclovir
    Foscarnet IV, intravitreal
    Idoxuridine 0.1% S
    Vidanibine 3% O
    Trifluridine 1% S
Antifungal:
    Amphoterecin B 0.1-0.5% S; 0.8-1.0 mg
    subconjunctival; 5 mcg intravitreal
    Natamycin 5% S
    Fluconazole oral
    Ketoconazole oral
    Miconazole 5-10 mg subconjuntival</code></div></pre><div class="st-emotion-cache-chk1w8 e1xss9yb3"><button data-testid="stCodeCopyButton" title="Copy to clipboard" data-clipboard-text="Antibacterial:
    Chloramphenicol 0.5% S, 1% O
    Ciprofloxacin 0.3% S
    Norfloxacin/Ofloxacin
    Besifloxacin 0.6% S
    Gatifloxacin 0.3% S,O
    Erythromycin 0.5% O
    Gentamicin/Tobramycin 0.3% S,O
    Sulfacetamide 10% S
    Tetracycline 1% S
    Combinations:
    Bacitracin + Polymyxin B
    Trimethoprim + Polymyxin B
Antiviral:
    Acyclovir 3% O; 400-800 mg tab oral
    Ganciclovir
    Foscarnet IV, intravitreal
    Idoxuridine 0.1% S
    Vidanibine 3% O
    Trifluridine 1% S
Antifungal:
    Amphoterecin B 0.1-0.5% S; 0.8-1.0 mg
    subconjunctival; 5 mcg intravitreal
    Natamycin 5% S
    Fluconazole oral
    Ketoconazole oral
    Miconazole 5-10 mg subconjuntival" style="top: 0px; right: 0px;" class="st-emotion-cache-1lyayqq e1xss9yb5"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><rect x="9" y="9" width="13" height="13" rx="2" ry="2"></rect><path d="M5 15H4a2 2 0 0 1-2-2V4a2 2 0 0 1 2-2h9a2 2 0 0 1 2 2v1"></path></svg></button></div></div></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>S</mi><mo>=</mo></mrow><annotation encoding="application/x-tex">S=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.05764em;">S</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span></span></span></span></span> Solution as eye drops.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>O</mi><mo>=</mo></mrow><annotation encoding="application/x-tex">O=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.02778em;">O</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span></span></span></span></span> Ointment
Antibacterial agents:
Acute blepharitis may be caused by staphylococci or by parasites such as the head lice. Since eye drops do not penetrate well into the eyelids, ointments are the mainstay of treatment, accompanied by removal of the crusts. Staphylococcal infection is best treated with topical erythromycin or sulfacetamide. Recurrent disease may need additional treatment with a topical glucocorticoid. Chronic blepharitis is due to a combination of staphylococcal infection and seborrhea. It requires additional anti-seborrhoeic treatment (Chapter 71). Angular blepharitis is mainly caused by the Gram-ve Moraxaxenfield bacilli. It responds to the topical application of sulfacetamide, gentamicin or zinc sulfate. For allergic blepharitis, see later.</p>
<p>Hordeolum (stye) is staphylococcal infection of sebaceous glands of the eyelids and is usually self limiting. The treatment comprises hot moist compresses, removal of the eyelashes to facilitate the drainage and antibacterial ointments. Repeated styes possibly indicate uncorrected refractive error.</p>
<p>Acute conjunctivitis and bacterial corneal ulcers can be treated with one of the preparations shown in Table 72.2. The bacteria commonly encountered are staphylococci, streptococci, pneumococci and Hemophilus species. Ophthalmia neonatorum, caused by chlamydia, gonococci or other organisms, needs more aggressive treatment. Gonococcal illness needs systemic as well as local therapy (Chapter 53). Chlamydial infection (trachoma) is best treated with topical tetracycline plus oral azithromycin Tetracycline ointment may be applied to the conjunctivae prophylactically in neonates at risk. For herpetic ophthalmia neonatorum see below.</p>
<p>Antiviral agents: The common viral infections of the eye are conjunctivitis, keratitis, iridocyclitis and retinitis. They are due to herpes simplex virus, herpes zoster virus and cytomegalovirus. Table 72.2 lists the antiviral preparations commonly used in the eye.</p>
<p>Viral keratitis is either (a) epithelial which responds to topical treatment with antiviral dugs; or (b) stromal and requires administration of the same drugs orally. Herpes zoster ophthalmicus is more serious and needs systemic acyclovir in addition to local antiviral therapy. Viral retinitis requires prolonged treatment with antiviral drugs, by either intravitreal or IV route.</p>
<p>Antifungal agents: Fungal infections of the eye are rare. The important ones are keratitis, scleritis, endophthalmitis and canaliculitis. They are best left to the specialists. The antifungal agents commonly used in ocular fungal infections are shown in Table 72.2.</p>
<p>Antiprotozoal agents: The protozoa causing eye infections are Toxoplasma gondii and Acanthamoeba. Ocular toxoplasmosis is the ocular manifestation of a systemic infection (Chapter 58). Acanthamoeba causes deep eye infections which occur more commonly in contact lens users. They require a combination of topical and systemic multi-drug therapy.</p>
<p>Onchocerciasis caused by Onchocerca volvulus is one of the major causes of blindness. Its treatment is described in Chapter 60.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="anti-inflammatory-drugs">Anti-inflammatory Drugs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#anti-inflammatory-drugs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The drugs belonging to this group are the NSAIDs such as diclofenac ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.1</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.1 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.1%</span></span></span></span></span> eye drops), flurbiprofen ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.03</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.03 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.03%</span></span></span></span></span> eye drops) and ketorolac ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.5%</span></span></span></span></span> eye drops). They are commonly used topically during and following ocular surgery such as cataract extraction, for prevention of intraoperative miosis and postoperative inflammation (Chapter 11).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="glucocorticoids-in-the-eye">Glucocorticoids in the Eye<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#glucocorticoids-in-the-eye" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Topical glucocorticoids (Table 72.3) are used for treating anterior uveitis and for reducing postoperative inflammation following eye operations. Posterior uveitis needs to be treated with oral or parenteral glucocorticoids or with sub-Tenon's-capsular injections of a glucocorticoid. Optic neuritis is treated with parenteral administration, followed by tapering oral doses of glucocorticoids.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="table-72-3">Table 72.3<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-72-3" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Glucocorticoid ocular preparations</p>
<ul>
<li>Betamethasone <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.1</mn><mi mathvariant="normal">%</mi><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">S</mi></mrow><mo separator="true">,</mo><mi mathvariant="normal">O</mi></mrow><annotation encoding="application/x-tex">0.1 \% \mathrm{~S}, \mathrm{O}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9444em; vertical-align: -0.1944em;"></span><span class="mord">0.1%</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">S</span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord mathrm">O</span></span></span></span></span></li>
<li>Dexamethasone <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.1</mn><mi mathvariant="normal">%</mi><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">S</mi></mrow><mo separator="true">,</mo><mi mathvariant="normal">O</mi></mrow><annotation encoding="application/x-tex">0.1 \% \mathrm{~S}, \mathrm{O}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9444em; vertical-align: -0.1944em;"></span><span class="mord">0.1%</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">S</span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord mathrm">O</span></span></span></span></span></li>
<li>Hydrocortisone <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">%</mi><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">S</mi></mrow><mo separator="true">,</mo><mn>0.5</mn><mi mathvariant="normal">%</mi><mi mathvariant="normal">O</mi></mrow><annotation encoding="application/x-tex">1 \% \mathrm{~S}, 0.5 \% \mathrm{O}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9444em; vertical-align: -0.1944em;"></span><span class="mord">1%</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">S</span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">0.5%</span><span class="mord mathrm">O</span></span></span></span></span></li>
<li>Prednisolone <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">%</mi><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">S</mi></mrow></mrow><annotation encoding="application/x-tex">1 \% \mathrm{~S}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">1%</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">S</span></span></span></span></span></span></li>
</ul>
<p>S = Solution as eye drops.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">O</mi><mo>=</mo></mrow><annotation encoding="application/x-tex">\mathrm{O}=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathrm">O</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span></span></span></span></span> Ointment
The main ocular adverse effects of glucocorticoids are posterior subcapsular cataract (steroid cataract), open angle glaucoma (steroid glaucoma) and secondary infection. Undiagnosed Red Eye may be due to Herpes simplex infection and glucocorticoids may aggravate the condition, leading to corneal ulceration and loss vision. Routine use of a combination of a glucocorticoid with an anti-infective agent is not justified.</p>
<p>Topical glucocorticoids are contraindicated in herpetic epithelial keratitis due to active viral replication, fungal disease of the eye, other viral diseases of the cornea and conjunctiva, ocular tuberculosis, hypersensitivity, and after removal of a superficial corneal foreign body.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="antihistaminics-and-mast-cell-stabilisers">Antihistaminics and Mast Cell Stabilisers<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#antihistaminics-and-mast-cell-stabilisers" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Allergic conjunctivitis can be treated with topical antihistaminics such as antazoline <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.05</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.05 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.05%</span></span></span></span></span>, emedastine <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.05</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.05 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.05%</span></span></span></span></span> and levocabastine <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.05</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.05 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.05%</span></span></span></span></span>.</p>
<p>Mast cell stabilisers such as cromolyn sodium <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">4 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">4%</span></span></span></span></span>, ketotifen <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.025</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.025 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.025%</span></span></span></span></span>, nedocromil <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">2 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">2%</span></span></span></span></span> and epinastin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.05</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.05 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.05%</span></span></span></span></span> can also be used to treat allergic and vernal conjunctivitis.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="mydriatics-and-miotics">Mydriatics and Miotics<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#mydriatics-and-miotics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Mydriatics: These drugs produce pupillary dilatation. They are of two types:</p>
<ul>
<li>Muscarinic receptor antagonists, atropine and atropine substitutes, which also cause paralysis of the iris and ciliary body and lead to cycloplegia (paralysis of accommodation) by blocking the muscarinic receptors.
The main drawback of atropine is its long duration of action so that the cycloplegia lasts for 7-10 days. Atropine substitutes which have a shorter duration of action and produce minimal cycloplegia are preferred.</li>
<li><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span>-Adrenergic receptor agonists (sympathomimetic agents) which directly stimulate the adrenergic receptors in the radial muscle fibres of the iris, and do not lead to cycloplegia.
Mydriasis is required for:
(1) Determination of refractive error.
(2) Fundoscopic examination of the eyes.
(3) Treatment of iridocyclitis, an inflammation of the iris and the ciliary body in which there is severe pain due to spasm of these muscles; atropine paralyses these muscles and relieves the pain; and
(4) Breaking the adhesions between the lens and the ciliary body, by alternating mydriatics with miotics.</li>
</ul>
<p>Miotics: These drugs produce constriction of the pupils by acting as:</p>
<ul>
<li>Muscarinic receptor agonists (pilocarpine), or</li>
<li>Anticholinesterases (physostigmine)</li>
</ul>
<p>They act on the circular fibres of the iris. They also constrict the ciliary muscle, thus improving trabecular pathway. They are used in the treatment of glaucoma (see below). Their ADR include headache, browache, vascular congestion, conjunctival congestion, burning and blurred vision. Prolonged use may cause myopia and vitreous hemorrhage.</p>
<p>Miotics are contraindicated in acute iritis and acute uveitis. They should be avoided in acute inflammatory diseases of the anterior segment.</p>
<p>Table 72.4 lists the mydriatics and miotics in common use (Chapters 19, 20).</p>
<p>Table 72.4
Mydriatics and miotics</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="antimuscarinic">Antimuscarinic<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#antimuscarinic" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Atropine <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mo>−</mo><mn>2</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.5-2 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">2%</span></span></span></span></span> drops
Homatropine 2-5% drops
Eucatropine 2-5% drops
Cyclopentolate <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mo>−</mo><mn>2</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.5-2 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">2%</span></span></span></span></span> drops
Tropicamide <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mo>−</mo><mn>2</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.5-2 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">2%</span></span></span></span></span> drops
Sympathomimetic
Phenylephrine <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.12</mn><mo>−</mo><mn>10</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.12-10 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.12</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">10%</span></span></span></span></span> drops
Miotics
Cholinomimetic
Pilocarpine <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.5%</span></span></span></span></span> drops;ocusert
Cholinesterase inhibitors
Physostigmine 1% drops
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo><mo>−</mo><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">--&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">−</span><span class="mord">−</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">&gt;</span></span></span></span></span></p>
<table><thead><tr><th style="text-align: left;">Mydriatics</th></tr></thead><tbody><tr><td style="text-align: left;">Antimuscarinic</td></tr><tr><td style="text-align: left;">Atropine <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mo>−</mo><mn>2</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.5-2 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">2%</span></span></span></span></span> drops</td></tr><tr><td style="text-align: left;">Homatropine <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mo>−</mo><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">2-5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span> drops</td></tr><tr><td style="text-align: left;">Eucatropine <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mo>−</mo><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">2-5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span> drops</td></tr><tr><td style="text-align: left;">Cyclopentolate <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mo>−</mo><mn>2</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.5-2 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">2%</span></span></span></span></span> drops</td></tr><tr><td style="text-align: left;">Tropicamide <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mo>−</mo><mn>2</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.5-2 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">2%</span></span></span></span></span> drops</td></tr><tr><td style="text-align: left;">Sympathomimetic</td></tr><tr><td style="text-align: left;">Phenylephrine <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.12</mn><mo>−</mo><mn>10</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.12-10 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.12</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">10%</span></span></span></span></span> drops</td></tr><tr><td style="text-align: left;">Miotics</td></tr><tr><td style="text-align: left;">Cholinomimetic</td></tr><tr><td style="text-align: left;">Pilocarpine <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.5%</span></span></span></span></span> drops;ocusert</td></tr><tr><td style="text-align: left;">Cholinesterase inhibitors</td></tr><tr><td style="text-align: left;">Physostigmine <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">1 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">1%</span></span></span></span></span> drops</td></tr></tbody></table>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drug-therapy-of-glaucoma">Drug Therapy of Glaucoma<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-therapy-of-glaucoma" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Glaucoma, the second most frequent cause of blindness in the world, is a disease of unknown origin. It is characterised by
(1) Progressive degeneration of retinal ganglion cells and optic nerve fibers, and
(2) Is usually accompanied by, but not always, increased intraocular pressure (IOP).</p>
<p>If untreated, it leads to optic neuropathy with loss of optic nerve tissue and excavation or 'cupping' of the ophthalmoscopically visible optic nerve head. This may be accompanied by loss of vision. Most forms of glaucoma are painless initially and the loss of vision is insidious. If diagnosed and treated early, most patients retain good vision. Reduction in IOP may protect against damage to the optic nerve head.</p>
<p>Glaucoma is classified into: (a) open angle, (b) closed angle, (c) congenital, and (d) drug induced. The condition may be either primary or secondary. The etiology of primary glaucoma is not known. The common causes of secondary glaucoma include inflammation, neovascularisation, pigment dispersion syndrome and drugs.</p>
<p>Fig. 72.1 shows the pathways for secretion and drainage of aqueous humour in the anterior chamber of the eye.</p>
<p>Drugs used in the treatment of glaucoma are classified in Table 72.5. Before starting the treatment, drugs as a cause of increased IOP should be ruled out.</p>
<p>Table 72.5
Drugs used in glaucoma
*Pilocarpine drops <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.25</mn><mo>−</mo><mn>4.0</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.25-4.0 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.25</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">4.0%</span></span></span></span></span>
Pilocarpine ocusert</p>
<ul>
<li>Cholinesterase inhibitors (Miotics)*</li>
</ul>
<ul>
<li>Physostigmine <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.25</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.25 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.25%</span></span></span></span></span> ointment
Demecarium <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.125</mn><mo>−</mo><mn>0.25</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.125-0.25 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.125</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.25%</span></span></span></span></span> drops.
Echothiophate <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.03</mn><mo>−</mo><mn>0.25</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.03-0.25 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.03</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.25%</span></span></span></span></span> drops</li>
</ul>
<ul>
<li>Prostaglandin analogues</li>
</ul>
<p>Latanoprost <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.005</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.005 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.005%</span></span></span></span></span> drops
Bimatoprost <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.01</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.01 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.01%</span></span></span></span></span>
Unoprostone <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.15</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.15 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.15%</span></span></span></span></span>
Travoprost <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.004</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.004 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.004%</span></span></span></span></span>
Tafluprost <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.0015</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.0015 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.0015%</span></span></span></span></span>
II Those which decrease the production of aqueous humor by the ciliary body</p>
<ul>
<li>Non selective beta adrenergic blockers:</li>
</ul>
<p>Timolol <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.25</mn><mo>−</mo><mn>0.5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.25-0.5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.25</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.5%</span></span></span></span></span> drops</p>
<ul>
<li>Selective beta1 adrenergic blocking agents</li>
</ul>
<p>Betaxolol 0.5% drops
Carteolol 1%
Levobunolol 0.5%
Metipranolol 0.3%</p>
<ul>
<li>Non selective adrenergic agonists</li>
</ul>
<p>Adrenaline hydrochloride <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.1</mn><mo>−</mo><mn>2.0</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.1-2.0 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.1</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">2.0%</span></span></span></span></span> drops</p>
<ul>
<li>Selective alpha2 adrenergic agonists</li>
</ul>
<p>Apraclonidine 0.5-1% drops
Brimonidine <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.2</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.2 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.2%</span></span></span></span></span> drops</p>
<ul>
<li>Carbonic anhydrase inhibitors
(a) Topical: Brinzolamide 1% suspension Dorzolamide 2% (b)</li>
</ul>
<p>Systemic: Acetazolamide (Diamox) 250 mg qid; Methazolamide 25 mg bid.</p>
<ul>
<li>Combinations of above agents</li>
</ul>
<p>Brinzolamide + Brimonidine
Timolol + Brimonidine
Timolol +Dorzolamide</p>
<p><img src="data:image/jpeg;base64,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" alt="img-4.jpeg"></p>
<p>All eyedrops except PG analogues are generally used twice daily; PG analogues are used once daily in the evening.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>=</mo></mrow><annotation encoding="application/x-tex">=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.3669em;"></span><span class="mrel">=</span></span></span></span></span> For details, see Chaper 19
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>=</mo></mrow><annotation encoding="application/x-tex">=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.3669em;"></span><span class="mrel">=</span></span></span></span></span> Now used rarely</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="elevated-iop-may-be-reduced-by">Elevated IOP may be reduced by:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#elevated-iop-may-be-reduced-by" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Increasing the outflow of aqueous humor through:
(1) The trabecular meshwork (cholinergic agonists and cholinesterase inhibitors),
(2) The uveoscleral pathway (PG analogues) or
(3) a surgically created pathway; and/or</li>
<li>Decreasing the production of aqueous humor by the ciliary body (Table 72.5).</li>
</ul>
<p>In acute (narrow angle) congestive glaucoma, the iris probably blocks the entrance to the trabecular space at the canal of Schlemm. This blockade causes a precipitous increase in IOP and severe pain, headache, nausea and often loss of vision due to optic atrophy. The reversible anti-cholinesterases are invaluable for reducing the increased IOP. The contraction of sphincter of iris induced by the anticholinesterases removes the iris blockade and facilitates the drainage of the intraocular fluid. Acute congestive glaucoma is a medical emergency and a combination of pilocarpine nitrate ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">4 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">4%</span></span></span></span></span> ), timolol and apraclonidine is the preferred treatment. Adjuvants such as acetazolamide (a carbonic anhydrase inhibitor) are also employed (Chapter 39). In an emergency, 20% mannitol (maximum 500 ml ) may be infused IV to lower the IOP. Once the acute attack is controlled, definitive surgery is advised. Even after surgery, continuation of drug therapy may be required.</p>
<p>Chronic open angle glaucoma has an insidious onset and needs lifelong drug therapy.</p>
<p>The cause of raised IOP is not known. Because the decline in vision is gradual, the diagnosis is often delayed. The mechanism of reduction of tension in this condition by drugs is not definitely understood; there is no physical obstruction.</p>
<p>The major goals of therapy are:
(1) To maintain an IOP below which further optic nerve damage is unlikely to occur (target IOP);
(2) To reset the IOP to a lower level if deterioration occurs;
(3) To minimise the local and systemic side effects of the drugs, and to improve the quality of life;
(4) To educate the patient about his/ her disease and emphasise the importance of compliance.</p>
<p>In general, the initial aim is to achieve a 20-50% reduction in the IOP at diagnosis, with the least amount of medication. The PG analogues eg. latanoprost are usually the drugs of choice to start with because of their once-a-day dosage, fewer systemic effects and good therapeutic efficacy. However, they are very expensive. Alternatively, a beta adrenergic blocker timolol may be used. The <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>α</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\alpha_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5806em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0037em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> adrenergic agonists appear to be less effective than the above two. Brimonidine should be avoided in children for fear of respiratory arrest.</p>
<p>Topical carbonic anhydrase inhibitor preparations, dorzolamide and brinzolamide, cause less systemic toxicity and are preferred to oral acetazolamide. The latter is used in resistant cases in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.25</mn><mo>−</mo><mn>1.0</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">0.25-1.0 \mathrm{~g}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.25</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">1.0</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span></span></span></span></span> daily, in 3-4 divided doses.</p>
<p>Reversible anticholinesterases give fairly satisfactory results in glaucoma following cataract surgery. They are avoided in patients with cataract because they may impair vision further; the long acting miotics may exacerbate cataract and increase the risk of complications (retinal detachment) during and after cataract surgery. Sufficient transconjunctival absorption of anti-ChE drugs can occur following their repeated instillation and can cause systemic adverse effects. Absorption can be minimised by digital compression of the inner canthus of the eye during and after instillation.</p>
<p>Pilocarpine is now less often used because of its short duration of action and ADR.
Beta adrenergic blockers may cause cardiovascular and respiratory adverse effects. PG agonists may cause increase in growth of eyelashes, irreversible darkening of the iris and rarely macular edema.</p>
<p>Finally, it is important to remember that lowering of IOP may not necessarily halt the progression of the disease and damage to the optic nerve in all cases of glaucoma.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="immunosuppressives-and-antimitotic-drugs">Immunosuppressives and Antimitotic Drugs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#immunosuppressives-and-antimitotic-drugs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Fluorouracil and mitomicin-C are used in ophthalmic practice (a) to limit scarring after certain types of surgical procedures; and (b) in certain systemic diseases such as Wegner's granulomatosis and Behcet's disease with life threatening ocular manifestations.</p>
<p>The mediator of neovascularisation in wet Age related Macular Degeneration (AMD) is believed to be Vascular Endothelial Growoth Factor (VEGF). It causes angiogenesis and increased vascular permeability. VEGF inhibitors act by binding to VEGF receptors. Ther are:</p>
<p>Bevacizumab: This humanised mAb, an angiogenesis inhibitor (Chapter 61), is reported to prevent further loss of vision in AMD and diabetic macular edema. It is administered intravitreally, once a month for three months initially, and then as required.</p>
<p>Ranibizumab: This derivative of bevacizumab, specially tailored for intraocular use, is also an angiogenesis inhibitor. It does the same thing as the parent drug in AMD, but at a very high cost.</p>
<p>Pegatenib, a selective VEGF antagonist and Verteporfin, an inhibitor of choroidal neovascularisation are the recently approved drugs for AMD.</p>
<p>Aflibercept: This is a fusion protein. It is claimed to be as effective as ranibizumab.
All these agents are administred intravitreally. They can cause pain, conjunctival hemorrhage and endophthalmitis.</p>
<p>Vitreomacular adhesion, a progressive ageing disorder, causes vitreomacular traction, retinal distortion and macular edema. It can now be managed non-surgically with intravitreal injection of ocriplasmin, a recombinant selective proteolytic enzyme, which cleaves extracellular matrix proteins resulting in their dissolution</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="local-anaesthetics">Local Anaesthetics<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#local-anaesthetics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>These agents are used topically to anaesthetise the ocular surface:
(a) To remove foreign bodies from the cornea and conjunctiva.
(b) Prior to tonometry.
(c) For pre-operative preparation. Usually, proparcaine and tetracaine are used.
(d) In the manipulation of the nasolacrimal system (tetracaine or lignocaine)
(e) During the use of Eximer laser for surgery for refractive errors (tetracaine), and
(f) For infiltration and retrobulbar block anaesthesia (lignocaine and bupivacaine; Chapter 16).</p>
<p>Local anaesthetics should never be used for management of ocular pain.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="diagnostic-agents">Diagnostic Agents<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#diagnostic-agents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The dyes fluorescein and rose Bengal are the most commonly used diagnostic agents for anterior and external lesions of the eye. Both are available as <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">2 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">2%</span></span></span></span></span> alkaline solutions and as impregnated paper strips.</p>
<p>Fluorescein is preferred for detecting epithelial defects (due to foreign body) in the cornea and the conjunctiva, and leakage of aqueous humor that may occur after trauma or surgery. It is also used to test the patency of the nasolacrymal system.</p>
<p>Rose Bengal stains devitalised tissue of the cornea and the conjunctiva, and helps to detect tears in those structures.</p>
<p>In the posterior segment of the eye, fluorescein and indocyanine green are used for retinal angiography. They may cause nausea and may precipitate allergic reactions.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="miscellaneous-agents">Miscellaneous Agents<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#miscellaneous-agents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Wetting agents and tear substitutes: Many systemic and local diseases damage/disrupt the precorneal tear film, leading to 'dry eyes'. The discomfort may be relieved symptomatically by using either (a) artificial tears which are aqueous, hypotonic or isotonic solutions containing sodium chloride and hydroxymethyl cellulose; or (b) ophthalmic lubricants which are complex, viscous formulations, including ointments. Appropriate treatment of any systemic, causative disease is important.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drug-induced-ocular-toxicity">Drug Induced Ocular Toxicity<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-induced-ocular-toxicity" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Some drugs used in therapeutics (Table 72.6) can cause ocular toxicity</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="table-72-6">Table 72.6<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-72-6" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Some drugs causing ocular toxicity</p>
<table><thead><tr><th style="text-align: left;">Drug</th><th style="text-align: left;">Ocular toxicity</th></tr></thead><tbody><tr><td style="text-align: left;">Ethambutol</td><td style="text-align: left;">Optic neuritis</td></tr><tr><td style="text-align: left;">Chloroquine</td><td style="text-align: left;">Retinopathy</td></tr><tr><td style="text-align: left;">Chlorpromazine</td><td style="text-align: left;">Retinal pigmentation</td></tr><tr><td style="text-align: left;">Chloramphenicol</td><td style="text-align: left;">Retinal pigmentation</td></tr><tr><td style="text-align: left;">Aminoglycosides</td><td style="text-align: left;">Optic neuritis</td></tr><tr><td style="text-align: left;">Sildenafil</td><td style="text-align: left;">Blue vision</td></tr><tr><td style="text-align: left;">Antimuscarinics</td><td style="text-align: left;">Glaucoma</td></tr><tr><td style="text-align: left;">Vigabatrine</td><td style="text-align: left;">Visual field constriction</td></tr><tr><td style="text-align: left;">Tamoxifen</td><td style="text-align: left;">Visual field constriction; cataract</td></tr><tr><td style="text-align: left;">Digoxin</td><td style="text-align: left;">Scotoma</td></tr><tr><td style="text-align: left;">Alendronate</td><td style="text-align: left;">Conjunctivitis; iritis</td></tr></tbody></table>
<p>It must be remembered that the three major causes of blindness in developing countries are: vitamin A deficiency; trachoma and onchocerciasis, all of which are preventable. They are discussed elsewhere.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="section-xv-immunopharmacology">SECTION XV Immunopharmacology<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#section-xv-immunopharmacology" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="outline">OUTLINE<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#outline" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Chapter 73: General Considerations: Vaccines and Antisera
Chapter 74: Immunoglobulins, Monoclonal antibodies, Immunosuppressants and Immunomodulators</p>
<p>73</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="general-considerations-vaccines-and-antisera">General Considerations: Vaccines and Antisera<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#general-considerations-vaccines-and-antisera" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The 'fight or flight' response by an animal to external danger preserves its integrity at the macro level but its safety from bodily invasion (external, by microbes; or internal, by errant native cells) at the micro level and survival depends upon the immune system. This is a complex system with genetic, cellular and molecular arms, which decide the immune response, commonly inflammation. Such responses are usually beneficial as they protect the body, but occasionally they can be detrimental to the host e.g. allergy (Chapter 2). Its original scope, focusing mainly on preventive inoculation, has now expanded to other areas such as diagnostics, allergy, autoimmunity, organ transplantation and therapeutics including that of cancer.</p>
<p>Antigens may be classified as 'self' and 'non-self or foreign'; antigens in 'dysregulated' tissues (tumours) can also be regarded as foreign. Immunity may be defined as the ability of an animal's body to react to a foreign antigen and eliminate it, in the interest of safety of the animal.</p>
<p>The immune system consists of two divisions:</p>
<ul>
<li>The innate immune system primitive immune recognition system; and</li>
<li>The adaptive immune system, recently evolved system of immune responses.</li>
</ul>
<p>Cells of the innate immune system include natural killer (NK) cells, macrophages, dendritic cells, neutrophils, basophils, eosinophils, tissue mast cells and epithelial cells. They recognise and destroy foreign antigens and pathogens without prior exposure. The recognition of pathogen molecules by the cells leads to activation of the complement cascade, and production of cytokines, and antimicrobial peptides as effector molecules. It has low affinity</p>
<p>In contrast, the adaptive immune system is characterised by antigen-specific responses to a foreign antigen or pathogen Unlike innate (immediate) immunity, it generally takes several days to develop. An important feature of this system is immunological memory for the antigen so that a subsequent exposure to the same antigen causes a rapid and vigorous immune response. It has high affinity.</p>
<p>The adaptive immune system consists of dual limbs of cellular and humoral immunity (Fig. 73.1). The main effectors of this immunity are lymphocytes which get activated after they recognise a specific antigenic determinant (epitope). These lymphocytes are of two types:</p>
<p><img src="data:image/jpeg;base64,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" alt="img-5.jpeg"></p>
<p>FIG. 73.1 Innate immunity and processing of bone marrow cells by thymus and gut associated central lymphoid tissue to become immunocompetent T- and B-lymphocytes respectively. Proliferation and transformation to cells of the lymphoblast and plasma cell series occurs on antigenic stimulation. (Modified from Essential Immunology by Ivan Roitt. Courtesy of Blackwell Scientific Publications and author).
(1) T lymphocytes, with several subtypes and,
(2) B lymphocytes.</p>
<p>T lymphocytes (thymus-derived) are so called because of their origin from lymphocytes which, after they arise in the bone marrow, are processed in the thymus. B lymphocytes are so called because of their relation to the Bursa of Fabricius, a lymphoid organ similar to thymus, present in chicken.</p>
<p>When a foreign antigen enters the body, the following responses may occur (Fig. 73.1):</p>
<ul>
<li>It may be recognised as foreign by the innate immune system and be destroyed.</li>
<li>The antigen may be taken up by macrophages as well as dendritic cells and presented to a T cell, which can recognise an epitope on the antigen. The T cell then proliferates into a cluster of T cells identical with the parent T cell (clone of T cells). These clones may be of several types: cytotoxic (directly destructive of the antigen as well of tissue cells), helper (which enhance immune response) and suppressor (which inhibit immune response). Each clone has the capacity to recognise and respond to only the parent epitope which led to its generation. The activated T cells secrete a variety of cytokines (Chapter 25) which regulate the inflammatory response as well as T cell function. Further, the cytokines make the activation of B lymphocytes (see below) by antigens more effective.
The various subtypes of T lymphocytes (cytotoxic, helper and suppressor) and their responses collectively constitute Cell Mediated Immunity (CMI). Further, as mentioned above the T cells regulate Humoral Immunity, primarily a B lymphocyte function, though they themselves do not secrete antibodies.</li>
</ul>
<p>T cells are often classified according to the antigens which they carry on their surface. Those bearing CD4 antigen (Cluster Differentiation Molecules) are mainly responsible for the helper function and the delayed-type hypersensitivity. Those carrying CD8 antigen are</p>
<p>responsible for the cytotoxic and suppressor functions. CD4 bearing T lymphocytes are further subdivided into Th1 and Th2 subtypes. Thl cells enhance CMI but inhibit humoral immunity; Th2 cells have the opposite effect. It has been found that CMI and humoral immunity are mutually exclusive in some situations. For example, during pregnancy CMI is inhibited whereas humoral immunity is enhanced. This is beneficial to the continuation of pregnancy as CMI against the foreign antigens of the fetus might otherwise damage it. Likewise, CMI mediated diseases such as rheumatoid arthritis undergo remission during pregnancy. In contrast, infections such as leprosy which are primarily fought by the body through CMI undergo aggravation during pregnancy.</p>
<ul>
<li>The antigen may be recognised by a specific receptor on the surface of a B lymphocyte: The B lymphocytes are concerned with the synthesis of circulating antibodies and hence with the humoral immunity. On interacting with a foreign antigen, the B lymphocyte is activated to proliferate into a clone of B lymphocytes, which finally differentiate into plasma cells. The plasma cell clone secretes an antibody which recognises and interacts only with the parent epitope which led to its synthesis. Thus, the blood simultaneously contains antibodies of a variety of specificities, made by a variety of plasma cell clones (polyclonal antibodies).
Antibodies are molecules (encoded by genes), produced in response to the presence of foreign substances (antigens or immunogens; antigens which stimulate IgE production are called allergens). The antibodies exist on B lymphocyte surface as antigen-recognition molecules or as secreted molecules in the plasma and body secretions. They are globulins, designated as immunoglobulins or Ig. Five major groups have been defined in man. They are IgG, IgA, IgM, IgD and IgE. IgG is the main immunoglobulin class (Table 73.1). Apart from their role in body's defence mechanism, certain antibodies (IgE) also have other properties such as fixing to basophils and mast cells (Homocytotropic or Reaginic antibodies), which can cause unpleasant and dangerous ADR.</li>
</ul>
<p>Table 73.1
Biological properties of major immunoglobulin classes</p>
<table><thead><tr><th style="text-align: center;">Property</th><th style="text-align: center;">IgG</th><th style="text-align: center;">IgA</th><th style="text-align: center;">IgM</th><th style="text-align: center;">IgD</th><th style="text-align: center;">IgE</th></tr></thead><tbody><tr><td style="text-align: center;">Molecular weight</td><td style="text-align: center;">150,000</td><td style="text-align: center;">160,000</td><td style="text-align: center;">900,000</td><td style="text-align: center;">185,000</td><td style="text-align: center;">200,000</td></tr><tr><td style="text-align: center;">Serum concentration ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">\mathrm{mg} \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9444em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">%</span></span></span></span></span> )</td><td style="text-align: center;">1,250</td><td style="text-align: center;">280</td><td style="text-align: center;">120</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.3</mn><mo>−</mo><mn>30</mn></mrow><annotation encoding="application/x-tex">0.3-30</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.3</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">30</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.002</mn><mo>−</mo><mn>0.2</mn></mrow><annotation encoding="application/x-tex">0.002-0.2</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.002</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">0.2</span></span></span></span></span></td></tr><tr><td style="text-align: center;">Plasma half life (days)</td><td style="text-align: center;">23</td><td style="text-align: center;">6</td><td style="text-align: center;">5</td><td style="text-align: center;">3</td><td style="text-align: center;">3</td></tr><tr><td style="text-align: center;">Found in</td><td style="text-align: center;">Internal body fluids</td><td style="text-align: center;">Seromucosal secretions, colostrum, saliva, tears, GI tract</td><td style="text-align: center;">Serum</td><td style="text-align: center;">On lymphocyte surface</td><td style="text-align: center;">On the surface of mast cells and basophils</td></tr><tr><td style="text-align: center;">Physiological role</td><td style="text-align: center;">Main Ab against infection; immunity against microbes in tissues and extravascular spaces</td><td style="text-align: center;">Mucosal immunity</td><td style="text-align: center;">Main intravascular Ab , important role in immunity in circulation</td><td style="text-align: center;">Role in B cell maturation</td><td style="text-align: center;">Immunity against helminthic infection</td></tr><tr><td style="text-align: center;">Injurious</td><td style="text-align: center;">Arthus reaction, serum sickness</td><td style="text-align: center;">Impaired mucosal immunity Autoimmune disorders</td><td style="text-align: center;">Arthus reaction, serum sickness</td><td style="text-align: center;">Anti D antibodies in Rhesus incompatibility</td><td style="text-align: center;">Local and systemic anaphylatic reaction</td></tr></tbody></table>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">A</mi><mi mathvariant="normal">b</mi></mrow><mo>=</mo></mrow><annotation encoding="application/x-tex">\mathrm{Ab}=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord"><span class="mord mathrm">Ab</span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span></span></span></span></span> Antibody. IgG alone crosses the placenta</p>
<p>The two important features of the immunological responses are:</p>
<ul>
<li>Specificity that is the ability to recognise and respond to a particular antigen; and</li>
<li>Memory that is the ability to recognise and respond more vigorously to an antigen encountered for the second or subsequent time.
The immune cells learn at an early stage in fetal life how to discriminate between self and foreign antigens, and do not attack the former. Serious consequences may follow if that ability is impaired or lost at any time in life so that the immune cells attack and damage the animal's own tissues (autoimmune disease); however it is actively and beneficially suppressed during pregnancy.</li>
</ul>
<p>Clinically, when a foreign agent invades the body, it reacts with immune system in the form of inflammation. The inflammatory response is characterised by pain, swelling, redness and warmth at the site of tissue damage/infection. It is accompanied by the recruitment of various cells, and release of cytokine and mediators of inflammation (Chapter 25), resulting in fever, bodyache, malaise and loss of appetite. Usually such immune responses act as body defense, and rapidly counter the causative agent, preventing the tissue damage and promoting repair. Occasionally however, the immune response is abnormal, not beneficial, giving rise to phenomena such as allergy, autoimmune disease or graft rejection. In case of infection, it can become chronic.</p>
<p>In practice immunological agents are used to induce/bolster immunity. It is subdivided into:
I Active immunity; and
II Passive immunity.
Active immunity: This type of immunity is due to the development of antibodies by the individual himself. It can be natural and species specific e.g. the relative immunity of horses, dogs and rats to tuberculosis, or it can be acquired by introduction of an antigen.</p>
<p>Passive immunity: Immunity acquired by the transfer of antibodies from a donor to a recipient, is called passive immunity. It can be acquired naturally e.g., by a foetus receiving maternal antibodies across the placenta, or artificially by the administration of antisera containing immunoglobulin (Ig) antibodies.</p>
<p>The various preparations employed for conferring immunity are:</p>
<ul>
<li>Vaccines: Vaccines are suspensions of dead microorganisms (inactivated vaccines) or attenuated but live microorganisms (live attenuated vaccines) which stimulate the immune system of the recipient, resulting in the development of either CMI e.g. BCG vaccine or humoral immunity from protective antibodies e.g. typhoid vaccine. Vaccines are employed prophylactically and are of no value if administered during the incubation period or in the active stage of a disease. In general, live, attenuated vaccines are antigenically superior to the inactivated vaccines and generally achieve almost lifelong immunity. Inactivated vaccines require a 'primary course' of doses, followed by booster doses. Viral vaccines are either live or inactivated. BCG and Typhoid oral vaccine are the only live bacterial vaccines; all other bacterial vaccines are either inactivated or toxoids. The antibody response occurs after 7-10 days. Initially, antibodies are usually of IgM type, followed later by IgG antibodies, which are produced in high concentrations, and are mainly responsible for resistance to infection.
Generally, vaccines (particularly those containing live organisms) are not administered in the presence of a severe acute illness, in patients with debilitating diseases or</li>
</ul>
<p>agammaglobulinemia and those receiving immuno-suppressive agents or radiotherapy.</p>
<ul>
<li>Toxoids: Toxoids are produced by addition of formalin to the toxins of microbes and incubating them at <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>37</mn><mo lspace="0em" rspace="0em">∘</mo></msup><mi mathvariant="normal">C</mi></mrow><annotation encoding="application/x-tex">37^{\circ} \mathrm{C}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord">3</span><span class="mord"><span class="mord">7</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6741em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∘</span></span></span></span></span></span></span></span></span><span class="mord mathrm">C</span></span></span></span></span> for 3 to 4 weeks. This results in loss of toxicity without reduction of the antigenicity. Toxoids adsorbed onto an adjuvant are more immunogenic.</li>
<li>Nucleic acid vaccines: Recently, nucleic acid vaccines, mainly DNA-vaccines have been developed. They have many advantages: they are safer, stable and heat-resistant. These vaccines are genetically engineered and induce both humoral immunity and CMI including cytotoxic T cells. The immunity persists for prolonged periods.</li>
<li>Immune animal serum (antiserum): This is the serum obtained from animals like horse and rabbit which have been injected with a vaccine, either a toxin or a toxoid. The sera of such animals contain antibodies either against the microorganisms or their toxins. Antisera containing antibodies against the toxins of C. diphtheriae, Cl. tetani and Cl . welchii are used commonly.</li>
<li>Immune human sera: These are derived from convalescent, immune or hyperimmunised adults, eg, human, hyperimmune antitetanus serum.</li>
<li>Immunoglobulin Ig (Human): Formerly termed as gamma globulin, this agent is a refined product prepared from pooled human blood plasma having a high antibody titre. Placentae of mothers immunised by the administration of a toxoid a few weeks before delivery have also been used as a source.</li>
<li>Monoclonal antibodies (see later).</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="active-immunisation">Active Immunisation<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#active-immunisation" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>This may be primary or secondary.</p>
<ul>
<li>Primary immunisation is commonly carried out in infants and in children to induce primary immunity and consists of administering two or more doses of the vaccine or the toxoid at suitable intervals. Combinations of multiple vaccines/toxoids are now available for primary immunisation.</li>
<li>Secondary immunisation is carried out to reinforce the primary immunity by giving a single 'booster' or 'recall' dose of the antigen.
All vaccines and antisera should be stored at temperature recommended by the manufacturer. Otherwise, the preparation may become denatured and ineffective. Refrigerator storage at <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mo>−</mo><msup><mn>8</mn><mo lspace="0em" rspace="0em">∘</mo></msup><mi mathvariant="normal">C</mi></mrow><annotation encoding="application/x-tex">2-8^{\circ} \mathrm{C}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord"><span class="mord">8</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6741em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∘</span></span></span></span></span></span></span></span></span><span class="mord mathrm">C</span></span></span></span></span> is usually necessary. Multi-dose vials without any preservative, once opened, should be used within 1 hour and those with a preservative within 3 hours.</li>
</ul>
<p>Adverse reactions to vaccines are generally mild and consists of local tenderness, erythema, induration, fever, arthralgia and malaise. Allergic reactions may occur. Any vaccine produced from the organisms grown in chick embryo culture is contraindicated in patients allergic to eggs, chicken or chicken feathers. Allergic reactions can also occur due to other components such as preservatives, antibiotics and stabilisers like gelatin used during vaccine manufacturing.</p>
<p>Many viral vaccines contain traces of antibiotics. They have to be withheld from individuals known to be allergic to the antibiotic concerned. Further, they should be avoided in individuals on corticosteroid therapy or immunosuppressive drugs and in those with impaired immune responses.</p>
<p>Corticosteroids induce immunosuppression that reduces the ability to respond to a killed vaccine or enhance the susceptibility to live vaccines which could result in disseminated disease. Live virus vaccines are usually avoided during pregnancy for fear of infecting the fetus; however, such risk has not been substantiated.</p>
<p>Although vaccination may be avoided during severe acute illnesses, mild upper and lower respiratory tract infections and other mild illnesses are no more considered as contraindications. In fact, it is now recommended that children with minor illnesses should be vaccinated regardless of the degree of fever. Prematurity does not increase the incidence of vaccine-induced adverse reactions.</p>
<p>The vaccines and toxoids employed for active immunisation are listed in Tables 73.2 and 73.3. Dosage schedules recommended by the manufacturer should be followed.</p>
<p>Table 73.2
Bacterial vaccines, toxoids and rickettsial vaccines</p>
<table><thead><tr><th style="text-align: center;">Vaccine/Tosoid</th><th style="text-align: center;">Immunising agent</th><th style="text-align: center;">Route</th><th style="text-align: center;">Adverse reactions</th><th style="text-align: center;">Efficacy and remarks</th></tr></thead><tbody><tr><td style="text-align: center;">Bacterial vaccines</td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">BCG</td><td style="text-align: center;">Live attenuated</td><td style="text-align: center;">ID</td><td style="text-align: center;">Fever; regional</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>75</mn><mo>−</mo><mn>80</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">75-80 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">75</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">80%</span></span></span></span></span> against miliary</td></tr><tr><td style="text-align: center;"></td><td style="text-align: center;">M. bovis</td><td style="text-align: center;"></td><td style="text-align: center;">adenitis</td><td style="text-align: center;">and meningeal TB; controversial in other forms</td></tr><tr><td style="text-align: center;">Pertussis</td><td style="text-align: center;">(a) Inactivated bacterial antigen</td><td style="text-align: center;">IM</td><td style="text-align: center;">Local reaction</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>80</mn><mo>−</mo><mn>90</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">80-90 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">80</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">90%</span></span></span></span></span>. Combined with diphtheria and tetanus vaccines DPT</td></tr><tr><td style="text-align: center;"></td><td style="text-align: center;">(b) Acellular</td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Typhoid oral (Typhoral)</td><td style="text-align: center;">Live mutant bacilli Ty2IA</td><td style="text-align: center;">Oral</td><td style="text-align: center;">Mild GI disturbance; fever</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mo>−</mo><mn>70</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50-70 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">50</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">70%</span></span></span></span></span></td></tr><tr><td style="text-align: center;">Typhoid (Vi)</td><td style="text-align: center;">Vi capsular polysaccharide</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mtable rowspacing="0.25em" columnalign="right left" columnspacing="0em"><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mtext>&nbsp;IM;&nbsp;</mtext></mrow></mstyle></mtd></mtr><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mtext>&nbsp;SC&nbsp;</mtext></mrow></mstyle></mtd></mtr></mtable><annotation encoding="application/x-tex">\begin{aligned} &amp; \text { IM; } \\ &amp; \text { SC } \end{aligned}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 3em; vertical-align: -1.25em;"></span><span class="mord"><span class="mtable"><span class="col-align-r"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.75em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span><span style="top: -2.25em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span><span class="col-align-l"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.91em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord text"><span class="mord">&nbsp;IM;&nbsp;</span></span></span></span><span style="top: -2.41em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord text"><span class="mord">&nbsp;SC&nbsp;</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;">Local reaction</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>70</mn><mo>−</mo><mn>75</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">70-75 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">70</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">75%</span></span></span></span></span>; single dose per course</td></tr><tr><td style="text-align: center;">Cholera (oral)</td><td style="text-align: center;">Whole cell killed (El tor strain)</td><td style="text-align: center;">Oral</td><td style="text-align: center;">None</td><td style="text-align: center;">2 doses, 2 wks apart; <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span>; protection 3 years</td></tr><tr><td style="text-align: center;">Plague</td><td style="text-align: center;">Inactivated bacteria</td><td style="text-align: center;">IM</td><td style="text-align: center;">Fever; swelling</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>90</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">90 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">90%</span></span></span></span></span> antibody response; efficacy variable</td></tr><tr><td style="text-align: center;">Anthrax</td><td style="text-align: center;">Inactivated, avirulent bacteria</td><td style="text-align: center;">SC</td><td style="text-align: center;">No serious reaction</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>90</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">90 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">90%</span></span></span></span></span> antibody response; efficacy variable</td></tr><tr><td style="text-align: center;">Bacterial toxoids</td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Diphtheria</td><td style="text-align: center;">Inactivated toxins</td><td style="text-align: center;">IM</td><td style="text-align: center;">Local reactions</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>95</mn><mi mathvariant="normal">%</mi><mi mathvariant="normal">/</mi><mn>98</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">95 \% / 98 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">95%/98%</span></span></span></span></span> Can be</td></tr><tr><td style="text-align: center;">Tetanus</td><td style="text-align: center;">Inactivated toxins</td><td style="text-align: center;">IM</td><td style="text-align: center;">Local reactions</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>95</mn><mi mathvariant="normal">%</mi><mi mathvariant="normal">/</mi><mn>98</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">95 \% / 98 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">95%/98%</span></span></span></span></span> combined</td></tr><tr><td style="text-align: center;">H. influenzae type B (Hib)</td><td style="text-align: center;">Bacterial polysaccharide</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mtable rowspacing="0.25em" columnalign="right left" columnspacing="0em"><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mtext>&nbsp;IM;&nbsp;</mtext></mrow></mstyle></mtd></mtr><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mtext>&nbsp;SC&nbsp;</mtext></mrow></mstyle></mtd></mtr></mtable><annotation encoding="application/x-tex">\begin{aligned} &amp; \text { IM; } \\ &amp; \text { SC } \end{aligned}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 3em; vertical-align: -1.25em;"></span><span class="mord"><span class="mtable"><span class="col-align-r"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.75em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span><span style="top: -2.25em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span><span class="col-align-l"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.91em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord text"><span class="mord">&nbsp;IM;&nbsp;</span></span></span></span><span style="top: -2.41em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord text"><span class="mord">&nbsp;SC&nbsp;</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;">Local reaction</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>90</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">90 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">90%</span></span></span></span></span>; not beyond</td></tr><tr><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>6</mn><mo lspace="0em" rspace="0em">∗</mo></msup></mrow><annotation encoding="application/x-tex">6^{*}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6887em;"></span><span class="mord"><span class="mord">6</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6887em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∗</span></span></span></span></span></span></span></span></span></span></span></span></span> birthday</td></tr><tr><td style="text-align: center;">Meningococci A,C,Y, W135</td><td style="text-align: center;">Bact. polysaccharide alone/conjugated with proteins</td><td style="text-align: center;">SC</td><td style="text-align: center;">Local reaction</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>90</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">90 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">90%</span></span></span></span></span>; given after 2nd birthday</td></tr><tr><td style="text-align: center;">Pneumococci PPSV23 &lt;br&gt; PCV13</td><td style="text-align: center;">Capsular polysaccharide, unconjugated, conjugate</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mtable rowspacing="0.25em" columnalign="right left" columnspacing="0em"><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mtext>&nbsp;IM;&nbsp;</mtext></mrow></mstyle></mtd></mtr><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mtext>&nbsp;SC&nbsp;</mtext></mrow></mstyle></mtd></mtr></mtable><annotation encoding="application/x-tex">\begin{aligned} &amp; \text { IM; } \\ &amp; \text { SC } \end{aligned}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 3em; vertical-align: -1.25em;"></span><span class="mord"><span class="mtable"><span class="col-align-r"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.75em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span><span style="top: -2.25em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span><span class="col-align-l"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.91em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord text"><span class="mord">&nbsp;IM;&nbsp;</span></span></span></span><span style="top: -2.41em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord text"><span class="mord">&nbsp;SC&nbsp;</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;">Local reaction</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mtable rowspacing="0.25em" columnalign="center" columnspacing="0em"><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mn>60</mn><mo>−</mo><mn>80</mn><mi mathvariant="normal">%</mi></mrow></mstyle></mtd></mtr><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mo>&gt;</mo><mn>90</mn><mi mathvariant="normal">%</mi></mrow></mstyle></mtd></mtr></mtable><annotation encoding="application/x-tex">\begin{gathered} 60-80 \% \\ &gt;90 \% \end{gathered}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 3em; vertical-align: -1.25em;"></span><span class="mord"><span class="mtable"><span class="col-align-c"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.91em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord">60</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord">80%</span></span></span><span style="top: -2.41em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mord">90%</span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span></span></span></span></span></span></span></td></tr><tr><td style="text-align: center;">Rickettsial vaccine</td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Typhus vaccine</td><td style="text-align: center;">Killed organisms</td><td style="text-align: center;">SC</td><td style="text-align: center;">Allergic reactions</td><td style="text-align: center;">High</td></tr></tbody></table>
<p>ID = Intradermal
SC = Subcutaneous
IM = Intramuscular
*= Not available</p>
<p>Table 73.3
Viral vaccines</p>
<table><thead><tr><th style="text-align: center;">Vaccine/Tosoid</th><th style="text-align: center;">Immunising agent</th><th style="text-align: center;">Route</th><th style="text-align: center;">Adverse reactions</th><th style="text-align: center;">Efficacy and remarks</th><th style="text-align: center;"></th></tr></thead><tbody><tr><td style="text-align: center;">Viral vaccines</td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Varicella (Chicken pox)</td><td style="text-align: center;">Live attenuated virus</td><td style="text-align: center;">IM</td><td style="text-align: center;">Local reaction</td><td style="text-align: center;">95%; CMI lasts longer</td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Measles</td><td style="text-align: center;">Live attenuated virus</td><td style="text-align: center;">SC</td><td style="text-align: center;">? Encephalopathy</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>95</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">95 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">95%</span></span></span></span></span></td><td style="text-align: center;">Usually given a MMR (Trevisac)</td></tr><tr><td style="text-align: center;">Mumps</td><td style="text-align: center;">Live attenuated virus</td><td style="text-align: center;">SC</td><td style="text-align: center;">Parotitis</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>90</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">90 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">90%</span></span></span></span></span></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Rubella</td><td style="text-align: center;">Live attenuated virus</td><td style="text-align: center;">SC</td><td style="text-align: center;">Arthralgia</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>95</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">95 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">95%</span></span></span></span></span></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Poliomyelitis: Sabin (Trivalent, oral OPV)</td><td style="text-align: center;">Live attenuated virus</td><td style="text-align: center;">Oral</td><td style="text-align: center;">Rare, vaccine associated polio</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>95</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">95 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">95%</span></span></span></span></span>; may eliminate carrier state</td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Salk (IPV)</td><td style="text-align: center;">Inactivated virus</td><td style="text-align: center;">SC</td><td style="text-align: center;">Local reaction</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>95</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">95 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">95%</span></span></span></span></span>; does not affect carrier state</td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Rabies:</td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">(a) Semple vaccine</td><td style="text-align: center;">Inactivated virus</td><td style="text-align: center;">SC</td><td style="text-align: center;">Local reaction; neurological complications</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>60</mn><mo>−</mo><mn>70</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">60-70 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">60</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">70%</span></span></span></span></span> response; short lived immunity; multiple doses</td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">(b) Human diploid vaccine</td><td style="text-align: center;">Inactivated virus</td><td style="text-align: center;">IM; ID</td><td style="text-align: center;">Local reaction; arthritis; angioedema</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>95</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">&gt;95 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">95%</span></span></span></span></span>; safer</td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">(c) Purified chick embryo vaccine (Rabipur)</td><td style="text-align: center;">Inactivated virus</td><td style="text-align: center;">IM</td><td style="text-align: center;">Local reaction; fever; allergy; arthralgia</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>95</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">95 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">95%</span></span></span></span></span>; safer</td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Hepatitis A</td><td style="text-align: center;">Killed virus</td><td style="text-align: center;">IM</td><td style="text-align: center;">Fever; arthralgia</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>95</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">95 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">95%</span></span></span></span></span></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Hepatitis B</td><td style="text-align: center;">Inactivated viral antigen</td><td style="text-align: center;">IM</td><td style="text-align: center;">Arthralgia</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>80</mn><mo>−</mo><mn>95</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">80-95 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">80</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">95%</span></span></span></span></span></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Hepatitis B rDNA</td><td style="text-align: center;">rDNA antigen</td><td style="text-align: center;">IM</td><td style="text-align: center;">None</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>80</mn><mo>−</mo><mn>95</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">80-95 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">80</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">95%</span></span></span></span></span></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Yellow fever</td><td style="text-align: center;">Live attenuated virus</td><td style="text-align: center;">SC</td><td style="text-align: center;">Neurological</td><td style="text-align: center;">High; life long</td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Japanese B encephalitis</td><td style="text-align: center;">Inactivated virus</td><td style="text-align: center;">SC</td><td style="text-align: center;">Allergic reactions</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>80</mn><mo>−</mo><mn>90</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">80-90 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">80</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">90%</span></span></span></span></span></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Influenza</td><td style="text-align: center;">Inactivated virus; or virus component</td><td style="text-align: center;">IM</td><td style="text-align: center;">? Neurological</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mo>−</mo><mn>60</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">40-60 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">40</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">60%</span></span></span></span></span>; efficacy varies due to changes in the infective strain</td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Rotavirus</td><td style="text-align: center;">Pentavalent</td><td style="text-align: center;">Oral</td><td style="text-align: center;">Diarrhoea</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>95</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">95 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">95%</span></span></span></span></span></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">HPV</td><td style="text-align: center;">Multivalent</td><td style="text-align: center;">IM</td><td style="text-align: center;">-</td><td style="text-align: center;">Under evaluation</td><td style="text-align: center;"></td></tr></tbody></table>
<p>ID = Intradermal; HPV = Human papilloma virus
BCG VACCINE: Discussed in Chapter 54.
PNEUMOCCOCAL VACCINE: These are available as unconjugated pneumococcal polysaccharide vaccine (PPSV23) and conjugate vaccine (PPV13). The former is a capsular polysaccharide of 23 serotypes while the latter is of 13 serotypes. PPV 23 has expanded spectrum but its efficacy is limited, while PCV 13 shows robust immune response and memory. Hence for individuals with high risk to invasive pneumococcal disease, both should be given. However, more data is needed for PCV 13 and till then its use in general population more than 65 years old is restricted.</p>
<p>TYPHOID VACCINE: It is available as live attenuated vaccine to be taken orally every other day as a single capsule 1 hour before eating, for a total of 4 doses. Capsules are to be refrigerated. It provides protection for 5 years. Generally, it is well tolerated.</p>
<p>Purified capsular polyssacharide typhoid vaccine is also available but has to be administered pareneterally.</p>
<p>MMR VACCINE: The contraindications to MMR vaccine (Table 73.3) include children with altered immunity and those on high doses of corticosteroids or immunosuppressants. It is avoided in children who have received another live virus by injection within the past three weeks. If it is given to an adult woman, pregnancy should be avoided for a month; the vaccine should not be given within 3 months of an immunoglobulin injection.</p>
<p>POLIOMYELITIS VACCINES: The Salk vaccine induces only limited resistance to growth of the virus in the intestine and thus, does not affect the carrier state (excretion of the virus in feces). It has to be given by SC or IM injection, 3 doses each of 0.5 ml ., at an interval of 4 to 6 weeks between the 1st and the 2nd dose, and 12 months between the 2nd and the 3rd. Adverse effects are usually mild and consist of local pain, induration and fever.</p>
<p>The Sabin vaccine (OPV), which is given orally in addition to systemic immunity, provides a local resistance (intestinal immunity) to reinfection by the poliovirus by inducing mucosal secretion of IgA antibodies. This leads to stoppage of fecal excretion of the virus and consequent elimination of the carrier state.</p>
<p>In contrast to the situation in the West, three doses of OPV do not provide immunity, especially to poliovirus type 3, in <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>100</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">100 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">100%</span></span></span></span></span> of infants, in the developing countries including India. Further, the median age of poliomyelitis in India is from 12 to 18 months; this means that about half the cases occur between about 6 and 12-18 months of age. It is thus important to complete the primary immunisation before the age for greatest risk of poliomyelitis. Hence, the recommendation is to give the first dose of OPV (along with BCG) at birth, followed by three more doses (along with Triple i.e. DTP antigen) at 6,10 and 14 weeks of age. A booster dose of OPV is given 12-15 months after the last dose of primary immunisation, and another at the time of school entry. Repeated mass vaccination with OPV upto the age of 5 years is also recommended (Pulse Polio Immunisation). Such simultaneous administration of OPV to all susceptible children blocks the circulation of wild poliovirus in the community and can eradicate polio.</p>
<p>ROTAVIRUS VACCINE: Rotavirus infects the intestines of virtually all children by the age of 3 years. Public health measures and personal hygiene are unable to prevent the gastroenteritis caused by it. A pentavalent, human-bovine reassortant rotavirus vaccine is now available. It is effective and safe. The oral vaccine is administered in three, monthly doses from the age of 6-12 weeks to the age of 32 weeks. It may cause mild diarrhea or vomiting in some children. It can be given concurrently with other vaccines.</p>
<p>HUMAN PAPILLOMA VIRUS VACCINE (HPV): This virus causes carcinoma of the uterine cervix and genital warts in women. A reassortant vaccine, now available, effectively protects against four HPV types and is considered to be safe. It is administered IM to girls/women between the ages of 9 and 26 years in three doses, the second and the third being given 2 and 6 months after the first dose. It is prohibitively expensive at present.</p>
<p>RABIES VACCINES: Rabies occurs commonly after the bite of an infected animal such as a dog. Rabies virus can be found in the animal saliva for upto 7 days before the appearance of signs of illness. Rabies infection can also occur witout direct animal contact by inhalation of the virus in bat infested caves or in the laboratory. Although the usual incubation period is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4</mn><mo>−</mo><mn>6</mn></mrow><annotation encoding="application/x-tex">4-6</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">4</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">6</span></span></span></span></span> weeks, a range of 5 days to more than 1 year has been reported.</p>
<p>In endemic areas, it must be emphasised that a bite is not necessary for transmission of the virus and that children must be guarded against contact with unknown animals.</p>
<p>In unvaccinated patients, the mortality from rabies is almost <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>100</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">100 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">100%</span></span></span></span></span>. Although it is never too late to vaccinate, the effect of vaccination decreases sharply with delay in excess of 2 weeks. Immunosuppression by drugs, HIV or chronic liver disease such as cirrhosis could prove rapidly fatal. Prophylactic treatment is started immediately in all cases with suspected bite. The course may be discontinued if it is proven that the animal is still alive and healthy 10</p>
<p>days after the bite.
It has been demonstrated that immediate thorough washing of the suspected wound with soap and water alone increases the survival by almost <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span>. Local dressing with povidone iodine, ethyl alcohol/methylated spirit is recommended.</p>
<p>The rabies vaccines available are:</p>
<ol>
<li>Nerve tissue vaccines:</li>
</ol>
<ul>
<li>Semple vaccine: This is a sterile suspension of sheep brain substance containing fixed virus of rabies, inactivated by the addition of phenol. The vaccine is given SC into the cellular tissue on the side of the abdominal wall below the costal margin. Immunity conferred by it lasts only for about 3 months, is incomplete and unpredictable.
The recommended dose is 2 ml SC on the lower abdominal wall daily, for 14 consecutive days, with booster doses on days 21,28 and 91 . The dose for a child less than 12 years is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow><annotation encoding="application/x-tex">1 / 2</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1/2</span></span></span></span></span> or <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3</mn><mi mathvariant="normal">/</mi><msup><mn>4</mn><mtext>th&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">3 / 4^{\text {th }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.0991em; vertical-align: -0.25em;"></span><span class="mord">3/</span><span class="mord"><span class="mord">4</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">th&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> that of the adult. The vaccine, however, offers protection only in <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>60</mn><mo>−</mo><mn>70</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">60-70 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">60</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">70%</span></span></span></span></span> of cases, even when it is started on the day of the bite. Further, serious neurological complications such as polyneuritis, myelitis and encephalomyelitis can occur though occasionally. Hence it is no more recommended.</li>
</ul>
<ol start="2">
<li>Tissue culture vaccines:</li>
</ol>
<ul>
<li>Purified chick embryo cell vaccine (PCECV): This vaccine is obtained by growing the virus in primary cultures of chick fibroblasts.</li>
<li>Human diploid cell inactivated vaccine (HDCV): This is obtained from human fibroblast culture.</li>
<li>Purified Verocell vaccine, (PVRV) grown in verocell line.</li>
</ul>
<p>Tissue culture vaccines give a better antibody response than the older vaccines. The immunity lasts longer and the vaccine is free from serious adverse reactions. Hence, they are now preferred. Various vaccine regimens recommended are given in Table 73.4.</p>
<p>Table 73.4
Suggested regimens for various rabies vaccines
OR
0.1 ml ID for three doses as above</p>
<p>Five doses IM on 0, 3, 7, 14, and 28 days Use anterolateral thigh in children</p>
<p>OR
1 ml in divided doses ID at eight sites (about 0.1 ml per site) on day zero; 0.1 ml at four sites on day 7 ; and 0.1 ml at one site on days 28 and 91
3 PCECV 1 ml vial Doses as above Doses as above 4 PVRV 0.5 ml vial -
Five, 0.5 ml doses IM, similar to HDCV
OR</p>
<p>0.1 ml intradermally at two sites on day 03 , 7 , and single ID dose given on day 28 and 91.
Similar schedule may be used as for HDCV and PCECV using 0.2 ml of PVRV instead of 0.1 ml .
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo><mo>−</mo><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">--&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">−</span><span class="mord">−</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">&gt;</span></span></span></span></span></p>
<table><thead><tr><th style="text-align: center;">Vaccine type</th><th style="text-align: center;">Pre-exposure treatment</th><th style="text-align: center;">Post-exposure treatment</th></tr></thead><tbody><tr><td style="text-align: center;">1 Semple vaccine (Sheep brain)</td><td style="text-align: center;">See text</td><td style="text-align: center;">See text</td></tr><tr><td style="text-align: center;">2 HDCV 1 ml vial</td><td style="text-align: center;">Three, 1 ml doses IM in deltoid on 0,7 , and 21 or 28 days. Booster after 1 year OR 0.1 ml ID for three doses as above</td><td style="text-align: center;">Five doses IM on <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0</mn><mo separator="true">,</mo><mn>3</mn><mo separator="true">,</mo><mn>7</mn><mo separator="true">,</mo><mn>14</mn></mrow><annotation encoding="application/x-tex">0,3,7,14</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">0</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">3</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">7</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">14</span></span></span></span></span>, and 28 days Use anterolateral thigh in children OR 1 ml in divided doses ID at eight sites (about 0.1 ml per site) on day zero; 0.1 ml at four sites on day 7 ; and 0.1 ml at one site on days 28 and 91</td></tr><tr><td style="text-align: center;">3 PCECV 1 ml vial</td><td style="text-align: center;">Doses as above</td><td style="text-align: center;">Doses as above</td></tr><tr><td style="text-align: center;">4 PVRV 0.5 ml vial</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo></mrow><annotation encoding="application/x-tex">-</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">−</span></span></span></span></span></td><td style="text-align: center;">Five, 0.5 ml doses IM, similar to HDCV OR 0.1 ml intradermally at two sites on day 03 , 7 , and single ID dose given on day 28 and 91 . Similar schedule may be used as for HDCV and PCECV using 0.2 ml of PVRV instead of 0.1 ml .</td></tr></tbody></table>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">D</mi><mi mathvariant="normal">C</mi><mi mathvariant="normal">V</mi></mrow><mo>=</mo></mrow><annotation encoding="application/x-tex">\mathrm{HDCV}=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">HDCV</span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span></span></span></span></span> human diploid cell vaccine
PVRV = Purified Verocell vaccine
PCECV = Purified chicken embryo cell vaccine
ID = Intradermal
All severely bitten persons should also receive rabies immunoglobulin (IgG). Human rabies immunoglobulin is safer than the antiserum but is more expensive.</p>
<p>Staff in attendance on a patient who is highly suspected of, or known to be suffering, from rabies should be offered immunisation. Four intradermal doses of 0.1 ml of HDCV given on the same day at different sites is the suggested regimen. There is no specific contraindication to HDC rabies vaccine.</p>
<p>HEPATITIS B VACCINE: This vaccine contains inactivated hepatitis B virus surface antigen (HBsAg). It is prepared using recombinant DNA technology. Adequate immunity against the infection develops after 6 months and lasts 5-7 years. Immunisation of infants is expected to provide long lasting immunity.</p>
<p>TETANUS TOXOID: After the full course of 7 doses (Table 73.5), booster doses are given every 10 years. Td can replace TT.</p>
<p>Table 73.5
Immunisation Schedule</p>
<table><thead><tr><th style="text-align: center;">Age</th><th style="text-align: center;">Vaccine</th></tr></thead><tbody><tr><td style="text-align: center;">Birth</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">B</mi><mi mathvariant="normal">C</mi><mi mathvariant="normal">G</mi></mrow><mo separator="true">,</mo><msub><mrow><mi mathvariant="normal">O</mi><mi mathvariant="normal">P</mi><mi mathvariant="normal">V</mi></mrow><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{BCG}, \mathrm{OPV}_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord mathrm">BCG</span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord"><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">OPV</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span></td></tr><tr><td style="text-align: center;">6 weeks</td><td style="text-align: center;">DTwP <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow></mrow><mn>1</mn></msub><mo separator="true">,</mo><msub><mrow><mi mathvariant="normal">O</mi><mi mathvariant="normal">P</mi><mi mathvariant="normal">V</mi></mrow><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">_{1}, \mathrm{OPV}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord"><span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord"><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">OPV</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>, Hepatitis <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">B</mi><mn>1</mn></msub><mo separator="true">,</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">b</mi></mrow><mn>2</mn></msub><mo separator="true">,</mo><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">C</mi><mi mathvariant="normal">V</mi></mrow><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{B}_{1}, \mathrm{Hib}_{2}, \mathrm{PCV}_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord mathrm">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Hib</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord"><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">PCV</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>, Rota virus <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow></mrow><mn>3</mn></msub><msup><mrow></mrow><mo lspace="0em" rspace="0em">∗</mo></msup></mrow><annotation encoding="application/x-tex">_{3}{ }^{*}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8387em; vertical-align: -0.15em;"></span><span class="mord"><span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6887em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∗</span></span></span></span></span></span></span></span></span></span></span></span></span></td></tr><tr><td style="text-align: center;">10 weeks &lt;br&gt; 14 weeks &lt;br&gt; <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>9</mn><mo>−</mo><mn>12</mn></mrow><annotation encoding="application/x-tex">9-12</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">9</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">12</span></span></span></span></span> months</td><td style="text-align: center;">DTwP <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow></mrow><mn>2</mn></msub><mo separator="true">,</mo><msub><mrow><mi mathvariant="normal">O</mi><mi mathvariant="normal">P</mi><mi mathvariant="normal">V</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">_{2}, \mathrm{OPV}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord"><span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord"><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">OPV</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>, Hepatitis <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">B</mi><mn>2</mn></msub><mo separator="true">,</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">b</mi></mrow><mn>2</mn></msub><mo separator="true">,</mo><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">C</mi><mi mathvariant="normal">V</mi></mrow><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{B}_{2}, \mathrm{Hib}_{2}, \mathrm{PCV}_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord mathrm">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Hib</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord"><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">PCV</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>, Rota virus <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow></mrow><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4511em; vertical-align: -0.15em;"></span><span class="mord"><span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> &lt;br&gt; DTwP <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow></mrow><mn>2</mn></msub><mo separator="true">,</mo><msub><mrow><mi mathvariant="normal">O</mi><mi mathvariant="normal">P</mi><mi mathvariant="normal">V</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">_{2}, \mathrm{OPV}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord"><span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord"><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">OPV</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>, Hepatitis <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">B</mi><mn>2</mn></msub><mo separator="true">,</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">b</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{B}_{2}, \mathrm{Hib}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord mathrm">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Hib</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> &lt;br&gt; PCV <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow></mrow><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4511em; vertical-align: -0.15em;"></span><span class="mord"><span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>, Rota virus <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow></mrow><mn>3</mn></msub><msup><mrow></mrow><mo lspace="0em" rspace="0em">∗</mo></msup></mrow><annotation encoding="application/x-tex">_{3}{ }^{*}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8387em; vertical-align: -0.15em;"></span><span class="mord"><span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6887em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∗</span></span></span></span></span></span></span></span></span></span></span></span></span> &lt;br&gt; Measles, Hepatitis <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="bold">A</mi><mn>1</mn></msub><mo stretchy="false">(</mo><mn>12</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">t</mi><mi mathvariant="normal">h</mi></mrow><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">\mathbf{A}_{1}(12 \mathrm{mth})</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathbf">A</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mopen">(</span><span class="mord">12</span><span class="mord"><span class="mord mathrm">mth</span></span><span class="mclose">)</span></span></span></span></span></td></tr><tr><td style="text-align: center;">15 months</td><td style="text-align: center;">PCV-B, Varicella, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mn>5</mn></msup></mrow><annotation encoding="application/x-tex">{ }^{5}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8141em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">5</span></span></span></span></span></span></span></span></span></span></span></span></span></td></tr><tr><td style="text-align: center;">16-24 months</td><td style="text-align: center;">DTwP-B <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow></mrow><mn>1</mn></msub><mo separator="true">,</mo><msub><mrow><mi mathvariant="normal">O</mi><mi mathvariant="normal">P</mi><mi mathvariant="normal">V</mi></mrow><mn>4</mn></msub><mo separator="true">,</mo><msub><mrow><mi mathvariant="normal">M</mi><mi mathvariant="normal">M</mi><mi mathvariant="normal">R</mi></mrow><mn>1</mn></msub><mo separator="true">,</mo><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">b</mi></mrow><msub><mi mathvariant="normal">B</mi><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">_{1}, \mathrm{OPV}_{4}, \mathrm{MMR}_{1}, \mathrm{Hib} \mathrm{B}_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord"><span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord"><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">OPV</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">MMR</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord"><span class="mord mathrm">Hib</span></span><span class="mord"><span class="mord mathrm">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span></td></tr><tr><td style="text-align: center;">18 months</td><td style="text-align: center;">Hepatitis <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="bold">A</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathbf{A}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8361em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathbf">A</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span></td></tr><tr><td style="text-align: center;">2 years</td><td style="text-align: center;">Typhoid, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mo lspace="0em" rspace="0em">†</mo></msup></mrow><annotation encoding="application/x-tex">{ }^{\dagger}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8491em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">†</span></span></span></span></span></span></span></span></span></span></span></span></span></td></tr><tr><td style="text-align: center;">5 years</td><td style="text-align: center;">DTwP B <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow></mrow><mn>2</mn></msub><mo separator="true">,</mo><msub><mrow><mi mathvariant="normal">O</mi><mi mathvariant="normal">P</mi><mi mathvariant="normal">V</mi></mrow><mn>4</mn></msub><mo separator="true">,</mo><msub><mrow><mi mathvariant="normal">M</mi><mi mathvariant="normal">M</mi><mi mathvariant="normal">R</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">_{2}, \mathrm{OPV}_{4}, \mathrm{MMR}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord"><span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord"><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">OPV</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">MMR</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> Typhoid <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4511em; vertical-align: -0.15em;"></span><span class="mord"><span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>, Varicella <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4511em; vertical-align: -0.15em;"></span><span class="mord"><span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span></td></tr><tr><td style="text-align: center;">10 years</td><td style="text-align: center;">TT/Tdap/Td, HPV (to girls) <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mrow><mn>6</mn><mo>∗</mo></mrow></msup></mrow><annotation encoding="application/x-tex">{ }^{6 *}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8141em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">6</span><span class="mord mtight">∗</span></span></span></span></span></span></span></span></span></span></span></span></span></td></tr><tr><td style="text-align: center;">16 years</td><td style="text-align: center;">TT/Tdap/Td</td></tr></tbody></table>
<p>Vaccines in bold <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>=</mo></mrow><annotation encoding="application/x-tex">=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.3669em;"></span><span class="mrel">=</span></span></span></span></span> additional vaccines recommended by IAP.
IAP recommends: Hepatitis B at birth, 6 weeks, 14 weeks; MMR, at 15 months; IPV (inactivated polio vaccine): IM/SC with OPV at <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>6</mn><mo separator="true">,</mo><mn>10</mn><mo separator="true">,</mo><mn>14</mn></mrow><annotation encoding="application/x-tex">6,10,14</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">6</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">10</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">14</span></span></span></span></span> wks and booster at <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>15</mn><mo>−</mo><mn>18</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">t</mi><mi mathvariant="normal">h</mi></mrow></mrow><annotation encoding="application/x-tex">15-18 \mathrm{mth}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">15</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord">18</span><span class="mord"><span class="mord mathrm">mth</span></span></span></span></span></span>; DTaP as an alternative to DTP; Tdap preferrable to TT/Td.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>B</mi><mo>=</mo></mrow><annotation encoding="application/x-tex">B=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span></span></span></span></span> booster OPV = Oral Polio Vaccine; <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>D</mi><mi>T</mi><mi>w</mi><mi>P</mi><mo>=</mo></mrow><annotation encoding="application/x-tex">D T w P=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.02778em;">D</span><span class="mord mathnormal" style="margin-right: 0.13889em;">TwP</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span></span></span></span></span> Diphtheria, Tetanus Toxoid, whole cell Pertussis; DTap contains acellular pertusis instead of whole cell pertusis. TT = Tetanus Toxoid, Tdap: TT, reduced dose diphtheria, acellular pertussis; Td = TT, reduced dose diphtheria; Hib = Hemphilus influenzae B; MMR = Mumps, Measles, Rubella; HPV= Human papilloma virus vaccine.
Ref. National Immunisation Schedule: Indian Academy of Paediatrics Immunisation Time table 2012
'2-3 doses based on brand at 4-8 week interval Hepatitis <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>B</mi><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">B_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0502em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> can be given at 6 months.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mn>5</mn></msup></mrow><annotation encoding="application/x-tex">{ }^{5}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8141em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">5</span></span></span></span></span></span></span></span></span></span></span></span></span> If started above 13 years, give 2 doses <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4</mn><mo>−</mo><mn>8</mn></mrow><annotation encoding="application/x-tex">4-8</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">4</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">8</span></span></span></span></span> weeks apart.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mn>6</mn></msup><mrow><mi mathvariant="normal">V</mi><mi mathvariant="normal">i</mi></mrow></mrow><annotation encoding="application/x-tex">{ }^{6} \mathrm{Vi}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8141em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">6</span></span></span></span></span></span></span></span></span><span class="mord"><span class="mord mathrm">Vi</span></span></span></span></span></span> polysaccharide vaccine. Revaccination every 3 years till 12 years of age.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>∗</mo><mo>=</mo><mn>0</mn><mo separator="true">,</mo><mn>1</mn><mo>−</mo><mn>2</mn></mrow><annotation encoding="application/x-tex">*=0,1-2</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4653em;"></span><span class="mord">∗</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">0</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">1</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">2</span></span></span></span></span> and 6 mths.
Hypersensitivity reactions are known to occur due to high concentrations of the antibody in persons given too frequent booster doses.</p>
<p>During pregnancy, 2 doses of TT or Td are administered at 4 weeks interval, at first contact or as early as possible, to women not previously immunised; this prevents neonatal tetanus. The <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>3</mn><mtext>rd&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">3^{\text {rd }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8491em;"></span><span class="mord"><span class="mord">3</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">rd&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> dose is given 6 months later. If immunisation history is unknown, at least 2 doses of TT or Td are given in <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>2</mn><mtext>nd&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">2^{\text {nd }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8491em;"></span><span class="mord"><span class="mord">2</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">nd&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> or <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>3</mn><mtext>rd&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">3^{\text {rd }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8491em;"></span><span class="mord"><span class="mord">3</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">rd&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> trimister. Tdap should preferrably be given between 27 and 36 weeks of pregnancy to protect the newborn against pertussis through maternal antibodies. If not administered during pregnancy, it should be given immediately postpartum. A dose of TT or Td may be replaced by Tdap, but may be given regardless of last dose of TT or Td.</p>
<p>Active immunisation programme: A majority of the serious infections with high mortality and morbidity rates can now be successfully prevented by prophylactic immunisation. Combined prophylaxis reduces the number of visits, the incidence of ADR and the cost. The recommended immunisation schedule is given in Table 73.5.</p>
<p>The neonate is naturally immune to a majority of infections because of maternal antibodies; such immunity, however, may last for only the first 6 to 10 months. The</p>
<p>newborn does not have any immunity against tuberculosis. Immunoprophylaxis is recommended right from birth so as to build up a substantial active immunity against a number of viral and bacterial infections, within the first few months of life. Ideally, the aim should be to achieve the goal of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>90</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">&gt;90 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">90%</span></span></span></span></span> vaccination coverage by the 2 years of age. Subsequently, the antibody titre can be maintained/augmented by the 'booster doses' of antigens at regular intervals. The principles of active immunisation are given in Table 73.6.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="table-73-6">Table 73.6<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-73-6" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="principles-of-active-immunisation">Principles of active immunisation<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#principles-of-active-immunisation" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Use only a properly stored vaccine.</li>
<li>Avoid all vaccines in the first trimester.</li>
<li>Avoid live virus vaccines in women who are pregnant or are likely to become pregnant within three months.</li>
<li>Killed or live vaccines do not affect the safety of breast feeding.</li>
<li>Avoid live vaccines also in immuno-compromised persons. They may be administered 3 months after stopping corticosteroids and 6 months after stopping cancer chemotherapy.</li>
<li>In infants, immunisation should not be postponed because of mild respiratory infections, diarrhoea or low grade fever.</li>
<li>In premature infants, vaccination should be carried out as per the usual schedule.</li>
<li>Healthcare workers should be immunised against hepatitis B, measles, rubella, influenza and varicella.</li>
<li>If a vaccine and Ig are to be administered concurrently, each should be administered at a separate site.</li>
<li>Many vaccines can be safely and effectively given simultaneously e.g. pneumococcal polysaccharide vaccine with whole virus influenza vaccine. But, two different vaccines should not be mixed in a syringe for administration. Use premised vaccine, if available.</li>
<li>If two live virus vaccines are to be given, they should be given on the same day, or at least 30 days apart. The response to tuberculin test may be hampered by live virus vaccines.</li>
<li>A vaccine should be injected IM into the lateral aspect of the thigh in infants.</li>
</ul>
<p>Simultaneous active and passive immunisation may be necessary because of imminent exposure to disease. There is little interaction between IgG and inactivated or non-live vaccines e.g. HIV and hepatitis B IgG. With live virus vaccines e.g. measles vaccine immunity may be compromised by IgG administration; so vaccination should be repeated after 3 months, unless specific antibodies are demonstrable on serological testing. However, OPV and yellow fever vaccines are not affected by IgG administration at any time.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="passive-immunisation">Passive Immunisation<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#passive-immunisation" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Passive immunisation involves the administration of antibodies in the form of serum, plasma or Ig to a person who is exposed to infection but in whom the disease has not yet developed. It provides readymade antibodies against the organisms; such immunity, however, is short lived. In addition, passive immunisation is often associated with allergic reactions including fatal anaphylaxis, particularly when a heterologous serum is used. Some authorities use adrenaline, glucocorticoids and an antihistaminic prophylactically with the hope of preventing such serious reactions. The current trend, however, is to use homologous antibody preparations and concentrated immuno-globulins.</p>
<p>It is advisable to determine the sensitivity of the patient before giving an injection of an antiserum regardless of whether or not he has previously received an injection of serum.</p>
<p>The intradermal test dose is 0.01 ml of a 1:100 dilution of the serum, injected intradermally. In subjects with a history of allergy it should be reduced to 0.02 ml of a 1:1,000 dilution. The test is considered as positive if a wheal develops within 30 minutes. In the scratch test, one drop of a <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo>:</mo><mn>100</mn></mrow><annotation encoding="application/x-tex">1: 100</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">1</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">:</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">100</span></span></span></span></span> dilution of the test serum in saline is applied to a superficial scratch on the skin. A positive reaction consists of erythema and wheal formation. For the conjunctival (eye) test, one drop of a 1:10 dilution of serum in normal saline solution is put into one eye; one drop of normal saline alone is instilled into the other eye as a control. The patient is considered as allergic if the treated eye shows lacrimation and conjunctivitis within 30 minutes. The intradermal skin test is performed if the conjunctival or scratch test is negative. Intradermal skin tests have rarely resulted in fatalities but eye and scratch tests have not.</p>
<p>A patient who is allergic but needs the antiserum can be desensitised by injecting small, graded doses of the antiserum. Thus, the following doses are injected either SC or IM generally at 15 minutes intervals under supervision, the next dose being injected if there is no reaction to the previous one:</p>
<ul>
<li>0.05 ml of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo>:</mo><mn>20</mn></mrow><annotation encoding="application/x-tex">1: 20</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">1</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">:</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">20</span></span></span></span></span> dilution, SC</li>
<li>0.1 ml of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo>:</mo><mn>10</mn></mrow><annotation encoding="application/x-tex">1: 10</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">1</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">:</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">10</span></span></span></span></span> dilution, SC</li>
<li>0.3 ml of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo>:</mo><mn>10</mn></mrow><annotation encoding="application/x-tex">1: 10</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">1</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">:</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">10</span></span></span></span></span> dilution, SC</li>
<li>0.1 ml of undiluted serum, SC</li>
<li>0.2 ml of undiluted serum, IM</li>
<li>0.5 ml of undiluted serum, IM</li>
</ul>
<p>Finally, the entire remaining dose is injected IM. In case of anaphylaxis 0.5 ml . of adrenaline 1:1,000 is injected IM (less dose in children) and repeated if necessary (See Chapter 22).</p>
<p>The important antisera available are:
DIPHTHERIA ANTITOXIN: This is a serum preparation from the horse, actively immunised against C. diphtheriae. It contains the antitoxin globulins. It neutralises the diphtheria toxin at the site of infection and also that circulating in the blood. However, it is probably ineffective in neutralising the toxin fixed to the tissues.</p>
<p>An IM injection of at least 4,000 units should be given immediately to all suspected cases even before taking throat swabs. The physician should then judge the severity of the case clinically and administer the additional dose without waiting for the results of investigations.</p>
<p>The dosage range of antitoxin is still controversial, but in mild diphtheria confined only to the nasal or laryngeal regions, a dose of 8,000 units by IM injection is usually adequate. Moderately severe cases require 10,000 to 30,000 units. In all severe cases, a portion of the dose is given IM, and the rest given IV <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>11</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow><annotation encoding="application/x-tex">11 / 2</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">11/2</span></span></span></span></span> to 2 hours later. The IM injection should be given in the lateral aspect of the thigh. In no case should the IV dose precede the IM dose, nor should it be resorted to in individuals with an allergic diathesis or a family history of allergic disorders.</p>
<p>The use of penicillin and erythromycin in diphtheria is discussed in Chapter 46.
TETANUS ANTITOXIN: This is a serum preparation from the horse, actively immunised against the toxins of Cl . tetani. It contains the antitoxin globulins.</p>
<p>The prophylactic dose of the antitoxin is 3,000-5,000 units, administered by SC or IM injection, after preliminary testing. The immunity conferred wears off within 1 to 3 weeks. The utility of this procedure is not clearly proven. In areas where tetanus is almost endemic, severely contaminated or deep penetrating wounds should be treated with wound toilet, ATS and a course of an antibiotic to give the maximum protection. Clean wounds or small abrasions or lacerations may be treated without ATS. A second dose of ATS, in a patient who has received ATS once before, is very rapidly eliminated and hence, is ineffective. In such cases, active immunisation should be started at once. Due to possible severe allergic reactions to ATS, tetanus human immunoglobulin is preferred to ATS.</p>
<p>The ideal thing to do is to immunise everyone in the country with pre-exposure tetanus toxoid injections. In such individuals, post-exposure prophylaxis is also with tetanus toxoid. This is safer and economical.</p>
<p>TETANUS IMMUNOGLOBULIN (Human): This preparation contains specific gamma globulin prepared from human plasma having a high titre of tetanus antitoxin. Such plasma is obtained from blood of hyperimmunised subjects, or from placentas from mothers who have received tetanus booster inoculations a few weeks before delivery. The preparation is less prone to cause serious allergic reactions.</p>
<p>The half life of human immune globulin is between 3 to 4 weeks. Its prophylactic dose is 250-500 IU, IM. Active immunisation with tetanus toxoid should be carried out simultaneously. It is also used in proven or suspected cases in the dose of 500-10000 units given IV. Serious adverse effects are rare.</p>
<p>GAS GANGRENE ANTITOXIN: Antitoxin is not so useful and is no longer recommended. The treatment of this condition consists of high dose IV penicillin G, surgical debridement of the lesion and hyperbaric oxygen (when available).</p>
<p>BOTULINUM ANTITOXIN: This is a horse serum preparation, containing the antitoxin globulins which neutralise the toxins formed by Cl . botulinum, types A, B and E.</p>
<p>For effective treatment, the polyvalent antitoxin must be administered in the very early stage of botulism. The antitoxin is administered for prophylaxis in the dose of 2-10 ml IM as soon as possible after exposure. For therapy, 10-20 ml is administered by slow IV infusion, followed by 10 ml 2 and 4 hours later; further doses at intervals of 12-24 hours may be administered if needed.</p>
<p>RABIES ANTISERUM: This is a hyperimmune, horse serum containing the globulins that have the specific power of neutralising the rabies virus. It is usually given along with rabies vaccine in patients who have received severe bites. For this purpose, not less than 400 units are infiltrated around the wound and at the same time, a dose of 40 units per kg is given IM, simultaneously with rabies vaccine. Due to possible severe allergic reactions to the</p>
<p>rabies horse antiserum, rabies immune globulin is now preferred.
A highly purified immunoglobulin prepared from plasma of hyperimmunised horses (Pasteur antirabies serum) is also available.</p>
<p>RABIES IMMUNE GLOBULIN prepared from plasma of donors hyperimmunised with the rabies vaccine is available. It is indicated for all persons with known or suspected severe exposure to rabies virus and is given in conjunction with rabies vaccine. The dose is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mrow><mi mathvariant="normal">I</mi><mi mathvariant="normal">U</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">20 \mathrm{IU} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">20</span><span class="mord"><span class="mord mathrm">IU</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span>; one half of the dose should be infiltrated around the wound if feasible.</p>
<p>HEPATITIS B GLOBULIN: This is immune globulin prepared from the pooled plasma of donors with high titres of antibody to the surface antigen but not containing the surface antigen ( HBsAg ). It is indicated for post-exposure prophylaxis in susceptible individuals. The adverse reactions consist of local pain and tenderness and angioedema. The antibodies persist for three months.</p>
<p>ANTI-D (Rho) IMMUNOGLOBULIN (Human): This is prepared from pooled plasma of naturally immunised women with high titre of anti-D antibodies or from the serum of suitably immunised males. A highly purified preparation (RhoGAM) is also available.</p>
<p>In an Rh negative woman with an Rh positive husband, if the foetus is Rh positive, the foetal erythrocytes may escape into the maternal circulation across the placenta, commonly during delivery but rarely even during pregnancy. In order to neutralise this antigen before it causes maternal rhesus immunisation and to prevent erythroblastosis foetalis in subsequent pregnancies, it is necessary to give a dose of Rho (D) Ig, 500 units within 72 hours of delivery. Antenatal dose at 28 weeks of pregnancy is now recommended.</p>
<p>Rho (D) immunoglobulin is contraindicated in Rh positive women and in Rh negative women who develop Rh antibodies because of a previous conception or transfusion of Rh positive blood. The preparation is to be given to the post partum mother and not to the neonate. It is also used after abortion. Adverse reactions are usually mild.</p>
<p>ANTI-SNAKE VENOM SERUM: The poisonous snakes belong to three families:</p>
<ul>
<li>Viperidae (phoorsa, rattle snake, daboia),</li>
<li>Elapidae (cobra, krait, mamba) and</li>
<li>Hydrophiidae (sea-snakes).</li>
</ul>
<p>The viper venom commonly kills by its action on the cardio-vascular system, though some venoms contain a neurotoxin as well. The elapid venom contains mainly a neurotoxin which causes muscle paralysis by its neuromuscular blocking action. Such paralysis is not always reversible with the antivenom, particularly in case of krait bite. However, it is spontaneously reversible after about two days. Hence, management involves general support such as artificial respiration, intragastric feeding and maintaining vital parameters.</p>
<p>The dangers of poisonous snakebite in human victims appear to be greatly exaggerated. Nearly half of the people bitten by poisonous snakes such as cobra and vipers develop no significant systemic poisoning because of very low dose of the venom injected. Obviously, such patients need no antivenom therapy. Hence, in doubtful cases it is better to wait and watch the patient carefully for clear clinical evidence of systemic poisoning such as ptosis, limb and neck muscle paresis, blood stained sputum and failure of the blood to clot, before giving antivenom. However, such patients must be hospitalised and examined at 10-15 minute intervals. Since antivenom can sometimes cause severe reactions e.g. anaphylaxis, sensitivity tests must be performed prior to its administration.</p>
<p>Polyvalent, anti-snake-venom serum (antivenin) obtained from immunised horses</p>
<p>contains the purified antitoxin globulins that have the power of neutralising the venom of cobra, krait, Russell's viper and saw-scaled viper. It is reconstituted by adding 10 ml of distilled water. A sensitivity test is performed by injecting <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.02</mn><mo>−</mo><mn>0.1</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">0.02-0.1 \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.02</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord">0.1</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span> of 1:10 diluted antivenom SC. If no reaction occurs within <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow><mo separator="true">,</mo><mn>20</mn><mo>−</mo><mn>40</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">30 \mathrm{~min}, 20-40 \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8623em; vertical-align: -0.1944em;"></span><span class="mord">30</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">min</span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">20</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord">40</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span> is injected IV, very slowly ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mo>−</mo><mn>1</mn></mrow><annotation encoding="application/x-tex">0.5-1</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">1</span></span></span></span></span> <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">\mathrm{ml} / \mathrm{min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm">ml</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">min</span></span></span></span></span></span> ) as the first dose and repeated thereafter, if necessary, every 3-4 hours upto a total of 100 ml , depending upon the severity of the case. In case of viper bite, some serum is injected around the site of the bite to prevent the development of gangrene. The serum can also be given IM or SC though the IV route is preferred.</p>
<p>The presence of allergy demands desensitisation and administration of the antiserum in small, multiple doses. Allergic reactions and anaphylaxis is treated by the conventional methods. In a serious case, one may not wait for the sensitivity test but give the serum immediately. In such circumstances, it is advisable to use prophylactic adrenaline, an antihistaminic and a glucocorticoid simultaneously, and repeat them later, if needed, to protect the patient against allergic reactions. Antivenin is probably not effective against the toxin fixed to the tissues, nor can it reverse the damage already caused by the toxin.</p>
<p>For the use of cholinesterase inhibitor, edrophonium, for antagonising neuromuscular blockade in the treatment of snake bite, see Chapter 19.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drug-therapy-of-scorpion-sting">Drug Therapy of Scorpion Sting<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-therapy-of-scorpion-sting" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>This is a hazardous and potentially lethal condition caused by the sting of poisonous scorpions including the Indian red scorpion (Mesobuthus tamulus). The scorpion venom is a potent ANS stimulant. In addition to intense pain at the site of the sting, there is initially transient cholinergic stimulation followed by a prolonged sympathetic storm, due to release of massive amounts of catecholamines. The initial manifestations are vomiting, profuse sweating, excessive salivation, transient hypertension followed by hypotension, priapism, bradycardia and ventricular ectopy. The later manifestations are hyperglycemia, tingling and numbness, restlessness, tachypnoea, arrhythmias, pulmonary edema, and circulatory collapse.</p>
<p>Without adequate treatment the mortality may be as high as <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">30 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">30%</span></span></span></span></span>. Temporary relief of local pain can be obtained by infiltrating with a local anaesthetic agent without adrenaline. Longer relief is given by a local injection of 0.1 to 0.2 ml of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.03</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.03 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.03%</span></span></span></span></span>. dehydroemetine Even if systemic signs are absent, patient should be under observation for at least the next 6 hours.</p>
<p>Anti-scorpion venom serum (AScVS) against the venom of Indian red scorpion, manufactured by Haffkine Biopharmaceuticals, Mumbai, is now available and has been shown to be effective. It can be administered IV after a test dose of 0.1 ml SC. The dose varies from <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mo>−</mo><mn>80</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">40-80 \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">40</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord">80</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span> based on the severity of envenomation (as judged by clinical manifestations). But exact dosing has not been established.</p>
<p>AScVS will not counteract established pathology. As the systemic manifestations are mainly due to sympathetic overactivity. The immediate rational treatment is prazosin in the dose of 0.25 to 0.5 mg (adult dose) orally, repeated six hourly till improvement occurs (Chapter 30). The initial dose must be administered with patient lying down to prevent the first dose effect. Prazosin reduces the mortality markedly. Combination therapy with AScVS further improves the survival rate.</p>
<p>In life-threatening pulmonary oedema, sodium nitroprusside by IV infusion under careful monitoring has been recommended. Aminophylline IV can also help in management of pulmonary edema. Although sublingual nifedipine can reduce the BP and afterload, Its the negative inotropic action nifedipine may precipitate or worsen pulmonary edema.</p>
<p>The following drugs should be used with caution or avoided in victims of scorpion sting as they are likely to worsen the clinical condition: atropine, antihistamines, glucocorticoids, digoxin, diuretics and dopamine.</p>
<p>74</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="immunoglobulins-monoclonal-antibodies-immunosuppressants-and-immunomodulators">Immunoglobulins, Monoclonal antibodies, Immunosuppressants and Immunomodulators<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#immunoglobulins-monoclonal-antibodies-immunosuppressants-and-immunomodulators" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Antibody molecule (immunoglobulin, Ig) consists of two light and two heavy chains composed of different domains (1) Fab fragment and (2) Fc fragment (Fig. 74.1).
<img src="data:image/jpeg;base64,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" alt="img-6.jpeg"></p>
<p>FIG. 74.1 Basic structure of an immunoglobulin molecule. Two heavy and two light chains of amino acids are linked by disulfide (S-S) bridges. At one end of the molecule, the three dimensional stearic configuration (idiotypic determinant) of each arm allows only one antigenic determinant to have best fit status. The Fab fractions are variable and have antibody activity; and the other fraction is relatively constant ( Fc ). The amino acid sequence of the Fc fraction determines the main functional activity of the molecule.</p>
<p>The Fab fraction serves as the antigen binding site. The specific antigen-binding properties of an IgG molecule are conferred by the three dimensional stearic arrangement inherent in the amino acid sequence of the variable region of the light and the heavy chains of the molecule. This portion of the IgG molecule is called the idiotypic determinant. Only one antigenic determinant can have a 'best fit' with this arrangement. Apart from the idio-typic region, the remainder of the Ig G molecule viz, the Fc fragment is relatively constant and determines the effector function of the antibody. The Fc domain is necessary for interaction with the effector cells and for activating the complement cascade.
'HUMAN NORMAL IMMUNO- GLOBULIN' (HNI): Roughly, plasma protein can be fractionated into four important components, viz. albumin and the alpha, beta and gamma globulins. The gamma globulin carries antibodies.</p>
<p>Immunoglobulin (Ig) is a sterile serum protein solution (15-18%) containing antibodies from human blood, which is derived from pooled human serum; it mainly consists of IgG ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>95</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">95 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">95%</span></span></span></span></span> ) and only small amounts of other Igs (IgM and IgA) and other serum proteins (Chapter 1).</p>
<p>The Ig obtained from pooled, human, adult blood is known as immune serum. More selective type of gamma globulin against a particular infection can be obtained from the blood of individuals convalescing from that disease or from the blood of subjects recently immunised against that disease. This is called Hyperimmune Serum or Human Specific Ig.</p>
<p>Ig can be used both for prophylactic and therapeutic purposes. It is administered IM.
Adverse reactions: Ig can cause pain at the site of injection. Allergic reactions can occur. It may give rise to fever, flushing, shivering, joint pain and nausea. Severe bronchospasm, hypotension and collapse, however, are rare and occur mostly following IV therapy. Human Ig preparations are contraindicated in patients with class specific antibodies to IgA.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-uses">Therapeutic uses:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Hypogammaglobulinemia: Normally, the total gamma globulins in the plasma vary between 600 and 1500 mg per 100 ml . Total serum gamma globulins in normal Indians are much higher than those in Western people. Patients with serum gamma globulin concentration of 200 mg or less are considered to be suffering from hypogammaglobulinemia. HNI is usually given in dose of 0.025 to 0.05 g per kg body weight, at weekly intervals. Usually, very prolonged therapy is necessary along with prophylactic antibiotics.</li>
<li>Measles and rubella prophylaxis: HNI will attenuate or prevent the symptoms of measles if given early in the incubation period. The doses recommended are: for attenuation, 250 mg at all ages; for prevention 250 mg below one year, 500 mg at 1-2 years and 750 mg at 3 years and above. The effect lasts only for a few weeks. In pregnant women exposed to rubella, the dose recommended is 1 g .</li>
<li>Infective hepatitis: Gammaglobulin can suppress the clinical symptoms and if they occur, they are usually mild. The dose of HNI recommended is 750 mg given prophylactically in contacts. The effect lasts for 6 months. It is not effective in preventing hepatitis.</li>
<li>Mumps and poliomyelitis: Immune gammaglobulin has been claimed to be useful in preventing the complications of mumps and in reducing the incidence of paralytic poliomyelitis.</li>
<li>Diphtheria: Hyperimmune specific serum can be used both prophylactically and therapeutically.
Specific immunoglobulins are available for hepatitis B, rabies and tetanus. (Chapter 73).
Currently it is considered that that with the exception of primary and secondary immunodeficiency states, inadequate immunoregulation is the fundamental cause of immunopathology. Thus, IgG appears to be involved in the regulation of both allergic and autoimmune reactions i.e. disease-inducing reactions to foreignness and self, respectively. Although allergy is commonly equated with IgE mediated immediate hypersensitivity reaction (Chapter 2), there is increasing recognition that the undisciplined and even chronic release of cytokines represents a form of allergy that may produce disease analogous to diseases caused by the undisciplined release of histamine like agents from the basophils and mast cells. Cytokines such as IL-1, IL-6, interferons <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi></mrow><annotation encoding="application/x-tex">\beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span> and TNF <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span> have an effect both on the cells of the immune system and on many other cells and body systems from the CNS to the liver.</li>
</ul>
<p>We all constantly make small amounts of antibodies to our own tissue proteins and in</p>
<p>turn also make anti-idiotypic antibodies to these auto-antibodies. This latter manoeuvre is designed to prevent any important immunologic attack on self. Highly concentrated IgG preparations, now available, contain a vast "library of antibodies" capable of reacting with thousands of determinants because of the diversity of the experience of the thousands of donors contributing to the pool. Among such antibodies will be many with anti-idiotypic specificities.</p>
<p>IV IMMUNOGLOBULIN-G (IV-IG): The various, purified IV-IG preparations commercially available differ to some extent with regard to their content of sodium and sugar, a stabilising agent, and traces of IgA. They are supplied in liquid or lyophilised form.</p>
<p>Adverse reactions: They can cause acute reactions like headache, fever, myalgia and nausea and rarely anaphylaxis, aseptic meningitis, thromboembolic events or renal tubular necrosis can occur.</p>
<p>Therapeutic uses: In addition to primary and secondary immunodeficiency states, it is recommended for treating idiopathic thrombocytopenic purpura, Kawasaki syndrome and pediatric HIV. It may be of some use in chronic inflammatory, demyelinating polyneuropathy, Guillain-Barre syndrome, multifocal motor neuropathy, dermatomyositis, SLE and renal transplant rejection. Doses vary according to the disease. It is usually given in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mo>−</mo><mn>1.0</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mi mathvariant="normal">d</mi></mrow><annotation encoding="application/x-tex">0.5-1.0 \mathrm{~g} / \mathrm{kg} / \mathrm{d}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1.0</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mord">/</span><span class="mord mathrm">d</span></span></span></span></span> for 5 days. For primary immunodeficiency, the dose is 300-600 <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">\mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> every 3-4 weeks. It is very expensive.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="monoclonal-antibodies-mab-in-therapeutics">Monoclonal Antibodies (mAb) in Therapeutics<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#monoclonal-antibodies-mab-in-therapeutics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The first Nobel Prize in Medicine was awarded to immunologist Emil von Behring in 1901 for his work on serum therapy against diphtheria. This showed a new mode of treating diseases apart from drugs. Later, two other Nobel laureates, Rodney Porter and Gerald Edelman, in 1959 discovered the structure of antibodies, immunoglobulins. However, the greatest impetus to the development of immunology came from the discovery of the hybridoma technique for producing monoclonal antibodies (mAb) by George Kohler and Cesar Milstein in 1975. They were awarded Nobel Prize in 1984.</p>
<p>Monoclonal antibodies (mAb) are antibodies produced by a single clone of B cells. Compared to polyclonal antibodies, mAb are monospecific and homogenous. Such antibodies are used for diagnostic procedures and therapeutic purposes.</p>
<p>Structure of mAb and its functions are described earlier (Fig. 74.1). Replacing some amino acid sequences of murine antibody proteins by human components led to development of chimeric antibodies. Currently, humanised antibodies are available in which mouse proteins are largly replaced by human proteins. Hence they are less immunogenic and more efficient than the earlier introduced mouse mAb. They remain in circulation for a longer time and are preferred. Fully human monoclonal antibodies derived from transgenic mice or human antibody libraries further reduce the immunogenicity risk.</p>
<p>All monoclonal antibodies have suffix "mab" (Table 74.1). Their names may sound difficult but are in reality very logical. All have a prefix, two or more syllables long, as an unique identity. This is followed by an infix indicating either target or disease e.g. if the antibody is against tumours, infix is -tu- or -t-. If it is against fungi, then -fu- or -f-. If immunomodulatory then, -li-or-l-. There is a second infix that precedes "mab" and indicates source. The latter refers to species on which the immunoglobulin sequence of the mAb is based e.g., -o- if the source is from mouse; -xi- if chimeric; -zu- if humanised and -u- if fully human.</p>
<p>Table 74.1
Monoclonal antibodies for clinical use</p>
<table><thead><tr><th style="text-align: center;">Generic name</th><th style="text-align: center;">Target/Receptor</th><th style="text-align: center;">Indications</th></tr></thead><tbody><tr><td style="text-align: center;">Muromonab</td><td style="text-align: center;">CD3 (T cell)</td><td style="text-align: center;">Graft rejection</td></tr><tr><td style="text-align: center;">Basilliximab</td><td style="text-align: center;">CD25 (IL2 -receptor)</td><td style="text-align: center;">- Do-</td></tr><tr><td style="text-align: center;">Daclizumab</td><td style="text-align: center;">CD25 (IL-2 receptor)</td><td style="text-align: center;">- Do-</td></tr><tr><td style="text-align: center;">Alemtuzumab</td><td style="text-align: center;">CD52</td><td style="text-align: center;">Graft rejection; CLL</td></tr><tr><td style="text-align: center;">Infliximab</td><td style="text-align: center;">TNF alpha</td><td style="text-align: center;">RA; Crohn's disease</td></tr><tr><td style="text-align: center;">Adalimumab</td><td style="text-align: center;">TNF alpha</td><td style="text-align: center;">- Do-</td></tr><tr><td style="text-align: center;">Trastuzumab</td><td style="text-align: center;">HER2/neu</td><td style="text-align: center;">Breast cancer</td></tr><tr><td style="text-align: center;">Rituximab</td><td style="text-align: center;">CD20 (B cell)</td><td style="text-align: center;">Lymphoma; CLL</td></tr><tr><td style="text-align: center;">Abciximab</td><td style="text-align: center;">GpIIb/IIIa</td><td style="text-align: center;">Antiplatelet</td></tr><tr><td style="text-align: center;">Palivizumab</td><td style="text-align: center;">Fusion Protein</td><td style="text-align: center;">Anti Resp. syncitial virus</td></tr><tr><td style="text-align: center;">Gentuzumab</td><td style="text-align: center;">CD 33</td><td style="text-align: center;">AML</td></tr><tr><td style="text-align: center;">Cetuximab</td><td style="text-align: center;">EGFR</td><td style="text-align: center;">Colorectal cancer; NSCLC</td></tr><tr><td style="text-align: center;">Panitumumab</td><td style="text-align: center;">EGFR</td><td style="text-align: center;">- Do-</td></tr><tr><td style="text-align: center;">Efalizumab</td><td style="text-align: center;">CD11_(LFA-1)</td><td style="text-align: center;">Psoriasis</td></tr><tr><td style="text-align: center;">Bevacizumab</td><td style="text-align: center;">VEGF</td><td style="text-align: center;">Colorectal, lung cancer;</td></tr><tr><td style="text-align: center;"></td><td style="text-align: center;">Neovascular AMD</td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Ranibizumab</td><td style="text-align: center;">VEGF</td><td style="text-align: center;">Neovascular AMD</td></tr><tr><td style="text-align: center;">Eculizumab</td><td style="text-align: center;">Complement</td><td style="text-align: center;">Paroxymal nocturnal</td></tr><tr><td style="text-align: center;"></td><td style="text-align: center;">protein C5</td><td style="text-align: center;">hemoglobinuria</td></tr><tr><td style="text-align: center;">Omalizumab</td><td style="text-align: center;">IgE receptor</td><td style="text-align: center;">Bronchial asthma</td></tr><tr><td style="text-align: center;">Natalizumab</td><td style="text-align: center;">Integrin</td><td style="text-align: center;">Crohn's disease; MS</td></tr><tr><td style="text-align: center;">Certolizumab</td><td style="text-align: center;">TNF alpha</td><td style="text-align: center;">Crohn's disease</td></tr></tbody></table>
<p>VEGF = Vascular Endothelial Growth Factor
MS = Multiple Sclerosis
AMD = Age related Macular Degeneration
NSCLC = Non-small cell lung carcinoma
Thus, immunomodulatory monoclonal antibody, infliximab is chimeric while Adalimumab is fully human. Anti-tumour Trastuzumab is a humanised monoclonal antibody while Rituximab is chimeric. Abciximab against platelets is a chimeric antibody with cardiovascular indication (-ci- as infix). Palivizumab is a humanised antibody against respiratory syncitial virus (-vi- for virus).</p>
<p>Mechanism of action: They specifically block the characteristic of the targeted antigen, its function, its cell surface density and tissue distribution. Their action is directed against T lymphocytes, B lymphocytes, TNF and interleukins. Addition of active compounds to mAb to produce immuno-conjugates can provide targeting specificity to cytotoxic actions. Thus, mAb can be conjugated with catalytic toxins, radioisotopes and chemotherapeutic agents, and can be used as therapeutic guided missiles to target specific tissues with cytotoxic payload (e.g. arcitumomab, capromab etc).</p>
<p>Epidermal Growth Factor Receptor (EGFR) is a cell surface receptor involved in regulation of cell proliferation and survival. Selective antibodies have now been produced which act as EGFR inhibitor and are used to treat cancer e.g. cetuximab in colorectal cancer).</p>
<p>Absorption fate and excretion: mAb are used IV and they remain essentially intravascular, the volume of distribution is small and tissue penetration is limited. Depending on their nature, they remain in human circulation for 2 days to 2 weeks.</p>
<p>Some of the currently available mAb and their indications are listed in Table 74.1. They are all very expensive.</p>
<p>Adverse reactions: These vary according to antibody used.</p>
<ul>
<li>Hypersensitivity reactions are rare. However, sometimes the first injection may induce an influenza like syndrome causing fever, headache, chills, tachycardia, vomiting,</li>
</ul>
<p>arthralgia and hypotension. The reaction is reversible. It is believed to be due to massive systemic release of cytokines, following activation of T lymphocytes. These can be controlled by glucocorticoids and/wor antihistaminics</p>
<ul>
<li>Suppression of physiologic function may occur depending on specificity of tissues targeted; thus, anti-lymphocytic mAb causes immunosuppression.</li>
<li>Activation of inflammatory cells; and</li>
<li>Increased risk of infection, bleeding, proteinuria and hypertension. Trastuzumab can depress cardiac activity.
Therapeutic uses of mAb: They are used:</li>
<li>As immunosuppressants, e.g., to prevent the rejection of renal transplant</li>
<li>In autoimmune disease, e.g., infliximab in RA (Chapter 75)</li>
<li>As antiplatelet agents (Chapter 33)</li>
<li>In cancer chemotherapy, they are usually combined with conventional cytotoxic agents; and</li>
<li>As antiviral agent in the treatment of respiratory syncitial virus infection in infants (see later).
Diagnostic uses of mAb: They are extensively used in immunoassay and other procedures in the laboratory.</li>
</ul>
<p>In addition to monoclonal antibodies, fusion proteins are available for therapeutic use. Fc fragment of immunoglobulin is linked to ligand binding portion of receptor to form fusion receptor protein. They have longer <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> The examples are abatacept, eternacept (Chapter 75).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="immunosuppressants">Immunosuppressants<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#immunosuppressants" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Drugs which are used to suppress the immunity are called immunosuppressants. Since immunity confers resistance to disease, the use of drugs for deliberately suppressing it appears odd at first sight. However, the ability of the body to recognise self from not-self or foreign, which is the basis of immunity, is liable to cause disorders due to failure to recognise and tolerate antigens produced by its own tissues. This may cause exacerbation of an existing disease process or even produce new ones called autoimmune diseases e.g. SLE, RA, systemic vasculitis, psoriasis, multiple sclerosis and myaesthenia gravis. All the immunosuppressants are likely to increase the susceptibility of organisms to infection.</p>
<p>Immunosuppressive drugs are useful in:
(1) Treating autoimmune diseases; and
(2) Preventing immunorejection of organ transplants. They are classified in Table 74.2.</p>
<p>Table 74.2
Immunosuppresants</p>
<table><thead><tr><th style="text-align: left;">(1) Calcineurin inhibitors:</th><th style="text-align: left;">Cyclosporine</th></tr></thead><tbody><tr><td style="text-align: left;"></td><td style="text-align: left;">Tacrolimus</td></tr><tr><td style="text-align: left;">(2) Glucocorticoids</td><td style="text-align: left;">Prednisolone</td></tr><tr><td style="text-align: left;">(3) Cytotoxic/antiproliferative agents</td><td style="text-align: left;">Azathioprine</td></tr><tr><td style="text-align: left;"></td><td style="text-align: left;">Mycophenolate</td></tr><tr><td style="text-align: left;"></td><td style="text-align: left;">Sirolimus</td></tr><tr><td style="text-align: left;">(4) Antibodies</td><td style="text-align: left;"></td></tr><tr><td style="text-align: left;">(a) T cell depleting</td><td style="text-align: left;">Muromonab</td></tr><tr><td style="text-align: left;">Antibodies</td><td style="text-align: left;">Antilymphocytic antibodies</td></tr><tr><td style="text-align: left;"></td><td style="text-align: left;">Antithymocytic antibodies</td></tr><tr><td style="text-align: left;">(b) Anti CD25</td><td style="text-align: left;">Basilliximab</td></tr><tr><td style="text-align: left;">Antibodies</td><td style="text-align: left;">Daclizumab</td></tr></tbody></table>
<p>(1) Calcineurin inhibitors:</p>
<p>CYCLOSPORINE: The drug, formerly known as cyclosporin A, is a cyclic undecapeptide (11 amino acid) produced by the fungus Beauveria nivea. It has now been synthesised.</p>
<p>Mechanism of action: Calcineurin is required for induction of a T cell specific transcription factor involved in synthesis of cytokines by activated T cells. Cyclosporine acts as a selective immunosuppressant; it blocks an early stage in the activation of cytotoxic T lymphocytes after the recipient is exposed to the antigen. Within the T lymphocytes, it binds to an intracellular protein cyclophilin the complex then inhibits calcineurin.</p>
<p>Absorption, fate and excretion: Given orally, its bioavailability is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mo>−</mo><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">20-50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">20</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span>. In the circulation, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span> is bound to erythrocytes, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">10 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">10%</span></span></span></span></span> to leucocytes and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">40 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">40%</span></span></span></span></span> to lipoproteins in the plasma. It is almost completely metabolised, by CYP3A4.</p>
<p>Adverse reactions: The major toxic manifestations of cyclosporine are nephrotoxicity, hypertension and hyperlipidemia; the others are hypertrichosis, gum hypertrophy, increased susceptibility to infection, leucopenia thrombocytopenia and development of lymphomas caused by Epstein-Barr virus.</p>
<p>Preparations: Cyclosporine, 25, 50 and 100 mg capsules; as <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>100</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">100 \mathrm{mg} / \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">100</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span> oily solution for oral use and as a <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">50 \mathrm{mg} / \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">50</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span> solution for IV administration. Ophthalmic solution is also available.</p>
<p>Therapeutic uses: It is mainly used for prophylaxis and treatment of organ rejection in transplantation surgery. In recipients of renal transplants, the renal function is not as good</p>
<p>in those treated with cyclosporine as in those treated with azathropine plus glucocorticoids. However, cyclosporine is the preferred drug in 'high risk' recipients of renal transplants viz. the elderly and the recipients of second and third grafts. It is combined with a glucocorticoid. Its other use is autoimmune diseases such as RA, uveitis etc.</p>
<p>TACROLIMUS: It is a macrolide antibiotic isolated from Streptomyces tsukubaensis. It binds to an immunophilin (FK binding protein); the complex inhibits calcineurin, thereby inhibiting activation of T cell specific transcription factor. Tacrolimus is 100 times more potent than cyclosporine as an immunosuppressant.</p>
<p>Given orally, its bioavailability is variable and is reduced by food. The drug is extensively metabolised in the liver and less than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">1 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">1%</span></span></span></span></span> is excreted unchanged. It can also be given IV.</p>
<p>Adverse reactions: These are similar to those of cyclosporine, with nephrotoxicity being the major toxic manifestation. Other adverse reactions include nausea, diarrhoea, neurotoxicity, hypertension, hypomagnesemia, hyperkalemia and hyperglycemia.</p>
<p>Therapeutic uses: These are similar to those of cyclosporine.
(2) Glucocorticoids are potent immuno-suppressants and are used to prevent organ transplant rejection. They also possess antiinflammatory action (Chapter 66).
(3) Cytotoxic/antiproliferative agents: These are cytotoxic drugs which act on the dividing cells. An immune response is associated with division of lymphoid cells and these drugs act by interfering with the dividing lymphoid cells in the body. They, however, are non-specific and produce toxicity as they also affect the other rapidly dividing cells, (Chapter 61). Continuous, prolonged immunosuppression with cytotoxic agents is associated with a number of hazards particularly increased susceptibility to infection.</p>
<p>AZATHIOPRINE: and METHOTREXATE are the most commonly employed compounds.</p>
<p>MYCOPHENOLATE MOFETIL: This prodrug, given orally, is rapidly hydrolysed to the active compound, mycophenolic acid, which inhibits purine synthesis. It has a potent cytostatic effect on both B and T lymphocytes. This results in inhibition of lymphocyte proliferation and antibody formation. Mycophenolic acid is metabolised in the liver. Its adverse effects include GI and urinary disturbances, headache, hypertension and neutropenia, which are predominantly dose-dependent. The drug is used for the prophylaxis of allograft rejection and in the treatment of psoriasis, pemphigus vulgaris, systemic vasculitis and nephrotic syndrome.</p>
<p>SIROLIMUS: though structurally related to tacrolimus, differs in its mechanism of action. It forms a complex with circulating immunophilin but does not inhibit calcineurin. Instead, the complex binds and blocks a component of cellular signalling pathway involved in growth, proliferation and angiogenesis. Hence it is also termed as proliferation signal inhibitor (PSI). It is given orally, has a long tA and is a substrate for CYP3A4 and pglycoprotein. Its main ADR include profound myelosuppression, especially thrombocytopenia, hepatotoxicity, diarrhoea, increase in cholesterol and triglyceride levels and pneumonitis. It is used alone or in combination with other immunosuppressants to prevent and treat rejection of solid organ transplant and GVH (graft versus host) reaction. Topically it is used for uveoretinitis. Sirolimus eluting intracoronary stents are also available (Chapter 1); it inhibits cell proliferation in the endothelium, decreases neointimal hyperplasia and reduces the risk of in-stent stenosis.</p>
<p>Everolimus is a new PSI which acts like sirolimus but has shorter <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi>t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">t^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathnormal">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span>
(4) Monoclonal Antibodies (See Table 74.2) For specific T cell depleting antibody muromonab, and anti CD25 antibodies, see Table 74.1.</p>
<p>Antilymphocytic serum (ALS): The serum or semipurified antilymphocytic globulin is obtained from horses immunised against human thymus, lymph node and spleen cells (lymphoid tissue).</p>
<p>Specific antithymocytic globulin is obtained by injecting into horses, T cells from the thymus glands of children undergoing open heart surgery. The T lymphocytes are more vulnerable to ALS, which depletes the thymus dependent areas of lymphoid tissue, the lymphocytes being replaced by histiocytes.</p>
<p>When administered IM, along with other immunosuppressants like azathioprine and corticosteroids, in patients undergoing renal homotransplantation, ALS enables a considerable reduction in the dose of the other immuno-suppressants. It, however, is not a substitute for these drugs.</p>
<p>ALS is of benefit during bone marrow transplantation and in the treatment of rejection crises after renal transplantation.</p>
<p>Adverse reactions reported include pain and induration at the site of injection, fever, occasionally anaphylactic response and thrombocytopenia. An increased incidence of malignant tumors like lymphomas has been reported in patients receiving it IV, repeatedly.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="immunostimulants-and-immunomodulators">Immunostimulants and Immunomodulators<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#immunostimulants-and-immunomodulators" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The use of a variety of agents to enhance immunological and nonspecific host defences and thus to modify the defences favourably is an exciting development in immunopharmacology. Such agents may act by:</p>
<ul>
<li>Increasing the humoral antibody responses,</li>
<li>Enhancing the phagocytic activity of macrophages, or</li>
<li>Modifying the cell-mediated immune responses.</li>
</ul>
<p>No ideal immunostimulant is yet available.
Drugs like amantadine and tilorane stimulate the humoral immune system. Nonspecific immunostimulation with BCG has been used along with the conventional therapy in the treatment of leukemias, melanoma and lung and bladder carcinoma with some beneficial results (Chapter 54).</p>
<p>THALIDOMIDE: This drug, chemically related to barbiturates, and introduced as a hypnotic and antiemetic, was found to be teratogenic and hence rejected. It has now staged a comeback in therapeutics as an immunomodulator.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="mechanism-of-action">Mechanism of action:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#mechanism-of-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(a) Anti-inflammatory: It inhibits the production of TNF alpha and interferon, and has stimulatory effects on IGF1, IL-6 and IL-2.
(b) Immunomodulatory: It reduces phagocytosis by neutrophils and enhances CMI by interacting with T cells.
(c) Antiangiogenic: It inhibits the induction of COX-2 and the biosynthesis of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">E</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGE}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGE</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> needed for angiogenesis.</p>
<p>Given orally, it is well absorbed and is metabolised to several metabolites. 5-Hydroxy thalidomide is an active metabolite. It is administered in the dose of 100-300 mg daily at bed time 1 hour after dinner.</p>
<p>Adverse reactions: It can cause sedation, dizziness, constipation, tremors, mood changes. Increased risk of DVT and rarely, peripheral neuropathy and hypothyroidism may occur. It is highly teratogenic.</p>
<p>Therapeutic uses:</p>
<ul>
<li>Drug of choice in symptomatic treatment of moderate to severe ENL (Chapter 55).</li>
<li>Multiple myeloma, refractory to other treatments.</li>
<li>Refractory cutaneous lupus lesions.</li>
<li>Crohn's disease.</li>
<li>Treatment of cachexia and weight loss in HIV and that due to TNF- <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span> in cancer patients. It counters nausea, vomiting and anorexia due to TNF- <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span> in cancer patients.</li>
<li>In advanced prostatic cancer, as an immunomodulator.</li>
<li>To inhibit angiogenesis.</li>
</ul>
<p>Lenalidomide is a derivative of thalidomide and is used for multiple myeloma and myelo-plastic syndrome. It is also teratogenic.</p>
<p>Levamisole, an anthelmintic has immuno-tropic properties and may help in restoring the efficiency of host defence mechanisms (Chapter 60). It probably acts by modulating cell mediated immune responses. It enhances T cell-mediated immunity. It restores or augments cutaneous-delayed hyper-sensitive reactions in anergic (state of immunologic deficiency) patients with cancer. Like BCG and clofazimine, (Chapter 55) its effect is</p>
<p>associated with enhanced phagocytic activity of the macrophages. The drug may cause GI disturbances, headache, dizziness, insomnia, thrombocytopenia and agranulocytosis.</p>
<p>Interferons are naturally occurring proteins with complex effects on immunity. They may act directly on normal cells and induce enzymes that attack viral RNA; or indirectly by stimulating the immune system. Interferons have been shown to produce some beneficial effect on certain human lymphoreticular and other cancers, in multiple sclerosis and in hepatitis B. (Chapter 61).</p>
<p>GLATIRAMER ACETATE: This is a synthetic co-polymer with some immunological similarity to myelin basic protein, one of the major components of myelin. Given SC, it is claimed to reduce the relapse rate in relapsing - remitting multiple sclerosis. It probably acts as an immunomodulator.</p>
<p>For use of monoclonal antibodies, see earlier.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="section-xvi-miscellaneous">SECTION XVI Miscellaneous<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#section-xvi-miscellaneous" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="outline">OUTLINE<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#outline" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Chapter 75: Pharmacotherapy of Gout, Rheumatoid Arthritis and Osteoarthritis
Chapter 76: Metals and Their Antagonists
Chapter 77: Gases: Therapeutic and Toxic
Chapter 78: Enzymes in Therapy
Chapter 79: Vitamins and Antioxidants
Chapter 80: Drugs, Pregnancy and the Infant</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="pharmacotherapy-of-gout-rheumatoid-arthritis-and-osteoarthritis">Pharmacotherapy of Gout, Rheumatoid Arthritis and Osteoarthritis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacotherapy-of-gout-rheumatoid-arthritis-and-osteoarthritis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Acute or chronic arthritis or penriarthritis can be caused by monosodium urate (MSU), calcium pyrophosphate dihydrate (CPPD), calcium hydroxyapatite (HA) and calcium oxalate (CaOx). In spite of differences in composition, the deposition of crystals in the joints causes clinically indistinguishable arthropathies. The definitive diagnosis of the type of arthritis can only be made by aspiration-analysis of the synovial effusion for the type of microcrystals.</p>
<p>Gout is a metabolic disorder that results from increase in body pool of urate and comprises of:</p>
<ul>
<li>Arthritis due to a reaction to the deposition of MSU in the joint. It is acute, recurrent, monoarticular, at least in the initial years, and usually involves a peripheral joint in the lower limbs.</li>
<li>Painless deposition of urate crystals in the soft tissues such as cartilage, bursae and tendons.</li>
<li>The development of 'tophi' in the latter after many years of recurring gouty arthritis; tophi may not be seen clinically but are often diagnosed radiologically and</li>
<li>Renal calculi and nephropathy</li>
</ul>
<p>The first episode of acute MSU gouty arthritis many times begins at night with dramatic joint pain and swelling which mimic cellulitis. Less commonly, the arthritis may be less severe and more indolent, and involve more than one joint at one time.</p>
<p>The diagnosis of MSU gout depends upon:</p>
<ul>
<li>A characteristic clinical arthritis</li>
<li>Tophi; and</li>
<li>The presence of typical urate crystals in the joint fluid and the tophi.</li>
</ul>
<p>The disease largely affects middle aged to elderly men and only 5-15% of women.
The incidence of gout rises with the serum uric acid level and the duration of hyperuricemia; however hyperuricemia per se does not confirm or exclude the diagnosis of gout. Hyperuricemia is necessary but not sufficient for the development of gout; only about 5% of patients with hyperuricemia, in fact, ever develop gout.</p>
<p>Hyperuricemia is due to either increased urate production or decreased urate excretion. It may be primary; or secondary to (a) Renal impairment; (b) Drugs (Table 75.1); or (c) Massive lysis of cells during cancer chemotherapy.</p>
<p>Table 75.1
Drugs causing hyperuricemia</p>
<div data-testid="stMarkdownPre" class="st-emotion-cache-acwcvw e1icttdg5"><div class="stCode st-emotion-cache-6ml83 e1xss9yb4" data-testid="stCode"><pre class="st-emotion-cache-1nqbjoj e1xss9yb2"><div style="background-color: transparent;"><code style="white-space: pre;"><span>- Alcohol
</span>    - Thiazides, Loop diureics, Amiloride
    - Cytotoxic drugs
    - Isotretinoin
    - Ethambutol, Pyrazinamide
    - Salicylates in low doses
    - Cyclosporine
    - Levodopa
    - Niacin</code></div></pre><div class="st-emotion-cache-chk1w8 e1xss9yb3"><button data-testid="stCodeCopyButton" title="Copy to clipboard" data-clipboard-text="- Alcohol
    - Thiazides, Loop diureics, Amiloride
    - Cytotoxic drugs
    - Isotretinoin
    - Ethambutol, Pyrazinamide
    - Salicylates in low doses
    - Cyclosporine
    - Levodopa
    - Niacin" style="top: 0px; right: 0px;" class="st-emotion-cache-1lyayqq e1xss9yb5"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><rect x="9" y="9" width="13" height="13" rx="2" ry="2"></rect><path d="M5 15H4a2 2 0 0 1-2-2V4a2 2 0 0 1 2-2h9a2 2 0 0 1 2 2v1"></path></svg></button></div></div></div>
<p>Only about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">10 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">10%</span></span></span></span></span> of patients with primary gout overproduce urate; majority of patients have diminished fractional renal clearance of urate in spite of normal overall renal function. In humans, who genetically lack uricase, urate which is less soluble circulates as such in the plasma. In MSU gout the patient has uric acid pool, several times that of normal.</p>
<p>Asymptomatic hyperuricemia (serum urate <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>6.8</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">&gt;6.8 \mathrm{mg} \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.9444em; vertical-align: -0.1944em;"></span><span class="mord">6.8</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">%</span></span></span></span></span> ) does not warrant drug treatment. But one should not ignore asymptomatic hyperuricemia as it is associated with increased risk of hypertension, cardiovascular diseases, diabetes, CKD and all cause mortality. Hence, the correction of reversible risk factors such as obesity, hyperlipidemia, excess alcohol consumption, high purine diet (meat and fish) and drugs known to cause hyperuricemia is wise. Preference should be given to losartan and fenofibrate in asymptomatic hyperuricemic patients with hypertension and hyperlipidemia respectively.</p>
<p>Table 75.2 outlines the principles of diet in prevention and treatment of hyperuricemia.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="table-75-2">Table 75.2<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-75-2" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Diet in prevention and treatment of hyperuricemia and gout</p>
<ul>
<li>Avoid/minimise consumption of fatty meats (red meat); sea food; and fats.</li>
<li>Consume regularly cereals; pulses; fruits; vegetables; nuts in moderation; and low fat milk and milk products.</li>
<li>Purine-rich fruits, beans and legumes have not been shown to be a risk factor in gout. Consumption of eggs is not a risk factor but they have high cholesterol content. Tea, coffee and spices pose no risk. Salt and pickles are not a risk factor in gout but an excess salt consumption is a risk factor in hypertension, and in hypercalciuria a renal calculi.</li>
<li>Carbonated beverages may contain added phosphoric acid and their regular consumption may be a risk factor for calcium oxalate renal calculi.</li>
</ul>
<p>Purine content of the diet contributes to at the most <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1.0</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">1.0 \mathrm{mg} \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9444em; vertical-align: -0.1944em;"></span><span class="mord">1.0</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">%</span></span></span></span></span> of the plasma urate concentration; nevertheless, reduction in excessive purine consumption is desirable.</p>
<p>Patients with clinical MSU gout need drug therapy (Table 75.3).</p>
<p>Table 75.3
Drugs used in gout</p>
<ul>
<li>Colchicine: Specific, slow-acting, adverse effects.</li>
<li>NSAID (short-acting such as ibuprofen and indomethacin): Non-specific, rapid, better tolerated.</li>
<li>Corticosteroids: Effective intraarticularly and systemically; potential for rebound inflammation and adverse effects.</li>
</ul>
<p>II To prevent acute attacks:</p>
<ul>
<li>Colchicine: Effective in a dose adjusted not to cause diarrhoea.</li>
<li>NSAID: Less well tolerated for this purpose but may be used if colchicine alone is not sufficient to prevent frequent acute attacks.
III To lower serum urate levels</li>
<li>Probenecid: Well tolerated; interferes with excretion of many drugs; risk of urolithiasis. Uricosuria is reversed by salicylates.</li>
<li>Allopurinol: Inhibits uric acid synthesis; once a day dosage increases convenience; excretion impaired in renal insufficiency.</li>
<li>Sulfinpyrazone and benzbromarone are less commonly used drugs.</li>
</ul>
<p>1 To treat acute gouty arthritis:</p>
<ul>
<li>Colchicine: Specific, slow-acting, adverse effects.</li>
<li>NSAID (short-acting such as ibuprofen and indomethacin): Non-specific, rapid, better tolerated.</li>
<li>Corticosteroids: Effective intraarticularly and systemically; potential for rebound inflammation and adverse effects.</li>
</ul>
<p>II To prevent acute attacks:</p>
<ul>
<li>Colchicine: Effective in a dose adjusted not to cause diarrhoea.</li>
<li>NSAID: Less well tolerated for this purpose but may be used if colchicine alone is not sufficient to prevent frequent acute attacks.</li>
</ul>
<p>III To lower serum urate levels</p>
<ul>
<li>Probenecid: Well tolerated; interferes with excretion of many drugs; risk of urolithiasis. Uricosuria is reversed by salicylates.</li>
<li>Allopurinol: Inhibits uric acid synthesis; once a day dosage increases convenience; excretion impaired in renal insufficiency.</li>
<li>Sulfinpyrazone and benzbromarone are less commonly used drugs.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drugs-used-during-acute-stage">Drugs Used During Acute Stage<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drugs-used-during-acute-stage" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>COLCHICINE is an alkaloid obtained from Autumn crocus (colchicum). It is a highly effective and specific for the treatment and prevention of acute gouty arthritis.</p>
<p>Mechanism of action: Sodium urate crystals in joints are coated by either anti-urate IgG antibody or lipoprotein containing apolipoprotein B and then ingested by granulocytes; the latter then release a glycoprotein which amplifies neutrophil infiltration into the joint. By binding to tubulin, colchicine damages the micro-tubules in the granulocytes and interferes with the mitotic spindles. It thereby inhibits migration of cells into the inflamed area. Thus, it prevents the intra-articular release of mediators of inflammation by neutrophils. It also inhibits the mast-cell release of histamine. It does not prevent phagocytosis of urate crystals.</p>
<p>Absorption, fate, excretion: Oral absorption of colchicine is variable. It is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span> protein bound and accumulates in the kidney, liver and spleen. It undergoes enterohepatic circulation. It appears to undergo oxidative demethylation by CYP3A4. Urinary excretion is only <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mo>−</mo><mn>20</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">10-20 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">10</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">20%</span></span></span></span></span>. Its plasma <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> is 9 hours. The drug is contraindicated in patients with hepatic or renal impairment.</p>
<p>Adverse reactions: Commonly, it produces GI upset and diarrhoea. Occasionally, it may cause anemia, alopecia, leucopenia and agranulocytosis. Prolonged therapy may rarely cause myopathy (proximal muscle weakness), but the incidence increases in patients taking statins/fibrates. Because of the troublesome diarrhoea, some workers prefer indomethacin to colchicine in the treatment of acute gouty arthritis.</p>
<p>Cimetidine and erythromycin reduce the metabolism of colchicine and increase its toxicity. P-glycoprotein efflux transporter inhibitors like cyclosporine can cause fatal toxicity of colchicine. Colchicine is rapidly degraded by exposure to light and loses its therapeutic efficacy.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="therapeutic-uses">Therapeutic uses:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Treatment of acute attacks of gouty arthritis: The drug is administered orally using single dose of 1.2 mg , followed by 0.6 mg 1 hour later. It relieves pain in most cases within 24-48 hours. If taken early in the attack, it can relieve the attack within a few hours or even abort it. Therapy must not be repeated within 4 days to avoid cumulative toxicity. Colchicine may be used for a therapeutic trial when the diagnosis of gouty arthritis is in doubt, because the response to colchicine is specific to gout. Unlike indomethacin, colchicine does not cause fluid retention; hence, is valuable in patients with heart failure. Further, it can be given to patients receiving anticoagulants.</li>
<li>Prevention of acute attacks of gouty arthritis: Prophylactically administered in small doses of 0.6 mg twice daily for 6 months, it can reduce the frequency of attacks in patients having 3 or more attacks in a year. For chronic use, in small doses it is better tolerated than NSAID. Prophylactic colchicine prevents precipitation of an acute attack by a surgical procedure or by initiation of hypouricemic drug therapy.</li>
<li>Prevention of attacks of familial Mediterranean fever (familial paroxysmal polyserositis.)
INDOMETHACIN: This NSAID, in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mo>−</mo><mn>50</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">25-50 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">25</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">50</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> tid for 5-7 days, can promptly relieve pain. However, the incidence of gastric intolerance is high. The drug can also be given as 100 mg suppositories. Naproxen, or ibuprofen is equally effective and less toxic</li>
</ul>
<p>(see Chapter 11).
GLUCOCORTICOIDS: Glucocorticoids can be used in very severe cases, refractory to colchicine and NSAID. Their action is not specific and the relapse rate is very high following the withdrawal. Prednisolone is given in the dose of 20 mg bid till the patient is asymptomatic for 1 week and then is progressively reduced by <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><mn>10</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">5-10 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">10</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> every day. When a large joint such as the knee joint is affected, aspiration and intra-articular injection of hydrocortisone acetate, methylprednisolone or triamcinolone may give dramatic relief.</p>
<p>In severe cases with excruciating pain colchicine, maximum dose NSAID and prednisolone may be combined. An opioid analgesic may be necessary until pain is relieved by other agents.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drugs-used-in-long-term-therapy-of-gout">Drugs Used in Long Term Therapy of Gout<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drugs-used-in-long-term-therapy-of-gout" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>These drugs are indicated when any of the following criteria are fulfilled:</p>
<ul>
<li>The cause of hyperuricemia cannot be corrected or such correction does not lower the plasma urate to less than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>7</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">7 \mathrm{mg} \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9444em; vertical-align: -0.1944em;"></span><span class="mord">7</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">%</span></span></span></span></span>.</li>
<li>The patient has had at least two definite attacks of acute gouty arthritis or has tophi;</li>
<li>The patient agrees to take the medication regularly almost lifelong; and</li>
<li>Acute attacks with serum uric acid level of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>9</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">9 \mathrm{mg} \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9444em; vertical-align: -0.1944em;"></span><span class="mord">9</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">%</span></span></span></span></span> or higher.</li>
</ul>
<p>The drugs act by reducing the plasma urate levels either by:
I Excreting uric acid e.g. Uricosuric drugs; or
II Preventing uric acid synthesis e.g. Xanthine oxidase inhibitors
They do not prevent the acute attacks, but they decrease the frequency of attacks and may diminish the incidence of renal damage and other complications due to urate deposition. Reduction of plasma urate level to less than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>6</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">6 \mathrm{mg} \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9444em; vertical-align: -0.1944em;"></span><span class="mord">6</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">%</span></span></span></span></span> is required to prevent acute gouty arthritis and less than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">4 \mathrm{mg} \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9444em; vertical-align: -0.1944em;"></span><span class="mord">4</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">%</span></span></span></span></span> for reabsorption of tophi.</p>
<p>Initial treatment is always with uric acid synthesis inhibitors. If they fail, then uricosuric drugs are supplemented with.</p>
<p>Therapy to reduce plasma urate level should be started only after the subsidence of acute joint inflammation as otherwise it may delay recovery from the acute attack. However, preexisting therapy with plasma urate lowering drugs should not be stopped in case of an acute attack. If started in the interval between acute attacks, it should be preceded by prophylactic treatment with colchicine as rapid lowering of uric acid sometimes precipitates an attack probably due to mobilisation of uric acid from the tophi. Prophylactic colchicine should be continued for one year after the plasma urate level has returned to the target level.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="xanthine-oxidase-inhibitors">Xanthine Oxidase Inhibitors<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#xanthine-oxidase-inhibitors" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>ALLOPURINOL: It is 4-hydroxy-pyrazolo 3, 4 d-pyrimidine (Fig. 75.1). It is useful for long term management of gout.
<img src="data:image/jpeg;base64,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" alt="img-7.jpeg"></p>
<p>Mechanism of action: During purine metabolism, the purine nucleotides are degraded to hypoxanthine and xanthine, which are then oxidised to uric acid by xanthine oxidase. Allopurinol and its metabolic product alloxanthine (oxipurinol), inhibit xanthine oxidase (Fig. 75.2) and hence, they:
<img src="data:image/jpeg;base64,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" alt="img-8.jpeg"></p>
<ul>
<li>Inhibit the oxidation of hypoxanthine and xanthine to uric acid.</li>
<li>Lower serum and urine uric acid;</li>
<li>Reduce size of tophi and</li>
<li>Increase the excretion of hypoxanthine and xanthine in the urine. Both these oxypurine compounds are cleared rapidly by the kidney and hence, there is less hazard of their crystallisation in the kidneys and causing urate nephrolithiasis. This is an advantage over uricosuric drugs.
Adverse reactions: The incidence of adverse reactions is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>15</mn><mi mathvariant="normal">%</mi><mo>−</mo><mn>20</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">15 \%-20 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.0833em;"></span><span class="mord">15%</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">20%</span></span></span></span></span>. The most common are allergic skin rash, nausea, vomiting, diarrhoea. Leucopenia, hepatic damage and vasculitis can occur. Haemosiderosis is a rare but serious complication. The other severe ADR are toxic epidermal necrolysis, bone marrow suppression and ototoxicity.</li>
</ul>
<p>Preparation and dosage: It is started in a dose of 100 mg per day with monitonring of serum uric acid levels after 2 weeks. The dose is increased gradually every 2 weeks till the serum uric acid fall below <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>6</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">6 \mathrm{mg} \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9444em; vertical-align: -0.1944em;"></span><span class="mord">6</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">%</span></span></span></span></span>. The maximum approved dose is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>800</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">800 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">800</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day. A single dose is preferred as the half life of the active metabolite, oxypurinol, is about 20 hours. In chronic renal failure, the dose of allopurinol should be reduced in the same proportion as GFR.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="therapeutic-uses">Therapeutic uses:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Gout: Allopurinol is used for controlling hyperuricemia. It is useful in patients with</li>
</ul>
<p>gouty tophi or uric acid calculi and in those with renal failure which renders uricosuric drugs less effective. Uricosuric drugs may be started as an initial therapy in patients who have urinary uric acid excretion less than 800 mg of uric acid per day but have normal renal function. Allopurinol may be combined with uricosuric drugs.
Use of these drugs makes rigid dietary control unnecessary though the control of risk factors, especially obesity, is essential.</p>
<ul>
<li>Secondary hyperuricemia: This occurs following the use of cytotoxic drugs in the treatment of leukemia and lymphoma. Therefore, allopurinol is started before starting chemotherapy. Inhibition of xanthine oxidase, which also metabolises 6-mercaptopurine, prolongs its <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi>t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">t^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathnormal">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span>; hence its dose is reduced to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">/</mi><msup><mn>2</mn><mtext>rd&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">1 / 2^{\text {rd }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.0991em; vertical-align: -0.25em;"></span><span class="mord">1/</span><span class="mord"><span class="mord">2</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">rd&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> or <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">/</mi><msup><mn>4</mn><mtext>th&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">1 / 4^{\text {th }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.0991em; vertical-align: -0.25em;"></span><span class="mord">1/</span><span class="mord"><span class="mord">4</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">th&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> to avoid serious toxicity.
FEBUXOSTAT: This orally active, nonpurine analogue of allopurunol acts as an inhibitor of xanthine oxidase. It is well tolerated and can be used in patients allergic to or intolerant of allopuriol. The maximum daily dose is 80 mg . It is mainly metabolised in the liver. Mild to moderate renal insufficiency does not alter its serum uric acid lowering ability. Its ADR include liver function abnormalities, headache, nausea, and Steven -Jhonson syndrome.</li>
</ul>
<p>Rasburicase is a recombinant urate oxidase which causes enzymatic degradation of uric acid to soluble allantoin. It is usually used to reduce the elevated uric acid levels in tumour lysis syndrome (TLS) that is seen following cancer chemotherapy. Its ADR include vomiting, fever, headache, GI upset, mucositis, acute renal failure, anaphylaxis and hemolysis in G6PD deficiency patients. Pegloticase is pegylated mammalian recombinant uricase produced by genetically modulated strain of E. coli. It is used for the treatment of chronic resistant gout. The ADR include infusion reactions, anaphylaxis and development of antipegloticase antibodies.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="uricosuric-drugs">Uricosuric Drugs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#uricosuric-drugs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>PROBENECID: This uricosuric agent (Fig 75.3) is given orally. It is given initially in doses of 0.5 g once daily, gradually increasing to three times daily. In low doses, it causes a decrease in distal tubular secretion of uric acid but in larger therapeutic doses, it increases its excretion, by blocking tubular reabsorption. After treatment for some months, the serum uric acid may return to normal levels together with significant mobilisation of gouty tophi.
<img src="data:image/jpeg;base64,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" alt="img-9.jpeg"></p>
<p>Adverse reactions: The drug is relatively non-toxic and is well tolerated. Occasionally, it causes dyspepsia, skin rashes and deposition of urate crystals in the renal tubules/pelvis; this risk can be minimised by maintaining a high volume of alkaline urine with 1 g of sodium bicarbonate orally 3-4 times a day. The drug inhibits the renal excretion of drugs such as penicillin, indomethacin, methotrexate and dapsone. It also impairs heparin metabolism thus reducing the dose of heparin necessary for anticoagulation.</p>
<p>SULFINPYRAZONE: This is a sulfoxide derivative of phenylbutazone (Fig 75.4) with some anti-inflammatory activity but marked uricosuric property. This effect is dose related. Like probenecid its smaller dose prevents the tubular secretion of uric acid while higher dose promotes its excretion. It is administered orally in doses of 100-200 mg tid. The daily dose should not exceed 600 mg .
<img src="data:image/jpeg;base64,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" alt="img-10.jpeg"></p>
<p>Adverse reactions: These include vomiting, upper abdominal discomfort and skin rashes. Rarely, it can aggravate an existing DU and may cause bone marrow depression. Sulfinpyrazone inhibits platelet aggregation.</p>
<p>Both probenecid and sulfinpyrazone are ineffective in the presence of impaired renal function.
Benzbromarone, a benzofuran compound, is another uricosuric drug. It is potent and is claimed to be effective even when the GFR is reduced to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mo>−</mo><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">25-50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">25</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span> of normal.</p>
<p>AZAPROPAZONE: This uricosuric agent has weak analgesic, antipyretic and anti-</p>
<p>inflammatory actions; it is a weak inhibitor of cyclooxygenase. The drug is rapidly and almost completely absorbed from the gut. It is relatively toxic. The common ADR comprise mild GI effects and headache. The dose in acute gout is 600 mg four times on the first day, followed by 1800 mg a day in divided doses until the acute attack has subsided; the maintenance dose is 1200 mg a day in divided doses. It has also been used for the treatment of RA and OA.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="uricosuric-drugs-can-be-hazardous-in">Uricosuric drugs can be hazardous in:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#uricosuric-drugs-can-be-hazardous-in" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Urate overproducers ( 24 hour urine urate more than 800 mg )</li>
</ul>
<p>Those with urine flow consistently less than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">1 \mathrm{ml} / \mathrm{min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1</span><span class="mord"><span class="mord mathrm">ml</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">min</span></span></span></span></span></span></p>
<ul>
<li>Those with creatinine clearance less than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">50 \mathrm{ml} / \mathrm{min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">50</span><span class="mord"><span class="mord mathrm">ml</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">min</span></span></span></span></span></span>; and</li>
<li>Those with history of renal calculi</li>
</ul>
<p>Aspirin, an analgesic, relieves joint pains (Chapter 11). Although it has a uricosuric action, the dose required for persistent uricosuria is large, which is unacceptable. In smaller doses it acts as anti-uricosuric and also blocks the uricosuric effect of other drugs. Salicylates, therefore, should be avoided in gout.</p>
<p>Other measures in gout: With the uricosuric drugs a fluid intake sufficient to yield daily urinary output of at least 2 litres and the maintenance of a neutral or slightly alkaline urine pH are desirable to prevent renal damage. This is particularly important during hot weather and in the tropics.</p>
<p>Other crystal-induced arthropathies: Acute CPPD arthritis was formerly known as pseudogout because of its similarities with MSU gout. There is no effective therapy to remove the synovial deposits, and the treatment is symptomatic viz. NSAID, colchicine and intra-articular glucocorticoid.</p>
<p>The treatment of HA arthritis and calcium oxalate arthritis is also symptomatic.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="pharmacotherapy-of-rheumatoid-arthritis-ra">Pharmacotherapy of Rheumatoid Arthritis (RA)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacotherapy-of-rheumatoid-arthritis-ra" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Rheumatoid arthritis (RA) is a chronic, systemic, inflammatory disease predominantly affecting joints, and periarticular (synovial) tissues. Of all the rheumatoid disorders, RA remains a formidable disease, being capable of producing severe crippling deformities and functional disabilities. Common clinical signs and symptoms are pain and/or joint swelling, morning stiffness at least for 1 hr , fatigue, fever and weight loss. The disorder is more common in women and elderly persons. Its etiology is unknown although the main risk factors include genetic factors and smoking. Infection as the initial trigger has been suspected.</p>
<p>Current evidence indicates that RA is an autoimmune disease. Autoantibodies to the Fc portion of IgG antibody are produced by B lymphocytes in the blood and synovial tissues in <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>80</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">80 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">80%</span></span></span></span></span> of RA patients. High titres of serum RA factor (RF), typically of the IgM isotype, is associated with more severe joint disease with extra-articular manifestations. Other important antibodies are those directed against citrullinated peptide (ACPA) which seems to be more specific and sensitive marker. About <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mo>−</mo><mn>80</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50-80 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">50</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">80%</span></span></span></span></span> of RA patients have RF or ACPA or both. Clinical diagnosis is confirmed by estimating ESR, autoantibody and radiographs. Antibodies are detected years before onset of disease.</p>
<p>Pathophysiology: RA is a clinical syndrome with many disease subsets. It comprises of three basic interrelated pathological processes:</p>
<ul>
<li>Inflammation</li>
<li>Synovial proliferation; and</li>
<li>Joint tissue destruction</li>
</ul>
<p>The focus of RA is the synovial lining. RA factor-containing immune-complexes found in the joints activate the pathological process.</p>
<p>The earliest lesion is vasculitis, an inflammation of small blood vessels. The inflammation causes edema of the synovium and infiltration with mononuclear cells, macrophages, lymphocytes and plasma cells. There is intense local production of IgG by the plasma cells. The activated macrophages, lymphocytes and fibroblasts produce a variety of cytokines that promote further synovial proliferation and inflammation. Tumour necrosis factor (TNF alpha), produced by activated macrophage like synoviocytes, exerts powerful effects on the immune system, including induction of pro-inflammatory mediators. Synovial fluid in RA contains PGs (mainly <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">E</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGE}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGE</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> ), leukotriene <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">B</mi><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{B}_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>, TNF-alpha, interleukins and other cytokines. It is now believed that the monokines IL-1 and IL-6, and TNF alpha are the central mediators of active rheumatoid process.</p>
<p>Joint damage occurs early in the course of RA. Fibroblasts like sinoviocytes invade the cartilage. Osteoclasts activation is considered to be a key event in bone destruction.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="classification-of-drugs-used-in-ra">Classification of drugs used in RA:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#classification-of-drugs-used-in-ra" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>I Anti-inflammatory-analgesic drugs: Aspirin and other NSAID (Chapter 11).
II Anti-inflammatory drugs with indirect analgesic action: Glucocorticoids (Chapter 66). They also have immunomodulatory activity.</p>
<p>These two groups act rapidly, relieve pain and control inflammation; they thus help to improve and maintain joint function. However, they do not halt the underlying destructive process.
III Disease Modifying Antirheumatic Drugs, (DMARD): e.g. Methotrexate, Sulfasalazine,</p>
<p>Chloroquine, Gold salts, and Leflunomide.
They have no analgesic or immediate anti-inflammatory effect and begin to act after 6-12 weeks. They remain in the body for a long time and probably modulate immune function. They arrest the basic destructive process in the joints and modify the course of the disease. They may induce remission.</p>
<p>IV Biological agents: This heterogenous group includes complex protein molecules which are developed using molecular biological techniques. Their action is predictable and results from interaction with cytokines or cell surface molecules. These are:
(a) TNF-alpha blockers: Infliximab, Adalimumab and Etanercept.
(b) IL-1 receptor antagonist - Anakinra.
(c) IL-6 receptor antagonist - Tocilizumab.
(d) T cell activation inhibitors - Abatacept.
(e) Anti B-lymphocyte antibody - Rituximab.
(f) Tyrosine kinase inhibitor - Tofacitinib.</p>
<p>V Immunosuppressants: Azathioprine and Cyclosporine-A. They can be life saving when severe vasculitis complicates the clinical picture.</p>
<p>I Anti-inflammatory analgesics: Detailed pharmacology of NSAID is discussed in Chapter 11. These drugs acting symptomatically, and relieve pain, decrease the swelling and help to improve the joint movements. No NSAID is consistently more effective than any other, but some patients may not tolerate a particular drug. Aspirin is required to be given in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3</mn><mo>−</mo><mn>5</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">3-5 \mathrm{~g}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">3</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">5</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span></span></span></span></span> daily to maintain therapeutic blood levels of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mo>−</mo><mn>30</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">20-30 \mathrm{mg} \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">20</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.9444em; vertical-align: -0.1944em;"></span><span class="mord">30</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">%</span></span></span></span></span>. Though useful, such high doses cause GI adverse reactions. Enteric coated aspirin may cause less gastric irritation. It should be avoided in the elderly. Aspirin and indomethacin can be given as rectal suppositories so as to avoid gastric irritation.</p>
<p>Other NSAID used are ibuprofen (200-400 mg thrice daily), diclofenac (75-100 mg twice daily), naproxen ( 250 mg twice daily) and ketoprofen ( 50 mg thrice daily), given with food. A single dose of naproxen 500 mg taken at bedtime may also be effective. Ibuprofen is perhaps the best tolerated among the NSAID. Since piroxicam and diclofenac have prolonged action, a single dose at bed-time often may be effective for relieving the night pain and the early morning stiffness (Chapter 11).</p>
<p>The risk of GI bleeding in patients taking NSAID and/or glucocorticoids is very high in RA. This can be prevented to some extent by prophylactic use of PPI (Chapter 43).</p>
<p>II Glucocorticoids: These drugs have potent anti-inflammatory action. Given orally, they produce dramatic symptomatic relief which lasts as long as they are used. They act by inhibiting the synthesis and/or by suppressing the actions of inflammatory mediators (Chapter 66). Prednisolone is started in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">1 \mathrm{mg} / \mathrm{kg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mord">/</span></span></span></span></span> day, and then tapered gradually to a maintenance dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>7.5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">7.5 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">7.5</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day. The small maintenance dose may be continued as needed.</p>
<p>Glucocorticoids are not used as monotherapy. Low doses of prednisolone ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">5 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">5</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day) that do not affect clinical inflammation may have a joint protective effect and can be combined with DMARD. Larger doses are required to control severe systemic manifestations of RA such as pericarditis and vasculitis. Their major drawback is their toxicity (Chapter 66). For long term therapy the overall risk-benefit ratio of glucocorticoids is considered unacceptable. Further, relapse rate after stoppage is high. The newer synthetic 'supersteroids' do not offer any advantages over prednisolone.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="iii-dmards">III DMARDs:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iii-dmards" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Gold salts: Water soluble gold preparations, sodium aurothiomalate, aurothiosulfate and aurothioglucose get deposited in synovial macrophages in inflamed joints and inhibit their function. They produce definite but slow and unpredictable improvement. Sodium aurothiomalate (Myocrisin) is usually employed in the dose of 10-25 mg IM weekly for prolonged periods or 50 mg weekly for 20 injections.</p>
<p>Absorption, fate and excretion: Sodium aurothiomalate is rapidly absorbed and is distributed in the kidney, liver, spleen and other tissues including syncytial lining cells. It is excreted in urine. Gold salts accumulate in the kidney and remains in the body for many years.</p>
<p>Adverse reactions: Gold salts can cause dermatitis, nephropathy, oral ulceration, bone marrow depression, peripheral neuropathy and liver damage. The incidence of toxicity is fairly high and regular clinical and hematological supervision is mandatory. Gold toxicity is treated with prednisolone ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mo>−</mo><mn>20</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">10-20 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">10</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">20</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> daily) and dimercaprol. They are now rarely used.</p>
<p>Auranofin, an oral gold compound, is better tolerated and less toxic than the injectable gold salts but is much less effective.</p>
<p>Chloroquine and Hydroxychloroquine: These antimalarials (Chatper 56) are taken up by macrophages and lymphocytes. They inhibit phagocytosis, decrease T-cell activation and and reduce inflammatory cytokines i.e. TNF <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span> They produce moderate benefit in active RA and systemic rheumatoid diseases. They have mild anti-inflammatory action and probably act as immunomodulators.</p>
<p>Chloroquine phosphate is given in the dose of 250 mg (maximum <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">4 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">4</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> ) daily. The improvement is slow and prolonged treatment (6-12 months) is necessary for full benefit. After getting good relief, the frequency of the daily dose is progressively reduced to once a week; the drug may have to be continued in that dose perhaps indefinitely, as the disease may recur on stopping the drug. The dose of hydroxychloroquine sulfate is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>400</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">400 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">400</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day; the maintenance dose is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>200</mn><mo>−</mo><mn>400</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">200-400 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">200</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">400</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> (maximum of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>6.5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">6.5 \mathrm{mg} / \mathrm{kg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">6.5</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mord">/</span></span></span></span></span> day. After good relief, its dose is reduced in the same manner as with chloroquine.</p>
<p>They are perhaps the best tolerated and relatively safe DMARD. Long term therapy may rarely cause retinopathy and irreversible visual impairment. Hence periodic ophthalmic examination during therapy is mandatory.</p>
<p>Methotrexate (MTX): This folic acid antagonist, given intermittently, appears to be highly effective, has acceptable long term toxicity and is cost effective. The initial dose is usually <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><mn>7.5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">5-7.5 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">7.5</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> orally, taken as a single dose once a week. In these small doses, methotrexate has anti-inflammatory action but no immunosuppressive or cytotoxic action. Its action is probably related to inhibition of aminoimidazole carboxamide (AICAR) transformylase and thymidylate synthetase, thereby preventing neutrophil chemotaxis (Chapter 61). Clinical response is usually seen in 4-8 weeks. If no response is seen even after 8 weeks of therapy, the dose may be increased by 2.5 mg every other week to a maximum of 15 mg once weekly and maintained until improvement occurs. After improvement sets in, it is given at the lowest possible effective dose indefinitely, as relapse occurs following its discontinuation. Its toxicity is dose-related. In the dose recommended ( 7.5 mg or less per week), the risk of toxicity is small. Folic acid <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">5 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">5</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day, may reduce its toxicity. However, long term use is suspected to cause cirrhosis of the liver and fibrosing alveolitis. Hence, it is best avoided in patients with preexisting liver disease and chronic alcoholics.</p>
<p>Methotrexate is teratogenic and it should not be used during pregnancy. Men should not take the drug for three months, and women for one menstrual cycle, before a planned pregnancy. It should also be avoided in patients with significant renal dysfunction.</p>
<p>Sulfasalazine: This drug, used in the treatment of ulcerative colitis, is discussed in Chapter 45. The mesalamine component of sulfasalazine inhibits pro-inflammatory cytokines, immuno-globulin, COX and lipo-oxygenase and thus exerts anti-inflammatory action. Sulfapyridine, which is absorbed more, reduces IL-8 synthesis and probably inhibits angiogenesis.</p>
<p>It is useful and much safer than gold salts in the treatment of RA. The dose required (1-2 <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">g</mi><mi mathvariant="normal">m</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">\mathrm{gm} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm">gm</span></span><span class="mord">/</span></span></span></span></span> per day) is larger than that required to treat ulcerative colitis. With this dosage, adverse reactions are common and include, allergy, nausea, vomiting and headache. Rarely, neutropenia, hemolytic anemia and thrombocytopenia may occur.</p>
<p>Leflunomide, a pyrimidine synthesis inhibitor, is as effective as sulfasalazine in decreasing signs and symptoms, and slowing the radiological progression of RA. After absorption, it is converted to active metabolite which inhibits RNA synthesis and cell growth; it also prevents T cell proliferation. It remains in the body for a long time (up to 2 years). The adverse effects are diarrhoea, reversible alopecia, skin rash, hypertension and hepatic damage. Anaphylaxis and Stevens-Johnson syndrome have been reported. The drug is carcinogenic and teratogenic. Hence, it is advisable for a woman to postpone conception and for a man to postpone fathering a child for at least two years after stopping the treatment. The dose is 100 mg daily for three days, followed by maintenance dose of 10-20 mg per day.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="iv-biological-agents">IV Biological agents<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iv-biological-agents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>All biological agents are very expensive and need to be given parenterally. Most of them can precipitate opportunistic infections.
(a) TNF-alpha blockers:</p>
<p>INFLIXIMAB: This is a chimeric, monoclonal anti-TNF antibody that is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>75</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">75 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">75%</span></span></span></span></span> human protein and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">25 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">25%</span></span></span></span></span> mouse protein. The cytokine TNF <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span> is actively produced at the synovial sites in RA. Infliximab binds to the TNF <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span> with high affinity, avidity and specificity. Given by IV infusion once in 2 months, it causes dose-dependent neutralisation of human TNF <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span>. It is distributed mostly in the vascular compartment with a terminal <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>8</mn><mo>−</mo><mn>12</mn></mrow><annotation encoding="application/x-tex">8-12</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">8</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">12</span></span></span></span></span> days. It can cause consistent and sustained benefit in patients with RA, even those who are resistant to DMARD, and methotrexate. The clinical improvement is associated with decrease in C reactive protein.</p>
<p>It is well tolerated in the doses used. The most common ADR are headache, nausea, rash and coughing. It may precipitate respiratory tract infections including TB. The recipient can develop antibodies to infliximab.</p>
<p>Infliximab has also been used in the treatment of Crohn's disease, psoriasis and ankylosing spondylitis.</p>
<p>ADALIMUMAB: This is a recombinant, human-anti-TNF monoclonal antibody. It is given SC every second week and has <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> of 9-14 days. It has similar actions as infliximab.</p>
<p>Certolizumab pegol and golimumab are the newer anti-TNF agents.
ETANERCEPT: This fusion protein is a dimer consisting of TNF receptor joined to Fc domain of human IgG molecule. Unlike infliximab, it selectively binds to active trimeric portion of TNF <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span>. In addition, it also binds to the cytokine lymphotoxin alpha (TNF beta). It is</p>
<p>given SC 25 mg twice a week, whereas infliximab is given by IV infusion once in 2 months.
(b) IL-1 receptor antagonist:</p>
<p>ANAKINRA is recombinant human IL-1 receptor antagonist and is given SC. It is used in combination with MTX. It is also used in inborn syndromes associated with high IL-1 production and also for systemic forms of juvenile inflammatory arthritis.
(c) IL-6 receptor antagonist:</p>
<p>TOCILIZUMAB, an anti-IL-6 receptor blocker, is effective in patients not responding to DMARD or anti-TNF agents, or both. It is administered IV. Its ADR are similar to anti-TNF agents. In addition, it may increase total and LDL-cholesterol and cause neutropenia.
(d) T cell activation inhibitors:</p>
<p>ABATACEPT: This is a fusion protein of cytotoxic T-lymphocyte antigen-4 linked to IgG1. It prevents T-cell activation and lowers the serum concentration of inflammatory cytokines in RA. It is given IV, slowly, on day one and repeated at two and four weeks thereafter. It has been used to treat RA not responding to other agents. Abatacept can be combined with DMARDs but not with TNF <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span> inhibitors or anakinra. The patient should be tested for tuberculosis before starting the treatment, and should be watched for any infection.
(e) Anti-B-lymphocytic antibody:</p>
<p>RITUXIMAB is a monoclonal antibody which selectively depletes the CD20 Blymphocytes which play a role in the autoimmune response and in the chronic synovitis associated with RA. It is claimed to be useful in RA which has proved resistant to TNF <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span> blockers.</p>
<p>The major concern about TNF <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span>. inhibitors and other biological agents is increased risk of infection. They should be avoided in the presence of infections, particularly tuberculosis and viral hepatitis, as well as in the presence of a demyelinating disease or CHF. Live virus vaccines are contraindicated in patients receiving biological agents.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="f-tyrosine-kinase-inhibitor">(f) Tyrosine kinase inhibitor<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#f-tyrosine-kinase-inhibitor" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>TOFACITINIB is the first oral janus kinase inhibitor approved for RA patients, who had inadequate response or are intolerant to methotrexate. Janus Kinase is a signalling mediator in various immune pathways.Tofacitinib prevents the phosphorylation and activation of intracellular mediators involved in immune response and inflammation that lead to joint destruction. Adverse effects include diarrhoea, nasopharynigitis, headache, hypertension, hypercholesterolemia, opportunistic infections, neutropenia, lymphopenia, anemia and increased liver enzymes. It is metabolised by CYP3A4. It should not be used with biological agents.</p>
<p>V Immunosuppressive agents (Chapter 74): Various alkylating agents like azathioprine, cyclosporine-A, cyclophosphamide have been used to induce remission in RA. These drugs act as suppressors of B and T lymphocytes. However, they are less effective and more toxic.</p>
<p>The current goals of therapy of RA are:</p>
<ul>
<li>Suppression of disease activity as soon as possible and reduction of symptoms</li>
<li>Arrest of the erosive and functional joint damage</li>
<li>Improvement in laboratory indices</li>
<li>Induction and maintenance of a long-term clinical and radiological remission after cessation of drug therapy. There is now convincing evidence that early treatment (preferably within 12 weeks) with DMARD has the potential to improve the quality of life and</li>
</ul>
<p>long term outcome in patients with RA.
The principles of management of RA are given in Table 75.4.</p>
<p>Table 75.4
Principles of management of RA</p>
<div data-testid="stMarkdownPre" class="st-emotion-cache-acwcvw e1icttdg5"><div class="stCode st-emotion-cache-6ml83 e1xss9yb4" data-testid="stCode"><pre class="st-emotion-cache-1nqbjoj e1xss9yb2"><div style="background-color: transparent;"><code style="white-space: pre;"><span>* Rest to acutely inflamed joints.
</span>* Reduction of pain and inflammation by use of antiinflammatory drugs.
* Prevention of articular damage by early use of drugs modifying the disease course (DMARD) with rapid escalation.
* Use of combination therapy
* Use of glucocorticoids as ancillary measures.
* Graded exercises and physiotherapy.
* Treatment of comorbid conditions such as infections and osteoporosis;
* Use of biological agents if DMARD fails
* Modification of the diet, using more omega-3 fatty acids in place of omega-9 fatty acids; in this respect, vegetarian diet may be beneficial.</code></div></pre><div class="st-emotion-cache-chk1w8 e1xss9yb3"><button data-testid="stCodeCopyButton" title="Copy to clipboard" data-clipboard-text="* Rest to acutely inflamed joints.
* Reduction of pain and inflammation by use of antiinflammatory drugs.
* Prevention of articular damage by early use of drugs modifying the disease course (DMARD) with rapid escalation.
* Use of combination therapy
* Use of glucocorticoids as ancillary measures.
* Graded exercises and physiotherapy.
* Treatment of comorbid conditions such as infections and osteoporosis;
* Use of biological agents if DMARD fails
* Modification of the diet, using more omega-3 fatty acids in place of omega-9 fatty acids; in this respect, vegetarian diet may be beneficial." style="top: 0px; right: 0px;" class="st-emotion-cache-1lyayqq e1xss9yb5"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><rect x="9" y="9" width="13" height="13" rx="2" ry="2"></rect><path d="M5 15H4a2 2 0 0 1-2-2V4a2 2 0 0 1 2-2h9a2 2 0 0 1 2 2v1"></path></svg></button></div></div></div>
<p>Choice of drug therapy: Patients with confirmed diagnosis of RA have a lifelong disease which persists, spreads and causes damage throughout its course. Choice of drug therapy would be guided by drug efficacy, safety and affordability. Although associated inflammation may be reversible, the cytokine-induced damage is not. Bone loss has been shown to occur rapidly at the onset of the clinical disease. Unfortunately, the prediction of which patients will have a rapidly downhill course and which will not is as yet not possible. The recommendations for optimum treatment are:
(a) Early use of DMARD (Methotrexate, chloroquine or sulfasalazine) in combination. Such combination treatment has been shown to reduce joint swelling and delay bone damage. (b) NSAID in adequate doses are added as bridge drugs for quick symptomatic relief of pain and fever. They are administered along with PPI for gastroprotection. These drugs do not cause a change in the cytokine-mediated acute phase reactants such as ESR and C reactive protein.
(c) Judicious use of low dose prednisolone ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><mn>10</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">5-10 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">10</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day) along with DMARD.
(d) In severe cases, short term glucocorticoid in high doses at the onset, which is to be tapered to a maintenance dose later.
(e) Use of biological agents is reserved for patient resistant to DMARD combination.
(f) Depending upon the response, quick changes in drug combination may be needed. Frequent follow up and monitouring of the progress is manadotory.</p>
<p>The treatement should be started immediately without waiting for results of lab tests if the clinical diagnosis and ESR indicate RA. Weekly methotrexate is currently favoured because of its relatively rapid onset of action, long term benefit, acceptable toxicity, good compliance and low cost. The maximum improvement usually occurs after 6 months of therapy. However, its efficacy in most patients is partial and disease remission occurs in minority. The drug may be supplemented by folic acid which may counter some of its toxicity without compromising its efficacy. It is usually combined with sulfasalazine and low dose prednisolone. Some experts advice more aggressive initial treatment with methotrexate, sulfasalazine, glucocorticoid and chloroquine.</p>
<p>The TNF <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span> inhibitors and other biological agents are prohibitively expensive and their long term safety is not clear. They should be used only in RA resistant to DMARDs. Combination of biological agents with MTX is synergistic.</p>
<p>Local intra-articular injection of a glucocorticoid is useful in controlling inflammation. Its indications are:</p>
<ul>
<li>One or two joints that are 'resistant' in the patient, otherwise well controlled on medical therapy; and</li>
<li>Patients with one active joint in whom oral NSAID are contraindicated.</li>
</ul>
<p>Usually, hydrocortisone acetate suspension is given in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mo>−</mo><mn>50</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">25-50 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">25</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">50</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> for big joints and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><mn>10</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">5-10 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">10</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> for small joints. The number of injections depends upon the response; but it is advisable to avoid them more often than once in 3 months. The drug may also be injected extra-articularly into painful ligaments, tendons and inflamed bursae with beneficial results.</p>
<p>Therapeutic response in RA is monitored by clinical improvement, laboratory test (ESR and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>C</mi></mrow><annotation encoding="application/x-tex">C</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.07153em;">C</span></span></span></span></span> reactive protein), improvement in functional ability and radiological evidence.</p>
<p>Supportive therapy: Rheumatoid arthritis being a chronic disease, general supportive therapy including good nutrition and attention to psychological aspect is as important as drug therapy. Both physical and mental rest is essential. During the acute stage the rest must be complete, along with proper splinting of affected joints. A firm mattress with only one firm, low pillow should be allowed at bed-time. Anti-anxiety and antidepressant drugs may be helpful along with analgesics to control anxiety and insomnia. In most patients with active disease, bed rest for 4 weeks followed by 2-6 weeks of planned rehabilitation is advisable. Immobilisation of inflamed joints is carried out for 4 weeks followed by active exercises. Light exercises should also be prescribed during complete rest, to be carried out in the recumbent position for improving circulation and correcting faulty posture. Proper exercises and physiotherapy during and after the recovery stage are essential for achieving maximum benefit.</p>
<p>Use of warm baths and hot packs helps to loosen joints and relieve the stiffness. Exercise following heat helps to maintain the mobility of joints. Anemia may respond to iron therapy. Other co-morbid states such as osteoporosis, CV disorders and depression should be treated. Patients may also need help to combat the serious social and economic problems that are usually associated with such a chronic and disabling ailment.</p>
<p>In spite of recent advances, 'cure' in rheumatoid arthritis is still elusive. Majority of patients recover partially and only a lucky few may get long remission. Since the definitions of terms 'active disease', 'improvement' and 'remission' are imprecise, caution is advocated before accepting any new remedy claimed to 'benefit many RA patients'.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="osteoarthritis-oa">Osteoarthritis (OA)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#osteoarthritis-oa" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Osteoarthritis is a common disease in the ageing population and results from a complex interplay of genetic, metabolic, biochemical and biomechanical factors with secondary local inflammation. The process involves the interaction of degradation and repair of the articular cartilage, bone and synovium. The most important cells in the entire disease process are the chondrocytes.</p>
<p>The initiating event in OA seems to be injury to the chondrocytes from a single macrotrauma or repeated microtraumas to the joint. The chondrocytes react by proliferation and release of enzymes which degrade the articular cartilage. The products of degradation, released into the synovial fluid, evoke the formation and release of mediators of inflammation by the synovial macrophages; the latter cause further damage to the cartilage. The cartilage also responds by misplaced attempts at repair with the formation of osteophytes at the edge of the cartilage.</p>
<p>OA is not an invariable and natural accompaniment of ageing; several other risk factors are involved in its pathogenesis e.g. obesity, lack of exercise, and occupational as well as sports trauma to the joints.</p>
<p>Early OA may be clinically silent. The important symptoms, when they occur, are pain, tenderness, movement limitation, disability and deformity. Muscle wasting is common and contributes to the disease process. Acute effusion occurs in large joints such as the knee in response to acute trauma. Unlike in RA, there are generally no systemic symptoms, and blood indicators of inflammation such as elevated ESR are generally absent. In most patients, the disease stabilises after initial progression.</p>
<p>Management: No treatment available at present can halt the degradation of the cartilage or stimulate its fresh synthesis nor reverse the pathological changes of OA. All treatment is aimed at (a) pain relief; and (b) increasing the range of joint mobility.</p>
<p>I Non-pharmacological treatment: This includes physical therapy (heat, cold and transcutaneous electrical nerve stimulation); and exercise. Proper posture and weight reduction are important. Intermittent rest during the day, use of a walking stick and properly cushioned shoes are helpful; a properly fitting brace can relieve backache.</p>
<p>II Pharmacological treatment: Local application of methylsalicylate ointment or diclofenac <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">1 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">1%</span></span></span></span></span> gel containing additional capsaicin may bring relief in mild cases. When oral therapy is required, preference should be given to paracetamol in the dose of 2-3 g/day in divided doses; this relieves the pain in most patients. A mild NSAID such as ibuprofen may be added to paracetamol in the presence of joint stiffness or swelling, or pain which interferes with work or sleep. Stronger NSAID should be avoided. This is especially important in the elderly who are particularly prone to the adverse effects of NSAID; they should be prescribed in the smallest possible dose for the shortest possible period. COX-2 inhibitors though 'stomach-friendly' can cause cardiovascular adverse effects (Chapter 11). Their routine use is not recommended.</p>
<p>The use of intra-articular glucocorticoids at three monthly intervals should be limited to patients with severe pain, especially with an effusion. Intra-articular injection of hyaluronic acid has also been claimed to relieve pain. Systemic glucocorticoids have no place in its treatment.</p>
<p>Glucosamine is derived from marine shells or is synthetic. It is the sulfate or</p>
<p>hydrochloride of aminomonosaccharide glucosamine, a normal constituent of glycosaminoglycan in the cartilage. Given orally in the dose of 1500 mg daily in divided doses for long periods (2-3 years), it is claimed to slow down the progression of OA. However, glucosamine and chondroitin sulfate, given individually or in combination have no clinically relevant effect on joint pain.</p>
<p>There is no evidence at present that these supplements prevent OA in healthy persons or in patients with knee pain but normal X-rays. Their usefulness as a DMARD in OA is also doubtful.</p>
<p>Surgical treatment: Joint replacement helps selective patients with advanced OA and unbearable pain.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="metals-and-their-antagonists">Metals and Their Antagonists<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#metals-and-their-antagonists" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The heavy metals are of great interest mainly from the toxicological point of view. It is, therefore, proposed to discuss briefly their toxicity and its treatment.</p>
<p>Pharmacological actions: The organic and the inorganic salts of heavy metals possess astringent, corrosive and caustic properties on local application. They also act as general protoplasmic poisons, interfering with various enzymes and altering cell membranes, thus impairing cell function. The heavy metal salts, in very small quantities, are lethal to several Gram-positive and Gram-negative organisms.</p>
<p>Heavy metals exert their toxic effects by combining with several reacting groups such as the SH groups, essential for normal physiological functions. The heavy metal antagonists (chelating agents) compete with these groups for the metals and spare the former; they prevent or reverse the toxic effects and enhance the excretion of the metals.</p>
<p>Adverse reactions: All the heavy metals are cumulative and potentially toxic. They can cause widespread damage to various organs tissues like the liver, the kidney, the gut and the brain. Rapidly proliferating tissues such as the bone marrow, the GI mucosa and other delicate cells such as neurons and renal tubular cells are also affected.</p>
<p>The major treatment of metal toxicity is to prevent or terminate exposure to them. Chelating agents are used to bind metals into stable cyclic compounds of low toxicity (see later). Activated charcoal does not bind metals and hence is not useful in acute metal poisoning.</p>
<p>Many herbomineral products available over the counter (OTC) and environmental pollution may contribute to heavy metal toxicity. Reckless disposal of industrial waste particularly in river water is perhaps the main cause of chronic poisoning.</p>
<p>ARSENIC: Arsenic, though ordinarily presumed to be a metal, is in fact a metalloid. Very minute quantities of arsenic have been detected in majority of the vertebrates. Its physiological role in such minute amounts is, however, not known. It is a notorious poison since ancient times. Arsenical compounds can be divided into:</p>
<ul>
<li>Inorganic arsenicals, used mainly as rodenticides, herbicides and insecticides and</li>
<li>Organic arsenicals, used in the chemotherapy of trypanosomiasis. They were once mainstay of treatment of syphilis.
The organic arsenicals can be further subdivided into trivalent and pentavalent compounds. The pentavalent compounds, which are anionic in character in body fluids, probably penetrate the host cells less readily than the trivalent compounds and consequently, have a higher therapeutic index than the latter. Although it is claimed that the therapeutic activity of pentavalent compounds is partly due to their reduction into trivalent forms in vivo, trivalent compounds as such are not used in therapeutics because of their high toxicity. Recently, arsenic trioxide (trivalent arsenic) has been introduced for the treatment of acute myeloblastic leukemia.</li>
</ul>
<p>Absorption, fate and excretion: Soluble arsenical salts are rapidly absorbed from the gut. Absorption also occurs through the skin. Arsenic is stored mainly in the gut, liver, spleen, kidney and lung, small amounts are also present in the brain and the skeletal muscle. It accumulates in bones and hair and is retained for years. Arsenic is mainly excreted in urine and feces. Small amounts also appear in sweat and in saliva. Urinary</p>
<p>excretion usually starts within 2 to 8 hours after oral administration and continues for 8 to 10 days. Repeated ingestion of small amounts can cause cumulative poisoning.</p>
<p>Arsenic poisoning: Arsenic poisoning is usually homicidal but occasionally, may occur accidentally, particularly in children, following ingestion of arsenical herbicides or insecticides. Ground water in some areas of the world (parts of West Bengal and Bihar in India) contains high concentrations of arsenic, and is responsible for chronic poisoning.</p>
<ul>
<li>Acute arsenical poisoning is characterised by severe GI irritation, vomiting, diarrhoea, circulatory collapse and renal failure. The GI symptoms usually begin within 1 hour after ingestion of the arsenical compound but may occasionally be delayed upto 12 hours. The symptomatology closely resembles that seen in cholera and a careful distinction is essential before institution of treatment. In severe poisoning, death may occur within 24 hours.
Treatment consists of correction of fluid and electrolyte imbalance and administration of the specific antidote, dimercaprol. Hemodialysis could be life-saving in the event of renal shutdown.</li>
<li>Chronic arsenic poisoning: Chronic arsenic poisoning has a relatively insidious onset and this is the main reason for its use as a poison for homicidal purposes. It affects almost every body tissue. The early symptoms are weight loss, anorexia, fatigue and diarrhoea or constipation. Later manifestations are edema, particularly of eyelids and ankles, hyperpigmentation of the skin, especially the eyelids, neck, nipples and the axillae, and dermatitis including exfoliative, and inflammatory lesions of the mucous membranes. There may be loss of hair; finger nails become brittle and may eventually drop off. The breath has a garlic odour. Late manifestations of arsenic poisoning include jaundice, aplastic anemia and peripheral neuropathy leading to numbness, paraesthesiae, wrist and foot drop. Necrosis and degeneration of renal tubules and liver cirrhosis may develop. Arsenical encephalopathy has also been reported. Hyperkeratosis of palms and soles may undergo malignant change in the form of basal cell carcinoma. Chemical analysis of hair and bones helps in establishing the diagnosis.
Treatment of chronic arsenic poisoning consists of prolonged administration of dimercaprol (see later). However, arsenical aplastic anemia and jaundice usually do not respond, while arsenical encephalopathy is relieved only partially.
Preparations: The organic arsenical compounds used in the therapeutics are discussed in Chapters 57 and 58.
LEAD: Lead compounds have hardly any therapeutic use. They are, however, used in various industries such as paint and plumbing fixtures and are responsible for causing chronic lead poisoning in workers. Poisoning may also occur from petrol containing lead and lead projectiles, particularly lead shots embedded in the skin or the muscle.</li>
</ul>
<p>Absorption, fate and excretion: Children absorb upto 50% of the ingested lead whereas adults absorb about 10-20%. Diets poor in calcium, iron and zinc promote its absorption. It can also be absorbed from the respiratory mucous membrane. Respiratory absorption of lead is more dangerous than its GI absorption where the liver acts as a barrier. Organic lead compounds like tetraethyl and tetramethyl lead are absorbed more rapidly by the respiratory mucosa than the inorganic compounds. In addition, they can also be absorbed from the unbroken skin.</p>
<p>Following absorption, inorganic lead is mainly associated with erythrocytes. High</p>
<p>concentrations are initially present in liver and kidneys. Subsequently, it is mobilised from these sites and deposited in bones in the form of insoluble tertiary lead phosphate, mainly in epiphyseal regions of growing long bones, where it can be detected radiologically. High phosphate intake and vitamin D favour the deposition of lead into bones whereas a high calcium and low phosphate intake, parathyroid hormone, dihydrotachysterol and iodides cause mobilisation of lead from the bones. Lead deposited in bones does not contribute to the toxicity. A small amount is also present in hair, nails, sweat and excrement. The <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi>t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">t^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathnormal">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> of lead is 25 days in the blood, 40 days in soft tissues and more than 25 years in the non-labile bone.</p>
<p>Lead deposited in soft tissues and in bones is excreted very slowly mainly by the kidneys, within a few weeks to years. A small amount is present in milk and sweat.</p>
<p>Toxicity of lead is due to its affinity for the cell membrane and mitochondria. It impairs the activity of calcium-dependent intracellular messengers and of brain protein kinases.</p>
<p>Lead poisoning can be acute or chronic.</p>
<ul>
<li>Acute lead poisoning: Acute lead poisoning is a rare entity, usually secondary to ingestion of soluble lead compounds like lead acetate. It is characterised by a metallic taste in mouth, GI irritation and occasionally, acute nervous system symptoms like paraesthesiae, muscle cramps and weakness. The stools have a dark colour owing to the presence of lead sulfide. An acute hemolytic crisis resulting in severe anemia and hemoglobinuria may occur and usually proves fatal.
Treatment of acute lead poisoning consists of prompt gastric lavage and administration of laxatives like magnesium sulfate to hasten its evacuation from the gut and use of calcium and phosphate salts and chelating agents for its elimination from the circulation. Anticholinergics like atropine are used to relieve the intestinal colic while parenteral fluids and vasopressor agents are employed to treat the shock, and diazepam for seizures.</li>
<li>Chronic lead poisoning: Chronic lead poisoning is commonly seen in young children from sucking lead paint or lead toys, in workers engaged in printing and paint industries, and in petroleum industry where organic lead compounds like tetraethyl lead and tetramethyl lead are added to petrol as anti-knock remedies. Environmental pollution also contributes to chronic poisoning. The manifestations of chronic poisoning are:
Gastrointestinal: The common symptoms are a metallic taste in mouth, anorexia, constipation and abdominal pain due to intestinal colic, termed 'lead colic'. Chronic constipation due to lead poisoning is often ignored and itself enhances its absorption from the gut. A diagnostic feature of importance is the grayish lead line which appears along the gingival margin and is due to periodontal deposition of lead sulfide; this may not be seen in the presence of good dental hygiene.</li>
</ul>
<p>Skeletal muscles: Muscle weakness and increased fatiguability leading subsequently to paralysis is described as 'lead palsy'. The paralysis may cause unilateral wrist drop, and less commonly, foot drop. The extraocular muscles are also occasionally involved. Degenerative changes in the motor neurones and their axons, and impairment of high energy phosphate metabolism of the affected muscles have been incriminated.</p>
<p>Haemopoietic system: Punctate basophilic stippling of erythrocytes is regarded as a cardinal manifestation of chronic lead poisoning. However, that stippling upto a limit of 800 to 1000 per million erythrocytes is physiological and it is only when this count exceeds 35,000 per million erythrocytes that the suspicion of lead poisoning should be entertained.</p>
<p>Other hemopoietic disturbances are a microcytic hypochromic anemia, jaundice secondary to increased hemolysis, and excretion of abnormal products of porphyrin metabolism in urine, which is attributed to defective hemoglobin synthesis.</p>
<p>Nervous system: Central nervous system toxicity is commoner in children than in adults and is described as lead encephalopathy. It is manifested by increased irritability, headache, restlessness and tremors, followed by delirium and convulsions or by lethargy and coma. Visual disturbances may occur and stippling of the retina adjacent to the optic disc is claimed to be an early diagnostic sign. Lead encephalopathy has a mortality of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">25 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">25%</span></span></span></span></span> and nearly <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>4</mn></mrow><annotation encoding="application/x-tex">1 / 4</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1/4</span></span></span></span></span> th of the survivors develop permanent mental deficiency.</p>
<p>Organic lead compounds produce acute CNS toxicity in adults, with similar manifestations.</p>
<p>Exposure to lead result in toxic peripheral neuropathy; motor neuropathy being more common.</p>
<p>Kidney: It may cause interstitial nephritis, tubular damage, hyperuricemia and renal failure.</p>
<p>Treatment: The drugs of choice in chronic lead poisoning are the chelating agents, calcium disodium edetate (see later) and dimercaptosuccinic acid (Succimer). The latter is more effective for mobilising lead from soft tissue. Hence a combination of succimer and calcium disodium edetate is to be preferred. Dimercaprol can be substituted for succimer. Lead colic can be controlled by the administration of antispasmodics and calcium gluconate 2 g IV. Convulsions are best treated with diazepam. Increased intracranial tension can be relieved by mannitol or by lumbar puncture.</p>
<p>ANTIMONY: This metal resembles arsenic in chemical and biological properties. Antimony, however, is more irritant locally and certain antimony salts like antimony potassium tartrate possess a powerful emetic activity.</p>
<p>The trivalent and pentavalent compounds are absorbed slowly from the gut. The trivalent compounds are more firmly bound to erythrocytes than pentavalent compounds and exhibit slower renal excretion than the latter.</p>
<p>The toxic effects of antimonials resemble those of arsenic. Dimercaprol is protective against the toxic effect of organic forms but its efficacy against the inorganic antimony compounds is doubtful. (For uses, see Chapters 58).</p>
<p>BISMUTH: Compounds such as carbonate, subsalicylate, subgallate and subnitrate are used to treat diarrhoea because of their mild astringent and mechanical coating effects. Bismuth subgallate is used orally to control fecal odour in an ileostomy. Bismuth subsalicylate is used to treat <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>H</mi></mrow><annotation encoding="application/x-tex">H</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.08125em;">H</span></span></span></span></span>. pylori infections in patients with peptic ulcer disease (Chapter 43).</p>
<p>Intoxication due to bismuth is rare. Chronic poisoning may lead to fever, GI disturbances, stomatitis, constipation, urticaria, nephritis and nephrosis. A metal line on the gums is often seen. Dimercaprol is an effective antidote.</p>
<p>MERCURY: The mercury compounds are sometimes used as antiseptics, preservatives, and spermicides and in industry; chronic toxicity is known to occur following contaminated well/river water due to effluent waste from the industry. Organic mercurials are lipid soluble and readily cross the blood brain barrier and the placenta. They accumulate in the kidney and the brain, and their <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> is almost 70 days. Fish, particularly tuna and sword-fish, can concentrate large amounts of methyl mercury.</p>
<ul>
<li>Acute mercury poisoning is usually due to accidental ingestion of mercuric chloride (corrosive sublimate) and other readily ionisable mercury salts. It is characterised by severe GI irritation, diarrhoea, electrolyte disturbances and circulatory collapse. The patient complains of a metallic taste in mouth; there is excessive salivation and inflammation of gums. Arrhythmias may develop due to its toxic effect on the myocardium. Marked renal impairment leading to death occurs due to its nephrotoxic action. Secretion of mercuric ion into the gut and its reabsorption prolong the toxic effects.
Treatment is directed towards removal of mercuric ions from the GI tract and towards its quick renal elimination. The former is achieved by administration of proteins in the form of raw eggs or milk, which form non-toxic proteinates and by giving medicinal charcoal in suspension. This is followed by gastric lavage, though it is of doubtful value after the first 15 minutes or so, since mercury is rapidly absorbed by the mucous membrane of the alimentary tract. Sodium formaldehyde sulfoxylate which reduces the mercuric ion to the less soluble mercurous form may also be used. About 200 to 250 ml of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span> solution is employed for gastric lavage and an equal volume is left in the stomach.</li>
</ul>
<p>Dimercaprol is an effective antidote for countering the toxicity. However, to be maximally effective, it must be injected within first hour or two after poisoning. It is ineffective in the event of extensive renal damage for which hemodialysis is indicated. Acetyl penicillamine and succimer have also been used. Supportive treatment with IV fluids, treatment of shock and prophylactic antibiotics to prevent secondary infection are also instituted.</p>
<ul>
<li>Chronic mercury poisoning is manifested by increased irritability, tremors, headache, easy fatiguability, stomatitis, colitis, increased salivation and dermatitis. Electrolyte imbalance, neurotoxicity, hepatotoxicity and renal damage are also observed. Minamata disease, reported from Japan was found to be due to consumption of fish from waters contaminated by methyl mercury from the industry. It was characterised by birth defects and neurological damage. Succimer is the treatment of choice for chronic poisoning. An allergic manifestation seen in children, due to systemic absorption of topically applied mercurial antiseptics is termed Pink disease or acrodynia. Its manifestations include marked swelling and erythema of the extremities with sweating, itching and polyarthritis. It responds to therapy with acetyl penicillamine. Fever and skin rashes of various types have also been reported in adults using mercurial antiseptics.</li>
</ul>
<p>GOLD: Chapter 75.
CADMIUM: This metal is employed in a wide range of manufacturing processes including cadmium batteries. Acute cadmium poisoning, when due to ingestion, is characterised by severe GI irritation and circulatory collapse; acute poisoning due to inhalation of cadmium fumes results in cough, sore throat, vertigo, dyspnoea, cyanosis and bronchopneumonia. Chronic poisoning can be caused by contaminated water due to industrial waste. It causes a characteristic yellow pigmentation of teeth (the yellow ring of cadmium), anosmia, emphysema, proteinuria and kidney damage. Calcium gluconate, administered IV in the early stages, is claimed to be of some value. Both dimercaprol and EDTA are not recommended for treatment as they may further aggravate the kidney damage caused by cadmium.</p>
<p>THALLIUM: This metal was employed as the acetate for depilation. When ingested or</p>
<p>inhaled, it is, however, highly toxic and may lead to marked neurological disturbances on systemic absorption. Treatment is symptomatic, including hemodialysis.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="heavy-metal-antagonists">Heavy Metal Antagonists<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#heavy-metal-antagonists" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The toxicity of the heavy metals is attributed to their ability to form complexes with important biological radicals like the sulfhydryl, the hydroxyl, the carboxyl, the amino and the imidazole. Inhibition of various enzymes leads to the toxic effects. Thus, affinity for sulfhydryl group leads to inhibition of vital SH-containing enzymes. Attempts were, therefore, made to develop organic compounds which would have a high affinity for the metallic ions. Such drugs would combine with the metallic ions to produce relatively nontoxic and easily water-soluble complexes which are subsequently eliminated by the kidneys. The process by which these organic compounds combine with the metals to form relatively stable nonionised ring complexes is called chelation (chele=claw), the compounds being designated as Chelating agents. (Table 76.1).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="table-76-1">Table 76.1<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-76-1" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Metal-chelating agents used in therapy</p>
<table><thead><tr><th style="text-align: left;">Drug</th><th style="text-align: left;">Used against</th></tr></thead><tbody><tr><td style="text-align: left;">CaNa, EDTA*</td><td style="text-align: left;">Lead</td></tr><tr><td style="text-align: left;">Dimercaprol</td><td style="text-align: left;">Arsenic, copper</td></tr><tr><td style="text-align: left;">Succimer</td><td style="text-align: left;">Lead, arsenic, mercury</td></tr><tr><td style="text-align: left;">Penicillamine</td><td style="text-align: left;">Copper, mercury, lead</td></tr><tr><td style="text-align: left;">Trientine</td><td style="text-align: left;">Copper</td></tr><tr><td style="text-align: left;">Desferrioxamine</td><td style="text-align: left;">Iron</td></tr><tr><td style="text-align: left;">Deferiprone</td><td style="text-align: left;">Iron</td></tr></tbody></table>
<p>*Given by injection. Others are effective orally.
DIMERCAPROL (BAL): Dimercaprol, or British Anti-Lewisite, was synthesised by Stocken and Thompson during the World War II to ensure protection against poisoning by the arsenical war gases such as Lewisite. Chemically, it is a dithiol having two SH groups (Fig. 76.1).
<img src="data:image/jpeg;base64,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" alt="img-11.jpeg"></p>
<p>FIG. 76.1 Mode of action of BAL
Pharmacological actions: Dimercaprol forms poorly dissociable complexes with arsenic, mercury, gold and cadmium ions and thus protects the sulfhydryl (SH) enzymes. In case of mercury and cadmium, the dimercaprol-metal complex further reacts with another molecule of dimercaprol to form a still more stable, inactive complex.</p>
<p>Even though the dimercaprol-metal complexes are poorly dissociable, some amount of dissociation does occur in vivo, causing the release of the toxic metal in the active form. To overcome this drawback, the dosage schedule of dimercaprol is adjusted in such a way that an excess of free drug is always present in the body to bind the free metal released as a result of dissociation. Dimercaprol also reactivates the inhibited enzymes. However, its ability to achieve reactivation is limited by the amount of the metallic ion present in circulation, and by the duration of poisoning. Thus, dimercaprol fails to protect or reactivate the sulfhydryl enzymes if administered late or in the presence of overwhelming amounts of the metal.</p>
<p>Dimercaprol itself inhibits enzymes peroxidase, catalase and carbonic anhydrase in which the heavy metals constitute prosthetic groups.</p>
<p>Absorption, fate and excretion: Following the IM administration, the peak plasma levels are reached in about 2 hours and the drug is largely metabolised within 6 to 24 hours. A part is excreted as a glucuronide in urine.</p>
<p>Adverse reactions: Injection of BAL is painful and can cause sterile abscesses and drug fever. Doses of dimercaprol in the range of 4 to 5 mg per kg body weight produce a variety of ADR in approximately <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span> of patients. These include nausea, vomiting, headache, burning sensation in the mouth and eyes, lachrimation, sialorrhoea, paraesthesiae of the extremities, muscle pain and muscle spasm. It can also cause anginal pain, tachycardia and hypertension.</p>
<p>Dimercaprol-metal complex dissociates more readily in an acidic medium. The urine, therefore, should be made alkaline during dimercaprol therapy to protect the kidneys from the toxic effects of the released free metal.</p>
<p>The use of dimercaprol is contraindicated in the presence of hepatic damage and in iron poisoning, as it forms a toxic complex with iron. Dimercaprol increases the urinary excretion of cadmium but the kidneys are likely to be damaged by the metallic ion. It should be used with caution in hypertensive individuals.</p>
<p>Preparation: Dimercaprol injection 50 mg per ml arachis oil. It has a strong characteristic smell.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-uses">Therapeutic uses:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Acute poisoning due to arsenic, mercury, gold, antimony, bismuth and thallium.</li>
</ul>
<p>In severe cases of arsenical and gold poisoning, 3 mg per kg is given deep IM, at 4 hourly intervals for the first 2 days, at 6 hourly intervals on the third day, and twice daily for the next 10 days or until the recovery is complete. In gold poisoning, the maintenance dose may have to be administered for as long as 3 months.
Dimercaprol is effective in protecting the eyes from the effects of accidental contamination by arsenical vesicants. Complete recovery is usually achieved if 5 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">10 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">10%</span></span></span></span></span> oily solution of dimercaprol is instilled into the conjunctival sac within 5 minutes of contamination.
In acute mercurial poisoning, dimercaprol is administered initially in the dose of 5 mg per kg followed by 2 or 3 injections of 2.5 mg per kg during the next 12 hours, or until recovery is assured.</p>
<ul>
<li>Wilson's disease: In patients with Wilson's disease allergic to penicillamine, dimercaprol is given IM in the dose of 2.5 mg per kg twice daily for first 2 days, followed by 2 days rest; and this course may be repeated as often as necessary. The drug causes a moderate</li>
</ul>
<p>increase in the urinary excretion of copper in this condition.</p>
<ul>
<li>Lead poisoning: Discussed earlier.</li>
</ul>
<p>SUCCIMER (2,3 - Dimercaptosuccinic acid): This water soluble analogue of dimercaprol, is effective orally. After absorption, it is biotransformed to a mixed disulfide with cysteine.It is an effective and better tolerated chelator of lead, arsenic, cadmium and mercury. Adverse effects are nausea, vomiting, diarrhoea, loss of appetite and skin rash. It is recommended for children with lead poisoning.
d-PENICILLAMINE: This compound, a monothiol (containing one SH group), is prepared by alkaline hydrolysis of benzyl penicillin. Chemically, it is beta dimethylcysteine.</p>
<p>Pharmacological actions: Penicillamine forms a water soluble complex with copper, mercury and lead ions and thus facilitates their excretion in urine. Like dimercaprol, it inhibits a number of enzymes, including transaminase and desulfhydrase which have one of these metals as the prosthetic group.</p>
<p>Penicillamine is well absorbed on oral administration and rapidly excreted in urine.
Adverse reactions: Penicillamine is a toxic drug. It causes:</p>
<ul>
<li>General toxicity such as headache, sore throat, fever, rash, nausea lymphadenopathy, and ecchymosis; loss or impairment of sense of taste can be very upsetting, neuritis.</li>
<li>Haematologic toxicity: Leucopenia, thrombocytopenia, agranulocytosis and aplastic anemia.</li>
<li>Renal toxicity: Proteinuria, reversible nephrotic syndrome, hematuria.</li>
<li>Autoimmune Syndrome: Myasthenia like syndrome, diabetes, polymyositis and SLE. Allergic reactions occur occasionally and patients who are sensitive to penicillin may have a similar reaction to penicillamine. Long term use may cause a myasthenia-like syndrome, iron and pyridoxine deficiency. Optic neuritis responding to pyridoxine has been reported.</li>
</ul>
<p>Preparation: d-Penicillamine capsules contain 250 mg of the base equivalent to 300 mg of the hydrochloride.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-uses">Therapeutic uses:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Hepatolenticular degeneration (Wilson's disease): Wilson's disease is a rare, hereditary disease of abnormal copper metabolism characterised by degenerative changes in the basal ganglia and cirrhosis of the liver. The copper content of the liver, brain, kidneys and other tissues is grossly increased, the total serum copper and ceruloplasmin copper content are reduced and the urinary excretion of copper is enhanced. The KayserFleischer ring, brownish pigmented ring at the corneal margin, is diagnostic of this condition.
Treatment is directed towards reducing the total body copper. This is achieved by administration of penicillamine or trientine, given in conjunction with a high protein, low copper diet with potassium disulfide ( 20 mg thrice daily with meals). The latter precipitates dietary copper and thereby reduces its absorption. Zinc acetate and zinc sulfate 50 mg tid also reduce copper absorption.
Penicillamine is administered in the dose of 1-2 g (base) daily, in divided doses, before food. Depending on the urinary levels of copper, the dose may be subsequently increased to 4 to 5 g daily and continued indefinitely.
Foods rich in copper (shell fish, nuts, chocolates, mushrooms and organ meats) should</li>
</ul>
<p>be avoided.</p>
<ul>
<li>Copper, arsenic and gold poisoning. Oral succimer is preferred in lead and mercury poisoning; and</li>
<li>Cystinuria.</li>
</ul>
<p>It is no more recommended in rheumatoid arthritis (Chapter 75).
ACETYL d-PENICIILLAMINE: This drug, a less toxic but weaker chelating agent than d-penicillamine, has been shown to be particularly effective in mercury poisoning. It is administered in the dose of 1 g daily in 3 or 4 divided portions, for 10 days. The course may be repeated after a week's interval.</p>
<p>TRIENTINE (Triethylene tetramine): Given in doses of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>400</mn><mo>−</mo><mn>800</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">400-800 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">400</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">800</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> thrice daily on empty stomach, it is as effective as penicillamine in reversing the neurological lesions of Wilson's disease. It appears to be less toxic than penicillamine and may cause less iron deficiency.</p>
<p>CALCIUM DISODIUM EDETATE AND DISODIUM EDETATE: The calciumdisodium and the disodium salts of ethylene diamine tetraacetic acid (EDTA) form stable and highly water soluble complexes with many divalent and trivalent metallic ions and owe their therapeutic application to this chelating property (Fig. 76.2).
<img src="data:image/jpeg;base64,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" alt="img-12.jpeg"></p>
<p>FIG. 76.2 Mode of action of disodium edetate 'M' stands for chelated metal.
The calcium disodium salt has a high affinity for lead, while the disodium salt exhibits a high affinity for calcium. The affinity for other metals like sodium, magnesium and potassium is much less and this permits their selective use in the treatment of lead poisoning and hypercalcemia respectively.</p>
<p>Absorption, fate and excretion: Both the salts are poorly absorbed from the GI tract and are given IV or IM routes. The latter is very painful. They are excreted almost completely within 24 hours, both by glomerular filtration and tubular secretion.</p>
<p>Adverse reactions: Besides thrombophlebitis, these agents cause nausea, diarrhoea and toxic nephrosis. Oliguria and renal failure have been reported but generally, the damage is reversible following the withdrawal of the drug. Renal damage has been attributed to the free metallic ion released as a result of dissociation of the metal-chelate complex.</p>
<p>A febrile reaction, followed by myalgia, nausea, vomiting, histamine like reaction with rhinorrhoea, lacrimation and dermatitis are the other adverse effects reported, particularly with the disodium salt. The disodium salt may also cause hypocalcemic tetany due to excessive chelation of calcium.</p>
<p>Preparations: (i) Calcium disodium edentate. It can be given IM mixed with local a aesthetic agent. Same preparation can be given by IV infusion by diluting with normal saline or <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span> dextrose.</p>
<p>(ii) Disodium edetate injection 20 ml ampoules containing 3 g of the drug. Therapeutic uses:</p>
<ul>
<li>Lead poisoning: Disodium calcium edetate is used in the treatment of acute and chronic lead poisoning. It acts by exchanging its calcium for lead in the blood to form a stable, nonionisable, water-soluble lead compound which is rapidly eliminated in urine. This exchange between lead and calcium is selective because other metals such as mercury, iron, copper and cobalt are more strongly bound to tissue proteins and hence, not available for exchange.
In acute lead poisoning, the agent is given by slow IV infusion in the dose of 40 mg per kg in two divided doses/day, as a 0.5 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">3 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">3%</span></span></span></span></span> solution in <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.9</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.9 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.9%</span></span></span></span></span> saline or <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span> dextrose, for a maximum period of 5 days. The course may then be repeated after an interval of 2 to 3 days. Smaller doses are recommended in the presence of encephalopathy and increased intracranial pressure. In children, the dose should not be larger than 55 mg per kg . This should be divided into two portions and given by IV drip. It is necessary to monitor urine output as the chelator-lead complex is nephrotoxic.</li>
</ul>
<p>The salt can also be used as a diagnostic test for lead poisoning. A total dose of 75 mg per kg divided into 3 doses, is administered as <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">20 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">20%</span></span></span></span></span> solution by deep IM injection with <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1.5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">1.5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">1.5%</span></span></span></span></span> procaine. If the excretion of lead is more than 500 mcg per 24 hours, the ingestion of lead is concluded to be excessive.</p>
<p>Disodium calcium edetate has also been used in the treatment of porphyria and in poisoning with iron, cadmium and plutonium.</p>
<p>Currently there is no conclusive evidence that repeated IV infusion of EDTA (Chelation therapy) is beneficial in any form of atherosclerotic cardiovascular disease.</p>
<p>DITHIOCARB: This agent, administered orally in the dose of 2 g daily for 7 days, preceded by an initial dose of 200 mg IV, has been found useful in the treatment of nickel carbonyl poisoning and also to some extent in acute thallium poisoning and in Wilson's disease. The toxicity reported in animals includes visual disturbance and blindness.</p>
<p>DESFERRIOXAMINE and other iron-chelating agents are discussed in Chapter 34.</p>
<p>77</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="gases-therapeutic-and-toxic">Gases: Therapeutic and Toxic<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#gases-therapeutic-and-toxic" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Apart from the anaesthetic gases, other gases of therapeutic importance are oxygen, carbon dioxide and nitric oxide. Helium, an inert gas present in the atmosphere in minute amounts, has also found therapeutic applications.</p>
<p>Some gases and organic solvent vapours exist as environmental pollutants and are of toxicological concern, e.g., carbon monoxide, sulfur dioxide and ozone.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-gases">Therapeutic Gases<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-gases" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>OXYGEN: Inspired air contains <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>21</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">21 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">21%</span></span></span></span></span> of oxygen. It is carried in the body largely in combination with hemoglobin and a small quantity is transported in physical solution in plasma. With an increase in the ambient pressure, the amount of oxygen carried in the form of physical solution progressively increases.</p>
<p>Effects of oxygen administration: Inhalation of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>100</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">100 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">100%</span></span></span></span></span> oxygen in a normal subject produces the following effects:</p>
<ul>
<li>Ventilation: Oxygen at atmospheric pressure initially depresses and later mildly stimulates the ventilation; the depressor effect is probably indirect, due to inhibition of the chemoreceptor activity. Oxygen also directly decreases the sensitivity of the respiratory centre to carbon dioxide. This effect is particularly apparent when the gas is given under more than one atmospheric pressure.</li>
<li>Cardiovascular system: In normal individuals, oxygen produces a slight reduction in both the heart rate and in the cardiac output. The coronary and the cerebral blood flow are probably reduced, while the pulmonary vessels are dilated. It does not modify the blood pressure significantly.</li>
<li>Nitrogen concentration: Inhalation of oxygen leads to a reduction in the partial pressure of nitrogen within the pulmonary alveoli, with its subsequent diffusion from the body cavities and blood into alveoli from where it is eliminated.
Methods of administration: Two types of equipment are available for administering oxygen:</li>
<li>Those that aim at ensuring the highest concentration of oxygen in the inspired air: These include the oxygen tent and the various types of closely fitting aero-nasal masks with a non-return valve and either a reservoir bag or a demand valve on the oxygen supply line. The tents are cumbersome and require careful vigilance particularly against fire. Masks are particularly useful at high altitudes and in the treatment of bronchial asthma, pulmonary edema and chronic pulmonary diseases. Because of its irritant effect on the respiratory tract, oxygen in high concentration is humidified by passing it through either a humidifier or a nebuliser. The common method of bubbling it through a Wolff's bottle containing cold water has been shown to be valueless.</li>
<li>Those that aim at achieving a steady concentration, less than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>60</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">60 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">60%</span></span></span></span></span> in the inspired air: These include such simple devices as the nasal cannula and the nasal catheter (inserted through the nostril into the nasopharynx) and the more sophisticated equipment such as the Ventimask. In different models designed to deliver oxygen at fixed concentrations, it operates according to Bernoulli's principle: the pressure of a flowing gas is least where the rate of flow is greatest. If one injects oxygen through a small orifice, it attains great velocity but its pressure falls; it, therefore, sucks the room air from the surroundings and thus gets diluted. A flow of 1 to 6 litres of oxygen per minute through a cannula or a catheter ensures an oxygen concentration of 24 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>44</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">44 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">44%</span></span></span></span></span> in the inspired air. Larger flow rates of oxygen flow do not achieve higher concentrations of oxygen and are, therefore, wasteful. Adverse reactions:
(a) Due to formation of reactive <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">O</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{O}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">O</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> species:</li>
<li>Respiratory tract: Inhalation of oxygen in the concentration of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>60</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">60 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">60%</span></span></span></span></span> or more for 36 hours or longer may damage the pulmonary epithelium and inactivate a substance (surfactant) secreted</li>
</ul>
<p>by the alveoli and which helps to keep the alveoli patent by reducing the surface tension within them; consequently, extensive pulmonary atelectasis may occur. This is especially likely to occur when high concentration is used along with assisted mechanical ventilation and the arterial oxygen tension is allowed to remain above 150 mm Hg for prolonged periods. Administration of oxygen at a pressure greater than 1 atmosphere may cause respiratory distress in neonates, particularly in premature ones.</p>
<ul>
<li>Central nervous system: Inhalation of pure oxygen at pressures greater than 2 atmospheres may lead to paraesthesiae, mental disturbances, twitching, loss of consciousness and generalised convulsions. Convulsions may develop within a few minutes or several hours after inhalation of the gas.</li>
<li>Retrolental fibroplasia: High arterial oxygen tension (over 100 mm Hg ) interferes with the retinal blood supply and produces an occlusive proliferative retinal disease termed retrolental fibroplasia. This is observed mainly in premature infants. Retinal changes appear within 3rd to 6th week of life and may either regress or progress to blindness. (b) Others:</li>
<li>Hyperoxia can reduce coronary blood flow.</li>
<li>Carbon dioxide narcosis: In patients with COPD, status asthmaticus, weakness of the respiratory muscles (from polyneuritis, poliomyelitis or myasthenia gravis), and in those with central respiratory depression (from narcotic poisoning, head injury or raised intracranial tension), the alveolar ventilation is inadequate to prevent a rise in the arterial carbon dioxide tension <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">(</mo><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">a</mi><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>2</mn></msub><mo fence="true">)</mo></mrow><annotation encoding="application/x-tex">\left(\mathrm{PaCO}_{2}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord"><span class="mord"><span class="mord mathrm">PaCO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">)</span></span></span></span></span></span>. With increasing hypercapnea (raised <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">a</mi><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PaCO}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PaCO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> ), the respiratory centre becomes progressively more tolerant of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{CO}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">CO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and its activity is solely maintained by the stimulus of hypoxemia (hypoxemic drive) reflexly through the carotid and aortic bodies. A removal of this stimulus by oxygen administration reduces the ventilation still further with a consequent rise in <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">a</mi><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PaCO}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PaCO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>. This gives rise to the syndrome of carbon dioxide narcosis with raised intracranial tension, clinically manifested by sweating, twitchings, drowsiness, convulsions, papilledema and coma. It is a potentially lethal condition.</li>
<li>Fire hazard: Every oxygen appliance is a potential fire hazard and no naked flame, lighted cigarette or electric switch should be brought near a patient receiving oxygen. Preparations: Oxygen is dispensed in a compressed state in cylinders painted black with a white shoulder. Cylinders of oxygen mixed with carbon dioxide are also painted black but have grey and white quarterings on neck and shoulder.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-uses">Therapeutic uses:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>(1) Correction of hypoxia: The primary indication of oxygen therapy is hypoxia. Hypoxia may be defined as inadequate tissue oxygenation. "Hypoxia" said Haldane "not only stops the machinery but also wrecks the machine". The brain is the organ most sensitive to hypoxia, and irreversible damage usually results within 3 to 4 minutes of its onset. Hypoxic damage to the kidney, liver and heart (multiple organ failure) is also seen.</p>
<p>Types of hypoxia are shown in Table 77.1.</p>
<p>Table 77.1
Types of hypoxia</p>
<p>IHypoxic, characterised by hypoxemia.
II Anemic, due to deficiency of hemoglobin as in anemia or due to inability of the altered hemoglobin to take up oxygen as in methemoglobinemia, and carbon monoxide poisoning. In this variety, the oxygen tension in the arterial blood is normal but the 'oxygen content' is reduced.
III Stagnant, due to excessive slowing of blood supply to the peripheral tissues e.g., in shock.
IV Histotoxic, due to increase in metabolic oxygen demand of the tissues as in thyrotoxicosis, and/or the tissue may be unable to utilise the available oxygen either as a result of paralysis of essential enzyme systems (cyanide poisoning) or due to a mechanical barrier (tissue edema).</p>
<p>A healthy person at rest, breathing room air with <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>21</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">21 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">21%</span></span></span></span></span> oxygen at a partial pressure of 160 mm Hg , maintains the partial pressure of oxygen in the pulmonary alveoli <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">(</mo><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">A</mi><mi mathvariant="normal">O</mi></mrow><mn>2</mn></msub><mo fence="true">)</mo></mrow><annotation encoding="application/x-tex">\left(\mathrm{PAO}_{2}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord"><span class="mord"><span class="mord mathrm">PAO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">)</span></span></span></span></span></span> at 100 mm Hg . The oxygen in the alveoli equilibrates with the blood in the pulmonary capillaries. It produces in the arterial blood a partial pressure of oxygen dissolved in the plasma (arterial oxygen tension, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">a</mi><mi mathvariant="normal">O</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PaO}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PaO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> ) of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>80</mn><mo>−</mo><mn>100</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">m</mi></mrow><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">80-100 \mathrm{~mm} \mathrm{Hg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">80</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord">100</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">mm</span></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">Hg</span></span></span></span></span></span> and an oxygen saturation <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">(</mo><msub><mrow><mi mathvariant="normal">S</mi><mi mathvariant="normal">a</mi><mi mathvariant="normal">O</mi></mrow><mn>2</mn></msub><mo fence="true">)</mo></mrow><annotation encoding="application/x-tex">\left(\mathrm{SaO}_{2}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord"><span class="mord"><span class="mord mathrm">SaO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">)</span></span></span></span></span></span> of over <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>95</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">95 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">95%</span></span></span></span></span>. A reduction in the arterial oxygen tension is called hypoxemia. This must be distinguished from hypoxia which means inadequate tissue oxygenation. Hypoxemia generally (but not always) leads to hypoxia; on the other hand, hypoxia can arise from causes other than hypoxemia.</p>
<p>The carotid and the aortic bodies are the chemoreceptors which sense hypoxemia and stimulate breathing (mechanical ventilation) and the heart reflexly so that the hypoxemia tends to be corrected. In this process, the additional breathing effort and cardiac work increase the oxygen requirement of the body. At a certain stage, the body finds the increased ventilation and cardiac work uneconomical in terms of oxygen consumption and settles for a lower level of mechanical ventilation (breathing) even at the risk of continued hypoxemia. This is what commonly happens when a patient with COPD gets an acute chest infection and starts hyperventilating in order to compensate for the increase in the hypoxemia.</p>
<p>Hypoxemia can arise in several ways and can be detected by measurement of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">a</mi><mi mathvariant="normal">O</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PaO}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PaO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>. Our understanding of hypoxemia and its treatment is incomplete without an understanding of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{CO}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">CO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> transport and disposal in the body. Carbon dioxide is one of the final metabolic waste products in the body and enters the blood through the peripheral tissue capillaries. In the blood, it is carried
(a) Dissolved in the plasma; it is this <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{CO}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">CO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> which accounts for the partial pressure of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{CO}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">CO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">(</mo><msub><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\left(\mathrm{CO}_{2}\right.</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord"><span class="mord"><span class="mord mathrm">CO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mclose nulldelimiter"></span></span></span></span></span></span> tension or <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">a</mi><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>2</mn></msub><mo fence="true">)</mo></mrow><annotation encoding="application/x-tex">\left.\mathrm{PaCO}_{2}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen nulldelimiter"></span><span class="mord"><span class="mord"><span class="mord mathrm">PaCO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">)</span></span></span></span></span></span>;
(b) As carboxyhemoglobin in the red blood cells; and
(c) As bicarbonate to which it is rapidly converted in the red blood cells with the help of enzyme carbonic anhydrase.</p>
<p>In the lungs, it diffuses rapidly across the alveolocapillary barrier into the pulmonary alveoli. The rate of washing out of carbon dioxide from the alveoli and hence from the blood, at a given rate of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{CO}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">CO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> production (i.e. at a given metabolic rate), is determined solely by the adequacy of alveolar ventilation. When more <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{CO}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">CO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> is produced as a result of increased metabolic rate (as in fever), the breathing increases proportionately to wash out the excess of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{CO}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">CO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and maintain the carbon dioxide tension in the alveoli <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">(</mo><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">A</mi><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>2</mn></msub><mo fence="true">)</mo></mrow><annotation encoding="application/x-tex">\left(\mathrm{PACO}_{2}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord"><span class="mord"><span class="mord mathrm">PACO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">)</span></span></span></span></span></span> and in</p>
<p>the arterial blood <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">(</mo><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">a</mi><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>2</mn></msub><mo fence="true">)</mo></mrow><annotation encoding="application/x-tex">\left(\mathrm{PaCO}_{2}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord"><span class="mord"><span class="mord mathrm">PaCO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">)</span></span></span></span></span></span> at the normal level of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mo>−</mo><mn>50</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">m</mi></mrow><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">30-50 \mathrm{~mm} \mathrm{Hg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">30</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord">50</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">mm</span></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">Hg</span></span></span></span></span></span>. Whenever ventilation fails to increase proportionately to the rise in <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{CO}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">CO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> production, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">a</mi><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PaCO}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PaCO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> is elevated above 50 mm Hg. In any situation of hyperventilation, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">a</mi><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PaCO}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PaCO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> falls below 30 mm Hg . Thus, the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">a</mi><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PaCO}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PaCO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> level faithfully reflects the adequacy or otherwise of alveolar ventilation. This has important implications in oxygen therapy. In any cardio-pulmonary disease where <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">a</mi><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PaCO}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PaCO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> is low or normal, it is safe to administer oxygen in high concentration without special precautions. In any condition accompanied by elevated <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">a</mi><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PaCO}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PaCO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>, oxygen in high concentration tends to precipitate carbon dioxide narcosis. These patients are, however, badly in need of oxygen which should not be withheld from them. Only, it should be administered in low concentration so that the hypoxemia is only partly corrected, unless they can also be given mechanical assistance to ventilation.</p>
<p>Administration of sedatives and hypnotics makes patients drowsy and abolishes their voluntary ventilatory drive, leading to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{CO}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">CO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> narcosis. So can the administration of depressants of the respiratory centre such as morphine.</p>
<p>The clinical recognition of 'hypoxia' is largely inferential. Hypoxia cannot be measured but has to be surmised by the presence of:</p>
<ul>
<li>A clinical situation known to produce hypoxia; and</li>
<li>Hypoxemia which can be detected by measurement of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">a</mi><mi mathvariant="normal">O</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PaO}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PaO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>.</li>
</ul>
<p>In acute lung disease, hypoxemia can be clinically diagnosed by the presence of central cyanosis. Cyanosis is difficult to make out in anemic patients. In patients with chronic hypoxemia due to COPD, it is difficult to clinically make out an increase in the hypoxemia such as occurs in a super-added acute chest infection. These patients then show signs of carbon dioxide narcosis or of right sided cardiac failure which should be taken as indications of increased hypoxemia. The other parameters useful in assessing a hypoxemic patient are (a) the clinical assessment of cardiac, circulatory and neurological status of the patient; and (b) laboratory measurement of hemoglobin, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">a</mi><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PaCO}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PaCO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>, acid-base and electrolyte status (Chapter 37).</p>
<p>The results of oxygen administration are the best in situations where there is deficiency of oxygen in the inspired air as at high altitude, where breathing 100% oxygen is beneficial.</p>
<p>In cardiopulmonary disorders, the conditions maximally helped by oxygen therapy are those associated with alveolar hypoventilation due to any cause, venous admixture as in COPD and alveolo-capillary block as in interstitial lung disease. Those in which <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">a</mi><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PaCO}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PaCO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> is elevated should be treated with oxygen in low concentration and the effect on the patient's clinical condition (and on the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">a</mi><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PaCO}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PaCO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> if possible) should be watched carefully. Others can be safely treated with high concentration oxygen therapy.</p>
<p>Conditions with an intrapulmonary shunt can be safely treated with and benefit from oxygen in high concentration. Conditions with ventilation in excess of perfusion e.g. pulmonary emphysema are likely to show less benefit.</p>
<p>Administration of oxygen in high concentration to patients in shock increases the amount of dissolved oxygen in the plasma. Though this may be small, it may be sufficient to tip the scales in patient's favour in this critical condition. Besides, it can relieve the pain of MI, an important cause of shock.</p>
<p>In severe anemia, oxygen in high concentration does the same thing that it does in shock viz. that it adds that little extra dissolved oxygen which helps the critically ill patient.</p>
<p>In a cyanotic, congenital heart disease such as Fallot's tetralogy, the patient has hypoxemia and reduced arterial oxygen content despite the compensatory polycythemia. These patients tolerate their hypoxemia very well in the ordinary circumstances but need oxygen in high concentration during a chest infection and during surgery.
(2) Reduction in the partial pressure of an inert gas: Oxygen is used by workers in pressurised spaces to reduce the inhaled nitrogen concentration and thus to prevent the decompression sickness. It is also commonly used during anaesthesia with the gaseous and the volatile general anaesthetic agents.
(3) Oxygen as a diluent: Oxygen is used as a diluent for anaesthetic gases. In this setting, oxygen also serves to cater to the metabolic demands, as the anaesthetic agents commonly depress the ventilation and circulation.</p>
<p>HYPERBARIC OXYGEN: According to Henry's law, the volume of a gas dissolved in a solution depends upon its partial pressure. Thus, the amount of oxygen dissolved in the plasma can be increased by breathing oxygen at an absolute atmospheric pressure greater than one. The larger amount of oxygen present in physical solution in the plasma enables better tissue oxygenation. Hyperbaric Oxygen (HBO) Therapy is defined as "a mode of treatment in which the patient is entirely immersed in a pressure chamber and breathes oxygen at a pressure greater than 1 atmosphere absolute (ATA)". One ATA is equal to 760 mm Hg at sea level. HBO is administered by using a special chamber which is pressurised by either (a) <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>100</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">100 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">100%</span></span></span></span></span> oxygen at 2-3 ATA, which the patient breathes; or (b) compressed air, with the patient breathing <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>100</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">100 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">100%</span></span></span></span></span> oxygen at 2-3 ATA through special masks or oxygen hoods. At these pressures, the amount of oxygen dissolved in the plasma rises from 0.3 ml <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">\%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">%</span></span></span></span></span> at 1 ATA to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4.4</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">4.4 \mathrm{ml} \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">4.4</span><span class="mord"><span class="mord mathrm">ml</span></span><span class="mord">%</span></span></span></span></span> at 2 ATA and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>6.8</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">6.8 \mathrm{ml} \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">6.8</span><span class="mord"><span class="mord mathrm">ml</span></span><span class="mord">%</span></span></span></span></span> at 3 ATA, respectively (hyperoxygenation).</p>
<p>Pharmacological actions: HBO exerts several beneficial actions in the body.
(1) Mechanical:</p>
<ul>
<li>
<p>Reduction in the size of the gas (mainly nitrogen) bubbles in the circulation and the tissues in patients with decompression sickness and air/gas embolism, leading to amelioration of the symptoms of the former and improvement in the circulation in the latter.
(2) Hyperoxygenation:</p>
</li>
<li>
<p>Displacement of carbon monoxide (CO) from carboxyhemoglobin in carbon monoxide poisoning and smoke inhalation.</p>
</li>
<li>
<p>Peripheral vasoconstriction in tissues, with, nonetheless, increased oxygen delivery to the tissues. This helps to restore oxygenation of the ischemic tissues and to clear edema surrounding an abscess, especially in the brain and spinal cord. The heart is slowed and the cardiac output is reduced. The effect on blood pressure is variable.</p>
</li>
<li>
<p>Increased neovascularisation in hypoxic areas.</p>
</li>
<li>
<p>Direct bactericidal action on anaerobic organisms.</p>
</li>
<li>
<p>Killing of other pathogens by stimulating phagocytic and killing capacity of the leucocytes; and</p>
</li>
<li>
<p>Promoting wound healing in radiation-damaged tissues e.g. osteonecrosis, cystitis, enteritis and so on.
Adverse reactions: Upto 3 ATA, HBO is safe. Yet, adverse effects and accidents can occur:
(a) In the patient</p>
</li>
<li>
<p>Claustrophobia</p>
</li>
<li>
<p>Damage to the ear drums (otic barotrauma).</p>
</li>
<li>
<p>Barotrauma to the lungs resulting in pneumothorax or air embolism.</p>
</li>
<li>
<p>Pulmonary and neurological toxicity from oxygen free radicals.</p>
</li>
<li>
<p>Retrolental fibroplasia.</p>
</li>
<li>
<p>Hypersensitivity to oxygen.
(b) In the attendants in the multiplace chambers, who may suffer from decompression sickness if the chamber is decompressed rapidly.
(c) Fire hazard is a real but avoidable risk.</p>
</li>
</ul>
<p>Therapeutic uses:</p>
<ul>
<li>Metabolic: Carbon monoxide poisoning, smoke inhalation and cyanide poisoning blood loss with severe anemia.</li>
<li>Mechanical: Decompression sickness and air/gas embolism.</li>
<li>Ischemic conditions: Acute traumatic ischemia and crush injuries; retinal artery thrombosis.</li>
<li>Infective conditions: Clostridial infections (gas gangrene). Other severe/refractory tissue infections such as chronic osteomyelitis and brain abscess.</li>
<li>Wound healing problems: Non-healing ulcers and wounds; compromised skin grafts, thermal burns.</li>
<li>Early and late radiation damage to bone (radio-osteonecrosis) and soft tissues (e.g. cystitis and enteritis).
CARBON DIOXIDE: Normally it is produced in the body during tissue and food metabolism. The inspired atmospheric air contains <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.04</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.04 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.04%</span></span></span></span></span> of carbon dioxide. Carbon dioxide has marked effects on the CNS, the respiration and circulation.</li>
</ul>
<p>Effects of carbon dioxide inhalation:</p>
<ul>
<li>Respiration: Carbon dioxide stimulates respiration by:
(1) its direct action on the brain stem areas and
(2) to a smaller extent by action on the peripheral arterial chemoreceptors.</li>
</ul>
<p>It increases both the rate and the tidal volume. This effect is seen with inhalation of even <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">2 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">2%</span></span></span></span></span> carbon dioxide. The respiratory response to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{CO}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">CO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> is considerably enhanced when the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">a</mi><mi mathvariant="normal">O</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PaO}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PaO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> is lowered.</p>
<ul>
<li>Circulation: Carbon dioxide, by a direct action, tends to decrease the heart rate and the myocardiac force of contraction. It also relaxes the vascular smooth muscle, tending to cause vasodilatation.
The direct circulatory effects are antagonised by the sympathetic activation, causing an increase in the peripheral release of the catecholamines. The total circulatory response, therefore, is the outcome of two opposite actions. Thus, inhalation of carbon dioxide in a normal man increases the heart rate, the cardiac output, the systolic and the diastolic blood pressures and the pulse pressure. Cerebral and coronary vessels, which are devoid of a significant sympathetic control, dilate after carbon dioxide inhalation and so do the splanchnic and the skeletal muscle blood vessels. It is probably the most potent cerebral vasodilator.</li>
<li>CNS: Inhaled in low concentration, it stimulates the cerebral cortex and reduces seizure threshold. Higher concentrations depress the cortex, while activating the subcortical areas that have cortical projections.
Adverse reactions: Above a concentration of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>7</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">7 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">7%</span></span></span></span></span> in inhaled air, carbon dioxide gives rise to headache, dizziness, mental confusion, palpitation, dyspnoea and an increase in BP.</li>
</ul>
<p>Loss of consciousness occurs when its concentration exceeds <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">10 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">10%</span></span></span></span></span>. Withdrawal of carbon dioxide after prolonged inhalation often leads to pallor, hypotension, dizziness, nausea and vomiting. These effects can be minimised by its tapered withdrawal. Carbon dioxide narcosis has already been discussed earlier.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="preparations">Preparations:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#preparations" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>(i) Carbon dioxide is marketed in steel cylinders painted grey, usually in a liquid form, under a pressure of 58 to 72 atmospheres.
(ii) Combinations of oxygen and 5-10% carbon dioxide are marketed as 'carbogen'.
(iii) Solid carbon dioxide is available in two forms: dry ice and carbon dioxide snow.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="therapeutic-uses">Therapeutic uses:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Hiccups: Hiccup represents the sound produced by the sudden contraction of inspiratory muscles terminated by abrupt closure of the glottis. It is a common disorder due to a wide variety of causes including gastric distension, alcohol ingestion, excessive smoking, psychogenic disorders, disorders of the CNS, toxic-metabolic causes, irritation of the diaphragm, drugs and so on. Hiccups appear to serve no useful purpose. Usually it is self limited and harmless; but, sometimes it is an indicator of a serious disease and may last for many days. Inhalation of 10 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">25 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">25%</span></span></span></span></span> of carbon dioxide may be used in the treatment of intractable hiccups. Rebreathing into a paper bag is a household method of achieving the same effect.
The other measures tried are:
(a) Non-pharmacological: Stimulation of the uvula or the nasopharynx (touching the uvula with a spoon; sipping iced water; sucking hard candy; swallowing dry, granulated sugar; inhalation of ammonia); valsalva manoeuvre; sneezing; breath holding; phrenic nerve block.
(b) Pharmacological: A variety of drugs have been used to treat hiccups with variable results. Chlorpromazine; Haloperidol; Metoclopramide; Carbamazepine orally; Phenytoin IV; Magnesium sulfate IM.</li>
</ul>
<p>Benzodiazepines are not useful in hiccups.</p>
<ul>
<li>Neuropsychiatry: Inhalation of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">30 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">30%</span></span></span></span></span> of carbon dioxide with <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>70</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">70 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">70%</span></span></span></span></span> oxygen has been employed for the treatment of anxiety neurosis and personality maladjustments. Its therapeutic value is not well established.</li>
<li>Local uses: Carbon dioxide snow, which has a temperature of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo><msup><mn>80</mn><mo lspace="0em" rspace="0em">∘</mo></msup><mi mathvariant="normal">C</mi></mrow><annotation encoding="application/x-tex">-80^{\circ} \mathrm{C}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7667em; vertical-align: -0.0833em;"></span><span class="mord">−</span><span class="mord">8</span><span class="mord"><span class="mord">0</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6741em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∘</span></span></span></span></span></span></span></span></span><span class="mord mathrm">C</span></span></span></span></span> is used to destroy warts and naevi by local application for 5 to 6 seconds. The procedure is almost painless and scarring is minimum. The surrounding tissue should be protected with soft paraffin.</li>
<li>Miscellaneous: Supersaturated solution of carbon dioxide or aerated waters possess a mild rubefacient action and are believed to increase the secretion of gastric juice particularly hydrochloric acid. They are often used as carminatives and for masking unpleasant taste of saline purgatives.
HELIUM: This inert gas, in the concentration of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>80</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">80 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">80%</span></span></span></span></span> along with <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">20 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">20%</span></span></span></span></span> oxygen, is used by intermittent inhalation for treating prolonged asthmatic attacks resistant to other forms of therapy. Because of its lower density, it minimises the breathing effort. It is also employed prophylactically for prevention of Caisson disease, and in the treatment of edema and spasm of larynx.</li>
</ul>
<p>NITRIC OXIDE (NO): (Chapter 29) When inhaled, it has selective vasodilatory effect on the pulmonary circulation. It is used to improve oxygenation in hypoxic respiratory failure</p>
<p>with pulmonary hypertension in term and near-term neonates; and in adults with various types of pulmonary hypertension, including primary pulmonary hypertension, and in adult respiratory distress syndrome (ARDS). The outcome is less satisfactory in adults than in the neonates. It is administered by inhalation in the concentration of 10-80 ppm. Higher concentrations can be toxic because of its metabolic degradation to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">O</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{NO}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">NO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and because of methemoglobinemia.</p>
<p>Water vapour: Water to be inspired is administered either as a vapour (from a humidifier) or in particulate form (from a nebuliser) in patients with respiratory infection/irritation. Such vaporisation with water containing drops of tincture benzoin or eucalyptus oil is used as a home remedy. It decreases crusting of the respiratory mucosa, liquefies thick secretions, promotes mucociliary drainage (Chapter 26), limits loss of body water and conserves body heat by reducing the evaporation in the airway. It is also useful in patients whose airways are chronically intubated. Aerosol are used to deliver drugs such as bronchodilators and mucolytics to the airways.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="toxic-gases">Toxic Gases<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#toxic-gases" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>In the pursuit of making life more and more comfortable and with increasing urbanisation, environmental pollution has become a major health problem in modern life. People are exposed to various pollutants in the air, which enter the body not only through the lungs but also through skin and eyes, and cause local and systemic toxicity. The major air pollutants are shown in Table 77.2.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="table-77-2">Table 77.2<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-77-2" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="major-gaseous-air-pollutants">Major gaseous air pollutants<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#major-gaseous-air-pollutants" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Carbon monoxide (CO)</li>
<li>Sulfur dioxide (SO) <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mclose">)</span></span></span></span></span></li>
<li>Nitrogen dioxide (NO) <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mclose">)</span></span></span></span></span></li>
<li>Hydrocarbon vapours and</li>
<li>Glycols (Chapter 6)</li>
</ul>
<p>CARBON MONOXIDE (CO): This is a colourless, odourless, non-irritating gas which constitutes almost <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span> of the air-pollutants. CO is responsible for many accidental deaths every year. The automobile is the largest source of CO. It is also generated by incomplete combustion of organic matter as well as from smoking.</p>
<p>Actions: Carbon monoxide combines with hemoglobin to form carboxyhemoglobin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">(</mo><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi><mi mathvariant="normal">H</mi><mi mathvariant="normal">b</mi></mrow><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">(\mathrm{COHb})</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mopen">(</span><span class="mord"><span class="mord mathrm">COHb</span></span><span class="mclose">)</span></span></span></span></span> which cannot carry oxygen, thus reducing the oxygen delivery to the issues. The affinity of CO for hemoglobin is more than 200 times that of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">O</mi><mn>2</mn></msub><mi mathvariant="normal">.</mi><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow></mrow><annotation encoding="application/x-tex">\mathrm{O}_{2} . \mathrm{CO}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">O</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord">.</span><span class="mord"><span class="mord mathrm">CO</span></span></span></span></span></span> interferes with ferroproteins such as myoglobin and cytochrome oxidase.</p>
<p>The signs and symptoms of acute CO poisoning are those of hypoxia. Acute CO poisoning causes headache, weakness, dizziness, nausea, vomiting, coma and intermittent convulsions. The patient is cyanosed. Sudden exposure to very high concentrations of CO can cause immediate death without any warning symptoms. Lack of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">O</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{O}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">O</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> causes cardiac and delayed neurological damage. Cherry-red colour of the blood is highly suggestive of the diagnosis, which is confirmed by spectroscopy of the blood.</p>
<p>Early symptoms of poisoning are flu-like and may be wrongly diagnosed.
Chronic exposure to low concentrations of CO probably facilitates the development of athero-sclerosis, cardiac disease, neurological damage and parkinsonism.</p>
<p>Treatment of acute CO poisoning: COHb is fully dissociable and CO is rapidly excreted through the lungs. Treatment, therefore, consists of transport to an open space with fresh air, rapid administration of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>100</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">100 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">100%</span></span></span></span></span> oxygen with a tight fitting mask, and supportive therapy to correct hypotension and acidosis in severe cases. Recovery is almost complete if the patient is treated early. It can also be treated with hyperbaric oxygen (see earlier).</p>
<p>SULFUR DIOXIDE <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">(</mo><msub><mrow><mi mathvariant="normal">S</mi><mi mathvariant="normal">O</mi></mrow><mn>2</mn></msub><mo fence="true">)</mo></mrow><annotation encoding="application/x-tex">\left(\mathrm{SO}_{2}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord"><span class="mord"><span class="mord mathrm">SO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">)</span></span></span></span></span></span> : This gas is primarily generated during burning of fossil fuels that contain sulfur. Though it rarely causes death, it is a respiratory irritant, leads to the production of thick mucus and causes bronchospasm. Chronic exposure results in abnormal pulmonary function and can predispose to chronic respiratory disease. A part of the atmospheric sulfur is converted to sulfuric acid and particulate sulfates. Sulfuric acid in the atmosphere causes further damage to the respiratory passages, increases airway resistance and predisposes to chronic respiratory diseases. Sulfuric acid also dissolves in</p>
<p>rain water and returns to the earth as 'acid rain' which can cause environmental damage. The treatment is essentially symptomatic.</p>
<p>OZONE <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">(</mo><msub><mi mathvariant="normal">O</mi><mn>3</mn></msub><mo fence="true">)</mo></mrow><annotation encoding="application/x-tex">\left(\mathrm{O}_{3}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord"><span class="mord mathrm">O</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">)</span></span></span></span></span></span> : This gas is formed from a complex reaction of a major atmospheric pollutant <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">O</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{NO}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">NO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> with UV light. Thus:</p>
<div class="math math-display"><span class="katex-display"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML" display="block"><semantics><mtable rowspacing="0.16em" columnalign="left left" columnspacing="1em"><mtr><mtd><mstyle scriptlevel="0" displaystyle="false"><msub><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">O</mi></mrow><mn>2</mn></msub></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="false"><mrow><mo>⟶</mo><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">O</mi></mrow><mo>+</mo><mi mathvariant="normal">O</mi></mrow></mstyle></mtd></mtr><mtr><mtd><mstyle scriptlevel="0" displaystyle="false"><mrow><mi mathvariant="normal">O</mi><mo>+</mo><msub><mi mathvariant="normal">O</mi><mn>2</mn></msub></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="false"><mrow><mo>⟶</mo><msub><mi mathvariant="normal">O</mi><mn>3</mn></msub></mrow></mstyle></mtd></mtr></mtable><annotation encoding="application/x-tex">\begin{array}{ll}
\mathrm{NO}_{2} &amp; \longrightarrow \mathrm{NO}+\mathrm{O} \\
\mathrm{O}+\mathrm{O}_{2} &amp; \longrightarrow \mathrm{O}_{3}
\end{array}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 2.4em; vertical-align: -0.95em;"></span><span class="mord"><span class="mtable"><span class="arraycolsep" style="width: 0.5em;"></span><span class="col-align-l"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.45em;"><span style="top: -3.61em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"><span class="mord"><span class="mord mathrm">NO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span><span style="top: -2.41em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord mathrm">O</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord"><span class="mord mathrm">O</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.95em;"><span></span></span></span></span></span><span class="arraycolsep" style="width: 0.5em;"></span><span class="arraycolsep" style="width: 0.5em;"></span><span class="col-align-l"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.45em;"><span style="top: -3.61em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mrel">⟶</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mord"><span class="mord mathrm">NO</span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord mathrm">O</span></span></span><span style="top: -2.41em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mrel">⟶</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mord"><span class="mord mathrm">O</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.95em;"><span></span></span></span></span></span><span class="arraycolsep" style="width: 0.5em;"></span></span></span></span></span></span></span></div>
<p>Ozone is a respiratory irritant and can cause pulmonary edema and death. It is a potent oxidant, and pulmonary injury may be due to the formation of highly reactive free radical intermediates. Chronic exposure to ozone may cause chronic bronchitis, emphysema and pulmonary fibrosis. It increases the sensitivity of the lung to other bronchoconstrictors such as histamine, acetylcholine and to allergens. The treatment of the toxicity is symptomatic. Anti-oxidants such as vitamins <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>C</mi></mrow><annotation encoding="application/x-tex">C</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.07153em;">C</span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>E</mi></mrow><annotation encoding="application/x-tex">E</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.05764em;">E</span></span></span></span></span> may be useful.</p>
<p>NITROGEN DIOXIDE <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">(</mo><msub><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">O</mi></mrow><mn>2</mn></msub><mo fence="true">)</mo></mrow><annotation encoding="application/x-tex">\left(\mathrm{NO}_{2}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord"><span class="mord"><span class="mord mathrm">NO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">)</span></span></span></span></span></span> : This pollutant gas is also a pulmonary irritant and, like ozone, can cause pulmonary edema and changes in pulmonary function.</p>
<p>ORGANIC SOLVENT VAPOURS: In addition to the above pollutant gases, we are constantly exposed to organic solvent vapours such as petrol, crude oil, aerosol sprays and floor cleaners. Some of these solvents andhydrocarbons cause pleasant sensations when inhaled, and are frequently abused. The common hazardous solvents are shown in Table 77.3.</p>
<p>Table 77.3
Common hazardous organic solvents</p>
<ul>
<li>Aliphatic hydrocarbons: Methane, Ethane, n-Hexane.</li>
<li>Aromatic hydrocarbons: Benzene, Toluene.</li>
<li>Halogenated hydrocarbons: Carbon Tetrachloride, Tetrachlorethylene.</li>
</ul>
<p>Kerosene and petroleum products contain a variety of hydrocarbons. Petroleum vapours, when inhaled, cause sensitisation of the myocardium to noradrenaline and may precipitate ventricular arrhythmias. Ingestion of kerosene causes symptoms like ethyl alcohol poisoning and pulmonary edema.</p>
<p>Many of the hydrocarbons are capable of causing GI disturbances, CNS depression, neurological damage, polyneuropathy and aplastic anemia. They are also carcinogenic.</p>
<p>CYANIDE: This is one of the deadliest of all poisons causing death within a matter of minutes when inhaled as hydrogen cyanide. If ingested, it may take several hours before serious symptoms develop. It acts by forming a complex with cytochrome C oxidase, thereby inhibiting cellular <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">O</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{O}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">O</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> use leading to marked tissue anoxia. Small amounts of cyanide normally present in the body is biotransformed to the much less toxic thiocyanate; this reaction is catalysed by an intracellular enzyme rhodanase which requires thiosulfate or colloidal sulfur as a substrate. As the availability of this substrate is limited, rhodanase is unable to biotransform large amounts of cyanide. Symptoms of acute poisoning include dizziness, anxiety, perspiration, chest pain and in serious cases acidosis, coma and death.</p>
<p>The breath smells of bitter almonds.
Treatment: The treatment must be instituted immediately to prevent the fatal outcome:
(1) Dicobalt edetate, a chelating agent, is the treatment of choice in cyanide poisoning. It is given IV in the dose of 300 mg (one 20 ml ampoule) over one minute followed by 50 ml of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span> glucose by IV infusion. Both may be repeated once or twice as necessary. The drug is toxic and can cause severe hypotension, particularly in those subjects who are suspected but in fact are not suffering from cyanide poisoning.</p>
<p>Owing to its serious toxicity its use should be limited to a serious patient who is tending to lose, or has lost, consciousness; it should not be used as a precautionary measure.
(2) Sodium nitrite, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>300</mn><mo>−</mo><mn>500</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">300-500 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">300</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">500</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> in 10 to 15 ml of water is given IV over 3 minutes. It acts rapidly by converting hemoglobin to methemoglobin. Methemoglobin competes with cytochrome C oxidase for cyanide, to form cyanmethemoglobin and thus protects the enzyme.
(3) This is followed by IV sodium thiosulfate given slowly in the dose of 25 ml of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5.0</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5.0 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5.0%</span></span></span></span></span> solution (containing 12.5 g of sodium thiosulfate) over a period of 10 minutes. This results in the formation of relatively non-toxic thiocyanate which is excreted in the urine. It is slow acting but more safe.
(4) Hydroxocobalamin in large doses (4-5 g) may also be useful and is safe. It is converted to cyanocobalamin.
(5) Hyperbaric oxygen and IV methylene blue as <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">1 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">1%</span></span></span></span></span> solution in the dose of 1 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">4 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">4</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> are the other measures employed.</p>
<p>78</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="enzymes-in-therapy">Enzymes in Therapy<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#enzymes-in-therapy" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Enzymes being extremely potent substances, the possibility of their therapeutic application is attractive. However, majority of these substances have to be administered parenterally as they are inactivated within the gastrointestinal tract. In addition, because of their proteinic nature, they are likely to evoke allergic reactions and because of their high potency, their careless use may result in alarming adverse effects. Lastly, because of the complicated method of their preparation, the cost of such therapy is likely to be high.</p>
<p>Enzymes such as pancreatin, diastase, pepsin and papain, used in the treatment of certain GI disturbances have been described in Chapter 40. The enzymes fibrinolysin, thromboplastin, urokinase and arvin involved in the process of blood coagulation are discussed in Chapter 33. The therapeutic application of dornase alpha is discussed in Chapter 26 and the use of asparaginase in Chapter 61.</p>
<p>The other enzymes used therapeutically are:
HYALURONIDASE: This enzyme, prepared from mammalian testes acts by depolymerizing hyaluronic acid, an essential component of the intercellular ground substances which determines the permeability of the tissues. Thus, hyaluronidase, administered SC, increases the tissue permeability or exhibits 'spreading activity'. Certain snake-venoms and bee-venoms also contain hyaluronidase. Similarly, certain virulent organisms also liberate hyaluronidase.</p>
<p>Hyaluronidase is an odourless, fluffy powder containing not less than 300 units of activity per mg. It is antigenic and may occasionally produce allergic reactions. Because of the danger of spreading the infection, the enzyme should not be injected into or around an infected area. Malignancy is also considered a contraindication for hyaluronidase for similar reasons.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="therapeutic-uses">Therapeutic uses:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>It is employed to promote the rapid absorption of drugs and fluids given SC or IM. The agent is particularly useful in aiding the absorption of relatively large quantities of fluids, administered SC in infants and young children, in whom IV injection may be difficult. For hypodermoclysis 1500 units are added to each litre of fluid to be administered.</li>
<li>Substances used in radiography are rapidly absorbed on IM injection with the aid of hyaluronidase, thus providing an alternative to their IV administration.</li>
<li>It can be used to promote the absorption of blood and fluid in traumatic or postoperative edema or hematoma.</li>
<li>Sodium hyaluronate in highly purified form is used in a number of ophthalmic surgical procedures. It should not be applied directly to the cornea and should not be used to reduce the swelling of bites and stings.
STREPTOKINASE AND STREPTODORNASE: Streptokinase, a non-enzyme protein produced by certain strains of beta hemolytic streptococci, causes fibrinolysis and dissolution of clot mainly by converting the intrinsic plasminogen present in the fibrin clot to its active form plasmin. In addition, it is also capable of activating the plasminogen in the body fluids (extrinsic plasminogen) to plasmin; but this mechanism is probably of secondary importance in its clot-dissolving effect. Its maximum activity is seen between</li>
</ul>
<p>pH 7.3 to 7.6 The use of streptokinase for lysing intra-vascular thrombi is discussed in Chapter 33.</p>
<p>Streptodornase is not a single enzyme but a group of rapidly acting enzymes which promote the depolymerization of the complex nucleoproteins derived from degenerated leucocytes and injured tissue cells. They act directly and not through plasminogen activation. Their action results in a rapid conversion of thick, viscous and purulent material to thin, easy flowing fluid. The enzymes do not attack the nucleoproteins of living cells. Their optimum activity is observed between the pH 7.0 and 8.5 and requires the presence of magnesium ions.</p>
<p>Both these are stable for several months in desiccated form but solutions at room temperature deteriorate rapidly.</p>
<p>Adverse reactions: As with other enzymes, the use of streptokinase-streptodornase may occasionally result in allergic reactions like urticaria, rash, fever and anaphylaxis. A febrile reaction may occur. Streptokinase-streptodornase should not be employed in the presence of acute cellulitis and inflammation, as it may encourage the spread of localised infection. Since these substances are bacterial antigens, therapy with them results in rapid antibody formation rendering further treatment ineffective.</p>
<p>Preparations and dosage: Powder for topical application containing 100,000 units of streptokinase and 25,000 units of strepodornase, buffered with sodium phosphate to pH 7.5 .</p>
<p>Therapeutic uses: Streptokinase/streptodornase is used topically, for debridement of chronic ulcers.</p>
<p>Streptodornase is no longer used for intracavitary instillation as in empyema of the pleural cavity; some physicians use streptokinase instead, for this purpose.</p>
<p>TRYPSIN: This enzyme is obtained from an extract of the ox pancreas. It is available as a white powder soluble in water. The enzyme is active at a pH range of 5 to 8 with optimum activity at pH 7 . Trypsin directly hydrolyzes natural proteins, including the respiratory mucins.</p>
<p>Adverse reactions: These are similar to those of streptokinase-streptodornase. Application of the dry powder to surface lesions may cause a severe burning sensation. Intramuscular injection causes pain and induration at the site of injection and occasionally fever, leucocytosis, angioneurotic edema and urticaria.</p>
<p>Contraindications and precautions for the use of trypsin are similar to those with streptokinase-streptodornase. The agent should be used cautiously in the presence of renal damage and be avoided in individuals with hepatic insufficiency. It should never be given IV.</p>
<p>Therapeutic uses: Trypsin has therapeutic applications similar to streptodornase. For infiltration or by instillation, it is used as a solution containing 3 to 5 mg of the enzyme per ml . The dry powder may be applied every 15 to 30 minutes to small areas and every 3 hours to large areas; wet dressings and irrigations should be repeated 3 hourly. Small gelatin capsules containing the enzyme may be inserted into non-irrigable sinuses and fistulae. An aerosol of trypsin has been used to liquefy excessive bronchial secretions but its irritant nature makes it of doubtful value.</p>
<p>Proteolytic enzymes from Carica papaya (papase) and concentrated protease (bromelains) obtained from pineapple plant have the same indications as trypsin. They act by depolymerising the soft fibrin deposits in the inflamed areas and by facilitating the</p>
<p>drainage of fluids. Their therapeutic use is not well established.
CHYMOTRYPSIN: This is a proteolytic enzyme obtained from the bovine pancreas. It is available as tablets containing 50,000 units of the enzyme per tablet. Tablets containing trypsin and chymotrypsin are also available.</p>
<p>Chymotrypsin is proposed for use as an adjunct to the conventional treatment of traumatically induced inflammation and edema of soft tissues. It is applied locally or given orally. However, its usefulness is doubtful. Its oral toxicity is mild.</p>
<p>ALPHA-CHYMOTRYPSIN: This proteolytic enzyme has been reported to dissolve the suspensory ligament of the lens to facilitate the dissection of the lens during intracapsular extraction of cataract. The procedure is called zonulolysis. It can also be applied locally. The adverse effects include transient glaucoma, wound disruption, loss of vitreous and rarely retinal damage, if it penetrates the vitreous.</p>
<p>COLLAGENASE: This enzyme is derived from fermentation of Cl. histolyticum. It acts on both denatured and undenatured collagen. Newly formed collagen and healthy tissue collagen are not attacked. The activity is optimal at <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">p</mi><mi mathvariant="normal">H</mi></mrow><mn>6</mn><mo>−</mo><mn>8</mn></mrow><annotation encoding="application/x-tex">\mathrm{pH} 6-8</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord mathrm">pH</span></span><span class="mord">6</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">8</span></span></span></span></span>. Adverse effects are uncommon. It is used for debridement of dermal ulcers and in severe burns. It is applied in the form of an ointment once daily.</p>
<p>Deoxyribonuclease: DNA released from neutrophils forms long fibrils that contribute to the viscosity of sputum in cystic fibrosis. Inhaled recombinant human deoxyribonuclease which cleaves DNA has been tried in patients with cystic fibrosis who have purulent sputum and airway obstruction.</p>
<p>Serratiopeptidase: This proteolytic enzyme, administered orally, is claimed to be useful for 'digesting' necrotic tissue, cell debris, cellular exudate and coagulated blood. It is promoted in combination with other active agents such as NSAID for the oral treatment of inflammatory edema and hematoma. Adequate evidence, however, is lacking to substantiate its usefulness.</p>
<p>79</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="vitamins-and-antioxidants">Vitamins and Antioxidants<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#vitamins-and-antioxidants" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A vitamin is an organic substance that is found in food, is not made in the body, and is required in small quantities. Some of the vitamins such as vitamin K, pantothenic acid, folic acid and cyano-cobalamin are also synthesised by the intestinal bacterial flora. Vitamins form components of important enzyme systems which catalyse the reactions by which the body metabolises carbohydrates, proteins and fats. It is beyond the scope of this book to discuss in detail the physiological aspects of vitamins. The discussion is, therefore, limited to the pharmacological aspects when vitamins are employed as drugs.</p>
<p>A normal individual ingesting a well balanced diet, containing a wide variety of foods, gets adequate supply of vitamins and needs no supplements. Vitamin deficiency, however, can arise in various ways:</p>
<ul>
<li>Deficient dietary intake: Undernutrition from any cause including food fads.</li>
<li>Inadequate absorption from the GI tract: Chronic diarrhoea, malabsorption syndrome, alcoholism obstructive jaundice, interference with the function of the intestinal flora by oral antibiotics and interference with absorption by drugs like liquid paraffin.</li>
<li>Interference with utilisation usually by drugs e.g. pyrimethamine, trimethoprim and methotrexate which interfere with folic acid utilisation; INH prevents the conversion of pyridoxal to pyridoxal phosphate.</li>
<li>Increased demand: During growth, in pregnancy, during lactation, under stress, in fevers and other catabolic conditions such as hyperthyroidism.
Vitamins are classified as:
I Fat soluble vitamins such as A, D, E and K; and
II Water soluble vitamins such as B complex and C.
The former are stored in the body and cannot be excreted easily; hence, excessive administration of these can cause serious toxicity. Water soluble vitamins, on the other hand, are rapidly excreted in the urine following excessive administration.</li>
</ul>
<p>Recommended daily allowances of vitamins exceed the nutrient requirement and they acknowledge the range of nutrient requirements in healthy subjects. They do not allow for such factors as illness and interaction with drugs. However, short illnesses where the normal eating pattern is resumed early are unlikely to lead to vitamin deficiency. Clinical manifestations of deficiency of B vitamins are often not specific e.g. glossitis may be due to a deficiency of riboflavin, niacin, pyridoxine, folic acid or vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">B_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0502em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>. Vitamin deficiency can occur, unless specifically prevented by supplements, during total parenteral nutrition therapy.</p>
<p>Groups vulnerable to develop vitamin deficiency, other than those already mentioned above, are socio-economically disadvantaged persons; institutionalised persons; elderly persons on medications; heavy smokers who often lose interest in eating; women of childbearing age; infants (especially premature infants); and food faddists. Oral contraceptive pills reduce the serum levels of vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>B</mi><mn>6</mn></msub></mrow><annotation encoding="application/x-tex">B_{6}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0502em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">6</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>, folic acid and vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>C</mi></mrow><annotation encoding="application/x-tex">C</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.07153em;">C</span></span></span></span></span>, but raise that of vitamin A.</p>
<p>A diet that is deficient in one vitamin is likely to be deficient in others as well. In general, vitamin supplements should be used only when a dietary solution is not available.</p>
<p>Using food as the source of vitamins is the best safeguard against vitamin toxicity; the only exception to this rule is the livers of certain marine and arctic animals which are very rich in vitamin A.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="fat-soluble-vitamins">Fat Soluble Vitamins<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#fat-soluble-vitamins" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>VITAMIN A: Vitamin A is available from the diet either:</p>
<ul>
<li>As preformed vitamin, retinol, which is a complex, primary alcohol; or</li>
<li>Esters of retinol in the form of carotenoid pigments (particularly beta carotene) which is considered as provitamin A.
Sources: Beta carotene, the major carotinoid in the food, is present in green and yellow vegetables and fruits: leafy vegetables, carrots, papaya, mango etc. Retinol is present in animal foods: eggs, milk, milk products and meat. Animal liver (cod, halibut and mammals) is a rich source of retinol.</li>
</ul>
<p>The daily requirements of vitamin A is about 5000 U in adults and older children and about 3000 U in children below 5 years. About 35 g of dark leafy vegetables or 100 g of mango will supply the daily dietary requirements of children. Small fish, eaten whole (with their livers), are a good supplementary source of vitamin A in diet. Human milk supplies sufficient vitamin A for infants unless the mother's diet is grossly inadequate; in the latter instance, enough vitamin A should be given during the first six months after birth to provide about 1500 U daily to normal birth-weight infants and 2000-2500 U daily to premature infants.</p>
<p>Vitamin A values are now expressed as the retinol activity equivalent (RAE). One RAE is equal to 3.33 IU ( 1 mcg ) of retinol and 20IU of beta carotene.</p>
<p>Vitamin A and the carotenes are stable to moderate heat in the absence of oxidising agents. The ordinary cooking processes do not destroy the vitamin A in vegetables. Prolonged, high temperature cooking, exposure to light and rancidity of fat hasten vitamin A destruction but frozen foods retain their vitamin A content for a long time.</p>
<p>Mechanism of action: Vitamin A binds to steroid family receptors; retinoic acid receptors (RAR) and retinoid <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>X</mi></mrow><annotation encoding="application/x-tex">X</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.07847em;">X</span></span></span></span></span> receptors (RXR) and form heterodimer which subsequently binds to specific DNA sequence called retinoic acid responsive elements that activate gene transcription.</p>
<p>Physiological functions: Vitamin A is essential for:
(a) The synthesis of rhodopsin, the photosensitive pigment of rods. Rhodopsin decomposes when light strikes the rod, thus initiating the nerve impulse.
(b) The integrity of epithelial cells,
(c) Maintenance of CMI,
(d) Normal morphogenesis, somatic growth and cell differentiation, and
(e) Protection against infection.</p>
<p>Deficiency of vitamin A affects the immune system at multiple sites. It affects certain subsets of T lymphocytes, natural killer (NK) cells, cytotoxic activity and the antibody response to bacterial polypeptides. Mortality from infectious diseases, which accompany xerophthalmia, can be reduced by intermittent, massive vitamin A therapy.</p>
<p>Clinical vitamin A deficiency is characterized by:</p>
<ul>
<li>Night blindness, xerosis of conjunctivae (manifested as Bitot's spots) and xerophthalmic or "dry eye".</li>
<li>Squamous metaplasia of the mucosal surface of the upper respiratory tract and the periodontal tissues;</li>
<li>Follicular hyperkeratosis of the skin (also termed toad skin), and</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="increased-incidence-of-renal-calculi">- Increased incidence of renal calculi.<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#increased-incidence-of-renal-calculi" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Similar changes may occur in the intestinal epithelium leading to diarrhoea. In advanced stages, true keratomalacia may occur, leading to blindness. The manifestations of this condition are necrosis, ulceration and finally, perforation of the cornea and panophthalmitis. Vitamin A deficiency is one of the major preventable causes of blindness in children in developing countries.</p>
<p>Absorption, fate and excretion: Retinol is readily absorbed from the GI tract but requires the presence of dietary protein. The absorption is reduced in the presence of biliary obstruction or liver disease; however, this is not due to bile deficiency as externally administered bile salts are unable to promote its absorption.</p>
<p>Following absorption, vitamin A is stored in the Kupffer cells of the liver as retinyl ester. Almost <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>90</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">90 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">90%</span></span></span></span></span> of vitamin A in the body is in the liver. It is released into the plasma as free alcohol (retinol) in combination with specific proteins, retinol binding protein. Liver disease, therefore, may be associated with low plasma retinol levels. In kwashiorkor, plasma retinol levels are low, probably owing to the deficiency of the carrier protein.</p>
<p>As opposed to vitamin A, GI absorption of carotene is slow and requires the presence of bile and absorbable fat. Carotene is converted to vitamin A in the intestinal wall and is subsequently stored in the liver. However, only about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">30 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">30%</span></span></span></span></span> of the dietary carotene is converted to retinol. In the event of large dietary intake of carotene, some of it may escape into the circulation, leading to carotenemia, which causes a characteristic yellow discolouration of the skin.</p>
<p>Vitamin A is metabolised in the body to:</p>
<ul>
<li>Esters which are stored in the liver.</li>
<li>The aldehyde retinal which is the active element of the visual pigment; and</li>
<li>Retinoic acid, an intracellular messenger that modulates cell differentiation.</li>
</ul>
<p>Normal human urine does not contain any vitamin A.
Adverse reactions: Pharmacological doses of vitamin. A are teratogenic and in pregnancy the daily dose must not exceed 6000-8000 IU.</p>
<ul>
<li>Acute intoxication: Consumption of the liver of polar bear (vitamin A content, 10,000 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>34</mn><mo separator="true">,</mo><mn>000</mn><mrow><mi mathvariant="normal">I</mi><mi mathvariant="normal">U</mi></mrow><mi mathvariant="normal">/</mi><mi mathvariant="normal">g</mi></mrow><annotation encoding="application/x-tex">34,000 \mathrm{IU} / \mathrm{g}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">34</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">000</span><span class="mord"><span class="mord mathrm">IU</span></span><span class="mord">/</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span></span></span></span> ) leads to anorexia, nausea, vomiting, abdominal pain, headache, papilloedema, diplopia, convulsions, delirium and coma. Several of these effects are similar to those of a brain tumour. Bulging of fontanelles and vomiting have been reported in infants given a single, large dose of 300,000 IU of vitamin A.</li>
<li>Chronic intoxication usually develops following the administration of large doses of vitamin A (over 25,000 units daily) for prolonged periods. The usual symptoms are anorexia, dry itching skin (hyperkeratosis), loss of weight, increased irritability, low grade fever, alopecia, dependent edema with erythema and ecchymosis, fissuring, refractory skin ulcer, anemia and hepatosplenomegaly. Headache increased ICT and papilloedema are often encountered. Subcutaneous swellings, tenderness over long bones and bony exostoses are other notable features. X-ray studies reveal premature closure of epiphyses and consequent retardation of growth in children. The symptoms usually appear after a latent period of 6 to 15 months. The characteristic skin desquamation is a major diagnostic point to hypervitaminosis <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>A</mi></mrow><annotation encoding="application/x-tex">A</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal">A</span></span></span></span></span>.
Large doses (more than 20,000 IU/day in the form offish oil) of vitamin A should not be used during pregnancy or in infants; similarly, large amounts of liver in the diet should be avoided.</li>
</ul>
<p>Although beta carotene/vitamin A is claimed to act as antioxidant, it also has pro-oxidant effect in vivo. Its excessive intake may in fact, increase the risk of lung cancer and prostatic cancer.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="preparations-and-dosage">Preparations and dosage:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#preparations-and-dosage" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>(i) Concentrated vitamin A solution contains not less than 50,000 units <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">/ \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span> of vitamin A activity. Dose: 0.06 to 0.6 ml .
(ii) Vitamin A tablet: Contains 50,000 units of vitamin A. Dose: 1 to 2 tablets daily.
(iii) Vitamin A injection: Contains 100,000 units per ml. Dose: 1 ml IM once or twice a week.</p>
<p>Synthetic and natural preparations containing both vitamin A and vitamin D are:
(i) Vitamin A and D capsule or tablet contains 4000 units of vitamin A and 400 units of antirachitic activity. Dose: 1-2 capsules daily.
(ii) Shark liver oil is obtained from the livers of the shark and allied species. It contains not less than 6,000 units of vitamin A activity in 1 g Dose: 0.2 to 1 ml orally, approximately equivalent to 1,500 to 7,500 units of vitamin A.
(iii) Halibut liver oil is extracted from the liver of halibut species belonging to the genus Hippoglosus. It contains not less than 30,000 units of vitamin A activity and 2,500 to 3,500 units of antirachitic activity per g. Dose: 0.2 to 0.5 ml daily.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="therapeutic-uses">Therapeutic Uses:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Prophylactic uses: Prophylactic use of this vitamin is important in the high risk, malnourished populations to prevent blindness and other disturbances. Further, even mild degree of vitamin A deficiency is associated with increased morbidity and mortality in children, largely as a result of vulnerability to diarrhoea and repeated infections.
The prophylactic schedule recommended by the WHO is shown in Table 79.1.</li>
</ul>
<p>Table 79.1
WHO recommended prophylactic, oral vitamin A doses (in units)</p>
<table><thead><tr><th style="text-align: left;">- At birth (neonate)</th><th style="text-align: left;">50,000 (single dose)</th></tr></thead><tbody><tr><td style="text-align: left;">- Upto 1 year</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo separator="true">,</mo><mn>00</mn><mo separator="true">,</mo><mn>000</mn></mrow><annotation encoding="application/x-tex">1,00,000</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">1</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">00</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">000</span></span></span></span></span> once in 4-6 months</td></tr><tr><td style="text-align: left;">- Children above 1 year</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mo separator="true">,</mo><mn>00</mn><mo separator="true">,</mo><mn>000</mn></mrow><annotation encoding="application/x-tex">2,00,000</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">2</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">00</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">000</span></span></span></span></span> once in 4-6 months</td></tr><tr><td style="text-align: left;">- Immediately after delivery (mother)</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3</mn><mo separator="true">,</mo><mn>00</mn><mo separator="true">,</mo><mn>000</mn></mrow><annotation encoding="application/x-tex">3,00,000</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">3</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">00</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">000</span></span></span></span></span> (single dose)</td></tr><tr><td style="text-align: left;">- Pregnant and lactating women</td><td style="text-align: left;">5,000 daily</td></tr></tbody></table>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="for-treatment">- For treatment:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#for-treatment" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(a) In the treatment of nightblindness and xerophthalmia, vitamin A is administered in the dose of 1,00,000 units by IM injection repeated if necessary. This condition rarely responds completely to vitamin A therapy except in the early stages. Improvement begins within a week after administration but several months are required for complete healing.
(b) Measles can precipitate acute, severe vitamin A deficiency by depleting the hepatic stores of vitamin A. WHO/UNICEF have recommended that "High dosage of vitamin A supplementation should be provided to all children diagnosed with measles in communities in which vitamin A deficiency is a recognised problem". The recommended dose, to be administered as soon as measles is diagnosed, is 100,000 units in children under the age of 12 months and 200,000 units in children over that age. If any ocular sign of vitamin A deficiency is present, repeat the same dose the next day and again after one to four weeks.</p>
<p>(c) Deficiency of vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>A</mi></mrow><annotation encoding="application/x-tex">A</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal">A</span></span></span></span></span> is also seen in coeliac disease, sprue, and with excessive use of liquid paraffin. This generally responds to the treatment outlined above.
Synthetic analogues of vitamin A: Vitamin A has the important antikeratinising property. Retinol, to be effective, must be administered in doses that cause hypervitaminosis A. Synthetic analogues of retinol (retinoids) are useful in a variety of skin disorders in doses that do not cause hypervitaminosis A. The analogues are:</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="i-first-generation">I First generation<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i-first-generation" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Tretinoin (Vitamin A acid, 13-transretinoic acid, Retin-A) which is used locally as a comedolytic in the treatment of acne vulgaris (Chapter 71). It is also used to treat promyelocytic leukemia.</li>
<li>Isotretinoin (13-cis retinoic acid) which is used locally and orally as a sebostatic in the treatment of severe acne vulgaris (Chapter 71).</li>
<li>Alitretinoin.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="ii-second-generation">II Second generation<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ii-second-generation" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Etretinate (a derivative of tretinoin) and acitretin (a metabolite of etretinate, Neotigason) which are used orally as inhibitors of keratinisation and of cell proliferation in the treatment of psoriasis (Chapter 71). They have also been used in the prevention and treatment of skin tumours in certain groups of people with high genetic predisposition to such tumours. Finally, they have been used to treat mycosis fungoides, basal cell carcinoma of the skin, oral leukoplakia and superficial bladder tumours.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="iii-third-generation">III Third generation<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iii-third-generation" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Tazarotene, Bexarotene and Adapalene are the newer retinoids. Tazarotene and adapalene are used in the treatment of acne and bexarotene for cutaneous T cell lymphoma.
VITAMIN D: Chapter 70.
VITAMIN E: Vitamin E is a family of 4 tocopherols and 4 tocotrienols. Human and animals acquire vitamin E from plants and plant products like soya bean oil, corn oil, sunflower oil, wheat germ oil, rice germ oil, nuts and in green leaves of lettuce. Natural vitamin E is gamma tocopherol in contrast to the synthetic vitamin E which is l-alpha tocopherol. The former is more bioavailable and is retained longer than the latter. The daily requirement of vitamin E is believed to be <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3</mn><mo>−</mo><mn>15</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">3-15 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">3</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">15</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span>.</li>
</ul>
<p>In rats its prolonged deprivation leads to sterility in the male and abortion and foetal resorption in the female. In guinea pigs, vitamin E deficiency gives rise to dystrophy of the cardiac and the skeletal muscle. Experimentally vitamin E has been shown to have antioxidant properties. It mops up free radicals produced during metabolic processes, which damage the PUFA in the cell membrane. PUFA is essential for the maintenance of normal structure and function of the nervous system. Vitamin E deficiency is characterised by low serum levels, and increased fragility of RBCs, hemolytic anaemia and peripheral neuropathy. These may occur particularly in low birth weight infants and in patients with prolonged malabsorption of fats from various causes such as cystic fibrosis and obstructive jaundice.</p>
<p>Administration of commercial vitamin E supplement, which is mostly alpha tocopherol, can block the antioxidant activity of natural vitamin E in diet and may have a pro-oxidant effect in vivo.Further higher dose of vitamin E (more than 800 mg ) interferes with vitamin K metabolism and reduces platelet aggregation. A meta-analysis of several clinical studies</p>
<p>clearly indicate that vitamin E alone or in combination with vitamin A/carotene has no protective effect on cancer or cardiovascular events. In fact, vitamin E supplements during pregnancy have been reported to increase the gestational hypertension and cause premature rupture of the membrane.
VITAMIN K: Chapter 33.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="water-soluble-vitamins">Water Soluble Vitamins<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#water-soluble-vitamins" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Vitamin B Complex group includes thiamine, riboflavine, nicotinic acid, pyridoxine, pantothenic acid, inositol, biotin, methionine, folic acid and cyanocobalamin.</p>
<p>THIAMINE (Aneurine, vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>B</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">B_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0502em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> ): This was the first member of the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>B</mi></mrow><annotation encoding="application/x-tex">B</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span></span></span></span></span> complex series identified chemically, and hence the designation, vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>B</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">B_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0502em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>. It can withstand boiling but is easily destroyed by an alkaline solution. Peas, beans, oatmeal, the outer germ layer of the cereal grains, peanuts and mammalian organ meat are rich sources of thiamine. Appreciable amounts are also present in yeast, vegetables and fruits. Interestingly, tea and coffee contain and enzyme thiaminase which can destroy thiamine.</p>
<p>Physiological functions: The physiologically active form, thiamine pyrophosphate constitutes the prosthetic group of the decarboxylases involved in the metabolism of pyruvic and alpha-ketoglutaric acids, amino acids and thus it plays an important role in the intermediary carbohydrate metabolism and energy generation. The daily thiamine requirement is estimated to be between 1 to 2 mg .</p>
<p>Thiamine deficiency produces a symptom complex with characteristic neuropathy termed beriberi. Beriberi occurs in three main forms:</p>
<ul>
<li>Wet beriberi characterised by neuritis edema and high output cardiac failure;</li>
<li>Infantile beriberi which occurs within the first few months of life, with a high output failure, cyanosis, tachycardia, convulsions, anorexia, vomiting, greenish stools and sometimes sudden death as the noteworthy features; and</li>
<li>Dry beriberi, which is usually seen in adults and in which symmetric peripheral neuropathy and muscular atrophy are predominant.
Even though neuropathy in some form is common to all the three varieties, it is the most important manifestation in dry beriberi, while nervousness, increased irritability and depression may occur in all the types. In addition to beriberi, Wernicke's encephalopathy, characterised by confusion, ophthalmoplegia, nystagamus, tremors and often peripheral neuropathy, is looked upon as a manifestation of severe thiamine deficiency; Korsakoff's psychosis encountered in chronic alcoholics may owe some of its symptoms due to the lack of this vitamin and so may the neuritis encountered in pregnancy and pellagra.</li>
</ul>
<p>Vague symptoms like epigastric pain, anorexia, flatulence, constipation and lethargy or easy fatiguability are also attributed to thiamine deficiency.</p>
<p>Absorption, fate and excretion: Thiamine is incompletely absorbed from the duodenum and the small intestine. It is distributed in all tissues. Thiamine appears in urine only when the minimal requirements are satisfied and the stores (liver, heart, brain, kidney) are saturated.</p>
<p>Adverse reactions: Thiamine administered orally usually does not evoke any adverse effects. Administration of large dose by IM/IV route, however, may rarely result in anaphylactoid shock. Large doses may also interfere with the metabolism of other members of B complex group. Except in the initial treatment of acute wet beriberi, there is no justification for exceeding the dose of 100 mg daily, parenterally.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="preparations-and-dosage">Preparations and dosage:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#preparations-and-dosage" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(i) Thiamine hydrochloride tablet contains 5 to 50 mg of the drug. Dose: prophylactic, 5 mg daily; therapeutic 25 to 100 mg daily.
(ii) Thiamine hydrochloride injection. Dose: <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mo>−</mo><mn>100</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">25-100 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">25</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">100</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> SC or IM.</p>
<p>Therapeutic uses: Thiamine deficiency can be prevented by improvement in the dietary intake and by preventing overmilling of cereals, particularly rice. Acute wet beriberi responds dramatically to oral or parenteral administration of thiamine. Treatment is initiated with 50 to 100 mg , given parenterally, for 7 days. A maintenance dose of 5 to 10 mg is given subsequently orally. Most of the edema fluid is eliminated within 48 to 72 hours.</p>
<p>In dry beriberi, it is advisable to use thiamine with other members of vitamin B complex. Alcoholic and pregnancy neuritis respond well to the oral administration of 5 to 10 mg daily. In Wernicke's encephalopathy, a dose of 50 mg is usually advocated; improvement is rapid, particularly in ophthalmoplegia. In contrast, the neuritis of Korsakoff's psychosis may respond slowly.</p>
<p>RIBOFLAVINE (Vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">B</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{B}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> ): Riboflavine occurs as yellow or orange yellow crystals; it is heat stable.</p>
<p>It is present in the yeast, green vegetables, legumes meat, fish, eggs and milk. In plants, it is present as a greenish fluorescent pigment. It is highly sensitive to sunlight and undergoes photodegradation. The daily riboflavine requirement in an adult is 1.5 to 3 mg and in a child 0.6 to 2 mg .</p>
<p>Physiological functions: The physiologically active form of riboflavine is formed by phosphorylation. The two coenzymes flavin mononucleotide (FMN) and flavine adenine dinucleotide (FAD), which contain this active form, play an important role in transfer of hydrogen and in oxidation of carbohydrates, fats and amino acids. FAD also modulates homocysteine metabolism.</p>
<p>Riboflavine deficiency in man is characterised by angular stomatitis, glossitis, a peculiar magenta pigmentation of the tongue and cheilosis (loss of epithelium at the mucocutaneous junction of lips resulting in reddened, shiny and denuded lips). The other features are seborrheic follicular keratosis of the nasolabial folds, nose and forehead, dermatitis of the ano-genital region and 'burning feet'. Certain ocular manifestations such as conjunctivitis, blepharospasm, photophobia, burning, lacrimation and vascularisation of the cornea leading to diminution in visual acuity are observed in some cases.</p>
<p>Absorption, fate and excretion: Riboflavine is synthesised in the large intestine, but whether it is available for absorption is uncertain.</p>
<p>Riboflavine and FMN are readily absorbed from the gut. Phosphorylation of riboflavine to the active form occurs in the intestinal wall, liver and erythrocytes. Excess of vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">B</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{B}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> is stored in liver and kidneys. Only <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>9</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">9 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">9%</span></span></span></span></span> of the orally administered dose appears in urine; the metabolic fate of the remainder is not known. Riboflavine does not produce any significant toxic effects. Excess of riboflavine is readily excreted in the urine to which it imparts yellow colour and fluorescence.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="preparations-and-dosage">Preparations and dosage:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#preparations-and-dosage" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>(i) Riboflavine tablet 2 mg . Dose: prophylactic, 2 to 4 mg daily; therapeutic, 5 to 10 mg daily.
(ii) Riboflavine injection 10 mg per ml . Dose: <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mo>−</mo><mn>5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">2-5 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">5</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> daily SC or IM.</p>
<p>Therapeutic uses: In the treatment of ariboflavinosis, 5 to 10 mg of the vitamin is given daily in combination with other members of vitamin B group.</p>
<p>NICOTINIC ACID AND NICOTINAMIDE (Vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">B</mi><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{B}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> ): Nicotinic acid and its, nicotinamide are used for in the treatment of pellagra. Nicotinic acid is present in large quantities in rice polishings, liver, milk, eggs and lean meat, and to a smaller extent in</p>
<p>potatoes and in vegetables. It is also synthesised from tryptophan in the intestines and in the tissues. The normal daily requirement is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>15</mn><mo>−</mo><mn>20</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">15-20 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">15</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">20</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span>.</p>
<p>Physiological functions and pharmacological actions: Nicotinic acid as nicotinamide adenine dinucleotide (NAD) and its phosphate (NADP) is the constituent of a number of coenzymes involved in the metabolism of proteins necessary for cellular respiration. They also play a possible role in DNA repair.</p>
<ul>
<li>Pellagra, a symptom complex due to deficiency of nicotinic acid, occurs endemically in individuals subsisting mainly on a diet of maize. The latter has poor nicotinic acid and tryptophan content. Non-endemic pellagra occurs in chronic alcoholism, malabsorption syndrome, carcinoid syndrome, cirrhosis, poorly controlled diabetes mellitus, and in cachexia secondary to malignancy.
The characteristic features are dermatitis and pigmentation of the skin, especially in regions exposed to sunlight (such as neckcasal's necklace) and at various pressure points, anorexia, lethargy, stomatitis, glossitis, diarrhoea, irritability mental confusion (dementia) and megaloblastic anemia. Hallucinations may occur. Spinal cord degeneration leading to spastic paraplegia has been rarely reported.</li>
</ul>
<p>Associated folic acid deficiency is responsible for the megaloblastic anemia while deficiency of riboflavine, which is necessary for the conversion of tryptophan into nicotinic acid, and of pyridoxine; may account for the cheilosis, stomatitis, dermatitis, vaginitis and proctitis.</p>
<ul>
<li>Vascular smooth muscle relaxation: Nicotinic acid, in pharmacological doses causes peripheral vasodilatation by direct action on the vascular smooth muscle and causes flushing. This may be accompanied by pruritus.</li>
<li>Serum lipids: Large doses lower the serum cholesterol and triglyceride levels and activate fibrinolysis (Chapter 40). Nicotinamide is devoid of these effects.
Absorption, fate and excretion: Both nicotinic acid and nicotinamide are readily absorbed from the GI tract and from parenteral sites. They are distributed to all the tissues. Inactivation occurs mainly by N -methylation and to some extent by conjugation; the products are eliminated in the urine. The vitamin may appear in urine in the active form if large doses are given orally.</li>
</ul>
<p>Adverse reactions: Besides flushing, urticaria and pruritus, large doses may cause furunculosis and other skin lesions, malaise, GI disturbances, activation of peptic ulcer, amblyopia, impairment of liver function, decrease in glucose tolerance and hyperuricemia. Nicotinic acid potentiates the action of vasodilator drugs.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="preparations-and-dosage">Preparations and dosage:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#preparations-and-dosage" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>(i) Nicotinic acid tablet 50 mg . Dose: prophylactic 15 to 30 mg daily; therapeutic, 50 to 250 mg daily.
(ii) Nicotinamide tablet 50 mg . Dose: similar to nicotinic acid.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="therapeutic-uses">Therapeutic uses:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Pellagra: Nicotinic acid or its amide is used in the treatment of pellagra in the daily dose of 50 to 500 mg . Usually, nicotinamide is preferred because of its lack of adverse effects. Therapy with the vitamin produces a striking improvement within 24 hours. The neuropathy and the lesions of face and lips, however, may need adjuvant treatment with riboflavine.</li>
<li>As a vasodilator: Nicotinic acid, in the dose of 100 to 300 mg by subcutaneous or oral</li>
</ul>
<p>route, has been employed as a vasodilator in the treatment of Meniere's disease and in peripheral vascular disorders including chilblains and frostbite.</p>
<ul>
<li>Hyperlipidemia: Large doses ( 3 to 6 g daily) are used (Chapter 40).</li>
</ul>
<p>PYRIDOXINE (Vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">B</mi><mn>6</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{B}_{6}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">6</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> ): Pyridoxine, pyridoxal and pyridoxamine are collectively called as vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>B</mi><mn>6</mn></msub></mrow><annotation encoding="application/x-tex">B_{6}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0502em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">6</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>. It is present in yeast, cereals, legumes, nuts, milk and meat. All the three forms are converted in the body to pyridoxal phosphate which is the physiologically active form. The daily requirement is estimated at 1-2 mg.</p>
<p>Physiological functions: Pyridoxal phosphate acts as a coenzyme for amino acid decarboxylases and transaminases. It is intimately involved in amino acid metabolism and the synthesis and degradation of biogenic amines like the catecholamines, 5-HT and other compounds like GABA, steroids.</p>
<p>A syndrome in infants secondary to ingestion of proprietary milk preparation deficient in pyridoxine has been described. The characteristic features include irritability, abdominal distension, twitching, failure to gain weight, hypochromic microcytic anemia and convulsions. The anemia is probably due to inadequate utilisation of iron for erythropoiesis. Pyridoxine deficiency in adults may lead to lesions of the skin and mouth resembling those seen in ariboflavinosis and pellagra, to peripheral neuritis and to mental changes. Its deficiency may cause abnormal GTT.</p>
<p>Absorption, fate and excretion: All the three forms of the vitamin are readily absorbed from the GI tract. The end product of metabolism, 4-pyridoxic acid, is eliminated in urine.</p>
<p>Adverse reactions: Pyridoxine, administered in physiological doses, does not produce any adverse effects. Administration of large doses has been reported to cause peripheral sensory neuropathy and ataxia. Pyridoxine interferes with therapeutic effect of levodopa (Chapter 15).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="preparations-and-dosage">Preparations and dosage:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#preparations-and-dosage" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>(i) Pyridoxine tablet 5 mg . Dose: 5 to 20 mg daily.
(ii) Pyridoxine injection. Dose: <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mo>−</mo><mn>100</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">25-100 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">25</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">100</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> IM or IV.</p>
<p>Therapeutic uses:</p>
<ul>
<li>Pyridoxine dependent inborn error of metabolism e.g. primary hyperoxaluria, homocystinuria.</li>
<li>Convulsions due to pyridoxine deficiency in infants: <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">4 \mathrm{mg} / \mathrm{kg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">4</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mord">/</span></span></span></span></span> day for short periods.</li>
<li>Anemia due to pyridoxine deficiency: <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mo>−</mo><mn>150</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">50-150 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">50</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">150</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day in divided doses.</li>
<li>Pellagra: As an adjuvant in the dose of 5-10 mg/day.</li>
<li>Vomiting of pregnancy, post-irradiation vomiting (Chapter 41).</li>
<li>Mental depression during oral contraceptive therapy (Chapter 68).</li>
<li>INH and alcohol induced peripheral neuropathy (Chapter 54 and 6).</li>
<li>Penicillamine induced optic nerve damage.</li>
</ul>
<p>There is no evidence to suggest that supplementation of vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>B</mi><mn>6</mn></msub></mrow><annotation encoding="application/x-tex">B_{6}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0502em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">6</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> with or without folate and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{B}_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> reduces the risk of stroke or cancer.</p>
<p>PANTOTHENIC ACID (Vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">B</mi><mn>7</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{B}_{7}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">7</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> ): This is an organic acid which serves its physiological function by being converted into coenzyme A. Yeast, wheat, peanuts, cereals, milk, vegetables and liver contain large amounts of pantothenic acid. The daily requirement of pantothenic acid is less than 5 mg .</p>
<p>Physiological actions: Coenzyme A is involved in several fundamental biological</p>
<p>reactions such as fatty acid metabolism, synthesis of cholesterol and steroid hormones and acetylation reactions.</p>
<p>Pantothenic acid deficiency in human beings under normal circumstances is not known. In animals, deficiency of the vitamin results in keratitis, dermatitis, arrest of growth, depigmentation of hair, neuromuscular degeneration and fatal bilateral adrenal hemorrhage. Artificial deficiency produced in human volunteers is characterised by fatigue, malaise, headache, somnolence, paraesthesiae, nausea, occasional vomiting, abdominal cramps, flatulence and possibly burning feet syndrome.</p>
<p>Absorption, fate and excretion: The vitamin remains stable in foodstuffs for long periods and little is destroyed during cooking. Pantothenic acid is rapidly absorbed from the gut and is concentrated in liver, heart and kidneys. It is mainly excreted in the urine.</p>
<p>Pantothenic acid is almost non-toxic.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="preparations-and-dosage">Preparations and dosage:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#preparations-and-dosage" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>(i) Calcium pantothenate: 10 mg tablets. Dose: 10 to 50 mg .
(ii) Dexpanthenol: This analogue of pantothenic acid is readily converted to the parent compound on administration. Dose of 250 to 500 mg given IM/IV. For topical application, 2 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span> cream/ointment.</p>
<p>Therapeutic uses: Calcium pantothenate has been employed in post-operative paralytic ileus and as a nutritional supplement along with other members of the B-complex group. Dexpanthenol has been employed systemically for the prevention and treatment of postoperative intestinal atony and topically for various skin lesions including burns, wounds and ulcers; their utility in these conditions, however, remains doubtful.</p>
<p>BIOTIN: Biotin is an organic acid which functions as a coenzyme for numerous carboxylation reactions. Biotin deficiency is not encountered naturally in humans but has been produced in volunteers by administering a diet containing large amounts of raw egg white, which binds to biotin and reduces its bioavailability. Deficiency is characterised by seborrheic dermatitis, lassitude, anorexia and paraesthesiae. The daily human requirement of the vitamin is unknown. The vitamin is synthesised by the intestinal flora. As a clinical deficiency syndrome has not been demonstrated clearly, it has no therapeutic application.</p>
<p>Miscellaneous: These include inositol, choline, methionine and para-aminobenzoic acid (PABA).</p>
<p>Choline plays a role in cholinergic transmission, lipid and cholesterol metabolism, methyl group metabolism and transmembrane signaling. Food like wheat germ, milk, eggyolk, meat contain lecithine- a choline compound. Choline is also synthesized by the liver. Its deficiency may occur in subjects given parenteral nutrition devoid of choline.</p>
<p>Choline and methionine, the so called "lipotropic factors", have been used in the treatment of liver cirrhosis; inositol has been used in the management of diseases associated with the metabolism of fat. This is based on the observation that their experimental deficiency in animals causes fatty livers. Their efficacy in human conditions is, however, equivocal. Methionine is used to treat acute paracetamol poisoning (Chapter 11).</p>
<p>For folic acid and vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="bold">B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">\mathbf{B}_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8361em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathbf">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>, see Chapter 35.
ASCORBIC ACID (Vitamin C): The dietary sources of ascorbic acid include citrus fruits, tomatoes, plants, potatoes and green vegetables. One ml of lemon juice contains about 0.5 mg of this vitamin. Lemon juice as a sole source of this vitamin is not reliable. Although cereals and other seeds are devoid of vitamin C, they produce it on germination. Levo</p>
<p>compound is more active. Vitamin C is unstable and is destroyed by boiling and by alkali.
Physiological actions: Ascorbic acid, along with its oxidation product dehydroascorbic acid, is intimately involved in several physiological actions:
(a) In biological oxidation-reduction reactions and in cellular respiration.
(b) For the functional integrity of sulfhydryl group of enzymes and also for the formation of collagen and intercellular matrix, and hence, for the development of cartilage, bone and teeth and for healing of wounds.
(c) As a potent antioxidant, in neutralising free radicals (oxidant)
(d) For absorption of non-heme iron, conversion of dopamine to NA
(e) The formation of hemoglobin, erythrocyte maturation, certain immunological reactions of the body and the conversion of folic acid to tetrahydrofolate and
(f) In carbohydrate metabolism and in the oxidation of phenylalanine and tyrosine. Scorbutic animals exhibit hyperglycemia, lowered glucose tolerance and resistance to insulin.</p>
<p>Ascorbic acid deficiency leads to the development of scurvy. The characteristic features in adults are perifollicular hemorrhages, petechiae, ecchymoses, particularly in "saddle areas" and posterior thighs, hemorrhages in subcutaneous tissues, muscles and joints; swollen, inflamed, bleeding and spongy gums and normocytic or microcytic anemia. In infants, loss of appetite, listlessness and subperiosteal hemorrhages leading to tenderness and restriction of limb movements are the cardinal features. Ecchymoses and gum changes may also be seen. Infantile scurvy is usually seen in bottle-fed babies as human milk contains appreciable amounts of ascorbic acid.</p>
<p>Patients suffering from extensive burns and those suffering from malabsorption syndrome may also develop ascorbic acid deficiency.</p>
<p>Absorption, fate and excretion: Ascorbic acid is synthesised in the liver by majority of the animals except man and guinea pigs and hence, deficiency of ascorbic acid can be produced in these two species.</p>
<p>The minimum daily requirement of ascorbic acid for an adult is about 30 mg and for infants, 5 mg per kg of body weight.</p>
<p>Ascorbic acid is almost completely absorbed from GIT when given in smaller doses. However, absorption is only <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span> when doses <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>1</mn><mrow><mi mathvariant="normal">g</mi><mi mathvariant="normal">m</mi></mrow></mrow><annotation encoding="application/x-tex">&gt;1 \mathrm{gm}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">1</span><span class="mord"><span class="mord mathrm">gm</span></span></span></span></span></span> are used. It is concentrated in the glandular tissues. The leucocyte and the platelet levels of ascorbic acid are higher than the corresponding plasma levels. It is partly metabolised and excreted in urine as oxalate and a part is eliminated in the free form. Urinary excretion depends upon saturation of body stores and in individuals with its deficiency, the vitamin may not appear in urine even on administration of large doses.</p>
<p>In ordinary doses ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&lt;</mo><mn>1</mn><mrow><mi mathvariant="normal">g</mi><mi mathvariant="normal">m</mi></mrow></mrow><annotation encoding="application/x-tex">&lt;1 \mathrm{gm}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&lt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">1</span><span class="mord"><span class="mord mathrm">gm</span></span></span></span></span></span> ), ascorbic acid is essentially non-toxic. Vitamin C in urine gives a false positive test for sugar while using Benedict's test and a false negative test while using glucose oxidase test.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="preparations-and-dosage">Preparations and dosage:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#preparations-and-dosage" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>(i) Ascorbic acid tablet contains 50 mg . Dose: Prophylactic, 25 to 75 mg daily; therapeutic 200 to 500 mg daily.
(ii) Ascorbic acid injection: <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.1</mn><mo>−</mo><mn>1</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">0.1-1 \mathrm{~g}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.1</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">1</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span></span></span></span></span> IM/IV</p>
<p>Adverse reactions: Prolonged ingestion of large quantities ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>2</mn><mrow><mi mathvariant="normal">g</mi><mi mathvariant="normal">m</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">&gt;2 \mathrm{gm} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">2</span><span class="mord"><span class="mord mathrm">gm</span></span><span class="mord">/</span></span></span></span></span> day) of vitamin C is known to lead to increased urinary excretion of oxalate and possibly stone formation and</p>
<p>kidney damage. Rebound scurvy may occur in the offspring of mothers taking high doses; and similar phenomenon is observed when a person habitually taking large amounts of vitamin C suddenly stops taking it.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-uses">Therapeutic uses:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Scurvy prevention and treatment: In the treatment of scurvy, ascorbic acid is administered in the dose of 100 to 500 mg per day. As a prophylactic measure, it is important to ensure adequate Vitamin C intake in infancy and old age. Infantile scurvy can be prevented by adding 5 mg of the vitamin to the feeds of bottle-fed infants. For prophylaxis, a daily dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mo>−</mo><mn>100</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">50-100 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">50</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">100</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> is advocated in adults. Ascorbic acid increases the absorption of iron from the GI tract by facilitating the conversion of ferric into ferrous form.</li>
<li>Methemoglobinemia: Because of its ability to function as a reducing agent, ascorbic acid in the daily dose of 300 to 600 mg is used in the treatment of methemoglobinemia; it is, however, less effective than methylene blue.
The vitamin is also used as an antioxidant in emulsions of fats and oils, in certain injections and eye drops, and as a preservative.</li>
</ul>
<p>It has been used empirically in a wide variety of conditions including nonspecific hemorrhagic states, anemia and dental infections, without clear benefit. High doses of vitamin C fail to reduce the risk of cancer or cardiovascular accidents. It does not have any beneficial effects in common cold. Such doses ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>1</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">&gt;1 \mathrm{~g}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">1</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span></span></span></span></span> ) are poorly absorbed and may cause abdominal pain diarrhea, increase in urinary excretion of oxalate and oxalate stones.</p>
<p>Multivitamin Combinations: Prophylactic multivitamin preparations should contain from one-half to one and one-half times the recommended dietary allowances (Table 79.2) except for vitamin D which should not exceed the daily recommended dietary allowance. Larger doses of ascorbic acid and B-complex in such preparations are wasteful and could be harmful. Multivitamin pills may be useful in old people, who for some reasons cannot get adequate nutrition, malnutrition and during recovery from acute illnesses.</p>
<p>Table 79.2
Recommended dietary allowances (RDA) of various vitamins per day for adults</p>
<table><thead><tr><th style="text-align: left;">Recommended by</th><th style="text-align: left;"></th><th style="text-align: left;"></th></tr></thead><tbody><tr><td style="text-align: left;">Vitamins</td><td style="text-align: left;">ICMR (for Indians)</td><td style="text-align: left;">WHO/FAO Expert Group</td></tr><tr><td style="text-align: left;">Thiamine</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1.2</mn><mo>−</mo><mn>2.0</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">1.2-2.0 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">1.2</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">2.0</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span></td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1.0</mn><mo>−</mo><mn>1.5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">1.0-1.5 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">1.0</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">1.5</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span></td></tr><tr><td style="text-align: left;">Riboflavin</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1.3</mn><mo>−</mo><mn>2.2</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">1.3-2.2 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">1.3</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">2.2</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span></td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1.3</mn><mo>−</mo><mn>2.1</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">1.3-2.1 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">1.3</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">2.1</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span></td></tr><tr><td style="text-align: left;">Pyridoxine</td><td style="text-align: left;">-</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1.5</mn><mo>−</mo><mn>2.0</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">1.5-2.0 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">1.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">2.0</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span></td></tr><tr><td style="text-align: left;">Niacin</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>16</mn><mo>−</mo><mn>26</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">16-26 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">16</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">26</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span></td><td style="text-align: left;">-</td></tr><tr><td style="text-align: left;">Vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="bold">B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">\mathbf{B}_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8361em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathbf">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi>μ</mi><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">1 \mu \mathrm{~g}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">1</span><span class="mord mathnormal">μ</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span></span></span></span></span></td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mi>μ</mi><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">2 \mu \mathrm{~g}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">2</span><span class="mord mathnormal">μ</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span></span></span></span></span></td></tr><tr><td style="text-align: left;">Folate</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>100</mn><mi>μ</mi><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">100 \mu \mathrm{~g}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">100</span><span class="mord mathnormal">μ</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span></span></span></span></span></td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>200</mn><mi>μ</mi><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">200 \mu \mathrm{~g}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">200</span><span class="mord mathnormal">μ</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span></span></span></span></span></td></tr><tr><td style="text-align: left;">Vitamin C</td><td style="text-align: left;">50 mg</td><td style="text-align: left;">30 mg</td></tr><tr><td style="text-align: left;">Vitamin A</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>750</mn><mi>μ</mi><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">750 \mu \mathrm{~g}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">750</span><span class="mord mathnormal">μ</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span></span></span></span></span></td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>750</mn><mi>μ</mi><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">750 \mu \mathrm{~g}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">750</span><span class="mord mathnormal">μ</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span></span></span></span></span></td></tr><tr><td style="text-align: left;">Vitamin D</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi>μ</mi><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow><mo stretchy="false">(</mo><mn>200</mn><mrow><mi mathvariant="normal">R</mi><mi mathvariant="normal">J</mi></mrow><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">5 \mu \mathrm{~g}(200 \mathrm{RJ})</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">5</span><span class="mord mathnormal">μ</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span><span class="mopen">(</span><span class="mord">200</span><span class="mord"><span class="mord mathrm">RJ</span></span><span class="mclose">)</span></span></span></span></span></td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2.5</mn><mi>μ</mi><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow><mo stretchy="false">(</mo><mn>100</mn><mrow><mi mathvariant="normal">R</mi><mi mathvariant="normal">J</mi></mrow><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">2.5 \mu \mathrm{~g}(100 \mathrm{RJ})</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">2.5</span><span class="mord mathnormal">μ</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span><span class="mopen">(</span><span class="mord">100</span><span class="mord"><span class="mord mathrm">RJ</span></span><span class="mclose">)</span></span></span></span></span></td></tr></tbody></table>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mn>1</mn></msup></mrow><annotation encoding="application/x-tex">{ }^{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8141em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span></span></span></span></span></span></span></span></span> ICMR-Indian Council of Medical Research
Routine prophylactic supplementation of vitamin D should be avoided in young, healthy</p>
<p>persons. Elderly subjects, particularly with dark skin on inadequate diet, may not get adequate vitamin D. The usually recommended daily dose is 600 IU for age group between 1-70 yrs and 800 IU for those above 70 yrs. More supplement ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>800</mn></mrow><annotation encoding="application/x-tex">&gt;800</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">800</span></span></span></span></span> IU) preferably with calcium supplements is advised for all post-menopausal women and the elderly who have inadequate exposure to sunlight. Selective deficiency of a single vitamin B factor occurs less commonly and hence, combined B-complex therapy is commonly employed prophylactically as well as therapeutically</p>
<p>Commercial multivitamin preparations may contain 4-5 times the recommended dietary allowances. They are expensive and should be used only for deficiency states and during periods of increased vitamin requirement. They are not a substitute for a balanced diet. Used indiscriminately as dietary supplements to 'keep up the energy and strength', they act no better than placebos. The major portion of large doses of water soluble vitamins is washed out in the urine within 24 hours. Often, costly multivitamin preparations with several minerals are promoted as general 'tonics' to keep 'good health' and to protect from 'stress.' This is irrational and wasteful.</p>
<p>Prolonged use of high doses of vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>A</mi></mrow><annotation encoding="application/x-tex">A</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal">A</span></span></span></span></span> and vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>D</mi></mrow><annotation encoding="application/x-tex">D</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.02778em;">D</span></span></span></span></span> can cause toxicity. There is no good reason to take vitamins <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>A</mi><mo separator="true">,</mo><mi>C</mi></mrow><annotation encoding="application/x-tex">A, C</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord mathnormal">A</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord mathnormal" style="margin-right: 0.07153em;">C</span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>E</mi></mrow><annotation encoding="application/x-tex">E</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.05764em;">E</span></span></span></span></span>, and many carotenoids to prevent diseases such as cancer, atherosclerosis and diabetes mellitus in humans. No one should take high doses of beta carotene supplements as well.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="antioxidants">Antioxidants<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#antioxidants" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Chemically, oxidation is the removal of electrons and reduction is the gain of electrons; oxidation is always coupled with reduction. Many biological oxidations can take place without the participation of molecular oxygen, e.g., dehydrogenations. Further, molecular oxygen has very little capability to oxidise other chemicals. Instead, it must first be converted to an 'active' form called reactive species of oxygen (an oxidant). Many of the reactive oxygen species are free radicals but all are not e.g. singlet oxygen and hydrogen peroxide are not free radicals. A free radical is an atom or a molecule with one or more unpaired electrons. Its tendency to acquire electron(s) from other substances makes it highly reactive. Table 79.3 lists the reactive oxygen species in the animal body.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="table-79-3">Table 79.3<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-79-3" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="reactive-oxygen-species">Reactive oxygen species<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#reactive-oxygen-species" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<table><thead><tr><th style="text-align: left;">Symbol</th><th style="text-align: left;">Name</th></tr></thead><tbody><tr><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mn>1</mn></msup><msub><mi mathvariant="normal">O</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">{ }^{1} \mathrm{O}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9641em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span></span></span></span></span><span class="mord"><span class="mord mathrm">O</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: left;">Singlet oxygen</td></tr><tr><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">O</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{O}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">O</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>,</td><td style="text-align: left;">Superoxide free radical</td></tr><tr><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mo lspace="0em" rspace="0em">∙</mo></msup><mrow><mi mathvariant="normal">O</mi><mi mathvariant="normal">H</mi></mrow></mrow><annotation encoding="application/x-tex">{ }^{\bullet} \mathrm{OH}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6741em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∙</span></span></span></span></span></span></span></span></span><span class="mord"><span class="mord mathrm">OH</span></span></span></span></span></span></td><td style="text-align: left;">Hydroxyl free radical</td></tr><tr><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">R</mi><mo lspace="0em" rspace="0em">+</mo></msup><msup><mi mathvariant="normal">O</mi><mo lspace="0em" rspace="0em">−</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{R}^{+} \mathrm{O}^{-}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">R</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mord"><span class="mord mathrm">O</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">−</span></span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: left;">Alkoxy free radical</td></tr><tr><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">R</mi><mi mathvariant="normal">O</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup><msup><mi mathvariant="normal">O</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{RO}^{+} \mathrm{O}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">RO</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mord"><span class="mord mathrm">O</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: left;">Peroxyl free radical</td></tr><tr><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>2</mn></msub><msub><mi mathvariant="normal">O</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{2} \mathrm{O}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord"><span class="mord mathrm">O</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: left;">Hydrogen peroxide</td></tr><tr><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">L</mi><mi mathvariant="normal">O</mi><mi mathvariant="normal">O</mi><mi mathvariant="normal">H</mi></mrow><mn>2</mn></msup></mrow><annotation encoding="application/x-tex">\mathrm{LOOH}^{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8873em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">LOOH</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8873em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: left;">Lipid peroxide</td></tr></tbody></table>
<p>These oxidants are generated during the normal metabolic reactions in the body. The other sources of free radicals and other oxidants are shown in Table 79.4.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="table-79-4">Table 79.4<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-79-4" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="sources-of-oxidants-in-the-body">Sources of oxidants in the body<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#sources-of-oxidants-in-the-body" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Cyclooxygenation</li>
<li>Lipooxygenation</li>
<li>Lipid peroxidation (auto-oxidation on exposure to oxygen).</li>
<li>Neutrophils stimulated by exposure to microbes.</li>
<li>Re-perfusion of ischemic organs.</li>
<li>Metabolism of xenobiotics (foreign chemicals) including alcohol, cigarette smoke and motor car exhaust; and</li>
<li>Ultraviolet and ionising radiation damage.</li>
</ul>
<p>Small amounts of oxidants are continually formed in the cell membrane and close to the cell organelles. They can damage most cell structures including membrane lipids, proteins, enzymes and nucleic acids. However, the body has inbuilt mechanisms to mop up the small amounts of oxidants normally formed during metabolic reactions (Table 79.5).</p>
<p>Table 79.5
Body defences against oxidants
Vitamins A, C, E.
Trace elements: selenium
Flavonoids and polyphenolic substances present in plant foods (fruits, vegetables, amla, tea, garlic and others).
Others present in spices such as coriander, clove, cardamom.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo><mo>−</mo><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">--&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">−</span><span class="mord">−</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">&gt;</span></span></span></span></span></p>
<ul>
<li>Intracellular enzymes (catalases, superoxide dismutases, glutathione peroxidases) which dispose of the oxidants.</li>
<li>Antioxidants obtained along with nutrients</li>
</ul>
<p>Vitamins A, C, E.
Trace elements: selenium
Flavonoids and polyphenolic substances present in plant foods (fruits, vegetables, amla, tea, garlic and others).
Others present in spices such as coriander, clove, cardamom.
Oxidants formed in controlled amounts by neutrophil leucocytes on exposure to microbes are beneficial to the body in that they participate in destroying the microbes. Excess of oxidants, however, can be harmful to the body. In fact, it has been proposed from epidemiological studies that free radicals and other oxidants may be involved in the pathogenesis of diseases such as cancer, diabetes mellitus, cardiovascular and neurological diseases. Attempts have been made to make a case for supplementation of human diet with antioxidants given as pharmacological agents. Currently, there is no pharmacological antioxidant agent available which has been convincingly shown to be useful in prevention or treatment of disease in humans. Hence, the current reommendation is to increase the consumption of cereals, pulses, nuts, fruits and vegetables which are good sources of antioxidants. Spices used in Indian cooking also contain antioxidants. Evidence indicates that increased fruit and vegetable intake raises plasma concentration of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi></mrow><annotation encoding="application/x-tex">\beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span> carotene, lycopene, beta cryptoxanthine and ascorbic acid and decreases both diastolic and systolic blood pressure. For vitamin E, see earlier.</p>
<p>Coenzyme Q10 (Ubiquinone): This is a fat-soluble antioxidant, currently sold as a dietary supplement. The humans synthesise as well as obtain it from dietary sources. It is present in the mitochondria of human cells, and high concentrations are found in the heart, liver, kidney and skeletal muscle. Tissue concentrations decline with age. Coenzyme Q10 is involved in ATP generation. The usual dose is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>100</mn><mo>−</mo><mn>200</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">100-200 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">100</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">200</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day in divided doses. It has been claimed to be of some benefit in conditions including Parkinson's disease and CHF. It is well tolerated and the adverse reactions are mild, comprising nausea, vomiting and abdominal discomfort. It may decrease response to warfarin. Its place in therapeutics needs further substantiation.</p>
<p>Spirulina: This product, obtained from the marine algae, has been promoted as the "most powerful food on earth". It is claimed to contain <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>70</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">70 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">70%</span></span></span></span></span> by weight of protein and many micronutrients. The daily dose recommended by the manufacturer is 2 tablets (each containing 500 mg of spirulina). This dose contains only 700 mg of protein and minuscule quantities of micronutrients, much below their Recommended Daily Allowance (RDA).</p>
<p>Hence, such claims are unjustified, and this expensive product cannot be recommended.</p>
<p>80</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drugs-pregnancy-and-the-infant">Drugs, Pregnancy and the Infant<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drugs-pregnancy-and-the-infant" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Drugs are likely to be self administered or prescribed by the physician during pregnancy. Intelligent use of drugs during pregnancy requires that the physician understands the interaction between drugs and pregnancy so as to avoid indiscriminate use of drugs with disastrous consequences as illustrated by the thalidomide tragedy. At the same time, overcautious timidity on the part of the physician casts the pregnant mother in the role of a therapeutic orphan. It must be remembered that most of the drugs prescribed during pregnancy are given for the benefit of the mother and that one must not deny her adequate treatment for a serious illness.</p>
<p>In addition to drugs, the pregnant woman is likely to be exposed to a variety of environmental, non-therapeutic or illicit agents which can affect the fetal health.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="pharmacokinetics-during-pregnancy">Pharmacokinetics During Pregnancy<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacokinetics-during-pregnancy" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Most of the available information on pharmacokinetics of drugs during pregnancy has been obtained from animal experiments and may not be directly applicable to humans. Although pregnant women do not differ qualitatively from the non-pregnant ones in their response to drugs, certain quantitative differences do occur because of physiological changes during pregnancy, with consequent alterations in pharmacokinetics of drugs. Further, the fetus has its own pharmacokinetic peculiarities.</p>
<p>Drug absorption: High circulating levels of progesterone slow the gastric emptying as well as gut motility, thus increasing the intestinal transit time. As a result, one might expect slower drug absorption during pregnancy. However, this does not occur except at term when parenteral drug administration is preferred in order to obtain a quick response. Administration of iron and antacids may also interfere with the absorption of certain drugs. Drug compliance may be poor during pregnancy because of nausea and fear of possible adverse effects.</p>
<p>Drug distribution: Pregnancy is accompanied by an increase in total body water by upto 8 litres and a <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">30 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">30%</span></span></span></span></span> increase in plasma volume, with consequent decrease ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mo>−</mo><mn>1.0</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.5-1.0 \mathrm{~g} \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.9444em; vertical-align: -0.1944em;"></span><span class="mord">1.0</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span><span class="mord">%</span></span></span></span></span> ) in plasma albumin due to hemodilution. Drugs which have low lipid solubility and are also highly plasma protein bound (e.g. warfarin, benzodiazepines) have a low apparent volume of distribution (Vd). The Vd of such drugs increases markedly during pregnancy. The protein bound fraction of the drug in the plasma diminishes and so does the concentration of the total drug in the plasma. Although the fraction of unbound drug increases, a greater pharmacodynamic effect is prevented by more rapid elimination of the drug by metabolism and/or excretion (see below). The therapeutic range for drugs whose use is monitored by measurement of total plasma concentration (e.g. phenytoin) must be adjusted downwards to make allowance for the above mentioned changes, if their plasma protein binding changes during pregnancy. There is also likely increase in body fat which acts as a reservoir for lipid soluble drugs.</p>
<p>Drug metabolism: Hepatic drug metabolising enzymes are induced during pregnancy, probably by the high concentrations of circulating progesterone. This can lead to more rapid metabolic degradation, especially of the highly lipid soluble drugs such as phenytoin and theophylline. However, this is of little clinical consequence because the metabolism of most such drugs is ordinarily so fast that their clearance is limited only by hepatic blood flow, which does not change appreciably during pregnancy e.g. pethidine. The contribution of the placenta and the fetal liver to the clearance of drugs from the maternal body is thought to be small.</p>
<p>Drug excretion: During pregnancy, the renal plasma flow increases by <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>100</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">100 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">100%</span></span></span></span></span> and the GFR by <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>70</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">70 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">70%</span></span></span></span></span>. Add to this the increase in the unbound fraction of the drug in the plasma. Hence, drugs which depend for their elimination mainly on the kidney are eliminated more rapidly than in the non-pregnant state. Examples are ampicillin, aminoglycosides, cephalexin and digoxin.</p>
<p>The conventional dose of ampicillin needs to be doubled during pregnancy if it is used for a systemic infection in the mother, but not if it is used for a urinary tract infection. An increase in the dose of cefuroxime and lithium is needed for similar reasons. In the case of phenytoin (whose unbound plasma level diminishes due to more rapid metabolism, in addition to</p>
<p>total plasma level), an increase in the daily dose by <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mo>−</mo><mn>100</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">25-100 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">25</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">100</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> may be required to maintain good seizure control; a similar increase is also required in the dose of phenobarbitone and carbamazepine. In spite of pharmacokinetic alterations, the doses of benzodiazepines, aspirin, propranolol, sulfafurazole and metronidazole do not require alterations during pregnancy. The pharmacokinetics of furosemide do not alter during pregnancy and no dose adjustment is required.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drugs-the-fetus-and-the-newborn">Drugs, the Fetus and the Newborn<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drugs-the-fetus-and-the-newborn" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Placental transfer of drugs: The placenta acts as an intravenous portal for entry of drugs into the fetus. Such entry of drugs is governed by several considerations. As pregnancy progresses and the placenta develops, the surface available for transfer between the maternal and fetal circulations increases; at the same time, the placento-fetal barrier becomes progressively thinner. Transfer across this barrier is governed by the same properties of drugs which regulate the transfer across other biological membranes: unbound, non-ionised, lipid-soluble molecules of low molecular weight cross the barrier more easily than those which do not possess these attributes; most of the drugs in use fulfil these criteria and are able to cross the placental barrier. However, because of the differences in the plasma protein concentration and the pH between maternal and fetal blood, the concentration of drugs in the two circulations, even at equilibrium, may differ considerably. Add to this, the differences in pharamacokinetics between the mother and the fetus. Further, the placenta is capable of metabolising drugs; this is of little relevance to the mother but can protect the fetus from the entry of many drugs. For example, prednisolone and hydrocortisone, which are metabolised by the placenta to inactive compounds are safer for the fetus than dexamethasone and betamethasone, which are not so metabolised.</p>
<p>The method of drug administration to the mother may also decide the fetal concentration. For example, at term, antibiotics given by intermittent intravenous infusion can achieve higher concentrations in the fetal blood and amniotic fluid than when the same total dose is given by continuous infusion; this may be important in the treatment of intrauterine infections.</p>
<p>In spite of above considerations, the fetal: maternal ratio of unbound drug concentration is generally close to unity. Further, the placenta is always available to the fetus as a route of drug elimination. After birth, the placental route of drug elimination is no longer available and the neonate is on its own.</p>
<p>Compared to adults, both fetus and infants differ in their handling of drugs, as related to pharmacokinetics as well as pharmacodynamics.</p>
<p>However, the data available regarding this is far from adequate.
Fetal/Neonatal pharmacokinetics: Human growth is not a linear phenomenon. Agerelated changes in body composition and organ function are dynamic and can be discordant during the first decade of life. Hence, the simplified dosage approaches calculated by standard formulae may not be adequate for individualising drug doses across the span of infancy and childhood.</p>
<p>During the neonatal period, intragastric pH is relatively higher ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>7.4</mn></mrow><annotation encoding="application/x-tex">&gt;7.4</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">7.4</span></span></span></span></span> ). Hence, orally administered drugs such as penicillin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>G</mi></mrow><annotation encoding="application/x-tex">G</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal">G</span></span></span></span></span> have greater bioavailability in neonates than in adults. On the other hand, weak acids such as phenobarbitone need higher doses in the young children. Generally, the rate at which majority of drugs are absorbed is slower in the neonates than in the older children. Further, developmental differences in the activity of intestinal drug metabolising enzymes and changes in the intestinal microflora may also affect the plasma levels of drugs.</p>
<p>Compared to adults, neonates and infants have relatively larger extracellular and total body water spaces. This, along with the adipose tissue stores that have a higher lipid/water</p>
<p>ratio, leads to lower EC concentrations when drugs are given on weight basis. Distribution of highly protein bound drugs is also modified by the amount of circulating plasma albumin and alpha 1-acidglycoprotein.</p>
<p>In infants and young children, the ratio of total body surface area (BSA) to body mass far exceeds that in adults. Hence, the relative systemic exposure of infants to topically applied drugs such as glucocorticoids may exceed that in adults, leading to adverse systemic effects.</p>
<p>Delayed maturation of hepatic drug metabolising enzymes in infants can cause increased drug toxicity e.g. chloramphenicol.</p>
<p>The expression of Phase I metabolising enzymes such as cytochrome P-450 undergoes marked changes during development of neonates. This affects the hepatic clearance of various drugs metabolised by the isoforms of these enzymes. The clearance of carbamazepine is greater in children than in adults. In the case of phenytoin, its <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> is about 75 hours in preterm infants, which decreases to about 20 hours during the first week of life and to 8 hours after the second week of life. The plasma clearance of morphine is known to quadruple between <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>27</mn><mtext>th&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">27^{\text {th }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8491em;"></span><span class="mord">2</span><span class="mord"><span class="mord">7</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">th&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>40</mn><mtext>th&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">40^{\text {th }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8491em;"></span><span class="mord">4</span><span class="mord"><span class="mord">0</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">th&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> weeks of gestational age, thus requiring corresponding increase in the dose of morphine for effective analgesia.</p>
<p>Because of significant developmental changes during the neonatal period, drugs such as methylxanthines, morphine, captopril and third generation cephalosporins need ageappropriate dosage regimens.</p>
<p>Various developmental changes in the kidney function during infancy can alter the plasma clearance of drugs that are primarily excreted by the kidney, e.g. aminoglycosides, famotidine, ceftazidime, digoxin, chlorpropamide, penicillin, salicylic acid, indomethacin and paracetamol. This obviously will need age-appropriate selection of dosage regimen.</p>
<p>In view of the above problems, it is safer to consult worked-out dosage tables for neonates and infants than to use formulae based on body weight and/or BSA.</p>
<p>Fetal-neonatal pharmacodynamics: Age-dependent differences in the interaction of the drugs with specific receptors does probably exist but the data are limited. This may modify the safety and efficacy of drugs in the neonates and infants. For a given plasma concentration, the response of the fetal tissues to most drugs is equal to or less than that of maternal tissues. There are some notable exceptions. Certain drugs given in the second and third trimesters produce either exaggerated effects or effects that are unique to the fetus. For example, tetracyclines get deposited in the fetal teeth and bones and retard their growth; coumarins can cause fetal and neonatal hemorrhages. Salicylates given at term can cause neonatal hemorrhage. PG synthetase inhibitors (NSAIDs) given near term can induce premature closure of ductus arteriosus and pulmonary hypertension in the fetus. Antithyroid drugs can inhibit fetal thyroxine synthesis and can cause goitre formation. Opiates and barbiturates (given to mother) achieve very high concentrations in the fetal brain and can cause respiratory depression at birth. Phenothiazines given to the mother can cause extrapyramidal toxicity in the neonate which may persist for several months. (Also see Chapter 13).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="effects-of-drugs-on-pregnancy">Effects of Drugs on Pregnancy<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#effects-of-drugs-on-pregnancy" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Effective treatment of maternal illness with drugs such as insulin, thyroxine, antibiotics and antihypertensives may be said to have a beneficial effect on the course of pregnancy.</p>
<p>On the other hand, in certain situations drugs can cause harm to the conceptus. These harmful effects depend upon the nature of the drug and its dose and route of administration; the stage of pregnancy at which the drug is used; and the genetic constitution and susceptibility of the fetus, which in turn, depend upon the age, nutritional status and health of the mother. Gestation may be divided into four major stages.</p>
<ul>
<li>Pre-implantation stage (blastocyst formation) which lasts about 16 days from conception to implantation. Exposure to harmful drugs (such as anticancer drugs) can kill the embryo or else the damaged cells are replaced by undifferentiated cells which have the potential to develop normally. This is an all-or-none effect.</li>
<li>Period of organogenesis from <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>17</mn><mtext>th&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">17^{\text {th }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8491em;"></span><span class="mord">1</span><span class="mord"><span class="mord">7</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">th&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>56</mn><mtext>th&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">56^{\text {th }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8491em;"></span><span class="mord">5</span><span class="mord"><span class="mord">6</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">th&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> day. Pre-implantation stage and the stage of organogenesis together constitute the first trimester. Exposure to harmful drugs (and other environmental influences) during the period of organogenesis can cause congenital malformations (teratogenicity) or abortion.</li>
<li>The second and third trimesters are periods during which considerable growth and development occur in teeth, bones and in central nervous, endocrine, genital and immune systems. During this period drugs can cause either teratogenesis or a variety of other effects such as retardation of physical or brain growth, behavioural teratogenicity, premature labour, neonatal toxicity and even late post natal effects such as cancer(s).</li>
<li>A short labour-delivery stage: Drug administration during this period is mainly fraught with the danger of toxicity in the neonatal period for reasons already discussed.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="teratogenicity">Teratogenicity<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#teratogenicity" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>This word was originally used in the sense of congenital malformations grossly visible at birth and caused by exposure to exogenous agents (teratogens) in the first trimester. The definition has now been broadened to include any birth defect (morphological, biochemical or behavioural) induced at any stage of pregnancy and detected at birth or later in life. Birth defects are known to occur in 2-4% of all births in the population. Out of all birth defects, the cause is unknown in <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>65</mn><mo>−</mo><mn>70</mn><mi mathvariant="normal">%</mi><mo separator="true">;</mo><mn>25</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">65-70 \% ; 25 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">65</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.9444em; vertical-align: -0.1944em;"></span><span class="mord">70%</span><span class="mpunct">;</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">25%</span></span></span></span></span> can be attributed to genetic defects and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">3 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">3%</span></span></span></span></span> to chromosomal aberrations. Only about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">3 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">3%</span></span></span></span></span> can be ascribed to environmental factors including maternal infection, radiation and drug administration. The overall incidence of congenital malformations does not appear to have increased in the last 30 years in spite of the dramatic increase in the number of drugs available.</p>
<p>Teratogenesis includes restricted growth of the fetus, malformations, carcinogenesis and behavioural teratogenicity (see later). It should be noted that fewer than 30 drugs have been proved to be teratogenic in humans when used in clinically effective doses. Many of the commonly used drugs, once thought to be teratogenic, have been shown by subsequent studies to be safe; they include salicylates, glucocorticoids, diazepam, combination OC pills and spermicides. Much of the information on teratogenicity of drugs has been obtained from animal experiments and mishaps in clinical practice. Because of species variability and the high doses used in these experiments, such data are not directly applicable to humans; but they have a high positive predictive value. Almost every drug that has been found to be teratogenic in humans has caused similar teratogenicity in animals. However, there are drugs that have caused teratogenic effects in animals in large doses that are not teratogenic in humans in clinically effective doses. Individual case reports and limited epidemiological surveys provide the information available about teratogenicity of drugs in humans.</p>
<p>Except in a few instances, congenital malformations produced by drugs are not unique. In animal experiments, a given drug may produce different congenital abnormalities whereas a given congenital abnormality may be produced by several drugs. Most drugs currently suspected of being teratogenic in humans are, in fact, weak teratogens and probably increase the frequency of congenital malformations only 2-3 fold. In fact, smoking and alcohol are more harmful to the fetus than most drugs. Table 80.1 lists the drugs which are known or suspected to be teratogenic in humans. Absence of a drug from the list should not be interpreted to mean that it is necessarily safe during pregnancy.</p>
<p>Table 80.1
Drug with proven teratogenic effects in humans</p>
<table><thead><tr><th style="text-align: left;">Drug</th><th style="text-align: left;">Teratogenic effect</th></tr></thead><tbody><tr><td style="text-align: left;">Methotrexate</td><td style="text-align: left;">CNS and limb malformations</td></tr><tr><td style="text-align: left;">ACE inhibitors</td><td style="text-align: left;">Prolonged renal failure in the neonate, renal tubular dysgenesis, decreased skull ossification</td></tr><tr><td style="text-align: left;">Anticholinergic drugs</td><td style="text-align: left;">Neonatal meconium ileus</td></tr><tr><td style="text-align: left;">Antithyroid drugs</td><td style="text-align: left;">Fetal and neonatal goitre and bypothyroidism, aplasia cutis (with methimazole)</td></tr><tr><td style="text-align: left;">Carbamazepine</td><td style="text-align: left;">Neural tube defects</td></tr><tr><td style="text-align: left;">Cyclophosphamide</td><td style="text-align: left;">CNS malformations, secondary cancer</td></tr><tr><td style="text-align: left;">Danazol and other androgenic drugs</td><td style="text-align: left;">Masculinisation of female fetus</td></tr><tr><td style="text-align: left;">Diethylstilbestrol</td><td style="text-align: left;">Vaginal carcinoma and other genitourinary defects in female and male offspring</td></tr><tr><td style="text-align: left;">Lithium</td><td style="text-align: left;">Elwteink anomaly</td></tr><tr><td style="text-align: left;">Misoprostol</td><td style="text-align: left;">Moebius syndrome</td></tr><tr><td style="text-align: left;">NSAID</td><td style="text-align: left;">Constriction of the ductus arteriosus, necrotising enterocolitis</td></tr><tr><td style="text-align: left;">Oral hypoglycemic drugs</td><td style="text-align: left;">Neonatal hypoglycemia</td></tr><tr><td style="text-align: left;">Phenytoin</td><td style="text-align: left;">Growth retardation, CNS defects</td></tr><tr><td style="text-align: left;">Psychoactive drugs</td><td style="text-align: left;">Neonatal withdrawl syndrome when drug is taken in late pregnancy</td></tr><tr><td style="text-align: left;">Systemic retinoids (isotretinoin, etretinate)</td><td style="text-align: left;">CNS, craniofacial, cardiovascular and other defects</td></tr><tr><td style="text-align: left;">Tetracycline</td><td style="text-align: left;">Anomalies of teeth and bones</td></tr><tr><td style="text-align: left;">Thalidomide</td><td style="text-align: left;">Limb-shortening, internal organ defects</td></tr><tr><td style="text-align: left;">Trimethadone</td><td style="text-align: left;">Malformed ears, cleft palate, cardiac, urogenital and skeletal defects</td></tr><tr><td style="text-align: left;">Valproic acid</td><td style="text-align: left;">Neural tube defects</td></tr><tr><td style="text-align: left;">Warfarin</td><td style="text-align: left;">Skeletal and CNS defects, Dandy-Walker syndrome</td></tr></tbody></table>
<p>FDA ratings for drug use in pregnancy are shown in Table 80.2.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="table-80-2">Table 80.2<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-80-2" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Drugs used in pregnancy, US FDA categories</p>
<table><thead><tr><th style="text-align: left;">FDA Rating Conditions</th><th style="text-align: left;">Examples</th><th style="text-align: left;"></th></tr></thead><tbody><tr><td style="text-align: left;">A</td><td style="text-align: left;">Controlled human studies show no risk</td><td style="text-align: left;">Folic acid</td></tr><tr><td style="text-align: left;">B</td><td style="text-align: left;">No confirmatory evidence of risk in humans</td><td style="text-align: left;">Metronidazole</td></tr><tr><td style="text-align: left;">C</td><td style="text-align: left;">Risk cannot be ruled out</td><td style="text-align: left;">Most drugs</td></tr><tr><td style="text-align: left;">D</td><td style="text-align: left;">Positive evidence of risk exists</td><td style="text-align: left;">Antiepileptics (Table 80.1)</td></tr><tr><td style="text-align: left;">X</td><td style="text-align: left;">Absolutely contraindated</td><td style="text-align: left;">Cytotoxics, Etretinate (Table 80.1)</td></tr></tbody></table>
<p>The teratogenic effects of thalidomide have been described in Chapter 1; those of alcohol in Chapter 6; tetracycline in Chapter 49 and retinoic acid derivatives in Chapter 71.</p>
<p>Patient is advised to delay pregnancy for certain periods of time after completing the course of certain drugs: one month after isotretinoin (Chapter 71); three months after mefloquine (Chapter 56); one year after cytotoxic drugs (methotrexate, cyclophosphamide); and three years after etretinate (Chapter 71) in order to allow the elimination of the drug. However, azathioprine following renal transplantation has not been found to pose an excess risk of congenital malformations in succeeding pregnancies.</p>
<p>Testosterone and its derivatives, including progestogens derived from 19nortestosterone, can masculinise the external genitals of a female fetus. Estrogens and progestins, on the other hand, are known to induce defective masculinisation of the external genitals of a male fetus. However, inadvertent continuation of a COC pill during the first month of gestation has not been found to be harmful to the fetus.
Diethylstilbestrol administration during pregnancy has been associated with the development of congenital anomalies of external genitals in fetuses of both sexes, and with the development of vaginal adenosis and vaginal adenocarcinoma in girls whose mothers had received the drug.</p>
<p>The use of coumarin anticoagulants is associated with congenital malformations and high incidence of fetal loss from abortion, retroplacental and intracerebral fetal bleeding.</p>
<p>Consumption of even one drink ( 10 g of alcohol) per day is associated with fetal growth</p>
<p>retardation and an increased incidence of abortion. Consumption of large quantities ( 40 g per day) is associated with 'fetal alcohol syndrome'.</p>
<p>Behavioural teratogenicity: Apart from the structural teratogenicity, drugs can also cause behavioural teratogenicity i.e. abnormal behaviour in the newborn. Such effects have been observed in animal models when drugs such as reserpine, phenothiazines, barbiturates, amphetamine and cannabis were administered during pregnancy. So far, behavioural teratogenicity has been observed in human newborns of mothers who were exposed to methylmercury by eating contaminated fish and those who smoked during pregnancy. Animal studies indicate that the developing CNS is highly susceptible to the effects of psychoactive drugs. In humans, the brain development extends into early infancy and hence, the extended vulnerability of the brain in humans to the effects of such drugs.</p>
<p>Table 80.3 lists points to remember while prescribing drugs to women who are of the reproductive age and sexually active.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="table-80-3">Table 80.3<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-80-3" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Points to remember while prescribing drugs to a woman of reproductive age</p>
<p><sup><a href="#user-content-fn-0" id="user-content-fnref-0-5" data-footnote-ref="true" aria-describedby="footnote-label">1</a></sup></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drug-prescribing-during-pregnancy">Drug-Prescribing During Pregnancy<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-prescribing-during-pregnancy" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Table 80.4 summarises the precautions to be taken while prescribing drugs to a pregnant woman.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="table-80-4">Table 80.4<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-80-4" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="precautions-while-prescribing-drugs-to-a-pregnant-woman">Precautions while prescribing drugs to a pregnant woman<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#precautions-while-prescribing-drugs-to-a-pregnant-woman" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Treat minor ailments without drugs.</li>
<li>If a drug must be prescribed, it should be one which is known to be safe during pregnancy.</li>
<li>Prefer a drug which has been in use for long periods of time to a newly introduced drug as the safety of the latter for the fetus is not likely to be known completely.</li>
<li>Adjust the dose of the drug to the pregnant state; with most drugs, it is generally at the lower end of the therapeutic range. However, because of pharmacokinetic factors (increased body weight and more rapid clearance), the dose of certain drugs such as lithium, digoxin and phenytoin is likely to be higher than in the non-pregnant state in some women.</li>
<li>Discourage the patient from self-administering OTC drugs.</li>
<li>Advise the patient that absolute safety of the fetus cannot be guaranteed even by not prescribing any drug to women between the ages of 15 and 45 . Therefore, do not sacrifice the mother's interest for the sake of the fetus.</li>
</ul>
<p>Nausea and vomiting of pregnancy can be treated without drugs in most women. Reassurance and high carbohydrate diet will help them. If required, an antihistaminicantiemetic (cyclizine, meclizine, diphenhydramine, dimenhydrinate) may be prescribed. Metoclopramide is safe in the third trimester of pregnancy and may be prescribed in resistant cases.</p>
<p>Heartburn is very common in pregnancy and is relieved by a small carbohydrate meal; by avoiding fatty food, smoking and alcohol; and by maintenance of upright posture. Consumption of aerated lemonade 2-3 times a day may also be helpful. Non-systemic antacids and metoclopramide may be needed in some cases. Anticholinergics usually worsen the heartburn by relaxing the lower esophageal sphincter.</p>
<p>Peptic ulcer should be treated with dietary modification and non-systemic antacids. Sucralfate which is not absorbed, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor blockers and bismuth subsalicylate are safe during pregnancy. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor blockers can also be used to treat GERD.</p>
<p>Constipation generally responds to high fibre diet, plenty of liquids and a mild laxative such as milk of magnesia, docusate sodium, glycerin, mineral oil or bisacodyl.</p>
<p>Antimicrobial drugs: Beta lactam antibiotics (penicillins and most of the cephalosporins) are safe during pregnancy. Ampicillin achieves very high concentrations in the fetal circulation and amniotic fluid and is very suitable for treatment of uterine infections during pregnancy. Erythromycin base is safe but erythromycin estolate should be avoided for fear of hepatotoxicity. Nitrofurantoin and methanamine mandelate are considered to be safe during pregnancy. So are nystatin and miconazole; but ketoconazole and 5-flucytosine should be avoided.</p>
<p>Aminoglycosides are ototoxic to the fetus and should be avoided; if one is needed to treat a serious systemic infection in the mother, gentamicin or tobramycin should be preferred. Tetracyclines damage the fetal teeth and bones and should be avoided. High doses of tetracycline IV have been associated with serious hepatotoxicity in the mother. Chloramphenicol is absolutely contraindicated during pregnancy; it can cause fetal bone marrow toxicity and 'grey baby syndrome' in the neonate. Cotrimoxazole should be avoided especially in the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>1</mn><mtext>st&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">1^{\text {st }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7936em;"></span><span class="mord"><span class="mord">1</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7936em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">st&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> trimester (because of its trimethoprim content) and the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>3</mn><mtext>rd&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">3^{\text {rd }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8491em;"></span><span class="mord"><span class="mord">3</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">rd&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> (because of its sulfonamide content). If there is anaerobic infection, metronidazole is considered to be safe. Griseofulvin and nalidixic acid are embryotoxic and should be avoided. The use</p>
<p>of sulfonamides at term can cause kernicterus in the neonate by displacing bilirubin from binding with albumin; aspirin, and water soluble vitamin K analogues can also displace bilirubin from albumin.</p>
<p>Tuberculosis: Isoniazid and ethambutol are safe during pregnancy. Rifampicin should be avoided as far as possible but may be used if a third drug is required. While using rifampicin, its hepatatoxicity should be kept in mind. Streptomycin is ototoxic to the fetus and should never be used in pregnant women.</p>
<p>Parasitic diseases: Amoebiasis is treated with the usual drugs: metronidazole, diodoquin and diloxanide. However, large dose, short term therapy (e.g. single daily doses of 30 <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">\mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> with metronidazole) should be avoided.</p>
<p>Primaquine, is contraindicated throughout the pregnancy. Pyrimethamine and mefloquine should be avoided in <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>1</mn><mtext>st&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">1^{\text {st }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7936em;"></span><span class="mord"><span class="mord">1</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7936em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">st&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> trimester but appear to be safe in <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>2</mn><mtext>nd&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">2^{\text {nd }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8491em;"></span><span class="mord"><span class="mord">2</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">nd&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>3</mn><mtext>rd&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">3^{\text {rd }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8491em;"></span><span class="mord"><span class="mord">3</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">rd&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> trimester. Chronic suppressive use of chloroquine weekly and its use to treat acute attacks of malaria during pregnancy are safe. Quinine may be used to treat acute attacks of chloroquine-resistant falciparum malaria.</p>
<p>Piperazine, bephenium and pyrantel are safe for use during pregnancy. Most people consider mebendazole unsafe during pregnancy. Unless the parasite load is heavy, the treatment of intestinal parasitic infections is best postponed till after delivery.</p>
<p>NSAID: Aspirin is not teratogenic but high dose aspirin treatment during the last 3 months is associated with increased gestation time, higher incidence of postmaturity and prolonged labour. Further, it can also cause serious post-partum haemorrhage and bleeding in the neonate. NSAID induce premature closure of ductus arteriosus with pulmonary hypertension in the fetus and the newborn. Aspirin and NSAID are, therefore, better be avoided during pregnancy, especially close to term. Paracetamol in the usual doses is safe during pregnancy.</p>
<p>Glucocorticoids: Chapter 66.
Antihypertensives: Methyl-dopa is usually safe and preferred. Labetalol IV may be used when rapid reduction in BP is desired. However, beta blockers in the second and third trimesters can cause general retardation, whereas ACEI and ARB can cause fetal abnormalities of renal function and skull development. These drugs probably interfere with the maturation of specific organ systems (Chapter 30).</p>
<p>Heart disease: This is treated as in non-pregnant women. Digoxin clearance by the kidney increases during pregnancy. If the dosage remains unchanged by the end of pregnancy, the serum concentration will have fallen to about half the value before pregnancy.</p>
<p>At the therapeutic concentration, quinidine appears to be safe and the drug has only mild oxytocic activity. Quinidine is normally <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>80</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">80 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">80%</span></span></span></span></span> bound to plasma protein. Changes in plasma protein concentration during pregnancy cause total plasma quinidine concentrations to fall and free concentration to be underestimated. After delivery, total concentration of quinidine increases by about half.</p>
<p>Vasopressor agents (noradrenaline, dopamine and dobutamine) all decrease the uterine blood flow and may stimulate uterine contractions. Their use in pregnancy is justified only if the mother's survival is at stake.</p>
<p>Anticoagulants: Warfarin is best avoided in pregnant women, except those who have an artificial heart valve; in these latter subjects, heparin does not give adequate anticoagulant</p>
<p>cover. In other patients, subcutaneous heparin should be used if anticoagulation is required. One dose of heparin should be omitted when labour is imminent, so as to avoid post-partum hemorrhage.</p>
<p>Deep vein thrombosis may be treated with heparin. The use of streptokinase is associated with the risk of bleeding.</p>
<p>Allergic rhinitis: This may be treated either locally (with glucocorticoids or decongestants) or systemically with antihistaminics (diphenhydramine, dimenhydrinate, tripelenamine).</p>
<p>Cough: Diphenhydramine, codeine and dextromethorphan may be used safely to treat dry cough during pregnancy.</p>
<p>Pruritus: This may be treated locally with topical moisturising creams or lotions e.g. calamine lotion, zinc oxide cream or ointment or glucocorticoids; or systemically with hydroxyzine, diphenhydramine or glucocorticoids.</p>
<p>Bronchial asthma is treated with inhaled beta adrenergic agonists, inhaled glucocorticoids, or with aminophylline. However, IV salbutamol used to delay labour is known to cause pulmonary edema especially (a) in individuals with mitral stenosis and (b) when corticosteroids are administered concurrently to promote fetal lung maturation. The combination may result in fetal death. This therapy should not be used in hypertensive subjects. Further, in diabetic subjects IV salbutamol can cause severe hyperglycemia and ketoacidosis, resistant even to aggressive insulin therapy.</p>
<p>Headache may be treated with paracetamol, codeine and benzodiazepines. Aspirin and NSAID may be used in the first and second but avoided in the third trimester.</p>
<p>Migraine may be treated with analgesics, propranolol, dimenhydrinate and amitryptiline.</p>
<p>Diabetes mellitus should be treated with dietary restriction and insulin, if required; the use of oral hypoglycemic agents is not recommended. In insulin dependent diabetics who become pregnant, the insulin requirement drops somewhat during the first trimester (owing to nausea and poor food intake), then rises progressively to 2-3 times the prepregnancy level upto 36 weeks, and then drops again upto term. After delivery, insulin requirement dives dramatically to pre-pregnancy level.</p>
<p>Thyrotoxicosis: Thioamides are the therapy of choice for thyrotoxicosis during pregnancy; propylthiouracil may be preferred to carbimazole/methimazole. The dose should be kept as low as possible. Stable iodine and radioactive iodine are contraindicated (Chapter 63).</p>
<p>Epilepsy: Adequate seizure control is important during pregnancy as convulsions themselves are harmful to the fetus. Phenobarbitone, phenytoin and carbamazepine may be used during pregnancy; as discussed earlier, their doses may have to be increased slightly in order to maintain seizure control. All pregnant women on antiepileptic drugs should be prescribed folic acid 5 mg per day throughout pregnancy. Vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">K</mi><mi mathvariant="normal">i</mi></msub></mrow><annotation encoding="application/x-tex">\mathrm{K}_{\mathrm{i}}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3175em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathrm mtight">i</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> should be administered to such patients routinely for 3 weeks before delivery and to their newborn babies at birth. The use of valproic acid is contraindicated during pregnancy.</p>
<p>Drugs acting on the CNS: Barbiturates, benzodiazepines and antidepressants have not been shown to have any significant teratogenic effects. Lithium has been reported to be teratogenic and also to be deleterious to the fetus in the last trimester.</p>
<p>The use of CNS depressants such as diazepam, antidepressants, phenothiazines and</p>
<p>opioids at term and specially during labour, exposes the neonate to the risk of serious CNS depression.</p>
<p>Benzodiazepines are best avoided towards the end of pregnancy.
Phenothiazines, tricyclic antidepressants and SSRI (except paroxetine) can be continued during pregnancy in minimum possible doses. Antiparkinsonian drugs, e.g. benzhexol commonly prescribed together with phenothiazine, should not be used during the first trimester. MAO inhibitors are contraindicated during pregnancy. Further, it is desirable to taper and omit tricyclic antidepressants in the last few weeks of pregnancy and to restart them after delivery.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="breast-feeding-and-drugs">Breast Feeding and Drugs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#breast-feeding-and-drugs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Nearly all agents received by the mother are likely to be found in her milk and could theoretically harm the infant. However, the data on excretion of drugs in milk and its possible harmful effects on the newborn are scanty.</p>
<p>Breast feeding is important not only from nutritional point of view but it also supplies IgA and IgM immunoglobulins which afford protection against gastroenteritis. More and more women are now electing to breast feed their babies. Although several drugs are known to increase prolactin secretion, no suitable drug is available at present, which could consistently augment the milk production in the human female. Thyrotropin releasing hormone (TRH) and metoclopramide have been shown to increase milk production in some studies. However, it appears that determination on the mother's part is more important than prolactin-inducing drugs. Lactation will stop if the breast is not suckled. Suckling stimulates the release of prolactin and oxytocin.</p>
<p>Most of the lipid soluble drugs get into breast milk, though not necessarily in concentrations that can adversely affect the infant. Milk is slightly more acidic ( pH 7.0 ) than plasma and hence, weak bases that become more ionised with decrease in pH will have equal or higher concentrations in milk than in plasma. Nonelectrolytes like alcohol (ethanol) can readily enter into the milk independently of the pH . Majority of the drugs get into the milk by passive diffusion although active transport may occur in a few cases e.g. iodide. The amount of a drug transferred into the milk depends on various factors. The maternal volume of distribution for lipid soluble drugs is larger than for water soluble drugs; this results in low plasma levels relative to the dose. Further, only the unbound drug in the plasma is able to diffuse into the milk. Highly protein bound drugs such as warfarin cannot be detected in breast milk. Even for a lipid soluble, poorly protein bound, basic drug the milk to plasma ratio does not exceed four. Hence, drug toxicity based on the principal pharmacological action of the drug is considered unlikely in breast fed infant. However, toxicity based on idiosyncrasy or a particular sensitivity of the infant to very low doses of a drug may occur.</p>
<p>The available data suggest that the net transfer of most drugs in breast milk is too small to produce significant adverse effect in the breast fed infant. However, in view of such a possibility, drugs, particularly the newer ones, must not be prescribed during parturition unless essential. It must be remembered that the elimination rate for most drugs is slower in neonates than in the adults and this may lead to accumulation of the drug in neonates, particularly when it is taken for long courses by the mother.</p>
<p>Table 80.5 gives a list of the drugs not recommended during breast feeding. Aspirin and paracetamol have been used extensively in the puerperium without apparent ill effects on the infant. Heparin and warfarin are not detected in the milk. There is no contraindication to thyroxine treatment for hypothyroidism during breast feeding. But, breast feeding should be discouraged in women taking antithyroid drugs. Radioiodine is absolutely contraindicated during breast feeding. Since most of the antibiotics pass into breast milk, it may be advisable to avoid drugs like chloramphenicol, tetracycline and sulfonamides in breast-feeding women. Penicillins, erythromycin, lincomycin, quinine and chloroquine appear to be safe for the treatment of nursing mothers. Aminoglycoside antibiotics, though they appear in breast milk, are not considered dangerous as they are not absorbed</p>
<p>from the gut. Metronidazole is considered quite safe during breast feeding but may make the milk taste bitter. Beta-blockers, thiazide diuretics, captopril and digoxin levels achieved in breast milk are probably too low to have any significant effect on the breast fed infants. All centrally acting drugs, being lipid soluble, have a high volume of distribution. Hence, the total amount of drug available for concentration in the milk is likely to be small. Opiate analgesics, phenothiazines, chloral hydrate and antiepileptics may, therefore, be used safely by the mothers, if necessary. However lithium has a high milk to plasma ratio and the dose available to breast fed infant is likely to be similar to that of the mother; it should be avoided during breast-feeding. Regular use of opioids in high doses by the mother may lead to dependence and withdrawal in the neonate. Ergotamine may lead to ergotism and chloroquine in the treatment of rheumatoid arthritis may cause retinal damage in the newborn infant. Amiodarone is present in the milk in significant quantities; it is best avoided because of the possible effects of the released iodine on the neonatal thyroid. The neonate has been reported to become irritable when the breast feeding mother is taking ephedrine, or 200 mg or more of aminophylline every 6 hours; slow release preparations of aminophylline are probably safe. High levels in breast milk have been reported for the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> blocker, cimetidine. Cytotoxic drugs, in general, are absolutely contraindicated in mothers who are breast feeding.</p>
<p>Table 80.5
Drugs to be avoided/not recommended in breast feeding women</p>
<ul>
<li>Radionuclides and radiopharmaceutical.</li>
<li>Antibacterials: Sulfonamides, Tetracyclines Chloramphenicol, Nalidixic acid, Isoniazid, Erythromycin estolate.</li>
<li>Analgesics: Indomethacin, Phenylbutazone, Aspirin (in large doses for long periods), Opioids (regular use of large doses).</li>
<li>Psychoactive drugs: Diazepam, Lithium.</li>
<li>Antihypertensives: Reserpine, Clonidine.</li>
<li>Antineoplastic drugs</li>
<li>Miscellaneous: Amantadine, Phenindione, Cimetidine, Anthraquinones, Amiodarone, Ephedrine, Aminophylline, Ergotamine, Vitamin D (prolonged use of large doses).</li>
</ul>
<p>It should be realised that certain chemicals like DDT or methyl mercury acquired environmentally, could appear in milk and cause chronic toxicity in breast fed babies. Finally, if a drug is used therapeutically in the neonatal period, one may use it safely in breast feeding women.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="appendix-guide-to-further-reading">APPENDIX: Guide to Further Reading<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#appendix-guide-to-further-reading" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>During revision for this edition, we have referred to many reviews and seminars published in journals: The Lancet, New England Journal of Medicine, Medical Letter, BMJClinical Pharmacology and Therapeutics, Drugs, WHO Drug Information, and so on, in addition to various books on pharmacology and therapeutics.</p>
<p>A selected list for further referencing and reading is given below. This, obviously, does not detract from the extensive and high-quality references available in the literature on various topics.
Bennet, P.N., Brown, M.J., Sharma, P. Clinical Pharmacology, 11th ed. Edinburgh: Elsevier, 2012.
Brunton L.L., Chabner B.A., Knollmann B.C., eds. Goodman &amp; Gilman's The Pharmacological Basis of Therapeutics, 12th ed., New York: McGraw-Hill, 2011.
British National Formulary 67. London: BMJ Group and Royal Pharmaceutical Society of Great Britain, UK, MarchSeptember 2014.
DiPiro J.T., Talbert R.L., Yee G.C., Matzke G.R., Wells B.G., Posey L.M., eds. Pharmacotherapy: A Pathophysiologic Approach, 8th ed., New York: McGraw-Hill Education, 2011.
Longo D.L., Fauci A., Kasper D., Hauser S., Jameson J., Loscalzo J., eds. Harrison's Principles of Internal Medicine, 18th ed., New York: The McGraw-Hill Co, Inc, 2012.
Guyton, A.C., Hall, J.E. Textbook of Medical Physiology, 11th ed. Philadelphia: Elsevier Inc, 2006.
Golan, DE, Tashjian, AH, Jr., Armstrong, EJ, Armstrong, AW. Principles of Pharmacology. The Pathophysiological Basis of Drug Therapy, 3rd ed. New Delhi: Wolters Kluver/Lippincott Williams &amp; Wilkins, 2012.
Katzung B.G., Masters S.B., Trevor A.J., eds. Basic and Clinical Pharmacology, 12 th Ed., New York: McGraw Hill Companies Inc., 2012.
Light D.W., ed. The Risks of Prescription Drugs. New York: Columbia University Press, 2010.
Male, D., Brostoff, J., Roth, D.B., Roitt, I.M. Immunology, 8th ed. Philadelphia: Elsevier Saunders, 2012.
Meyers, M.A. Happy Accidents, 1st ed. New York: Arcade Publishing, 2007.
Rang, H.P., Dale, M.M., Ritter, J.M., Flower, R.J., Henderson, J. Rang and Dale's Pharmacology, 7th ed. Edinburgh, London: Elsevier Inc, 2012.
WHO guidelines approved by the Guidelines Review Committee. (<a href="http://www.who.int/publications/guidelines" target="_blank" rel="noopener noreferrer">http://www.who.int/publications/guidelines</a>).</p>
<p>.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="index">Index<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#index" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="a">A<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#a" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>4-Aminoquinolines, 779
5-Alpha reductase inhibitors, 990
6-APA nucleus, 661
7-Amino cephalosporanic acid, 689
8-Aminoquinolines, 781
Abacavir, 744
Abarelix, 838
Abatacept
in rheumatoid arthritis (RA), 1079
Abciximab, 480, 1065
Abortion
therapeutic, 641
Absorption
of drugs, 11
Acamprosate, 94
Acanthosis nigricans, 1032
Acarbose, 902
Acebutolol, 280
Acetazolamide, 558
as anti-epileptic, 141
in mountain sickness, 560
Acetylcholine, 256, 286
mechanism of action, 286
sites of action, 256
Acetylcysteine, 360
Acetyl d-penicillamine, 1090
Acetyl salicylic acid (aspirin), 170
Acidosis, 538, 540
treatment of, 541
Acid rain, 1099
Acids as antiseptics, 846
Acitretin, 1108
in psoriasis, 1029
Acne vulgaris, 1023
drug treatment used, 1024
drug therapy of, 1025
Acquired tolerance, 60</p>
<p>Acriflavine, 853
Acrivastine, 328
Acrodynia, 1087
Acromegaly, 946
Actinomycin-D, 829
Activated charcoal, 48
Activated wood charcoal, 606
Active immunisation
principles of, 1057
Active transport, 12
Acute drug poisoning
principles of therapy, 48
Acute renal failure (ARF), 572
Acyclovir, 809
Acylated plasminogen-streptokinase activator (APSAC) complex, 490
Acylovir
in herpes zoster, 1018
Adalimumab, 654, 1065
in psoriasis, 1030
in rheumatoid arthritis (RA), 1079
Adapalene, 1108
in acne, 1024
Addiction, morphine, 166
Addison's disease
management, 932
Additive effect (summation), 39
Adefovir, 811
Adenosine, 393
Adenosyl cobalamin, 511
Adhesive unit, 10
Adrenal cortex
hormones, 922
Adrenal corticosteroids
synthesis and metabolism, 922
Adrenal function tests, 937
Adrenaline
as hemostatic agent, 494
for control of haemorrhage, 270
in anaphylaxis, 326
in bronchial asthma, 366
nebulised, 356
pharmacological actions, 266
therapeutic uses, 270</p>
<p>Adrenal insufficiency
acute, principles of treatment, 933
chronic, 932
Adrenergic drugs
classification, 262
Adrenergic neuron blockers, 421
Adrenergic receptors, 263
agonists and antagonists, 265
distribution and responses, 264
Adrenergic receptor blockers, 277
Adrenocorticotropin (ACTH), 920
Adverse drugs reactions (ADR), 40
ADR and p-glycoproteins, 48
classification, 42
definition, 42
due to drug withdrawal, 47
manifestations, 45
Aerosols
metered dose, 8
Aflibercept, 1045
Agar, 616
Agomelatine, 220
Agonist, 33
AIDS and pregnancy, 746
Albendazole, 818, 823
in filariasis, 823
Albiglutide, 906
Alcohol
acute intoxication, 91
and CYP450, 89
dependence, treatment, 92
drug interactions, 95
metabolism, 90
pharmacologic actions, 87
withdrawal syndrome, 92
withdrawal syndrome, treatment, 92
Alcoholism chronic, 92
lithium in, 94
nalmefene in, 93
naltrexone in, 93
Alcohol level, 91
and behavioural changes, 91
Aldosterone, 935</p>
<p>Aldosterone antagonist, 565
in hypertension, 431
Alefacept
in psoriasis, 1029
Alemtuzumab, 244, 840, 1065
Alendronate, 1007
Alfacalcidiol, 1004
Alfentanil, 108, 162
Alfuzosin, 280, 424
in benign prostatic hyperplasia (BPH), 990
Aliskiren, 428
Alitretinoin, 1107
Alkalies
as antiseptics, 847
Alkaloids, 4
Alkalosis, 538, 541
treatment of, 542
Alkylating agents, 829
Allergic conjunctivitis
treatment, 331
Allergic contact dermatitis, 1026
Allergic disorders
therapy, 330
Allergic reaction, 43
IgE mediated, 43
Allergic skin disorders
drug therapy of, 1026
Allergy, 43
cell mediated reaction, 45
immune complex mediated, 44
Allergy, cytotoxic type, 44
Allethrin, 858
Allopathy, 1
Allopurinol, 1073
Allylestrenol, 958
Almiprine bismethylate, 376
Almotriptan, 339
Aloe, 613
Alogliptin, 904
Alopecia
drug therapy of, 1030
Alosetron, 341, 609
Alpha2-adrenergic receptor</p>
<p>stimulants, selective, 277
Alpha adrenergic blockers
in benign prostatic hyperplasia (BPH), 990
Alpha adrenergic receptor blockers
in hypertension, 424
Alpha and beta adrenergic
blocking drugs, 285
Alpha-chymotrypsin, 1103
Alpha glucosidase inhibitors, 902
Alpha methyldopa, 420
Alphaprodine, 162
Alpha receptor blockers
classification, 278
Alprazolam, 115
in anxiety disorder, 210
in panic disorder, 211
Alprostadil (PGE), 351
Alteplase, recombinant
tissue-type plasminogen
activator (rt-PA), 490
Aluminium chlorhydrate, 1035
Aluminium hydroxide gel, 626
Aluminium phosphate gel, 626
Alverine, 609
Alvimopan, 166
Alzheimer's disease, 242
Amantadine, 236, 812
humoral immunity stimulation, 1068
Ambenonium, 293
Ambroxol, 360
Ambrisentan, 446
Amenorrhoea, 952
Amethocaine (Tetracaine), 250
Amikacin, 686
in tuberculosis, 754
Amiloride hydrochloride, 566
Aminocidin, 803
in leishmaniasis, 803
Aminoglycosides
common features, 682
in UTI, 731
therapeutic use, 682
Aminophylline, 191</p>
<p>as diuretics, 558
in bronchial asthma, 366, 368
mixture of theophylline and
ethylenediamine, 366
Amiodarone, 392
Amiodarone-induced
thyroid disease, 883
Amitriptyline, 216
in insomnia, 123
Amlodipine, 407, 427
Ammonium salts, 358
Amodiaquine, 781
Amoebiasis acute intestinal, drugs used in, 799
chronic intestinal, drugs used in, 799
extra-intestinal, drugs used in, 800
hepatic, drugs used in, 800
iodochlorohydroxyquinoline in, 794
management of, 798
prevention, 800
Amopyroquine, 781
Amoxapine, 216
Amoxicillin, 673
in typhoid fever, 705
Amoxicillin-clavulanic acid
in UTI, 730
Amphetamine, 191, 226, 274
as anorexiant, 582
withdrawal symptoms, 275
Ampholytic surfactants, 849
Amphotericin B, 710, 803
Ampicillin, 672
in typhoid fever, 705
in UTI, 730
Ampicillin-sulbactum
in UTI, 730
Amprenavir, 745
Amrinone, 461
Amylinomimetics, 905
Anabolic steroids, 986
abuse of, 987
Anaerobic infections
metronidazole in, 795
Anaesthesia</p>
<p>epidural, 248
infiltration, 247
spinal, 247
surface, 247
Anagrelide, 839
in polycythemia vera, 835
Analeptics, 188
therapeutic uses, 192
Anal fissure
treatment of, 620
Analgesia, 171
obstetric, 186
patient-controlled, 186
Analgesic
adjuvant, 185
classification, 151
definition, 151
experimental evaluation, 151
opioid as, 151
Anandamide, 229
Anaphylactic-reaction, 326
shock, treatment, 326
Anaphylactoid reactions, 43, 326
Anaphylaxis, 43, 326
Anastrozole, 837
Androgens
physiology, 980
Anemias
classification, 499
Angina of efforts
principles of treatment, 410
Angina pectoris
clinical types, 401
drugs used in, 401
pharmacotherapy of, 410
Angina therapy
stepwise approach, 411
Angioedema
treatment, 331
Angiotensin converting enzyme
inhibitors (ACEI)
in heart failure, 451
in hypertension, 428</p>
<p>and doses in hypertension, 429
Angiotensin II
action, 344
Angiotensin receptor blockers (ARB)
in hypertension, 430
Angiotensin receptors, 344
Angiotensins, 344
Anhidrotics and deodorants, 1034
Anidulafugin, 714
Animal toxicity studies, 69
Anion gap, 539
Anionic
surfactants, 847
Anorexia, 577
Anorexia nervosa, 577
Anorexiants (appetite suppressants), 579, 582
centrally acting, limitations of, 583
Antacids, 625
choice of, 628
drug interactions of, 628
non-systemic, 625
systemic, 627
Antacid therapy, 627
Antagonism, 40
chemical, 40
competitive, 40
irreversible, 41
non-competitive, 41
physiological, 41
reversible, 40
Antagonists, 33
Antazoline <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">C</mi><mi mathvariant="normal">l</mi></mrow><mo separator="true">,</mo><mn>328</mn></mrow><annotation encoding="application/x-tex">\mathrm{HCl}, 328</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord mathrm">HCl</span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">328</span></span></span></span></span>
Anterior pituitary hormones, 865
Anthelmintics, 815
mechanisms of action, 817
Anthraquinone laxatives, 613
Anti-amoebic drugs
classification, 794
Anti-androgens, 987
benign prostatic hyperplasia (BPH), 990
Anti-arrhythmic drugs
classification, 384, 385
effects on the heart, 394</p>
<p>Anti-asthmatic drugs
classification, 364
Anti B lymphocyte antibody
in RA, 1079
Antibiotic
definition, 645
Anti-cancer drugs
classification, 828
Anti-cholinergic drugs
in parkinsonism, 237
Anti-cholinergics, 364, 367
Anti-cholinesterases, 290
in snake venom poisoning, 295
irreversible, 295
reversible, 291
Anti-CMV Drugs, 809
Anti-coagulant drugs
actions of, 488
classification, 481
contraindications, 489
indications, 488
in vitro, 490
slow acting, oral, 485
Anti-coagulant, coumarins., 486
drug interactions, 486
Anti-convulsants, 129
Anti-depressants, 195
classification, 212
newer, 220
SSRI, 218
tricyclic, 214
Anti-depressants, tricyclic
in panic disorder, 211
Anti-diabetic drugs
non-insulin classification, 897
Anti-digoxin antibodies, 459
Anti-diuretic agents, 573
Anti-diuretic hormone (ADH), 573
Anti-emetics
as preanaesthetic medication, 110
choice of, 600
classification, 596
Anti-epileptic drugs, 133</p>
<p>action on GABA metabolism, 138
classification, 133
in non-epileptic disorders, 148
Anti-epileptics, 129
Antiestrogenic agents, 971
Anti-flatulents, 579
Anti-fungal agents
choice in infection, 714
classification, 708
in skin diseases, 1018
Anti-fungal therapy
for skin infection, choice of, 1020
Anti-gonadotropic compounds, 978
Anti-haemophilic globulin, 495
Anti-hepatitis B drugs, 811
Anti-hepatitis C drugs, 812
Anti-herpes drugs, 809
Anti-histaminic drugs
as anti-emetics, 597, 600
as cough suppressants, 359
as preanaesthetic medication, 109
hypnotic effect, 123
in anaphylactic shock, 327
in bronchial asthma, 372
in motion sickness, 599
in parkinsonism, 238
non-sedative, 332
therapeutic uses, 330
Anti-hormonal drugs
in malignancy, 837
Anti-hyperlipidemic
classification, 586
Anti-hypertension drugs
experimental evaluation, 418
Anti-hypertensive drugs
classification, 419
centrally acting, classification, 419
experimental evaluation, 418
symptom profiling, 438
Anti-inflammatory activity
experimental evaluation, 168
Anti-inflammatory analgesics
in RA, 1077</p>
<p>Anti-influenza drugs, 812
Anti-leishmanial drugs
classification, 802
Anti-lymphocytic globulin, 1068
Anti-lymphocytic serum (ALS), 1068
Anti-malarial drugs
actions on malarial life cycle, 777
classification, 776
Anti-malignancy antibiotics, 835
Anti-metabolites, 832
Anti-microbial
for diarrhoea, 602
in acne, 1025
in IBD, 654
prophylaxis, 722
therapy, dangers of, 725
therapy, failure of, 726
used in the eye, 1040
Anti-microbial agents classification, 647
combinations, 720
drugs of choice in, 718, 719
misuse of, 725
non-renal clearance, 717
renal excretion, 717
selection of, 715
Anti-microbial drugs
classification, 647
in Gram negative anaerobic
infections, 720
mechanisms of action, 647
Anti-microbial effect
concentration dependent, 646
time dependent, 646
Anti-microbial resistance
avoidance of, 725
Anti-mitotic drugs
in the eye, 1044
Antimitotic natural products, 836
Antimony, 1086
Antimony-potassium tartrate (tartar emetic), 595
Anti-muscarinic, 109
as preanaesthetic medication, 109
Anti-oxidants, 1115</p>
<p>Anti-parkinsonian drugs
classification, 233
Anti-platelet agents
classification, 479
Anti-platelet drugs, 478
in angina, 409
Anti-progestins, 973
Anti-psychotic drugs, 195
companison of typical and
atypical, 201
for MDP treatment, 206
mechanism of action, 195
neuroleptics, 195
Anti-psychotics, atypical, 195
Anti-psychotics (second generation), 201
comparison of efficacy and
toxicity, 202
Anti-resorptive drug, 1008
Anti-retroviral drugs
classification, 743
combinations, 746
Anti-scorpion venom serum (AScVS), 1060
Anti-secretory agents, 628
Anti-seizure drugs, 129
Antiseptics
classification, 844
definition, 844
mechanisms of action, 845
Anti-serum, 1050
rabies, 1059
Anti-snake venom serum, 1059
Anti-thrombin III concentrate
human, 484
Anti-thymocytic globulin, 1068
Anti-thyroid drugs
classification, 878
indications, 882
ion inhibitors, 878
Anti-toxin
botulinum, 1058
gas gangrene, 1058
Anti-tuberculosis drugs
properties, 753</p>
<p>Anti-tussives, 357
Anti-tussives
classification, 356
Anti-viral drugs
classification, 809
therapeutic uses, 814
Anovlar, 969
Anxiety-associated disorder, 209
Anxiety disorders
treatment, 209
Anxiolytics, 208
Aplastic anemia, 519
Apomorphine, 160
as emetic, 595
stereotyped behaviour
syndrome, 160
Appetite stimulants, 577
Appetite suppressants, 582
Apixaban, 484
Apraclonidine, 1043
Aprinidine, 392
Aprotinin, 346, 497
Aqueous diffusion, 11
Arbaprostil, 631
Area under curve (AUC), 12
Arecholine, 290
Arformoterol, 364, 375
Argatroban, 484
Arginine vasopressin (AVP), 573
Aripiprazole, 202
Aromatase inhibitors, 837
Aromatic volatile oils
for flatulence &amp; colics, 579
Arsenic, 1083
Arsenic poisoning, 1057
acute treatment, 1084
chronic treatment, 1084
Artemether, 784
Artemisinin-based combination therapy (ACT), 790</p>
<p>Artemisinin compounds, 784
Artesunate, 784
Artether, 784</p>
<p>Arthus reaction, 44
Arvin, 493
Ascorbic acid (Vitamin C), 1113
Aspartame, 919
Aspirin (acetyl salicylic acid), 170, 409
as anti-platelet agent, 479
avoidance in gout, 1075
in angina, 409
in diarrhoea, 607
Aspirin and Reye's syndrome, 174
Asthma
acute, preventive, 367
acute, treatment, 365, 373
chronic persistent, treatment of, 369
severe, acute, treatment of, 373
steroid resistant, 374
Astringent effect, 32
Asymptomatic cyst passers
treatment of, 799
Atazanavir, 745
Atenolol, 280
Atherosclerosis, 584
Atomoxetine, 227
Atopic dermatitis
drug therapy of, 1026
Atorvastatin, 588
Atosiban
as tocolytic, 643
Atovaquone, 785
in toxoplasmosis, 806
Atovaquone-proguanil
combination, 785
ATP binding cassettes, 11
Atracurium, 319
Atrial fibrillation, 460
drug treatment of, 396
Atrial natriuretic peptide (ANP), 452, 528
Atropa belladonna, 299
Atropine (dl-hyoscyamine), 299
as preanaesthetic medication, 303
in cardiac arrhythmias, 394
in organophosphorus compound
poisoning, 297, 303</p>
<p>poisoning, treatment, 302
substitutes classification, 304
synthetic, substitutes in
parkinsonism, 238, 239
therapeutic uses, 303
Atropine methonitrate, 304
Attention deficit hyperactivity
disorder (ADHD), 226, 275
Atypical mycobacterial (M. avium
complex) infection, 660
Auranofin, 1077
Aurothioglucose, 1077
Aurothiosulfate, 1077
Autonomic nervous system physiology, 251
Axitinib, 841
Axosemide, 564
Ayurveda, 1
Azalides, 676
Azapropazone, 1075
Azathioprine, 654, 834
as immunosuppressants, 1067
in rheumatoid arthritis (RA), 1080
Azidocillin, 671
Azidothymidine, 744
Azithromycin, 677
in syphilis, 737
in toxoplasmosis, 806
in UTI, 731
Azilsartan, 431
Azlocillin, 674
Azole derivatives, 711
Azoles
for dermal skin infections, 1019
systemic use, 1019
topical use, 1019
Aztreonam, 688</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="b">B<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#b" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Bacillary dysentery
therapy of, 706
Bacitracin, 680
Backache therapy, 176
Baclofen, 242, 314</p>
<p>Bacterial endocarditis, 685
therapy of, 668
Bacterial resistance
R-factor, 724
Bacterial vaccines and toxoids, 1052
Bactericidal, 645
Bactericidal drugs, 716
Bacteriostatic, 645
Bacteriostatic drugs, 716
Bacteriuria
asymptomatic, 728,734
significant, 728
Balsalazine, 653
Barbiturates, 117
adverse drug reactions, 119
classification, 117
for narcoanalysis, 120
in anaesthesia, 104
in epilepsy, 135
interactions, 120
mechanism of action, 117
pharmacological actions, 117
poisoning, treatment, 120
therapeutic uses, 120
ultra short acting, 104
withdrawal syndrome, 119
Basilliximab, 1065
Bazedoxifene, 951
BCG, 1051
as immunomodulator, 1068
BCG vaccine, 764
for leprosy, 773
Beclomethasone dipropionate, 368, 370, 932
Bedaquiline (TMC, 207), 755
Belladonna alkaloids, 299
Benazepril, 429
Bendamustine, 832
Bendroflumethiazide, 562
Benign prostatic hyperplasia (BPH), 990
drugs used in, 990
Benserazide, 235
Benzalkonium chloride, 848
Benzamphetamine, 582</p>
<p>Benzathine penicillin, 663
Benzbromarone, 1075
Benzene, 1100
Benzhexol hydrochloride, 237
Benznidazole, 805
Benzocaine, 250
Benzodiazepine derivatives, 115
Benzodiazepines, 208
adverse reactions, 115
as anti-convulsants, 139
as hypnotics, 113
classification, 115
mechanism of action, 113
pharmacological actions, 114
therapeutic uses, 115
withdrawal syndrome, 115
Benzoic acid, 846
Benzonatate, 359
Benzothiadiazine
as diuretics, 560
in diabetes insipidus, 574
Benzoyl peroxide
as keratolytic agents, 1017
in acne, 1025
Benzpyrinium, 295
Benzthiazide, 562
Benztropine, 238
Benztropine mesylate, 238
Benzyl benzoate, 1021
Benzylpenicillin, 662
Bephenium hydroxynaphthoate, 820
Beractant, 377
Beriberi, 1109
Beta-adrenergic blocker
agents in cardiac arrhythmias, 390
in angina pectoris, 405
in congestive heart failure, 452
in hypertension, 425
Beta-adrenergic blocker in panic disorder, 211
Beta2-adrenergic, receptor
stimulants, selective, 277
Beta <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4511em; vertical-align: -0.15em;"></span><span class="mord"><span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> selective
agents in acute asthma, 364</p>
<p>Beta-adrenergic receptor blockers
classification, 280
Beta agonists, selective, short acting: SABA, 365
Beta blockers, 280
contraindications, 285
for variceal bleeding prevention, 498
long active: LABA, 368
therapeutic uses, 284
Beta-endorphin, 151
Betahistine <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">C</mi><mi mathvariant="normal">l</mi></mrow><mo separator="true">,</mo><mn>325</mn><mo separator="true">,</mo><mn>601</mn></mrow><annotation encoding="application/x-tex">\mathrm{HCl}, 325,601</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord mathrm">HCl</span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">325</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">601</span></span></span></span></span>
Beta-lactam antibiotics, 661
Beta lactamase, 661
Beta lactamase inhibitors, 674
Beta lactam ring, 661
Betamethasone, 928
Betamethasone valerate, 932
Bethanechol, 289, 306
bladder hypotonicity, 307
Bethanidine, 422
Betoxolol, 280
Bevacizumab, 840, 1044, 1065
Bevirimat, 746
Bexarotene, 1108
Bezafibrate, 591
Bicalutamide, 838, 988
Bicarbonate deficit, 539
Biguanides, 901
as anti-diabetic agents, 901
in malaria, 783
Bile acids, 578
Biliary cirrhosis, 578
Bioassay, 76
Bioavailability, definition, 12
Bioavailability, factors affecting, 13
Bioequivalent, 13
Biological agents
in psoriasis, 1029
in rheumatoid arthritis (RA), 1079
Biological half-life, 23
Biological response modifiers
in malignancy, 841
Biologicals, 3
Biopharmaceutics, 14</p>
<p>Biotin, 1112
Bio-transformation effects on drugs, 18
Biperiden <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">C</mi><mi mathvariant="normal">l</mi></mrow><mo separator="true">,</mo><mn>238</mn></mrow><annotation encoding="application/x-tex">\mathrm{HCl}, 238</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord mathrm">HCl</span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">238</span></span></span></span></span>
Bipolar depression (Manic
Depressive Psychosis (MDP))
pharmacotherapy, 205
Bisacodyl, 614
Bishydroxycoumarin (dicoumarol), 485
Bismuth salts, 1086
in peptic ulcer, 631
Bisoprolol, 280, 285
Bisphosphonates, 1005
in hypercalcemia, 996
in osteoporosis, 1007
preparations with doses, 1007
therapeutic uses, 1007
Bithionol, 826, 850
Bitolterol, 366
Bivalirudin, 484
Black water fever, 778
Bladder dysfunction
drug used in, 306
pharmacology, 305
Bleomycin, 835
Blood whole, 467
Blood-Brain Barrier (BBB), 17
Blood coagulation
mechanism, 476
Blood pressure
regulation, 416
Blood transfusion
autologous, 467
complications, 468
indications, 468
Boceprevir, 812
Body fluids
distribution, 522
Booster PI regimen, 745
Boric acid, 846
Bortezomib, 841
Bosentan, 445
Botanical compounds
as insecticides, 858</p>
<p>Botulinum toxin
in anal fissure, 620
Type A, 321
Type B, 321
Bougie, 6
Bradykinin, 345
Brain natriuretic peptide (BNP), 528
Bran, 616
Breast
fibrocystic disease of, therapy of, 961
Breast feeding
drugs to be avoided, 1127
Brilliant green, 853
Brinzolamide, 1044
British National Formulary (BNF), 5
British pharmaceutical codex (BPC), 3
Bromelains, 1103
Bromhexine, 360
Bromocriptine, 237, 945
Bromoergocriptine (Bromocriptine), 638, 945
Bronchial asthma, 361
clinical forms, 363
pathophysiology, 361
Bronchodilators
for cough, 359
Brucellosis
treatment, 684
Bucindolol, 280
Buclizine, 328
Bucricaine, 250
Budesonide, 270, 368, 932
Bufotenine, 228
Bulaquine, 782
Bulimia nervosa, 218
Bulk anorexiants, 583
Bulk laxatives, 615
Bumetanide, 564
Bunazosin, 280
Bupivacaine, 249
Buprenorphine, 164
Bupropion, 216, 221, 583
for MDP treatment, 206
in treatment of tobacco dependence, 312</p>
<p>Buserelin acetate, 942
Buspirone, 208, 338
Busulfan, 831
Butenafine, 1019
Butoconazole
Butopyronoxyl
as mosquito repellents, 792
Butorphanol, 163
Butyrophenones
anti-emetic, 597</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="c">C<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#c" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Cabergoline, 946
adverse reactions, 237
Cadmium, 1087
Caffeine, 226
Calamine, 854
Calcifediol, 1004
Calciferol (Vitamin D), 999, 1003
Calcipotriol in psoriasis, 1028
Calcitonin, 998
in hypercalcemia, 996, 999
in osteoporosis, 1009
Calcitonin gene related peptide (CGRP)
and migraine, 341
Calcitriol, 1004
Calcitropic hormones
actions, 1006
Calcium
homeostasis, mechanisms, 1000
oral, preparations, calcium
content in, 994
parenteral preparations, 995
Calcium absorption
agents and conditions
interfering with, 992
agents and conditions
stimulating, 992
Calcium carbonate, 626
Calcium channel blockers (CCB), 409
in angina pectoris, 401
in cardiac arrhythmias, 393
in hypertension, 427</p>
<p>properties, 407
Calcium chloride, 994
Calcium disodium edetate, 1090
Calcium gluconate, 994
Calcium laevulinate, 995
Calcium pantothenate, 1112
Calcium salts therapeutic uses, 995
Calfactant, 377
Camphor, 191
Camphorated tincture of opium, 607
Camptothecin analogues, 836
Canagliflozin, 905
Cancer
cell cycle, 827
Candesartan, 430
Cannabis (marijuana), 228
Capreomycin, 754
Capsaicin, 185
in cancer pain, 185
Captopril, 429
Caramiphene, 357
Carbachol, 289
Carbamate insecticides, 858
Carbamazepine, 135, 203
adjunct in schizophrenia, 203
drug interactions, 136
for deafferentiation pain, 136
for MDP treatment, 207
for trigeminal neuralgia, 135
in chronic neuropathic pain, 186
in diabetes insipidus, 575
Carbapenems, 694
in UTI, 731
Carbenicillin, 673
in UTI, 730
Carbidopa, 235
Carbimazole, 878
Carbocysteine, 360
Carbogen, 1097
Carbon dioxide, 192, 1097
Carbon dioxide narcosis, 1093
Carbonic anhydrase inhibitors
as diuretics, 558</p>
<p>Carbon monoxide, 1098
Carbon monoxide poisoning, 1098
acute, treatment, 1099
Carbon tetrachloride, 1100
Carboplatin, 832
Carboprost, 641
Carcinogenicity studies, 70
Carcinoid syndrome, 336
Cardiac arrhythmias
choice of treatment, 395
mechanisms, 383
Cardiac contraction
physiology, 447
Cardiac glycosides, 454
digitalis glycosides, 456
Cardiac syndrome X, 401
Cardiac tissue
clectrophysiology, 380
Cardio-pulmonary resuscitation, 270
steps, 270
Cardiovascular drugs
in shock, 473
Carfilzomib, 841
Carisoprodol, 314
Carminatives, 579
Carmustine, 832
Carotene, 1106
Carrier protein, 12
Carteolol, 280
Carvedilol, 280, 285, 426
Cascara sagrada, 613
Caspofungin, 714
Castor oil, 613
Cataplexy
treatment, 226
Catecholamine depletors
in hypertension, 422
Catecholamines, 262
biosynthesis, 256
comparision of pharmacological
actions, 269
mechanism of action, 263
metabolism, 268</p>
<p>uptake mechanisms, 259
Catechol-O-methyl transferase (COMT) inhibitors, 236, 259, 268
Cation exchange resin, 508, 568
Cationic
surfactants, 848
Cawthorne-cooksey exercises, 600
Cedar wood oil, 357, 792
Cefaclor, 691
Cefadroxil, 691
Cefalexin, 691
Cefamandole, 691
Cefaperazone, 692
Cefazolin, 691
Cefepime, 692
Cefixime, 692
Cefotaxime, 692
Cefoxitin, 691
Cefpirome, 693
Cefpodoxime proxetil, 692
Ceftaroline, 693
Ceftazidime, 692
Ceftibuten, 692
Ceftizoxime, 692
Ceftolozane, 692
Ceftriaxone, 692
Cefuroxime, 691
Cefuroxime axetil, 691
Ceiling dose, 38
Celecoxib, 169
Celiprolol, 280
Cenestin, 950
Centbutandol, 201
Centchroman
ormeloxifene, 971
Cephalosporins, 689
first generation, 693
fourth generation, 693
in typhoid fever, 705
in UTI, 731
second generation, 693
third generation, 693
Cephamycins, 689
Cerebral malaria</p>
<p>treatment, 776
Certolizumab, 654, 1065, 1179
in psoriasis, 1030
Certolizumab pegol, 1079
Cetirizine, 328
Cetrimide, 849
Cetrorelix, 942
Cetuximab, 1065
Cetylpyridinium chloride, 849
Cevimeline, 290
Chagas' disease
drug therapy, 805
Chancroid
drug therapy of, 741
Chaulmoogra oil, 770
Chelating agents, 1088
used in therapy, 1088
Chelation, 31
Chemical assay, 76
Chemoprophylaxis
for MAC, 766
tuberculosis, 763
Chemotherapy, 2, 644
definition, 2
Chemotherapeutic agents
factors affecting, efficacy of, 645
Chenodeoxycholic acid (CDCA), 578
Chimeric antibodies, 1064
Chirality, 30
Chlamydial infections drugs used in, 702
Chloral hydrate, 122
Chlorambucil, 831
Chloramines, 851
Chloramphenicol, 703
therapeutic uses, 704
Chloride channel activators, 617
Chloride channel Inhibitor
in diarrhoea, 607
Chlorcyclizine, 357
Chlordiazepoxide, 115
Chlorexolone, 563
Chlorhexidine, 850
Chlorinated lime (bleaching powder), 851</p>
<p>Chlorine, 851
Chlormadinone, 955
Chlormethiazole, 208
Chlorophenothane (DDT), 856
Chloroquine, 779
in amoebiasis, 797
in rheumatoid arthritis (RA), 1077
Chlorothiazide, 562
Chlorothymol, 850
Chlorotrianisene (TACE), 948
Chloroxylenol, 850
Chlorpheniramine maleate, 328
Chlorpromazine, 197
Chlorpropamide, 899
in diabetes insipidus, 575, 900
Chlorprothixene, 201
Chlorthalidone, 562
Chlorzoxazone, 315
Choice, 969
Cholecalciferol (Vitamin D), 999
Cholecystokinin (CCK), 578
Cholera therapy of, 702
Choleretics, 578
Cholestyramine resin, 591
Choline, 1112
Choline esters, 286
Cholinergic crisis, 293
Cholinergic drugs
classification, 286
Cholinesterase inhibitors
anti-cholinesterases, 286
classification, 290
Cholinesterase reactivators, 298
Cholinomimetic alkaloids, 290
Chondrodendron tomentosum, 317
Chondroitin sulfate, 1082
Chronic bronchitis
exacerbations, 707
management, 707
pharmacotherapy, 706
Chronic cough hypersensitivity
syndrome, 360
Chronic heart failure</p>
<p>therapy, 450
Chronic obstructive pulmonary
disease (COPD)
management, 374
Chronic suppressive therapy
in UTI, 731
Chymotrypsin, 1103
Ciclesonide, 370
Ciclopiroxolamine, 1019
Cidofovir, 811
Cilastatin, 694
Cilomilast, 367
Cilostazol, 415, 480
Cimetidine, 629
Cimetropium, 609
Cinacalcet, 996
Cinchocaine, 250
Cinchona alkaloids, 776
Cinchonism, 388, 778
Cinnarizine, 328, 601
Ciprofloxacin, 659
Cisapride, 339, 598
Cisplatin, 832
Citalopram, 216
Citrate, 490
Citronella oil, 792
as mosquito repellent, 792
Cituximab, 840
Clarithromycin, 677
for MAC, 766
in leprosy, 770
in toxoplasmosis, 806
Clavulanic acid, 674
Clevidipine, 409
Clindamycin, 678
in malaria, 785
in toxoplasmosis, 806
Clinical evaluation, 71
Clinical pharmacology, 71
Clinical pharmacy, 2
Clinical trial
double blind, controlled, 74
phases, 72</p>
<p>Clobazam, 139
Clobetasol propionate, 932
Clobetasone butyrate, 932
Clofazimine, 769
in erythema nodosum leprosum (ENL), 773
immunomodulator, 1069
in tuberculosis, 755
Clofibrate, 591
Clomiphene citrate, 976
Clonazepam, 115, 139
anxiety disorders, 210
Clonidine, 419
Clopamide, 563
Clopenthixol, 201
Clopidogrel, 479
Clorazepate, 115
Clotting factors, 477
Clotrimazole, 712, 1019
Cloxacillin, 671
Clozapine, 201, 341
CNS, 81
drug action, 81
functions of various parts, 81
neurochemical transmission, 82
neuromediation, 83
neuromodulation, 83
neurotransmitters, 84
neurotrophic factors, 85
stimulants, 188
Coal tar
crude, in psoriasis, 1028
Cobalamins, 510
Cocaine, 248
Coconut oil, 587
Codeine, 159, 358
as antitussive, 358
Coenzyme Q10, 1116
Cognitive-behavioural therapy, 211
Colchicine, 1071
Colesevalam, 591
Colestipol, 591
Colistin, 687
Colitis, pseudomembraneous, 678</p>
<p>Collagen
microfibrillar, 494
Collagenase, 1103
Colony stimulating factors (CSF), 352
Combination OC pills, 964
adverse reactions, 966
contraindications, 967
drug interactions of, 967
in acne, 1024
non-contraceptive benefits, 969
preparations, 969
preparations, extended cycle, 964
Combined OC pills, 959
oral, method of
administration, 964
in hirsutism, 989
Comedolytics
in acne, 1024
Computerised, miniature, syringe pumps, 10
COMT inhibitors, 236
Conivaptan, 534, 575
Conjugated estrogens
as hemostatic, 497
Conn syndrome, 565
Constipation
and laxatives, 618
Contraception
male, 974
postcoital, 974
Contraceptives
injectable, 971
injectable doses, 972
postcoital, various regimens for, 974
transdermal system, 972
Controlled release, 7
Convulsions
emergency management, 148
Convulsions, febrile, 146
COPD, bronchodilator regimens, 375
Copper-containing IUCDs, 974
Corn oil, 587
Coronary circulation
assessment, 400</p>
<p>physiology, 398
Cortisone, 928
Cosmetics, tooth powders, 1033
Cotrimoxazole (sulfamethoxazole + trimethoprim), 654
in toxoplasmosis, 806
in UTI, 730
therapeutic uses, 655
Cough
expectorants, 357
pathophysiology, 355
suppressants, 358
Coumarin derivatives, 485
Counterirritant, 32
COX-2 inhibitors, selective, 169
Cramps, quinine in, 779
Creosote, 357
Cresol, 850
Cretinism
drug therapy, 875
Crofelemer, 607
Crohn's disease, 652
Cromolyn
disodium chromoglycate, 371
Cromolyn sodium
in conjunctivitis, 331
Cross tolerance, 60
Crotamiton, 1022
Croup, 356
Cryptorchism, 943
Crystal induced arthropathies, 1075
Curare poisoning, 295
Cushingoidism, 929
Cushing's syndrome, 930
Cyanide poisoning
treatment, 1100
Cyanocobalamin, 510
Cyclic lipopeptides, 680
Cyclizine <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">C</mi><mi mathvariant="normal">l</mi></mrow><mo separator="true">,</mo><mn>328</mn></mrow><annotation encoding="application/x-tex">\mathrm{HCl}, 328</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord mathrm">HCl</span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">328</span></span></span></span></span>
Cyclobenzaprine, 314
Cyclofenil, 978
Cycloguanil, 783
Cyclo-oxygenase (COX), 169
Cyclopenthiazide, 562</p>
<p>Cyclophosphamide, 830
Cycloserine, 687, 754
Cyclosporine, 1066
in psoriasis, 1029
Cycrimine HCl, 238
CYP, 450
system, 19
CYP enzymes
substrates and inhibitors, 67
Cyproheptadine, 340, 577
Cyproterone acetate, 987
in acne, 1024
Cystitis
postcoital, 734
Cystitis-urethritis
acute, uncomplicated
therapy of, 732
Cytokines, 350
classification, 352
functions, 353
Cytoprotection in angina, 409
Cytosine arabinoside, 834
Cytotoxic antibodies, 835
Cytotoxic effect, 32</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="d">D<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#d" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>1-Deamino-8-D-arginine-vasopressin (DDAVP) (Desmopressin), 574
Dabigatran, 484
Dacarbazine, 831
Daclizumab, 1065
Daidzein, 3
Dalbavancin, 679
Dale's vasomotor reversal, 266
Dalteparin, 483
Danaparoid, 484
Danazol, 961, 978
Dandruff treatment of, 1017
Dantrolene, 242, 321
in malignant hyperthermia, 320
Dapagliflozin, 905
Dapsone (4-4' diamino-diphenyl
sulfone (DDS)), 768
dermatitis herpetiformis, 769</p>
<p>in malaria, 784
Daptomycin, 680
Darbepoietin alfa, 508
Darifenacin, 307
Darunavir, 745
Dasatinib, 298, 841
Datura stramonium, 299
Daunorubicin, 835
Daytime Excessive
Sleepiness (DES), 226
Dazoxiben, 349, 479
Debrisoquine, 422
Decarboxylase inhibitors (DCI), 235
Decompression sickness, 1097
Defaecation
physiology of, 611
Deferasirox, 508
Deferiprone, 507
Dehydration due to diarrhoea management, 603</p>
<p>Dehydrocholic acid, 578
Dehydroemetine, 797
Delamanid, 756
Delavirdine, 745
Delirium tremens, 92
Demecarium, 293
Demelanising agents, 1032
Demethylchlortetracycline, 700
Denosumab, 1009
Dental caries, 1010
Deoxycorticosterone, 935
Deoxyribonuclease, 1103
Depot-medroxyprogesterone acetate (DMPA), 971</p>
<p>Depression,
mental, treatment of, 220
severe, therapy of, 224
Dequalinium acetate, 849
Dermal fillers, 1034
Dermatological
adverse reactions, 1036
Dermatological preparation
choice of, 1016</p>
<p>Dermatology
drug application in, principles
of, 1014
Desensitisation, 45, 46
Desferrioxamine, 507, 1091
Desflurane, 103
Desimipramine, 212
Desipramine, 216
Desirudin, 484, 489
Desloratadine, 328
Desmopressin, 497
as hemostatic agent, 494, 497
in diabetes insipidus, 574
in variceal bleeding, 498
Desogestrel, 956, 957, 958
Desoxycorticosterone, 935
Dexamethasone, 924
in mountain sickness, 560
Dexfenfluramine, 582
Dexmedetomidine, 109, 123
Dexpanthenol, 1112
Dextran, 471
Dextromethorphan hydrobromide, 358
Dextrose, 472
Diabetes insipidus, 574
Diabetes mellitus
pharmacotherapy, 906
types, 906
Diabetic coma
keto-acidotic, 915
non-ketotic, 917
Diabetic ketoacidosis
principles of management, 916
Diacetylmonoxime (DAM), 298
Diagnostic agents
in the eye, 1045
Diamidine derivatives, 802
in leishmaniasis, 802
Diamorphine
for cancer induced cough, 358
Diastolic dysfunction, 450
Diarrhoea
atropine and its substitutes, 607</p>
<p>bismuth salts in, 606
chronic, 608
codeine in, 607
dehydration due to,
management of, 542
drug therapy of, 601
infectious, specific treatment, 603
irritable bowel syndrome (IBS), 608
malabsorption of, 609
nutmeg in, 607
pathophysiology, 601
prostaglandin inhibitors in, 607
tricyclic anti-depressants in, 609
Diazepam, 115, 313
as anti-anxiety agent, 208
as preanaesthetic medication, 109
in epilepsy, 139
in status epileptics, 147
Diazoxide, 427, 918
Dibenamine, 278
Dibucaine, 250
Dichlorovas, 296
Dichlorphenamide, 560
Diclofenac, 178
Dicloxacillin, 671
Dicobalt edetate in cyanide poisoning, 1100
Dicophane (DDT), 1023
in pediculosis, 1023
Dicyclomine, 304, 609
Didanosine, 744
Dieldrin, 857
Dietary fat, 587
Dietary fibre
and bowel disorders, 616
Diethazine, 196
Diethylcarbamazine, 822
Diethyl ether, 101
Diethylpropion, 582
Diethylstilbestrol, 950
for prostatic cancer, 837
Difenoxin, 162
Diffusion,
passive, 11</p>
<p>facilitated, 12
Diffusion hypoxia, 104
Diflunisal, 177
Digestants, 578
Digitalisation, 461
Digitalis glycosides, 456
Digitalis toxicity, treatment, 458
Digitoxin, 457
Digoxin, 393, 457
as antiarrhythmic, 393
contraindications, 461
drug interaction, 458
mechanism of action, 454
therapeutic uses, 460
toxicity, 457
Digoxin toxicity
treatment, 458
Dihydroergocornine, 636
Dihydroergocristine, 636
Dihydroergocryptine, 636
Dihydroergotamine (DHE), 279
Dihydroergotamine (ergot alkaloids), 636
Dihydrogenated alkaloids, 278
Dihydrogenated ergot
alkaloids, 278, 424
Dihydrotachysterol (DHT), 1005
Dihydrotestosterone, 981
Dihydroxyacetone (DHA)
for tanning, 1033
Dihydroxystilbamidine isethionate, 803
Diiodohydroxyquinoline, 796
Diisopropyl flurophosphate (DFP), 295
Diloxanide furoate, 798
Diltiazem, 408, 427
in cardiac arrhythmias, 393
Dimenhydrinate, 328
Dimercaprol (BAL), 1088
Dimethicone
as barrier preparation, 1033
Dimethisterone, 958
Dimethyl fumarate, 244
Dimethyl phenylpiperazinium (DMPP), 308
Dimethyl phthalate (DMP)</p>
<p>as mosquito repellent, 792
Dimethylpolysiloxane, 579
Dinoprost, 641
Dinoprostone, 641
Dioctyl sodium sulfosuccinate, 617
stool softener, 848
Diphenhydramine, 123, 238, 328, 357
Diphenoxylate, 162, 607
Diphenylbutylpiperidines, 200
Diphtheria anti-toxin, 1058
Diphtheria toxoid, 1052
Dipivefrine, 1039
Dipyridamole, 409, 480
Dipyrone, 178
Directly observed treatment, short course (DOTS), 757
Direct smooth muscle relaxants, 609
Direct thrombin inhibitors, 484
Disease modifying anti-rheumatic drugs (DMARD), 1076
Disinfectant, 844
definition, 844
Disinfection
chemical methods of high level, 856
Disodium chromoglycate, 371
Disodium edetate, 1090
Disopyramide phosphate, 389
Dissociation constant, 16
Dissociative anaesthesia, 106
Distigmine, 293
for blader hypotonicity, 307
Distribution
of drugs, 15
Disulfiram (antabuse), 94
Dithiocarb, 1091
Dithranol
in psoriasis, 1028
Diuretic
choice of, 569
classification, 555
combination, 570
indications, 567
in heart failure, 453
non-diuretic uses, 567
potassium sparing, 565</p>
<p>resistance, 570
sites and mechanisms of actions, 556
therapy, complications of, 570
therapy, indications, 567
therapy, pattern of electrolyte
excretion, 567
tolerance, 570
Dobutamine, 272
in heart failure, 461
in shock, 473
Docetaxel, 836
Docosanol, 810
Dodecyldi-(aminoethyl)-glycine hydrochloride, 849
Dofetilide, 392
Domperidone, 598
Donepezil, 243
Doloverine, 609
Dopamine, 256, 272
in heart failure, 461
in parkinsonism, 231
in shock, 473
pharmacological effects, 272
receptors, 272
Dopamine agonists
in parkinsonism, 237
Dopaminergic pathways, 83
Dopexamine, 272
Doripenem, 694
Dornase alpha, 360
Dorzolamide, 1044
Dose dependent elimination, 24
Dose determination, 24
Dose response relationship, 37
graded, 36
quantal, 38
Dosing frequency, 24
Dothiepin, 216
DOTS-Plus programme, 761
Doxacurium, 319
Doxapram, 191, 376
Doxazosin, 280, 424
benign prostatic hyperplasia (BPH), 990
Doxepin</p>
<p>as anti-pruritic, 1026
for pruritus, 1017
Doxorubicin (adriamycin), 835
Doxycycline, 701
in filariasis, 823
in malaria, 785
in syphilis, 737
Doxylamine, 327, 599
DPP-4 inhibitors, 904
Dracunculosis (guinea worm infestation), 795
Dronabinol, 229, 599
Dronedarone, 392
Droperidol, 107, 200
Drospirenone, 956, 967
Drugs
absorption, 11
action, site, 28
additive effect, 39
adverse reactions, 41
adverse reactions and
p-glycoproteins, 48
affinity, 33
allergy, 43
amplifier system, 34
and breast feeding, 1126
and memory, 242
and vasopressin release, 573
antagonism, 40
apparent volume of distribution, 15
as replacement, 31
biostandardisation, 78
biotransformation, 18
causing enzyme inhibition, 31
causing enzyme stimulation, 31
controlled release preparations, 7
cumulation, 59
definition, 3
delivery system, special, 26
dependence, drugs causing, 62
disintegration time, 14
dissolution rate, 14
distribution, 15
dosage forms, 6</p>
<p>dose, median effective, 39, 338
dose, median lethal, 39
dose-response relationship, 37
effect of genetic factors, 58
effects, factors modifying, 56
effects on pregnancy, 1120
efficacy, intrinsic activity, 33
essential, 55
evaluation, 56
excretion, 21
expiry date, 54
fate, 18
first order kinetics, 22
fixed-dose combinations, 52, 55
formulation, 14
from mineral, 3
from plant, 3
idiosyncrasy, 42
in elderly, 57
in pregnancy, 1117
interactions, 63
intolerance, 42
low therapeutic index, 25
mechanism of actions, 30
metabolism, 18
methods of prolonging duration
of action, 26
of animal origin, 3
of microbial origin, 3
orphan, 55
pediatric doses, 56
placental transfer of, 17, 1118
plasma concentration, 16
plasma half-life, 22
poisoning, acute, treatment, 48
potency, 34
prescribing, 50
protein binding, 16
receptor-effector system, 33
receptors, 32
receptor, spare, 34
receptor, types, 36
risky, 64</p>
<p>routes of administration, 6
SAR, 29
secretion by proximal tubules, 21
selectivity, 33
side effects, 41
sources, 3
spurious, 54
steady state concentration, 23
storage, 17
synergism, 39
synthetic, 3
tachyphylaxis, 61
therapeutic index, 39
time release preparations, 7
time synergism, 40
to be avoided in CHF, 464
tolerance, 34, 60
transmembrane transport, 11
types of effects, 31
untoward effects, 41
used during pregnancy
US FDA categories, 1122
withdrawal syndrome, 47, 63
with low therapeutic index, 25
zero order kinetics, 24
Drug absorption
effect of food on, 15
Drug abuse, 62
factors facilitating, 63
Drug assay, 76
Drug avoidance
in breast-feeding women, 1127
Drug dependence, 61
principles of treatment, 63
psychic, physical, 61
Drug-eluting stents, 27
Drug generations, 54
Drugs for treatment of cough
classification, 356
Drug-induced
abnormalities of taste and smell, 46
acceleration of drug metabolism, 66
anaemias, 519</p>
<p>anorexia, 584
anti-muscarinic side effects, 305
behavioural toxicity, 47
bronchospasm, 372
carcinogenesis, 47
cardiotoxicity, 46
constipation, 620
cough, 356
dermal toxicity, 46
diarrhoea, 608
electrolyte disturbances, 46
endocrine disturbances, 46
extrapyramidal reactions (EPR), 241
fluid retention, 569
gastro-intestinal (GI) toxicity, 45
haemopoietic toxicity, 45
hemolysis, 520
hepatotoxicity, 45
hyperglycemia, 918
hyperprolactinemia, 945
hypertension, 444
hyperuricemia, 1070
hypoglycemia, 918
iatrogenic diseases, 47
immunosuppression, 47
infertility, 46, 979
inhibition of drug metabolism, 66
insomnia, 127
methemoglobinemia, 520
nephrotic syndrome, 576
nephrotoxicity, 575
neutropenia, 521
ocular toxicity, 46, 1045
osteoporosis, 1009
ototoxicity, 46
parkinsonism, 232
prolongation of QTc, 387
psychiatric syndromes, 230
renal toxicity, 46
sedation, 123
seizures, 143
serotonergic reaction, 219
sexual impotence, 984</p>
<p>skin disorders, 1035
teratogenicity, 47, 1121
thrombocytopenia, 521
thyroid disease, 883
vomiting, 596
weight gain, 584
Drug information
sources, 5
Drug interactions, 63
outside the body, 64
pharmacodynamic, 67
pharmacokinetic, 65
Drug invention, 68
Drug metabolism
factors affecting, 20
Drug poisoning
acute treatment, 48
antidotes, 48
Drug-prescription
during pregnancy, precautions, 1123
for women of reproductive age, 1123
Drugs used in pregnancy
USFDA categories, 1122
d-Tubocurarine (curare), 317
Dulaglutide, 906
Duloxetine, 216, 221
Dunomycin, 835
Duoluton, 969
Dutasteride, 990
Dydrogesterone, 958
Dydrogesterone (dehydrogesterone), 955
Dyes
as antiseptics, 853
Dynorphins, 151
Dysfunctional uterine bleeding (DUB), 957
management of, 959
Dysmenorrhoea
therapy of, 960
Dyspepsia
treatment, 579</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="e">E<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#e" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Ebstein's anomaly, 1121
Ecallantide, 331, 497
Ecamsule, 1033
Echinocandins, 714
Echothiophate, 295
Econazole, 711
Ecothiophate, 295
Eculizumab, 1065
Eczema, 1026
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">E</mi><mi mathvariant="normal">D</mi></mrow><mn>50</mn></msub><mo separator="true">,</mo><mn>39</mn></mrow><annotation encoding="application/x-tex">\mathrm{ED}_{50}, 39</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">ED</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">50</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">39</span></span></span></span></span>
Edema
cardiac, 568
cerebral, treatment, 569
cirrhotic, 568
drug-induced, 567
management, 567
nutritional, 569
pulmonary, 569
renal, 569
Edible oils, 617
Edoxaban, 484
Edrophonium, 293
in cardiac arrythmics, 394
in snake bite, 1069
Estrogens, 947
classification, 948
conjugated equine, 950
for prostate cancer, 837
pharmacological actions, 948
preparations, 950</p>
<p>receptors, 948
therapeutic uses, 951
Efalizumab, 1065
Efavirenz, 745
Efflux transporters, 12
Efinaconazole, 712
Eflornithine
in hirsutism, 988
Eflornithine hydrochloride, 805
E. histolytica
life cycle of, 793
Eicosanoids
biosynthesis, 348
Electrolytes
functions of, 523
Electrophysiology
of cardiac tissue, 380
Electroversion
in cardiac arrhythmias, 397
Eltrombopag, 518
Elvitegravir, 746
Emedastine
in conjunctivitis, 331
Emetics
classification, 595
therapeutic uses, 596
Emetine, 797
Emollients
in psoriasis, 1028
Emtricitabine, 744
Enalapril, 430
Enalaprilat</p>
<p>in hypertensive crises, 444
Enantiomers, 30
Encainide, 390
Endemic goitre, 877
Endocannabinoids, 229, 351
Endocrine physiology, 860
Endocytosis, 12
Endogenous opioids, 151
Endometriosis
drugs used in, 961
therapy of, 961, 979
Endomorphins, 151
Endosulfan, 858
Endothelin (ET), 445
Endotracheal route, 10
Endrin, 857
Enemas, 618
evacuant, 6
retention, 6
Energy balance
neuropeptides affecting, 580
regulation, 580
Energy metabolism
physiology of, 885
Enflurane, 102
Enfuvirtide, 746
Enkephalins, 151
Enoxaparin, 483
Enprostil, 631
Entacapone, 236
Entecavir, 811
Enteral route, 6</p>
<p>Enteric coating, 7
Enteric nervous system (ENS), 254
Enterohepatic cycling, 22
Entry inhibitors, 746
Enzyme induction, 20
Enzyme inhibition, 31
Enzyme linked immunoabsorbent assays, 79
Enzyme stimulation, 31
Ephedrine, 273, 364, 366
in bronchial asthma, 368
Epidermal growth factor
receptor (EGFR) inhibitors, 1064
Epidural route, 9
Epilepsy
and Pregnancy, 143
choice of therapy, 145
drug therapy, 144
focal therapy, 146
grand mal, therapy, 144
neurophysiology, 131
pathophysiology, 131
petit mal, therapy, 144
points to remember, therapy, 148
principles of management, 141
types, 129
Epirubicin, 835
Eplerenone, 431, 566
Epoetin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi><mo separator="true">,</mo><mn>508</mn></mrow><annotation encoding="application/x-tex">\beta, 508</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">508</span></span></span></span></span>
Epoprostenol (PGI2), 351, 479
Epoxide hydroxylases (EH), 19
Eprosartan, 430
Epsilon aminocaproic acid (EACA), 496</p>
<p>Eptifibatide, 480
Erectile dysfunction, 984
sexual impotence, 983
Ergocalciferol (Vitamin D), 999
Ergolines
adverse reactions, 237
Ergometrine, 279, 636, 638
Ergosine, 636
Ergot alkaloids
classification, 636
pharmacological actions, 636
Ergotamine, 636
in migrain, 342
Ergotoxin, 636
Erlotinib, 841
Ertapenem, 694
Erythema nodosum leprosum (ENL)
treatment, 773
Erythromycin, 598, 675
drug interactions of, 676
in syphilis, 737
preparations, 675
prokinetic, 598
Erythropoiesis, 499
Erythropoietin, 352, 508
Escitalopram, 212
Eslicarbazepine, 136
Esmolol, 280, 391
in hypertensive crises, 444
Esomeprazole, 629
Estradiol, 950
ethinyl, 950</p>
<p>succinate, 950
transdermal, 950
valerate, 950
Estramustine, 832
Estriol
succinate, 950
Estrogens, 944
classification, functions, 948
in malignancy, 837
pharmacological actions, 948
receptors, 948
Estrogen-progestin combination
pill, 964
Eszopiclone, 117
Etanercept, 1079
in psoriasis, 1030
Ethacridine lactate, 975
Ethacrynic acid, 564
Ethambutol, 752
for MAC, 765
Ethamsylate, 497, 959
Ethane, 1100
Ethanol, 122
as antiseptic, 847
as hypnotic, 122
Ethanolamine oleate, 498
Ethics committee, 71
Ethinylestradiol, 972
transdermal patch, 972
Ethionamide, 754
in leprosy, 769
in tuberculosis, 754</p>
<p>Ethohexadiol
as mosquito repellent, 792
Ethopropazine, 196
Ethosuximide, 136
Ethoxy scleral, 498
Ethyl alcohol (ethanol), 87
as antiseptic, 847
Ethyl chloride, 103
Ethylenediamine tetraacetic
acid (EDTA), 490
Ethylene glycol, 96
Ethylene oxide, 854
Ethylestrenol, 986
Ethynodiol diacetate, 958, 970
Etomidate, 107
Etonogestrel implant, 972
Etoposide, 836
Etoricoxib, 181
Etravirine, 745
Etretinate, 1108
in psoriasis, 1029
Eucalyptus oil, 357
Eugynon 30, 969
Eusol, 851
Eutectic mixture, 249
Everolimus, 1068
Excitatory amino acids (EEA), 85
Exemestane, 837
Exenatide, 905
Exertional angina,
acute attack, therapy, 410
chronic prophylaxis, 410</p>
<p>principles of treatment, 410
Expectorants types of, 357
Extrapyramidal syndromes
therapy, 241
Eye anatomy and physiology, 1037
classification, drugs used in, 1039
Ezetimibe, 590
Ezogabine, 140</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="f">F<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#f" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>5-Fluorouracil, 834
Fluorouracil
for ocular disorders, 1044
Factor Xa inhibitors, 484
Famciclovir, 810
Familial mediterranean fever
colchicine for, 1072
Famotidine, 630
Febuxostat, 1074
Felodipine, 408
Femilon, 969
Fenfluramine, 582
Fenofibrate, 591
Fenoldopam, 272
in hypertensive crises, 444
Fenoprofen, 179
Fenoterol, 277, 364, 366
Fentanyl, 107, 162
Fenthion, 295
Fenticonazole, 712
Feropenem, 694
Ferric carboxymaltose, 506</p>
<p>Ferric gluconate, 506
Ferrous fumerate, 503
Ferrous gluconate, 503
Ferrous sulfate, 503
Fertility control, 963
Ferumoxytol, 506
Fesoterodine, 305
Fetal alcohol syndrome, 89
Fexofenadine, 329
Fibrates, 591
Fibre, 591
Fibrin, 494
Fibrino agents, 490
Fibrinogen
human, 495
Fidaxomicin, 677
Filariasis
drug therapy, 821
mass treatment, 824
prophylaxis, 823
Filgrastim, 517
Filtration
for sterilisation, 845
Finasteride
benign prostatic hyperplasia (BPH), 990
in alopecia, 1031
Fingolimod, 244
Fish oil, 592
Flavin containing monooxygenases (FMOs), 19
Flavonoids, 4, 1116
Flavoxate, 305
Flecainide, 390</p>
<p>Floppy baby syndrome, 115
Flucloxacillin, 671
Fluconazole, 713, 1019
Flucytosine, 711
Fludrocortisone, 937
in orthostatic hypotension, 446
Fluke infestations
drug therapy, 826
Flumazenil, 116
Flunarizine, 328
Flunisolide, 370
Fluocinolone acetonide, 932
Fluorescein, 1045
Fluoride, 1009
Fluoroquinolones, 657
for MAC, 765
in bacillary dysentery, 706
in leprosy, 768
in MDR tuberculosis, 761
in tuberculosis, 754
in typhoid fever, 705
in UTI, 731
therapeutic uses, 660
Fluoxetine, 216, 219, 582
in panic disorder, 211
Fluoxymesterone, 982
Flupentixol, 195
Fluphenazine, 196
Flurazepam, 115
Flurbiprofen, 179
Fluspirilene, 195
Flutamide, 838, 988</p>
<p>Fluticasone, 369, 370, 932
Fluvastatin, 590
Fluvoxamine, 216
Folate
metabolic actions, 515
Folic acid (pteroyl mono-glutamic
acid), 515
inhibitors, 519
homocysteinemia prevention, 593
therapeutic uses, 516
Folinic acid, 517
Follitropin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi><mo separator="true">,</mo><mn>944</mn></mrow><annotation encoding="application/x-tex">\alpha, 944</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">944</span></span></span></span></span>
follitropin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi><mo separator="true">,</mo><mn>944</mn></mrow><annotation encoding="application/x-tex">\beta, 944</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">944</span></span></span></span></span>
Fomepizole, 96
Fomivirsen, 811
Fondaparinux, 484
Formaldehyde, 847
Formoterol, 368
Formulary, 5
Fortified benzylpenicillin, 663
Fosamprenavir, 745
Foscarnet sodium, 811
Fosfomycin, 687
in UTI, 731
Fosinopril, 429
Fosphenytoin sodium, 134
Framycetin, 686
Free radicals, 1115
Frovotriptan, 339
Fulvestrant, 838
Fungal infections, 708
Fungi</p>
<p>and infections, 708
Furazolidone, 657
in giardiasis, 807
Furosemide, 563
in hypercalcemia, 995
Furuncle, 1015
therapy, 1018</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="g">G<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#g" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Gabapentin, 138
for MDP, 207
in chronic neuropathic pain, 186
Gabapentin-encarbil, 139
Galantamine, 243
Gallstones
therapy of, 579
Gamma amino butyric acid (GABA), 84
receptors, 113
Gamma benzene hexachloride (GBHC), 856, 1022
in pediculosis, 1023
Gamma globulin, 814
Gamma-hydroxybutyric acid, 226
Gamolenic acid, 961
Ganciclovir, 811
Ganglion blocking agents/drugs, 312
in hypertension, 421
Ganglion stimulating drugs, 308
Ganirelix, 942
Gases, 8
therapeutic, 1092
toxic, 1098
Gastric secretion</p>
<p>phases of, 623
physiology, 621
Gastritis
acute erosive treatment, 634
Gastroesophageal reflux disease (GERD), 634
treatment, 635
Gastrointestinal (GI) motility
and drugs, 612
regulation of, 610
Gatifloxacin, 660
Gating theory, 32
Gefitinib, 841
Gelatin polymers, 472
Gel foam, 494
Gemcitabine, 834
Gemeprost, 641
medical termination of
pregnancy (MTP), 975
Gemfibrozil, 591
Gemifloxacin, 659
General anaesthesia, 99
drugs administered during, 110
methods of administration, 98
stages, 99
General anaesthetics, 97
classification, 97
gaseous, 103
inhalational, 98
mechanisms of action, 97
non-volatile, 104
volatile liquid, 101
General anxiety disorder</p>
<p>treatment, 211
Genetic engineering, 3
Genistein, 3
Genital herpes
drug therapy of, 742
Genital warts
drug therapy of, 741
Gentamicin, 685
for bacterial endocarditis, 685
for gram negative bacillary infections, 685
Gentian violet, 853
Gentuzumab, 1065
Gepirone, 209
Gestodene, 957
Gestrinone, 979
Ghrelin, 580
GH-RH, 867
GH-RIH (somatostatin), 869
GI motility
regulation, 610
GI protectives
in diarrhoea, 606
Giardiasis
chemotherapy, 807
Ginger, 599
Ginkgo biloba, 243
Ginkgolides, 354
Glatiramer acetate, 244, 1069
Glaucoma acute congestive treatment, 1043
chronic, open angle treatment, 1044
drug therapy of, 295
Glibenclamide, 899</p>
<p>Gliclazide, 899
Glimepiride, 899
Glipizide, 899
GLP-1, 904
GLP-1 agonists, 905
Glucagon, 473, 917
in shock, 473
Glucocorticoids, 359, 924
actions, 924
adverse reactions, 929
adverse skin reactions, 930
as immunosuppressants, 1067
comparison, 928
drug interactions, 931
for cough, 359
for pharmacological therapy, 933
for replacement therapy, 932
in anaphylactic shock, 327
in asthma, 368
in gout, 1072
in heart block, 397
in hypercalcemia, 996
in IBD, 653
in malignancy, 838
in psoriasis, 1028
in rheumatoid arthritis (RA), 1077
in the eye, 1041
intra-articular, 1081
in tuberculosis, 763
in thyroid disorders, 884
preparations, 931
synthetic, 930</p>
<p>therapeutic uses, 932
therapy, precautions during, 935
topical preparations, 932
Glucomannan, 583
Glucosamine, 1082
Glucose-6-phosphate
dehydrogenase (G6PD) deficiency, 59
anemia due to, 520
Glutaraldehyde, 847, 1035
Glycerin, 615
Glycerol, 558
Glycerrhiza, 357
Glyceryl guaiacolate, 357
Glyceryl trinitrate
mechanism of action, 404
Glycopeptide antibiotics, 679
Glycoprotein IIb/IIIa antagonists, 480
Glycopyrrolate, 305
Glycosides, 4
GnRH (LH-RH), 939, 941
GnRH (LH-RH) agonists
benign prostatic hyperplasia (BPH), 990
GnRH (LH-RH) analogues, 942
GnRH (LH-RH) (gonadorelin), 942
Goitres
non-toxic, 876
Goitrogens, 878
Gold salts, 1077
in rheumatoid arthritis (RA), 1077
Golimumab, 1079
in psoriasis, 1030
Gonadorelin, 942</p>
<p>Gonadotropins, 943
human, chorionic, 943
human menopausal, urinary, 944
physiology, 938
Gonorrhoea
antimicrobial regimens for
acute uncomplicated drug
therapy of, 739
antimicrobial regimens for
acute complicated drug
therapy of, 740
Goserelin acetate, 942
Gossypol, 975
Gout diet in, 1071
drug used in, 1071
long term therapy of, 1073
pathophysiology, 1070
pharamacotherapy of, 1071
G-proteins, 36
Gramicidine, 687
Granisetron, 341, 597
Granuloma inguinale drug therapy of, 741
Gray baby syndrome, 704
Gripe water mixtures, 579
Griseofulvin, 709
Groundnut oil, 587
Growth hormone (GH), 866
deficiency, treatment, 868
Guaifenesin, 357
Guanabenz, 420
Guanethidine, 421
Guanfacine, 420</p>
<p>Guar gum, 583
Gugulipid, 591
Guinea worm
drug therapy of, 824
Gums, 4
Gynovlar 21, 969</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="h">H<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#h" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>5-Hydroxytryptamine (5-HT, serotonin), 84, 333
5-Hydroxytryptamine (5-HT, serotonin) receptors, 333
agonists, 337, 338
antagonists, 338
classification, 333
depletors, 338
functions of, 335
in metabolism, 337
significance, migraine, 334
synthesis, 333
uptake inhibitors, 338
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor antagonists
classification, 327
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor antagonists, 332
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors, 332
Halibut liver oil, 1107
Haliv, 616
Hallucinogens, 227
Halofantrine, 782
Haloperidol, 200
Halothane, 101
Harmine, 228
Heart failure
chronic prevention, 464</p>
<p>diastolic, 450
management, protocol, 462
non-pharmacological treatment, 464
pathophysiology, 448
Heat
as sterilisation, 845
Heavy metals, 1083
antagonists, 1087
as antiseptics, 853
Helium, 1098
Helminthiasis
drugs used in, 816
Hemochromatosis, 507
Hemolysis
drugs causing, 520
Hemophilia
therapy, 495
Hemorrhoids
treatment of, 620
Hemostasis, 476
Hemostatic agents, 495
Hemostatic therapy, 494
drugs used for, 494
Heparin, 481
low molecular weight, 483
preparations and dosage, 482
regimens, 482
antagonists, 484
Hepatitis B globulin (HBIG), 1059
Hepatitis B vaccine, 1055
Herbal remedies, 52
Heroin, 160</p>
<p>Herpes simplex
local therapy of, 1018
therapy of, 810
Herpes zoster
therapy of, 810
Hexachlorophane, 850
Hexane, 1100
Hiccup therapy, 200, 1097
High altitude illness
treatment of, 559
Hirsutism
drugs therapy, 989
management, 988
Hirudin, 484
Histamine, 322
biosynthesis, 322
in anaphylaxis and allergy, 326
liberators, 326
receptors, functions, 323
HIV and MAC, 766
HMG-CoA reductase
inhibitors, 588
Homatropine methylbromide, 305
Homeopathy, 1
Hookworm (ancylostomiasis)
drug therapy of, 819
Hormone, 860
Hormone receptors, 864
Hormone replacement therapy (HRT), 952
in osteoporosis, 1009
regimens, 954
contraindications of, 954</p>
<p>Hormones, 860
as drugs, 864
differences between peptides
and steroids, 863
in cancer, 837
H. pylori infection
in peptic ulcer, 621
treatment of, 633
Human growth hormone (hGH)
recombinant, 868
Human immunodeficiency virus (HIV)
drug therapy of, 742
life cycle and pathophysiology, 742
post-exposure prophylaxis (PEP), 747
Human normal immunoglobulin (HNI), 1062
Human papilloma virus vaccine, 1054
Human recombinant IL-2, 354
Human serum albumin, 470
Hyaluronic acid, 1034
Hyaluronidase, 1101
Hydergine, 636
Hydnocarpus oil, 770
Hydralazine, 426
Hydrion, 538
Hydrocarbons
poisoning, 1100
Hydrochlorothiazide, 562
Hydrocodone, 159
Hydrocortisone, 928
Hydroflumethiazide, 562
Hydrogen peroxide, 852
Hydromorphone, 159</p>
<p>Hydroquinone
for skin pigmentation, 1032
Hydroxocobalamin, 510, 514
in cyanide poisoning, 1100
Hydroxychloroquine, 781
Hydroxyethyl starch, 471
Hydroxyprogesterone caproate, 958
in endometrial cancer, 838
Hydroxyurea, 831, 839
in polycythemia vera, 835
Hydroxyzine, 1017
for pruritus, 1017
Hyoscine-N-butyl bromide, 304
Hyperaldosteronism, 937
Hyperbaric oxygen, 1096
in cyanide poisoning, 1100
Hypercalcemia, 994
causes, 994
management, 995
Hypercalciuria, 993
Hyperglycemic agents, 917
Hyperkalemia, 537
treatment of, 538
Hyperlipoproteinemias (hyperlipidemia)
classification, 586
diet therapy, 586
diet therapy, principle, 587
indication for drug therapy, 585
Hypernatremia, 533
treatment, 534
Hyperpituitarism
effects of, 866</p>
<p>Hyperprolactinemia, 945
Hypersensitivity (drug allergy), 43
Hypersomnia, 124
Hyperstimulation syndrome, 944
Hypertension
aetiology, 416
choice of drugs, 436
drug combinations in, 436
in diabetics, 418
in elderly, 439
in pregnancy, 440
isolated systolic, 440
lifestyle modification, 433
management with drugs, 436
pharmacotherapy, 433
principles of drug therapy, 435
supportive treatment, 441
Hypertensive crises, 442
drugs used in, 443
treatment, 441
Hyperthyroidism
Graves' disease, 881
therapy of, 881
Hypertonic saline, 472, 532
Hyperuricemia
diet for prevention and
treatment, 1071
drugs induced, 1070
Hypnotics, 113
classification, 113
definition, 113
Hypocalcemia</p>
<p>causes, 994
Hypocalciuria, 993
Hypodermoclysis, 8
Hypogammaglobulinemia, 1063
Hypoglycemia, 894
symptoms of, 895
principles of management, 896
unawareness, 895
unresponsiveness, 895
Hypogonadism
use of testosterone in, 983
Hypokalemia, 535
causing digoxin toxicity, 457
treatment of, 537
Hypomagnesemia
common causes of, 1011
Hyponatremia, 532
Hypoparathyroidism, 1004
management, 1004
Hypophosphatemia, 997
management, 997
Hypopituitarism, 866
effects of, 866
Hyposensitisation, 379
Hypothalamic regulatory hormones, 862
Hypothalamo-pituitary-ovarian relationship, 940
Hypothalamus
role of, 862
Hypothyroidism
treatment of, 876
Hypotonic saline, 472
Hypoxemia, 1094</p>
<p>Hypoxia
treatment of, 1094</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="i">I<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mn>131</mn></msup></mrow><annotation encoding="application/x-tex">{ }^{131}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8141em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">131</span></span></span></span></span></span></span></span></span></span></span></span></span>-Iodine-tositumomab, 840
Ibandronate, 1007
Ibuprofen, 179
Ibutilide, 392
Ichthammol, 1019
Icosapent ethyl, 592
Idarubicin, 835
Idoxuridine, 809
IGF 1, 867
IGF 1, rDNA, 869
IL-1 receptor antagonist
in RA, 1079
Iloperidone, 202
Iloprost, 351
Imatinib, 840
Imidazoles, 711
Imidazoline derivatives, 279
Imipenem, 694
cilastatin combination, 694
Imipramine, 214
drug interactions of, 217
in nocturia, 307
Imiquimod
in genital warts, 742
Immunisation
active, 1050
passive, 1056
Immunisation schedule, 1056</p>
<p>Immunity, 1046
active, 1049
passive, 1049
Immunoassay, 78
Immunoglobulin Ig, 1050
intravenous (IV-Ig), 1063
Immunoglobulins, 1062
anti D, 1059
biological properties, 1048
Immunomodulators, 1068
in atopic dermatitis, 1026
Immunostimulants, 1068
Immunosuppressants, 1066
classification, 1066
in IBD, 654
in rheumatoid arthritis, 1080
in the eye, 1044
Impetigo, 1017
Implanton, 972
Impotence
drugs used in treatment, 985
sexual, erectile dysfunction, 984
Impromidine, 324
Incretinomimetic, 904
Indacaterol, 364
Indandione derivaties, 487
Indapamide, 432, 563
Indocyanine green, 1045
Indomethacin
as tocolytic, 642
in gout, 1072
Indoramin, 280, 424</p>
<p>Induction of abortion
therapeutic termination of pregnancy, 975
Induction of labour, 640
Infantile spasms, 145
Inflammatory bowel disease (IBD), 652
Infliximab, 654, 1079, 1065
in psoriasis, 1029
Informed consent, 71
Inhalation, 8
Injections, 8
Inositol, 1108, 1112
Insecticides
classification, 856
Insomnia
chronic, 124
in elderly, pharmacotherapy, 127
non-pharmacological therapy, 124
pharmacotherapy, 123
principles of therapy, 125
Insulin
actions on target organs, 890
adverse reactions, 894
analogues, 893
aspart, 893
comparison, 894
degludec, 893
detemir, 893
glargine, 893
glulisine, 893
human, standard recombinant, 892
indications in diabetes mellitus (DM), 910</p>
<p>inhaled, 894
lispro, 893
mechanism of action, 889
preparation, route and time of administration, 897
preparations, 892
resistance, 915
sensitisers, 903
synthesis, release and storage, 887
therapeutic uses of, 897
time course of actions, 895
Integrase strand transfer inhibitor (INSTI), 746
Interferon (INF) alpha-n1, 814
Interferon (INF) alpha-n3, 814
Interferon (INF) alpha 2a, 814
Interferon (INF) alpha 2b, 814
Interferon (INF) beta 1a, 814
Interferon (INF) beta 1b, 814
Interferon (INF) beta, 244
Interferons (INF), 352, 813
as immunomodulator, 1069
Interleukin, 352
Intra-arterial route, 9
Intra-articular route, 9
Intracavernosal route, 9
Intradermal (ID) route, 8
Intra-lesional, 9
Intramuscular (IM) route, 8
Intraosseous (intramedullary) route, 8
Intraperitoneal route, 9
Intrathecal route, 9
Intrauterine contraceptive
devices (IUCD), 973</p>
<p>Intravenous (IV) route, 8
Inverse agonists, 33
Inunction, 10
Iodide, 879
Iodine, 851, 877
Iodine containing contrast media, 884
Iodine glycerin preparation (Mandl's Paint), 852
Iodine tincture, 851
Iodochlorohydroxyquinoline, 796
Iodophors, 852
Ion channel, 36
Ionisation, 3
Ionising radiation, 846
Ionodilator effect, 461
Iontophoresis, 9
Ipecacuanha
as emetic, 595
as expectorant, 358
Ipodate, 880
Ipratropium, 305
Ipratropium bromide, 367
Iproniazid, 212
Ipsapirone, 209
Irbesartan, 430
Irinotecan, 836
Iron
adjuvants to therapy, 507
metabolism, 499
oral, ADR, 505
oral, preparations, 503
parenteral, ADR, 507
parenteral, indications, 505</p>
<p>parenteral preparations, 506
poisoning, treatment, 507
requirements, 503
Iron absorption
factors affecting, 501
Iron and ammonium citrate, 503
Iron deficiency anemia
treatment, 504
Iron dextran, 506
high molecular weight, 506
low molecular, 506
Iron saccharate, 506
Iron-sorbitol-citric acid complex, 506
Iron therapy
indications, 504
Irritable bowel syndrome (IBS)
diarrhoea in, 608
therapy, 609
Irritation, 31
Isapgol, 616
Isavuconazole, 714
Isconazole, 712
Isocarboxazid, 212
Isoetharine, 277, 364
Isoflurane, 102
Isonicotinic acid hydrazide (INH), 749
Isopropamide, 609
Isoprenaline (isoproterenol, isopropyl arterenol), 271
in cardiac arrhythmias, 397
in shock, 473
Isopropyl alcohol, 847
Isosorbide dinitrate, 404</p>
<p>Isosorbide mononitrate, 404
Isotretinoin, 1022, 1108
in acne, 1025
Isoxsuprine hydrochloride, 277
Isradipine, 408
Itopride, 598
Itraconazole, 712, 1019
Ivabradine, 410
Ivermectin, 820, 823
in onchocerciasis, 823
in pediculosis, 1023
in scabies, 823, 1022
Ixabepilone, 835</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="j">J<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#j" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Jarisch-Herxheimer reaction, 665, 738
Jet injection, 10
Jod-Basedow effect, 879</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="k">K<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#k" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Kala-azar (visceral leishmaniasis), 801
drug therapy, 802
life cycle, 801
Kallidin, 345
Kallikreins, 345
Kallman syndrome, 942
Kanamycin, 685, 754
Kaolin, 606
Karaya gum, 583
Katayama's fever, 825
Keratolytic agents, 1017
Kerosene</p>
<p>as pediculocide, 1023
Ketamine, 106
Ketanserin, 280, 340
Ketoconazole, 712
Ketolide antibiotic, 677
Ketoprofen, 179
Ketorolac, 179
Ketotifen, 371
in conjunctivitis, 331
Kinins, 345
Korsakoff's psychosis, 1108
Kurchi, 798</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="l">L<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#l" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>LABA, 368
l-alpha tocopherol, 1108
Labetalol, 280, 285, 425
in hypertensive crises, 444
Lacosamide, 140
Lactitol, 615
Lactulose, 615
Lambert-Eaton syndrome, 294
Lamivudine, 744, 811
Lamotrigine, 139
adjunctive for MDP, 206
Lanreotide, 838, 869
Lansoprazole, 629
Lapatinib, 841
Laquinimod, 244
Larva migrans
therapy of, 822
L-Asparaginase, 839</p>
<p>Latanoprost, 351, 1039, 1044
Laxatives
classification of, 612
harmful effects, 619
therapeutic uses, 617
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">L</mi><mi mathvariant="normal">D</mi></mrow><mn>50</mn></msub><mo separator="true">,</mo><mn>39</mn></mrow><annotation encoding="application/x-tex">\mathrm{LD}_{50}, 39</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">LD</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">50</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">39</span></span></span></span></span>
Lead, 1084
Lead poisoning, 1085
Ledipasvir, 812
Leflunomide
in rheumatoid arthritis, 1078
Left ventricular failure (LVF)
acute, management, 463
Lemon
as pharyngeal demulcent, 357
Lenalidomide, 1069
Lenograstim, 518
Lepirudin, 484
Lepra reactions, 772
Leprosy
dapsone resistant drugs used in, 772
drug and duration, 771
drugs used in, 768
management of, 770
multibacillary, treatment, 771
paucibacillary, treatment, 771
prophylaxis, 773
types, 767
WHO regimen in, 771
Leptin, 580
Letrozole, 837
for ovulation induction, 978</p>
<p>Leucorrhoea, 806
Leukotriene modifiers, 368
Leukotrienes (LTs), 346
Leuprorelin acetate, 942
Levallorphan, 166
Levamisole (l-tetramisole), 819
as immunomodulator, 1069
Levetiracetam, 140
Levocabastine
in conjunctivitis, 331
Levodopa, 219, 233
adverse reactions, 234
drug interactions, 235
Levodropropizine, 359
Levofloxacin, 659
Levomethadyl acetate, 163
Levonorgestrel, 954, 970
implant, 972
releasing IUD, 959
Levopropoxyphene mesylate, 359
Levorphanol, 163
Levosalbutamol, 366
Levothyroxine, 875
LH-RH agonists
in malignancy, 838
Ligands, 32
Light Kaolin, 606
Lignocaine, 249, 359
in anal fissure, 620
in cardiac arrhythmias, 389
Limonoids, 859
Linaclotide, 617</p>
<p>Linagliptin, 904
Lincomycin, 678
Linezolid, 681
in tuberculosis, 755
Lipid diffusion, 11
Lipid lowering drugs
choice of, 593
effects on lipid fractions, 591
Lipoproteins, 584
Liposomes, 27
Lipotropic factors, 1113
Liquid paraffin, 617
Liquor ammonia, 192
Liraglutide, 906
Lisinopril, 429
Lisuride, 946
Lithium, 224
for MDP treatment, 206
in chronic alcoholism, 94
in hyperthyroidism, 880
Local anaesthetics
classification, 245
in the eye, 1045
mechanism of action, 246
prevention of toxicity of, 247
therapeutic uses, 247
Local application, 6
Local eye
therapy, principles, 1039
Local hormones
ACh and NA, 261
Loestrin, 969</p>
<p>Loestrin, 1/20, 969
Loestrin, 24 Fe, 968
Lomefloxacin, 659
Lomustine, 831
Loop diuretics, 563
Loperamide, 162, 607
Lopinavir, 745
Losartan, 430
Loratadine, 328
Lorazepam, 115
anxiety disorders, 210
as anti-convulsants, 139
in status epileptics, 146
Lorcaserin, 582
Lornoxicam, 180
Lovastatin, 588
Lubiprostone, 617
Lugol's iodine, 880
Lugol's solution, 851
Lumefantrine, 783
Lutropin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi><mo separator="true">,</mo><mn>944</mn></mrow><annotation encoding="application/x-tex">\alpha, 944</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">944</span></span></span></span></span>
Lymecycline, 701
Lymphogranuloma venereum drug therapy of, 740
Lynestrenol, 958
Lysergic acid
diethylamide (LSD), 227, 338
Lysine-8-vasopressin, 574
Lysol, 850</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="m">M<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#m" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>4-Methyl pyrazole, 96
6-Mercaptopurine, 833</p>
<p>Macitentan, 446
Macrolides, 675
in tuberculosis, 755
Macrolides, newer, 677
Mafenide, 650
Magnesium
as anti-convulsant, 1012
in cardiac arrythmias, 393
metabolism, 1011
salt, therapeutic uses of, 1012
Magnesium carbonate, 615, 626
Magnesium citrate, 615
Magnesium peroxide, 852
Magnesium sulfate (epsom salt), 614
as tocolytic, 643
Magnesium trisilicate, 626
Maintenance dose, 24
Major Depression
pharmacotherapy, 220
Mala D, 969
Malaria
acute attack, treatment, 786
chemotherapy in children, 789
chemotherapy in pregnancy, 789
chloroquine resistant, treatment, 790
chloroquine sensitive, treatment, 788
eradication, 791
in G6PD deficient persons, 790
management of, 786
MDR, treatment, 791
prophylaxis, 786
radical cure in, 791</p>
<p>recrudescence, 791
parasite life cycle, 774
Malarone, 783
Malathion, 295
in pediculosis, 1023
Male hypogonadism, 981
Malignancy
palliative treatment, 842
principles, 842
Malignant hyperthermia, 110
dantrolene for, 321
Malignant diseases
drug therapy, 841
Mandl's paint (iodine glycerin preparation), 851
Mannitol, 557
contraindications to, 557
Mansonelliasis
treatment, 824
MAO inhibitors, 213
hypertensive crisis, 213
potentiation of action of
other drugs, 214
hypertensive crisis, 213
MAO-B inhibitors, 236
parkinsonism, 236
Maprotiline, 216
Maraviroc, 746
Materia Medica, 1
Martindale, The Complete
Drug Reference, 5
Mastocytosis, 331
M. avium complex (MAC)</p>
<p>infections, 765
Mazindol, 582
Mazzotti reaction, 822
management, 761
Mebendazole, 817
Mebeverine, 609
Mecasermin, 869
Mechlorethamine, 830
Mecillinam, 674
Meclizine <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">C</mi><mi mathvariant="normal">l</mi></mrow><mo separator="true">,</mo><mn>328</mn></mrow><annotation encoding="application/x-tex">\mathrm{HCl}, 328</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord mathrm">HCl</span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">328</span></span></span></span></span>
Medical termination of pregnancy (MTP), 975
drugs used for, 975
Medroxyprogesterone acetate, 192, 958
Mefenamic acid, 180
Mefloquine, 782
Megaloblastic anemia, 509
Megestrol, 958
as appetite stimulants, 577
in endometrial cancer, 838
Meglitinides
in diabetes mellitus, 901
Meglumine antimonate, 802
Melarsonyl potassium (Mel W), 805
Melarsoprol (Mel B), 804
Melatonin, 111, 123
Meloxicam, 180
Melphalan, 831
Memantine, 243
Menadione, 495
Meniere's disease syndrome, 325, 601
Meningitis
drug therapy of bacterial, 695</p>
<p>tuberculosis, 762
Menopause, 953
Menthol, 356
Menotropins, 944
Mephentermine, 276, 473
Mephenytoin, 519
Mephobarbitone, 135
Mepivacaine, 250
Mepolizumab, 372
Meptazinol, 164
Mepyramine maleate, 327
Mercury poisoning, 1086
Meropenem, 694
Mesalazine, 652
preparations, 653
Mescaline, 228
Mesna, 830
Mesterolone, 982
Mestranol, 950
Metabolic syndrome, 581
Metakelfin
in malaria, 784
Metaraminol, 276, 473
Metaxalone, 315
Metered dose inhalation, 365
Metformin, 583, 901
as anorexiant, 583
Methacholine, 289
Methacycline, 701
Methadone, 162, 358
for cancer induced cough, 358
Methadone congeners, 163</p>
<p>Methandienone, 986
Methane, 1100
Methantheline, 304
Methaqualone, 123
Methazolamide, 560
Methemoglobinemia, 520
vitamin C in, 1114
Methenamine mandelate
in UTI, 731
Methenolone acetate, 986
Methicillin, 671
Methimazole, 878
Methionine, 1112
Methocarbamol, 315
Methohexitone, 104
Methotrexate, 832, 975
as immunosuppressants, 1067
in psoriasis, 1029
medical termination of
pregnancy, 975
in rheumatoid arthritis, 1078
Methoxamine, 276, 473
Methoxsalen, 1029
Methoxy polyethylene glycol epoetin beta, 508
Methscopolamine bromide, 304
Methyl alcohol, 95
Methylamphetamine, 582
Methyl cellulose, 583, 616
Methylcobalamin, 511, 514
Methylcysteine, 360
Methyldihydromorphinone, 160
Methylene blue, 853</p>
<p>in cyanide poisoning, 1100
Methylergometrine, 638
Methylnaltrexone bromide, 165
Methylphenidate, 191, 226
Methylprednisolone, 928, 930
pulse therapy, 933
Methyltestosterone, 982
Methyl xanthines
mechanism of action, 189
Methysergide, 338
Metoclopramide, 338, 597
Metolazone, 563
Metoprolol, 280, 405
Metrifonate, 295, 826
Metrodin, 944
Metronidazole, 794
in giardiasis, 807
in guinea worm infestation, 824
in trichomoniasis, 807
non-specific vaginitis,
drug therapy, 807
Metyrosine, 432
Mexiletine, 389
Mezlocillin, 674
Mianserin, 338
Micafugin, 714
Miconazole, 712, 1019
Microbial drug resistance, 722
Microgynon, 969
Microsomal enzyme systems, 18
Midazolam, 106, 115
as anti-convulsants, 139</p>
<p>in status epileptics, 147
Midodrine, 276
in orthostatic hypotension, 446
Mifepristone, 973
medical termination of
pregnancy, 975
Miglitol, 903
Migraine
acute attack, drugs used in, 342
pathophysiology, 341
pharmocotherapy, 341
prophylaxis, drugs for, 343
Milk-alkali syndrome, 542
Milk of magnesia, 615, 626
Milrinone, 461
Miltefosine, 803
Minamata disease, 1087
Mineralocorticoids, 935
Minipills, 970
Minocycline, 701
in leprosy, 770
Minovlar ED, 969
Minoxidil, 428
in alopecia, 1031
Mipafox, 296
Mirabegron, 307
Mirena, 972
Mirtazapine, 216, 221
Misoprostol, 351, 631, 641
medical termination of
pregnancy, 975
Mithramycin, 835</p>
<p>Mitomicin-C
for ocular disorders, 1044
Mitomycin C, 835
Mitotane, 839
Mitoxantrone, 244
Mivacurium, 319
Mixed agonist-antagonists, 33
Moclobemide, 214
Modafinil, 226
Moebius syndrome, 1121
Moguisteine, 359
Molality, 523
Molgramostim, 517
Molindone, 201
Mometasone furoate, 370
Monoamine oxidase inhibitors (MAOI), 213
hypertensive crisis, 213
potentiation of drug action, 213
Mono-amine oxidase (MAO), 259, 268
Monobactams, 688
in UTI, 731
Monobenzone, 1032
Monoclonal antibodies, 27, 840, 1064
for clinical use, 1065
nomenclature, 1064
types, 1064
Monocrotophos, 295
Monosulphiram, 1022
Mono-unsaturated fats (MFA), 587
Montelukast, 369
Mood stabilisers, 224
Moricizine, 390</p>
<p>Morphazinamide, 752
Morphinan compounds (levorphanol), 163
Morphine, 153
adverse reactions, 156
as analgesic, 153
dependence, treatment, 156
in acute LVF, 158
intrathecal and epidural, 158
pharmacological actions, 153
poisoning, 157
precautions, 158
synthetic substitutes, 160
therapeutic uses, 157
Mosapride, 598
Mosquito repellents, 792
Motion sickness
therapy of, 599
Motor neuron disease (MND)
therapy of, 242
Mountain sickness, 561
acute and cerebral syndrome, 559
Moxifloxacin, 659
Moxonidine, 421
Mucoactive drug, 357
Mucocutaneous leishmaniasis
treatment, 803
Mucolytic agents, 360
Mucosal protective drugs, 631
Mucuna pruriens, 236
Multiple sclerosis (MS), 243
Multivitamin therapy, 1114
Mupirocin, 680</p>
<p>Muromonab, 1065
Muscarine, 290
Muscarinic receptor/s, 286
Mustard
as emetic, 595
Mustard oil, 587
Myasthenia gravis
drugs aggravating symptoms, 295
treatment, 294
Myasthenic crisis, 294
Mycophenolate mofetil, 1067
in psoriasis, 1029
Myocardial infarction
acute, management, 413
treatment, 412
Myotonia congenita
quinine in, 779
Myxedema coma
treatment, 877</p>
<p>N
Nabilone, 229, 598
Nabumetone, 181
Nadifloxacin, 658
Nadolol, 280
Nafarelin, 942
Nafcillin, 671
Naftidofuryl oxalate, 415
Nalbuphine, 163
Nalidixic acid, 657
in UTI, 732
Nalmefene, 165</p>
<p>in chronic alcoholism, 93
Nalorphine, 165
Naloxone, 164
Naltrexone, 165, 583
in chronic alcoholism, 93
Nandrolone decanoate, 986
Nandrolone phenylpropionate, 986
Nanomedicines, 5
Naproxen, 179
Naratriptan, 339
Narcolepsy, 226, 275
treatment, 226
Nasal decongestants, 276
Natalizumab, 244, 654, 1065
Nateglinide, 901
Natriuretic peptide (NP), 528
Natural tolerance, 60
Nebivolol, 280, 285
Nebramycins, 686
Nebuliser, 365
Nebulised solutions, 8
Nedocromil sodium, 371
in conjunctivitis, 331
Neem oil, 859
Nefazodone, 216, 221
Nelfinavir, 745
Neomycin, 686
Neostigmine, 292
for bladder hypotonicity, 307
Neotame, 919
Nerve block, 248
Nesiritide, 452, 529</p>
<p>Netilmicin, 685
Neuralgia
post-herpetic, therapy of, 1018
Neurohumoral transmission, 254
in the ANS, 254
Neurohumoral transmitters, 255
of ANS, 255
Neuroleptanalgesia, 107
Neuroleptic malignant syndrome, 199
Neuroleptics, 195
causes for non-response, 205
equipotent oral doses, 205
Neuromuscular blockers
comparison, 319
competitive, 316
Neuropeptide Y, 580
Neurosyphilis
treatment of, 738
Neurotic disorders, 193
Neurotransmitter
enteric, 611
release, regulation, 85
uptake mechanisms and drugs, 259
Neurotrophic factors, 242
Neutral endopeptidase (NEP), 452
Neutropenia
drugs used in, 517
Nevirapine, 745
Nicardipine, 408
Niclosamide, 824
Nicorandil, 409, 427
Nicotinamide, 1110</p>
<p>Nicotine, 308
chronic, toxicity, 310
dependence, 309
formulations, 312
substitution therapy, 312
Nicotinic acid, 1110
as anti-hyperlipidemic agent, 593
Nicotinic receptors, 287
Nifedipine, 408, 560, 642
as tocolytic, 642
in hypertensive crises, 444
in mountain sickness, 560
Nifuroxime, 657
Nifurtimox, 805
Nightmares, 127
Night terrors, 126
Nikethamide, 191
Nilotinib, 841
Nilutamide, 838
Nimodipine, 409
Nisoldipine, 408
Nitazoxanide
in amoebiasis, 798
in giardiasis, 807
Nitrates
organic, 402
therapeutic uses, 405
Nitrazepam, 115
Nitric oxide, 399, 1098
Nitric oxide synthases (NOS), 399
Nitrofuran compounds, 656
Nitrofurantoin, 656</p>
<p>in UTI, 731
Nitrofurazone, 657
in trypanosomiasis, 805
Nitrogen dioxide, 1099
Nitrogen mustards, 829
Nitroglycerine
as tocolytic, 643
IV in hypertensive crises, 444
Nitroglycerine ointment
in anal fissure, 620
Nitrosoureas, 831
Nitrous oxide, 103
Nitutamide, 988
Nizatidine, 630
N, N diethyl-m-toluamide (DEET), 792
as mosquito repellent, 792
Nociceptin/orphanin FQ, 151
Nocturnal enuresis, 217
Non-barbiturate sedative, 209
Non-benzodiazepine
benzodiazepine receptor agonists, 116
Noncatecholamines, 273
as vasopressor agents, 275
Nociception, 150
Non-gonococcal urethritis (NGU)
drug therapy of, 740
Non-insulin anti-diabetic drugs
parenteral, 905
Non-insulin dependent DM (NIDDM)
management, 912
Non-microsomal enzyme systems, 19
Non-nucleoside reverse trancriptase inhibitors (NNRTI), 744</p>
<p>Non-opioid analgesics, 167
Nonoxynol 9, 963
Non-steroidal anti-inflammatory drugs (NSAID)
and renal damage, 186
anti-inflammatory doses, 187
classification, 169
mechanism of action, 169
properties, 169
Nontuberculous mycobacterial infections, 765
Nootropics, 243
Noradrenaline, 256
in shock, 473
pharmacological actions, 266
therapeutic uses, 271
Norethandrolone, 986
Norethisterone, 951, 958, 970
Norethisterone acetate, 958
Norethisterone enanthate (NET-EN), 971
Norethynodrel, 956, 958
Norfloxacin, 659
Norgestimate, 957
Norgestrel, 970
Norgestrel releasing IUCD, 972
Norelgestromin, 972
Norlestrin, 969
Normal saline, 472
Norplant-2 implant, 972
Nortriptyline, 216
Noscapine, 159, 359
as anti-tussive, 359
Novelon, 969
Nucleoside reverse transcriptase</p>
<p>inhibitors (NRTI), 744, 745
Nutrition enteral, 545
parenteral, 547
requirements in acute illness, 544
total parenteral (TPN), 549
Nutritional requirements
in healthy adults, 543
Nutritional supplementation
indications, 547
Nystatin, 708</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="0">0<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#0" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>22-Oxacalcitriol, 1005
Obesity
classification of drugs, 582
principles of treatment, 581
treatment, 581
Obsessive compulsive disorder
therapy, 217
Obidoxime, 298
Octamethylpyrophosphphotetramide (OMPA), 295
Octreotide, 623, 869
somatostatin analogues, in cancer, 838
Ocular
anti-histaminics and mast cell
stabilisers, 1042
anti-inflammatory drugs, 1041
drug delivery, factors affecting, 1038
toxicity, drug induced, 1045
Ocular drugs
topical, pharmacokinetics, 1038
Ocusert, 27</p>
<p>Ofloxacin, 659
in leprosy, 770
in tuberculosis, 754
Oils
fixed, 4
mineral, 4
volatile, 4
olanzapine, 201
Oil of lemon eucalyptus
as mosquito repellent, 792
Oleondomycin, 676
Oleoresins, 4
Olestra, 583
Olive oil, 587
Olmesartan, 430
Olsalazine, 653
Omalizumab, 371, 1065
Omapatrilat, 452
Omecamtiv mecarbil, 462
Omega-3 PUFA, 592
Omega-3-fatty acids, 587
Omeprazole, 628
Onabotulinum toxin A, 307
Onchocerciasis therapy of, 823
Ondansetron, 340, 599
Onychomycosis
drug therapy of, 710, 1020
Opioid
agonists, 151
in diarrhoea, 607
mechanism of action, 152
mixed agonist-antagonists, 151</p>
<p>partial agonists, 151
analgesics, as preanaesthetic
medication, 109
antagonists, 164
receptors, 152
Opium alkaloids, 153
Oral anti-coagulants, 485
comparisons, 487
factors affecting dosage, 487
Oral anti-diabetic agents, 898
Oral anti-diabetic drug combinations, 905
Oral rehydration solution (ORS)
composition of, 605
WHO recommended, modified, 604
Oral rehydration therapy (ORT), 604
cereal-based (CORS), 605
Orciplasmin, 1045
Orciprenaline, 277, 366
Orgalutin, 969
Organic solvent vapours, 1099
Organophosphorus insecticides, 295, 858
poisoning, treatment, 296
Oriental sore
drug therapy, 803
Orlest, 969
Orlistat, 583
Ormeloxifene, 960, 971
Ornidazole, 795
Orphenadrine <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">C</mi><mi mathvariant="normal">l</mi></mrow><mo separator="true">,</mo><mn>237</mn><mo separator="true">,</mo><mn>315</mn></mrow><annotation encoding="application/x-tex">\mathrm{HCl}, 237,315</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord mathrm">HCl</span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">237</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">315</span></span></span></span></span>
Orthonovin, 969
Orthostatic hypotension, 446
Ovral G, 969</p>
<p>Ovral L, 969
Oseltamivir, 812
Osmotic diuretics, 556
Osmotic laxatives, 614
Ospemifene, 951
Osteoarthritis (OA)
management, 1082
pathophysiology, 1081
Osteomalacia
treatment of, 1004
Osteopenia, 1008
Osteoporosis
post menopausal, prevention
and treatment, 953
principles of management, 1008
Osteoprotegerin, 1007
Ototoxicity
drugs causing, 46
Oxidants
body defences against, 1116
Oxytocics, 636
Oxytocin
for medical termination
of pregnancy, 975
Otilonium bromide, 609
Ouabain, 461
Ovarian hyperstimulation, 977
Ovulation inducing drugs, 976
classification, 976
Oxalate, 490
Oxaliplatin, 832
Oxamniquine, 826</p>
<p>Oxandrolone, 986
Oxantel pamoate, 818
Oxazepam, 115
anxiety disorders, 210
Oxazolidinones, 681
Oxcarbazepine, 136
Oxeladine, 359
Oxiconazole, 712
Oxidised cellulose, 494
Oximes, 298
Oxitropium bromide, 367
Oxprenolol, 280
Oxybutynin, 305
Oxycodone, 184
Oxygen, 1092
adverse reactions, 1093
hyperbaric, 1096
uses, 1094
Oxymesterone, 986
Oxymetazoline, 276
Oxymetholone, 986
Oxymorphone, 160
Oxypertine, 195
Oxyphenonium, 304
Oxytetracycline, 700
Oxytocin, 638
Ozone, 1099</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="p-mathbf-p-p"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="bold">P</mi></mrow><annotation encoding="application/x-tex">\mathbf{P}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6861em;"></span><span class="mord mathbf">P</span></span></span></span></span><span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#p-mathbf-p-p" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Packed red cells, 469
indications for, 469
Paclitaxel, 836
Paget's disease
of bone, 1007
Pain
acute, thereby, 183
anti-depressants in, 185
of chronic cancer, therapy, 185
of chronic neuropathic, therapy, 186
dull aching, chronic, 183
in inflammatory conditions, therapy, 184
local treatment of, 186
pathways and types, 149
Palanosetron, 341
Paliperidone, 202
Palivizumab, 812, 1065
Pamaparin, 483
Pamidronate, 1007
Pancreatin, 578
Pancuronium, 319
Panic disorder, 211
Panitumumab, 840, 1065
Pantoprazole, 629
Papain, 578
Papase, 1103
Papaverine, 159
Para-aminobenzoic acid, 1112
Para-aminosalicylic acid (PAS), 755
Paramomycin</p>
<p>in giardiasis, 807
Parasomnia, 126
Parasympathetic nervous system, 252
Parasympathomimetic agents clasification, 286
Parathormone (PTH), 998
osteoporosis, 1009
Perampanel, 140
Parenteral routes, 7
Paricalcitol, 1005
Parkinsonism
bromoergocriptine for, 946
drugs therapy, 232
management, 238
pathophysiology, 231
treatment strategies, 240
Paromomycin, 686
in amoebiasis, 798
Paroxetine, 216, 219
in panic disorder, 211
Partial agonist, 33
Patient compliance, 53
Patient, vulnerable, 64
Pazopanib, 841
PDE-4 inhibitors
selective, in asthma, 367
P-drug concept, 54
Pectin, 606
Pediculosis
drug therapy of, 1022
Pefloxacin, 659
in leprosy, 770
Pegatenib, 1044</p>
<p>Pegfilgrastim, 518
Pegloticase, 1074
Pegvisomant, 869
Pegylated interferon (INF) alpha, 814
for hepatitis C, 812
Pellagra, 1110
Pelvic inflammatory disease
acute, 739
Pemoline, 227
Penciclovir, 810
Penfluridol, 200
Penicillin, 661
acid resistant, 670
allergic reactions, 664
anaphylaxis, 664
classification, 670
extended spectrum, 673
for gram-positive and
Gram-negative organisms, 672
prophylaxis, 669
penicillinase resistant, 671
regimens, 666
Penicillin allergy
skin tests for, 665
d-Penicillamine, 1089
Penicillinase, 661
Penicillin preparations
in syphilis, 737
Penicillin regimen
choice in common infections, 667
Penicilloic acid, 664
Penicilloyl-polylysine, 665</p>
<p>Pentaerythritol tetranitrate, 404
Pentagastrin, 624
Pentamidine isethionate
in trypanosomiasis, 804
Pentamidine (isethionate, mesylate), 802
Pentavalent antimony compounds, 802
Pentazocine, 163
Pentoxifylline, 415
Pentylenetetrazole, 191
Pepsin, 578
Peptic ulcer
anti-muscarinic drugs in, 631
drugs to be avoided, 634
drugs used in, classification, 624
management of, 632
prevention of recurrence of, 633
therapy, principles of, 624
Perchlorate
uses, 878
Pergolide
adverse reactions, 237
Perinatal toxicity, 70
Peripheral vascular disorders
drugs used in, 415
Permethrin, 792, 858, 1022
as mosquito repellent, 792
in pediculosis, 1022
Peroxisome proliferator activated
Receptor-alpha (PPAR- <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span> ), 591
Peroxisome Proliferator-Activated
Receptors gamma (PPAR <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>γ</mi></mrow><annotation encoding="application/x-tex">\gamma</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.625em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05556em;">γ</span></span></span></span></span> ) agonist, 903
Perphenazine, 196</p>
<p>Persistent depolariser, 316
Pertuzumab, 840
Pessary, 6
Pethidine, 160
congeners, 162
Petrolatum, 173
PGE
intracavernosal injection, 985
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">E</mi></mrow><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGE}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGE</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>
transurethral injection, 985
PG-synthetase inhibitors, 959
p-glycoproteins, 17
Pharmacodynamics, 2
in fetus and neonates, 1120
Pharmacoeconomics, 3, 52
Pharmacoepidemiology, 2
Pharmacogenetics, 3
Pharmacogenomics, 3, 58
Pharmacognosy, 2
Pharmacokinetics, 2
in fetus and neonates, 1119
Pharmacology, 1
Pharmacopoeia, 5
Pharmacovigilance, 3, 74
Pharmacy, 2
Pharyngeal demulcents, 357
Phase I reactions, 19
hydrolysis, 19
oxidation, 19
reduction, 19
Phase II reactions, 20
Phenanthrene methanol, 782</p>
<p>Phenazopyridine, 186, 735
Phendimetrazine, 582
Phenelzine, 214
Phenindione, 487
Pheniramine maleate, 328
Phenobarbitone, 135
Phenol, 849
as sclerosing agent, 498
Phenolphthalein, 614
Phenothiazine compounds, 195
Phenothiazines, 195
adverse reactions, 198
as anti-emetics, 597
depot, preparations, 200
drug interactions, 200
in vertigo, 601
uses, 200
Phenothiazines derivatives, 196
Phenothiazines groups
according to adverse reaction, 198
Phenoxybenzamine, 278
in hypertension, 424
Phenoxymethyl penicillin
potassium (Penicillin V), 670, 671
Phenteramine, 583
Phentolamine, 279, 424
Phenylbutazone, 177
Phenylephrine, 276, 473
in orthostatic hypotension, 446
in shock, 473
Phenylpropanolamine, 277, 359
Phenytoin sodium (diphenylhydantoin), 132, 389</p>
<p>drug interactions, 134
Phobic anxiety, 210
Pholcodeine, 359
Phosphate binders
in chronic kidney disease, 998
Phosphorus metabolism, 996
Phosphate mixture
neutral, 997
Photoallergy, 1036
Photosensitivity, 1035
Phototoxicity, 1035
Physostigmine, 292
Phytochemicals, 3
Phytoestrogens, 3, 951
Picaridin, 792
as mosquito repellent, 792
Pickwickian syndrome, 192
Picrotoxin, 191
Pilocarpine, 290, 1043
ocusert, 290
Pimozide, 200
Pinacidil, 409, 427
Pinaverium, 609
Pindolol, 280
Pink disease (Acrodynia), 1087
Pinocytosis, 12
Pinworms
drug therapy of, 820
Pioglitazone, 903
Piperacillin, 674
in UTI, 731
Piperazine, 818</p>
<p>Piperidone, 359
Pipezethate, 359
Pipradrol, 191, 226
Piracetam, 243
Pirbuterol, 366
Pirenzepine, 303, 631
Piretanide, 564
Pirfenidone, 446
Piroxicam, 180
Pitavastatin, 588
Pituitary gland, 865
Pituitary-thyroid relationship, 872
Pivampicillin, 673
Pivmecillinam, 674
Pizotifen, 340
Placebo, 74
Placental hormones, 947
Plague
treatment, 684
Plant constituents
active principles of, 3
Plasma, 470
fresh, frozen, as hemostatic, 495
Plasma expanders
colloidal, 470
crystalloid, 472
Plasma fractions, 470
Plasma iodine, 871
Platelet activating factor (PAF), 354
Pneumococcal vaccine
in chronic bronchitis, 706
Podophyllin</p>
<p>for warts, 1018
Podophyllotoxin
in genital warts, 741
Pollutants
gaseous, 1099
Polycystic ovary syndrome (PCOS), 978
Polycythemia vera therapy of, 835
Polyethylene glycol (PEG), 49, 615
Polymyxin B, 687
Polysorbates, 849
Polythiazide, 562
Polyunsaturated fats (PFA), 590
Polyvinylpyrrolidone (PVP), 472
Posaconazole, 713
Postcoital contraception
various regimens for, 974
Post-marketing surveillance, 74
Postpartum hemorrhage (PPH)
methylergometrine in, 638
oxytocin in, 640
Post-tetanic potentiation (PTP), 133
Post-traumatic seizures, 146
Potassium
depletion, 535
depletion, treatment of, 537
excess, 537
in cardiac arrhythmias, 393
metabolism, 534
sparing diuretics, 555
Potassium canreonate, 565
Potassium channel activators
in hypertension, 427</p>
<p>Potassium citrate, 358, 537
Potassium iodide as expectorant, 358
saturated solution (SSKI), 880
Potassium oxalate, 490
Potassium perchlorate, 878
uses, 878
Potassium permanganate, 853
for hyperhydrosis, 1035
Potassium thiocyanate, 878
Potentiation, 40
Povidone iodine, 852
Pralidoxime (P-2-AM), 298
Pramipexole, 230, 237
Pramlintide, 905
Pranlukast, 369
Prasugrel, 480
Pravastatin, 588
Praziquantel, 824
in fluke infestation, 826
in schistosomiasis, 825
in taeniasis, 824
Prazosin, 279, 424
in benign prostatic
hyperplasia, 990
in scorpion sting, 1060
Pre-anaesthetic medication, 109
Precocious puberty, 961
Prednisolone, 928, 930
in erythema nodosum
leprosum (ENL), 773
Pregabalin, 139, 186
in chronic neuropathic pain, 186</p>
<p>Pregnancy drug prescribing during, 1123
medical termination of, 642, 975
pharmacokinetics of drugs in, 1117
Pregnancy termination drugs used for, 975
Premetrexed, 833
Prepared chalk, 606
Prescription writing, principles of, 53
Prilocaine, 249
Primaquine, 781
Primidone, 135
Primovlar, 969
Probenecid, 664, 1074
Probiotics, 607
Procainamide, 388
Procaine, 249
Procaine benzylpenicillin, 663
Procarbazine hydrochloride, 831
Prochlorperazine, 196
Procyclidine, 237
Prodrug, 27
Progestasert, 27, 960, 972
Progesterone, 951, 955, 958
Progestins, 955
classification, 955
in intrauterine contraceptive
devices (IUCDs), 960
injectable contraceptives, contraindications, 971
in malignancy, 838
in use, 958
only pills, as contraceptives, 970
pharmacological actions of, 956
synthetic, comparative biological properties, 968</p>
<p>therapeutic uses of, 957
Progestins-IUCD, 972
Programmatic management of
drug resistant TB (PMDT), 761
Proguanil, 783
Proguanil-atovaquone combination, 783
Prokinetic drugs, 597
Prolactin, 944
Promazine, 196
Promethazine, 123, 196, 328
as pre-anaesthetic medication, 110
in parkinsonism, 238
Promethazine chloro-theophyllinate, 328
Prontosil, 645
Propafenone, 390
Propantheline, 304, 609
Proparacaine, 247
Propofol, 105
Propranolol, 280
in cardiac arrhythmias, 391
in thyrotoxicosis, 883
Propylene glycol
as keratolytic, 1017
d-Propoxyphene, 163
Propylhexedrine, 277
Propylthiouracil, 878
Prostacyclin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mo fence="true">(</mo><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">I</mi></mrow><mn>2</mn></msub><mo fence="true">)</mo></mrow><mo separator="true">,</mo><mn>350</mn><mo separator="true">,</mo><mn>479</mn></mrow><annotation encoding="application/x-tex">\left(\mathrm{PGI}_{2}\right), 350,479</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord"><span class="mord"><span class="mord mathrm">PGI</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">)</span></span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">350</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">479</span></span></span></span></span>
Prostaglandins (PGs), 347
as oxytocics, 640
in peptic ulcer, 631
Prostanoic acid, 347
Protamine sulfate, 484</p>
<p>Protease inhibitors (PI), 745
Proteasome inhibitors, 841
Prothionamide, 769
Prothipendyl, 201
Proton pump inhibitors (PPI), 628
Protriptyline, 216
Pruritus
management, 1016
treatment, 330
Pseudoephedrine, 274
in orthostatic hypotension, 446
Pseudogout
treatment, 1075
Pseudotolerance, 60
Psilocybine, 227
Psoriasis
drug therapy of, 1027
drugs used in, 1028
systemic therapy, 1029
topical therapy, 1028
Psychoactive/Psychotropic drugs
classification, 195
combinations, 225
definition, 193
experimental evaluation, 193
Psychoanaleptics, 212
Psychomotor stimulants, 226
therapeutic uses, 226
Psychosis, senile, 200
Psychotic disorders, 193
Psychotogenic drugs, 227
Psychotomimetic, 227</p>
<p>Pulmonary edema
management, 463
Pulmonary embolism
anti-coagulants for, 488
Pulmonary hypertension, 445
drugs used in, 446
Pulmonary syndrome
treatment, 560
Pulmonary tuberculosis
management, 756
Pulse polio immunization, 1051
Pyelonephritis
treatment of, 734
Pyrantel pamoate, 818
Pyrazinamide, 46, 752
Pyrethroids, 792, 858
as insecticide, 858
Pyrethrum flowers
as insecticide, 858
Pyridostigmine, 292
Pyridoxine
during vomiting in pregnancy, 599
Pyrimethamine, 783
Pyrimethamine-sulfonamide
combination, 784
Pyrogens endogenous, 168
Pyronaridine, 781</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="q">Q<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#q" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Qinghaosu, 784
Quetiapine, 201
Quinagolide, 947</p>
<p>Quinapril, 429
Quinazolines, 279
Quinazolinones, 563
Quinethazone, 563
Quinidine, 386
Quinine, 776
Quinoline derivatives in amoebiasis, 796
Quinoline methanol, 782
Quinolones, 657
Quinupristin (Q)/Dalfopristin (D), 680</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="r-mathbf-r-r"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="bold">R</mi></mrow><annotation encoding="application/x-tex">\mathbf{R}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6861em;"></span><span class="mord mathbf">R</span></span></span></span></span><span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#r-mathbf-r-r" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Rabeprazole, 629
Rabies
tissue culture vaccines, 1054
immune globulin, 1059
regimens, 1055
vaccines, 1054
Racecadotreil, 607
Radiation
for sterilisation, 846
Radioactive iodine, 834, 880
Radioactive indications, 882
Radioactive isotopes, 834
Radioactive phosphorus, 835
Radiogold, 829
Radio-immunoassay
principles, 79
Radiomimetic drugs, 830
Radio-iodine, 834
indications, 882
Raloxifene, 951</p>
<p>in osteoporosis, 1009
Raltegravir, 746
Ramelteon, 123
Ramipril, 429
Ranibizumab, 1044
Ranitidine, 630
Ranolazine, 409
Rapacuronium, 319
Rasagiline, 236
Rasburicase, 1074
Rauwolfia serpentina (Benth), 203
Raynaud's syndrome
drugs used in, 415
Reactive oxygen species, 1115
Rebapimide, 632
Reboxetine, 216, 221
Receptor
down-regulation, 35
G-protein coupled, 36
ion channel linked, 36
nuclear, 37
protein kinase linked, 37
spare, 34
up-regulation, 35
Receptor-effector system, 33
Recombinant human IL-11, 518
Rectal route, 6
Red man syndrome, 679
Remifentanil, 108, 162
Renal circulation
modulating agents, 531
Renal failure, acute, 572</p>
<p>management principles, 572
Renin inhibitors
in hypertension, 428
Rennin, 578
Repaglinide, 901
Reproduction
physiology, 962
Reserpine
5HT depletor, 338
as anti-psychotic, 203
in hypertension, 422
Resins, 4
Resmethrin, 858
Respiratory distress syndrome
surfactants in, 377
Respiratory failure
acute, treatment, 376
Reteplase, 490
Retinoids, 1107
Retrolental fibroplasia, 1093
Reversible anti-cholinesterases
therapeutic uses, 294
Reverse transcriptase inhibitors, 744
Reviparin, 484
Revised National Tuberculosis
Control Programme (RNTCP) DOTS regimen, 759
Rheumatic fever treatment, 669
Rheumatoid arthritis (RA) choice of drug therapy, 1080
classification, drugs used in, 1076
pathophysiology of, 1076
principles of management, 1080
supportive therapy, 1081</p>
<p>Rhinitis drug therapy of, 377
Rhubarb, 613
Ribavirin, 812
for hepatitis C, 812
Rice conjee, 605
Ricinoleic acid, 613
Ricinus communis, 613
Rickets
treatment of, 1004
Rickettsial vaccines, 1052
Rifabutin, 694, 752, 765
for MAC, 765
Rifampicin, 694, 750
in leprosy, 769
in tuberculosis, 750
Rifamycins, 694
Rifapentine, 751
Rifaximin, 696
Rilpivirine, 745
Riluzole, 242
Rimantadine, 812
Rimiterol, 366
Rimonabant, 230, 582
Riociguat, 446
Rioprostil, 631
Risendronate, 1007
Risperidone, 202, 338
r-thrombopoietin, 518
Ritodrine, 277
as tocolytic, 642
Ritonavir, 745
Rituximab, 840, 1065</p>
<p>in rheumatoid arthritis (RA), 1079
Rivaroxaban, 484
Rivastigmine, 243, 292
Rizatriptan, 339
Rocuronium, 319
Roflumilast, 367
Romiplostim, 518
Ropinirole, 237
Ropivacaine, 250
Rose Bengal, 1045
Rosuvastatin, 588
Rotenone, 859
Rotigotine, 237
Roundworms (ascariasis)
drug therapy of, 817
Roxatidine, 630
Roxithromycin, 677
Rubidomycin, 835
Rufinamide, 140</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="s">S<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#s" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Sabin vaccine, 1051
Sabza, 616
Saccharin, 919
Safflower oil, 587
Salbutamol, 277, 365
as tocolytic, 642
Salcalcitonin, 999
Salicylic acid, 846
as keratolytic, 1017
in acne, 1024
in psoriasis, 1028</p>
<p>local application, 175
Salicylic acid collodion, 846
Salicylism, 174
Saline expectorants, 358
Salk vaccine, 1051
Salmeterol, 277, 368
Saquinavir, 745
Saralasin, 430
Sarin, 295
Saturation kinetics, 24
Saxagliptin, 904
Scabies
drug therapy, 1021
Schistosomiasis
drug therapy of, 825
Schizophrenia
management, 203
Sclerosing agents, 498
Scopolamine (hyoscine), 299
in motion sickness, 303, 599
sedative effect, 123
Scorpion sting
drug therapy of, 1060
treatment, 1060
Scurvy
prevention and treatment, 1114
Seasonique, 968
Seborrhoeic dermatitis
treatment, 1020
Sebostatics, 1021
in acne, 1024
Secnidazole, 795</p>
<p>in trichomoniasis, 807
nonspecific vaginitis, drug
therapy, 807
Second gas effect, 104
Second messengers, 34
Sedative
definition, 113
Sedatives and tranquillisers
as preanaesthetic medication, 109
Seidlitz powder, 615
Seizures
types, 129
Selective estrogen receptor
modulators (SERMs), 838, 951
in malignancy, 838
Selective serotonin reuptake
inhibitor (SSRI)
in depression therapy, 223
in panic disorder, 211
Selegiline, 236
MAO-B inhibitors, 236
Selenium sulfide, 1019
Semisynthetic penicillins, 670
Senna, 613
Sera, immune animal, 1050
Sera, immune human, 1050
Serotonergic syndrome, 218
Sermorelin, 869
Serratiopeptidase, 1103
Sertaconazole, 712
Sertraline, 216
Serum</p>
<p>anti-snake venom, 1059
Sevelamer, 998
Sevoflurane, 103
Sex steroids
synthesis, 939
Sexual impotence, 982
Sexually transmitted diseases (STD)
chemoprophylaxis, 747
prophylaxis, 747
single dose regimens for
treatment of, 741
viral, drug therapy of, 741
SGLT-2 inhibitors, 905
Shark liver oil, 1003, 1107
Shock
anaphylactic, 326
anaphylactic treatment of, 475
bacteremic treatment, 475
hemo-obstructive treatment of, 475
hypovolemic, treatment, 474
in myocardial infarction, 475
mechanisms, 465
neurogenic treatment of, 475
principles of management, 474
treatment of, 474
Shohl's mixture, 541
Sibutramine, 582
Sildenafil, 985
Silodosin
benign prostatic hyperplasia (BPH), 990
Silver compounds
as antiseptic, 853</p>
<p>Silver nitrate, 853
Silver sulfadiazine, 650
Simprevir, 812
Simethicone, 579
Simvastatin, 588
Sinocatechines
in genital warts, 742
Sirolimus, 1067
Sitagliptin, 904
Skeletal muscle contraction
physiology, 316
ways to block, 316
Skeletal muscle relaxants
centrally acting, 313
classification, 313
directly acting, 321
peripherally acting, 316
Skeletal muscle relaxants, peripheral
classification, 316
therapeutic uses, 320
Skin
anatomy and physiology of, 1013
anti-bacterial and anti-viral
infections, therapy, 1017
lesions, 1014
vehicles and formulations, therapy, 1015
Skin disorders
drug induced, 1035
Skin pigmentation
drugs affecting, 1032
Sleep
disorders, 126</p>
<p>physiology, 111
Sleepwalking, 126
Slow reacting substances (SRS), 346
Snake bite
treatment, 1059
Snake venoms
and cogulation, 497
Sodium
depletion, 529
depletion, treatment, 532
excess, 533
metabolism, 526
Sodium aurothiomalate
in rheumatoid arthritis, 1077
Sodium bicarbonate, 627
Sodium carboxymethyl cellulose, 616
Sodium cetostearyl sulfate, 848
Sodium chloride
as emetic, 595
Sodium citrate, 490
Sodium dehydrocholate, 578
Sodium fusidate (Fucidin), 680
Sodium iodate, 877
Sodium lauryl sulfate, 848
Sodium linoleate, 498
Sodium metabolism
hormonal control of, 528
Sodium morrhuate, 498
Sodium N-dodecyl alanate, 849
Sodium nitrite, 1073
in cyanide poisoning, 1100
Sodium nitroprusside, 426</p>
<p>in hypertensive crises, 442
Sodium picosulfate, 614
Sodium polystyrene sulfonate, 568
Sodium potassium tartrate (Rochelle salt), 615
Sodium stibogluconate, 802
Sodium tetradecyl sulfate
as sclerosing agent, 498
Sodium thiosulfate, 1073
in cyanide poisoning, 1100
Sodium valproate, 137
for MDP treatment, 207
Sofosbuvir, 812
Soft soaps, 848
Solifenacin, 307
Solute carriers, 11
Soman, 295
Somogyi effect, 895
Somatonorm, 868
Somatorelin, 869
Somatostatin, 623, 869
in variceal bleeding, 498
Somatrem, 868
Somatropin, 869
Sorafinib, 841
Sorivudine, 811
Sotalol, 280, 391
Spansules, 7
Sparfloxacin, 659
Spectinomycin, 687
Spinal opioid analgesia, 250
Spiramycin, 676
in toxoplasmosis, 806</p>
<p>Spironolactone, 431, 565, 936, 988
in acne, 1024
in heart failure, 453
Spirulina, 1116
Stanozolol, 986
Staphylococcal infections
community-acquired, drugs for, 668
Statins, 588
choice of, 590
doses of asians, 590
lipid-independent effects, 590
Status asthmaticus, 373
treatment, 373
Status epilepticus
management, 146
Stavudine, 744
Steam inhalation, 357
Stem cell therapy, 5
STEMI, 412
Sterilisation methods
choice of, 854
Steroid
experimental evaluation, 923
local, therapy, 934
synthesis, blockers, 922
Stevia rebaudiana, 919
Stevens Johnson Syndrome, 650
St. John's Wort, 220
Stokes-Adams syndrome, 271
Streptodornase, 1102
Streptogramins, 680
Streptokinase, 490, 1102</p>
<p>Streptomycin, 683
in tuberculosis, 753
Strongyloidiasis
drug therapy, 820
Strontium ranolate
in osteoporosis, 1009
Strychnine, 192
poisoning, treatment, 192
Subacute myelo-optic neuropathy (SMON), 796
Subcutaneous (SC) route, 8
Sublingual administration, 10
Sublingual route, 10
Succimer, 1089
Succinylcholine, 318
Sucralfate, 631
Sucralose, 919
Sufentanil, 108
Sulbactam, 674
Sulconazole, 711
Sulfacetamide, 650
Sulfadiazine, 651
in toxoplasmosis, 806
Sulfadimidine, 651
Sulfadoxine, 648
Sulfamethoxazole, 648
Sulfasalazine, 652, 653
in rheumatoid arthritis, 1078
Sulfidopeptide: cysteinyl LTs, 347
Sulfinpyrazone, 1075
Sulfisoxazole, 648
Sulfonamides, 647
drug interactions, 651</p>
<p>in malaria, 784
in UTI, 730
uses, 651
Sulfones, 768
in malaria, 784
Sulfonylurea, 898
limitations, 901
preparations, choice of, 900
Sulformethoxine (sulfadoxine), 648
Sulfur, 1021
Sulfur dioxide, 1072, 1099
Sulpiride, 201
Sumatriptan, 339
Sumithion, 295
Sunflower oil, 587
Sunitinib, 841
Sunscreens and barrier
preparations, 1033
Superinfections, 725
Supersensitivity, 261
denervation, 261
Suppository, 6
Suramin sodium, 804
Surfactants, 847
Sweetening agents, 919
Sympathetic blocking drugs, 277
Sympathetic nervous system, 253
Sympathomimetic decongestants in cough mixtures, 359
Synthetic ACTH, 921
cosyntropin, 921
Syphilis
and pregnancy, 738</p>
<p>drug therapy of, 736
late latent and cardiovascular
treatment, 738
primary, treatment of, 737
secondary, latent and tertiary, treatment of, 737</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="t">T<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#t" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>1-Thyroxine
for thyroid carcinoma, 839
6-Thioguanine, 834
Tabun, 295
Tacalcitol
in psoriasis, 1029
Tacrine (tetrahydroaminoacridine), 243, 292
Tacrolimus, 1068
in atopic dermatitis, 1026
Tadalafil, 985
benign prostatic hyperplasia (BPH), 990
Tafenoquine, 782
Talampicillin, 673
Tamoxifene, 837, 951, 976
for MTP, 976
Tamsulosin, 280, 307
benign prostatic hyperplasia (BPH), 990
Tannins, 4
Tapentadol, 159
Tapeworms
drug therapy of, 824
Targetted delivery systems, 27
Tasimelteon, 123
Tavaborole
for onychomycosis, 1020</p>
<p>Tazarotene, 1108
in psoriasis, 1029
Tazobactam, 674
T cell activation inhibitors
in RA, 1079
Tear substitutes, 1045
Tedizolid, 681
Tegaserod, 617
Teicoplanin, 679
Telaprevir, 812
Telavancin, 679
Telbivudine, 812
Telcagepant, 343
Telithromycin, 677
Telmisartan, 430
Temazepam, 115
Temozolomide, 831
Temperature regulation, 167
Tenamphetamine, 228
Tenecteplase, 490
Teniposide, 836
Tenofovir, 745, 812
Tenoxicam, 180
Teratogenicity, 1120
drug induced, 1121
Terazosin, 280, 307, 424
benign prostatic hyperplasia (BPH), 990
Terbinafine, 714, 1019
Terbutaline, 277, 366
as tocolytic, 642
Terconazole, 712
Teriflunomide, 244</p>
<p>Terlipressin
in variceal bleeding, 498
Terpene hydrochloride, 357
Testosterone, 981
adverse reactions, 982
pharmocological actions, 981
preparations, 983
therapeutic uses, 983
transdermal preparations, 983
Testosterone cypionate, 983
Testosterone enanthate, 983
Testosterone esters, 983
Testosterone implants, 983
Testosterone phenylpropionate, 983
Testosterone propionate, 983
Testosterone undeconate, 983
Tetanus
treatment of, 1058
Tetanus anti-toxin, 1058
Tetanus immunoglobulin, 1058
Tetanus toxoid, 1052, 1055
Tetrachlorethylene, 1100
Tetracyclines, 697
and superinfection, 699
commonly used, properties of, 698
drug interactions, 700
in amoebiasis, 798
in chlamydia infections, 702
in rickettsial infections, 702
in trachoma, 702
semisynthetic, 700
therapeutic uses, 702</p>
<p>Tetraethyl pyrophosphate (TEPP), 296
Tetrahydrocannabinol (THC), 228
Tetramethrin, 858
Tetramethylammonium (TMA), 308
Thalidomide, 47, 1068
in erythema nodosum
leprosum (ENL), 773
Thallium, 1087
Theophylline, 368
Theophylline derivatives
aminophylline, 364
Therapeutic audit, 52
Therapeutic drug monitoring, 25
Therapeutic equivalent, 13
Therapeutics, 2
Thiabendazole, 821
Thiacetazone, 755
Thiamine (aneurine, Vitamin B1), 1108
Thiazides
as diuretics, 562
as anti-hypertensives, 431
Thiazide-like diuretics, 562
Thiazolidinediones (glitazones), 903
Thiethylperazine, 196
Thioamides, 878
Thiopental sodium, 104
Thioridazine, 196
Thiotepa, 831
Threshold dose, 37
Thrombin, 494
Thrombocytopenia
drugs used in, 518</p>
<p>Thrombogenesis, 478
Thrombolytic agents
properties of, 491
Thrombolytic therapy
contraindications, 492
therapeutic uses, 492
Thromboplastin, 494
Thrombopoietin, 352
Thromboprophylaxis, 489
Thromboxane <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">A</mi><mn>2</mn></msub><mrow><mo fence="true">(</mo><msub><mrow><mi mathvariant="normal">T</mi><mi mathvariant="normal">X</mi><mi mathvariant="normal">A</mi></mrow><mn>2</mn></msub><mo fence="true">)</mo></mrow><mo separator="true">,</mo><mn>350</mn></mrow><annotation encoding="application/x-tex">\mathrm{A}_{2}\left(\mathrm{TXA}_{2}\right), 350</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm">A</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord"><span class="mord"><span class="mord mathrm">TXA</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">)</span></span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">350</span></span></span></span></span>
Thrombus arterial, 478
venous, 478
Thymol, 850
Thyroid hormones actions, 873
mechanism of action, 872
synthesis of, 870
therapeutic uses, 875
Thyroid stimulating hormone (TSH), 870
Thyrotoxic crisis
treatment, 883
Thyrotoxicosis
indications for surgery, 883
Thyrotropin releasing hormone (TRH), 872
Tiagabine, 138
Tibolone, 951
Ticagrelor, 480
Ticarcillin, 674
Ticlopidine, 479
Tigecycline, 701
Til oil, 587
Tilorane, 1068
for humoral immunity stimulation, 1068</p>
<p>Time release, 7
Timolol, 280, 1044
Timsules, 7
Tincture benzoin, 356
Tinidazole, 795, 807
in trichomoniasis, 807
Tinzaparin, 483
Tiotropium, 305, 367
Tipranavir, 745
Tirofiban, 480
Tizanidine, 242, 314
Tmax, 12
TNF <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi><mo separator="true">,</mo><mn>352</mn></mrow><annotation encoding="application/x-tex">\alpha, 352</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">352</span></span></span></span></span>
TNF-alpha blockers
in rheumatoid arthritis, 1079
Tobacco amblyopia, 311
Tobacco dependence
drugs used in, 312
treatment of, 312
Tobacco smoking, 310
Tobramycin, 686
Tocainide, 390
Tocilizumab
in rheumatoid arthritis, 1079
1-alpha tocopherol (Vitamin E), 1108
Tocolytics, 642
Tofacitinib, 1080
in RA, 1080
Tolazoline, 279
Tolbutamide, 899
Tolcapone, 236
COMT inhibitors, 236</p>
<p>Tolmetin, 179
Tolnaftate, 1019
Tolterodine, 305
Tolubuterol, 366
Toluene, 1100
Tolvaptan, 533, 575
Topical ocular drugs pharmacokinetics, 1038
Topiramate, 140, 583
Topotecan, 836
Toremifene, 951
Torsemide, 564
Total parenteral nutrition (TPN), 551
complications, 551
indications, 549
Toxic effects, 40
Toxicology, 2
Toxidromes, 41
Toxikinetics, 41
Toxoids, 1050
Toxoplasmosis
drug therapy of, 805
Tramadol, 159
Tranexamic acid, 497, 959
Trans-cutaneous/transdermal route, 9
inunction, 10
iontophoresis, 9
Transdermal drug delivery system, 10
Transdermal contraceptive
system (TCS), 969
Transdermal route, 9
Transforming growth factor (TGF <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi></mrow><annotation encoding="application/x-tex">\beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span> ), 352
Trans forms of fatty acids (TFA), 587</p>
<p>Trans-mucosal route, 10
Trans-nasal route, 10
Transport
active, 12
Transporters
transmembrane, 11
Trans-rectal route, 10
Trans-urethral route, 9
Tranylcypromine, 214
Trastuzumab, 840, 1065
Trazodone, 221
Tretinoin, 1107
as keratolytic, 1017
in acne, 1024
Triacetyloleandomycin, 676
Triamcinolone, 370, 928, 930
Triamterene, 566
Triazolam, 115
Triazoles, 712
Trichloroethanol, 122
Trichloroethylene, 103
Trichlorophos, 296
Trichomoniasis local drug therapy, 807
systemic drug therapy, 807
Trichuriasis drug therapy, 821
Triclobisonium chloride, 849
Tricyclic anti-depressants (TCA), 212
in depression therapy, 223
mechanism of action, 214
Trientine, 1090
Triethylene thiophosphoramide (Thio-TEPA), 828
Trifluoperazine, 196, 205</p>
<p>Trifluperidol, 200
Triflupromazine, 196
Trifluridine, 809
Trigeminal neuralgia, 135
Triglycyl lysine vasopressin, 574
in variceal bleeding, 574
Triiodothyronine (liothyronine), 875
Trimebutine, 609
Trimeprazine, 328
Trimetazidine, 409, 809
Trimethadone, 1114
Trimethaphan camphor sulfonate, 421
Trimethoprim, 654, 656
in UTI, 730
Trimipramine, 216
Triorthocresyl phosphate (TOCP), 296
Trioxsalen, 1032
Tripamide, 564
Triprolidine, 328
Triptan analogues, 339
Triptorelin microspheres, 942
Triquilar, 969
Tropical eosinophilia
therapy of, 822
Trospirone, 209
Trospium, 305
Troxidone, 521
Trypanosomiasis
drug therapy, 804
Trypsin, 1102
TSH, rDNA, 872
Tetracyclines</p>
<p>drug interactions, 700
Tuamino heptane sulfate, 276
Tuberculosis
and HIV, 766
chemoprophylaxis, 763
chemotherapy, 748
chemotherapy, classifcation, 748
chemotherapy, extrapulmonary, 762
dosages of drugs used in, 758
DOTS regimen, 758
drug treatment failure, causes, 760
during pregnancy, 760
drug regimen, 757
extensively drug resistant (XDR), treatment, 762
MDR, treatment, 761
meningitis, 762
resistant, treatment, 762
Tuberculous lymphadenitis
treatment, 763
Tumor necrosis factor (TNF), 352, 353
Turner syndrome (primary hypogonadism), 952
Tween 80, 849
Type 1 DM (T1DM)
pathogenesis, 907
pharmacotherapy, 911
Type 2 DM (T2DM)
drugs used in, 913
pathogenesis, 908
pharmacotherapy, insulin therapy, 910
pharmacotherapy, sulfonylureas
in, 900
with complications, management, 915</p>
<p>without complications, management, 911
Typhoid fever
carriers, treatment, 705
therapy of, 705
Tyrocidine, 687
Tyrosine kinase inhibitors, 840
in RA, 1080
Tyrosine kinases, 37
Tyrothricin, 687</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="u">U<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#u" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Ubiquinone, 1089
UGDP and UKPDS studies, 902
Ulcerative colitis
therapy, 652
Ulcerative gingivitis
drug therapy, 795
Ulcers
NSAID-induced, 635
protective drugs, 631
Ulipristal acetate, 974
Undecoylium chloride iodine, 852
Undecylenic acid, 1019
Unipolar depression, 220
Universal antidote, 49
Unsaturated fatty acids (UFA), 587
Unstable angina
therapy, 412
treatment, 412
Untoward effects, 41
Uptake transporters, 11, 17
Urapidil, 280</p>
<p>Urea
as keratolytic, 1017
Uric acid synthesis inhibitors, 1073
Uricosuric drugs, 1074
Urinary antiseptics, 730
Urinary tract infection (UTI), 727
acute infection, 727
anti-microbial prophylaxis, 735
choice of therapy, 732
chronic infection, 727
chronic persistent, 733
drugs, classification, 730
lower, treatment of, 732
pathogenesis and bacteriology, 728
recurrent, 733
therapy, general principles, 729
upper, treatment in renal
impairment, 734
upper, treatment of, 734
Urine formation
physiology, 552
Urokinase, 491
Ursodeoxycholic acid, 578
Urticaria, 331, 1026
treatment, 331
Ustekinumab
in psoriasis, 1030
Uterine relaxants (Tocolytics)
classification, 642</p>
<p>V
V2 receptor antagonist, 575</p>
<p>Vaccines, 1049
anthrax, 1052
cholera, 1052
haemophilus influenzae, 1052
hepatitis A, 1053
hepatitis B, 1053
human papilloma virus (HPV), 1053
influenza, 1053
Japanese B encephalitis, 1053
measles, 1053
meningococcal, 1052
MMR, 1051
mumps, 1053
nucleic acid, 1050
pertussis, 1052
plague, 1052
pneumococcal, 1051
poliomyelitis, 1051
rabies, 1054
rotavirus, 1053
rubella, 1053
semple, 1053
typhoid, 1051
typhus, 1052
varicella - zoster, 1053
yellow fever, 1053
Vaginitis
drug therapy of, 741
Valacyclovir, 810
Valganciclovir, 811
Valsartan, 430
Vancomycin, 679</p>
<p>Vardenafil, 985
Varenicline, 312
Variant angina
therapy, 411
treatment, 412
Variceal bleeding
acute management, 497
Varicella zoster virus infection
treatment, 810
Vasicine, 358
Vasicinone, 358
Vasodilator drugs
in heart failure, 451
in hypertension, 426
in shock, 475
Vasopeptidase, 529
Vasopeptidase inhibitors, 452
Vasopressin
preparations, 574
therapeutic uses, 574
Vasopressin receptors, 573
Vasopressin receptor antagonists, 575
Vasopressin tannate, 574
Vasopressor agents
in shock, 475
Vasospastic diseases
drugs used in, 415
Vecuronium, 319
Vedolizumab, 654
Venlafaxine, 216, 221
Ventricular fibrillation
cardioversion in, 397</p>
<p>Ventricular premature beats, 388
Verapamil, 408
in cardiac arrhythmias, 393
Vermicidal drugs, 815
Vermifuge drugs, 815
Vernakalant, 392
Verteporfin, 1045
Vertigo
anti-histaminics, 601
central anti-cholinergics, 601
drugs used in, 601
diuretics in, 601
glucocorticoids in, 601
phenothiazines in, 601
therapy of, 600
Vidarabine
in herpes zoster, 1018
Vigabatrin, 138
Vildagliptin, 904
Vinblastine, 836
Vinca alkaloids, 836
Vincristine, 836
Vindesine, 836
Vinorelbine, 836
Viral vaccines, 1053
Viruses
types, 808
Vitamins allowances (RDA) in, 1114
classification, 1104
combinations, 1114
fat soluble, 1105
recommended dietary water soluble, 1108</p>
<p>Vitamin A, 1105
prophylaxis, 1107
synthetic analogues, 1107
theurapeutic uses, 1107
Vitamin B2 (riboflavine), 1109
Vitamin B3 (nicotinic acid), 1110
Vitamin B6 (pyridoxine), 1111
Vitamin B7 (pantothenic acid), 1112
Vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">B_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0502em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> (cyanocobalmin)
metabolic actions, 512
physiological role, 510
preparations, 513
therapeutic uses, 514
Vitamin B complex, 1108
Vitamin C, 1113
in scorbutic (scurvy) bleeding, 497
Vitamin D
actions, 1000
activity, compounds with, 1005
analogues, synthetic, 1004
levels, significance, 1004
preparations, 1003
resistant rickets, treatment, 1004
Vitamin D3
oily injection, 1003
Vitamin E, 1108
Vitamin K, 495
preparations, 496
Vitiligo, 1032
Voglibose, 903
Vomiting
drug therapy of, 596</p>
<p>during pregnancy, anti-histaminics
in, 599
during pregnancy, therapy of, 599
physiology of, 594
Vorapaxar, 480
Voriconazole, 713</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="w">W<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#w" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Warfarin sodium, 486
Warts
therapy of, 1018
Water
as a diuretic, 555
depletion, 525
excess, 526
metabolism, 524
Water vapour, 1098
Wernicke's encephalopathy, 1109
Wetting agents
in the eye, 1045
Whitfield's ointment (benzoic acid and salicylic acid), 846, 1019
WHO Model Formulary, 5
Whooping cough treatment, 676
Wilson's disease
treatment, 1089
Wolff-Chaikoff effect, 879
Wolff's bottle, 1092</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="x">X<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#x" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Xanthine alkaloids, 188
theobromine, 188
theophylline, 188</p>
<p>Xanthine oxidase inhibitors, 1073
Xanthines
as diuretics, 558
XDR-TB, 762
Xenobiotics, 48
Xerophthalmia, 1105
Xipamide, 432, 563
Xylometazoline hydrochloride, 276</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="y-mathbf-y-y"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="bold">Y</mi></mrow><annotation encoding="application/x-tex">\mathbf{Y}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6861em;"></span><span class="mord mathbf" style="margin-right: 0.02875em;">Y</span></span></span></span></span><span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#y-mathbf-y-y" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Yasmin, 969
Yaz, 968
Yohimbine, 280, 985</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="z">Z<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#z" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Zafirlukast, 369
Zalcitabine, 744
Zaleplon, 116
Zanamivir, 813
Zero order kinetics/dose
dependent elimination/
saturation kinetics, 23
Ziconotide, 186
Zileuton, 369
Zinc oxide, 854, 1033
Zinc permanganate, 853
Zinc peroxide, 852
Zinc salts
uses, 854
Zinc sulfate, 854
Zinc supplemented ORS, 605
Ziprasidone, 202</p>
<p>Zolendronate, 1007
Zollinger-Ellison syndrome
therapy, 630
Zolmitriptan, 339
Zolpidem, 116
Zonisamide, 140
Zopiclone, 116
Zuclopenthixol, 195</p>
<section data-footnotes="true" class="footnotes"><div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 class="sr-only" level="2" id="footnotes">Footnotes<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#footnotes" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li id="user-content-fn-0">
<ul>
<li>For topical use:</li>
</ul>
<p>Clotrimazole, Miconazole, Econazole, Butaconazole, Oxiconazole, Sulconazole, Ticonazole, Sertraconazole, Luliconazole</p>
<ul>
<li>For systemic use:</li>
</ul>
<p>Ketoconazole, Itraconazole, Fluconazole, Voriconazole. (These can also be used locally.) <a href="#user-content-fnref-0" data-footnote-backref="true" class="data-footnote-backref" aria-label="Back to content">↩</a> <a href="#user-content-fnref-0-2" data-footnote-backref="true" class="data-footnote-backref" aria-label="Back to content">↩<sup>2</sup></a> <a href="#user-content-fnref-0-3" data-footnote-backref="true" class="data-footnote-backref" aria-label="Back to content">↩<sup>3</sup></a> <a href="#user-content-fnref-0-4" data-footnote-backref="true" class="data-footnote-backref" aria-label="Back to content">↩<sup>4</sup></a> <a href="#user-content-fnref-0-5" data-footnote-backref="true" class="data-footnote-backref" aria-label="Back to content">↩<sup>5</sup></a></p>
</li>
</ol>
</section></div></div></div></div></div></div></div><div data-testid="stAppIframeResizerAnchor" data-iframe-height="true" class="st-emotion-cache-1dumvfu eht7o1d9"></div></section></div></div></div><div data-testid="portal" id="portal" class="st-emotion-cache-1q6lfs0 e19n7mk11"></div></div><div class=""></div></div>
  

</body></html>